<SEC-DOCUMENT>0001193125-18-036987.txt : 20180209
<SEC-HEADER>0001193125-18-036987.hdr.sgml : 20180209
<ACCEPTANCE-DATETIME>20180209062219
ACCESSION NUMBER:		0001193125-18-036987
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		27
FILED AS OF DATE:		20180209
DATE AS OF CHANGE:		20180209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222412
		FILM NUMBER:		18587527

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d482402ds4a.htm
<DESCRIPTION>AMENDMENT NO. 3 TO FORM S-4
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 3 to Form S-4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on February 9, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-222412</FONT> </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT
NO. 3 </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>5912</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">05-0494040</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or Other Jurisdiction of<BR>Incorporation or Organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>One CVS Drive, Woonsocket, RI 02895 (401) <FONT STYLE="white-space:nowrap">765-1500</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>David M. Denton </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Executive
Vice President and Chief Financial Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>One CVS Drive </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Woonsocket,
RI 02895 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(401) <FONT STYLE="white-space:nowrap">765-1500</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Thomas M. Moriarty<BR>Executive&nbsp;Vice&nbsp;President,&nbsp;Chief Policy and External Affairs Officer and General Counsel<BR>CVS Health Corporation<BR>One CVS Drive<BR>Woonsocket, RI 02895<BR>(401) <FONT
STYLE="white-space:nowrap">765-1500</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Creighton O&#146;M. Condon<BR>Robert M. Katz<BR>Daniel Litowitz<BR>Shearman&nbsp;&amp; Sterling LLP<BR>599 Lexington Avenue<BR>New York, NY 10022<BR>(212) <FONT STYLE="white-space:nowrap">848-4000</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Thomas J. Sabatino, Jr.<BR>Executive Vice President<BR>and General Counsel<BR>Aetna Inc.<BR>151 Farmington Avenue<BR>Hartford, CT 06156<BR>(860) <FONT STYLE="white-space:nowrap">273-0123</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>H. Oliver Smith<BR>John A. Bick<BR>Harold Birnbaum<BR>Davis&nbsp;Polk&nbsp;&amp;&nbsp;Wardwell&nbsp;LLP<BR>450 Lexington Avenue<BR>New York, NY 10017<BR>(212)
<FONT STYLE="white-space:nowrap">450-4000</FONT></B></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale of the securities to the public: </B>As soon as practicable after the effective date of this registration
statement and completion of the merger of Hudson Merger Sub Corp. (&#147;<B>Merger Sub</B>&#148;), a wholly-owned subsidiary of CVS Health Corporation (&#147;<B>CVS Health</B>&#148;), with and into Aetna Inc. (&#147;<B>Aetna</B>&#148;), as described
in the Agreement and Plan of Merger, dated as of December&nbsp;3, 2017, among CVS Health, Merger Sub and Aetna. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If the securities being registered on this
form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the
&#147;<B>Securities Act</B>&#148;), check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148;
and &#147;smaller reporting company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (the &#147;<B>Exchange Act</B>&#148;). </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If
applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Exchange Act Rule <FONT
STYLE="white-space:nowrap">13e-4(i)</FONT> (Cross-Border Issuer Tender Offer)&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Exchange Act Rule 14d-l(d) (Cross-Border Third-Party
Tender Offer)&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on
such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>Information contained herein is subject to completion or amendment. A registration
statement relating to these securities has been filed with the Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This joint proxy
statement/prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>PRELIMINARY&#151;SUBJECT TO
COMPLETION&#151;DATED FEBRUARY 9, 2018 </B></FONT></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g482402g86h55.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g482402g22g61.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MERGER PROPOSAL&#151;YOUR VOTE IS VERY IMPORTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">February 9, 2018 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear CVS Health
Stockholders and Aetna Shareholders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of the boards of directors of CVS Health and Aetna, we are pleased to enclose the joint
proxy statement/prospectus relating to the merger of Aetna with a wholly-owned subsidiary of CVS Health pursuant to the terms of a merger agreement entered into by CVS Health and Aetna on December&nbsp;3, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>If the merger is completed, Aetna shareholders immediately prior to the effective time of the merger will be entitled to receive $145.00 in
cash and 0.8378 of a share of CVS Health common stock for each Aetna common share held by them, as described in more detail in the accompanying joint proxy statement/prospectus under the heading &#147;The Merger Agreement&#151;Merger
Consideration.&#148;</B> Based on the closing price of a share of CVS Health common stock on February 8, 2018, the most recent trading day prior to the date of the accompanying joint proxy statement/prospectus for which this information was
available, the merger consideration represented approximately $204.11 in value per Aetna common share. The value of the consideration to be received by Aetna shareholders will fluctuate with changes in the price of the shares of CVS Health common
stock. We urge you to obtain current market quotations for shares of CVS Health common stock and Aetna common shares. Shares of CVS Health common stock and Aetna common shares are traded on the New York Stock Exchange (NYSE) under the symbols
&#147;CVS&#148; and &#147;AET&#148;, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the merger, CVS Health stockholders are cordially invited to attend
a special meeting of the stockholders of CVS Health to be held on March 13, 2018 at the offices of Shearman &amp; Sterling LLP, located at 599 Lexington Avenue, New&nbsp;York, NY 10022, at 11:00 a.m. Eastern Time, and Aetna shareholders are
cordially invited to attend a special meeting of the shareholders of Aetna to be held on March 13, 2018 at the offices of Davis Polk &amp; Wardwell LLP, located at 450 Lexington Avenue, New York, NY 10017, at 11:00 a.m. Eastern Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Your vote is very important, regardless of the number of shares you own. We cannot complete the merger and the merger consideration will
not be paid unless (i)&nbsp;CVS Health stockholders approve the issuance of shares of CVS Health common stock in the merger and (ii)&nbsp;Aetna shareholders approve and adopt the merger agreement. Approval of the issuance of shares of CVS Health
common stock in the merger requires the affirmative vote of holders of a majority of the votes cast thereon at the special meeting of stockholders of CVS Health. Approval and adoption of the merger agreement requires the affirmative vote of holders
of at least a majority of the outstanding Aetna common shares entitled to vote thereon. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the special meeting of the stockholders of
CVS Health, CVS Health stockholders will be asked to vote on (i)&nbsp;a proposal to approve the issuance of shares of CVS Health common stock in the merger and (ii)&nbsp;a proposal to approve the adjournment from time to time of the CVS Health
special meeting if necessary to solicit additional proxies if there are not sufficient votes at the time of the CVS Health special meeting, or any adjournment or postponement thereof, to approve the issuance of shares of CVS Health common stock in
the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVS Health&#146;s board of directors unanimously determined that the merger agreement and the transactions contemplated by
the merger agreement, including the merger and the issuance of shares of CVS Health common stock in the merger, are advisable, fair to and in the best interests of CVS Health and its stockholders and unanimously recommends that CVS Health
stockholders vote (i) &#147;FOR&#148; the approval of the issuance of shares of CVS Health common stock in the merger and (ii) &#147;FOR&#148; the approval of the adjournment from time to time of the CVS Health special meeting if necessary to
solicit additional proxies if there are not sufficient votes at the time of the CVS Health special meeting, or any adjournment or postponement thereof, to approve the issuance of shares of CVS Health common stock in the merger. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the special meeting of the shareholders of Aetna, Aetna shareholders will be asked to vote on (i)&nbsp;a proposal to approve and adopt the
merger agreement, (ii)&nbsp;a proposal to approve the adjournment from time to </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time of the Aetna special meeting if necessary to solicit additional proxies if there are not sufficient votes to approve and adopt the merger agreement at the time of the Aetna special meeting
or any adjournment or postponement thereof, and (iii)&nbsp;a proposal to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation that will or may be paid or provided by Aetna to its named executive
officers in connection with the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Aetna&#146;s board of directors unanimously determined that the merger agreement and the
transactions contemplated by the merger agreement (including the merger) are fair to and in the best interests of Aetna and its shareholders and unanimously recommends that Aetna shareholders vote (i) &#147;FOR&#148; the approval and adoption of the
merger agreement, (ii) &#147;FOR&#148; the approval of the adjournment from time to time of the Aetna special meeting if necessary to solicit additional proxies if there are not sufficient votes to approve and adopt the merger agreement at the time
of the Aetna special meeting or any adjournment or postponement thereof, and (iii) &#147;FOR&#148; the proposal to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation that will or may be paid or
provided by Aetna to its named executive officers in connection with the merger. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health expects to issue approximately
280&nbsp;million shares of its common stock to Aetna shareholders in the merger. Based on the number of shares of CVS Health common stock outstanding as of February 5, 2018, and the number of Aetna common shares outstanding as of February 5, 2018,
immediately following completion of the merger, CVS Health stockholders immediately prior to the merger are expected to own approximately 78% of the outstanding shares of CVS Health common stock and former Aetna shareholders are expected to own
approximately 22% of the outstanding shares of CVS Health common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying joint proxy statement/prospectus provides
important information regarding the CVS Health and Aetna special meetings and a detailed description of the merger agreement, the merger, the issuance of shares of CVS Health common stock in the merger, the adjournment proposals and the proposal to
approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation that will or may be paid or provided by Aetna to its named executive officers in connection with the merger. We urge you to read carefully the
accompanying joint proxy statement/prospectus (and any documents incorporated by reference into the accompanying joint proxy statement/prospectus). <B>Please pay particular attention to the section entitled &#147;<A HREF="#rom482402_37">Risk
Factors</A>&#148; beginning on page 62 of the accompanying joint proxy statement/prospectus.</B> You can also obtain information about CVS Health and Aetna from documents that CVS Health and Aetna previously have filed with the Securities and
Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the material U.S. federal income tax consequences of the merger, see &#147;Aetna Proposal I:
Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Material U.S. Federal Income Tax Consequences&#148; beginning on page 167 of the accompanying joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not you expect to attend your company&#146;s special meeting, the details of which are described in the accompanying joint proxy
statement/prospectus, please immediately submit your proxy by telephone, by the Internet or by completing, signing, dating and returning your signed proxy card(s) in the enclosed prepaid return envelope so that your shares may be represented at the
applicable special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If CVS Health stockholders have any questions or require assistance in voting their shares of CVS Health
common stock, they should call Okapi Partners LLC, CVS Health&#146;s proxy solicitor for its special meeting, toll-free at (855) 305-0855 or collect at (212) 297-0720. If Aetna shareholders have any questions or require assistance in voting their
Aetna common shares, they should call Georgeson LLC, Aetna&#146;s proxy solicitor for its special meeting, toll-free at (888) <FONT STYLE="white-space:nowrap">658-3624</FONT> or (781) <FONT STYLE="white-space:nowrap">575-2137</FONT> for
international callers. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hope to see you at the applicable special meeting and look forward to the successful
completion of the merger. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g18f24.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David W. Dorman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the Board of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CVS Health Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g45i23.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark T. Bertolini</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman and Chief Executive Officer of</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Aetna Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g18u21.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Larry J. Merlo</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer of</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CVS Health
Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the
securities to be issued under the accompanying joint proxy statement/prospectus or determined that the accompanying joint proxy statement/prospectus is accurate or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying joint proxy statement/prospectus is dated February 9, 2018 and is first being mailed to stockholders and shareholders on or about February
12, 2018. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The accompanying document is the proxy statement of Aetna Inc. for its special meeting of shareholders, the proxy statement of CVS Health
Corporation for its special meeting of stockholders and the prospectus of CVS Health Corporation for the shares of its common stock to be issued in the merger. The accompanying joint proxy statement/prospectus incorporates by reference important
business and financial information about CVS Health Corporation and Aetna Inc. from documents that are not included in or delivered with the accompanying joint proxy statement/prospectus. You can obtain the documents that are incorporated by
reference into the accompanying joint proxy statement/prospectus (other than certain exhibits or schedules to those documents), without charge, by requesting them in writing or by telephone from CVS Health Corporation or Aetna Inc. at the following
addresses and telephone numbers, or through the Securities and Exchange Commission website at www.sec.gov: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CVS Health Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One CVS Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Woonsocket, RI
02895</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (800) <FONT STYLE="white-space:nowrap">201-0938</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aetna Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 Farmington Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hartford, CT
06156</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (860) <FONT STYLE="white-space:nowrap">273-2402</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In addition, if you have questions about the merger or the accompanying joint proxy statement/prospectus,
would like additional copies of the accompanying joint proxy statement/prospectus or need to obtain proxy cards or other information related to the proxy solicitation, please contact Okapi Partners LLC, the proxy solicitor for CVS Health
Corporation, toll-free at (855) 305-0855 or collect at <FONT STYLE="white-space:nowrap">(212)&nbsp;297-0720,</FONT> or Georgeson LLC, the proxy solicitor for Aetna Inc., toll-free at (888) <FONT STYLE="white-space:nowrap">658-3624</FONT> or (781) <FONT
STYLE="white-space:nowrap">575-2137</FONT> for international callers. You will not be charged for any of these documents that you request. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>To obtain timely delivery of the documents, you must request them no later than five business days before the date of the applicable
special meeting. Therefore, if you would like to request documents from CVS Health Corporation, please do so by March 6, 2018 in order to receive them before the CVS Health Corporation special meeting. If you would like to request documents from
Aetna Inc., please do so by March 6, 2018 in order to receive them before the Aetna Inc. special meeting. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>See &#147;Where You
Can Find More Information&#148; beginning on page 254</B><B> of the accompanying joint proxy statement/prospectus for further information. </B> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g482402g86h55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>One CVS Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Woonsocket, RI 02895 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(401) <FONT STYLE="white-space:nowrap">765-1500</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF CVS HEALTH CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON TUESDAY, MARCH 13, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11:00 a.m. Eastern Time </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the
Stockholders of CVS Health Corporation: </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOTICE IS HEREBY GIVEN that a special meeting of stockholders of CVS Health Corporation, a
Delaware corporation (which is referred to in this notice as CVS Health), will be held at the offices of Shearman &amp; Sterling LLP, located at 599 Lexington Avenue, New York, NY 10022, on Tuesday, March&nbsp;13, 2018, at 11:00 a.m. Eastern Time,
for the following purposes: </B></P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">to consider and vote on a proposal to approve the issuance of shares of CVS Health common stock, par value $0.01&nbsp;per share (which is referred to in this notice as CVS Health common stock), in the merger
contemplated by the Agreement and Plan of Merger, dated as of December&nbsp;3, 2017, as it may be amended from time to time (which is referr </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ed</TD>
<TD ALIGN="left" VALIGN="top">to in this notice as the merger agreement), among CVS Health, Hudson Merger Sub Corp., a Pennsylvania corporation and wholly-owned subsidiary of CVS Health, and Aetna Inc., a Pennsylvania corporation (which is referred
to in this notice at Aetna), pursuant to which Hudson Merger Sub Corp. will be merged with and into Aetna (which is referred to in this notice as the merger), with Aetna surviving the merger as a wholly-owned subsidiary of CVS Health (a copy of the
merger agreement is attached as Annex A to the accompanying joint proxy statement/prospectus); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">to consider and vote on a proposal to approve the adjournment from time to time of the special meeting of stockholders of CVS Health (which is referred to in this notice as the CVS Health special meeting) if necessary
to solicit additional proxies if there are not sufficient votes at the time of the CVS Health special meeting, or any adjournment or postponement thereof, to approve the issuance of shares of CVS Health common stock in the merger. </TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s board of directors has fixed the close of business on February&nbsp;5, 2018 as the record date for the determination of
the stockholders entitled to vote at the CVS Health special meeting or any adjournment or postponement thereof. Only stockholders of record at the record date are entitled to notice of, and to vote at, the CVS Health special meeting or any
adjournment or postponement thereof. CVS Health is commencing its solicitation of proxies on or about February 12, 2018. CVS Health will continue to solicit proxies until the date of the CVS Health special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you plan to attend the CVS Health special meeting, please be prepared to provide valid government-issued photo identification (e.g., a
driver&#146;s license or a passport) to be admitted to the CVS Health special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares of CVS
Health common stock held in &#147;street name,&#148; meaning that your shares are held by a broker, bank or other nominee holder of record at the record date, in addition to proper identification, you will also need an account statement or letter
from the nominee indicating that you were the beneficial owner of the shares at the record date to be admitted to the CVS Health special meeting. If you want to vote your shares of CVS Health common stock held in &#147;street name&#148; in person at
the CVS Health special meeting, you will have to obtain a written legal proxy in your name from the broker, bank or other nominee holder of record that holds your shares. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the issuance of shares of CVS Health common stock in the merger requires the
affirmative vote of a majority of the votes cast at the CVS Health special meeting by holders of shares of CVS Health common stock (assuming a quorum is present). Approval of the adjournment proposal requires the affirmative vote of a majority of
the votes cast at the CVS Health special meeting by holders of shares of CVS Health common stock (whether or not a quorum is present). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVS Health&#146;s board of directors unanimously determined that the merger agreement and the transactions contemplated by the merger
agreement, including the merger and the issuance of shares of CVS Health common stock in the merger, are advisable, fair to and in the best interests of CVS Health and its stockholders and unanimously recommends that CVS Health stockholders vote (i)
&#147;FOR&#148; the approval of the issuance of shares of CVS Health common stock in the merger and (ii) &#147;FOR&#148; the approval of the adjournment from time to time of the CVS Health special meeting if necessary to solicit additional proxies
if there are not sufficient votes at the time of the CVS Health special meeting, or any adjournment or postponement thereof, to approve the issuance of shares of CVS Health common stock in the merger. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g09x94.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Colleen M. McIntosh </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President and Corporate Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Woonsocket, Rhode
Island </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 9, 2018 </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>IMPORTANT INFORMATION
IF YOU PLAN TO ATTEND THE CVS HEALTH SPECIAL MEETING IN PERSON: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Don&#146;t forget your government-issued ID (e.g., a driver&#146;s license or
passport). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you hold your shares of CVS Health common stock through a brokerage account (in &#147;street name&#148;), you will also need an
account statement or letter from the nominee indicating that you were the beneficial owner of the shares at the record date to be admitted to the CVS Health special meeting. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Please leave all cameras, audio and video recording devices, cell phones and other electronic devices at home. They will not be allowed in the meeting
room. </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR VOTE IS IMPORTANT! </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHETHER OR NOT YOU EXPECT TO ATTEND THE CVS HEALTH SPECIAL MEETING IN PERSON, WE URGE YOU TO SUBMIT YOUR PROXY AS PROMPTLY AS POSSIBLE
(1)</B><B></B><B>&nbsp;VIA THE INTERNET, (2)</B><B></B><B>&nbsp;BY TELEPHONE OR (3)</B><B></B><B>&nbsp;BY COMPLETING, SIGNING AND DATING THE ENCLOSED CVS HEALTH PROXY CARD AND RETURNING IT IN THE POSTAGE-PAID ENVELOPE PROVIDED. IF YOU ATTEND THE CVS
HEALTH SPECIAL MEETING IN PERSON</B> <B>AND WISH TO VOTE YOUR SHARES OF CVS HEALTH COMMON STOCK AT THE CVS HEALTH SPECIAL MEETING, YOU MAY DO SO AT ANY TIME PRIOR TO THE CLOSING OF THE POLLS AT THE CVS HEALTH SPECIAL MEETING</B>. You may revoke your
proxy or change your vote for shares of CVS Health common stock you hold directly in your name by (i)&nbsp;signing another proxy card with a later date and delivering it to Broadridge Financial Solutions, Inc. before the date of the CVS Health
special meeting, (ii)&nbsp;submitting revised votes over the Internet or by telephone before 11:59 p.m. Eastern Time on March 12, 2018, or (iii)&nbsp;attending the CVS Health special meeting in person and voting your shares of CVS Health common
stock at the CVS Health special meeting. If your shares of CVS Health common stock are held in the name of a bank, broker or other nominee holder of record, please follow the instructions on the voting instruction form furnished to you by such
record holder. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We urge you to read the accompanying joint proxy statement/prospectus, including all documents incorporated by
reference into the accompanying joint proxy statement/prospectus, and its annexes carefully and in their entirety. If you have any questions concerning the merger agreement, the merger, the issuance of shares of CVS Health common stock in the
merger, the adjournment proposal, the CVS Health special meeting or the accompanying joint proxy statement/prospectus, would like additional copies of the accompanying joint proxy statement/prospectus or need help voting your shares of CVS Health
common stock, please contact: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g482402g11n44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Okapi Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1212 Avenue of the Americas, 24th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10036 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone
(Toll-Free): (855) 305-0855 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone (Collect): (212) 297-0720 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: cvsproxyinfo@okapipartners.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CVS Health Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One CVS Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Woonsocket, RI 02895
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: <FONT STYLE="white-space:nowrap">(800)&nbsp;201-0938</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: investorinfo@cvshealth.com </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g482402g22g61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>151 Farmington Avenue </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hartford, CT 06156 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(860)
<FONT STYLE="white-space:nowrap">273-0123</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF SPECIAL MEETING OF SHAREHOLDERS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AETNA INC. </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE
HELD ON TUESDAY, MARCH 13, 2018 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11:00 a.m. Eastern Time </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders of Aetna Inc.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOTICE IS HEREBY GIVEN that a special meeting of shareholders of Aetna Inc., a Pennsylvania corporation (which is referred to in this notice
as Aetna), will be held at the offices of Davis Polk &amp; Wardwell LLP, located at 450 Lexington Avenue, New York, NY 10017, on Tuesday, March 13, 2018, at 11:00 a.m. Eastern Time, for the following purposes: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">to consider and vote on a proposal to approve and adopt the Agreement and Plan of Merger, dated as of December&nbsp;3, 2017, as it may be amended from time to time (which is referred to in this notice as the merger
agreement), among CVS Health Corporation, a Delaware corporation (which is referred to in this notice as CVS Health), Hudson Merger Sub Corp., a Pennsylvania corporation and wholly-owned subsidiary of CVS Health, and Aetna, pursuant to which Hudson
Merger Sub Corp. will be merged with and into Aetna (which is referred to in this notice as the merger), with Aetna surviving the merger as a wholly-owned subsidiary of CVS Health (a copy of the merger agreement is attached as Annex A to the
accompanying joint proxy statement/prospectus); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">to consider and vote on a proposal to approve the adjournment from time to time of the special meeting of shareholders of Aetna (which is referred to in this notice as the Aetna special meeting) if necessary to solicit
additional proxies if there are not sufficient votes to approve and adopt the merger agreement at the time of the Aetna special meeting or any adjournment or postponement thereof; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">to consider and vote on a proposal to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation that will or may be paid or provided by Aetna to its named executive officers
in connection with the merger. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of record of Aetna common shares, par value $0.01 per share (which are
referred to in this notice as Aetna common shares), at the close of business on February&nbsp;5, 2018 are entitled to notice of and to vote at the Aetna special meeting or any adjournment or postponement thereof. Aetna is commencing its solicitation
of proxies on or about February 12, 2018. Aetna will continue to solicit proxies until the date of the Aetna special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold
Aetna common shares in your name at the record date and plan to attend the Aetna special meeting, because of security procedures, you will need to obtain an admission ticket in advance. In addition to obtaining an admission ticket in advance, you
will be required to provide valid government-issued photo identification (e.g., a driver&#146;s license or a passport) to be admitted to the Aetna special meeting. You may apply for an admission ticket by mail to Office of the Corporate Secretary,
151 Farmington Avenue, RW61, Hartford, CT 06156 or by facsimile to (860) <FONT STYLE="white-space:nowrap">293-1361.</FONT> Ticket requests will not be accepted by phone or email. Aetna&#146;s Corporate Secretary must receive your request for an
admission ticket on or before March 6, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of Aetna common shares held in &#147;street name,&#148;
meaning that your shares are held by a broker, bank or other nominee holder of record at the record date, and you plan to attend the Aetna special meeting, in addition to following the security procedures described above, you will also need to
provide proof of beneficial ownership at the record date to obtain your admission ticket for the Aetna special meeting. A brokerage statement or letter from a bank or broker are examples of proof of beneficial ownership. If you wish to vote your
Aetna common shares held in &#147;street name&#148; in person at the Aetna special meeting, you will have to obtain a written legal proxy in your name from the broker, bank or other nominee holder of record who holds your shares. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval and adoption of the merger agreement requires the affirmative vote, in person or by
proxy, of the holders of a majority of the Aetna common shares outstanding and entitled to vote thereon. Approval of the adjournment proposal requires the affirmative vote of a majority of the votes cast at the Aetna special meeting by holders of
Aetna common shares (whether or not a quorum, as defined under Pennsylvania law, is present). Approval of the proposal to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation that will or may be paid
or provided by Aetna to its named executive officers in connection with the merger requires the affirmative vote of a majority of the votes cast at the Aetna special meeting by holders of Aetna common shares (assuming a quorum, as defined under
Pennsylvania law, is present). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Aetna&#146;s board of directors unanimously determined that the merger agreement and the transactions
contemplated by the merger agreement (including the merger) are fair to and in the best interests of Aetna and its shareholders and unanimously recommends that Aetna shareholders vote (i)&nbsp;&#147;FOR&#148; the proposal to approve and adopt the
merger agreement, (ii)&nbsp;&#147;FOR&#148; the proposal to approve the adjournment from time to time of the Aetna special meeting if necessary to solicit additional proxies if there are not sufficient votes to approve and adopt the merger agreement
at the time of the Aetna special meeting or any adjournment or postponement thereof and (iii)&nbsp;&#147;FOR&#148; the proposal to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation that will or may
be paid or provided by Aetna to its named executive officers in connection with the merger. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Aetna special meeting will be
audiocast live on the Internet at www.aetna.com/investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors, </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g85b19.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam F. McAnaney </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice
President and Corporate Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford, Connecticut </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 9, 2018 </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>IMPORTANT INFORMATION IF YOU PLAN TO
ATTEND THE AETNA SPECIAL MEETING IN PERSON: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em" ALIGN="center">


<IMG SRC="g482402g27l76.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">Don&#146;t forget your admission ticket and government-issued ID (e.g., a driver&#146;s license or passport).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">


<IMG SRC="g482402g54x49.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">You must request an admission ticket in advance by following the instructions on pages 10 and 82 of the accompanying joint proxy
statement/prospectus. Aetna&#146;s Corporate Secretary must receive your written request for an admission ticket on or before March 6, 2018.</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you hold your Aetna common shares through a brokerage account (in &#147;street name&#148;), your request for an
admission ticket must include a copy of a brokerage statement reflecting stock ownership as of the record date. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Please leave all weapons,
cameras, audio and video recording devices and other electronic devices at home. They will not be allowed in the meeting room. </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR VOTE IS IMPORTANT! </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHETHER OR NOT YOU EXPECT TO ATTEND THE AETNA SPECIAL MEETING IN PERSON, WE URGE YOU TO SUBMIT YOUR PROXY AS PROMPTLY AS POSSIBLE
(1)</B><B></B><B>&nbsp;VIA THE INTERNET, (2)</B><B></B><B>&nbsp;BY TELEPHONE OR (3)</B><B></B><B>&nbsp;BY COMPLETING, SIGNING AND DATING THE ENCLOSED AETNA PROXY CARD AND RETURNING IT IN THE POSTAGE-PAID ENVELOPE PROVIDED. IF YOU ATTEND THE AETNA
SPECIAL MEETING IN PERSON AND WISH TO VOTE YOUR SHARES AT THE AETNA SPECIAL MEETING, YOU MAY DO SO AT ANY TIME PRIOR TO THE CLOSING OF THE POLLS AT THE AETNA SPECIAL MEETING. </B>You may revoke your proxy or change your vote for Aetna common shares
you hold directly in your name by (i)&nbsp;signing another proxy card with a later date and delivering it to Broadridge Financial Solutions, Inc. before the date of the Aetna special meeting, (ii)&nbsp;submitting revised votes over the Internet or
by telephone before 11:59 p.m. Eastern Time on March 12, 2018, or (iii)&nbsp;attending the Aetna special meeting in person and voting your Aetna common shares at the Aetna special meeting. If your Aetna common shares are held in the name of a bank,
broker or other nominee holder of record, please follow the instructions on the voting instruction form furnished to you by such record holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We urge you to read the accompanying joint proxy statement/prospectus, including all documents incorporated by reference into the accompanying
joint proxy statement/prospectus, and its annexes carefully and in their entirety. If you have any questions concerning the merger agreement, the merger, the vote on the merger agreement, the adjournment proposal, the advisory <FONT
STYLE="white-space:nowrap">(non-binding)</FONT> proposal to approve the compensation that will or may be paid or provided by Aetna to its named executive officers in connection with the merger, the Aetna special meeting or the accompanying joint
proxy statement/prospectus, would like additional copies of the accompanying joint proxy statement/prospectus or need help voting your Aetna common shares, please contact: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g482402g04o86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Georgeson LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1290 Avenue of the Americas, 9th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10104 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone
(Toll-Free): (888) <FONT STYLE="white-space:nowrap">658-3624</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">International Callers: (781)
<FONT STYLE="white-space:nowrap">575-2137</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: aetna@georgeson.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aetna Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 Farmington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hartford, CT
06156 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: <FONT STYLE="white-space:nowrap">(860)&nbsp;273-2402</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: investorrelations@aetna.com </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_1">QUESTIONS AND ANSWERS ABOUT THE MERGER AND THE SPECIAL
MEETINGS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_3">The Companies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_4">The Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_5">Special Meeting of Stockholders of CVS Health</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_6">Special Meeting of Shareholders of Aetna</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_7">What Aetna Shareholders Will Receive in the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_8">Treatment of Aetna Equity Awards</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_9">Recommendations of the Aetna Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_10">Recommendations of the CVS Health Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_11">Opinions of Aetna&#146;s Financial Advisors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_12">Opinions of CVS Health&#146;s Financial Advisors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_13">Ownership of CVS Health Common Stock After the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_14">Governance and Social Matters Following Completion of the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_15">Interests of Aetna&#146;s Directors and Executive Officers in the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_16">Listing of CVS Health Common Stock; Delisting and Deregistration of Aetna Common
 Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_17">Appraisal or Dissenters&#146; Rights Not Available to Aetna
Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_18">Completion of the Merger Is Subject to Certain Conditions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_19">The Merger May Not Be Completed Without All Required Regulatory
Approvals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_20">Description of Debt Financing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_21">CVS Health and Aetna Expect the Merger to be Completed in the Second Half of
 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_22">No Solicitation by Aetna or CVS Health</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_23">Termination of the Merger Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_24">Termination Fees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_25">Specific Performance; Remedies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_26">Material U.S. Federal Income Tax Consequences</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_27">Accounting Treatment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_28">Rights of Aetna Shareholders Will Change as a Result of the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_28a">Litigation Relating to the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_29">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_30">SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF CVS HEALTH</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_31">SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF AETNA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_32">COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA COMBINED PER SHARE
DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_33">CVS HEALTH AND AETNA UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_34">COMPARATIVE PER SHARE MARKET PRICE AND DIVIDEND INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_35">Market Prices</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_36">Dividends</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_37">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_38">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_39">THE COMPANIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_40">CVS Health Corporation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_41">Aetna Inc.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_42">Hudson Merger Sub Corp.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_43">SPECIAL MEETING OF STOCKHOLDERS OF CVS HEALTH</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_44">Date, Time and Location</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_45">Purpose</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_46">Recommendations of the CVS Health Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_47">CVS Health Record Date; Outstanding Shares; Stockholders Entitled to
Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_48">Quorum</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_49">Required Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_50">Stock Ownership of and Voting by CVS Health Directors and Executive Officers
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_51">Voting of Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_52">Revocability of Proxies; Changing Your Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_53">Solicitation of Proxies; Expenses of Solicitation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_54">Householding</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_55">Adjournment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_56">Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_57">Assistance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_58">SPECIAL MEETING OF SHAREHOLDERS OF AETNA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_59">Date, Time and Location</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_60">Purpose</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_61">Recommendations of the Aetna Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_62">Aetna Record Date; Outstanding Shares; Shareholders Entitled to
Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_63">Quorum</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_64">Required Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_65">Share Ownership of and Voting by Aetna Directors and Executive
Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_66">Voting of Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_67">Revocability of Proxies; Changing Your Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_68">Solicitation of Proxies; Expenses of Solicitation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_69">Householding</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_70">Adjournment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_71">Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_72">Assistance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_73">AETNA PROPOSAL I: APPROVAL AND ADOPTION OF THE MERGER AGREEMENT AND CVS HEALTH
 PROPOSAL I: APPROVAL OF THE STOCK ISSUANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_74">General</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_75">Background of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_76">Certain Relationships between CVS Health and Aetna</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_77">Aetna&#146;s Reasons for the Merger; Recommendation of the Aetna Board of Directors
 that Aetna Shareholders Approve and Adopt the Merger Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_78">CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board
of Directors that CVS Health Stockholders Approve the Stock Issuance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_79">Opinions of Aetna&#146;s Financial Advisors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_80">Opinions of CVS Health&#146;s Financial Advisors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_81">Unaudited Prospective Financial Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_82">Regulatory Approvals Required for the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_83">No Appraisal or Dissenters&#146; Rights for Aetna
Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_84">Material U.S. Federal Income Tax Consequences</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_85">Accounting Treatment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_86">Listing of CVS Health Common Stock; Delisting and Deregistration of Aetna Common
 Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_87a">Description of Debt Financing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_87b">Litigation Relating to the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_88">THE MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_89">Structure of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_90">Completion and Effectiveness of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_91">Merger Consideration</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_92">Fractional Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_93">No Appraisal or Dissenters&#146; Rights for Aetna
Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_94">Procedures for Surrendering Aetna Share Certificates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_95">Treatment of Aetna Equity Awards</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_96">Listing of CVS Health Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_97">Governance and Social Matters Following Completion of the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_98">Conditions to Completion of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_99">Representations and Warranties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_100">Definition of &#147;Material Adverse Effect&#148;</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_101">Conduct of Business Pending the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_102">Obligations to Call Shareholders&#146; and Stockholders&#146;
Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_103">Obligations to Recommend the Approval and Adoption of the Merger Agreement and
 the Approval of the Stock Issuance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_104">No Solicitation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_105">Reasonable Best Efforts Covenant</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_106">Financing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_107">Proxy Statement and Registration Statement Covenant</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_108">Indemnification and Insurance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_109">Employee Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_110">Other Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_111">Termination of the Merger Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_112">Termination Fees and Expenses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_113">Exclusive Remedy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_114">Other Expenses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_115">Specific Performance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_116">Third-Party Beneficiaries</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_117">Amendments; Waivers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_118">INTERESTS OF AETNA&#146;S DIRECTORS AND EXECUTIVE OFFICERS IN THE
MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_119">Continuing Board Service</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_120">Treatment of Outstanding Aetna Equity Awards</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_121">Vested Equity Interests of Aetna&#146;s Directors and Executive
Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_122">Unvested Equity Interests of Aetna&#146;s Directors and Executive Officers
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_123">Deferred Compensation Programs</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_124">Arrangements with CVS Health</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_125">Director and Officer Indemnification</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_126">Mr.&nbsp;Bertolini&#146;s Employment Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_127">Ms.&nbsp;Lynch&#146;s Employment Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_128">Letter Agreements with Other Named Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_129">Other Severance Arrangements with Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_130">Restrictive Covenants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_131">Annual Incentive Plans</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_132">280G Mitigation Payments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_133">Quantification of Potential Payments to Aetna Named Executive Officers in Connection
with the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_134">AETNA PROPOSAL II: ADJOURNMENT OF THE AETNA SPECIAL MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_135">AETNA PROPOSAL III: ADVISORY VOTE ON MERGER-RELATED EXECUTIVE COMPENSATION ARRANGEMENTS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_136">CVS HEALTH PROPOSAL II: ADJOURNMENT OF THE CVS HEALTH SPECIAL
MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_137">DESCRIPTION OF CVS HEALTH CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_138">Authorized Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_139">CVS Health Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_140">No Preemptive Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_141">Book-Entry Shareholding</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_142">CVS Preferred Stock and Preference Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_143">Provisions Relating to Amendments to CVS Health&#146;s Certificate of Incorporation
 and <FONT STYLE="white-space:nowrap">By-Laws</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_144">COMPARISON OF STOCKHOLDER RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_145">Material Differences in Stockholder Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_146">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_147">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_148">FUTURE STOCKHOLDER PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_149">CVS Health</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_150">Aetna</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_151">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_152">ANNEXES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_153">Annex A&#151;Agreement and Plan of Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A&#150;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_154">Annex B&#151;Opinion of Lazard Fr&egrave;res&nbsp;&amp; Co.
LLC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B&#150;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_155">Annex C&#151;Opinion of Allen&nbsp;&amp; Company LLC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">C&#150;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_156">Annex D&#151;Opinion of Barclays Capital Inc.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D&#150;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_157">Annex E&#151;Goldman Sachs&nbsp;&amp; Co. LLC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">E&#150;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_158">Annex F&#151;Centerview Partners LLC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F&#150;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom482402_159">PART II INFORMATION NOT REQUIRED IN THE PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">II&#150;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_1"></A>QUESTIONS AND ANSWERS ABOUT THE MERGER AND THE SPECIAL MEETINGS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following are some questions that you, as a stockholder of CVS Health Corporation, which is referred to in this joint proxy
statement/prospectus as CVS Health, or a shareholder of Aetna Inc., which is referred to in this joint proxy statement/prospectus as Aetna, may have regarding the merger, the stock issuance, the Aetna adjournment proposal, the CVS Health adjournment
proposal, the Aetna compensation advisory proposal and the special meetings as well as brief answers to those questions. You are urged to read carefully this joint proxy statement/prospectus, including all documents incorporated by reference into
this joint proxy statement/prospectus, and its annexes, in their entirety because this section may not provide all of the information that is important to you with respect to the merger, the stock issuance, the Aetna adjournment proposal, the CVS
Health adjournment proposal, the Aetna compensation advisory proposal and the special meetings. Additional important information is contained in the annexes to, and the documents incorporated by reference into, this joint proxy statement/prospectus.
See &#147;Where You Can Find More Information&#148; beginning on page 254 of this joint proxy statement/prospectus. </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Why am I receiving this document and why am I being asked to vote on the merger agreement? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">CVS Health and Aetna have agreed to a merger, which is referred to in this joint proxy statement/prospectus as the merger, pursuant to which Aetna will become a wholly-owned subsidiary of CVS Health and will no longer
be a publicly traded corporation. In order to complete the merger, CVS Health stockholders must vote to approve the issuance of shares of CVS Health common stock to Aetna shareholders in the merger, which issuance is referred to in this joint proxy
statement/prospectus as the stock issuance, and Aetna shareholders must vote to approve and adopt the Agreement and Plan of Merger, dated as of December&nbsp;3, 2017, among CVS Health, Aetna and Hudson Merger Sub Corp., a wholly-owned subsidiary of
CVS Health that is referred to in this joint proxy statement/prospectus as Merger Sub. This merger agreement, as it may be amended from time to time, is referred to in this joint proxy statement/prospectus as the merger agreement. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aetna is holding a special meeting of shareholders, which is referred to in this joint proxy statement/prospectus as the Aetna special meeting,
in order to obtain the shareholder approval necessary to approve and adopt the merger agreement. <B>Approval and adoption of the merger agreement requires the affirmative vote of holders of at least a majority of the outstanding Aetna common shares
entitled to vote thereon.</B> Aetna shareholders will also be asked to approve the adjournment from time to time of the Aetna special meeting if necessary to solicit additional proxies if there are not sufficient votes to approve and adopt the
merger agreement at the time of the Aetna special meeting or any adjournment or postponement thereof, which is referred to in this joint proxy statement/prospectus as the Aetna adjournment proposal, and to approve, on an advisory <FONT
STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation that will or may be paid or provided by Aetna to its named executive officers, who are referred to in this joint proxy statement/prospectus as the named executive officers, in
connection with the merger, which is referred to in this joint proxy statement/prospectus as the Aetna compensation advisory proposal. <B>It is important that Aetna&#146;s shareholders vote their Aetna common shares on each of these matters,
regardless of the number of shares owned.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CVS Health is holding a special meeting of stockholders, which is referred to in this joint
proxy statement/prospectus as the CVS Health special meeting, in order to obtain the stockholder approval necessary to approve the stock issuance. <B>Approval of the stock issuance requires the affirmative vote of holders of a majority of the votes
cast thereon at the CVS Health special meeting. </B>CVS Health stockholders will also be asked to approve the adjournment from time to time of the CVS Health special meeting if necessary to solicit additional proxies if there are not sufficient
votes at the time of the CVS Health special meeting, or any adjournment or postponement thereof, to approve the stock issuance, which is referred to in this joint proxy statement/prospectus as the CVS Health adjournment proposal. <B>It is important
that CVS Health&#146;s shareholders vote their shares of CVS Health common stock on each of these matters, regardless of the number of shares owned.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This document is being delivered to you as both a joint proxy statement of Aetna and CVS
Health and a prospectus of CVS Health in connection with the merger and the stock issuance. It is the proxy statement by which Aetna&#146;s board of directors is soliciting proxies from Aetna shareholders to vote at the Aetna special meeting, or at
any adjournment or postponement of the Aetna special meeting, on the approval and adoption of the merger agreement, the approval of the Aetna adjournment proposal and the approval, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT>
basis, of the Aetna compensation advisory proposal. It is also the proxy statement by which CVS Health&#146;s board of directors is soliciting proxies from CVS Health stockholders to vote at the CVS Health special meeting, or at any adjournment or
postponement of the CVS Health special meeting, on the approval of the stock issuance and the approval of the CVS Health adjournment proposal. In addition, this document is the prospectus of CVS Health pursuant to which CVS Health will issue shares
of CVS Health common stock to Aetna shareholders as part of the merger consideration. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Is my vote important? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"><B>Yes, your vote is very important</B>. For Aetna shareholders, an abstention from voting or a failure to vote will have the same effect as a vote <B>&#147;AGAINST&#148;</B> the approval and adoption of the merger
agreement. If you hold your Aetna common shares through a broker, bank or other nominee holder of record and you do not give voting instructions to that broker, bank or other nominee holder of record, that broker, bank or other nominee holder of
record will not be able to vote your shares on the approval and adoption of the merger agreement, and your failure to give those instructions will have the same effect as a vote <B>&#147;AGAINST&#148;</B> the approval and adoption of the merger
agreement. Aetna&#146;s board of directors unanimously recommends that Aetna shareholders vote <B>&#147;FOR&#148;</B> the approval and adoption of the merger agreement, and CVS Health&#146;s board of directors unanimously recommends that CVS Health
stockholders vote <B>&#147;FOR&#148;</B> the approval of the stock issuance. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What will happen in the merger? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">In the merger, Merger Sub will be merged with and into Aetna. Aetna will be the surviving corporation in the merger and will be a wholly-owned subsidiary of CVS Health following completion of the merger and will no
longer be a publicly traded corporation. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What will Aetna shareholders receive in the merger? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">If the merger is completed, each Aetna common share automatically will be cancelled and converted into the right to receive $145.00 in cash without interest thereon, which is referred to in this joint proxy
statement/prospectus as the cash consideration, and 0.8378 of a share of CVS Health common stock, which is referred to in this joint proxy statement/prospectus as the share consideration. The cash consideration and the share consideration are
collectively referred to in this joint proxy statement/prospectus as the merger consideration. Each Aetna shareholder will be entitled to receive cash for any fractional share of CVS Health common stock that the Aetna shareholder would otherwise be
entitled to receive in the merger. </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Based on the closing price of shares of CVS Health common stock on the New York Stock
Exchange, which is referred to in this joint proxy statement/prospectus as the NYSE, on October&nbsp;25, 2017, the last trading day prior to news reports of a potential transaction between CVS Health and Aetna, which is referred to in this joint
proxy statement/prospectus as the unaffected date, the merger consideration represented approximately $208.28 in value for each Aetna common share. Based on the closing price of shares of CVS Health common stock on the NYSE on February 8, 2018, the
most recent trading day prior to the date of this joint proxy statement/prospectus for which this information was available, the merger consideration represented approximately $204.11 in value for each Aetna common share. <B>Because CVS Health will
issue a fixed fraction of a share of CVS Health common stock in exchange for each Aetna common share, the value of the share consideration will depend on the market price of shares of CVS Health common stock at the time the merger is completed. The
market price of shares of CVS Health common stock when</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<B>Aetna shareholders receive those shares after the merger is completed could be greater than, less than or the same as the market price of shares of CVS Health common stock on the date of
this</B> <B>joint proxy statement/prospectus or at the time of the Aetna special meeting or any adjournment or postponement thereof.</B> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What happens if the merger is not completed? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">If the merger agreement is not approved and adopted by Aetna shareholders, the stock issuance is not approved by CVS Health stockholders or if the merger is not completed for any other reason, Aetna shareholders will
not receive any payment for their Aetna common shares in connection with the merger. Instead, Aetna will remain an independent public company and its common shares will continue to be listed and traded on the NYSE. If the merger agreement is
terminated under specified circumstances, Aetna may be required to pay CVS Health a termination fee of $2.1&nbsp;billion, and if the merger agreement is terminated under certain other circumstances, CVS Health may be required to pay Aetna a
termination fee of $2.1&nbsp;billion. See &#147;The Merger Agreement&#151;Termination Fees and Expenses&#148; beginning on page 205 of this joint proxy statement/prospectus for a more detailed discussion of the termination fees. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What are Aetna shareholders being asked to vote on? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Aetna shareholders are being asked to vote on the following three proposals: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve and adopt the merger agreement, a copy of which is attached as Annex A to this joint proxy statement/prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve the Aetna adjournment proposal; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the Aetna compensation advisory proposal. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The approval and adoption of the merger agreement by Aetna shareholders is a condition to the obligations of Aetna and CVS Health to complete
the merger. Neither the approval of the Aetna adjournment proposal nor the approval of the Aetna compensation advisory proposal is a condition to the obligations of Aetna or CVS Health to complete the merger. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What are CVS Health stockholders being asked to vote on? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">CVS Health stockholders are being asked to vote on the following proposals: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve the stock issuance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve the CVS Health adjournment proposal. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The approval of the stock issuance by CVS
Health stockholders is a condition to the obligations of Aetna and CVS Health to complete the merger. The approval of the CVS Health adjournment proposal is not a condition to the obligations of Aetna or CVS Health to complete the merger. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Does Aetna&#146;s board of directors recommend that Aetna shareholders approve and adopt the merger agreement? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Yes. Aetna&#146;s board of directors unanimously determined that the merger agreement and the transactions contemplated by the merger agreement (including the merger) are fair to and in the best interests of Aetna and
its shareholders and unanimously recommends that Aetna shareholders vote <B>&#147;FOR&#148;</B> the approval and adoption of the merger agreement at the Aetna special meeting. See &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement
and CVS Health Proposal I: Approval of the Stock Issuance&#151;Aetna&#146;s Reasons for the Merger; Recommendation of the Aetna Board of Directors that Aetna Shareholders Approve and Adopt the Merger Agreement&#148; beginning on page 101 of this
joint proxy statement/prospectus. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Does Aetna&#146;s board of directors recommend that shareholders approve the Aetna adjournment proposal? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Yes. Aetna&#146;s board of directors unanimously recommends that you vote <B>&#147;FOR&#148;</B> the Aetna adjournment proposal. See &#147;Aetna Proposal II: Adjournment of the Aetna Special Meeting&#148; beginning on
page 219 of this joint proxy statement/prospectus. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What is the Aetna compensation advisory proposal and why am I being asked to vote on it? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">The Securities and Exchange Commission, which is referred to in this joint proxy statement/prospectus as the SEC, has adopted rules that require Aetna to seek an advisory
<FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote on compensation that is tied to or based on completion of the merger and that will or may be paid or provided by Aetna to its named executive officers in connection with the merger.
</TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Does Aetna&#146;s board of directors recommend that Aetna shareholders approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the Aetna compensation advisory proposal?
</I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Yes. The Aetna board of directors unanimously recommends that Aetna shareholders vote <B>&#147;FOR&#148;</B> the Aetna compensation advisory proposal. See &#147;Aetna Proposal III: Advisory Vote On Merger-Related
Executive Compensation Arrangements&#148; beginning on page 220 of this joint proxy statement/prospectus. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What happens if the Aetna compensation advisory proposal is not approved? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Approval of the Aetna compensation advisory proposal is not a condition to the obligations of Aetna or CVS Health to complete the merger. The vote is an advisory vote and is not binding. If the merger is completed,
Aetna may pay the applicable compensation in connection with the merger to its named executive officers even if Aetna shareholders fail to approve the Aetna compensation advisory proposal. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Does CVS Health&#146;s board of directors recommend that CVS Health stockholders approve the stock issuance? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Yes. CVS Health&#146;s board of directors unanimously determined that the stock issuance was advisable, fair to and in the best interests of CVS Health and its stockholders and unanimously recommends that CVS Health
stockholders vote <B>&#147;FOR&#148;</B> the approval of the stock issuance. See &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;CVS Health&#146;s Reasons for the
Merger; Recommendation of the CVS Health Board of Directors that CVS Health Stockholders Approve the Stock Issuance&#148; beginning on page 106 of this joint proxy statement/prospectus. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Does CVS Health&#146;s board of directors recommend that CVS Health stockholders approve the CVS Health adjournment proposal? </I></B></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Yes. CVS Health&#146;s board of directors unanimously recommends that CVS Health stockholders vote <B>&#147;FOR&#148;</B> the CVS Health adjournment proposal. See &#147;CVS Health Proposal II: Adjournment of the CVS
Health Special Meeting&#148; beginning on page 221 of this joint proxy statement/prospectus. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What Aetna shareholder vote is required for the approval of each proposal? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">The following are the vote requirements for the proposals at the Aetna special meeting: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Approval and Adoption of the Merger Agreement</I>: The affirmative vote of holders of at least a majority of the outstanding Aetna common shares entitled to vote on this proposal. Accordingly, an Aetna
shareholder&#146;s abstention from voting, the failure of an Aetna shareholder who holds his or her shares in &#147;street name&#148; through a broker, bank or other nominee holder of record to give voting instructions to that broker, bank or other
nominee holder of record or any other failure of an Aetna shareholder to vote will have the same effect as a vote <B>&#147;AGAINST&#148;</B> this proposal. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Approval of Aetna Adjournment Proposal (if necessary)</I>: A majority of the votes cast affirmatively or negatively on this proposal (whether or not a quorum, as defined under Pennsylvania law, is present).
Accordingly, an Aetna shareholder&#146;s abstention from voting, the failure of an Aetna shareholder who holds his or her shares in &#147;street name&#148; through a broker, bank or other nominee holder of record to give voting instructions to that
broker, bank or other nominee holder of record or any other failure of an Aetna shareholder to vote will have no effect on the approval of this proposal. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Approval of the Aetna Compensation Advisory Proposal</I>: A majority of the votes cast affirmatively or negatively on this proposal (assuming a quorum, as defined under Pennsylvania law, is present). Accordingly, an
Aetna shareholder&#146;s abstention from voting, the failure of an Aetna shareholder who holds his or her shares in &#147;street name&#148; through a broker, bank or other nominee holder of record to give voting instructions to that broker, bank or
other nominee holder of record or any other failure of an Aetna shareholder to vote will have no effect on the approval of this proposal. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What CVS Health stockholder vote is required for the approval of each proposal at the CVS Health special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">The following are the vote requirements for the proposals at the CVS Health special meeting: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Approval of the Stock Issuance</I>: The affirmative vote of a majority of the votes cast at the CVS Health special meeting by holders of shares of CVS Health common stock (assuming a quorum is present). Under the
current rules and interpretive guidance of the NYSE, &#147;votes cast&#148; on the stock issuance consist of votes &#147;for&#148; or &#147;against&#148; as well as elections to abstain from voting on the stock issuance. As a result, a CVS Health
stockholder&#146;s election to abstain from voting on the stock issuance will have the same effect as a vote <B>&#147;AGAINST&#148;</B> the approval of this proposal. The failure of a CVS Health stockholder who holds his or her shares in
&#147;street name&#148; through a broker, bank or other nominee holder of record to give voting instructions to that broker, bank or other nominee holder of record or any other failure of a CVS Health stockholder to vote will have no effect on the
approval of this proposal because these failures to vote are not considered &#147;votes cast.&#148; However, these failures to vote will make it more difficult to meet the requirement under Delaware law that the holders of a majority of the
outstanding shares of CVS Health common stock entitled to vote at the CVS Health special meeting be present in person or represented by proxy to constitute a quorum at the CVS Health special meeting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Approval of the CVS Health Adjournment Proposal (if necessary)</I>: The affirmative vote of a majority of the votes cast at the CVS Health special meeting by CVS Health stockholders (whether or not a quorum, as
defined under Delaware law, is present). For purposes of the CVS Health adjournment proposal, &#147;votes cast&#148; means votes &#147;for&#148; or &#147;against&#148; the proposal. As a result, a CVS Health stockholder&#146;s election to abstain
from voting, the failure of a CVS Health stockholder who holds his or her shares in &#147;street name&#148; through a broker, bank or other holder of record to give voting instructions to that broker, bank or other holder of record or any other
failure of a CVS Health stockholder to vote will have no effect on the approval of this proposal. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What constitutes a quorum for the Aetna special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">The holders of a majority of the outstanding Aetna common shares entitled to vote being present in person or represented by proxy constitutes a quorum for the Aetna special meeting. Aetna common shares whose holders
elect to abstain from voting will be deemed present at the Aetna special meeting for the purpose of determining the presence of a quorum. Aetna common shares held in &#147;street name&#148; with respect to which the beneficial owner fails to give
voting instructions to the broker, bank or other nominee holder of record will not be deemed present at the Aetna special meeting for the purpose of determining the presence of a quorum. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What constitutes a quorum for the CVS Health special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">A majority of the outstanding shares of CVS Health common stock entitled to vote being present in person or represented by proxy constitutes a quorum for the CVS Health special meeting. Elections to abstain from voting
will be deemed present at the CVS Health special meeting for the purpose of determining the presence of a quorum. Shares of CVS Health common stock held in &#147;street name&#148; with respect to which the beneficial owner fails to give voting
instructions to the broker, bank or other nominee holder of record will not be deemed present at the CVS Health special meeting for the purpose of determining the presence of a quorum. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Who is entitled to vote at the Aetna special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">All holders of Aetna common shares who held shares at the record date for the Aetna special meeting (the close of business on February&nbsp;5, 2018) are entitled to receive notice of, and to vote at, the Aetna special
meeting. As of the close of business on February 5, 2018, there were 326,942,525 Aetna common shares outstanding. Each holder of Aetna common shares is entitled to one vote for each Aetna common share owned at the record date. </TD></TR></TABLE>
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Who is entitled to vote at the CVS Health special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">All holders of shares of CVS Health common stock who held shares at the record date for the CVS Health special meeting (the close of business on February&nbsp;5, 2018) are entitled to receive notice of, and to vote at,
the CVS Health special meeting. As of the close of business on February&nbsp;5, 2018, there were 1,015,460,751 shares of CVS Health common stock outstanding. Each holder of shares of CVS Health common stock is entitled to one vote for each share of
CVS Health common stock owned at the record date. </TD></TR></TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What if I hold shares in both Aetna and CVS Health? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">If you are both an Aetna shareholder and a CVS Health stockholder, you will receive separate packages of proxy materials from each company. A vote as an Aetna shareholder for the approval and adoption of the merger
agreement (or any other proposal to be considered at the Aetna special meeting) will not constitute a vote as a CVS Health stockholder to approve the stock issuance (or any other proposal to be considered at the CVS Health special meeting), and vice
versa. <B>Therefore, please complete, sign and date and return all proxy cards and/or voting instructions that you receive from Aetna or CVS Health, or submit your proxy or voting instructions for each set of voting materials over the Internet or by
telephone in order to ensure that all of your shares are voted. </B> </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>When and where is the Aetna special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">The Aetna special meeting will be held on March 13, 2018, at the offices of Davis Polk &amp; Wardwell LLP, located at 450 Lexington Avenue, New York, NY 10017, at 11:00 a.m. Eastern Time. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>When and where is the CVS Health special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">The CVS Health special meeting will be held on March 13, 2018, at the offices of Shearman &amp; Sterling LLP, located at 599 Lexington Avenue, New York, NY 10022, at 11:00 a.m. Eastern Time. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>How do I vote my shares at the Aetna special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"><I>Via the Internet or by Telephone</I> </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares directly in your
name as a shareholder of record, you may vote via the Internet at www.proxyvote.com or by telephone by calling <FONT STYLE="white-space:nowrap">(800)&nbsp;690-6903</FONT> toll-free. In order to vote your shares via the Internet or by telephone, you
will need the control number on your proxy card (which is unique to each Aetna shareholder to ensure all voting instructions are genuine and to prevent duplicate voting). Votes may be submitted via the Internet or by telephone, 24 hours a day, seven
days a week, and must be received by 11:59 p.m. (Eastern Time) on March 12, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares in &#147;street name,&#148; meaning through a broker, bank
or other nominee holder of record, you may submit voting instructions via the Internet or by telephone only if Internet or telephone voting is made available by your broker, bank or other nominee holder of record. Please follow the voting
instructions provided by your broker, bank or other nominee holder of record with these materials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>By Mail </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares directly in your name as a shareholder of record, in order to vote by mail, you may submit a proxy card. You
will need to complete, sign and date your proxy card and return it using the postage-paid return envelope provided or return it to Vote Processing, c/o Broadridge Financial Solutions, Inc., 51 Mercedes Way, Edgewood, New York 11717. Broadridge
Financial Solutions, Inc., which is referred to in this joint proxy statement/prospectus as Broadridge, must receive your proxy card no later than the close of business on March 12, 2018. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares in &#147;street name,&#148; meaning through a broker, bank or other nominee holder of record, in order to
provide voting instructions by mail you will need to complete, sign and date the voting instruction form provided by your broker, bank or other nominee holder of record with these materials and return it in the postage-paid return envelope provided.
Your broker, bank or other nominee holder of record must receive your voting instruction form in sufficient time to vote your shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>In Person </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold
Aetna common shares directly in your name as a shareholder of record, you may vote in person at the Aetna special meeting. Shareholders of record also may be represented by another person at the Aetna special meeting by executing a proper proxy
designating that person and having that proper proxy be presented to the judge of election with the applicable ballot at the Aetna special meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares in &#147;street name,&#148; meaning through a broker, bank or other nominee holder of record, you must obtain a
written legal proxy from that institution and present it to the judge of election with your ballot to be able to vote in person at the Aetna special meeting. To request a legal proxy, please contact your broker, bank or other nominee holder of
record. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Please carefully consider the information contained in this joint proxy statement/prospectus. Whether or not you plan to attend
the Aetna special meeting, Aetna encourages you to vote via the Internet, by telephone or by mail so that your shares will be voted in accordance with your wishes even if you later decide not to attend the Aetna special meeting. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aetna encourages you to register your vote via the Internet, by telephone or by mail. If you attend the Aetna special meeting, you may also
vote in person, in which case any votes that you previously submitted&#151;whether via the Internet, by telephone or by mail&#151;will be revoked and superseded by the vote that you cast at the Aetna special meeting. Your attendance at the Aetna
special meeting alone will not revoke any proxy previously given. To vote in person at the Aetna special meeting, beneficial owners who hold shares in &#147;street name&#148; through a broker, bank or other nominee holder of record will need to
contact the broker, bank or other nominee holder of record to obtain a written legal proxy to bring to the meeting. Whether your proxy is submitted via the Internet, by telephone or by mail, if it is properly completed and submitted, and if you do
not revoke it prior to or at the Aetna special meeting, your shares will be voted at the Aetna special meeting in the manner specified by you, except as otherwise set forth in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>You may vote via the Internet or by telephone until 11:59 p.m. (Eastern Time) on March 12, 2018, or Broadridge must receive your proxy card
by mail no later than the close of business on March 12, 2018. </B></P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>If my Aetna common shares are held in &#147;street name,&#148; will my broker, bank or other nominee holder of record automatically vote my shares for me? </I></B></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No. If your shares are held in an account at a broker, bank or other nominee holder of record (i.e., in
&#147;street name&#148;), you must instruct the broker, bank or other nominee holder of record on how to vote your shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Your broker, bank or other nominee holder of record will vote your shares only if you provide instructions on how to vote by filling out the voting instruction form sent to you by your broker,
bank or other nominee holder of record with this joint proxy statement/prospectus. Brokers, banks and other nominee holders of record who hold Aetna common shares in &#147;street name&#148; typically have the authority to vote in their discretion on
&#147;routine&#148; proposals when they have not received instructions on how to vote from the beneficial owner. However, brokers, banks and other nominee holders of record typically are not allowed to exercise their voting discretion on matters
that are <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> without specific instructions on how to vote from the beneficial owner. Under the current rules of the NYSE, each of the three proposals to be considered at the Aetna special
meeting as described in this joint proxy statement/prospectus are considered <FONT STYLE="white-space:nowrap">non-routine.</FONT> Therefore brokers, banks and other nominee holders of record do not have discretionary authority to vote on any of the
three proposals to be considered at the Aetna special meeting. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are
shares held by a broker, bank or other nominee holder of record that are present in person or represented by proxy at the Aetna special meeting, but with respect to which the broker, bank or other nominee holder of record is not instructed by the
beneficial owner of such shares on how to vote on a particular proposal and the broker does not have discretionary voting power on such proposal. Because brokers, banks and other nominee holders of record do not have discretionary voting authority
with respect to any of the three proposals to be considered at the Aetna special meeting as described in this joint proxy statement/prospectus, if a beneficial owner of Aetna common shares held in &#147;street name&#148; does not give voting
instructions to the broker, bank or other nominee holder of record, then those shares will not be present in person or represented by proxy at the Aetna special meeting. As a result, there will not be any broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with any of the three proposals to be considered at the Aetna special meeting as described in this joint proxy statement/prospectus. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>How will my shares be represented at the Aetna special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">If you correctly register your vote via the Internet, by telephone or by mail, the directors of Aetna named in your proxy card will vote your shares in the manner you requested. If you sign your proxy card and return it
without indicating how you would like to vote your shares, your proxy will be voted as Aetna&#146;s board of directors unanimously recommends, which is: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;FOR&#148;</B> the approval and adoption of the merger agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;FOR&#148;</B> the Aetna adjournment proposal; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;FOR&#148;</B> the Aetna compensation advisory proposal. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">However, if you indicate that
you wish to vote against the approval and adoption of the merger agreement, your shares will only be voted in favor of the Aetna adjournment proposal and/or the Aetna compensation advisory proposal if you indicate that you wish to vote in favor of
that proposal. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>How do I vote my shares at the CVS Health special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"><I>Via the Internet or by Telephone </I> </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health common stock
directly in your name as a stockholder of record, you may vote via the Internet at www.proxyvote.com or by telephone by calling <FONT STYLE="white-space:nowrap">(800)&nbsp;690-6903</FONT> toll-free. In order to submit a proxy to vote via the
Internet or by telephone, you will need the control number on your proxy card (which is unique to each CVS Health stockholder to ensure all voting instructions are genuine and to prevent duplicate voting). Votes may be submitted via the Internet or
by telephone 24 hours a day, seven days a week, and must be received by 11:59 p.m. (Eastern Time) on March 12, 2018. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold
shares of CVS Health common stock in &#147;street name,&#148; meaning through a broker, bank or other nominee holder of record, you may vote via the Internet or by telephone only if Internet or telephone voting is made available by your broker, bank
or other nominee holder of record. Please follow the voting instructions provided by your broker, bank or other nominee holder of record with these materials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>By Mail </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health common stock directly in your name as a stockholder of record, you may submit a proxy card to vote your shares
by mail. You will need to complete, sign and date your proxy card and return it using the postage-paid return envelope provided or return it to Vote Processing, c/o Broadridge Financial Solutions, Inc., 51 Mercedes Way, Edgewood, New York 11717.
Broadridge must receive your proxy card no later than the close of business on March 12, 2018. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health
common stock in &#147;street name,&#148; meaning through a broker, bank or other nominee holder of record, in order to provide voting instructions by mail, you will need to complete, sign and date the voting instruction form provided by your broker,
bank or other nominee holder of record with these materials and return it in the postage-paid return envelope provided. Your broker, bank or other nominee holder of record must receive your voting instruction form in sufficient time to vote your
shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>In Person </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health common stock directly in your name as a stockholder of record, you may vote in person at the CVS Health
special meeting. Stockholders of record also may be represented by another person at the CVS Health special meeting by executing a proper proxy designating that person and having that proper proxy be presented to the judge of election with the
applicable ballot at the CVS Health special meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health common stock in &#147;street name,&#148; meaning
through a broker, bank or other nominee holder of record, you must obtain a written legal proxy from that institution and present it to the judge of election with your ballot to be able to vote in person at the CVS Health special meeting. To request
a legal proxy, please contact your broker, bank or other nominee holder of record. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Please carefully consider the information contained
in this joint proxy statement/prospectus. Whether or not you plan to attend the CVS Health special meeting, CVS Health encourages you to vote via the Internet, by telephone or by mail so that your shares will be voted in accordance with your wishes
even if you later decide not to attend the CVS Health special meeting. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CVS Health encourages you to register your vote via the
Internet, by telephone or by mail. If you attend the CVS Health special meeting, you may also vote in person, in which case any votes that you previously submitted&#151;whether via the Internet, by telephone or by mail&#151;will be revoked and
superseded by the vote that you cast at the CVS Health special meeting. To vote in person at the CVS Health special meeting, beneficial owners who hold shares in &#147;street name&#148; through a broker, bank or other nominee holder of record will
need to contact the broker, bank or other nominee holder of record to obtain a written legal proxy to bring to the meeting. Whether your proxy is submitted via the Internet, by phone or by mail, if it is properly completed and submitted, and if you
do not revoke it prior to or at the CVS Health special meeting, your shares will be voted at the CVS Health special meeting in the manner specified by you, except as otherwise set forth in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>You may vote via the Internet or by telephone until 11:59 p.m. (Eastern Time) on March 12, 2018, or Broadridge must receive your paper proxy
card by mail no later than the close of business on March&nbsp;12, 2018. </B></P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>If my shares of CVS Health common stock are held in &#147;street name,&#148; will my broker, bank or other nominee holder of record automatically vote my shares for me? </I></B></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No. If your shares are held in an account at a broker, bank or other nominee holder of record (i.e., in
&#147;street name&#148;), you must instruct the broker, bank or other nominee holder of record on how to vote your shares. Your broker, bank or other nominee holder of record will vote your shares only if you provide instructions on how to vote by
filling out the voting instruction form sent to you by your broker, bank or other nominee holder of record with this joint proxy statement/prospectus. Brokers, banks and other nominee holders of record who hold shares of CVS Health common stock in
&#147;street name&#148; typically have the authority to vote in their discretion on &#147;routine&#148; proposals when they have not received instructions on how to vote from the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
beneficial owner. However, brokers, banks and other nominee holders of record typically are not allowed to exercise their voting discretion on matters that are
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> without specific instructions on how to vote from the beneficial owner. Under the current rules of the NYSE, both proposals to be considered at the CVS Health special meeting as
described in this joint proxy statement/prospectus are considered <FONT STYLE="white-space:nowrap">non-routine.</FONT> Therefore brokers, banks and other nominee holders of record do not have discretionary authority to vote on either proposal.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are shares held by a broker, bank or other nominee holder of record
that are present in person or represented by proxy at the CVS Health special meeting, but with respect to which the broker, bank or other nominee holder of record is not instructed by the beneficial owner of such shares on how to vote on a
particular proposal and the broker does not have discretionary voting power on such proposal. Because brokers, banks and other nominee holders of record do not have discretionary voting authority with respect to either of the proposals to be
considered at the CVS Health special meeting as described in this joint proxy statement/prospectus, if a beneficial owner of shares of CVS Health common stock held in &#147;street name&#148; does not give voting instructions to the broker, bank or
other nominee holder of record, then those shares will not be present in person or represented by proxy at the CVS Health special meeting. As a result, there will not be any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with
either of the proposals to be considered at the CVS Health special meeting as described in this joint proxy statement/prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>How will my shares be represented at the CVS Health special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">If you correctly submit your proxy via the Internet, by telephone or by mail, the persons named in your proxy card will vote your shares in the manner you requested. If you sign your proxy card and return it without
indicating how you would like to vote your shares, your proxy will be voted as CVS Health&#146;s board of directors unanimously recommends, which is: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;FOR&#148;</B> the stock issuance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;FOR&#148;</B> the approval of the CVS Health adjournment proposal. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">However, if you
indicate that you wish to vote against the approval of the stock issuance, your shares will only be voted in favor of the CVS Health adjournment proposal if you indicate that you wish to vote in favor of that proposal. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Who may attend the Aetna special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Aetna shareholders at the record date for the Aetna special meeting (the close of business on February&nbsp;5, 2018), or their proxy holders, may attend the Aetna special meeting. If you hold shares in your name at the
record date and plan to attend the Aetna special meeting, because of security procedures, you will need to obtain an admission ticket in advance. In addition to obtaining an admission ticket in advance, you will be required to provide valid
government-issued photo identification (e.g., a driver&#146;s license or a passport) to be admitted to the Aetna special meeting. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of Aetna common shares held in &#147;street name&#148; by a broker, bank or other nominee holder of record at the
record date (the close of business on February&nbsp;5, 2018), and you plan to attend the Aetna special meeting, in addition to following the security procedures described above, you will also need proof of beneficial ownership at the record date to
obtain your admission ticket to the Aetna special meeting. A brokerage statement or letter from a bank or broker are examples of proof of beneficial ownership. If you wish to vote your Aetna common shares held in &#147;street name&#148; in person at
the Aetna special meeting, you will have to obtain a written legal proxy in your name from the broker, bank or other nominee holder of record that holds your shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aetna shareholders may contact Georgeson LLC at (888) <FONT STYLE="white-space:nowrap">658-3624</FONT> (toll-free) or (781) <FONT
STYLE="white-space:nowrap">575-2137</FONT> (for international callers) to obtain directions to the location of the Aetna special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Who may attend the CVS Health special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">CVS Health stockholders at the record date for the CVS Health special meeting (the close of business on February&nbsp;5, 2018), or their proxy holders, may attend the CVS Health special meeting. You may not appoint more
than one person to act as your proxy at the CVS Health special meeting. If you would like to attend the CVS Health special meeting, please be prepared to provide valid government-issued photo identification (e.g., a driver&#146;s license or a
passport) to be admitted to the CVS Health special meeting. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares of CVS Health common
stock held in &#147;street name&#148; by a broker, bank or other nominee holder of record at the record date (the close of business on February&nbsp;5, 2018), in addition to proper identification, you will also need an account statement or letter
from the nominee indicating that you were the beneficial owner of the shares at the record date to be admitted to the CVS Health special meeting. If you wish to vote your shares of CVS Health common stock held in &#147;street name&#148; in person at
the CVS Health special meeting, you will have to obtain a written legal proxy in your name from the broker, bank or other nominee holder of record that holds your shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CVS Health stockholders may contact Okapi Partners LLC at (855) 305-0855 (toll-free) or (212) 297-0720 (collect) or CVS Health&#146;s Investor
Relations at <FONT STYLE="white-space:nowrap">(800)&nbsp;201-0938</FONT> to obtain directions to the location of the CVS Health special meeting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Can I revoke my proxy or change my voting instructions? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Yes. You may revoke your proxy or change your vote at any time before the closing of the polls at the applicable special meeting. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a shareholder of record at the record date for the Aetna special meeting or a stockholder of record at the record date for the CVS
Health special meeting (in each case, the close of business on February&nbsp;5, 2018), you can revoke your proxy or change your vote by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sending a signed notice stating that you revoke your proxy: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if you are an Aetna shareholder, to Vote Processing, c/o Broadridge Financial Solutions, Inc. by mail at 51&nbsp;Mercedes&nbsp;Way, Edgewood NY 11717 or by fax at (631) <FONT STYLE="white-space:nowrap">254-7733;</FONT>
or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if you are a CVS Health stockholder, to Vote Processing, c/o Broadridge Financial Solutions, Inc. by mail at 51&nbsp;Mercedes&nbsp;Way, Edgewood NY 11717 or by fax at (631)
<FONT STYLE="white-space:nowrap">254-7733;</FONT> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">in each case, that bears a date later than the date of the proxy you want
to revoke and is received prior to the applicable special meeting; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submitting a valid, later-dated proxy via the Internet or by telephone before 11:59 p.m. (Eastern Time) on March 12, 2018, or by mail that is received prior to the applicable special meeting; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attending the applicable special meeting (or, if the applicable special meeting is adjourned or postponed, attending the applicable adjourned or postponed meeting) and voting in person, which automatically will cancel
any proxy previously given, or revoking your proxy in person, but your attendance alone will not revoke any proxy previously given. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold your shares in &#147;street name&#148; through a broker, bank or other nominee holder of record, you must contact your broker, bank
or other nominee holder of record to change your vote or obtain a written legal proxy to vote your shares if you wish to cast your vote in person at the applicable special meeting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What happens if I sell my Aetna common shares after the record date but before the Aetna special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">The record date for the Aetna special meeting (the close of business on February&nbsp;5, 2018) is earlier than the date of the Aetna special meeting and earlier than the date that the merger is expected to be completed.
If you sell or otherwise transfer your Aetna common shares after the record date but before the date of the Aetna special meeting, you will retain your right to vote at the Aetna special meeting. However, you will not have the right to receive the
merger consideration to be received by Aetna shareholders in the merger. In order to receive the merger consideration, you must hold your shares immediately prior to completion of the merger. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What happens if I sell my CVS Health shares after the record date but before the CVS Health special meeting? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">The record date for the CVS Health special meeting (the close of business on February&nbsp;5, 2018) is earlier than the date of the CVS Health special meeting. If you sell or otherwise transfer your shares of CVS Health
common stock after the record date but before the date of the CVS Health special meeting, you will retain your right to vote at the CVS Health special meeting. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What do I do if I receive more than one set of voting materials? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">You may receive more than one set of voting materials, including multiple copies of this joint proxy statement/prospectus, the related proxy card or the voting instruction forms. This can occur if you hold your shares
in more than one brokerage account, if you hold shares directly as a record holder and also in &#147;street name,&#148; or otherwise through another nominee holder of record, and in certain other circumstances. In addition, if you are a holder of
shares of both Aetna common shares and shares of CVS Health common stock, you will receive one or more separate proxy cards or voting instruction cards for each company. If you receive more than one set of voting materials, please separately submit
votes for each set of voting materials in order to ensure that all of your shares are voted. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Are Aetna shareholders entitled to appraisal rights? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">No. In accordance with Section&nbsp;1571(b) of the Pennsylvania Business Corporation Law, which is referred to in this joint proxy statement/prospectus as the PBCL, holders of Aetna common shares will not be entitled to
appraisal or dissenters&#146; rights in connection with the merger. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Is completion of the merger subject to any conditions? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Yes. CVS Health and Aetna are not required to complete the merger unless a number of conditions are satisfied (or, to the extent permitted by applicable law, waived). These conditions include the approval and adoption
of the merger agreement by Aetna shareholders, the approval of the stock issuance by CVS Health stockholders, termination or expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act&nbsp;of&nbsp;1976, as amended, which
is referred to in this joint proxy statement/prospectus as the HSR Act, and the receipt of certain other regulatory approvals. For a more complete summary of the conditions that must be satisfied (or, to the extent permitted by applicable law,
waived) prior to completion of the merger, see &#147;The Merger Agreement&#151;Conditions to Completion of the Merger&#148; beginning on page 181 of this joint proxy statement/prospectus. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>When do you expect to complete the merger? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">As of the date of this joint proxy statement/prospectus, Aetna and CVS Health expect to complete the merger in the second half of 2018, subject to the approval and adoption of the merger agreement by Aetna shareholders,
the approval of the stock issuance by CVS Health stockholders, early termination or expiration of the waiting period under the HSR Act, the receipt of certain other regulatory approvals and the satisfaction (or, to the extent permitted by applicable
law, waiver) of the other conditions that must be satisfied (or, to the extent permitted by applicable law, waived) prior to completion of the merger. However, no assurance can be given as to when, or if, the merger will be completed.
</TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Is the transaction expected to be taxable to Aetna shareholders? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exchange of Aetna common shares for the merger consideration pursuant to the merger will be a taxable
transaction for U.S. federal income tax purposes. Accordingly, an Aetna shareholder that is a U.S. holder (as defined in &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock
Issuance&#151;Material U.S. Federal Income Tax Consequences&#148; beginning on page 167 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of this joint proxy statement/prospectus) will recognize taxable capital gain or loss in an amount equal to the difference, if any, between (i)&nbsp;the sum of (x)&nbsp;the amount of cash,
including cash in lieu of fractional shares, received by such U.S. holder in the merger and (y)&nbsp;the fair market value of the shares of CVS Health common stock received by such U.S. holder in the merger and (ii)&nbsp;such U.S. holder&#146;s
adjusted tax basis in the Aetna common shares exchanged therefor. With respect to an Aetna shareholder that is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (as defined in &#147;Aetna Proposal I: Approval and Adoption of the Merger
Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Material U.S. Federal Income Tax Consequences&#148; beginning on page 167 of this joint proxy statement/prospectus), the exchange of Aetna common shares for the merger
consideration pursuant to the merger generally will not result in tax to such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder under U.S. federal income tax laws unless such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has certain
connections with the United States. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Aetna shareholder is urged to read the discussion in the section entitled
&#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Material U.S. Federal Income Tax Consequences&#148; beginning on page 167 of this joint proxy statement/prospectus
and to consult its tax advisor to determine the particular U.S. federal, state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income or other tax consequences to it of the merger. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>What do I need to do now? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Carefully read and consider the information contained in and incorporated by reference into this joint proxy statement/prospectus, including its annexes. Then, please vote your Aetna common shares and/or shares of CVS
Health common stock, as applicable, which you may do by: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completing, dating, signing and returning the enclosed proxy card for the applicable company in the accompanying postage-paid return envelope; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submitting your proxy via the Internet or by telephone by following the instructions included on your proxy card for such company; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attending the applicable special meeting and voting by ballot in person. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold shares in
&#147;street name&#148; through a broker, bank or other nominee holder of record, please instruct your broker, bank or other nominee holder of record to vote your shares by following the instructions that the broker, bank or other nominee holder of
record provides to you with these materials. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;&#151;How will my shares be represented at the Aetna special meeting?&#148;
beginning on page 8 of this joint proxy statement/prospectus and &#147;&#151;How will my shares be represented at the CVS Health special meeting?&#148; beginning on page 10 of this joint proxy statement/prospectus. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>Should I send in my Aetna share certificates now? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">No. Aetna shareholders should not send in their share certificates at this time. After completion of the merger, CVS Health&#146;s exchange agent will send you a letter of transmittal and instructions for exchanging
your Aetna common shares for the merger consideration. The shares of CVS Health common stock you receive in the merger will be issued in book-entry form and, unless otherwise requested, physical certificates will not be issued. See &#147;The Merger
Agreement&#151;Procedures for Surrendering Aetna Share Certificates&#148; beginning on page 179 of this joint proxy statement/prospectus. CVS Health stockholders will keep their existing share certificates, if any, and will not be required to take
any action with respect to their certificates. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>As a holder of stock appreciation rights issued by Aetna representing the right to receive a payment in Aetna common shares, or a holder of Aetna restricted stock units or performance stock units, what will I
receive in the merger? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each vested stock appreciation right representing the right to receive a payment in Aetna common shares, which
are referred to in this joint proxy statement/prospectus as Aetna stock appreciation rights (including </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
those Aetna stock appreciation rights that vest by their terms as of completion of the merger) that is outstanding as of completion of the merger will be cancelled and converted into the right to
receive a cash amount (without interest) equal to the product of (a)&nbsp;the excess, if any, of (x)&nbsp;the sum of $145.00 plus the value equal to the product of the average of the volume weighted averages of the trading prices for shares of CVS
Health common stock on the NYSE on each of the five consecutive trading days ending on the trading day that is two trading days prior to completion of the merger, which average is referred to in this joint proxy statement/prospectus as the CVS
Health closing price, multiplied by the ratio of 0.8378 of a share of CVS Health common stock for each Aetna common share (which is referred to in this joint proxy statement/prospectus as the exchange ratio) (the sum of such amounts is referred to
in this joint proxy statement/prospectus as the equity award cash consideration) over (y)&nbsp;the applicable per share exercise price of the Aetna stock appreciation right multiplied by (b)&nbsp;the total number of Aetna common shares subject to
such Aetna stock appreciation right. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Aetna stock appreciation right that is not vested as of completion of the merger
or that is granted after the date of the merger agreement (to the extent permitted under the merger agreement), at completion of the merger, will be assumed by CVS Health and will become a stock appreciation right, which is referred to in this joint
proxy statement/prospectus as an assumed stock appreciation right, representing the right to receive a payment in shares of CVS Health common stock on the same terms and conditions, except that the number of shares of CVS Health common stock subject
to the assumed stock appreciation right will equal the product of (a)&nbsp;the number of Aetna common shares that were subject to such Aetna stock appreciation right immediately prior to completion of the merger, multiplied by (b)&nbsp;the sum of
(x)&nbsp;the exchange ratio plus (y)&nbsp;the quotient of $145.00, divided by the CVS Health closing price (the sum of such amounts&nbsp;is referred to in this joint proxy statement/prospectus as the equity award exchange ratio), with such product
rounded down to the nearest whole share of CVS Health Common stock. The per share exercise price for each assumed stock appreciation right will equal the exercise price per share of such Aetna stock appreciation right immediately prior to completion
of the merger divided by the equity award exchange ratio, rounded up to the nearest whole cent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to completion of the
merger, each outstanding Aetna restricted stock unit, which is referred to in this joint proxy statement/prospectus as an Aetna RSU, and each outstanding Aetna performance stock unit, which is referred to in this joint proxy statement/prospectus as
an Aetna PSU, that provides for accelerated vesting upon completion of the merger will vest and will be converted into the right to receive, with respect to each Aetna common share underlying the Aetna RSU or Aetna PSU, the merger consideration,
less applicable tax withholdings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Aetna RSU or Aetna PSU that is not converted into a right to receive the merger consideration or is
granted after the date of the merger agreement (to the extent permitted under the merger agreement) will be assumed by CVS Health and will be converted into a time-based restricted stock unit award covering the number of whole shares of CVS Health
common stock equal to the product of the number of Aetna common shares underlying such assumed Aetna RSU or Aetna PSU immediately prior to completion of the merger (with the performance of each Aetna PSU to be determined based on the applicable
award agreement relating to such Aetna PSU) multiplied by the equity award exchange ratio, with such product rounded down to the nearest whole share of CVS Health common stock. Except as provided in the immediately preceding sentence, each assumed
Aetna RSU or Aetna PSU will continue to have, and be subject to, the same terms and conditions as applied to the corresponding Aetna RSU or Aetna PSU immediately prior to completion of the merger (including any terms and conditions relating to
accelerated vesting upon a termination of the holder&#146;s employment in connection with or following the merger). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The description above
does not apply to equity awards held by Aetna&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, who will receive a cash payment for their restricted and deferred units in accordance with the Aetna Inc. <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Plan, which is referred to in this joint proxy statement/prospectus as the Aetna Director Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;The Merger Agreement&#151;Treatment of Aetna Equity Awards&#148; beginning on page 180 of this joint proxy statement/prospectus. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>How can I vote the shares of CVS Health common stock I hold through the 401(k) Plan and Employee Stock Ownership Plan of CVS Health Corporation and Affiliated Companies? </I></B></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Participants in the 401(k) Plan and Employee Stock Ownership Plan of CVS Health Corporation and Affiliated Companies, which is referred to in this joint proxy statement/prospectus as the CVS Health 401(k) Plan, who
receive this joint proxy statement/prospectus in their capacity as participants in the CVS Health 401(k) Plan are entitled to vote using the enclosed proxy card. The proxy card directs the trustee of the CVS Health 401(k) Plan to vote a
participant&#146;s shares as indicated on the card. Shares of CVS Health common stock held through the CVS Health 401(k) Plan for which no instructions are received will be voted by the trustee of the CVS Health 401(k) Plan in the same percentage as
the shares of CVS Health common stock held through the CVS Health 401(k) Plan for which the trustee receives voting instructions. The trustee of the CVS Health 401(k) Plan must receive your voting instructions by 11:59 p.m. (Eastern Time) on March
8, 2018. </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Please note that you cannot vote the shares of CVS Health common stock you hold through the CVS Health 401(k)
Plan in person at the CVS Health special meeting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>How can I vote the Aetna common shares I hold through Aetna&#146;s 401(k) plan? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">Participants in the Aetna Inc. 401(k) Plan, which is referred to in this joint proxy statement/prospectus as the Aetna 401(k) Plan, who receive this joint proxy statement/prospectus in their capacity as participants in
the Aetna 401(k) Plan will receive voting instruction cards instead of proxy cards. The voting instruction card directs the trustee of the Aetna 401(k) Plan to vote the shares shown on the card as indicated on the card. Aetna common shares held
through the Aetna 401(k) Plan may be voted by using the Internet, by calling a toll-free telephone number or by completing, signing and dating the voting instruction card and mailing it to the trustee of the Aetna 401(k) Plan in accordance with the
trustee&#146;s instructions. Aetna common shares held through the Aetna 401(k) Plan for which no instructions are received will be voted by the trustee of the Aetna 401(k) Plan in the same percentage as the Aetna common shares held through the Aetna
401(k) Plan for which the trustee receives voting instructions unless contrary to ERISA. The trustee of the Aetna 401(k) Plan must receive your voting instructions by 11:59 p.m. (Eastern Time) on March 8, 2018. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Please note that you cannot vote the Aetna common shares you hold through the Aetna 401(k) Plan in person at the Aetna special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>If I am an Aetna shareholder, whom should I call with questions? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">If you have any questions about the merger agreement, the merger, the proposal to approve and adopt the merger agreement, the Aetna adjournment proposal, the Aetna compensation advisory proposal or the Aetna special
meeting, or this joint proxy statement/prospectus, desire additional copies of this joint proxy statement/prospectus, proxy cards or voting instruction forms or need help voting your Aetna common shares, you should contact: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g482402g04o86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Georgeson LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1290 Avenue of the Americas, 9th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10104 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone
(Toll-Free): (888) <FONT STYLE="white-space:nowrap">658-3624</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">International Callers: (781)
<FONT STYLE="white-space:nowrap">575-2137</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: aetna@georgeson.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aetna Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 Farmington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hartford, CT
06156 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (860) <FONT STYLE="white-space:nowrap">273-2402</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: investorelations@aetna.com </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>If I am a CVS Health stockholder, whom should I call with questions? </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top">If you have any questions about the merger agreement, the merger, the stock issuance, the proposal to approve the stock issuance, the CVS Health adjournment proposal or the CVS Health special meeting or this joint proxy
statement/prospectus, desire additional copies of this joint proxy statement/prospectus, proxy cards or voting instruction forms or need help voting your shares of CVS Health common stock, you should contact: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g482402g11n44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Okapi Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1212 Avenue of the Americas, 24th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10036 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone
(Toll-Free): (855) 305-0855 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone (Collect): (212) 297-0720 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: cvsproxyinfo@okapipartners.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CVS Health Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One CVS Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Woonsocket, RI 02895
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: <FONT STYLE="white-space:nowrap">(800)&nbsp;201-0938</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: investorinfo@cvshealth.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information from this joint proxy statement/prospectus. It may not contain all of the information that is
important to you. You are urged to read carefully the entire joint proxy statement/prospectus and the other documents attached to or referred to in this joint proxy statement/prospectus in order to fully understand the merger agreement and the
proposed merger. See &#147;Where You Can Find More Information&#148; beginning on page 254 of this joint proxy statement/prospectus. Each item in this summary refers to the page of this joint proxy statement/prospectus on which the more detailed
discussion of that subject begins. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_3"></A>The Companies (see page 73) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>CVS Health Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health Corporation was incorporated in the State of Delaware on August&nbsp;22, 1996. CVS Health, together with its subsidiaries, is a
pharmacy innovation company helping people on their path to better health. At the forefront of a changing health care landscape, CVS Health has an unmatched suite of capabilities and the expertise needed to drive innovations that will help shape the
future of health care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through more than 9,700 retail locations, more than 1,100 <FONT STYLE="white-space:nowrap">walk-in</FONT> health
care clinics, a leading pharmacy benefits manager with nearly 90&nbsp;million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services and a leading stand-alone
Medicare Part D prescription drug plan, CVS Health enables people, businesses and communities to manage health in more affordable, effective ways. CVS Health is delivering break-through products and services, from advising patients on their
medications at CVS Pharmacy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> locations, to introducing unique programs to help control costs for CVS Health&#146;s clients at CVS
Caremark<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, to innovating how care is delivered to CVS Health&#146;s patients with complex conditions through CVS Specialty<SUP STYLE="font-size:85%; vertical-align:top"></SUP><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, to improving pharmacy care for the senior community through Omnicare<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or by expanding access to high-quality, <FONT
STYLE="white-space:nowrap">low-cost</FONT> care at CVS MinuteClinic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
principal trading market for shares of CVS Health common stock (NYSE: CVS) is the NYSE. The principal executive offices of CVS Health are located at One CVS Drive, Woonsocket, RI 02895; its telephone number is (401)
<FONT STYLE="white-space:nowrap">765-1500;</FONT> and its website is www.cvshealth.com. Information on CVS Health&#146;s Internet website is not incorporated by reference into or otherwise part of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus incorporates important business and financial information about CVS Health from other documents that are
not included in or delivered with this joint proxy statement/prospectus. For a list of the documents that are incorporated by reference, see &#147;Where You Can Find More Information&#148; beginning on page 254 of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Aetna Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna Inc. was incorporated in the Commonwealth of Pennsylvania on December&nbsp;20, 1982. Aetna, together with its subsidiaries, is one of the
nation&#146;s leading diversified health care benefits companies, serving an estimated 37.9&nbsp;million people as of December 31, 2017. Aetna has the information and resources to help its members, in consultation with their health care
professionals, make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health,
group life and disability plans, medical management capabilities, Medicaid health care management services, Medicare Advantage and Medicare supplement plans, workers&#146; compensation administrative services and health information technology
products and services. Aetna&#146;s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. On
November&nbsp;1, 2017, Aetna sold its domestic group life insurance, group disability insurance and absence management businesses to Hartford Life and Accident Insurance Company. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal trading market for Aetna common shares (NYSE: AET) is the NYSE. The principal
executive offices of Aetna are located at 151 Farmington Avenue, Hartford, CT 06156; its telephone number is (860) 273-0123; and its website is www.aetna.com. Information on Aetna&#146;s Internet website is not incorporated by reference into or
otherwise part of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus incorporates important business and
financial information about Aetna from other documents that are not included in or delivered with this joint proxy statement/prospectus. For a list of the documents that are incorporated by reference, see &#147;Where You Can Find More
Information&#148; beginning on page 254 of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Hudson Merger Sub Corp. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Sub was incorporated in the Commonwealth of Pennsylvania on November&nbsp;14, 2017, and is a wholly-owned subsidiary of CVS Health.
Merger Sub was formed solely for the purpose of completing the merger. Merger Sub has not carried on any activities to date, except for activities incidental to its formation and activities undertaken in connection with the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal executive offices of Merger Sub are located at One CVS Drive, Woonsocket, RI 02895; and its telephone number is (401) <FONT
STYLE="white-space:nowrap">765-1500.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_4"></A>The Merger (see page 177) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health, Merger Sub and Aetna have entered into the merger agreement. Subject to the terms and conditions of the merger agreement and in
accordance with applicable law, in the merger, Merger Sub will be merged with and into Aetna, with Aetna continuing as the surviving corporation and a wholly-owned subsidiary of CVS Health. Upon completion of the merger, Aetna common shares will no
longer be publicly traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the merger agreement is attached as Annex A to this joint proxy statement/prospectus. <B>You should
read the merger agreement carefully because it is the legal document that governs the merger. </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_5"></A>Special Meeting of
Stockholders of CVS Health (see page 75) </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Meeting</I></B>. The CVS Health special meeting will be held on March 13, 2018, at
the offices of Shearman &amp; Sterling LLP, located at 599 Lexington Avenue, New York, NY 10022, at 11:00 a.m. Eastern Time. At the CVS Health special meeting, CVS Health stockholders will be asked to consider and vote on the following proposals:
</P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve the stock issuance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve the CVS Health adjournment proposal. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Record Date</I></B>. CVS
Health&#146;s board of directors has fixed the close of business on February&nbsp;5, 2018, as the record date for the determination of the stockholders entitled to notice of and to vote at the CVS Health special meeting or any adjournment or
postponement of the CVS Health special meeting. Only CVS Health stockholders of record at the record date are entitled to receive notice of, and to vote at, the CVS Health special meeting or any adjournment or postponement of the CVS Health special
meeting. As of the close of business on February&nbsp;5, 2018, there were 1,015,460,751 shares of CVS Health common stock outstanding and entitled to vote at the CVS Health special meeting. Each holder of shares of CVS Health common stock is
entitled to one vote for each share of CVS Health common stock owned at the record date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quorum</I></B>. The presence at the
CVS Health special meeting, in person or by proxy, of the holders of a majority of the outstanding shares of CVS Health common stock at the record date (the close of business on </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
February&nbsp;5, 2018) will constitute a quorum. Elections to abstain from voting will be deemed present at the CVS Health special meeting for the purpose of determining the presence of a quorum.
Shares of CVS Health common stock held in &#147;street name&#148; with respect to which the beneficial owner fails to give voting instructions to the broker, bank or other nominee holder of record, and shares of CVS Health common stock with respect
to which the beneficial owner otherwise fails to vote, will not be deemed present at the CVS Health special meeting for the purpose of determining the presence of a quorum. There must be a quorum for the vote on the stock issuance to be taken at the
CVS Health special meeting. Failure of a quorum to be present at the CVS Health special meeting will necessitate an adjournment of the meeting and will subject CVS Health to additional expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Required Vote</I></B>. Assuming a quorum is present, approval of the stock issuance requires the affirmative vote of a majority of the
votes cast at the CVS Health special meeting by holders of shares of CVS Health common stock. <B>CVS Health cannot complete the merger unless its stockholders approve the stock issuance</B>. Under the current rules and interpretive guidance of the
NYSE, &#147;votes cast&#148; on the stock issuance consist of votes &#147;for&#148; or &#147;against&#148;, as well as elections to abstain from voting on the stock issuance. As a result, a CVS Health stockholder&#146;s election to abstain from
voting on the stock issuance will have the same effect as a vote <B>&#147;AGAINST&#148;</B> the proposal. Assuming a quorum is present, the failure of a CVS Health stockholder who holds his or her shares in &#147;street name&#148; through a broker,
bank or other nominee holder of record to give voting instructions to that broker, bank or other nominee holder of record or any other failure of a CVS Health stockholder to vote will have no effect on the outcome of any vote to approve the stock
issuance because these failures to vote are not considered &#147;votes cast.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the CVS Health adjournment proposal,
whether or not a quorum, as defined under Delaware law, is present, requires the affirmative vote of a majority of the votes cast at the CVS Health special meeting by CVS Health stockholders. For purposes of the CVS Health adjournment proposal,
&#147;votes cast&#148; means votes &#147;for&#148; or &#147;against&#148; the proposal. As a result, a CVS Health stockholder&#146;s election to abstain from voting on the CVS Health adjournment proposal, the failure of a CVS Health stockholder who
holds his or her shares in &#147;street name&#148; through a broker, bank or other nominee holder of record to give voting instructions to that broker, bank or other nominee holder of record or any other failure of a CVS Health stockholder to vote
will have no effect on the outcome of any vote on the CVS Health adjournment proposal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Ownership of and Voting by CVS
Health Directors and Executive Officers</I></B>. At the record date for the CVS Health special meeting (the close of business on February 5, 2018), CVS Health&#146;s directors and executive officers and their affiliates beneficially owned and had
the right to vote in the aggregate 1,279,586 shares of CVS Health common stock at the CVS Health special meeting, which represents approximately 0.13% of the shares of CVS Health common stock entitled to vote at the CVS Health special meeting.
Approval of the stock issuance requires the affirmative vote of a majority of the votes cast at the CVS Health special meeting by holders of shares of CVS Health common stock (assuming a quorum is present). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of CVS Health&#146;s directors and executive officers is expected, as of the date of this joint proxy statement/prospectus, to vote his
or her shares of CVS Health common stock <B>&#147;FOR&#148;</B> the stock issuance and <B>&#147;FOR&#148;</B> the CVS Health adjournment proposal, although none of CVS Health&#146;s directors and executive officers has entered into any agreement
requiring them to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_6"></A>Special Meeting of Shareholders of Aetna (see page 82) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Meeting</I></B>. The Aetna special meeting will be held on March 13, 2018, at the offices of Davis Polk &amp; Wardwell LLP, located at
450 Lexington Avenue, New York, NY 10017, at 11:00 a.m. Eastern Time. At the Aetna special meeting, Aetna shareholders will be asked to consider and vote on the following proposals: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve and adopt the merger agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve the Aetna adjournment proposal; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis the Aetna compensation advisory proposal. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Record Date</I></B>. A committee of Aetna&#146;s board of directors has fixed the
close of business on February&nbsp;5, 2018, as the record date for the determination of the Aetna shareholders entitled to notice of and to vote at the Aetna special meeting or any adjournment or postponement of the Aetna special meeting. Only Aetna
shareholders of record at the record date are entitled to receive notice of, and to vote at, the Aetna special meeting or any adjournment or postponement of the Aetna special meeting. As of the close of business on February 5, 2018, there were
326,942,525 Aetna common shares outstanding and entitled to vote at the Aetna special meeting. Each holder of Aetna common shares is entitled to one vote for each Aetna common share owned at the record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quorum</I></B>. The presence at the Aetna special meeting, in person or by proxy, of the holders of a majority of the outstanding Aetna
common shares at the record date (the close of business on February&nbsp;5, 2018) will constitute a quorum. Aetna common shares whose holders elect to abstain from voting will be deemed present at the Aetna special meeting for the purpose of
determining the presence of a quorum. Aetna common shares held in &#147;street name&#148; with respect to which the beneficial owner fails to give voting instructions to the broker, bank or other nominee holder of record, and Aetna common shares
with respect to which the beneficial owner otherwise fails to vote, will not be deemed present at the Aetna special meeting for the purpose of determining the presence of a quorum. There must be a quorum for the vote on the approval and adoption of
the merger agreement and the vote on the Aetna compensation advisory proposal to be taken at the Aetna special meeting. Failure of a quorum to be present at the Aetna special meeting will necessitate an adjournment of the meeting and will subject
Aetna to additional expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Required Vote</I></B>. Pursuant to Aetna&#146;s amended and restated articles of incorporation, which
are referred to in this joint proxy statement/prospectus as Aetna&#146;s articles, to approve and adopt the merger agreement, the affirmative vote of the holders of a majority of Aetna common shares outstanding and entitled to vote thereon is
required. <B>Aetna cannot complete the merger and the merger consideration will not be paid unless its shareholders approve and adopt the merger agreement. Because approval and adoption of the merger agreement requires the affirmative vote of the
holders of at least a majority of Aetna common shares outstanding and entitled to vote thereon, an Aetna shareholder&#146;s abstention from voting, the failure of an Aetna shareholder who holds his or her shares in &#147;street name&#148; through a
broker, bank or other nominee holder of record to give voting instructions to that broker, bank or other nominee holder of record or any other failure of an Aetna shareholder to vote will have the same effect as a vote &#147;AGAINST&#148; the
proposal to approve and adopt the merger agreement. </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To approve (i)&nbsp;the Aetna adjournment proposal (whether or not a quorum, as
defined under Pennsylvania law, is present) and (ii)&nbsp;on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the Aetna compensation advisory proposal (assuming a quorum, as defined under Pennsylvania law, is present), the
affirmative vote of a majority of the votes cast at the Aetna special meeting by holders of Aetna common shares is required. For purposes of each of the Aetna adjournment proposal and the Aetna compensation advisory proposal, &#147;votes cast&#148;
means votes &#147;for&#148; or &#147;against&#148; the applicable proposal. As a result, an Aetna shareholder&#146;s abstention from voting, the failure of an Aetna shareholder who holds his or her shares in &#147;street name&#148; through a broker,
bank or other nominee holder of record to give voting instructions to that broker, bank or other nominee holder of record or any other failure of an Aetna shareholder to vote will have no effect on the outcome of any vote on the Aetna adjournment
proposal or any vote to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the Aetna compensation advisory proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Share Ownership of and Voting by Aetna Directors and Executive Officers</I></B>. At the record date for the Aetna special meeting (the
close of business on February 5, 2018), Aetna&#146;s directors and executive officers and their affiliates beneficially owned and had the right to vote in the aggregate 1,357,761 Aetna common shares at the Aetna special meeting, which represents
approximately 0.42% of the Aetna common shares entitled to vote at the Aetna special meeting. To approve and adopt the merger agreement, the affirmative vote of the holders of a majority of Aetna common shares outstanding and entitled to vote
thereon is required. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Aetna&#146;s directors and executive officers is expected, as of the date of this
joint proxy statement/prospectus, to vote his or her Aetna common shares <B>&#147;FOR&#148;</B> the proposal to approve and adopt the merger agreement, <B>&#147;FOR&#148;</B> the Aetna adjournment proposal and <B>&#147;FOR&#148;</B> the Aetna
compensation advisory proposal, although none of Aetna&#146;s directors or executive officers has entered into any agreement requiring them to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_7">
</A>What Aetna Shareholders Will Receive in the Merger (see page 178) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is completed, Aetna shareholders will be entitled
to receive, in exchange for each Aetna common share that they own immediately prior to the effective time of the merger, $145.00 in cash without interest thereon and 0.8378 of a share of CVS Health common stock, together with cash payable in lieu of
any fractional shares as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health will not issue any fractional shares in the merger. Instead, the total number of
shares of CVS Health common stock that each Aetna shareholder will be entitled to receive in the merger will be rounded down to the nearest whole number, and each Aetna shareholder will be entitled to receive cash, without interest thereon, for any
fractional share of CVS Health common stock that he or she otherwise would be entitled to receive in the merger. The amount of cash for fractional shares will be calculated by multiplying the fraction of a share of CVS Health common stock that the
Aetna shareholder otherwise would be entitled to receive in the merger by the CVS Health closing price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Example: If you own 100 Aetna
common shares at the time the merger is completed, you will be entitled to receive $14,500.00 in cash without interest thereon and 83 shares of CVS Health common stock. In addition, you will be entitled to receive an amount of cash equal to 0.78 of
a share of CVS Health common stock multiplied by the CVS Health closing price. </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange ratio is fixed, which means that it
will not change between now and the date of the merger, regardless of whether the market price of either shares of CVS Health common stock or Aetna common shares changes. Therefore, the value of the share consideration will depend on the market
price of shares of CVS Health common stock at the time Aetna shareholders receive shares of CVS Health common stock in the merger. Based on the closing price of a share of CVS Health common stock on the NYSE on October&nbsp;25, 2017, the last
trading day prior to news reports of a potential transaction between CVS Health and Aetna, the merger consideration represented approximately $208.28 in value for each Aetna common share. Based on the closing price of a share of CVS Health common
stock on the NYSE on February 8, 2018, the most recent trading day prior to the date of this joint proxy statement/prospectus for which this information was available, the merger consideration represented approximately $204.11 in value for each
Aetna common share. <B>The market price of shares of CVS Health common stock has fluctuated since the date of the announcement of the merger agreement and will continue to fluctuate from the date of this joint proxy statement/prospectus to the date
of the Aetna special meeting and the date the merger is completed and thereafter. The market price of shares of CVS Health common stock when received by Aetna shareholders after the merger is completed could be greater than, less than or the same as
the market price of shares of CVS Health common stock on the date of this joint proxy statement/prospectus or at the time of the Aetna special meeting or any adjournment or postponement thereof</B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_8"></A>Treatment of Aetna Equity Awards (see page 180) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At completion of the merger, each outstanding vested Aetna stock appreciation right (including those Aetna stock appreciation rights that vest
by their terms at completion of the merger), will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the excess, if any, of the equity award cash consideration over the applicable per share exercise
price of such Aetna stock appreciation right multiplied by the total number of Aetna common shares subject to such Aetna stock appreciation right. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Aetna stock appreciation right that is not vested as of completion of the merger or
that is granted after the date of the merger agreement (to the extent permitted under the merger agreement), at completion of the merger, will be assumed by CVS Health and will become an assumed stock appreciation right representing the right to
receive a payment in shares of CVS Health common stock on the same terms and conditions, except that the number of shares of CVS Health common stock subject to the assumed stock appreciation right will equal the product of the number of Aetna common
shares that were subject to such Aetna stock appreciation right immediately prior to completion of the merger multiplied by the equity award exchange ratio, with such product rounded down to the nearest whole share of CVS Health common stock. The
per share exercise price for each assumed stock appreciation right will equal the exercise price per share of such Aetna stock appreciation right immediately prior to completion of the merger divided by the equity award exchange ratio, rounded up to
the nearest whole cent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to completion of the merger, each outstanding Aetna RSU and each outstanding Aetna PSU that
provides for accelerated vesting upon completion of the merger will vest and will be converted into the right to receive, with respect to each Aetna common share underlying the Aetna RSU or Aetna PSU, the merger consideration, less applicable tax
withholdings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Aetna RSU or Aetna PSU that is not converted into a right to receive the merger consideration or is granted after the
date of the merger agreement (to the extent permitted under the merger agreement) will be assumed by CVS Health and will be converted into a time-based restricted stock unit award covering the number of whole shares of CVS Health common stock equal
to the product of the number of Aetna common shares underlying such assumed Aetna RSU or Aetna PSU immediately prior to completion of the merger (with the performance of each Aetna PSU to be determined based on the applicable award agreement
relating to such Aetna PSU) multiplied by the equity award exchange ratio, with such product rounded down to the nearest whole share of CVS Health common stock. Except as provided in the immediately preceding sentence, each assumed Aetna RSU or
Aetna PSU will continue to have, and be subject to, the same terms and conditions as applied to the corresponding Aetna RSU or Aetna PSU immediately prior to completion of the merger (including any terms and conditions relating to accelerated
vesting upon a termination of the holder&#146;s employment in connection with or following the merger). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description above does not
apply to equity awards held by Aetna&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, who will receive a cash payment for their restricted and deferred units in accordance with the Aetna Director Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_9"></A>Recommendations of the Aetna Board of Directors (see page 101) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna&#146;s board of directors unanimously determined that the merger agreement and the transactions contemplated by the merger agreement
(including the merger) are fair to and in the best interests of Aetna and its shareholders. <B>Aetna&#146;s board of directors unanimously recommends that Aetna shareholders vote &#147;FOR&#148; the proposal to approve and adopt the merger
agreement.</B> For the factors considered by Aetna&#146;s board of directors in reaching this decision, see &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock
Issuance&#151;Aetna&#146;s Reasons for the Merger; Recommendation of the Aetna Board of Directors that Aetna Shareholders Approve and Adopt the Merger Agreement&#148; beginning on page 101 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna&#146;s board of directors unanimously recommends that Aetna shareholders vote <B>&#147;FOR&#148;</B> the Aetna adjournment proposal. See
&#147;Aetna Proposal II: Adjournment of the Aetna Special Meeting&#148; beginning on page&nbsp;219 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Aetna&#146;s board of directors unanimously recommends that Aetna shareholders vote <B>&#147;FOR&#148;</B> the Aetna compensation
advisory proposal. See &#147;Aetna Proposal III: Advisory Vote On Merger-Related Executive Compensation Arrangements&#148; beginning on page 220 of this joint proxy statement/prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_10"></A>Recommendations of the CVS Health Board of Directors (see page 106) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s board of directors unanimously determined that the merger agreement and the transactions contemplated by the merger
agreement, including merger and the stock issuance, are advisable, fair to and in the best interests of CVS Health and its stockholders. <B>CVS Health&#146;s board of directors unanimously recommends that CVS Health stockholders vote &#147;FOR&#148;
the stock issuance</B>. For the factors considered by CVS Health&#146;s board of directors in reaching this decision, see &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal&nbsp;I: Approval of the Stock
Issuance&#151;CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of Directors that CVS Health Stockholders Approve the Stock Issuance&#148; beginning on page 106 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s board of directors unanimously recommends that CVS Health stockholders vote <B>&#147;FOR&#148;</B> the CVS Health
adjournment proposal. See &#147;CVS Health Proposal II: Adjournment of the CVS Health Special Meeting&#148; beginning on page 221 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_11"></A>Opinions of Aetna&#146;s Financial Advisors (see page 111) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of Lazard Fr&egrave;res&nbsp;&amp; Co. LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna has engaged Lazard Fr&egrave;res&nbsp;&amp; Co. LLC, which is referred to in this joint proxy statement/prospectus as Lazard, as a
financial advisor in connection with the merger. In connection with the merger, Lazard delivered a written opinion, dated December&nbsp;3, 2017, to the Aetna board of directors as to the fairness, from a financial point of view and as of such date,
of the consideration to be paid to the holders of Aetna common shares in the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of Lazard&#146;s written opinion,
dated December&nbsp;3, 2017, which sets forth the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken, is attached as Annex B to this joint proxy statement/prospectus and is
incorporated herein by reference. The description of Lazard&#146;s opinion set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of Lazard&#146;s opinion. Lazard&#146;s opinion was for the
benefit of the Aetna board of directors (in its capacity as such) in connection with its evaluation of the merger and did not address any terms or other aspects (other than the merger consideration to the extent expressly specified in Lazard&#146;s
opinion) of the merger. <B>Lazard&#146;s opinion did not address the relative merits of the merger as compared to any other transaction or business strategy in which Aetna might engage or the merits of the underlying decision by Aetna to engage in
the merger. Lazard&#146;s opinion is not intended to and does not constitute a recommendation to any shareholder as to how such shareholder should vote or act with respect to the merger or any matter relating thereto.</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of Allen&nbsp;&amp; Company LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna also has engaged Allen&nbsp;&amp; Company LLC, which is referred to in this joint proxy statement/prospectus as Allen&nbsp;&amp; Company,
as a financial advisor in connection with the merger. In connection with the merger, Allen&nbsp;&amp; Company delivered a written opinion, dated December&nbsp;3, 2017, to the Aetna board of directors as to the fairness, from a financial point of
view and as of the date of the opinion, of the consideration to be received by holders of Aetna common shares pursuant to the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of Allen&nbsp;&amp; Company&#146;s written opinion, dated December&nbsp;3, 2017, which describes the assumptions made,
procedures followed, matters considered and qualifications and limitations on the review undertaken, is attached as Annex C to this joint proxy statement/prospectus and is incorporated herein by reference. The description of Allen&nbsp;&amp;
Company&#146;s opinion set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of Allen&nbsp;&amp; Company&#146;s opinion. <B>Allen</B><B></B><B>&nbsp;&amp; Company&#146;s opinion was intended
for the benefit and use of the Aetna board of directors (in its capacity as such) in connection</B> </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>with its evaluation of the merger consideration from a financial point of view and did not address any other terms, aspects or implications of the merger. Allen</B><B></B><B>&nbsp;&amp;
Company&#146;s opinion did not constitute a recommendation as to the course of action that Aetna (or the Aetna board of directors) should pursue in</B> <B>connection with the merger or otherwise address the merits of the underlying decision by Aetna
to engage in the merger, including in comparison to other strategies or transactions that might be available to Aetna or which Aetna might engage in or consider. Allen</B><B></B><B>&nbsp;&amp; Company&#146;s opinion does not constitute advice or a
recommendation to any shareholder as to how such shareholder should vote or act on any matter relating to the merger or otherwise.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_12">
</A>Opinions of CVS Health&#146;s Financial Advisors (see page 128) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Opinions of Barclays Capital Inc. and Goldman
Sachs&nbsp;&amp; Co. LLC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health engaged Barclays Capital Inc., which is referred to in this joint proxy statement/prospectus
as Barclays, and Goldman Sachs&nbsp;&amp; Co. LLC, which is referred to in this joint proxy statement/prospectus as Goldman Sachs, to act as its financial advisors with respect to the merger. Barclays delivered its opinion to CVS Health&#146;s board
of directors that, as of December&nbsp;3,&nbsp;2017 and based upon and subject to the qualifications, limitations, factors and assumptions set forth in the opinion, the merger consideration to be paid by CVS Health in the merger was fair, from a
financial point of view, to CVS Health. Goldman Sachs delivered its opinion to CVS Health&#146;s board of directors that, as of December&nbsp;3, 2017 and based upon and subject to the qualifications, limitations, factors and assumptions set forth in
the opinion, the merger consideration to be paid by CVS Health in the merger was fair, from a financial point of view, to CVS Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
full text of the written opinion of Barclays, dated as of December&nbsp;3, 2017, is attached as Annex D to this joint proxy statement/prospectus.<B> Barclays&#146; written opinion sets forth, among other things, the assumptions made, procedures
followed, factors considered and limitations on the review undertaken by Barclays in connection with the opinion. Barclays provided advisory services and its opinion for the information and assistance of CVS Health&#146;s board of directors in
connection with its consideration of the merger. The Barclays opinion is not a recommendation as to how any holder of shares of CVS Health common stock or Aetna common shares should vote with respect to the merger or any other matter. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of the written opinion of Goldman Sachs, dated as of December&nbsp;3, 2017, is attached as Annex E to this joint proxy
statement/prospectus.<B> Goldman Sachs&#146; written opinion sets forth, among other things, the assumptions made, procedures followed, factors considered and limitations on the review undertaken by Goldman Sachs in connection with the opinion.
Goldman Sachs provided advisory services and its opinion for the information and assistance of CVS Health&#146;s board of directors in connection with its consideration of the merger. The Goldman Sachs opinion is not a recommendation as to how any
holder of shares of CVS Health common stock or Aetna common shares should vote with respect to the merger or any other matter.</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of Centerview Partners LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health also retained Centerview Partners LLC, which is referred to in this joint proxy statement/prospectus as Centerview, as financial
advisor to CVS Health in connection with the proposed merger and the other transactions contemplated by the merger agreement, which are collectively referred to as the transaction throughout this section and the summary of Centerview&#146;s opinion
below under the caption &#147;Opinions of CVS Health&#146;s Financial Advisors&#151;Opinion of Centerview Partners LLC&#148; beginning on page 145 of this joint proxy statement/prospectus. In connection with this engagement, the board of directors
of CVS Health requested that Centerview evaluate the fairness, from a financial point of view, to CVS Health, of the merger consideration to be paid by CVS Health in the merger pursuant to the merger agreement. On December&nbsp;3, 2017, Centerview
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rendered to the board of directors of CVS Health its oral opinion, which was subsequently confirmed by delivery of a written opinion dated December&nbsp;3, 2017 that, as of such date and based
upon and subject to the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, the merger consideration proposed to be paid by CVS Health in
the merger pursuant to the merger agreement was fair, from a financial point of view, to CVS Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of Centerview&#146;s
written opinion, dated December&nbsp;3, 2017, which describes the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, is attached as Annex F
and is incorporated herein by reference. <B>Centerview&#146;s financial advisory services and opinion were provided for the information and assistance of the board of directors of CVS (in their capacity as directors and not in any other capacity) in
connection with and for purposes of its consideration of the transaction and Centerview&#146;s opinion addressed only the fairness, from a financial point of view, as of the date of Centerview&#146;s written opinion, to CVS of the merger
consideration to be paid by CVS in the merger pursuant to the merger agreement. Centerview&#146;s opinion did not address any other term or aspect of the merger agreement or the transaction and does not constitute a recommendation to any stockholder
of CVS or any other person as to how such stockholder or other person should vote with respect to the merger or otherwise act with respect to the transaction or any other matter.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The full text of Centerview&#146;s written opinion should be read carefully in its entirety for a description of the assumptions made,
procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_13">
</A>Ownership of CVS Health Common Stock After the Merger (see page 89) </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of Aetna common shares (including the
number of shares underlying Aetna stock appreciation rights, Aetna RSUs, Aetna PSUs and unexercised rights under the Aetna employee stock purchase plan) outstanding as of February 5, 2018, and the treatment of Aetna common shares, stock appreciation
rights, Aetna RSUs, Aetna PSUs and unexercised rights under the Aetna employee stock purchase plan in the merger, CVS Health expects to issue approximately 280&nbsp;million shares of CVS Health common stock to Aetna shareholders and Aetna equity
award holders upon completion of the merger and reserve for issuance additional shares of CVS Health common stock in connection with the assumption, exercise and settlement of Aetna stock appreciation rights, Aetna RSUs and Aetna PSUs that are not
vested as of completion of the merger or that are granted after the date of the merger agreement (to the extent permitted by the merger agreement). The actual number of shares of CVS Health common stock to be issued and reserved for issuance upon
completion of the merger will be determined at completion of the merger based on the exchange ratio and the number of Aetna common shares (including the number of shares underlying Aetna stock appreciation rights, Aetna RSUs, Aetna PSUs and
unexercised rights under the Aetna employee stock purchase plan) outstanding at that time. Based on the number of Aetna common shares (including the number of shares underlying Aetna stock appreciation rights, Aetna RSUs, Aetna PSUs and unexercised
rights under the Aetna employee stock purchase plan) outstanding as of February 5, 2018, and the number of shares of CVS Health common stock outstanding as of February 5, 2018, it is expected that, immediately after completion of the merger, former
Aetna shareholders will own approximately 22% of the outstanding shares of CVS Health common stock. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_14"></A>Governance and
Social Matters Following Completion of the Merger (see page 180) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At completion of the merger, the size of the board of directors of
CVS Health will be increased by three and the vacancies created thereby will be filled by Mark T. Bertolini, the Chairman and Chief Executive Officer of Aetna, and two other individuals who are serving on the board of directors of Aetna immediately
prior to completion of the merger who meet CVS Health&#146;s independence criteria as in effect as of such time and who will </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be jointly designated by Aetna and CVS Health prior to completion of the merger. See &#147;The Merger Agreement&#151;Governance and Social Matters Following Completion of the Merger&#148;
beginning on page 180 for further information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that, for at least three years following completion of the
merger, CVS Health will preserve Aetna Foundation, Inc. in a manner consistent in all material respects with the past practice of Aetna, including by maintaining its name and its charitable mission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement also provides that, for at least five years following completion of the merger, CVS Health will maintain
&#147;Aetna&#148; as the primary brand for the insurance businesses of CVS Health and its subsidiaries (including Aetna and its subsidiaries). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_15">
</A>Interests of Aetna&#146;s Directors and Executive Officers in the Merger (see page 209) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the
Aetna board of directors to approve and adopt the merger agreement, Aetna shareholders should be aware that Aetna&#146;s directors and executive officers have interests in the merger that may be different from, or in addition to, the interests of
Aetna shareholders generally. Aetna&#146;s board of directors was aware of these interests and considered them, among other matters, in evaluating and negotiating the merger agreement, in reaching its decision to approve the merger agreement and the
transactions contemplated by the merger agreement (including the merger), and in recommending to Aetna shareholders that the merger agreement be approved and adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These interests include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to the terms of the merger agreement and the outstanding equity awards, outstanding equity awards held by Aetna&#146;s non-employee directors will vest upon completion of the merger. Outstanding unvested equity
awards currently held by Aetna&#146;s executive officers will either vest upon the completion of the merger or upon an involuntary termination of employment (other than for cause) in connection with completion of the merger. Assuming a closing date
for the merger of December 3, 2018 and price per Aetna common share of $205.03, which is calculated based on the price of a share of CVS Health common stock of $71.65, which is the average closing price of a share of CVS Health common stock over the
five-business-day period following the first public announcement of the merger agreement, the aggregate value of vesting of outstanding unvested equity awards upon completion of the merger or upon an involuntary termination of employment (other than
for cause) in connection with completion of the merger payable in the aggregate to Aetna&#146;s non-employee directors and executive officers is estimated to be approximately $48.7 million for Aetna stock appreciation rights, approximately $1.7
million for Aetna RSUs and approximately $30.2 million for Aetna PSUs. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pursuant to individual employment arrangements and the terms of Aetna&#146;s severance plan, each of Aetna&#146;s
executive officers is eligible to receive severance benefits either upon an involuntary termination of employment without &#147;cause&#148; or a resignation for &#147;good reason&#148; in connection with completion of the merger. Pursuant to
individual employment arrangements and Aetna&#146;s severance plan, upon a qualifying termination, Mr.&nbsp;Bertolini and Ms.&nbsp;Lynch are eligible to receive 24 months of cash compensation (calculated as annual base salary and target annual cash
bonus opportunity) payable in equal installments over a period of two years and a pro rata portion of their target bonus opportunity for the year of termination, and Aetna&#146;s other executive officers are eligible to receive between 38 and 100
weeks of salary continuation. In addition, upon a qualifying termination, all of Aetna&#146;s executive officers will continue to receive Aetna-provided benefits for nine weeks, and may elect to continue coverage under Aetna&#146;s medical plan at
employee rates for an additional two months thereafter. Any annual bonus will be paid in accordance with the terms of the merger agreement, except that any executive officer terminated without &#147;cause&#148; in connection with completion of the
merger will receive </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
a bonus payment for the full calendar year. Assuming a qualifying termination of employment for all of Aetna&#146;s executive officers upon completion of the merger, the aggregate value of
severance benefits to be paid or provided (including benefits continuation) to Aetna&#146;s executive officers is estimated to be approximately $24.6&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna&#146;s directors and executive officers are entitled to continued indemnification and insurance coverage under the merger agreement. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These interests are described in further detail, including more information on the assumptions used in calculating the estimated amounts set
forth above, under &#147;Interests of Aetna&#146;s Directors and Executive Officers in the Merger&#148; and &#147;The Merger Agreement&#151;Indemnification and Insurance&#148; beginning on pages 209 and 201, respectively, of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_16"></A>Listing of CVS Health Common Stock; Delisting and Deregistration of Aetna Common Shares (see
page&nbsp;170) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health will apply to have the shares of CVS Health common stock to be issued in the merger approved for listing on
the NYSE, where shares of CVS Health common stock are currently traded. If the merger is completed, Aetna common shares will no longer be listed on the NYSE and will be deregistered under the Securities Exchange Act of 1934, as amended, which is
referred to in this joint proxy statement/prospectus as the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_17"></A>Appraisal or Dissenters&#146; Rights Not
Available to Aetna Shareholders (see page 167) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Pennsylvania law, Aetna shareholders will not be entitled to appraisal or
dissenters&#146; rights in connection with the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_18"></A>Completion of the Merger Is Subject to Certain Conditions (see page
181) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As more fully described in this joint proxy statement/prospectus and in the merger agreement, the obligation of each of CVS
Health and Merger Sub, on the one hand, and Aetna, on the other hand, to complete the merger is subject to the satisfaction (or, to the extent permitted by applicable law, waiver) of a number of conditions, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval and adoption of the merger agreement by the affirmative vote of the holders of at least a majority of the outstanding Aetna common shares; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval of the stock issuance by the affirmative vote of the holders of a majority of the votes cast at the CVS Health special meeting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">absence of any applicable law (including any order) enacted, adopted or promulgated after of the date of the merger agreement being in effect in the U.S. that enjoins, prevents or prohibits completion of the merger;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectiveness of, and absence of any stop order with respect to, the registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this joint proxy statement/prospectus forms a part, relating to
the stock issuance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval for the listing on the NYSE of the shares of CVS Health common stock to be issued in the merger, subject to official notice of issuance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accuracy of the representations and warranties made in the merger agreement by the other party, subject to certain materiality thresholds; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance (or cure of any <FONT STYLE="white-space:nowrap">non-performance)</FONT> in all material respects by the other party of the covenants and agreements required to be performed by it prior to completion of the
merger; and </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the absence of a material adverse effect on the other party (see &#147;The Merger Agreement&#151;Definition of &#145;Material Adverse Effect&#146;&#148; beginning on page 184 of this joint proxy statement/prospectus for
the definition of material adverse effect). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the conditions to all parties&#146; obligations, the obligations
of CVS Health and Merger Sub to complete the merger are subject to the satisfaction (or, to the extent permitted by applicable law, waiver) of certain additional conditions, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expiration or early termination of the waiting period relating to the merger under the HSR Act without the imposition of any term or condition that would have or would reasonably be expected to have, individually or in
the aggregate, a regulatory material adverse effect on CVS Health or Aetna (see &#147;The Merger Agreement&#151;Reasonable Best Efforts Covenant&#148; beginning on page 194 of this joint proxy statement/prospectus for the definition of regulatory
material adverse effect); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain actions by or in respect of, and filings with, certain governmental authorities, which are referred to in this joint proxy statement/prospectus as the required governmental authorizations, having been made or
obtained without the imposition of any term or condition that would have or would reasonably be expected to have, individually or in the aggregate, a regulatory material adverse effect on CVS Health or Aetna. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the conditions to all parties&#146; obligations, the obligation of Aetna to complete the merger is subject to the satisfaction
(or, to the extent permitted by applicable law, waiver) of certain additional conditions, including (i)&nbsp;expiration or early termination of the waiting period relating to the merger under the HSR Act and (ii)&nbsp;the required governmental
authorizations having been made or obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health and Aetna cannot be certain when, or if, the conditions to the merger will be
satisfied or waived, or that the merger will be completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_19"></A>The Merger May Not Be Completed Without All Required Regulatory
Approvals (see page 165) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the merger is conditioned upon the expiration or early termination of the waiting period
relating to the merger under the HSR Act and the required governmental authorizations having been made or obtained and being in full force and effect, and in the case of CVS Health, without the imposition of any term or condition that would have or
would reasonably be expected to have, individually or in the aggregate, a regulatory material adverse effect on CVS Health or Aetna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the HSR Act, certain transactions, including the merger, may not be completed unless certain waiting period requirements have expired or
been terminated. The HSR Act provides that each party must file a <FONT STYLE="white-space:nowrap">pre-merger</FONT> notification with the Federal Trade Commission, which is referred to in this joint proxy statement/prospectus as the FTC, and the
Antitrust Division of the U.S. Department of Justice, which is referred to in this joint proxy statement/prospectus as the DOJ. A transaction notifiable under the HSR Act may not be completed until the expiration of a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-calendar-day</FONT></FONT> waiting period following the parties&#146; filings of their respective HSR Act notification forms or the early termination of that waiting period. The
merger is being reviewed by the DOJ. If the DOJ issues a Request for Additional Information and Documentary Material prior to the expiration of the initial waiting period, the parties must observe a second <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">30-calendar-day</FONT></FONT> waiting period, which would begin to run only after both parties have substantially complied with the request for additional information, unless the waiting period is terminated earlier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of CVS Health and Aetna filed its respective HSR Act notification and report with respect to the merger on January&nbsp;2, 2018. On
February 1, 2018, CVS Health and Aetna each received a request for additional information, which is referred to in this joint proxy statement/prospectus as the second request, from the DOJ in connection with the DOJ&#146;s review of the transactions
contemplated by the merger agreement. Issuance of the second request extends the waiting period under the HSR Act until 30 days after both CVS Health and Aetna </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have substantially complied with the second request or such later time as the parties may agree with the DOJ, unless the waiting period is terminated earlier by the DOJ. CVS Health and Aetna have
been cooperating with the DOJ staff since shortly after the announcement of the merger agreement and are continuing to cooperate with the DOJ staff in its review of the transactions contemplated by the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to federal health care laws and regulations and, in some instances, the health care and insurance laws and regulations of certain
states, and pursuant to certain licenses and contracts of certain of Aetna&#146;s subsidiaries, applicable federal and state regulatory and governmental authorities must approve, or be notified of, CVS Health&#146;s acquisition of control of
Aetna&#146;s health maintenance organizations, insurance companies, pharmacy businesses and other regulated businesses or entities. To obtain these approvals and provide such notices, CVS Health, or the applicable CVS Health subsidiary, and in some
instances Aetna, or the applicable Aetna regulated entity, as the case may be, has filed and/or will file acquisition of control and/or material modification or other statements, notices or applications, as required by federal health care law or
regulation and the insurance and health care laws and regulations of each applicable state and country or the Aetna regulated entities&#146; licenses and contracts. In addition, certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental
authorities must approve, or be notified of, the merger, and CVS Health and/or Aetna and/or their respective subsidiaries will file all such statements, notices, or applications, as are required by the laws of applicable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> governmental authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither CVS Health nor Aetna is aware of any material governmental
approvals or actions that are required for completion of the merger other than those described above. It is presently contemplated that if any such additional material governmental approvals or actions are required, those approvals or actions will
be sought. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health and Aetna have agreed to use their respective reasonable best efforts to obtain all regulatory approvals required
to complete the merger, which reasonable best efforts include contesting any proceeding brought by a governmental authority seeking to prohibit completion of the merger or seeking damages or to impose any terms or conditions in connection with the
merger. In using its reasonable best efforts, under the terms of the merger agreement, CVS Health is required to take all actions and do all things necessary, proper or advisable to complete the merger in connection with (i)&nbsp;the expiration or
early termination of the waiting period relating to the merger under the HSR Act, (ii)&nbsp;any other antitrust law or (iii)&nbsp;the required governmental authorizations, except that CVS Health is not required to take any action or agree to any
term or condition in connection with those matters if that action, term or condition would have or would reasonably be expected to have, individually or in the aggregate, a regulatory material adverse effect on CVS Health or on Aetna (see &#147;The
Merger Agreement&#151;Reasonable Best Efforts Covenant&#148; beginning on page 194 of this joint proxy statement/prospectus for the definition of regulatory material adverse effect). In addition, in connection with obtaining the regulatory approvals
required to complete the merger, (x)&nbsp;neither CVS Health nor Aetna is required to take any action or agree to any term or condition that is not conditioned upon completion of the merger and (y)&nbsp;Aetna is not permitted to take any action or
agree to any term or condition without CVS Health&#146;s consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_20"></A>Description of Debt Financing (see page 170) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger is not subject to a financing condition. On December&nbsp;3, 2017, CVS Health entered into a bridge facility commitment letter,
which is referred to in this joint proxy statement/prospectus as the bridge facility commitment letter, with Barclays Bank PLC, Goldman Sachs Bank USA, Goldman Sachs Lending Partners LLC, Bank of America, N.A. and Merrill Lynch, Pierce,
Fenner&nbsp;&amp; Smith Incorporated (solely in its capacity as an arranger), to finance up to $49.0&nbsp;billion of the cash consideration and fees, commissions and expenses payable by CVS Health in connection with the merger to the extent that CVS
Health has not received $49.0&nbsp;billion of net cash proceeds from a combination of (a)&nbsp;the issuance by CVS Health or one of its wholly-owned subsidiaries of a combination of equity securities, equity-linked securities or unsecured debt
securities and/or (b)&nbsp;unsecured term loans, in each case, at or prior to completion of the merger, which is referred to in this joint proxy statement/prospectus as the bridge facility. Barclays Bank PLC, Goldman Sachs Bank USA, Goldman Sachs
Lending Partners LLC and Bank of America, N.A. each provided a commitment to fund loans under the bridge facility </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and are collectively referred to in this joint proxy statement/prospectus as the initial bridge commitment parties. On December&nbsp;15, 2017, CVS Health, the initial bridge commitment parties
and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated entered into a joinder agreement to the bridge facility commitment letter, which is referred to in this joint proxy statement/prospectus as the bridge joinder agreement, with JPMorgan
Chase Bank, N.A., Wells Fargo Bank, N.A., The Bank of New York Mellon, The Bank of Tokyo-Mitsubishi UFJ, Ltd., Mizuho Bank, Ltd., Royal Bank of Canada, SunTrust Bank, U.S. Bank National Association, Fifth Third Bank, KeyBank National Association,
PNC Bank, National Association, Banco Santander, S.A., New York Branch, Sumitomo Mitsui Banking Corporation, Bank of China, New York Branch, Industrial and Commercial Bank of China Limited, New York Branch, The Toronto-Dominion Bank, New York Branch
and Guggenheim Life and Annuity Company which are collectively referred to in this joint proxy statement/prospectus as the additional bridge commitment parties. The bridge joinder agreement amends the bridge facility commitment letter and
reallocates the commitments of the initial bridge commitment parties to fund loans under the bridge facility among the initial bridge commitment parties and the additional bridge commitment parties. The initial bridge commitment parties together
with the additional bridge commitment parties are collectively referred to in this joint proxy statement/prospectus as the bridge commitment parties. The bridge commitment parties&#146; obligation to fund the bridge facility is subject to several
limited conditions as set forth in the bridge facility commitment letter, including, among others, completion of the merger, the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of a material adverse effect (as defined in the bridge facility
commitment letter) on Aetna, the accuracy in all material respects of certain representations and warranties related to both CVS Health and Aetna, the absence of certain defaults by CVS Health, the delivery of certain financial statements of CVS
Health and Aetna and other customary conditions to completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2017, CVS Health entered into a term loan agreement,
which is referred to in this joint proxy statement/prospectus as the term loan agreement, with a group of twenty banks and other financial institutions, which are collectively referred to in this joint proxy statement/prospectus as the term lenders,
consisting of a $3.0&nbsp;billion three-year tranche and a $2.0&nbsp;billion five-year tranche, to finance $5.0&nbsp;billion of the cash consideration and fees, commissions and expenses payable by CVS Health in connection with the merger, which is
referred to in this joint proxy statement/prospectus as the term loan facility. The occurrence of the effective date under the term loan agreement on December&nbsp;15, 2017 had the effect of reducing the bridge facility by a principal amount of
$5.0&nbsp;billion to $44.0&nbsp;billion. The term lenders&#146; obligation to fund the term loan facility is subject to several limited conditions as set forth in the term loan agreement, including, among others, completion of the merger, the <FONT
STYLE="white-space:nowrap">non-occurrence</FONT> of a material adverse effect (as defined in the term loan agreement) on Aetna, the accuracy in all material respects of certain representations and warranties related to both CVS Health and Aetna, the
absence of certain defaults by CVS Health, the delivery of certain financial statements of CVS Health and Aetna and other customary conditions to completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2017, CVS Health and its current group of lenders entered into a first amendment to each of CVS Health&#146;s existing
revolving credit facilities (consisting of (i)&nbsp;a $1.0&nbsp;billion, <FONT STYLE="white-space:nowrap">364-day</FONT> unsecured credit facility expiring on May&nbsp;17, 2018, (ii) a $1.25&nbsp;billion, five-year unsecured <FONT
STYLE="white-space:nowrap">back-up</FONT> credit facility expiring on July&nbsp;24, 2019, (iii) a $1.25&nbsp;billion, five-year unsecured <FONT STYLE="white-space:nowrap">back-up</FONT> credit facility expiring on July&nbsp;1, 2020 and (iv)&nbsp;a
$1.0&nbsp;billion, five-year unsecured <FONT STYLE="white-space:nowrap">back-up</FONT> credit facility expiring on May&nbsp;18, 2022, which is referred to in this joint proxy statement/prospectus as the 2017 five-year revolving credit facility, to
(w)&nbsp;amend the covenant restricting the incurrence of debt by CVS Health&#146;s subsidiaries to up to 15% of net tangible assets, which is referred to in this joint proxy statement/prospectus as the net tangible assets test, by
(a)&nbsp;excluding any indebtedness of Aetna and its subsidiaries existing as of completion of the merger (other than any increase, refinancing or replacement thereof), which is referred to in this joint proxy statement/prospectus as the Aetna
existing indebtedness, from indebtedness for purposes of determining compliance with the net tangible assets test, and (b)&nbsp;restricting the indebtedness that may be incurred by all of CVS Health&#146;s subsidiaries (excluding the Aetna existing
indebtedness and other indebtedness under capital leases incurred in connection with a sale and leaseback transaction) to an amount not exceeding $900.0&nbsp;million in the aggregate, in each case, on and following completion of the merger until the
date that CVS Health is in compliance with the net tangible assets </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
test without giving effect to the exclusion set forth in clause (a)&nbsp;above, (x) expressly permit completion of the merger under the acquisition covenant, (y)&nbsp;amend the financial covenant
by (a)&nbsp;increasing the consolidated indebtedness to total capitalization ratio from 0.60:1.00 to 0.65:1.00 from completion of the merger through and including the fiscal quarter ending September&nbsp;30, 2019, and (b)&nbsp;excluding unsecured
indebtedness in an aggregate principal amount not exceeding $49.0&nbsp;billion incurred by CVS Health for the purpose of financing the merger (including all of the transaction costs, fees, commissions and expenses in connection therewith) and which
is redeemable or prepayable if the merger is not consummated, from the calculation of consolidated indebtedness and total capitalization, until the earliest of the occurrence of completion of the merger, the date that is 30 days following the
termination of the merger agreement in accordance with its terms and August&nbsp;31, 2019, and (z)&nbsp;increase the threshold amount of specified events of default to (a)&nbsp;prior to the later of (i)&nbsp;the termination or other expiration of
the bridge facility commitment letter in accordance with its terms and (ii)&nbsp;the termination or other expiration of the bridge facility if it is entered into, $250.0&nbsp;million, and (b)&nbsp;at all other times, $200.0&nbsp;million. In this
joint proxy statement/prospectus, CVS Health&#146;s existing revolving credit agreements are referred to as the revolving credit agreements, and the lenders under the revolving credit agreements are referred to as the revolving lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a more complete description of CVS Health&#146;s debt financing for the merger, see &#147;Aetna Proposal I: Approval and Adoption of the
Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Description of Debt Financing&#148; beginning on page 170 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_21"></A>CVS Health and Aetna Expect the Merger to be Completed in the Second Half of 2018 (see page 177) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will occur three business days after the conditions to its completion have been satisfied or, to the extent permitted by applicable
law, waived, unless otherwise mutually agreed by the parties. As of the date of this joint proxy statement/prospectus, CVS Health and Aetna expect the merger to be completed in the second half of 2018. However, there can be no assurance as to when,
or if, the merger will occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_22"></A>No Solicitation by Aetna or CVS Health (see page 190) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As more fully described in this joint proxy statement/prospectus and in the merger agreement, and subject to the exceptions described below and
in the merger agreement, each of Aetna and CVS Health has agreed not to, among other things, (i)&nbsp;solicit, initiate or take any action to knowingly facilitate or knowingly encourage the submission of any acquisition proposal from any third
party, (ii)&nbsp;enter into or participate in any discussions or negotiations with any third party that such party knows is seeking to make, or has made, an acquisition proposal, (iii)&nbsp;fail to make or withdraw or qualify, amend or modify in any
manner adverse to the other party the recommendation of such party&#146;s board of directors that its shareholders approve and adopt the merger agreement, in the case of Aetna, or its stockholders approve the stock issuance, in the case of CVS
Health, or (iv)&nbsp;fail to enforce or grant any waiver or release under any standstill or similar agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, at any time prior
to the approval and adoption of the merger agreement by Aetna shareholders, in the case of Aetna, or the approval of the stock issuance by CVS Health stockholders, in the case of CVS Health, subject to the terms and conditions described in the
merger agreement, each of Aetna or CVS Health, as applicable, is permitted to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">engage in negotiations or discussions with any third party that has made after the date of the merger agreement a superior proposal or an acquisition proposal that is reasonably likely to lead to a superior proposal;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following receipt of a superior proposal after the date of the merger agreement, withdraw or modify in a manner
adverse to the other party the recommendation of such party&#146;s board of directors that its shareholders approve and adopt the merger agreement, in the case of Aetna, or its stockholders approve the stock issuance, in the case of CVS Health,
and/or terminate the merger agreement to enter into a </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
definitive agreement providing for such superior proposal and pay concurrently a termination fee to the other party (See &#147;The Merger Agreement&#151;Termination of the Merger Agreement&#148;
beginning on page 203 of this joint proxy statement/prospectus); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in response to certain events other than receipt of a superior proposal, withdraw or modify in a manner adverse to the other party the recommendation of such party&#146;s board of directors that its shareholders approve
and adopt the merger agreement, in the case of Aetna, or its stockholders approve the stock issuance, in the case of CVS Health. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna or CVS Health, as applicable, is only permitted to take the actions described above if its board of directors determines that the
failure to take that action would be reasonably likely to be inconsistent with its fiduciary duties under applicable law. In addition, Aetna&#146;s board of directors is not permitted to withdraw or modify its recommendation that Aetna shareholders
approve and adopt the merger agreement or to terminate the merger agreement in order to enter into a definitive agreement with respect to a superior proposal, and CVS Health&#146;s board of directors is not permitted to withdraw or modify its
recommendation that CVS Health stockholders approve the stock issuance or to terminate the merger agreement in order to enter into a definitive agreement with respect to a superior proposal, unless, before taking that action, the applicable party
notifies the other party that it intends to take that action and, if requested by the other party, negotiates in good faith with the other party for certain periods of time regarding any proposal by the other party to amend the terms of the merger
agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_23"></A>Termination of the Merger Agreement (see page 203) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As more fully described in this joint proxy statement/prospectus and in the merger agreement, and subject to the terms and conditions set forth
in the merger agreement, the merger agreement may be terminated at any time before completion of the merger in any of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by mutual written consent of CVS Health and Aetna; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by either CVS Health or Aetna, if: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the merger has not been completed on or before December&nbsp;3, 2018, which is referred to in this joint proxy statement/prospectus as the initial end date, unless all conditions to completion of the merger have been
satisfied or waived on the initial end date other than the regulatory approvals condition (as defined under &#147;The Merger Agreement&#151;Conditions to Completion of the Merger&#148;), and either CVS Health or Aetna elects to extend the initial
end date to March&nbsp;3, 2019, which is referred to in this joint proxy statement/prospectus as the extended end date, in which case the merger agreement may be terminated by either CVS Health or Aetna if the merger has not been completed on or
before March&nbsp;3, 2019, unless all conditions to completion of the merger have been satisfied or waived on the extended end date other than the regulatory approvals condition, and CVS Health elects to extend the extended end date to June&nbsp;3,
2019, which together with the initial end date and the extended end date is referred to in this joint proxy statement/prospectus as the end date, in which case the merger agreement may be terminated by either CVS Health or Aetna if the merger has
not been completed on or before June&nbsp;3, 2019; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there is in effect any applicable law or final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> order of any governmental authority in the U.S., in each case, enacted, adopted or promulgated after the date of
the merger agreement, that enjoins, prevents or prohibits completion of the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna shareholders fail to approve and adopt the merger agreement upon a vote taken on a proposal to approve and adopt the merger agreement at the Aetna special meeting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health stockholders fail to approve the stock issuance upon a vote taken on a proposal to approve the stock issuance at the CVS Health special meeting; or </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there has been a breach of any representation or warranty or failure to perform any covenant or agreement on the part of the other party that would cause the other party to fail to satisfy the applicable condition to
completion of the merger related to accuracy of representations and warranties or performance of covenants and agreements, as applicable, and that breach or failure to perform either is incapable of being cured by the end date or has not been cured
within 45 days following notice from the <FONT STYLE="white-space:nowrap">non-breaching</FONT> party of such breach or failure to perform; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by CVS Health: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if Aetna&#146;s board of directors withdraws or modifies in a manner adverse to CVS Health its recommendation that Aetna shareholders approve and adopt the merger agreement or fails to publicly confirm that
recommendation within seven business days after a request to do so from CVS Health; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if Aetna has breached in any material respect any of its obligations described under &#147;The Merger Agreement&#151;No Solicitation&#148; beginning on page 190 of this joint proxy statement/prospectus or its obligation
to call and hold a meeting of its shareholders for purposes of approving and adopting the merger agreement described under &#147;The Merger Agreement&#151;Obligations to Call Shareholders&#146; and Stockholders&#146; Meetings&#148; beginning on page
189 of this joint proxy statement/prospectus; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the approval of the stock issuance by CVS Health stockholders, in order to enter into a definitive agreement providing for a superior proposal (which definitive agreement must be entered into concurrently with,
or immediately following, the termination of the merger agreement), provided that CVS Health concurrently pays to Aetna the applicable termination fee; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If CVS Health&#146;s board of directors withdraws or modifies in a manner adverse to Aetna its recommendation that CVS Health stockholders approve the stock issuance or fails to publicly confirm that recommendation
within seven business days after a request to do so from Aetna; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if CVS Health has breached in any material respect any of its obligations described under &#147;The Merger Agreement&#151;No Solicitation&#148; beginning on page 190 of this joint proxy statement/prospectus or its
obligations to call and hold a meeting of its stockholders for purposes of approving the stock issuance described under &#147;The Merger Agreement&#151;Obligations to Call Shareholders&#146; and Stockholders&#146; Meetings&#148; beginning on page
189 of this joint proxy statement/prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the approval and adoption of the merger agreement by Aetna shareholders, in order to enter into a definitive agreement providing for a superior proposal (which definitive agreement must be entered into
concurrently with, or immediately following, the termination of the merger agreement), provided that Aetna concurrently pays to CVS Health the applicable termination fee; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if (i)&nbsp;there is in effect any order in respect of certain regulatory matters that prohibits completion of the merger, which order has not become final and <FONT STYLE="white-space:nowrap">non-appealable,</FONT>
(ii)&nbsp;within 30 days after the order taking effect, CVS Health has not instituted appropriate proceedings seeking to have the order terminated and (iii)&nbsp;CVS Health&#146;s failure to institute appropriate proceedings has not been cured
within 10 days following notice to CVS Health from Aetna of Aetna&#146;s intent to terminate the merger agreement. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_24"></A>Termination Fees (see page 205) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As more fully described in this joint proxy statement/prospectus and in the merger agreement, and subject to the terms and conditions of the
merger agreement, Aetna has agreed to pay CVS Health a termination fee of $2.1&nbsp;billion if the merger agreement is terminated under any of the following circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by CVS Health because Aetna&#146;s board of directors withdraws or modifies in a manner adverse to CVS Health its recommendation that Aetna shareholders approve and adopt the merger agreement or fails to publicly
confirm that recommendation within seven business days after a request to do so from CVS Health; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by CVS Health because Aetna has breached in any material respect any of its obligations described under &#147;The Merger Agreement&#151;No Solicitation&#148; beginning on page 190 of this joint proxy
statement/prospectus or its obligation to call and hold a meeting of its shareholders for purposes of approving and adopting the merger agreement described under &#147;The Merger Agreement&#151;Obligations to Call Shareholders&#146; and
Stockholders&#146; Meetings&#148; beginning on page 189 of this joint proxy statement/prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna, prior to the approval and adoption of the merger agreement by Aetna shareholders, in order to enter into a definitive agreement providing for a superior proposal (which definitive agreement must be entered
into concurrently with, or immediately following, the termination of the merger agreement); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by CVS Health or Aetna because Aetna shareholders fail to approve and adopt the merger agreement upon a vote taken on a proposal to approve and adopt the merger agreement at the Aetna special meeting and, at or prior to
the Aetna special meeting, an acquisition proposal for Aetna has been publicly disclosed or announced, and on or prior to the first anniversary of such termination Aetna enters into a definitive agreement, or completes a transaction, relating to an
acquisition proposal for Aetna. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As more fully described in this joint proxy statement/prospectus and in the merger
agreement, and subject to the terms and conditions of the merger agreement, CVS Health has agreed to pay Aetna a termination fee of $2.1&nbsp;billion if the merger agreement is terminated under any of the following circumstances: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna because CVS Health&#146;s board of directors withdraws or modifies in any manner adverse to Aetna its recommendation that CVS Health stockholders approve the stock issuance or fails to publicly confirm that
recommendation within seven business days after a request to do so from Aetna; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna because CVS Health has breached in a material respect any of its obligations described under &#147;The Merger Agreement&#151;No Solicitation&#148; beginning on page 190 of this joint proxy statement/prospectus
or its obligations to call and hold a meeting of its stockholders for purposes of approving the stock issuance described under &#147;The Merger Agreement&#151;Obligations to Call Shareholders&#146; and Stockholders&#146; Meetings&#148; beginning on
page 189 of this joint proxy statement/prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by CVS Health, prior to obtaining the approval of the stock issuance by CVS Health stockholders, in order to enter into a definitive agreement providing for a superior proposal (which definitive agreement must be
entered into concurrently with, or immediately following, the termination of the merger agreement); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna or CVS Health because CVS Health stockholders fail to approve the stock issuance upon a vote taken on a proposal to approve the stock issuance at the CVS Health special meeting and, at or prior to the CVS
Health special meeting, an acquisition proposal for CVS Health has been publicly disclosed or announced, and on or prior to the first anniversary of such termination CVS Health enters into a definitive agreement, or completes a transaction, relating
to an acquisition proposal for CVS Health. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as more fully described in this joint proxy statement/prospectus and in the
merger agreement, and subject to the terms and conditions of the merger agreement, CVS Health has agreed to pay Aetna a termination fee of $2.1&nbsp;billion if both (x)&nbsp;the merger agreement is terminated under any the following circumstances:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna or CVS Health because the merger has not been completed on or before the end date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna or CVS Health because there is in effect any applicable law or final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> order enacted, adopted or promulgated after the date of the merger agreement in
respect of certain regulatory matters in the U.S. that prohibits completion of the merger; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna because (i)&nbsp;there is in effect any order in respect of certain regulatory matters that prohibits completion of the merger, which order has not become final and
<FONT STYLE="white-space:nowrap">non-appealable,</FONT> (ii)&nbsp;within 30 days after the order taking effect, CVS Health has not instituted appropriate proceedings seeking to have the order terminated and (iii)&nbsp;CVS Health&#146;s failure to
institute appropriate proceedings has not been cured within 10 days following notice to CVS Health from Aetna of Aetna&#146;s intent to terminate the merger agreement; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and (y)&nbsp;at the time of termination of the merger agreement, all of the conditions to CVS Health&#146;s and Merger Sub&#146;s obligations to complete the
merger are satisfied or waived other than (i)&nbsp;the regulatory approvals condition and (ii)&nbsp;the condition requiring the absence of any applicable law or order being in effect in the U.S. that prohibits completion of the merger (but only if
that condition is not satisfied solely due to any applicable law or final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> order in respect of certain regulatory matters). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except in the case of fraud, if either party receives a termination fee in accordance with the provisions of the merger agreement, the receipt
of the termination fee will be the receiving party&#146;s sole and exclusive remedy against the paying party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;The Merger
Agreement&#151;Termination Fee and Expenses&#148; beginning on page 205 of this joint proxy statement/prospectus for a more complete description of the circumstances under which Aetna or CVS Health will be required to pay a termination fee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_25"></A>Specific Performance; Remedies (see page 207) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the merger agreement, each of CVS Health and Aetna is entitled to an injunction or injunctions to prevent breaches of the merger
agreement and to specifically enforce the terms and provisions of the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_26"></A>Material U.S. Federal Income Tax
Consequences (see page 167) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange of Aetna common shares for the merger consideration pursuant to the merger will be a taxable
transaction for U.S. federal income tax purposes. Accordingly, an Aetna shareholder that is a U.S. holder (as defined in &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock
Issuance&#151;Material U.S. Federal Income Tax Consequences&#148;) will recognize taxable capital gain or loss in an amount equal to the difference, if any, between (i)&nbsp;the sum of (x)&nbsp;the amount of cash, including cash in lieu of
fractional shares, received by such U.S. holder in the merger and (y)&nbsp;the fair market value of the shares of CVS Health common stock received by such U.S. holder in the merger and (ii)&nbsp;such U.S.&nbsp;holder&#146;s adjusted tax basis in the
Aetna common shares exchanged therefor. With respect to an Aetna shareholder that is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (as defined in &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health
Proposal I: Approval of the Stock Issuance&#151;Material U.S. Federal Income Tax Consequences&#148;), the exchange of Aetna common shares for the merger consideration pursuant to the merger generally will not result in tax to such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder under U.S. federal income tax laws unless such <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> has certain connections with the United States. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Aetna shareholder is urged to read the discussion in the section entitled &#147;Aetna
Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Material U.S. Federal Income Tax Consequences&#148; beginning on page 167 of this joint proxy statement/prospectus and to
consult its tax advisor to determine the particular U.S. federal, state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income or other tax consequences to it of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_27"></A>Accounting Treatment (see page 169) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will be accounted for as an acquisition of a business. CVS Health will record assets acquired and liabilities assumed from Aetna
primarily at their respective fair values at the date of completion of the merger. Any excess of the purchase price (as described under <I>Note 4. Estimate of Consideration Expected to be Transferred</I> under &#147;CVS Health and Aetna Unaudited
Pro Forma Condensed Combined Financial Statements&#148; beginning on page 42 of this joint proxy statement/prospectus) over the net fair value of such assets and liabilities will be recorded as goodwill. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_28"></A>Rights of Aetna Shareholders Will Change as a Result of the Merger (see page 225) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna shareholders will have different rights once they become CVS Health stockholders due to differences between the organizational documents
of CVS Health and Aetna and differences between Delaware law, under which CVS Health is incorporated, and Pennsylvania law, under which Aetna is incorporated. These differences are described in more detail under &#147;Comparison of Stockholder
Rights&#148; beginning on page 225 of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="rom482402_28a"></A><B>Litigation Relating to the Merger</B> <B>(see
page 176)</B> </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February 8, 2018, seven complaints had been filed by purported Aetna shareholders challenging the merger. The
first, a putative class action complaint, was filed by Olivier Miramond in the United States District Court for the District of Connecticut and is captioned <I>Miramond v. Aetna, Inc., et al.</I>, case number 3:18-cv-00083. The second complaint,
filed in the United States District Court for the District of Connecticut by Shiva Stein individually, is captioned <I>Stein v. Aetna, Inc., et al</I>., case number 3:18-cv-00136. The third complaint, a putative class action, was filed by Robert
Freedman in the United States District Court for the Eastern District of Pennsylvania and is captioned <I>Freedman v. Aetna, Inc., et al</I>., case number 2:18-cv-00323. The fourth complaint, filed in the United States District Court for the
District of Connecticut by Luan Pham individually, is captioned <I>Pham v. Aetna, Inc., et al.</I>, case number 3:18-cv-00154. The fifth complaint, filed in the United States District Court for the Eastern District of Pennsylvania by Vladimir
Gusinsky Rev. Trust individually, is captioned <I>Vladimir Gusinsky Rev. Trust v. Aetna Inc. et al.</I>, case number 2:18-cv-00361. The sixth complaint, a putative class action complaint, was filed by Dr. Eli Inzlicht-Sprei in the United States
District Court for the District of Connecticut and is captioned <I>Inzlicht-Sprei v. Aetna, Inc., et al.</I>, case number 3:18-cv-00176. The seventh complaint, a putative class action complaint, was filed by Joel Rosenfeld in the United States
District Court for the District of Connecticut and is captioned <I>Rosenfeld v. Aetna, Inc., et al., </I>case number 3:18-cv-00213. The complaints name as defendants Aetna and each member of Aetna&#146;s board of directors. In addition, the
<I>Vladimir Gusinsky Rev. Trust</I> complaint names CVS Health and Merger Sub as defendants. The complaints generally allege, among other things, that the merger consideration in the proposed transaction is unfair, inadequate and undervalues Aetna;
that the defendants failed to conduct a fair and reasonable sales process; that the merger agreement&#146;s deal protection provisions improperly deter other suitors from submitting a superior offer for Aetna; that Aetna&#146;s board of directors
and executive officers are conflicted because they have secured unique benefits for themselves from the proposed transaction not available to Aetna shareholders generally; and that the defendants authorized the filing of a materially incomplete and
misleading registration statement. Among other remedies, the complaints seek to enjoin the Aetna special meeting and the closing of the merger, as well as costs and attorneys&#146; fees. Defendants believe that the complaints are without merit. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_29"></A>Risk Factors (see page 62) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should also carefully consider the risks that are described in the section entitled &#147;Risk Factors&#148; beginning on page 62 of this
joint proxy statement/prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_30"></A>SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF CVS HEALTH
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents selected historical consolidated financial data of CVS Health. The selected historical consolidated
financial data of CVS Health for each of the years ended December&nbsp;31, 2016, 2015 and 2014, and as of December&nbsp;31, 2016 and 2015, are derived from CVS Health&#146;s audited consolidated financial statements and related notes contained in
its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, which is incorporated by reference into this joint proxy statement/prospectus. The selected historical consolidated financial data of
CVS Health for each of the years ended December&nbsp;31, 2013 and 2012, and as of December&nbsp;31, 2014, 2013 and 2012, have been derived from CVS Health&#146;s audited consolidated financial statements for such years, which have not been
incorporated by reference into this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected historical consolidated financial data of CVS Health
as of, and for the nine months ended, September&nbsp;30, 2017 and for the nine months ended September&nbsp;30, 2016, are derived from CVS Health&#146;s unaudited consolidated financial statements and related notes contained in its Quarterly Report
on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September&nbsp;30, 2017, which is incorporated by reference into this joint proxy statement/prospectus. The selected historical consolidated financial data of CVS
Health as of September&nbsp;30, 2016 are derived from CVS Health&#146;s unaudited consolidated financial statements and related notes contained in its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period
ended September&nbsp;30, 2016, which has not been incorporated by reference into this joint proxy statement/prospectus. CVS Health&#146;s management believes that CVS Health&#146;s unaudited consolidated financial statements have been prepared on a
basis consistent with its audited financial statements and include all normal and recurring adjustments necessary for a fair presentation of the results for each interim period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the following selected historical consolidated financial data of CVS Health
in conjunction with CVS Health&#146;s audited consolidated financial statements contained in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016 and unaudited consolidated financial
statements and related notes contained in its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September&nbsp;30, 2017. In particular, see the notes to CVS Health&#146;s audited consolidated
financial statements for significant events affecting the comparability of results as well as material uncertainties regarding CVS Health&#146;s future financial condition and results of operations. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of/For the</B><br><B>Nine Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of/For the</B><br><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>9/30/17</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>9/30/16</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015 (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(millions of dollars, except per share amounts, number of stores, growth rates and ratios)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on early extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations attributable to CVS Health</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total working capital (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total CVS Health shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Per Common Share Data</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations attributable to CVS Health:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash dividends per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Operating Data</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio of earnings to fixed charges (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">x&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.11</TD>
<TD NOWRAP VALIGN="bottom">x&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.58</TD>
<TD NOWRAP VALIGN="bottom">x&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.26</TD>
<TD NOWRAP VALIGN="bottom">x&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.39</TD>
<TD NOWRAP VALIGN="bottom">x&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.81</TD>
<TD NOWRAP VALIGN="bottom">x&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.72</TD>
<TD NOWRAP VALIGN="bottom">x&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total same store sales growth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pharmacy same store sales growth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of stores (at end of period)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes the acquired operations of Omnicare, Inc. from August&nbsp;18, 2015 and the acquired operations of the clinics and pharmacies of Target Corporation from December&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">As of January&nbsp;1, 2016, CVS Health early adopted Accounting Standard Update <FONT STYLE="white-space:nowrap">No.&nbsp;2015-17,</FONT> <I>Income Taxes </I>(Topic 740) issued by the Financial Accounting Standards
Board in November 2015. The effect of the retrospective adoption on CVS Health&#146;s historical consolidated balance sheets is a reduction in current assets and deferred income taxes of $985&nbsp;million, $902&nbsp;million and $693&nbsp;million as
of December&nbsp;31, 2014, 2013 and 2012 respectively. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">&#147;Fixed charges&#148; consist of interest expense, capitalized interest, amortization of debt discount, and a portion of net rental expense deemed to be representative of the interest factor.&nbsp;The ratio of
earnings to fixed charges is calculated as income from continuing operations, before provision for income taxes, plus fixed charges (excluding capitalized interest), plus amortization of capitalized interest, with the sum divided by fixed charges.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_31"></A>SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF AETNA
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents selected historical consolidated financial data of Aetna. The selected historical consolidated financial
data of Aetna for each of the years ended December&nbsp;31, 2016, 2015 and 2014, and as of December&nbsp;31, 2016 and 2015, are derived from Aetna&#146;s audited consolidated financial statements and related notes contained in its Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, which is incorporated by reference into this joint proxy statement/prospectus. The selected historical consolidated financial data of Aetna for each of the
years ended December&nbsp;31, 2013 and 2012, and as of December&nbsp;31, 2014, 2013 and 2012, are derived from Aetna&#146;s audited consolidated financial statements for such years, which have not been incorporated by reference into this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected historical consolidated financial data of Aetna as of, and for the nine months ended,
September&nbsp;30, 2017 and for the nine months ended September&nbsp;30, 2016, are derived from Aetna&#146;s unaudited consolidated financial statements and related notes contained in its Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September&nbsp;30 2017, which is incorporated by reference into this joint proxy statement/prospectus. The selected historical consolidated financial data of Aetna as of
September&nbsp;30, 2016 are derived from Aetna&#146;s unaudited consolidated financial statements and related notes contained in its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended
September&nbsp;30, 2016, which has not been incorporated by reference into this joint proxy statement/prospectus. Aetna&#146;s management believes that Aetna&#146;s unaudited consolidated financial statements have been prepared on a basis consistent
with its audited financial statements and include all normal and recurring adjustments necessary for a fair presentation of the results for each interim period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the following selected historical consolidated financial data of Aetna in conjunction with Aetna&#146;s audited consolidated
financial statements contained in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016 and unaudited consolidated financial statements and related notes contained in its Quarterly Report on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September&nbsp;30, 2017. In particular, see the notes to Aetna&#146;s audited consolidated financial statements for significant events affecting the comparability of
results as well as material uncertainties regarding Aetna&#146;s future financial condition and results of operations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of/For the Nine<BR>Months Ended,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of/For the Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>9/30/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>9/30/2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013 (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012 (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(millions of dollars, except per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income Statement Data</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to Aetna</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net realized capital gains (losses), net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Aetna shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Per Common Share Data</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends declared in period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to Aetna:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Aetna acquired Coventry Health Care, Inc. in May 2013, which impacts the comparability of operating results for the years ended December&nbsp;31, 2013 to 2016 to prior periods. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Amounts as of December&nbsp;31, 2012 to 2015 have been retroactively restated to reflect the reclassification of debt issuance costs from other current and long-term assets to a reduction of long-term debt as a result
of the adoption of new accounting guidance during the year ended December&nbsp;31, 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_32"></A>COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA COMBINED PER
SHARE DATA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth selected historical and unaudited pro forma combined per share information for CVS Health
and Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Historical Per Common Share Information of CVS Health and Aetna</I></B>. The historical per common share information of
each of CVS Health and Aetna below is derived from the audited consolidated financial statements of each of CVS Health and Aetna as of and for the year ended December&nbsp;31, 2016, and the unaudited consolidated financial statements of each of CVS
Health and Aetna as of and for the nine months ended September&nbsp;30, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Combined per CVS Health Common
Share Data</I></B>. The unaudited pro forma combined per CVS Health common share data set forth below give effect to the merger under the acquisition method of accounting, as if the merger had been effective on January&nbsp;1, 2016, the first day of
CVS Health&#146;s fiscal year ended December&nbsp;31, 2016, in the case of income from continuing operations per share. The unaudited pro forma combined book value per CVS Health common share data set forth below give effect to the merger under the
acquisition method of accounting, as if the merger had been effective September&nbsp;30, 2017, assuming that each outstanding Aetna common share, the vested Aetna RSUs and vested Aetna PSUs had been converted into shares of CVS Health common stock
based on the exchange ratio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined per CVS Health common share data is derived from the audited consolidated
financial statements of each of CVS Health and Aetna as of and for the year ended December&nbsp;31, 2016, and the unaudited condensed consolidated financial statements of each of CVS Health and Aetna as of and for the nine months ended
September&nbsp;30, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The acquisition method of accounting is based on Financial Accounting Standards Board, Accounting Standards
Codification (which is referred to in this joint proxy statement/prospectus as ASC) 805, <I>Business Combinations</I>, and uses the fair value concepts defined in ASC 820, <I>Fair Value Measurements</I>, which CVS Health has adopted as required.
Acquisition accounting requires, among other things, that most assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. Fair value measurements recorded in acquisition accounting are dependent upon
certain valuation studies of Aetna&#146;s assets and liabilities and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. Accordingly, the pro forma adjustments reflect
the assets and liabilities of Aetna at their preliminary estimated fair values. Differences between these preliminary estimates and the final values in acquisition accounting will occur, and these differences could have a material impact on the
unaudited pro forma combined per share information set forth in the following table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined per CVS Health
common share data does not purport to represent the actual results of operations that CVS Health would have achieved had the companies been combined during these periods or to project the future results of operations that CVS Health may achieve
after completion of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Combined per Aetna Equivalent Share Data</I></B>. The unaudited pro forma
combined per Aetna equivalent share data set forth below shows the effect of the merger from the perspective of an owner of Aetna common shares. The information was calculated by multiplying the unaudited pro forma combined per share of CVS Health
common stock amounts by the exchange ratio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Generally</I></B>. You should read the below information in conjunction with the
selected historical consolidated financial data included elsewhere in this joint proxy statement/prospectus and the historical consolidated financial statements of CVS Health and Aetna and related notes that have been filed with the SEC, certain of
which are incorporated by reference into this joint proxy statement/prospectus. See &#147;Selected Historical Consolidated Financial Data of CVS Health&#148;, &#147;Selected Historical Consolidated Financial Data of Aetna&#148; and &#147;Where You
Can Find More Information&#148; beginning on pages 37, 39 and 254, respectively, of this joint proxy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement/prospectus. The unaudited pro forma combined per CVS Health common share data and the unaudited pro forma combined per Aetna equivalent share data is derived from, and should be read in
conjunction with, the CVS Health and Aetna unaudited pro forma condensed combined financial statements and related notes included in this joint proxy statement/prospectus. See &#147;CVS Health and Aetna Unaudited Pro Forma Condensed Combined
Financial Statements&#148; beginning on page 42 of this joint proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of/For&nbsp;the&nbsp;Nine<BR>Months Ended<BR>September&nbsp;30,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of/For&nbsp;the&nbsp;Year<BR>Ended&nbsp;December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health Historical per Common Share Data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash dividends declared</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna Historical per Common Share Data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash dividends declared</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unaudited Pro Forma Combined per CVS Health Common Share Data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash dividends declared (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unaudited Pro Forma Combined per Aetna Equivalent Share Data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations&#151;basic (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations&#151;diluted (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash dividends declared (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amounts calculated by dividing the applicable total shareholders&#146; equity by the applicable common shares outstanding. Pro forma combined book value per share as of December&nbsp;31, 2016 is not applicable as the
estimated pro forma adjustments were calculated as of September&nbsp;30, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Pro forma combined dividends per share data is not provided due to the fact that the dividend policy for the combined company will be determined by CVS Health&#146;s board of directors following completion of the
merger. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Amounts calculated by multiplying unaudited pro forma combined per share amounts by the exchange ratio. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_33"></A>CVS HEALTH AND AETNA UNAUDITED PRO FORMA CONDENSED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMBINED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined statements of income for the year ended December&nbsp;31, 2016, and for the nine months ended
September&nbsp;30, 2017, combine the historical consolidated statements of income of CVS Health and Aetna, giving effect to the merger as if it had occurred on January&nbsp;1, 2016, the first day of the fiscal year ended December&nbsp;31, 2016. The
unaudited pro forma condensed combined balance sheet as of September&nbsp;30, 2017, combines the historical consolidated balance sheets of CVS Health and Aetna, giving effect to the merger as if it had occurred on September&nbsp;30, 2017. The
historical consolidated financial information has been adjusted in the unaudited pro forma condensed combined financial statements to give effect to pro forma events that are (i)&nbsp;directly attributable to the merger, (ii)&nbsp;factually
supportable, and (iii)&nbsp;with respect to the statements of income, expected to have a continuing impact on the combined company&#146;s results. The unaudited pro forma condensed combined financial statements should be read in conjunction with the
accompanying notes to the unaudited pro forma condensed combined financial statements. In addition, the unaudited pro forma condensed combined financial information was based on, and should be read in conjunction with, the following historical
consolidated financial statements and accompanying notes, which are incorporated by reference into this joint proxy statement/prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">separate audited historical consolidated financial statements of CVS Health as of, and for the year ended, December&nbsp;31, 2016, and the related notes included in CVS Health&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">separate audited historical consolidated financial statements of Aetna as of, and for the year ended, December&nbsp;31, 2016, and the related notes included in Aetna&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">separate unaudited historical consolidated financial statements of CVS Health as of, and for the nine months ended, September&nbsp;30, 2017, and the related notes included in CVS Health&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September&nbsp;30, 2017; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">separate unaudited historical consolidated financial statements of Aetna as of, and for the nine months ended, September&nbsp;30, 2017, and the related notes included in Aetna&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September&nbsp;30, 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma
condensed combined financial information has been prepared by CVS Health using the acquisition method of accounting in accordance with U.S. generally accepted accounting principles, which are referred to in this joint proxy statement/prospectus as
GAAP. CVS Health has been treated as the acquirer in the merger for accounting purposes. The acquisition accounting is dependent upon certain valuation and other studies that have yet to commence or progress to a stage where there is sufficient
information for a definitive measurement. The merger has not yet received the necessary approvals from governmental authorities. Under the HSR Act and other relevant laws and regulations, before completion of the merger, there are significant
limitations regarding what CVS Health can learn about Aetna. The assets and liabilities of Aetna have been measured based on various preliminary estimates using assumptions that CVS Health believes are reasonable based on information that is
currently available to it. Differences between these preliminary estimates and the final acquisition accounting will occur, and those differences could have a material impact on the accompanying unaudited pro forma condensed combined financial
statements and the combined company&#146;s future results of operations and financial position. The pro forma adjustments are preliminary and have been made solely for the purpose of providing unaudited pro forma condensed combined financial
statements prepared in accordance with the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health intends to commence the necessary valuation and
other studies required to complete the acquisition accounting promptly upon completion of the merger and will finalize the acquisition accounting as soon as practicable within the required measurement period, but in no event later than one year
following completion of the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been presented for
informational purposes only. The unaudited pro forma condensed combined financial information does not purport to represent the actual results of operations that CVS Health and Aetna would have achieved had the companies been combined during the
periods presented in the unaudited pro forma condensed combined financial statements and is not intended to project the future results of operations that the combined company may achieve after the merger. The unaudited pro forma condensed combined
financial information does not reflect any potential divestitures that may occur prior to, or subsequent to, completion of the merger or cost savings that may be realized as a result of the merger and also does not reflect any restructuring or
integration-related costs to achieve those potential cost savings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Pro Forma Condensed Combined Statement of Income for the Year Ended
December&nbsp;31, 2016 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CVS<BR>Health</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aetna</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Adjustments<BR>(Note 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(Millions, except per common share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Pharmacy, consumer products and other</I></B>:<B><I> </I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,828</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(j)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">167,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Insurance</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premiums (i)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees and other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net investment income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(k)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating costs and expenses</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Pharmacy, consumer products and other</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(j)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Insurance</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit costs (i)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;(l)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;(m)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on early extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(n)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations before income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(o)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Income) loss from continuing operations attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations attributable to CVS Health</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share from continuing operations attributable to CVS Health:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(q)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(q)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(p)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(p)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the accompanying notes to the unaudited pro forma condensed combined financial statements, which are an
integral part of these statements. The pro forma adjustments shown above are explained in <I>Note 6. Income Statement Pro Forma Adjustments</I>, beginning on page 53 of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Pro Forma Condensed Combined </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement of Income </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>for
the Nine Months Ended September&nbsp;30, 2017 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CVS<BR>Health</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aetna</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Adjustments<BR>(Note 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(Millions, except per common share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Pharmacy, consumer products and other</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(j)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Insurance</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premiums (i)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees and other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net investment income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(k)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating costs and expenses</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Pharmacy, consumer products and other</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(j)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Insurance</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit costs (i)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(j)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,153&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(l)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(m)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on early extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(n)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations before income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(o)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Income) loss from continuing operations attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations attributable to CVS Health</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share from continuing operations attributable to CVS Health:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.65&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(q)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.63&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(q)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,296&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(p)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,308&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(p)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the accompanying notes to the unaudited pro forma condensed combined financial statements, which are an
integral part of these statements. The pro forma adjustments shown above are explained in <I>Note 6. Income Statement Pro Forma Adjustments</I>, beginning on page 53 of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Pro Forma Condensed Combined </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheet </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of
September&nbsp;30, 2017 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CVS<BR>Health</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aetna</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Adjustments<BR>(Note 7)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(r)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(s)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;(t)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;(u)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Separate Account assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(v)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pharmacy claims and discounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Health care costs payable and other insurance liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(s)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;(w)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term debt and current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;(x)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;(y)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Separate Account liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term insurance liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock and capital surplus&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(z)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock and shares held in trust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;(aa)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;(bb)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;(cc)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">On an historical basis, share information of CVS Health is as follows: 3.2&nbsp;billion common shares authorized; 1.7&nbsp;billion common shares issued and 1.0&nbsp;billion shares outstanding. On a pro forma combined
basis, share information is as follows: 3.2&nbsp;billion common shares authorized; 2.0&nbsp;billion common shares issued and 1.287&nbsp;billion common shares outstanding. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the accompanying notes to the unaudited pro forma condensed combined financial statements, which are an integral part of these statements.
The pro forma adjustments shown above are explained in <I>Note </I>7.<I> Balance Sheet Pro Forma Adjustments</I>, beginning on page 57 of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Description of Transaction </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;3, 2017, CVS Health, Merger Sub and Aetna
entered into the merger agreement, pursuant to which, subject to the terms and conditions set forth in the merger agreement, Aetna will become a wholly owned subsidiary of CVS Health. Upon completion of the merger, each Aetna common share issued and
outstanding immediately prior to the effective time of the merger will be converted into the right to receive $145.00 in cash, without interest, and 0.8378 of a share of CVS Health common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of completion of the merger, each vested Aetna stock appreciation right (including those Aetna stock appreciation rights that vest by their
terms as of completion of the merger) will be cancelled and converted into the right to receive a cash amount (without interest) equal to the product of (a)&nbsp;the excess, if any, of (i)&nbsp;the sum of $145.00 plus&nbsp;the value equal to the
product of the CVS Health closing price multiplied by the exchange ratio over (ii)&nbsp;the applicable per share exercise price of such Aetna stock appreciation right multiplied by (b)&nbsp;the total number of Aetna common shares subject to such
Aetna stock appreciation right. Each outstanding vested Aetna stock appreciation right (including those Aetna stock appreciation rights that vest by their terms as of completion of the merger) with a per share exercise price greater than or equal to
the equity award cash consideration will be cancelled for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of completion of the merger, each Aetna stock appreciation
right that is not vested as of completion of the merger or that is granted after the date of the merger agreement (to the extent permitted under the merger agreement), will be assumed by CVS Health and will become a stock appreciation right
representing the right to receive a payment in shares of CVS Health common stock on the same terms and conditions, except that (i)&nbsp;the number of shares of CVS Health common stock subject to the assumed stock appreciation right will equal the
product of (A)&nbsp;the number of Aetna common shares that were subject to such Aetna stock appreciation right immediately prior to completion of the merger multiplied by (B)&nbsp;the equity award exchange ratio (with such product rounded down to
the nearest whole share of CVS Health common stock) and (ii)&nbsp;the per share exercise price will equal the exercise price per share of the Aetna stock appreciation right immediately prior to completion of the merger divided by the equity award
exchange ratio (rounded up to the nearest whole cent). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to completion of the merger, each outstanding Aetna RSU and
Aetna PSU that provides for accelerated vesting upon completion of the transactions contemplated by the merger agreement will vest and will be converted into the right to receive, with respect to each Aetna common share underlying the Aetna RSU or
Aetna PSU, the merger consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of completion of the merger, each Aetna RSU or Aetna PSU that is not converted into a right to
receive the merger consideration, or that is granted after the date of the merger agreement (to the extent permitted under the merger agreement), will be assumed by CVS Health and will be converted into a time-vesting CVS Health RSU award
corresponding to the merger consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the merger is subject to the approval of and adoption of the merger agreement by
Aetna shareholders, the approval of the stock issuance by CVS Health stockholders, termination or expiration of the waiting period under the HSR Act, the required governmental authorizations having been obtained and being in full force and effect
and certain other conditions to completion of the merger. As of the date of this joint proxy statement/prospectus, and subject to the satisfaction or, to the extent permitted by law, waiver of the conditions described in the preceding sentence, CVS
Health and Aetna expect the merger to be completed in the second half of 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of Presentation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements
were prepared using the acquisition method of accounting and are based on the historical consolidated financial statements of CVS Health and Aetna. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The acquisition method of accounting is based on ASC 805, <I>Business Combinations</I>, and uses the fair value concepts defined in ASC&nbsp;820, <I>Fair Value Measurement</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 805 requires, among other things, that most assets acquired and liabilities assumed be recognized at their fair values as of the
acquisition date. In addition, ASC 805 requires that the consideration transferred be measured at the date the merger is completed at the then-current market price. This requirement will likely result in a per share equity component that is
different from the amount assumed in these unaudited pro forma condensed combined financial statements, since the market price of the shares of CVS Health common stock at the date the merger is completed is likely to be different than the $78.79
market price that was used in the preparation of the unaudited pro forma condensed combined financial statements. The market price of $78.79 was based upon the closing price of shares of CVS Health common stock on the NYSE on February&nbsp;1, 2018.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 820 defines the term &#147;fair value,&#148; sets forth the valuation requirements for any asset or liability measured at fair
value, expands related disclosure requirements and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined in ASC 820 as &#147;the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#148; This is an exit price concept for the valuation of the asset or liability. In addition, market participants are
assumed to be buyers and sellers in the principal (or the most advantageous) market for the asset or liability. Fair value measurements for an asset assume the highest and best use by these market participants. As a result of these standards, CVS
Health may be required to record the fair value of assets which are not intended to be used or sold and/or to value assets at fair value measures that do not reflect CVS Health&#146;s intended use of those assets. Many of these fair value
measurements can be highly subjective, and it is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the acquisition method of accounting, the assets acquired and liabilities assumed will be recorded, as of completion of the merger,
primarily at their respective fair values and added to those of CVS Health. Financial statements and reported results of operations of CVS Health issued after completion of the merger will reflect these values, but will not be retroactively restated
to reflect the historical financial position or results of operations of Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC 805, acquisition-related transaction costs
(e.g., advisory, legal and other professional fees) are not included as a component of consideration transferred but are accounted for as expenses in the periods in which such costs are incurred. Acquisition-related transaction costs expected to be
incurred by CVS Health include estimated fees related to a bridge financing commitment and agreement. Total acquisition-related transaction costs expected to be incurred by CVS Health and Aetna are estimated to be approximately $400&nbsp;million and
$165&nbsp;million, respectively. During the nine months ended September&nbsp;30, 2017, neither CVS Health nor Aetna incurred any material acquisition-related transaction costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet as of September&nbsp;30, 2017 is required to include adjustments which give effect to
events that are directly attributable to the merger regardless of whether they are expected to have a continuing impact on the combined results or are <FONT STYLE="white-space:nowrap">non-recurring.</FONT> Therefore, acquisition-related transaction
costs expected to be incurred by CVS Health and Aetna subsequent to September&nbsp;30, 2017 of approximately $400&nbsp;million and $165&nbsp;million, respectively, are reflected as a pro forma adjustment to the unaudited pro forma condensed combined
balance sheet as of September&nbsp;30, 2017, with the after-tax impact presented as an increase to accrued expenses and other current liabilities and a decrease to retained earnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements do not reflect any potential divestitures that may occur prior to, or
subsequent to, completion of the merger, or the projected realization of cost savings following completion of the merger. These cost savings opportunities are from administrative cost savings as well as reduced health care costs due to medical
management. Although CVS Health projects that cost savings will result from the merger, there can be no assurance that these cost savings will be achieved. The unaudited pro forma </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condensed combined financial statements do not reflect any projected <FONT STYLE="white-space:nowrap">pre-tax</FONT> restructuring and integration-related costs associated with the projected
annual cost savings. The annual cost savings are projected to be approximately $750&nbsp;million in the second full year following completion of the merger. The restructuring and integration-related costs will be expensed in the appropriate
accounting periods after completion of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements do not reflect
(a)&nbsp;any changes in applicable law (including applicable tax law) after September&nbsp;30, 2017 or (b)&nbsp;Aetna&#146;s sale of its domestic group life insurance, group disability insurance and absence management businesses on November&nbsp;1,
2017. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Accounting Policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At completion of the merger, CVS Health will review Aetna&#146;s
accounting policies. As a result of that review, CVS Health may identify differences between the accounting policies of the two companies that, when conformed, could have a material impact on the combined financial statements. With the exception of
one accounting policy related to recently issued accounting guidance that CVS Health early adopted in the first quarter of 2017 (see Note 6(l)), CVS Health is not aware of any differences that would have a material impact on the combined financial
statements, and therefore, the unaudited pro forma condensed combined financial statements assume there are no other differences in accounting policies other than the one described in Note 6(l). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Estimate of Consideration Expected to be Transferred </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a preliminary
estimate of consideration expected to be transferred to effect the acquisition of Aetna: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions,&nbsp;except&nbsp;per<BR>common share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash consideration</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by merger agreement cash consideration per share paid to Aetna shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preliminary estimate of cash consideration paid to Aetna shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stock appreciation right holders</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna vested
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> stock appreciation rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by merger consideration value of $211.01 less exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preliminary estimate of cash consideration paid to holders of vested Aetna stock<BR>appreciation
rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RSU and PSU holders</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested Aetna RSUs and Aetna PSUs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by merger agreement cash consideration per share paid to Aetna shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preliminary estimate of cash consideration paid to Aetna RSU and Aetna PSU holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preliminary fair value estimate of total cash consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Share consideration</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by merger agreement per share exchange ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by per share price of CVS Health common stock on February&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preliminary estimate of fair value of common stock issued to Aetna shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions,&nbsp;except&nbsp;per<BR>common share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RSU and PSU holders</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested Aetna RSUs and Aetna PSUs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by merger agreement per share exchange ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by per share price of CVS Health common stock on February&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preliminary estimate of fair value of common stock issued to Aetna RSU and Aetna PSU
holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preliminary fair value estimate of total share consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total consideration</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common share consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other consideration transferred (a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimate of total consideration expected to be transferred (b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain amounts may reflect rounding adjustments. </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">As further described in <I>Note 1. Description of Transaction</I>, beginning on page 47 of this joint proxy statement/prospectus, certain outstanding equity awards granted to Aetna employees will not be settled upon
completion of the merger, and instead will be converted into replacement awards issued by CVS Health, which are referred to in this joint proxy statement/prospectus as replacement equity awards. The above table excludes approximately
1.4&nbsp;million aggregate Aetna RSUs and PSUs and approximately 3.3&nbsp;million Aetna stock appreciation rights, each outstanding at February&nbsp;1, 2018, from the estimate of total consideration expected to be transferred. Other consideration
transferred will include the portion of the fair value of the replacement awards that is attributed to <FONT STYLE="white-space:nowrap">pre-merger</FONT> services. The fair value attributable to post-merger services will be recorded as compensation
expense in CVS Health&#146;s post-merger financial statements. At this time, CVS Health is unable to reasonably estimate the respective amounts attributable to <FONT STYLE="white-space:nowrap">pre-</FONT> and post-merger services. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">The estimated total consideration expected to be transferred reflected in these unaudited pro forma condensed combined financial statements does not purport to represent the actual consideration that will be transferred
when the merger is completed. In accordance with ASC 805 the fair value of equity securities issued as part of the consideration transferred will be measured on the date the merger is completed at the then-current market price. This requirement will
likely result in a different value of the common share component of the purchase consideration and a per Aetna share equity component different from the $66.01 assumed in these unaudited pro forma condensed combined financial statements, and that
difference may be material. For example, if the per share price of CVS Health&#146;s common stock on the date the merger is completed increased or decreased by 10% from the price assumed in these unaudited pro forma condensed combined financial
statements, the consideration transferred would increase or decrease by approximately $2.2&nbsp;billion, which would be reflected in these unaudited pro forma condensed combined financial statements as an increase or decrease to goodwill.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Estimate of Assets to be Acquired and Liabilities to be Assumed </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a
preliminary estimate of the assets to be acquired and the liabilities to be assumed by CVS Health in the merger, reconciled to the estimate of total consideration expected to be transferred: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At<BR>September&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets Acquired and Liabilities Assumed</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net book value of net assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less historical:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt issuance costs and net debt discounts/premiums</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred acquisition costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets on outstanding equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets on debt premiums</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities on deferred acquisition costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities on historical capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities on historical intangible assets and tax deductible goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted book value of net assets acquired</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill (c)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Identifiable intangible assets (d)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities (e)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment to debt (f)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of noncontrolling interest (g)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (h)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consideration transferred</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Goodwill is calculated as the difference between the acquisition date fair value of the total consideration expected to be transferred and the aggregate values assigned to the assets acquired and liabilities assumed.
Goodwill is not amortized. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">As of completion of the merger, identifiable intangible assets are required to be measured at fair value, and these acquired assets could include assets that are not intended to be used or sold or that are intended to
be used in a manner other than their highest and best use. For purposes of these unaudited pro forma condensed combined financial statements and consistent with the ASC 820 requirements for fair value measurements, it is assumed that all assets will
be used, and that all acquired assets will be used in a manner that represents the highest and best use of those acquired assets, but it is not assumed that any market participant synergies will be achieved. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The fair value of identifiable intangible assets is determined primarily using variations of the &#147;income approach,&#148; which is based on the present value of the future
<FONT STYLE="white-space:nowrap">after-tax</FONT> cash flows attributable to each identifiable intangible asset. Other valuation methods, including the market approach and cost approach, were also considered in estimating the fair value. Under the
HSR Act and other relevant laws and regulations, there are significant limitations on CVS Health&#146;s ability to obtain specific information about Aetna&#146;s intangible assets prior to completion of the merger. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of the date of this joint proxy statement/prospectus, CVS Health does not have sufficient information as to the amount, timing and risk of the cash flows from all of Aetna&#146;s identifiable intangible assets to
determine their fair value. Some of the more significant assumptions inherent in the development of intangible asset values, from the perspective of a market participant, include, but are not limited to: the amount and timing of projected future
cash flows (including revenue and profitability); the discount rate selected to measure the risks inherent in the future cash flows; the assessment of the asset&#146;s life cycle; and the competitive trends impacting the asset. However, for purposes
of these unaudited pro forma condensed combined financial statements and using publicly available information, such as historical revenues, Aetna&#146;s cost structure, industry information for comparable intangible assets and certain other
high-level assumptions, the fair value of Aetna&#146;s identifiable intangible assets and their weighted average useful lives have been preliminarily estimated as follows: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated</B><br><B>Fair&nbsp;Value</B><br><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Useful</B><br><B>Life</B><br><B>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer relationships</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provider networks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definite-lived trade names/trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indefinite-lived trade name/trademark</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These preliminary estimates of fair value and weighted average useful life will likely be different from the
amounts included in the final acquisition accounting, and the difference could have a material impact on the accompanying unaudited pro forma condensed combined financial statements. Once CVS Health has full access to information about Aetna&#146;s
intangible assets, additional insight will be gained that could impact (i)&nbsp;the estimated total value assigned to identifiable intangible assets, (ii)&nbsp;the estimated allocation of value between finite-lived and indefinite-lived intangible
assets and/or (iii)&nbsp;the estimated weighted average useful life of each category of intangible assets. The estimated intangible asset values and their useful lives could be impacted by a variety of factors that may become known to CVS Health
only upon access to additional information and/or by changes in such factors that may occur prior to completion of the merger. These factors include, but are not limited to, changes in the regulatory, legislative, legal, technological and/or
competitive environments. Increased knowledge about these and/or other elements could result in a change to the estimated fair value of the identifiable Aetna intangible assets and/or to the estimated weighted average useful lives from what CVS
Health has assumed in these unaudited pro forma condensed combined financial statements. The combined effect of any such changes could then also result in a significant increase or decrease to CVS Health&#146;s estimate of associated amortization
expense. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">As of completion of the merger, CVS Health will establish net deferred tax liabilities and make other tax adjustments as part of the accounting for the merger, primarily related to estimated fair value adjustments for
identifiable intangible assets and debt (see (d)&nbsp;and (f)). The pro forma adjustment to record the effect of deferred taxes was computed as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of identifiable intangible assets to be acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value adjustment of debt to be assumed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total estimated fair value adjustments of assets to be acquired and liabilities to be
assumed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred taxes associated with the estimated fair value adjustments of assets to be acquired and
liabilities to be assumed, at 39% (*)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:3%;border-bottom:1px solid #000000; width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(*) The tax impacts of the acquisition were estimated based on applicable law as in effect on September&nbsp;30, 2017. CVS Health assumed a 39%
effective income tax rate when estimating the deferred tax impacts of the acquisition. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">As of completion of the merger, Aetna&#146;s debt is required to be measured at fair value. CVS Health has calculated the pro forma adjustment using publicly available information and believes the pro forma adjustment
amount to be reasonable. This adjustment reflects the incremental fair value of Aetna&#146;s long-term debt over the par value of such debt. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">The net book value of Aetna&#146;s noncontrolling interest is assumed to approximate its fair value in the pro forma condensed combined balance sheet. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">As of completion of the merger, various other assets and liabilities are required to be measured at fair value, including, but not limited to: accounts receivable, property and equipment, insurance liabilities, and
legal contingencies. As of the date of this joint proxy statement/prospectus, CVS Health does not have sufficient information to make a reasonable preliminary estimate of the fair value of these assets and liabilities. Accordingly, for purposes of
these unaudited pro forma condensed combined financial statements, CVS Health has assumed that the historical Aetna book values represent the best estimate of fair value. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income Statement Pro Forma Adjustments </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">For the year ended December&nbsp;31, 2016 and the nine months ended September&nbsp;30, 2017, CVS Health&#146;s insurance premiums from its SilverScript Insurance Company Medicare Part D prescription drug plan of
$2.1&nbsp;billion and $2.2&nbsp;billion, respectively, have been reclassified and presented separately from net revenues from pharmacy, consumer products and other. The related costs and benefits for the year ended December&nbsp;31, 2016 and the
nine months ended September&nbsp;30, 2017 of $1.7&nbsp;billion and $1.9&nbsp;billion, respectively, have been reclassified and presented separately from cost of revenues from pharmacy, consumer products and other. These reclassifications made in
these pro forma condensed combined financial statements were made to conform to Aetna&#146;s insurance-related presentation. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top">To eliminate pharmacy and clinical services revenue CVS Health earned from Aetna of $7,828&nbsp;million and $6,713&nbsp;million for the year ended December&nbsp;31, 2016 and the nine months ended September&nbsp;30,
2017, respectively. The related costs eliminated and their financial statement line items are as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine<BR>Months&nbsp;Ended<BR>September&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of administrative fees from selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total elimination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top">For purposes of these unaudited pro forma condensed combined financial statements, this adjustment reflects CVS Health&#146;s estimated forgone interest income associated with adjusting the amortized cost of
Aetna&#146;s debt securities investment portfolio to fair value as of completion of the merger. Forgone interest income due to the fair value adjustment to Aetna&#146;s debt securities investment portfolio under the acquisition method of accounting
is projected to be approximately $131&nbsp;million and $87&nbsp;million for the year ended December&nbsp;31, 2016 and the nine months ended September&nbsp;30, 2017, respectively. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">During the first quarter of 2017, CVS Health early adopted on a retrospective basis ASU <FONT
STYLE="white-space:nowrap">2017-07,</FONT> <I>Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</I>. ASU <FONT STYLE="white-space:nowrap">2017-07</FONT> requires entities to disaggregate the current
service cost component from the other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
components of net benefit cost and present it with other current compensation costs for related employees in the income statement and present the other components of net benefit cost elsewhere in
the income statement and outside of operating income. For the year ended December&nbsp;31, 2016, CVS Health reclassified $28&nbsp;million from selling, general and administrative expenses to other expense. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Below is Aetna&#146;s reclassification from selling, general and administrative expenses to other expense (income) to conform with CVS
Health&#146;s current accounting policy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine<BR>Months&nbsp;Ended<BR>September&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net periodic benefit income for pension plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net periodic benefit expense for other postretirement employee benefit plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of net periodic benefit income from selling, general and administrative expenses
to other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses is adjusted, as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine<BR>Months&nbsp;Ended<BR>September&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of net periodic benefit income to other expense (income), as discussed
above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical administrative fees paid to CVS Health (see (j))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical intangible asset amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical deferred acquisition cost amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical capitalized software amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated transaction-related intangible asset amortization (*)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated adjustment to selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(*) Assumes an estimated $21.3&nbsp;billion of finite-lived intangibles and a weighted average amortization
period of approximately 10 years (Refer to<I> Note 5</I>.<I> Estimate of Assets to be Acquired and Liabilities to be Assumed</I>, beginning on page 51 of this joint proxy statement/prospectus). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(m) CVS estimates interest expense, net to increase due to the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine<BR>Months&nbsp;Ended<BR>September&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional interest expense associated with the issuance of $40.0&nbsp;billion of long-term
fixed-rate and/or floating rate debt that CVS Health expects to issue to partially fund the merger with various maturity tranches ranging from 2 to 30 years and an assumed weighted average annual interest rate of 4.11% (**)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional interest expense associated with the issuance of $5.0&nbsp;billion of fixed-rate term
loans to partially fund the merger with an assumed maturity of 3 to 5 years and an assumed weighted average annual interest rate of 3.46% (***)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health estimated foregone interest income associated with cash used to partially fund a
portion of the merger consideration. The estimated forgone interest income for the combined entity is based on a weighted average annual interest rate of 0.89% and 1.47% for the year ended December&nbsp;31, 2016 and the nine months ended
September&nbsp;30, 2017, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate historical amortization of net debt premiums/debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of estimated debt issuance costs of $230&nbsp;million associated with the long-term
debt and term loans to be issued to partially fund the merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of the estimated fair value adjustment to Aetna&#146;s debt assumed by CVS Health
over the remaining life of Aetna&#146;s outstanding debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated adjustment to interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(**) If interest rates were to increase or decrease by 0.125% from the rates assumed in estimating this
pro&nbsp;forma adjustment to interest expense, pro forma interest expense would increase or decrease by approximately $50&nbsp;million in the year ended December&nbsp;31, 2016 and $38&nbsp;million in the nine months ended September&nbsp;30, 2017.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(***) If interest rates were to increase or decrease by 0.125% from the rates assumed in estimating this pro&nbsp;forma adjustment to
interest expense, pro forma interest expense would increase or decrease by approximately $6&nbsp;million in the year ended December&nbsp;31, 2016 and $5&nbsp;million in the nine months ended September&nbsp;30, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top">To adjust other expense (income) for the following: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine<BR>Months&nbsp;Ended<BR>September&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of net periodic benefit income from selling, general and administrative expenses
to other expense as discussed in&nbsp;(l)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment to net periodic benefit income to eliminate the amortization of prior service credit
and deferred actuarial losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma tax adjustments are estimated at the applicable statutory income tax rates as in effect on September&nbsp;30, 2017, generally 39%. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top">The combined basic and diluted earnings per share from continuing operations for the periods presented are based on the combined weighted average basic and diluted common shares of CVS Health and Aetna. The historical
weighted average basic and diluted shares of Aetna were assumed to be replaced by the shares expected to be issued by CVS Health to effect the merger. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the computation of the unaudited pro forma combined weighted average basic and diluted shares outstanding: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine<BR>Months&nbsp;Ended<BR>September&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health weighted average shares used to compute basic earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna shares outstanding at February&nbsp;1, 2018, converted at the exchange ratio of
(326.9*0.8378)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combined weighted average basic shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Aetna RSUs and Aetna PSUs at February&nbsp;1, 2018, expected to vest at closing
converted at the exchange ratio (0.3*0.8378)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average basic shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive effect of CVS Health&#146;s outstanding stock-based awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive effect of Aetna&#146;s outstanding stock-based awards, converted at the exchange ratio
(CVS Health awards to be issued to replace Aetna awards)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares used to compute diluted earnings per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>Note:</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Certain amounts may reflect rounding adjustments. </I></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top">The following is a reconciliation of pro forma basic and diluted earnings per share for the respective periods: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine<BR>Months&nbsp;Ended</B><br><B>September&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator for earnings per share calculation:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma income from continuing operations attributable to CVS Health </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator for earnings per share calculation:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma earnings per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Balance Sheet Pro Forma Adjustments </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top">To reflect the use of available cash to partially fund the merger. This estimate is derived as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">To record issuance of CVS Health long-term debt and term loans to effect the merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated debt issuance costs incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">To record the cash portion of the merger consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top">To eliminate trade receivables and payables between CVS Health and Aetna. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top">To adjust goodwill to an estimate of acquisition date goodwill, as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated transaction goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(u)</TD>
<TD ALIGN="left" VALIGN="top">To adjust intangible assets to their estimated fair value, as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of intangible assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">To adjust other assets to their estimated fair value, as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical deferred acquisition costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(w)</TD>
<TD ALIGN="left" VALIGN="top">To adjust accrued expenses and other current liabilities: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">To accrue estimated acquisition-related transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">To reduce current tax liabilities related to estimated
<FONT STYLE="white-space:nowrap">tax-deductible</FONT> acquisition-related transactions costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top">To record issuance of CVS Health long-term debt and related debt issuance costs, eliminate the Aetna historical debt issuance costs that have no future economic benefit, and adjust Aetna&#146;s debt to an estimate of
fair value, as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Establish incremental CVS Health long-term debt to effect the merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Establish incremental CVS Health term loans to effect the merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of unamortized debt issuance costs and net debt discounts/premiums</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value increase over par value of assumed Aetna debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(y)</TD>
<TD ALIGN="left" VALIGN="top">Adjustment of deferred income tax liabilities (assets) as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical deferred tax liability on intangible assets and tax deductible
goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical deferred tax liability on capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical deferred tax asset on debt premiums</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical deferred tax asset on outstanding equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate Aetna&#146;s historical deferred tax liability on deferred acquisition costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated transaction-related deferred tax liability on identifiable intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated transaction-related deferred tax asset for fair value increase in assumed debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(z)</TD>
<TD ALIGN="left" VALIGN="top">To eliminate Aetna&#146;s historical common shares and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital of $4.7&nbsp;billion. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(aa)</TD>
<TD ALIGN="left" VALIGN="top">Issuance of shares of CVS Health common stock from treasury stock to record the stock portion of the merger consideration. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(bb)</TD>
<TD ALIGN="left" VALIGN="top">To eliminate Aetna&#146;s historical retained earnings and to record the estimated <FONT STYLE="white-space:nowrap">after-tax</FONT> portion of the acquisition-related transaction costs projected to be incurred after
September&nbsp;30, 2017: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of Aetna&#146;s historical retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated transaction costs incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(cc)</TD>
<TD ALIGN="left" VALIGN="top">To eliminate Aetna&#146;s historical accumulated other comprehensive income. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited
pro forma condensed combined financial statements do not present a combined dividend per share amount. On each of February&nbsp;2, 2017, May&nbsp;1, 2017, August&nbsp;3, 2017, November&nbsp;3, 2017 and February 2, 2018, CVS Health paid a dividend of
$0.50 per share of CVS Health common stock. On January&nbsp;27, 2017, Aetna </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
paid a dividend of $0.25 per Aetna common share. On each of April&nbsp;28, 2017, July&nbsp;28, 2017, October&nbsp;27, 2017 and January 26, 2018, Aetna paid a dividend of $0.50 per Aetna common
share. Under the terms of the merger agreement, during the period prior to completion of the merger, Aetna is not permitted to declare, set aside or pay any dividend or other distribution other than its regular cash dividend in the ordinary course
of business consistent with past practice in an amount not to exceed $0.50 per share per quarter. Under the terms of the merger agreement, during the period before completion of the merger, CVS Health is not permitted to declare, set aside or pay
any dividend or other distribution other than its regular cash dividend in the ordinary course of business consistent with past practice in an amount not to exceed $0.50 per share per quarter. The dividend policy of CVS Health following completion
of the merger will be determined by CVS Health&#146;s board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_34"></A>COMPARATIVE PER SHARE MARKET PRICE AND DIVIDEND INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_35"></A>Market Prices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the calendar periods indicated, the <FONT STYLE="white-space:nowrap">intra-day</FONT> high and low sales
prices per share of CVS Health common stock and per Aetna common share as reported on the NYSE. The shares of CVS Health common stock are traded on the NYSE under the symbol &#147;CVS&#148;, and the Aetna common shares are traded on the NYSE under
the symbol &#147;AET&#148;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;CVS&nbsp;Health<BR>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aetna<BR>Common Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2015</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;93.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2016:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2017:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Calendar Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2018</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Calendar Quarter (through February 8, 2018)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">178.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the closing sale price per share of CVS Health common stock and per
Aetna common share as reported on the NYSE on the unaffected date, on December&nbsp;1, the last trading day prior to the public announcement of the transaction, and on February 8, 2018, the most recent trading day prior to the date of this joint
proxy statement/prospectus for which this information was available. The table also shows the implied value of the merger consideration for each Aetna common share as of the same two dates. This implied value was calculated by multiplying the
closing sale price of a share of CVS Health common stock on the relevant date by the exchange ratio and adding $145.00, the cash component of the merger consideration. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of CVS<BR>Health</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Implied&nbsp;Per&nbsp;Share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Value&nbsp;of&nbsp;Merger</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;25, 2017 (the unaffected date)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">208.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">181.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">207.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 8, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">178.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market prices of shares of CVS Health common stock and Aetna common shares have fluctuated since the
date of the announcement of the merger agreement and will continue to fluctuate from the date of this joint proxy statement/prospectus to the dates of the CVS Health special meeting and the Aetna special meeting and the date the merger is completed.
No assurance can be given concerning the market prices of shares of CVS Health common stock or Aetna common shares before completion of the merger or shares of CVS Health common stock after completion of the merger. The exchange ratio is fixed in
the merger agreement, but the market price of shares of CVS Health common stock (and therefore the value of the merger consideration) when received by Aetna </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders after the merger is completed could be greater than, less than or the same as shown in the table above. Accordingly, Aetna shareholders are advised to obtain current market
quotations for shares of CVS Health common stock and Aetna common shares in deciding whether to vote for approval and adoption of the merger agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_36"></A>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS
Health currently pays a quarterly dividend on shares of CVS Health common stock and last paid a dividend on February 2, 2018 of $0.50 per share. Under the terms of the merger agreement, during the period before completion of the merger, CVS Health
is not permitted to declare, set aside or pay any dividend or other distribution other than its regular cash dividend in the ordinary course of business consistent with past practice in an amount not to exceed $0.50&nbsp;per share per quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna currently pays a quarterly dividend on Aetna common shares and last paid a dividend on January 26, 2018 of $0.50 per share. Under the
terms of the merger agreement, during the period before completion of the merger, Aetna is not permitted to declare, set aside or pay any dividend or other distribution other than its regular cash dividend in the ordinary course of business
consistent with past practice in an amount not to exceed $0.50&nbsp;per share per quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the merger agreement provides
that CVS Health and Aetna will coordinate the declaration of, record dates for and payment of dividends in respect of their respective shares in order that holders of shares of CVS Health common stock and Aetna common shares do not receive two
dividends or fail to receive one dividend for any quarter in respect of Aetna common shares, on the one hand, and shares of CVS Health common stock issuable in the merger, on the other hand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After completion of the merger, each former Aetna shareholder who holds shares of CVS Health common stock into which Aetna common shares have
been converted in connection with the merger will receive whatever dividends are declared and paid on shares of CVS Health common stock. However, no dividend or other distribution having a record date after completion of the merger will actually be
paid with respect to any shares of CVS Health common stock into which Aetna common shares have been converted in connection with the merger until the certificates formerly representing Aetna common shares have been surrendered (or the book-entry
shares formerly representing Aetna common shares have been transferred), at which time any accrued dividends and other distributions on those shares of CVS Health common stock will be paid without interest. Subject to the limitations set forth in
the merger agreement described above, any future dividends by CVS Health will be made at the discretion of CVS Health&#146;s board of directors. Subject to the limitations set forth in the merger agreement described above, any future dividends by
Aetna will be made at the discretion of Aetna&#146;s board of directors. There can be no assurance that any future dividends will be declared or paid by CVS Health or Aetna or as to the amount or timing of those dividends, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_37"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>In addition to the other information contained or incorporated by reference into this joint proxy statement/prospectus, including the
matters addressed in &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; beginning on page 72 of this joint proxy statement/prospectus, you should carefully consider the following risk factors in determining whether to vote for the
approval and adoption of the merger agreement or approval of the stock issuance. You also should read and consider the risk factors associated with each of the businesses of CVS&nbsp;Health and Aetna because these risk factors may affect the
operations and financial results of the combined company. These risk factors may be found under Part I, Item&nbsp;1A, &#147;Risk Factors&#148; in each company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year
ended December&nbsp;31, 2016, as updated by their respective Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and future filings with the SEC, each of which is on file or will be filed with the SEC and all of which are
incorporated by reference into this joint proxy statement/prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Because the exchange ratio is fixed and the market price of
shares of CVS Health common stock has fluctuated and will continue to fluctuate, Aetna shareholders cannot be sure of the value of the merger consideration they will receive in the merger. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the merger, each Aetna common share outstanding immediately prior to the effective time of the merger (other than those held
by Aetna as treasury stock, by CVS Health or by any subsidiary of Aetna or CVS Health) will be converted into the right to receive $145.00 in cash without interest thereon and 0.8378 of a share of CVS Health common stock.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>Because the exchange ratio of 0.8378 of a share of CVS Health common stock is fixed, the value of the share consideration will depend on the market price of shares of CVS&nbsp;Health common stock at
the time the merger is completed. The market price of shares of CVS Health common stock has fluctuated since the date of the announcement of the merger agreement and will continue to fluctuate from the date of this joint proxy statement/prospectus
to the date of the Aetna special meeting and the date the merger is completed, which could occur a considerable amount of time after the date of the Aetna special meeting, and thereafter. Accordingly, at the time of the Aetna special meeting, Aetna
shareholders will not know or be able to determine the market value of the merger consideration they would be entitled to receive upon completion of the merger. Stock price changes may result from a variety of factors, including, among others,
general market and economic conditions, changes in CVS Health&#146;s and Aetna&#146;s respective businesses, operations and prospects, risks inherent in their respective businesses, changes in market assessments of the likelihood that the merger
will be completed and/or the value that may be generated by the merger, and changes with respect to expectations regarding the timing of the merger and regulatory considerations. Many of these factors are beyond CVS Health&#146;s and Aetna&#146;s
control. CVS Health stockholders and Aetna shareholders are urged to obtain current market quotations for shares of CVS Health common stock in deciding whether to vote for the stock issuance or the approval and adoption of the merger agreement, as
applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The market price of shares of CVS Health common stock after the merger may be affected by factors different from those
that are currently affecting or historically have affected the market price of Aetna common shares. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the merger,
holders of Aetna common shares will become holders of shares of CVS&nbsp;Health common stock. The market price of CVS Health common stock may fluctuate significantly following completion of the merger, and holders of Aetna common shares could lose
the value of their investment in CVS Health common stock. The issuance of shares of CVS Health common stock in the merger could on its own have the effect of depressing the market price for CVS Health common stock. In addition, many Aetna
shareholders may decide not to hold the shares of CVS Health common stock they receive as a result of the merger. Other Aetna shareholders, such as funds with limitations on their permitted holdings of stock in individual issuers, may be required to
sell the shares of CVS Health common stock they receive as a result of the merger. Any such sales of CVS Health common stock could have the effect of depressing the market price for CVS Health common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, general fluctuations in stock markets could have a material adverse effect on the
market for, or liquidity of, the CVS Health common stock, regardless of CVS Health&#146;s actual operating performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The businesses of
CVS Health differ from those of Aetna in important respects and, accordingly, the results of operations of CVS Health after the merger, as well as the market price of shares of CVS Health common stock, may be affected by factors different from those
that are currently affecting, historically have affected or would in the future affect the results of operations of Aetna as a stand-alone public company, as well as the market price of Aetna common shares. For further information on the respective
businesses of CVS Health and Aetna and certain factors to consider in connection with those businesses, see the documents incorporated by reference into this joint proxy statement/prospectus and referred to under &#147;Where You Can Find More
Information&#148; beginning on page 254 of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>After completion of the merger, CVS Health may fail
to realize the anticipated benefits and cost savings of the merger, which could adversely affect the value of shares of CVS Health common stock. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of the merger will depend, in part, on CVS Health&#146;s ability to realize the anticipated benefits and cost savings from
combining the businesses of CVS Health and Aetna. CVS Health&#146;s ability to realize these anticipated benefits and cost savings is subject to certain risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health&#146;s ability to successfully combine the businesses of CVS Health and Aetna; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the combined businesses will perform as expected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility that CVS Health paid more for Aetna than the value CVS Health will derive from the acquisition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the reduction of CVS Health&#146;s cash available for operations and other uses and the incurrence of indebtedness to finance the acquisition; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption of known and unknown liabilities of Aetna. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If CVS Health is not able to
successfully combine the businesses of CVS Health and Aetna within the anticipated time frame, or at all, the anticipated cost savings and other benefits of the merger may not be realized fully or may take longer to realize than expected, the
combined businesses may not perform as expected and the value of the shares of CVS Health common stock may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS
Health and Aetna have operated and, until completion of the merger will continue to operate, independently, and there can be no assurances that their businesses can be integrated successfully. It is possible that the integration process could result
in the loss of key CVS Health or Aetna employees, the disruption of either company&#146;s or both companies&#146; ongoing businesses or in unexpected integration issues, higher than expected integration costs and an overall post-completion
integration process that takes longer than originally anticipated. Specifically, issues that must be addressed in integrating the operations of Aetna and CVS Health in order to realize the anticipated benefits of the merger so the combined business
performs as expected include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">combining the companies&#146; separate operational, financial, reporting and corporate functions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">integrating the companies&#146; technologies, products and services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and eliminating redundant and underperforming operations and assets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">harmonizing the companies&#146; operating practices, employee development, compensation and benefit programs, internal controls and other policies, procedures and processes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">addressing possible differences in business backgrounds, corporate cultures and management philosophies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">consolidating the companies&#146; corporate, administrative and information technology infrastructure; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">coordinating sales, distribution and marketing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">managing the movement of certain businesses and positions to different locations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining existing agreements with customers, providers and vendors and avoiding delays in entering into new agreements with prospective customers, providers and vendors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">operating in industry sectors in which CVS Health and its current management may have little or no experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">coordinating geographically dispersed organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">consolidating offices of Aetna and CVS Health that are currently in or near the same location; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effecting potential actions that may be required in connection with obtaining regulatory approvals. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at times, the attention of certain members of each company&#146;s management and each company&#146;s resources may be focused on
completion of the merger and the integration of the businesses of the two companies and diverted from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations, which may disrupt each
company&#146;s ongoing business and the business of the combined company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVS Health has limited experience in the insurance and
managed health care industry, which may hinder CVS Health&#146;s ability to achieve the combined company&#146;s objectives. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health
has limited experience operating an insurance and managed health care business, and will rely in large part on the existing management of Aetna to continue to manage the Aetna business following the merger. However, there is no assurance that CVS
Health will be able to retain the services of such management. If CVS Health fails to retain the existing management of Aetna, CVS Health&#146;s ability to realize the anticipated benefits of the transaction may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVS Health and Aetna may have difficulty attracting, motivating and retaining executives and other key employees in light of the merger.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As CVS Health will be operating in industry sectors for which its existing management team has little or no experience, CVS
Health&#146;s success after the transaction will depend in part on the ability of CVS Health to retain key executives and other employees of Aetna. Uncertainty about the effect of the merger on CVS Health and Aetna employees may have an adverse
effect on each of CVS Health and Aetna separately and consequently the combined business. This uncertainty may impair CVS Health&#146;s and/or Aetna&#146;s ability to attract, retain and motivate key personnel. Employee retention may be particularly
challenging during the pendency of the merger, as employees of CVS Health and Aetna may experience uncertainty about their future roles in the combined business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Aetna&#146;s officers and employees may hold Aetna common shares, as well as Aetna stock appreciation rights, Aetna RSUs and
Aetna PSUs that are subject to accelerated vesting on a change in control, and, if the merger is completed, these officers and employees may be entitled to cash and/or the merger consideration in respect of such Aetna common shares, stock
appreciation rights, Aetna RSUs and Aetna PSUs. These payouts could also make retention of these officers and employees more difficult. Additionally, pursuant to employment agreements and/or other agreements or arrangements with Aetna, certain key
employees of Aetna are entitled to receive severance payments upon a termination without cause and/or a resignation for &#147;good reason&#148; following completion of the merger. Under these agreements, certain key employees of Aetna potentially
could resign from his or her employment following specified circumstances set forth in his or her applicable agreement, including an adverse change in his or her title, authority or responsibilities, compensation and benefits or primary office
location. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if key employees of CVS Health or Aetna depart or are at risk of departing, including because of issues relating
to the uncertainty and difficulty of integration, financial security or a desire not to become </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees of the combined business, CVS Health may have to incur significant costs in retaining such individuals or in identifying, hiring and retaining replacements for departing employees and
may lose significant expertise and talent relating to the business of Aetna, and CVS Health&#146;s ability to realize the anticipated benefits of the merger may be materially and adversely affected. Accordingly, no assurance can be given that CVS
Health will be able to attract or retain key employees of Aetna to the same extent that Aetna has been able to attract or retain employees in the past. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In order to complete the merger, CVS Health and Aetna must obtain certain governmental authorizations, and if such authorizations are not
granted or are granted with conditions that become applicable to the parties, completion of the merger may be jeopardized or prevented or the anticipated benefits of the merger could be reduced. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the merger is conditioned upon the expiration or early termination of the waiting period relating to the merger under the HSR Act
and certain other applicable laws or regulations and the required governmental authorizations having been obtained and being in full force and effect. Although CVS Health and Aetna have agreed in the merger agreement to use their reasonable best
efforts, subject to certain limitations, to make certain governmental filings or obtain the required governmental authorizations, as the case may be, there can be no assurance that the relevant waiting periods will expire or authorizations will be
obtained and no assurance that the merger will be completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the governmental authorities from which these authorizations
are required have broad discretion in administering the governing laws and regulations, and may take into account various facts and circumstances in their consideration of the merger, including other potential transactions in the health care
industry or other industries. These governmental authorities may initiate proceedings seeking to prevent, or otherwise seek to prevent, the merger. As a condition to authorization of the merger or related transactions, these governmental authorities
also may impose requirements, limitations or costs, require divestitures or place restrictions on the conduct of CVS Health&#146;s business after completion of the merger. Under the terms of the merger agreement, CVS Health is not required, and
Aetna is not permitted without CVS Health&#146;s consent, to take any actions or agree to any terms or conditions in connection with (i)&nbsp;the expiration or early termination of the waiting period relating to the merger under the HSR Act,
(ii)&nbsp;any other antitrust law or (iii)&nbsp;the required governmental authorizations, in each case if such action, term or condition would have, or would reasonably be expected to have, individually or in the aggregate, a regulatory material
adverse effect on CVS Health or Aetna (see the section entitled &#147;The Merger Agreement&#151;Conditions to Completion of the Merger&#148; beginning on page 181 of this joint proxy statement/prospectus for the definition of regulatory material
adverse effect). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, notwithstanding the provisions of the merger agreement, either CVS Health or Aetna could become subject to
terms or conditions in connection with such waiting periods, laws or other authorizations (whether because such term or condition does not rise to the specified level of materiality or CVS Health otherwise consents to its imposition) the imposition
of which could adversely affect CVS Health&#146;s ability to integrate Aetna&#146;s operations with CVS Health&#146;s operations, reduce the anticipated benefits of the merger or otherwise materially and adversely affect CVS Health&#146;s business
and results of operations after completion of the merger. See &#147;The Merger Agreement&#151;Conditions to Completion of the Merger&#148; and &#147;The Merger Agreement&#151;Reasonable Best Efforts Covenant&#148; beginning on pages 181 and 194,
respectively, of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In addition to receipt of certain governmental authorizations, completion of
the merger is subject to a number of other conditions, and if these conditions are not satisfied or waived, the merger will not be completed. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of CVS Health and Aetna to complete the merger are subject to satisfaction or waiver of a number of conditions in addition to
receipt of certain governmental authorizations, including, among other conditions: (i)&nbsp;approval and adoption of the merger agreement by Aetna shareholders at the Aetna special </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting, (ii)&nbsp;approval of the stock issuance by CVS Health stockholders at the CVS Health special meeting, (iii)&nbsp;approval for the listing on the NYSE of the shares of CVS Health common
stock to be issued in the merger, (iv)&nbsp;absence of any applicable law or order that prohibits completion of the transaction, (v)&nbsp;declaration of effectiveness of the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT>
of which this joint proxy statement/prospectus forms a part, and absence of any stop order suspending such effectiveness and any proceedings for such purpose pending before the SEC, (vi)&nbsp;accuracy of the representations and warranties made in
the merger agreement by the other party, subject to certain materiality qualifications, (vii)&nbsp;performance in all material respects by the other party of the material obligations required to be performed by it at or prior to completion of the
transaction, and (viii)&nbsp;the absence of a material adverse effect on the other party (see &#147;The Merger Agreement&#151;Definition of &#145;Material Adverse Effect&#146;&#148; beginning on page 184 of this joint proxy statement/prospectus for
the definition of material adverse effect). For a more complete summary of the conditions that must be satisfied or waived prior to completion of the merger, see &#147;The Merger Agreement&#151;Conditions to Completion of the Merger&#148; beginning
on page 181 of this joint proxy statement/prospectus. There can be no assurance that the conditions to completion of the merger will be satisfied or waived or that the merger will be completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the CVS Health special meeting and the Aetna special meeting may take place before certain governmental authorizations have been
obtained and, therefore, before the terms on which such governmental authorizations may be obtained, or the conditions to obtaining such governmental authorizations that may be imposed, are known. As a result, if CVS Health stockholders approve the
stock issuance at the CVS Health special meeting, or Aetna shareholders approve and adopt the merger agreement at the Aetna special meeting, CVS Health and Aetna may make decisions after the respective meetings to waive a condition as to the receipt
of certain governmental authorizations or to take certain actions required to obtain such governmental authorizations without seeking further stockholder or shareholder approval, as applicable, and such actions could have an adverse effect on the
combined company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVS Health&#146;s and Aetna&#146;s business relationships may be subject to disruption due to uncertainty associated
with the merger. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties with which CVS Health or Aetna does business may experience uncertainty associated with the merger, including
with respect to current or future business relationships with CVS Health, Aetna or the combined business. CVS Health&#146;s and Aetna&#146;s business relationships may be subject to disruption as customers, providers, vendors and others may attempt
to negotiate changes in existing business relationships or consider entering into business relationships with parties other than CVS Health, Aetna or the combined business. These disruptions could have a material adverse effect on the businesses,
financial condition, results of operations or prospects of CVS Health, Aetna and/or the combined business, including a material adverse effect on CVS&nbsp;Health&#146;s ability to realize the anticipated benefits of the merger. The risk and adverse
effect of such disruptions could be exacerbated by a delay in completion of the merger or termination of the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Certain
of Aetna&#146;s executive officers and directors have interests in the merger that may be different from your interests as a shareholder of Aetna. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering the recommendation of Aetna&#146;s board of directors that Aetna shareholders vote in favor of the approval and adoption of
the merger agreement, Aetna shareholders should be aware that certain of the executive officers and directors of Aetna have interests in the merger that may be different from, or in addition to, the interests of Aetna shareholders generally. These
include, among others, continuing service on the CVS&nbsp;Health board of directors for Mr.&nbsp;Bertolini and two other individuals who are serving on the Aetna board of directors immediately prior to completion of the merger, payments pursuant to
certain equity awards, severance payments upon qualifying terminations and rights to continuing indemnification and directors&#146; and officers&#146; liability insurance. See &#147;Interests of Aetna&#146;s Directors and Executive Officers in the
Merger&#148; beginning on page&nbsp;209 of this joint proxy statement/prospectus for a more detailed description of these interests. Aetna&#146;s board of directors and CVS Health&#146;s board of directors were aware of these interests and
considered them, among other things, in evaluating and negotiating the merger agreement and in recommending that Aetna shareholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approve and adopt the merger agreement and that the CVS Health stockholders approve the stock issuance, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The merger agreement contains provisions that may make it more difficult for CVS Health and Aetna to pursue alternatives to the merger.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement contains provisions that make it more difficult for Aetna to sell its business to a party other than CVS Health,
or for CVS Health to sell its business. These provisions include a general prohibition on each party soliciting any acquisition proposal. Further, there are only limited exceptions to each party&#146;s agreement that its board of directors will not
withdraw or modify in a manner adverse to the other party the recommendation of its board of directors in favor of the approval and adoption of the merger agreement, in the case of Aetna, or the approval of the stock issuance, in the case of CVS
Health, and the other party generally has a right to match any acquisition proposal that may be made. However, at any time prior to the approval and adoption of the merger agreement by Aetna shareholders, in the case of Aetna, or the approval of the
stock issuance by CVS Health stockholders, in the case of CVS Health, such party&#146;s board of directors is permitted to take certain of these actions if it determines in good faith that the failure to take such action would be reasonably likely
to be inconsistent with its fiduciary duties under applicable law. See &#147;The Merger Agreement&#151;No Solicitation&#148; and &#147;The Merger Agreement&#151;Termination Fees and Expenses&#148; beginning on pages 190 and 205, respectively, of
this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties believe these provisions are reasonable and not preclusive of other offers, but these
restrictions might discourage a third party that has an interest in acquiring all or a significant part of either Aetna or CVS&nbsp;Health from considering or proposing that acquisition, even if that party were prepared to pay consideration with a
higher <FONT STYLE="white-space:nowrap">per-share</FONT> value than the currently proposed merger consideration, in the case of Aetna, or that party were prepared to enter into an agreement that may be favorable to CVS Health or its stockholders, in
the case of CVS Health. Furthermore, the termination fees described below may result in a potential competing acquirer proposing to pay a lower <FONT STYLE="white-space:nowrap">per-share</FONT> price to acquire the applicable party than it might
otherwise have proposed to pay because of the added expense of the termination fee that may become payable by such party in certain circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Failure to complete the merger could negatively impact the stock price and the future business and financial results of CVS Health and
Aetna. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is not completed for any reason, including as a result of Aetna shareholders failing to approve and adopt the
merger agreement or CVS Health stockholders failing to approve the stock issuance, the ongoing businesses of CVS Health and Aetna may be materially and adversely affected and, without realizing any of the benefits of having completed the merger, CVS
Health and Aetna would be subject to a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health and Aetna may experience negative reactions from the financial markets, including negative impacts on trading prices of CVS Health common stock, Aetna common shares and both companies&#146; other securities,
and from their respective customers, providers, vendors, regulators and employees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna may be required to pay CVS Health a termination fee of $2.1&nbsp;billion if the merger agreement is terminated under certain circumstances, and CVS Health may be required to pay Aetna a termination fee of
$2.1&nbsp;billion if the merger agreement is terminated under certain other circumstances (see &#147;The Merger Agreement&#151;Termination Fees and Expenses&#148; beginning on page 205 of this joint proxy statement/prospectus); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health and Aetna will be required to pay certain transaction expenses and other costs incurred in connection with the merger, whether or not the merger is completed; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger agreement places certain restrictions on the conduct of Aetna&#146;s and CVS Health&#146;s businesses
prior to completion of the merger, and such restrictions, the waiver of which is subject to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the consent of the other party, may prevent Aetna and CVS Health from making certain acquisitions, taking certain other specified actions or otherwise pursuing business opportunities during the
pendency of the merger that Aetna or CVS Health would have made, taken or pursued if these restrictions were not in place (see &#147;The Merger Agreement&#151;Conduct of Business Pending the Merger&#148; beginning on page 185 of this joint proxy
statement/prospectus for a description of the restrictive covenants applicable to Aetna and CVS Health); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">matters relating to the merger (including arranging permanent financing and integration planning) will require substantial commitments of time and resources by CVS Health and Aetna management and the expenditure of
significant funds in the form of fees and expenses, which would otherwise have been devoted to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations and other opportunities that may have been
beneficial to either CVS&nbsp;Health or Aetna as an independent company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the risks described
above will not materialize. If any of those risks materialize, they may materially and adversely affect CVS Health&#146;s and/or Aetna&#146;s businesses, financial condition, financial results, ratings, stock prices and/or bond prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, CVS Health and Aetna could be subject to litigation related to any failure to complete the merger or related to any proceeding to
specifically enforce CVS Health&#146;s or Aetna&#146;s obligation to perform their respective obligations under the merger agreement. If the merger is not completed, these risks may materialize and may materially and adversely affect CVS
Health&#146;s and/or Aetna&#146;s businesses, financial condition, financial results, ratings, stock prices and/or bond prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The
shares of CVS Health common stock to be received by Aetna shareholders upon completion of the merger will have different rights from Aetna common shares. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the merger, Aetna shareholders will no longer be shareholders of Aetna, a Pennsylvania corporation, but will instead become
stockholders of CVS Health, a Delaware corporation, and their rights as CVS Health stockholders will be governed by Delaware law and the terms of CVS Health&#146;s amended and restated certificate of incorporation, as it may be amended from time to
time, which is referred to in this joint proxy statement/prospectus as CVS Health&#146;s certificate of incorporation, and CVS Health&#146;s amended and restated <FONT STYLE="white-space:nowrap">by-laws,</FONT> as they may be amended from time to
time, which are referred to in this joint proxy statement/prospectus as CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws.</FONT> Delaware law and the terms of CVS Health&#146;s certificate of incorporation and CVS Health&#146;s <FONT
STYLE="white-space:nowrap">by-laws</FONT> are in some respects materially different than Pennsylvania law and the terms of Aetna&#146;s articles and Aetna&#146;s amended and restated by-laws, as they may be amended from time to time, which are
referred to in this joint proxy statement/prospectus as Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> which currently govern the rights of Aetna shareholders. See &#147;Comparison of Stockholder Rights&#148; beginning on page 225 of
this joint proxy statement/prospectus for a discussion of the different rights associated with Aetna common shares and shares of CVS Health common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Current CVS Health stockholders and Aetna shareholders will have a reduced ownership and voting interest after the merger and will exercise
less influence over the management of the combined company. </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the merger, CVS Health expects to issue
approximately 280 million shares of CVS&nbsp;Health common stock to Aetna shareholders in connection with the transactions contemplated by the merger agreement. As a result, it is expected that, immediately after completion of the merger, former
Aetna shareholders will own approximately 22% of the outstanding shares of CVS Health common stock. Consequently, current CVS Health stockholders in the aggregate will have less influence over the management and policies of CVS Health than they
currently have over the management and policies of CVS Health, and Aetna shareholders in the aggregate will have significantly less influence over the management and policies of CVS Health than they currently have over the management and policies of
Aetna. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Lawsuits have been filed against Aetna and its board of directors and other lawsuits may
be filed against Aetna, CVS Health and/or their respective boards of directors challenging the merger. An adverse ruling in any such lawsuit may prevent the merger from being completed. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February 8, 2018, seven complaints had been filed by purported Aetna shareholders challenging the merger. The first, a putative class
action complaint, was filed by Olivier Miramond in the United States District Court for the District of Connecticut and is captioned <I>Miramond v. Aetna, Inc., et al.</I>, case number 3:18-cv-00083. The second complaint, filed in the United States
District Court for the District of Connecticut by Shiva Stein individually, is captioned <I>Stein v. Aetna, Inc., et al</I>., case number 3:18-cv-00136. The third complaint, a putative class action, was filed by Robert Freedman in the United States
District Court for the Eastern District of Pennsylvania and is captioned <I>Freedman v. Aetna, Inc., et al</I>., case number 2:18-cv-00323. The fourth complaint, filed in the United States District Court for the District of Connecticut by Luan Pham
individually, is captioned <I>Pham v. Aetna, Inc., et al.</I>, case number 3:18-cv-00154. The fifth complaint, filed in the United States District Court for the Eastern District of Pennsylvania by Vladimir Gusinsky Rev. Trust individually, is
captioned <I>Vladimir Gusinsky Rev. Trust v. Aetna Inc. et al.</I>, case number 2:18-cv-00361. The sixth complaint, a putative class action complaint, was filed by Dr. Eli Inzlicht-Sprei in the United States District Court for the District of
Connecticut and is captioned <I>Inzlicht-Sprei v. Aetna, Inc., et al.</I>, case number 3:18-cv-00176. The seventh complaint, a putative class action complaint, was filed by Joel Rosenfeld in the United States District Court for the District of
Connecticut and is captioned <I>Rosenfeld v. Aetna, Inc. et al.,</I> case number 3:18-cv-00213. The complaints name as defendants Aetna and each member of Aetna&#146;s board of directors. In addition, the <I>Vladimir Gusinsky Rev. Trust</I>
complaint names CVS Health and Merger Sub as defendants. The complaints generally allege, among other things, that the merger consideration in the proposed transaction is unfair, inadequate and undervalues Aetna; that the defendants failed to
conduct a fair and reasonable sales process; that the merger agreement&#146;s deal protection provisions improperly deter other suitors from submitting a superior offer for Aetna; that Aetna&#146;s board of directors and executive officers are
conflicted because they have secured unique benefits for themselves from the proposed transaction not available to Aetna shareholders generally; and that the defendants authorized the filing of a materially incomplete and misleading registration
statement. Among other remedies, the complaints seek to enjoin the Aetna special meeting and the closing of the merger, as well as costs and attorneys&#146; fees. Defendants believe that the complaints are without merit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Proposal I: Approval of the Stock Issuance&#151;Litigation
Relating to the Merger&#148; beginning on page 176 of this joint proxy statement/prospectus for more information about litigation related to the merger that has been commenced prior to the date of this joint proxy statement/prospectus. There can be
no assurance that additional complaints will not be filed with respect to the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the conditions to completion of the merger
is the absence of any applicable law (including any order) being in effect that prohibits completion of the merger. Accordingly, if a plaintiff is successful in obtaining an order prohibiting completion of the merger, then such order may prevent the
merger from being completed, or from being completed within the expected timeframe. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The indebtedness of CVS Health following
completion of the merger will be substantially greater than CVS Health&#146;s indebtedness on a stand-alone basis and greater than the combined indebtedness of CVS Health and Aetna existing prior to the announcement of the merger agreement. This
increased level of indebtedness could adversely affect CVS Health&#146;s business flexibility, and increase its borrowing costs. Downgrades in CVS Health&#146;s and/or Aetna&#146;s ratings could adversely affect CVS Health&#146;s, Aetna&#146;s
and/or the combined company&#146;s respective businesses, cash flows, financial condition and operating results. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of
the merger, CVS Health expects to incur acquisition-related debt financing of approximately $45.0&nbsp;billion and assume Aetna&#146;s existing indebtedness of approximately $8.2&nbsp;billion. CVS&nbsp;Health&#146;s substantially increased
indebtedness and higher <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debt-to-equity</FONT></FONT> ratio following completion of the merger in comparison to that of CVS Health prior to the merger will have the effect, among other
things, of reducing CVS Health&#146;s flexibility to respond to changing business and economic conditions and will increase CVS Health&#146;s borrowing costs. In addition, the amount of cash required to service CVS Health&#146;s increased
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indebtedness levels and thus the demands on CVS Health&#146;s cash resources will be greater than the amount of cash flows required to service the indebtedness of CVS Health or Aetna individually
prior to the merger. The increased levels of indebtedness could also reduce funds available to fund CVS Health&#146;s efforts to combine its business with Aetna and realize expected benefits of the merger and/or engage in investments in product
development, capital expenditures, dividend payments, share repurchases and other activities and may create competitive disadvantages for CVS Health relative to other companies with lower debt levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, CVS Health&#146;s credit ratings impact the cost and availability of future borrowings, and, as a result, CVS Health&#146;s cost
of capital. CVS Health&#146;s ratings reflect each rating organization&#146;s opinion of CVS&nbsp;Health&#146;s financial strength, operating performance and ability to meet CVS Health&#146;s debt obligations or, following completion of the merger,
obligations to the combined company&#146;s insureds. Each of the ratings organizations reviews CVS Health&#146;s and Aetna&#146;s ratings periodically, and there can be no assurance that CVS Health&#146;s or Aetna&#146;s current ratings will be
maintained in the future. Following the announcement of the merger agreement, each of Standard&nbsp;&amp; Poor&#146;s and Moody&#146;s placed certain of CVS Health&#146;s debt, financial strength and other credit ratings under review for a possible
downgrade. Following the announcement of the merger agreement, Standard&nbsp;&amp; Poor&#146;s, A.M. Best and Fitch placed Aetna&#146;s debt, financial strength and other credit ratings under review with negative implications. Downgrades in CVS
Health&#146;s and/or Aetna&#146;s ratings could adversely affect CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s businesses, cash flows, financial condition and operating results. In addition, if the merger is completed and, in
certain circumstances, Aetna&#146;s debt securities are rated below investment grade, this may constitute a change of control triggering event under the indentures governing such debt. Upon the occurrence of a change of control triggering event,
Aetna, as the surviving corporation of the merger, would be required to offer to repurchase most of Aetna&#146;s outstanding notes at 101% of the principal amount thereof plus accrued and unpaid interest if any, to, but not including, the date of
repurchase. However, it is possible that Aetna (or CVS Health) would not have sufficient funds at the time of the change of control triggering event to make the required repurchase of notes or that restrictions in other debt instruments would not
allow such repurchases. CVS Health and Aetna cannot provide any assurance that there will be sufficient funds available for Aetna (or CVS Health) to make any required repurchases of the notes upon a change of control triggering event. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVS Health will incur significant transaction and integration-related costs in connection with the merger. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health expects to incur a number of <FONT STYLE="white-space:nowrap">non-recurring</FONT> costs associated with the merger and combining
the operations of the two companies. CVS Health will incur significant transaction costs related to the merger, including with respect to the financing for the cash consideration to be paid to Aetna shareholders. CVS Health also will incur
significant integration-related fees and costs related to formulating and implementing integration plans, including facilities and systems consolidation costs and employment-related costs. CVS Health continues to assess the magnitude of these costs,
and additional unanticipated costs may be incurred in the merger and the integration of the two companies&#146; businesses. Although CVS Health expects that the elimination of duplicative costs, as well as the realization of other efficiencies
related to the integration of the businesses, should allow CVS&nbsp;Health to offset integration-related costs over time, this net benefit may not be achieved in the near term, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The merger may not be accretive, and may be dilutive, to CVS Health&#146;s earnings per share, which may negatively affect the market price
of shares of CVS Health common stock. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health currently projects that the merger will result in a number of benefits, including
enhanced competitive positioning and a platform from which to accelerate growth, and that it will be accretive to earnings per share in the second full year after the close of the transaction. This projection is based on preliminary estimates that
may materially change. In addition, future events and conditions could decrease or delay the accretion that is currently projected or could result in dilution, including adverse changes in market conditions, additional transaction and
integration-related costs and other factors such as the failure to realize some or all of the anticipated benefits of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the merger. Any dilution of, decrease in or delay of any accretion to, CVS Health&#146;s earnings per share could cause the price of shares of CVS Health common stock to decline or grow at a
reduced rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The unaudited pro forma combined financial information and prospective financial information included in this joint
proxy statement/prospectus is presented for illustrative purposes only and does not represent the actual financial position or results of operations of the combined company following completion of the merger or reflect the effect of any divestitures
that may be required in connection with the merger. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information and prospective financial
information contained in this joint proxy statement/prospectus is presented for illustrative purposes only, contains a variety of adjustments, assumptions and preliminary estimates and does not represent the actual financial position or results of
operations of CVS Health and Aetna prior to the merger or that of the combined company following the merger for several reasons. Among other things, the unaudited pro forma combined financial information does not reflect the effect of any potential
divestitures that may occur prior to or subsequent to completion of the merger, the projected realization of cost savings following completion of the merger, any changes in applicable law (including applicable tax law) after September&nbsp;30, 2017,
Aetna&#146;s sale of its domestic group life insurance, group disability insurance and absence management businesses on November&nbsp;1, 2017, or CVS Health&#146;s projected reduction of its adjusted <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">debt-to-EBITDA</FONT></FONT> ratio following completion of the merger. See the sections entitled &#147;CVS Health and Aetna Unaudited Pro Forma Condensed Combined Financial Statements&#148;, &#147;Aetna Proposal I:
Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Unaudited Prospective Financial Information&#148; and &#147;Comparative Historical and Unaudited Pro Forma Combined Per Share Data&#148;
beginning on pages 42, 155 and 40, respectively, of this joint proxy statement/prospectus. The actual financial positions and results of operations of Aetna and CVS Health prior to the merger and that of the combined company following the merger may
not be consistent with, or evident from, the unaudited pro forma combined financial information or prospective financial information included in this joint proxy statement/prospectus. In addition, the assumptions used in preparing the unaudited pro
forma combined financial information and/or the prospective financial information included in this joint proxy statement/prospectus may not be realized and may be affected by other factors. Any significant changes in the market price of shares of
CVS Health common stock may cause a significant change in the purchase price used for CVS Health&#146;s accounting purposes and the pro forma combined financial information contained in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The future results of the combined company may be adversely impacted if the combined company does not effectively manage its expanded
operations following completion of the merger. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the merger, the size of the combined company&#146;s business
will be significantly larger than the current size of either CVS Health&#146;s or Aetna&#146;s respective businesses. The combined company&#146;s ability to successfully manage this expanded business will depend, in part, upon management&#146;s
ability to implement an effective integration of the two companies and its ability to manage a combined business with significantly larger size and scope with the associated increased costs and complexity. There can be no assurances that the
management of the combined company will be successful or that the combined company will realize the expected operating efficiencies, cost savings and other benefits currently anticipated from the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Risks relating to CVS Health and Aetna. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health and Aetna are, and following completion of the merger CVS Health will continue to be, subject to the risks described in Part I,
Item&nbsp;1A in CVS Health&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, filed with the SEC on February&nbsp;9, 2017, and Part I, Item&nbsp;1A in Aetna&#146;s Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, filed with the SEC on February&nbsp;17, 2017, as updated by their respective Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and
future filings with the SEC, in each case, incorporated by reference into this joint proxy statement/prospectus. See &#147;Where You Can Find More Information&#148; beginning on page 254 of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_38"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health and Aetna have included in this joint proxy statement/prospectus certain statements that may constitute forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (which is referred to in this joint proxy statement/prospectus as the Securities Act), and Section&nbsp;21E of the Exchange Act. In addition, the management
of CVS Health or Aetna may make forward-looking statements to analysts, investors, representatives of the media and others. You can generally identify forward-looking statements by the use of forward-looking terminology such as
&#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;can,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;explore,&#148; &#147;evaluate,&#148; &#147;forecast,&#148; &#147;guidance,&#148;
&#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;probable,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148;
&#147;view,&#148; or &#147;will,&#148; or the negatives thereof or other variations thereon or comparable terminology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health&#146;s and Aetna&#146;s control. Statements in this joint proxy statement/prospectus regarding CVS Health and
Aetna that are forward-looking, including CVS Health&#146;s and Aetna&#146;s projections as to the timing of completion of the merger, the extent of, and the time necessary to obtain, the regulatory approvals required for the merger, the anticipated
benefits of the merger, the impact of the merger on CVS Health&#146;s and Aetna&#146;s businesses, the expected terms, types and amount of the expected financing for the merger, the ownership percentages of CVS Health&#146;s common stock of CVS
Health stockholders and Aetna shareholders upon completion of the merger, the aggregate amount of indebtedness of CVS Health following completion of the merger, CVS Health&#146;s expectations regarding debt repayment and its debt to capital ratio
following completion of the merger, CVS Health&#146;s and Aetna&#146;s respective share repurchase programs and ability and intent to declare future dividend payments, the number of members served by the combined company&#146;s pharmacy benefits
business, the amount, composition and timing of synergies from the merger, CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s future operating results, including the timing and amount of any accretion to earnings, the public debt and
insurer financial strength ratings of CVS Health and Aetna and their respective subsidiaries, CVS Health&#146;s and Aetna&#146;s acquisition-related merger costs and CVS Health&#146;s restructuring and integration-related costs and charges, and the
estimates and assumptions underlying the pro forma combined financial information and other financial projections contained in this joint proxy statement/prospectus are based on CVS Health&#146;s and Aetna&#146;s respective management&#146;s
estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond CVS Health&#146;s and Aetna&#146;s control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this joint proxy statement/prospectus may contain forward-looking statements regarding CVS&nbsp;Health&#146;s or Aetna&#146;s
respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently believe
to be immaterial, that may cause CVS Health&#146;s or Aetna&#146;s actual results to differ materially from those expressed in the forward-looking statements or adversely impact their respective businesses, CVS Health&#146;s ability to complete the
merger and/or CVS Health&#146;s ability to realize the expected benefits from the merger. Should any risks and uncertainties develop into actual events or actual events develop differently from any assumptions, these developments could have a
material adverse effect on the merger and/or CVS Health or Aetna, CVS Health&#146;s ability to successfully complete the merger and/or realize the expected benefits from the merger. Additional information concerning these risks, uncertainties and
assumptions can be found in the section entitled &#147;Risk Factors&#148; beginning on page 62 of this joint proxy statement/prospectus and in CVS Health&#146;s and Aetna&#146;s respective filings with the SEC, including the risk factors discussed
in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and Aetna&#146;s most recent Annual Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;as</FONT> updated by their Quarterly Reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;and</FONT> future filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue
reliance on CVS Health&#146;s and Aetna&#146;s forward-looking statements. These forward-looking statements are and will be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are
applicable only as of the dates of such statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of
operations, financial condition and/or cash flows of CVS Health or Aetna. Actual results may differ materially from those discussed in this joint proxy statement/prospectus. Neither CVS Health nor Aetna assumes any duty to update or revise
forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise, as of any future date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_39"></A>THE COMPANIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_40"></A>CVS Health Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health Corporation was incorporated in the State of Delaware on August&nbsp;22, 1996. CVS Health, together with its subsidiaries, is a
pharmacy innovation company helping people on their path to better health. At the forefront of a changing health care landscape, CVS Health has an unmatched suite of capabilities and the expertise needed to drive innovations that will help shape the
future of health care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through more than 9,700 retail locations, more than 1,100 <FONT STYLE="white-space:nowrap">walk-in</FONT> health
care clinics, a leading pharmacy benefits manager with nearly 90&nbsp;million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services and a leading stand-alone
Medicare Part D prescription drug plan, CVS Health enables people, businesses and communities to manage health in more affordable, effective ways. CVS Health is delivering break-through products and services, from advising patients on their
medications at CVS Pharmacy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> locations, to introducing unique programs to help control costs for CVS&nbsp;Health&#146;s clients at CVS
Caremark<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, to innovating how care is delivered to CVS Health&#146;s patients with complex conditions through CVS Specialty<SUP STYLE="font-size:85%; vertical-align:top"></SUP><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, to improving pharmacy care for the senior community through Omnicare<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or by expanding access to high-quality, <FONT
STYLE="white-space:nowrap">low-cost</FONT> care at CVS MinuteClinic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
principal trading market for shares of CVS Health common stock (NYSE: CVS) is the NYSE. The principal executive offices of CVS Health are located at One CVS Drive, Woonsocket, RI 02895; its telephone number is (401)
<FONT STYLE="white-space:nowrap">765-1500;</FONT> and its website is www.cvshealth.com. Information on CVS Health&#146;s Internet website is not incorporated by reference into or otherwise part of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus incorporates important business and financial information about CVS&nbsp;Health from other documents
that are not included in or delivered with this joint proxy statement/prospectus. For a list of the documents that are incorporated by reference, see &#147;Where You Can Find More Information&#148; beginning on page 254 of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_41"></A>Aetna Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna Inc. was incorporated in the Commonwealth of Pennsylvania on December&nbsp;20, 1982. Aetna, together with its subsidiaries, is one of the
nation&#146;s leading diversified health care benefits companies, serving an estimated 37.9 million people as of December&nbsp;31, 2017. Aetna has the information and resources to help its members, in consultation with their health care
professionals, make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health,
group life and disability plans, medical management capabilities, Medicaid health care management services, Medicare Advantage and Medicare supplement plans, workers&#146; compensation administrative services and health information technology
products and services. Aetna&#146;s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. On
November&nbsp;1, 2017, Aetna sold its domestic group life insurance, group disability insurance and absence management businesses to Hartford Life and Accident Insurance Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal trading market for Aetna common shares (NYSE: AET) is the NYSE. The principal executive offices of Aetna are located at 151
Farmington Avenue, Hartford, CT 06156; its telephone number is (860) <FONT STYLE="white-space:nowrap">273-0123;</FONT> and its website is www.aetna.com. Information on Aetna&#146;s Internet web site is not incorporated by reference into or otherwise
part of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus incorporates important business and financial
information about Aetna from other documents that are not included in or delivered with this joint proxy statement/prospectus. For a list of the documents that are incorporated by reference, see &#147;Where You Can Find More Information&#148;
beginning on page 254<B></B> of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_42"></A>Hudson Merger Sub Corp. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Sub was incorporated in the Commonwealth of Pennsylvania on November&nbsp;14, 2017, and is a wholly-owned subsidiary of CVS Health.
Merger Sub was formed solely for the purpose of completing the merger. Merger Sub has not carried on any activities to date, except for activities incidental to its formation and activities undertaken in connection with the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal executive offices of Merger Sub are located at One CVS Drive, Woonsocket, RI 02895; and its telephone number is (401) <FONT
STYLE="white-space:nowrap">765-1500.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_43"></A>SPECIAL MEETING OF STOCKHOLDERS OF CVS HEALTH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVS Health is providing this joint proxy statement/prospectus to its stockholders in connection with the solicitation of proxies to be
voted at the CVS Health special meeting of stockholders (or any adjournment or postponement thereof) that CVS Health has called to consider and vote on a proposal to approve the stock issuance and a proposal to approve the adjournment from time to
time of the CVS Health special meeting if necessary to solicit additional proxies if there are not sufficient votes at the time of the CVS Health special meeting, or any adjournment or postponement thereof, to approve the stock issuance. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_44"></A>Date, Time and Location </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Together with this joint proxy statement/prospectus, CVS Health is also sending CVS Health stockholders a notice of the CVS Health special
meeting and a form of proxy card that is solicited by CVS Health&#146;s board of directors for use at the CVS Health special meeting to be held on March 13, 2018, at the offices of Shearman &amp; Sterling&nbsp;LLP, located at 599 Lexington Avenue,
New York, NY 10022, at 11:00 a.m. Eastern Time, and any adjournments or postponements of the CVS Health special meeting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only
stockholders or their proxy holders may attend the CVS Health special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you plan to attend the CVS Health special meeting,
please be prepared to provide valid government-issued photo identification (e.g., a driver&#146;s license or a passport) to be admitted to the CVS Health special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares of CVS Health common stock held in &#147;street name&#148; by a broker, bank or other nominee holder
of record at the record date (the close of business on February&nbsp;5, 2018), in addition to proper identification, you will also need an account statement or letter from the nominee indicating that you were the beneficial owner of the shares at
the record date to be admitted to the CVS Health special meeting. If you want to vote your shares of CVS Health common stock held in &#147;street name&#148; in person at the CVS Health special meeting, you will have to obtain a written legal proxy
in your name from the broker, bank or other nominee holder of record that holds your shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_45"></A>Purpose </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the CVS Health special meeting, CVS Health stockholders will be asked to consider and vote on the following proposals: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve the stock issuance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve the CVS Health adjournment proposal. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under CVS Health&#146;s <FONT
STYLE="white-space:nowrap">by-laws,</FONT> the business to be conducted at the CVS Health special meeting will be limited to the proposals set forth in the notice to CVS Health stockholders provided with this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_46"></A>Recommendations of the CVS Health Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s board of directors unanimously determined that the merger agreement and the transactions contemplated by the merger
agreement, including the merger and the stock issuance, are advisable, fair to and in the best interests of CVS Health and its stockholders. CVS Health&#146;s board of directors unanimously recommends that CVS Health stockholders vote
<B>&#147;FOR&#148;</B> the stock issuance. CVS Health&#146;s board of directors further unanimously recommends that CVS Health stockholders vote <B>&#147;FOR&#148;</B> the CVS Health adjournment proposal. See &#147;Aetna Proposal I: Approval and
Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Directors that CVS Health Stockholders Approve the Stock Issuance&#148; beginning on page 106 of this joint proxy statement/prospectus for a more detailed discussion of the recommendation of CVS
Health&#146;s board of directors that CVS Health stockholders approve the stock issuance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_47"></A>CVS Health Record Date;
Outstanding Shares; Stockholders Entitled to Vote </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s board of directors has fixed the close of business on
February&nbsp;5, 2018, as the record date for the determination of the CVS Health stockholders entitled to vote at the CVS Health special meeting or any adjournment or postponement of the CVS Health special meeting. Only CVS Health stockholders of
record at the record date are entitled to receive notice of, and to vote at, the CVS Health special meeting or any adjournment or postponement thereof. As of the close of business on February&nbsp;5, 2018, there were 1,015,460,751 shares of CVS
Health common stock outstanding and entitled to vote at the CVS Health special meeting, held by approximately 21,454 holders of record. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_48">
</A>Quorum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence at the CVS Health special meeting, in person or by proxy, of the holders of a majority of the outstanding
shares of CVS Health common stock at the record date (the close of business on February&nbsp;5, 2018) will constitute a quorum. Elections to abstain from voting will be deemed present at the CVS Health special meeting for the purpose of determining
the presence of a quorum. Shares of CVS Health common stock held in &#147;street name&#148; with respect to which the beneficial owner fails to give voting instructions to the broker, bank or other nominee holder of record, and shares of CVS Health
common stock with respect to which the beneficial owner otherwise fails to vote, will not be deemed present at the CVS Health special meeting for the purpose of determining the presence of a quorum. There must be a quorum for the vote on the stock
issuance to be taken at the CVS Health special meeting. Failure of a quorum to be present at the CVS Health special meeting will necessitate an adjournment of the meeting and will subject CVS Health to additional expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_49"></A>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present, approval of the stock issuance requires the affirmative vote of a majority of the votes cast at the CVS Health
special meeting by holders of shares of CVS Health common stock. <B>CVS Health cannot complete the merger unless its stockholders approve the stock issuance. </B>Under the current rules and interpretive guidance of the NYSE, &#147;votes cast&#148;
on the stock issuance consist of votes &#147;for&#148; or &#147;against&#148; as well as elections to abstain from voting. As a result, a CVS Health stockholder&#146;s election to abstain from voting on the stock issuance will have the same effect
as a vote <B>&#147;AGAINST&#148;</B> the proposal. Assuming a quorum is present, the failure of a CVS Health stockholder who holds his or her shares in &#147;street name&#148; through a broker, bank or other nominee holder of record to give voting
instructions to that broker, bank or other nominee holder of record or any other failure of a CVS Health stockholder to vote will have no effect on the outcome of any vote to approve the stock issuance because these failures to vote are not
considered &#147;votes cast.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the CVS Health adjournment proposal, whether or not a quorum is present, requires the
affirmative vote of a majority of the votes cast at the CVS Health special meeting by CVS Health stockholders. For purposes of the CVS Health adjournment proposal, &#147;votes cast&#148; means votes &#147;for&#148; or &#147;against&#148; the
proposal. As a result, a CVS Health stockholder&#146;s election to abstain from voting on the CVS Health adjournment proposal, the failure of a CVS Health stockholder who holds his or her shares in &#147;street name&#148; through a broker, bank or
other nominee holder of record to give voting instructions to that broker, bank or other nominee holder of record or any other failure of a CVS Health stockholder to vote will have no effect on the outcome of any vote on the CVS Health adjournment
proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_50"></A>Stock Ownership of and Voting by CVS Health Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the record date for the CVS Health special meeting (the close of business on February 5, 2018), CVS Health&#146;s directors and executive
officers and their affiliates beneficially owned and had the right to vote in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate 1,279,586 shares of CVS Health common stock at the CVS Health special meeting, which represents approximately 0.13% of the shares of CVS Health common stock entitled to vote at the CVS
Health special meeting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of CVS Health&#146;s directors and executive officers is expected, as of the date of this joint proxy
statement/prospectus, to vote his or her shares of CVS Health common stock <B>&#147;FOR&#148;</B> the stock issuance and <B>&#147;FOR&#148;</B> the CVS Health adjournment proposal, although none of CVS Health&#146;s directors and executive officers
has entered into any agreement requiring them to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_51"></A>Voting of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Via the Internet or by Telephone </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health common stock directly in your name as a stockholder of record, you may vote via the Internet at
www.proxyvote.com or by telephone by calling <FONT STYLE="white-space:nowrap">(800)&nbsp;690-6903</FONT> toll-free. In order to vote your shares via the Internet or by telephone, you will need the control number on your proxy card (which is unique
to each CVS Health stockholder to ensure all voting instructions are genuine and to prevent duplicate voting). Votes may be submitted via the Internet or by telephone, 24 hours a day, seven days a week, and must be received by 11:59&nbsp;p.m.
(Eastern Time) on March 12, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health common stock in &#147;street name&#148; through a broker, bank or
other nominee holder of record, you may provide voting instructions via the Internet or by telephone only if Internet or telephone voting is made available by your broker, bank or other nominee holder of record. Please follow the voting instructions
provided by your broker, bank or other nominee holder of record with these materials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>By Mail </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health common stock directly in your name as a stockholder of record, in order to vote by mail, you may submit a
proxy card. You will need to complete, sign and date your proxy card and return it using the postage-paid return envelope provided or return it to Vote Processing, c/o Broadridge Financial Solutions, Inc., 51 Mercedes Way, Edgewood, New York 11717.
Broadridge must receive your proxy card no later than the close of business on March 12, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health
common stock in &#147;street name&#148; through a broker, bank or other nominee holder of record, in order to provide voting instructions by mail you will need to complete, sign and date the voting instruction form provided by your broker, bank or
other nominee holder of record and return it in the postage-paid return envelope provided. Your broker, bank or other nominee holder of record must receive your voting instruction form in sufficient time to vote your shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>In Person </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you
hold shares of CVS Health common stock directly in your name as a stockholder of record, you may vote in person at the CVS Health special meeting. Stockholders of record also may be represented by another person at the CVS Health special meeting by
executing a proper proxy designating that person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a stockholder of record submits a proxy via the Internet or by telephone, his or
her proxy is recorded immediately. You are encouraged to register your vote via the Internet or telephone whenever possible. If you submit a proxy via the Internet or by telephone, please do not return your proxy card by mail. If you attend the CVS
Health special meeting, you may also vote in person. Any votes that you previously submitted&#151;whether via the Internet, by telephone or by mail&#151;will be revoked and superseded by any vote that you cast at the CVS Health special meeting. Your
attendance at the CVS Health special meeting alone will not revoke any proxy previously given. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold shares of CVS Health common stock in &#147;street name&#148; through a broker,
bank or other nominee holder of record, you must obtain a written legal proxy from that institution and present it to the judge of election with your ballot to be able to vote in person at the CVS Health special meeting. To request a legal proxy,
please contact your broker, bank or other nominee holder of record. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>By Participants in the CVS Health 401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participants in the CVS Health 401(k) Plan who receive this joint proxy statement/prospectus in their capacity as participants in the CVS
Health 401(k) Plan are entitled to vote using the enclosed proxy card. The proxy card directs the trustee of the CVS Health 401(k) Plan to vote a participant&#146;s shares as indicated on the card. Shares of CVS Health common stock held through the
CVS Health 401(k) Plan for which no instructions are received will be voted by the trustee of the CVS Health 401(k) Plan in the same percentage as the shares of CVS Health common stock held through the CVS Health 401(k) Plan for which the trustee
receives voting instructions. The trustee of the CVS Health 401(k) Plan must receive voting instructions from participants by 11:59 p.m. (Eastern Time) on March 8, 2018. Participants cannot vote the shares of CVS Health common stock they hold
through the CVS Health 401(k) Plan in person at the CVS Health special meeting. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Generally </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in an account at a broker, bank or other nominee holder of record (i.e., in &#147;street name&#148;), you must instruct
the broker, bank or other nominee holder of record on how to vote your shares. Your broker, bank or other nominee holder of record will vote your shares only if you provide instructions on how to vote by filling out the voting instruction form sent
to you by your broker, bank or other nominee holder of record with this joint proxy statement/prospectus. Brokers, banks and other nominee holders of record who hold shares of CVS Health common stock in &#147;street name&#148; typically have the
authority to vote in their discretion on &#147;routine&#148; proposals when they have not received instructions on how to vote from the beneficial owner. However, brokers, banks and other nominee holders of record typically are not allowed to
exercise their voting discretion on matters that are <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> without specific instructions on how to vote from the beneficial owner. Under the current rules of the NYSE, both proposals to be
considered at the CVS Health special meeting as described in this joint proxy statement/prospectus are considered <FONT STYLE="white-space:nowrap">non-routine.</FONT> Therefore, brokers, banks and other nominee holders of record do not have
discretionary authority to vote on either proposal. A beneficial owner&#146;s failure to instruct the broker, bank or other nominee holder of record how to vote shares of CVS Health common stock held in &#147;street name&#148; will have no effect on
the proposal to approve the stock issuance or the CVS Health adjournment proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> are shares held by a broker, bank or other nominee holder of record that are present in person or represented by proxy at the CVS Health special meeting, but with respect to which the broker, bank or
other nominee holder of record is not instructed by the beneficial owner of such shares on how to vote on a particular proposal and the broker, bank or other nominee holder of record does not have discretionary voting power on such proposal. Because
brokers, banks and other nominee holders of record do not have discretionary voting authority with respect to either of the proposals to be considered at the CVS Health special meeting, if a beneficial owner of shares of CVS Health common stock held
in &#147;street name&#148; does not give voting instructions to the broker, bank or other nominee holder of record, then those shares will not be present in person or represented by proxy at the CVS Health special meeting. As a result, there will
not be any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with either of the proposals to be considered at the CVS Health special meeting as described in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares represented by each properly completed and valid proxy received before or at the CVS Health special meeting will be voted in
accordance with the instructions given in the proxy. If a CVS Health stockholder signs a proxy card and returns it without giving instructions for voting on any proposal, the shares of CVS Health common stock represented by that proxy card will be
voted <B>&#147;FOR&#148;</B> the stock issuance and <B>&#147;FOR&#148;</B> the CVS Health adjournment proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Your vote is very important, regardless of the number of shares you own. Whether or not
you expect to attend the CVS Health special meeting in person, please vote or otherwise submit a proxy to vote your shares as promptly as possible so that your shares may be represented and voted at the CVS Health special meeting. If your shares are
held in the name of a bank, broker or other nominee holder of record, please follow the instructions on the voting instruction form furnished to you by such record holder. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_52"></A>Revocability of Proxies; Changing Your Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may revoke your proxy or change your vote at any time before the closing of the polls at the CVS Health special meeting. If you are a
stockholder of record at the record date (the close of business on February&nbsp;5, 2018), you can revoke your proxy or change your vote by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sending a signed notice stating that you revoke your proxy to Vote Processing, c/o Broadridge Financial Solutions, Inc. by mail at 51 Mercedes Way, Edgewood, NY 11717 or by fax at
<FONT STYLE="white-space:nowrap">(631)&nbsp;254-7733</FONT> that bears a date later than the date of the proxy you want to revoke and is received prior to the CVS Health special meeting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submitting a valid, later-dated proxy via the Internet or telephone before 11:59 p.m. (Eastern Time) on March 12, 2018, or by mail that is received prior to the CVS Health special meeting; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attending the CVS Health special meeting (or, if the CVS Health special meeting is adjourned or postponed, attending the adjourned or postponed meeting) and voting in person, which automatically will cancel any proxy
previously given, or revoking your proxy in person, but your attendance at the CVS Health special meeting alone will not revoke any proxy previously given. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold your shares in &#147;street name&#148; through a broker, bank or other nominee holder of record, you must contact your broker,
bank or other nominee holder of record to change your vote or obtain a written legal proxy to vote your shares if you wish to cast your vote in person at the CVS Health special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_53"></A>Solicitation of Proxies; Expenses of Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus is being provided to holders of shares of CVS Health common stock in connection with the solicitation of
proxies by CVS Health&#146;s board of directors to be voted at the CVS Health special meeting and at any adjournments or postponements of the CVS Health special meeting. CVS Health will bear all costs and expenses in connection with the solicitation
of proxies, including the costs of filing, printing and mailing this joint proxy statement/prospectus for the CVS Health special meeting. CVS Health has engaged Okapi Partners LLC to assist in the solicitation of proxies for the CVS Health special
meeting and will pay Okapi Partners LLC an initial retainer of $20,000 and additional fees to be determined at the conclusion of the solicitation plus reimbursement of reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to solicitation by
mail, directors, officers and employees of CVS Health or its subsidiaries may solicit proxies from stockholders by telephone, telegram, email, personal interview or other means. CVS Health currently expects not to incur any costs beyond those
customarily expended for a solicitation of proxies in connection with approval of any issuance of shares of CVS Health common stock. Directors, officers and employees of CVS Health will not receive additional compensation for their solicitation
activities, but may be reimbursed for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by them in connection with the solicitation. Brokers, dealers, commercial banks, trust
companies, fiduciaries, custodians and other nominees have been requested to forward proxy solicitation materials to their customers, and such nominees will be reimbursed for their reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_54"></A>Householding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has adopted a rule concerning the delivery of annual reports and proxy statements. It permits CVS Health, with your permission, to send
a single notice of meeting and, to the extent requested, a single copy of this joint proxy statement/prospectus to any household at which two or more CVS Health stockholders reside if they </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appear to be members of the same family. This rule is called &#147;householding,&#148; and its purpose is to help reduce printing and mailing costs of proxy materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of brokerage firms have instituted householding for shares held in &#147;street name.&#148; If you and members of your household have
multiple accounts holding shares of CVS Health common stock, you may have received a householding notification from your broker. Please contact your broker directly if you have questions, require additional copies of this joint proxy
statement/prospectus or wish to revoke your decision to household. These options are available to you at any time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_55"></A>Adjournment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health stockholders are being asked to approve a proposal that will give CVS Health&#146;s board of directors authority to adjourn from
time to time the CVS Health special meeting for the purpose of soliciting additional proxies in favor of the approval of the stock issuance if there are not sufficient votes at the time of the CVS Health special meeting, or any adjournment or
postponement thereof, to approve the stock issuance. If the CVS Health adjournment proposal is approved, the CVS Health special meeting could be adjourned to any date. In addition, CVS Health&#146;s board of directors, with or without stockholder
approval, could postpone the CVS Health special meeting before it commences, whether for the purpose of soliciting additional proxies or for other reasons. If the CVS Health special meeting is adjourned for the purpose of soliciting additional
proxies, stockholders who have already submitted their proxies will be able to revoke them at any time prior to their use. If you sign and return a proxy and do not indicate how you wish to vote on any proposal, or if you indicate that you wish to
vote in favor of the approval of the stock issuance but do not indicate a choice on the CVS Health adjournment proposal, your shares will be voted in favor of the CVS Health adjournment proposal. But if you indicate that you wish to vote against the
approval of the stock issuance, your shares will only be voted in favor of the CVS Health adjournment proposal if you indicate that you wish to vote in favor of that proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_56"></A>Other Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The matters to be considered at the CVS Health special meeting are of great importance to the stockholders of CVS Health. Accordingly, you are
urged to read and carefully consider the information contained in or incorporated by reference into this joint proxy statement/prospectus and submit your proxy via the Internet or by telephone or complete, date, sign and promptly return the enclosed
proxy card in the enclosed postage-paid envelope. <B>If you submit your proxy via the Internet or by telephone, you do not need to return the enclosed proxy card. </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_57"></A>Assistance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>If you need assistance in completing your proxy card or have questions regarding the CVS Health special meeting, please contact: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g482402g89e77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Okapi Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1212 Avenue of the Americas, 24th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10036 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone
(Toll-Free): (855) 305-0855 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone (Collect): (212) 297-0720 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: cvsproxyinfo@okapipartners.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CVS Health Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One CVS Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Woonsocket, RI 02895
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: <FONT STYLE="white-space:nowrap">(800)&nbsp;201-0938</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: investorinfo@cvshealth.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_58"></A>SPECIAL MEETING OF SHAREHOLDERS OF AETNA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Aetna is providing this joint proxy statement/prospectus to its shareholders in connection with the solicitation of proxies to be voted at
the Aetna special meeting of shareholders (or any adjournment or postponement thereof) that Aetna has called to consider and vote on (i)&nbsp;a proposal to approve and adopt the merger agreement, (ii)&nbsp;a proposal to approve the adjournment from
time to time of the Aetna special meeting if necessary to solicit additional proxies if there are not sufficient votes to approve and adopt the merger agreement at the time of the Aetna special meeting or any adjournment or postponement thereof and
(iii)&nbsp;a proposal to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation that will or may be paid or provided by Aetna to its named executive officers in connection with the merger. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_59"></A>Date, Time and Location </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Together with this joint proxy statement/prospectus, Aetna is also sending Aetna shareholders a notice of the Aetna special meeting and a form
of proxy card that is solicited by Aetna&#146;s board of directors for use at the Aetna special meeting to be held on March 13, 2018, at the offices of Davis Polk &amp; Wardwell LLP, located at 450 Lexington Avenue, New York, NY 10017, at 11:00 a.m.
Eastern Time, and any adjournments or postponements of the Aetna special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only shareholders or their proxy holders may attend the
Aetna special meeting. If you hold shares in your name at the record date and plan to attend the Aetna special meeting, because of security procedures, you will need to obtain an admission ticket in advance. In addition to obtaining an admission
ticket in advance, you will be required to provide valid government-issued photo identification (e.g., a driver&#146;s license or a passport) to be admitted to the Aetna special meeting. You may apply for an admission ticket by mail to Office of the
Corporate Secretary, 151 Farmington Avenue, RW61, Hartford, CT 06156 or by facsimile to (860) <FONT STYLE="white-space:nowrap">293-1361.</FONT> Ticket requests will not be accepted by phone or email. Aetna&#146;s Corporate Secretary must receive
your request for an admission ticket on or before March 6, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of Aetna common shares held in
&#147;street name&#148; by a broker, bank or other nominee holder of record at the record date (the close of business on February&nbsp;5, 2018), and you plan to attend the Aetna special meeting, in addition to following the security procedures
described above, you will also need proof of beneficial ownership at the record date to obtain your admission ticket to the Aetna special meeting. A brokerage statement or letter from a bank or broker are examples of proof of beneficial ownership.
If you wish to vote your Aetna common shares held in &#147;street name&#148; in person at the Aetna special meeting, you will have to obtain a written legal proxy in your name from the broker, bank or other nominee holder of record that holds your
shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_60"></A>Purpose </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Aetna special meeting, Aetna shareholders will be asked to consider and vote on the following proposals: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve and adopt the merger agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve the Aetna adjournment proposal; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the Aetna compensation advisory proposal. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> the business to be conducted at the Aetna special meeting will be limited
to the proposals set forth in the notice to Aetna shareholders provided with this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_61"></A>Recommendations of the Aetna Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna&#146;s board of directors unanimously determined that the merger agreement and the transactions contemplated by the merger agreement
(including the merger) are fair to and in the best interests of Aetna and its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders. Aetna&#146;s board of directors unanimously recommends that Aetna shareholders vote <B>&#147;FOR&#148;</B> the proposal to approve and adopt the merger agreement. Aetna&#146;s board
of directors further unanimously recommends that Aetna shareholders vote <B>&#147;FOR&#148;</B> the Aetna adjournment proposal and <B>&#147;FOR&#148;</B> the Aetna compensation advisory proposal. See &#147;Aetna Proposal I: Approval and Adoption of
the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Aetna&#146;s Reasons for the Merger; Recommendation of the Aetna Board of Directors that Aetna Shareholders Approve and Adopt the Merger Agreement&#148; beginning on
page 101 of this joint proxy statement/prospectus for a more detailed discussion of the recommendation of Aetna&#146;s board of directors that Aetna shareholders approve and adopt the merger agreement. See &#147;Aetna Proposal II: Adjournment of the
Aetna Special Meeting&#148; beginning on page 219 of this joint proxy statement/prospectus for a more detailed discussion of the Aetna adjournment proposal. See &#147;Aetna Proposal III: Advisory Vote On Merger-Related Executive Compensation
Arrangements&#148; beginning on page 220 of this joint proxy statement/prospectus for a more detailed discussion of the Aetna compensation advisory proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_62"></A>Aetna Record Date; Outstanding Shares; Shareholders Entitled to Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A committee of Aetna&#146;s board of directors has fixed the close of business on February&nbsp;5, 2018, as the record date for the
determination of the Aetna shareholders entitled to notice of and to vote at the Aetna special meeting or any adjournment or postponement of the Aetna special meeting. Only Aetna shareholders of record at the record date are entitled to receive
notice of, and to vote at, the Aetna special meeting or any adjournment or postponement of the Aetna special meeting. As of the close of business on February 5, 2018, there were 326,942,525 Aetna common shares outstanding and entitled to vote at the
Aetna special meeting, held by approximately 6,100 holders of record. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_63"></A>Quorum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence at the Aetna special meeting, in person or by proxy, of the holders of a majority of the outstanding Aetna common shares at the
record date (the close of business on February&nbsp;5, 2018) will constitute a quorum. Aetna common shares whose holders elect to abstain from voting will be deemed present at the Aetna special meeting for the purpose of determining the presence of
a quorum. Aetna common shares held in &#147;street name&#148; with respect to which the beneficial owner fails to give voting instructions to the broker, bank or other nominee holder of record, and Aetna common shares with respect to which the
beneficial owner otherwise fails to vote, will not be deemed present at the Aetna special meeting for the purpose of determining the presence of a quorum. There must be a quorum for the vote on the approval and adoption of the merger agreement and
the vote on the Aetna compensation advisory proposal to be taken at the Aetna special meeting. Failure of a quorum to be present at the Aetna special meeting will necessitate an adjournment of the meeting and will subject Aetna to additional
expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_64"></A>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Aetna&#146;s articles, to approve and adopt the merger agreement, the affirmative vote of the holders of a majority of Aetna common
shares outstanding and entitled to vote thereon is required. <B>Aetna cannot complete the merger and the merger consideration will not be paid unless its shareholders approve and adopt the merger agreement. Because approval and adoption of the
merger agreement requires the affirmative vote of the holders of at least a majority of Aetna common shares outstanding and entitled to vote thereon, an Aetna shareholder&#146;s abstention from voting, the failure of an Aetna shareholder who holds
his or her shares in &#147;street name&#148; through a broker, bank or other nominee holder of record to give voting instructions to that broker, bank or other nominee holder of record or any other failure of an Aetna shareholder to vote will have
the same effect as a vote &#147;AGAINST&#148; the proposal to approve and adopt the merger agreement. </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To approve (i)&nbsp;the Aetna
adjournment proposal (whether or not a quorum, as defined under Pennsylvania law, is present) and (ii)&nbsp;on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the Aetna compensation advisory proposal (assuming
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a quorum, as defined under Pennsylvania law, is present), the affirmative vote of a majority of the votes cast at the Aetna special meeting by holders of Aetna common shares is required. For
purposes of each of the Aetna adjournment proposal and the Aetna compensation advisory proposal, &#147;votes cast&#148; means votes &#147;for&#148; or &#147;against&#148; the applicable proposal. As a result, an Aetna shareholder&#146;s abstention
from voting, the failure of an Aetna shareholder who holds his or her shares in &#147;street name&#148; through a broker, bank or other nominee holder of record to give voting instructions to that broker, bank or other nominee holder of record or
any other failure of an Aetna shareholder to vote will have no effect on the outcome of any vote on the Aetna adjournment proposal or any vote to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the Aetna
compensation advisory proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_65"></A>Share Ownership of and Voting by Aetna Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the record date for the Aetna special meeting (the close of business on February&nbsp;5, 2018), Aetna&#146;s directors and executive
officers and their affiliates beneficially owned and had the right to vote in the aggregate 1,357,761 Aetna common shares at the Aetna special meeting, which represents approximately 0.42% of the Aetna common shares entitled to vote at the Aetna
special meeting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Aetna&#146;s directors and executive officers is expected, as of the date of this joint proxy
statement/prospectus, to vote his or her Aetna common shares <B>&#147;FOR&#148;</B> the proposal to approve and adopt the merger agreement, <B>&#147;FOR&#148;</B> the Aetna adjournment proposal and <B>&#147;FOR&#148;</B> the Aetna compensation
advisory proposal, although none of Aetna&#146;s directors or executive officers has entered into any agreement requiring them to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_66">
</A>Voting of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Via the Internet or by Telephone </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares directly in your name as a shareholder of record, you may vote via the Internet at www.proxyvote.com or by
telephone by calling (800) <FONT STYLE="white-space:nowrap">690-6903</FONT> toll-free. In order to vote your shares via the Internet or by telephone, you will need the control number on your proxy card (which is unique to each Aetna shareholder to
ensure all voting instructions are genuine and to prevent duplicate voting). Votes may be submitted via the Internet or by telephone, 24 hours a day, seven days a week, and must be received by 11:59 p.m. (Eastern Time) on March 12, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares in &#147;street name&#148; through a broker, bank or other nominee holder of record, you may provide voting
instructions via the Internet or by telephone only if Internet or telephone voting is made available by your broker, bank or other nominee holder of record. Please follow the voting instructions provided by your broker, bank or other nominee holder
of record with these materials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>By Mail </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares directly in your name as a shareholder of record, in order to vote by mail, you may submit a proxy card. You
will need to complete, sign and date your proxy card and return it using the postage-paid return envelope provided or return it to Vote Processing, c/o Broadridge Financial Solutions, Inc., 51 Mercedes Way, Edgewood, New York 11717. Broadridge must
receive your proxy card no later than the close of business on <B></B>March 12<B></B>, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares in
&#147;street name&#148; through a broker, bank or other nominee holder of record, in order to provide voting instructions by mail you will need to complete, sign and date the voting instruction form provided by your broker, bank or other nominee
holder of record with these materials and return it in the postage-paid return envelope provided. Your broker, bank or other nominee holder of record must receive your voting instruction form in sufficient time to vote your shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>In Person </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you
hold Aetna common shares directly in your name as a shareholder of record, you may vote in person at the Aetna special meeting. Shareholders of record also may be represented by another person at the Aetna
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
special meeting by executing a proper proxy designating that person and having that proper proxy be presented to the judge of election with the applicable ballot at the Aetna special meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a shareholder of record submits a proxy via the Internet or by telephone, his or her proxy is recorded immediately. You are
encouraged to register your vote via the Internet or telephone whenever possible. If you submit a proxy via the Internet or by telephone, please do not return your proxy card by mail. If you attend the Aetna special meeting, you may also vote in
person, in which case any votes that you previously submitted&#151;whether via the Internet, by telephone or by mail&#151;will be revoked and superseded by any vote that you cast at the Aetna special meeting. Your attendance at the Aetna special
meeting alone will not revoke any proxy previously given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>By Participants in the Aetna 401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participants in the Aetna 401(k) Plan who receive this joint proxy statement/prospectus in their capacity as participants in the Aetna 401(k)
Plan will receive voting instruction cards instead of proxy cards. The voting instruction card directs the trustee of the Aetna 401(k) Plan to vote the Aetna common shares shown on the card as indicated on the card. Aetna common shares held through
the Aetna 401(k) Plan may be voted by using the Internet, by calling a toll-free telephone number or by marking, signing and dating the voting instruction card and mailing it to the trustee of the Aetna 401(k) Plan in accordance with the
trustee&#146;s instructions. Internet and telephone voting of shares held through the Aetna 401(k) Plan will be available until 11:59 p.m. Eastern time on March 8, 2018. Aetna common shares held through the Aetna 401(k) Plan for which no
instructions are received will be voted by the trustee of the Aetna 401(k) Plan in the same percentage as the Aetna common shares held through the 401(k) Plan for which the trustee receives voting instructions unless contrary to ERISA. You may not
vote the Aetna common shares you hold through the Aetna 401(k) Plan at the Aetna special meeting. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Generally </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold Aetna common shares in &#147;street name&#148; through a broker, bank or other nominee holder of record, you must obtain a written
legal proxy from that institution and present it to the judge of election with your ballot to be able to vote in person at the Aetna special meeting. To request a legal proxy, please contact your broker, bank or other nominee holder of record. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your Aetna common shares are held in an account at a broker, bank or other nominee holder of record (i.e., in &#147;street name&#148;), you
must instruct the broker, bank or other nominee holder of record on how to vote your shares. Your broker, bank or other nominee holder of record will vote your shares only if you provide instructions on how to vote by filling out the voting
instruction form sent to you by your broker, bank or other nominee holder of record with this joint proxy statement/prospectus. Brokers, banks and other nominee holders of record who hold Aetna common shares in &#147;street name&#148; typically have
the authority to vote in their discretion on &#147;routine&#148; proposals when they have not received instructions on how to vote from the beneficial owner. However, brokers, banks and other nominee holders of record typically are not allowed to
exercise their voting discretion on matters that are <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> without specific instructions on how to vote from the beneficial owner. Under the current rules of the NYSE, each of the three
proposals to be considered at the Aetna special meeting as described in this joint proxy statement/prospectus are considered <FONT STYLE="white-space:nowrap">non-routine.</FONT> Therefore brokers, banks and other nominee holders of record do not
have discretionary authority to vote on any of the three proposals to be considered at the Aetna special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> are shares held by a broker, bank or other nominee holder of record that are present in person or represented by proxy at the Aetna special meeting, but with respect to which the broker, bank or other
nominee holder of record is not instructed by the beneficial owner of such shares on how to vote on a particular proposal and the broker, bank or other nominee holder of record does not have discretionary voting power on such proposal. Because
brokers, banks and other nominee holders of record do not have discretionary voting authority with respect to any of the proposals to be considered at the Aetna special meeting as described in this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
joint proxy statement/prospectus, if a beneficial owner of Aetna common shares held in &#147;street name&#148; does not give voting instructions to the broker, bank or other nominee holder of
record, then those shares will not be present in person or represented by proxy at the Aetna special meeting. As a result, there will not be any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with any of the three proposals
to be considered at the Aetna special meeting as described in this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A beneficial owner&#146;s failure to
instruct the broker, bank or other nominee holder of record how to vote Aetna common shares held in &#147;street name&#148; will therefore have the same effect as a vote <B>&#147;AGAINST&#148;</B> the approval and adoption of the merger agreement. A
beneficial owner&#146;s failure to instruct the broker, bank or other nominee holder of record how to vote Aetna common shares held in &#147;street name&#148; will have no effect on the proposal to approve the Aetna adjournment proposal or the
proposal to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the Aetna compensation advisory proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares represented by each properly completed and valid proxy received before or at the Aetna special meeting will be voted in accordance
with the instructions given in the proxy. If an Aetna shareholder signs a proxy card and returns it without giving instructions for voting on any proposal, the Aetna common shares represented by that proxy card will be voted <B>&#147;FOR&#148;</B>
the proposal to approve and adopt the merger agreement, <B>&#147;FOR&#148;</B> the Aetna adjournment proposal and <B>&#147;FOR&#148;</B> the Aetna compensation advisory proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Your vote is very important, regardless of the number of shares you own. Whether or not you expect to attend the Aetna special meeting in
person, please vote or otherwise submit a proxy to vote your shares as promptly as possible so that your shares may be represented and voted at the Aetna special meeting. If your Aetna common shares are held in the name of a bank, broker or other
nominee holder of record, please follow the instructions on the voting instruction form furnished to you by such record holder. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_67">
</A>Revocability of Proxies; Changing Your Vote </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may revoke your proxy or change your vote at any time before the closing of the
polls at the Aetna special meeting. If you are an Aetna shareholder of record at the record date (the close of business on February&nbsp;5, 2018), you can revoke your proxy or change your vote by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sending a signed notice stating that you revoke your proxy to Broadridge Financial Solutions, Inc. by mail at 51 Mercedes Way, Edgewood, NY 11717 or by fax at (631) <FONT STYLE="white-space:nowrap">254-7733</FONT> that
bears a date later than the date of the proxy you want to revoke and is received prior to the Aetna special meeting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submitting a valid, later-dated proxy via the Internet or telephone before 11:59 p.m. (Eastern Time) on March 12, 2018, or by mail that is received prior to the Aetna special meeting; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attending the Aetna special meeting (or, if the Aetna special meeting is adjourned or postponed, attending the adjourned or postponed meeting) and voting in person, which automatically will cancel any proxy previously
given, or revoking your proxy in person, but your attendance at the Aetna special meeting alone will not revoke any proxy previously given. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold your shares in &#147;street name&#148; through a broker, bank or other nominee holder of record, you must contact your broker,
bank or other nominee holder of record to change your vote or obtain a written legal proxy to vote your shares if you wish to cast your vote in person at the Aetna special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_68"></A>Solicitation of Proxies; Expenses of Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus is being provided to holders of Aetna common shares in connection with the solicitation of proxies by
Aetna&#146;s board of directors to be voted at the Aetna special meeting and at any adjournments or postponements thereof. Aetna will bear all costs and expenses in connection with the solicitation of proxies, including the costs of filing, printing
and mailing this joint proxy statement/prospectus for the Aetna </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
special meeting. Aetna has engaged Georgeson LLC to assist in the solicitation of proxies for the Aetna special meeting and will pay Georgeson LLC a fee of approximately $35,000, plus
reimbursement of reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to solicitation by mail, directors, officers and employees of Aetna or its subsidiaries may solicit proxies from shareholders by telephone, telegram, email, personal interview or other means. Aetna currently expects not to incur any costs
beyond those customarily expended for a solicitation of proxies in connection with the approval and adoption of a merger agreement. Directors, officers and employees of Aetna will not receive additional compensation for their solicitation
activities, but may be reimbursed for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by them in connection with the solicitation. Brokers, dealers, commercial banks, trust
companies, fiduciaries, custodians and other nominees have been requested to forward proxy solicitation materials to their customers, and such nominees will be reimbursed for their reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_69"></A>Householding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has adopted a rule concerning the delivery of annual reports and proxy statements. It permits Aetna, with your permission, to send a
single notice of meeting and, to the extent requested, a single copy of this joint proxy statement/prospectus to any household at which two or more shareholders reside if they appear to be members of the same family. This rule is called
&#147;householding,&#148; and its purpose is to help reduce printing and mailing costs of proxy materials. In 2016, Aetna began householding for registered shareholders. If you are a registered shareholder, please check the appropriate box on your
proxy card or select the householding option when you vote by Internet or phone if you would like to participate in Aetna&#146;s householding program. Shareholders who participate in householding will continue to receive separate proxy cards, and
householding will not affect the mailing of account statements or special notices in any way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of brokerage firms have instituted
householding for shares held in &#147;street name.&#148; If you and members of your household have multiple accounts holding Aetna common shares, you may have received a householding notification from your broker. Please contact your broker directly
if you have questions, require additional copies of this joint proxy statement/prospectus or wish to revoke your decision to household. These options are available to you at any time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_70"></A>Adjournment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna shareholders are being asked to approve a proposal that will give Aetna&#146;s board of directors authority to adjourn the Aetna special
meeting one or more times for the purpose of soliciting additional proxies in favor of the approval and adoption of the merger agreement if there are not sufficient votes to approve and adopt the merger agreement at the time of the Aetna special
meeting or any adjournment or postponement thereof. If the Aetna adjournment proposal is approved, the Aetna special meeting could be adjourned to any date. In addition, Aetna&#146;s board of directors, with or without shareholder approval, could
postpone the Aetna special meeting before it commences, whether for the purpose of soliciting additional proxies or for other reasons. If the Aetna special meeting is adjourned for the purpose of soliciting additional proxies, shareholders who have
already submitted their proxies will be able to revoke them at any time prior to their use. If you sign and return a proxy and do not indicate how you wish to vote on any proposal, or if you indicate that you wish to vote in favor of the approval
and adoption of the merger agreement but do not indicate a choice on the Aetna adjournment proposal or the Aetna compensation advisory proposal, your shares will be voted in favor of the Aetna adjournment proposal and the Aetna compensation advisory
proposal. But if you indicate that you wish to vote against the approval and adoption of the merger agreement, your shares will only be voted in favor of the Aetna adjournment proposal or the Aetna compensation advisory proposal if you indicate that
you wish to vote in favor of that proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_71"></A>Other Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The matters to be considered at the Aetna special meeting are of great importance to the shareholders of Aetna. Accordingly, you are urged to
read and carefully consider the information contained in or incorporated by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reference into this joint proxy statement/prospectus and submit your proxy via the Internet or by telephone or complete, date, sign and promptly return the enclosed proxy card in the enclosed
postage-paid envelope. <B>If you submit your proxy via the Internet or by telephone, you do not need to return the enclosed proxy card.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_72">
</A>Assistance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>If you need assistance in completing your proxy card or have questions regarding the Aetna special meeting, please
contact: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g482402g04o86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Georgeson LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1290 Avenue of the Americas, 9th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10104 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone
(Toll-Free): (888) <FONT STYLE="white-space:nowrap">658-3624</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">International Callers: (781)
<FONT STYLE="white-space:nowrap">575-2137</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: aetna@georgeson.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aetna Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 Farmington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hartford, CT
06156 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (860) <FONT STYLE="white-space:nowrap">273-2402</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: investorrelations@aetna.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_73"></A>AETNA PROPOSAL I: APPROVAL AND ADOPTION OF THE MERGER AGREEMENT
AND </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH PROPOSAL I: APPROVAL OF THE STOCK ISSUANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_74"></A>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
joint proxy statement/prospectus is being provided to holders of Aetna common shares in connection with the solicitation of proxies by the board of directors of Aetna to be voted at the Aetna special meeting and at any adjournments or postponements
of the Aetna special meeting. At the Aetna special meeting, Aetna will ask its shareholders to vote on (i)&nbsp;a proposal to approve and adopt the merger agreement, (ii)&nbsp;the Aetna adjournment proposal and (iii)&nbsp;the Aetna compensation
advisory proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus is being provided to holders of shares of CVS Health common stock in connection
with the solicitation of proxies by the board of directors of CVS Health to be voted at the CVS Health special meeting and at any adjournments or postponements of the CVS Health special meeting. At the CVS Health special meeting, CVS Health will ask
its stockholders to vote on (i)&nbsp;a proposal to approve the stock issuance and (ii)&nbsp;the CVS Health adjournment proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
merger agreement provides for the merger of Merger Sub with and into Aetna, with Aetna continuing as the surviving corporation and a wholly-owned subsidiary of CVS Health. <B>The merger will not be completed and the merger consideration will not be
paid unless Aetna shareholders approve and adopt the merger agreement and CVS Health stockholders approve the stock issuance. </B>A copy of the merger agreement is attached as Annex A to this joint proxy statement/prospectus. You are urged to read
the merger agreement in its entirety because it is the legal document that governs the merger. For additional information about the merger, see &#147;The Merger Agreement&#151;Structure of the Merger&#148; and &#147;The Merger Agreement&#151;Merger
Consideration&#148; beginning on pages 177 and 178, respectively, of this joint proxy statement/prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the
merger, each Aetna common share will be converted into the right to receive $145.00 in cash without interest thereon and 0.8378 of a share of CVS Health common stock. Based on the number of Aetna common shares (including the number of shares
underlying Aetna stock appreciation rights, Aetna RSUs, Aetna PSUs and unexercised rights under the Aetna employee stock purchase plan) outstanding as of February 5, 2018, CVS Health expects to issue approximately 280 million shares of CVS Health
common stock to Aetna shareholders and Aetna equity award holders pursuant to the merger. The actual number of shares of CVS Health common stock to be issued pursuant to the merger will be determined at completion of the merger based on the exchange
ratio of 0.8378 and the number of Aetna common shares (including the number of shares underlying Aetna stock appreciation rights, Aetna RSUs, Aetna PSUs and unexercised rights under the Aetna employee stock purchase plan) outstanding at such time.
Based on the number of Aetna common shares (including the number of shares underlying Aetna stock appreciation rights, Aetna RSUs, Aetna PSUs and unexercised rights under the Aetna employee stock purchase plan) outstanding as of February 5, 2018,
and the number of shares of CVS Health common stock outstanding as of February 5, 2018, it is expected that, immediately after completion of the merger, former Aetna shareholders will own approximately 22% of the outstanding shares of CVS Health
common stock. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_75"></A>Background of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the ongoing review of their respective companies&#146; businesses, the boards of directors and management of each of CVS Health and
Aetna regularly evaluate their respective companies&#146; historical performance, future growth prospects and overall strategic objectives and consider potential opportunities to enhance stockholder value. For each company, these reviews have
included consideration of various potential strategic alternatives, including potential strategic partnerships, joint ventures and business combination transactions, including, in Aetna&#146;s case, its proposed acquisition of Humana Inc., which is
referred to in this joint proxy/statement prospectus as Humana, announced in July 2015 and terminated in February 2017, and the potential benefits and risks of such transactions in light of, among other things, industry developments in the health
care and retail industries, as applicable, and such company&#146;s competitive position in its respective industries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, since 2010, Aetna and CVS Health have been party to a long-term agreement
pursuant to which CVS Health provides certain pharmacy benefit management services to Aetna and certain of its customers and members, as more fully described below in the section &#147;&#151;Certain Relationships between CVS Health and Aetna&#148;
beginning on page 100 of this joint proxy statement/prospectus. Throughout the term of this agreement, members of senior management of each of Aetna and CVS Health, including, from time to time, Mark T. Bertolini, Chairman and Chief Executive
Officer of Aetna, and Larry J. Merlo, President and Chief Executive Officer of CVS Health, regularly discussed the companies&#146; relationship under their existing pharmacy benefit management agreement, opportunities to partner more effectively for
their customers and members and industry developments in the health care industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of the reviews by the Aetna board of
directors described in the first paragraph of this section of this joint proxy statement/prospectus, at various meetings of the Aetna board of directors, the board of directors reviewed and discussed, among other things, conversations that
Mr.&nbsp;Bertolini had, from time to time, with the chief executive officers of other companies in the health care industry, including Mr.&nbsp;Merlo. The topics of these conversations included, among other things, developments in the health care
industry and potential industry consolidation and, from time to time, the prospect of Aetna entering into strategic partnerships, joint ventures, business combinations or other transactions. Starting in September 2016, members of Aetna&#146;s
management also met from time to time with representatives of Aetna&#146;s financial advisors, Lazard and Allen&nbsp;&amp; Company, to discuss Aetna&#146;s business and potential strategic opportunities, including potential opportunities with
companies in the retail industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of the reviews by the CVS Health board of directors described in the first paragraph
of this section of this joint proxy statement/prospectus, at various meetings of the CVS Health board of directors, CVS Health management reviewed and discussed with the board of directors potential strategic opportunities with companies in the
health care insurance and managed care industries, including Aetna, and the benefits that could be expected to be achieved therefrom, including reduced medical costs, a shift to lower-cost sites of health care services, improved quality of care,
improved care management, synergies and other value-creation opportunities, as well as the feasibility of completing the relevant transactions. As part of these discussions, the CVS Health board of directors and management also reviewed and
discussed existing proposed business combinations in the health care industry, including Aetna&#146;s proposed acquisition of Humana. Following the termination of Aetna&#146;s proposed acquisition of Humana in February 2017, CVS Health increased its
focus on Aetna but CVS Health&#146;s management continued to have discussions with multiple managed care companies, including Aetna, regarding potential strategic partnerships, joint ventures, business combinations or other transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2017, members of senior management of Aetna and CVS Health had discussions, including an
<FONT STYLE="white-space:nowrap">in-person</FONT> meeting between Mr.&nbsp;Merlo and Mr.&nbsp;Bertolini on March&nbsp;15, 2017 and a subsequent telephone call between Mr.&nbsp;Merlo and Mr.&nbsp;Bertolini on March&nbsp;22, 2017, concerning certain
publicly available business information regarding the companies and potential opportunities presented by the companies&#146; shared interest in a retail health operating model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2017, members of Aetna and CVS Health senior management held <FONT STYLE="white-space:nowrap">in-person</FONT> meetings to
discuss the potential benefits of working more closely together, including a strategic partnership, joint venture or other opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2017, the Aetna board of directors held a regularly scheduled meeting at which, among other things, the board of directors
received an update from Aetna management on these discussions with CVS Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;9 and 10, 2017, the CVS Health board of
directors held a regularly scheduled meeting that was attended by members of CVS Health&#146;s senior management. At the meeting, management reviewed and discussed with the board of directors a number of alternative strategic partnerships, business
combinations and other opportunities, including, in each case, potential synergies and future growth potential. Management also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discussed with the board of directors the outcome of proposed mergers of managed care companies, including the proposed acquisition of Humana by Aetna and the proposed acquisition of Cigna
Corporation by Anthem, Inc. Following the discussions, the board of directors authorized CVS Health&#146;s management to further evaluate managed care companies for a potential acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout May 2017, members of Aetna management had several telephonic conversations and meetings with members of management of CVS Health
and two other retail and health care industry participants, which are referred to in this joint proxy statement/prospectus as Party X and Party Y, regarding potential strategic partnerships, joint ventures and other opportunities. Discussions with
Party Y led to a pilot program beginning in this timeframe with respect to Aetna members visiting Party Y&#146;s retail health-service clinics in a particular state. Members of the management of Aetna and Party Y also discussed data analytics and a
potential <FONT STYLE="white-space:nowrap">co-branded</FONT> Medicare product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;19, 2017, the Aetna board of directors held a
regularly scheduled meeting at which, among other things, the board of directors received an update from Aetna management on the discussions with CVS Health, Party X and Party Y, and discussed potential value-creating opportunities with
nontraditional partners in the retail and health care industries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;23, 2017, representatives of Aetna management, including
Mr.&nbsp;Bertolini and Shawn M. Guertin, Executive Vice President, Chief Financial Officer and Chief Enterprise Risk Officer, met with representatives of CVS Health management, including Mr.&nbsp;Merlo and David M. Denton, Executive Vice President
and Chief Financial Officer, to discuss the potential benefits of working more closely together, including potential strategic partnerships, joint ventures, business combinations and other opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;25, 2017, representatives of CVS Health management sent representatives of Aetna management a draft mutual <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;31, 2017, Mr.&nbsp;Merlo had a telephone conversation with
Mr.&nbsp;Bertolini to advise him that at the meeting of the CVS Health board of directors on May&nbsp;9 and 10, 2017, Mr.&nbsp;Merlo had discussed with the CVS Health board of directors potential strategic partnerships, business combinations and
other opportunities between CVS Health and Aetna, and the desire to discuss such potential opportunities further. On June&nbsp;6, 2017, Mr.&nbsp;Guertin had a telephone conversation with Mr.&nbsp;Denton to discuss such potential opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;7, 2017, after negotiation of the terms thereof, with, in Aetna&#146;s case, the assistance of Davis Polk&nbsp;&amp; Wardwell
LLP, which is referred to in this joint proxy statement/prospectus as Davis Polk, outside legal counsel to Aetna, Aetna and CVS Health executed a mutual <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement containing, among other terms,
a mutual <FONT STYLE="white-space:nowrap">12-month</FONT> standstill provision (subject to customary exceptions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2017,
after negotiation of the terms thereof, with, in Aetna&#146;s case, the assistance of Davis Polk, Aetna also entered into a mutual <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement with Party X containing a nine-month standstill
provision (subject to customary exceptions). This <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement does not currently restrict Party X from making a proposal to Aetna regarding a potential business combination transaction with Aetna.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on June&nbsp;14, 2017, representatives of Aetna management met with representatives of Party X management to discuss certain
business information regarding the companies and the potential benefits of working more closely together, including a potential strategic partnership, business combination or other opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2017, members of Aetna and CVS Health management held meetings to discuss certain information regarding the companies and the
potential benefits of working more closely together, including a strategic partnership, joint venture, business combination or other opportunity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout June 2017 through September 2017, members of Aetna management had telephonic
conversations and meetings with members of management of CVS Health, Party X and Party Y regarding potential strategic partnerships, joint ventures and other opportunities and discussed, among other things, potential benefits and operating models
with respect thereto. Mr.&nbsp;Guertin and Mr.&nbsp;Denton met on June&nbsp;29, 2017 and had telephonic conversations on August&nbsp;11, 2017 and September&nbsp;21, 2017 regarding these matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2017, the CVS Health board of directors held a regularly scheduled meeting attended by members of CVS Health&#146;s senior
management. The board of directors received an update on continued analysis and discussions that management had been having with three managed care companies, including Aetna, regarding various potential strategic opportunities. Management then
reviewed and discussed with the board of directors the potential value creation opportunities presented by those potential strategic opportunities, including reduced medical costs, a shift to lower-cost sites of health care services, improved
quality of care, improved care management and synergies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;14, 2017, members of management of each of Aetna and Party Y had a
telephone conversation to discuss a potential strategic partnership or joint venture between the parties regarding retail health services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;20, 2017, the Aetna board of directors held a regularly scheduled meeting, which was attended by Aetna&#146;s senior management.
At the meeting, among other things, Aetna management reviewed with the board of directors Aetna&#146;s strategic plan and a potential new integrated health care operating model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;7, 2017, representatives of Aetna management met with representatives of Party X management to continue their previous
discussions regarding potential benefits of working more closely together, including a potential strategic partnership, business combination or other opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;7, 2017, members of management of each of Aetna and Party Y met, or joined via teleconference, to discuss a potential
strategic partnership or joint venture between the parties regarding retail health services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;19 and 20, 2017, the CVS
Health board of directors held a regularly scheduled meeting. At the meeting, the board of directors and members of CVS Health&#146;s senior management reviewed and discussed potential value creation opportunities that would be made possible by the
acquisition of a managed care company, including reduced medical costs, a shift to lower-cost sites of health care services, improved quality of care, improved care management and synergies. The board of directors and management focused more closely
on Aetna and another managed care company. At the meeting, Mr.&nbsp;Merlo discussed the risks and challenges of each potential acquisition, Mr.&nbsp;Denton presented certain preliminary financial analyses prepared by Barclays, CVS Health&#146;s
regular financial advisor, related to each potential acquisition, and Thomas M. Moriarty, Executive Vice President, Chief Policy and External Affairs Officer and General Counsel of CVS Health, discussed the regulatory environment and approvals
associated with a potential acquisition. Following these discussions, the CVS Health board of directors authorized management to continue to explore a potential acquisition of Aetna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, Mr.&nbsp;Bertolini and Mr.&nbsp;Guertin met with Mr.&nbsp;Merlo and Mr.&nbsp;Denton to discuss a potential
strategic partnership, joint venture, business combination or other opportunity. At this meeting, Mr.&nbsp;Merlo and Mr.&nbsp;Denton discussed the potential challenges of a strategic partnership or joint venture and indicated a potential desire on
the part of CVS Health to move forward with a potential business combination with Aetna, subject to the approval of the Aetna and CVS Health boards of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2017, the Aetna board of directors held a regularly scheduled meeting, which was attended by Aetna&#146;s senior
management. At the meeting, the board of directors received an update from management on discussions with CVS Health and reviewed the potential new integrated health care operating model previously discussed with the board of directors at their
meeting on July&nbsp;20, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2017, the CVS Health board of directors held a telephonic special
meeting that was attended by members of CVS Health&#146;s senior management. At the meeting, Mr.&nbsp;Merlo provided the board of directors with an update on management&#146;s discussions with Aetna and Mr.&nbsp;Denton presented certain preliminary
financial analyses related to Aetna and an analysis of precedent transactions in the health care industry. Mr.&nbsp;Denton also informed the board of directors that CVS Health planned to engage Goldman Sachs as an additional financial advisor in
connection with the potential acquisition of Aetna. Also at the meeting, Mr.&nbsp;Moriarty informed the board of directors that Shearman&nbsp;&amp; Sterling LLP, which is referred to in this joint proxy statement/prospectus as Shearman, had been
retained as outside legal counsel to CVS Health in connection with the potential acquisition of Aetna. Mr.&nbsp;Moriarty then reviewed with the board of directors their fiduciary duties in connection with a potential acquisition of Aetna, as well as
a preliminary antitrust and regulatory analysis and an overview of the regulatory approval process. Mr.&nbsp;Denton then reviewed with the board of directors potential terms of the proposed transaction, including the per share acquisition price and
allocation of cash and shares of CVS Health common stock to be paid in the proposed transaction. Following further discussion of these matters, the board of directors authorized management to extend to Aetna a nonbinding written proposal for the
acquisition of Aetna and to enter into negotiations with Aetna regarding such acquisition proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;11, 2017,
Mr.&nbsp;Bertolini received a letter from Mr.&nbsp;Merlo containing a <FONT STYLE="white-space:nowrap">non-binding</FONT> indication of interest from CVS Health to acquire all of the outstanding Aetna common shares for an aggregate purchase price of
$195.00 per share consisting of approximately 55% in cash and 45% in shares of CVS Health common stock. The letter indicated that CVS Health would be open to discussing representation for Aetna&#146;s directors on the board of directors of the
combined company consistent with comparable precedent transactions, and that CVS Health expected there to be a significant opportunity for Aetna management to be part of the combined company, given Aetna&#146;s industry expertise. Aetna&#146;s
management arranged for CVS Health&#146;s letter to be distributed to the Aetna board of directors on October&nbsp;12, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;13, 2017, Mr.&nbsp;Bertolini and the chief executive officer of Party X had a telephonic conversation in which the chief executive officer of Party X indicated that, while Party X remained interested in a strategic partnership or joint
venture with Aetna, Party X was not in a position to make a proposal to acquire Aetna at such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on October&nbsp;13, 2017,
Mr.&nbsp;Bertolini and other members of management of Aetna held a videoconference with the chief executive officer and other members of management of Party Y to discuss certain publicly available business information regarding the companies and a
potential strategic partnership or joint venture between the parties regarding retail health services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;15, 2017, the
Aetna board of directors held a telephonic special meeting, which was attended by Aetna&#146;s senior management and representatives of Lazard, Allen&nbsp;&amp; Company and Davis Polk. The board of directors discussed with management and
Aetna&#146;s advisors CVS Health&#146;s letter and the terms of its indication of interest, potential next steps and information that would be needed in advance of responding to CVS Health&#146;s letter. The board of directors reviewed with
management its prior discussions regarding potential industry consolidation and potential risks and merits of partnering with a company with a large retail footprint, including the potential for improving the health of Aetna&#146;s members,
generating meaningful medical cost savings and making Aetna&#146;s products more competitive. Representatives of Davis Polk advised the board of directors regarding its fiduciary duties in the context of exploring potential business combination
transactions and CVS Health&#146;s <FONT STYLE="white-space:nowrap">non-binding</FONT> indication of interest. After discussion, with input from management and Aetna&#146;s advisors, the Aetna board of directors directed management to obtain from
CVS Health additional information regarding CVS Health&#146;s proposed operating model for the combined company and regarding regulatory considerations so that the board of directors could better understand and evaluate CVS Health&#146;s proposal.
The board of directors directed Aetna management to review these matters with the board of directors at its next regularly scheduled meeting on October&nbsp;27, 2017, and also to review Aetna&#146;s stand-alone plan with the board of directors at
that meeting. Consistent with its past practice (including on the Humana transaction), the board of directors determined to engage lawyers affiliated with Simpson Thacher&nbsp;&amp; Bartlett LLP, which is referred to in this joint
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proxy statement/prospectus as Simpson Thacher, as outside legal counsel to the <FONT STYLE="white-space:nowrap">non-management</FONT> members of the board of directors in connection with CVS
Health&#146;s proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2017, Mr.&nbsp;Bertolini had a telephonic conversation with Mr.&nbsp;Merlo to inform him
regarding the meeting of the Aetna board of directors and the board of directors&#146; request for additional information on the proposed operating model for the combined company and regulatory considerations relating to the proposed transaction.
Mr.&nbsp;Guertin had a telephonic conversation with Mr.&nbsp;Denton regarding the same subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2017, Aetna and
Party Y entered into a mutual <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement. This <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement does not restrict Party Y from making a proposal to Aetna regarding a potential
business combination transaction with Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;20, 2017, Mr.&nbsp;Moriarty and a representative of Dechert LLP, outside
antitrust counsel to CVS Health, which is referred to in this joint proxy statement/prospectus as Dechert, met with Thomas&nbsp;J. Sabatino, Jr., Executive Vice President and General Counsel of Aetna, and representatives of Davis Polk to discuss
regulatory approvals that would be required for the proposed transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;24, 2017, Mr.&nbsp;Guertin had a telephonic
conversation with Mr.&nbsp;Denton regarding CVS Health&#146;s indication of interest and potential next steps. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During trading hours on
October&nbsp;26, 2017, the Wall Street Journal reported that there had been discussions between Aetna and CVS Health regarding a potential acquisition of Aetna by CVS Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;27, 2017, the Aetna board of directors held a regularly scheduled meeting, which was attended by Aetna&#146;s senior
management, representatives of Lazard, Allen&nbsp;&amp; Company and Davis Polk and a representative of Simpson Thacher and Charles I. Cogut, a retired partner of Simpson Thacher, acting in his individual capacity (the representative of Simpson
Thacher and Mr.&nbsp;Cogut being referred to in this joint proxy statement/prospectus collectively as representatives of Simpson Thacher). The board of directors discussed (without Mr.&nbsp;Bertolini or other members of Aetna&#146;s management,
Lazard, Allen&nbsp;&amp; Company or Davis Polk present) CVS Health&#146;s indication of interest and the terms of its proposal, and representatives of Simpson Thacher advised the board of directors regarding its fiduciary duties in the context of
exploring potential business combination transactions. Members of Aetna&#146;s management, Lazard, Allen&nbsp;&amp; Company and Davis Polk then joined the meeting, and the board of directors discussed a potential combination with CVS Health versus
other potential partners and other strategic alternatives, including remaining a stand-alone company, and the potential transactions under discussion with Party X and Party Y, as well as the unlikelihood that either Party X or Party Y would be
interested in a potential business combination transaction with Aetna at such time. The board of directors reviewed with management how the proposed transaction with CVS Health would be consistent with Aetna&#146;s strategy of building local,
community-based health care access points and that, based on preliminary conversations with CVS Health, it appeared that a retail-enabled strategy could drive meaningful synergies for the combined company. The board of directors reviewed with
management materials provided by CVS Health regarding the combined company, and reviewed financial forecasts prepared by Aetna management that reflected developments in the business since the board of directors&#146; review of Aetna&#146;s strategic
plan at its July&nbsp;20, 2017 meeting. Representatives of Lazard and Allen&nbsp;&amp; Company discussed with the board of directors Lazard&#146;s and Allen&nbsp;&amp; Company&#146;s respective preliminary financial analyses regarding each of Aetna
and CVS Health on a stand-alone basis based on information provided by Aetna&#146;s management and publicly available information and the evolving health care landscape, including the growth of new business models in the health care sector.
Representatives of Davis Polk provided the board of directors with their antitrust analysis for the potential transaction. Representatives of Davis Polk also summarized for the board of directors information provided by Lazard and Allen&nbsp;&amp;
Company regarding their respective material relationships with CVS Health, Party X and Party Y. After discussion, the board of directors directed Aetna&#146;s management to conduct a due diligence review of CVS Health, including with respect to
certain litigation and regulatory matters, in order to evaluate whether to pursue the proposed transaction, and determined to hold another meeting to continue its discussion of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposed transaction following completion of that review. The board of directors also determined to engage a separate financial advisor for the sole purpose of advising the <FONT
STYLE="white-space:nowrap">non-management</FONT> members of the board of directors in connection with the proposed transaction, and Aetna subsequently engaged Evercore Group L.L.C., which is referred to in this joint proxy statement/prospectus as
Evercore, in such capacity, after Aetna&#146;s lead director received from Simpson Thacher a summary of information provided by Evercore regarding its material relationships with CVS Health, Party X and Party Y. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2017, at the requests of the respective managements of Aetna and CVS Health, representatives of Lazard and
Allen&nbsp;&amp; Company had a telephonic conversation with representatives of Barclays and Goldman Sachs during which they discussed the nature of the business and financial information needed by each party and its advisors in connection with a
proposed transaction. Aetna&#146;s financial advisors, consistent with Aetna&#146;s instructions, communicated that Aetna was not yet authorized to negotiate transaction terms and instead was focused on completing its due diligence review of CVS
Health so that Aetna and its board of directors could better understand and evaluate the proposed transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the weeks of
October&nbsp;30, 2017 and November&nbsp;6, 2017, members of management of Aetna and CVS Health met for due diligence meetings, during which their respective advisors were present. During this period, in furtherance of CVS Health&#146;s due diligence
review of Aetna as well as Aetna&#146;s due diligence review of CVS Health, the two parties held numerous <FONT STYLE="white-space:nowrap">in-person</FONT> and telephonic due diligence sessions attended by employees from each company, covering a
variety of financial, legal and operational matters. During this timeframe, each of Aetna and CVS Health also made available to the other party and its advisors an electronic dataroom containing certain
<FONT STYLE="white-space:nowrap">non-public</FONT> financial, legal and other information of such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2017,
Shearman delivered an initial draft merger agreement for the proposed transaction to Davis Polk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on November&nbsp;1, 2017 and again
on November&nbsp;6, 2017, at the requests of the respective managements of Aetna and CVS Health, representatives of Lazard, Allen&nbsp;&amp; Company and Evercore had <FONT STYLE="white-space:nowrap">in-person</FONT> and telephonic discussions with
representatives of Barclays and Goldman Sachs regarding a number of topics relating to the proposed transaction and the financial information that Aetna and CVS Health had exchanged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;7 and 8, 2017, the CVS Health board of directors held a regularly scheduled meeting that was attended by members of CVS
Health&#146;s senior management and representatives of Barclays and Goldman Sachs. At the meeting, the board of directors received an update from management on its discussions with Aetna and the due diligence review of Aetna. Representatives of each
of Barclays and Goldman Sachs reviewed with the board of directors their respective preliminary financial analyses of the proposed transaction, including the financial impact of differing levels of cash and stock in the proposed consideration. The
board of directors further reviewed and discussed with management the strategic rationale for the proposed transaction and its expected value creation opportunities as well as certain terms of the proposed transaction. Although no specific
negotiations of price had yet occurred with Aetna&#146;s representatives, CVS Health&#146;s management discussed with the board of directors an increase in the cash component of the consideration to provide greater certainty to Aetna and its
shareholders of the ultimate value of the consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2017, members of management of each of Aetna and Party Y
met to discuss a potential strategic partnership or joint venture between the parties regarding retail health services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;11, 2017, representatives of Aetna and CVS Health and their respective advisors met for a diligence presentation by Aetna management. At this meeting, Mr.&nbsp;Denton conveyed CVS Health&#146;s revised proposal to increase the cash
component of the proposed purchase price to approximately 70%, with the remaining 30% to be paid in shares of CVS Health common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;14, 2017, the Aetna board of directors held a special meeting, which was
attended by representatives of Evercore and Simpson Thacher. At the meeting, the board of directors continued its discussion (without Mr.&nbsp;Bertolini or representatives of Evercore present) of CVS Health&#146;s indication of interest and the
terms of its proposal, including in the context of Aetna&#146;s stand-alone strategic plan. Representatives of Simpson Thacher advised the board of directors regarding its fiduciary duties in the context of exploring potential business combination
transactions. Mr.&nbsp;Bertolini then joined the meeting and provided the board of directors with an update on the process and status of Aetna&#146;s due diligence review of CVS Health. Mr.&nbsp;Bertolini briefed the board of directors on CVS
Health&#146;s revised proposal, including the increase in the cash component of the proposed purchase price to approximately 70%, with the remaining 30% to be paid in shares of CVS Health common stock. Mr.&nbsp;Bertolini discussed with the board of
directors Aetna&#146;s stand-alone strategic plan as well as management&#146;s views on the potential operating model and potential synergies of the combined company. The board of directors discussed the advantages and disadvantages of Aetna
exploring strategic alternatives with CVS Health or other companies with retail pharmacy operations as opposed to continuing to operate as a stand-alone company. Representatives of Evercore discussed with the board of directors their views on
certain potential longer term risks that could affect the combined company. After discussion, the board of directors directed management to prepare a more detailed analysis of strategic alternatives potentially available to Aetna on a stand-alone
basis, including alternatives involving acquisitions and building Aetna&#146;s own clinics. The board of directors also directed management to continue Aetna&#146;s due diligence review of CVS Health. Management was authorized by the board of
directors to commence negotiations on the terms and conditions of the merger agreement, and to indicate to CVS Health and its advisors that CVS Health&#146;s proposed purchase price would need to be increased meaningfully. The board of directors
determined to hold another meeting to continue its discussion of the proposed transaction and Aetna&#146;s stand-alone strategic plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;15, 2017, at the requests of the respective managements of Aetna and CVS Health, representatives of Lazard and Allen&nbsp;&amp; Company had a telephonic conversation with representatives of Barclays and Goldman Sachs. During that call,
consistent with Aetna&#146;s instructions, representatives of Lazard and Allen&nbsp;&amp; Company communicated that CVS Health needed to increase its proposed purchase price meaningfully and that Aetna was focused on certainty of closing as well as
the potential operating model of the combined company. CVS Health&#146;s financial advisors requested a specific proposal on price, which Aetna&#146;s financial advisors declined to provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;17, 2017, Davis Polk delivered a revised draft of the merger agreement to Shearman. Between November&nbsp;17, 2017 and the
execution of the merger agreement on December&nbsp;3, 2017, representatives of Aetna, CVS Health, Davis Polk and Shearman had multiple meetings and telephone calls to negotiate the terms of the merger agreement, including with respect to the
representations and warranties, interim operating covenants of the parties, the regulatory commitments of CVS Health, closing conditions, fiduciary and termination provisions, including termination fees, and the structure of the transaction, and
exchanged numerous drafts of the merger agreement reflecting such discussions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;19, 2017, the CVS Health board of
directors held a telephonic special meeting that was attended by members of CVS Health&#146;s senior management. At the meeting, the board of directors received an update on the principal open issues in the revised draft of the merger agreement
received from Davis Polk on November&nbsp;17, 2017. The board of directors also reviewed and discussed with management preliminary financial analyses prepared by representatives of Barclays and Goldman Sachs and discussed the proposed organization
and operating model of the combined company following the proposed acquisition of Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2017, the Aetna board of
directors held a telephonic special meeting, which was attended by Aetna&#146;s senior management and representatives of Lazard, Allen&nbsp;&amp; Company, Davis Polk, Evercore and Simpson Thacher. At the meeting, management provided the board of
directors with an update on discussions with CVS Health. The board of directors discussed with members of Aetna management Aetna&#146;s stand-alone strategic plan as well as Aetna management&#146;s financial forecasts for Aetna and certain pro forma
financial information relating to Aetna and CVS Health as a combined company. The board of directors reviewed with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management certain strategic alternatives to a transaction with CVS Health potentially available to Aetna, including building its own clinics, collaborating with one or more national retailers to
develop clinics and acquiring a retail pharmacy operator, and the potential benefits, risks and challenges of each alternative. Representatives of Lazard and Allen&nbsp;&amp; Company then discussed with the board of directors Lazard&#146;s and
Allen&nbsp;&amp; Company&#146;s respective preliminary financial analyses regarding the proposed transaction with CVS Health and the financial advisors also discussed potential strategic alternatives identified by Aetna&#146;s management for Aetna
as a stand-alone company. Representatives of Evercore then discussed with the board of directors their preliminary analyses regarding these strategic alternatives, including the relative value creation opportunity for each alternative and the
proposed transaction with CVS Health. The board of directors also discussed with management potential synergies in a combination of Aetna and CVS Health. The board of directors discussed the advantages and disadvantages of Aetna exploring a business
combination with CVS Health as opposed to continuing to operate as a stand-alone company. The board of directors directed management to continue Aetna&#146;s due diligence review of CVS Health and negotiation of the merger agreement, and determined
to continue its discussions at the next regularly scheduled board of directors meeting to be held on December&nbsp;1, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;22, 2017, Mr.&nbsp;Bertolini and Mr.&nbsp;Merlo had an <FONT STYLE="white-space:nowrap">in-person</FONT> meeting to discuss the proposed transaction, including the proposed operating model for the combined company and the management of
the health care benefits business of the combined company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;27, 2017, the CVS Health board of directors held a telephonic
special meeting that was attended by members of CVS Health&#146;s senior management and representatives of each of Barclays, Goldman Sachs and Shearman. At the meeting, Mr.&nbsp;Moriarty reviewed with the board of directors their fiduciary duties in
connection with the proposed transaction. The board of directors and management then reviewed and discussed, among other things, summaries of the legal, financial and operational due diligence review of Aetna, the efforts to arrange the bridge
financing for the proposed transaction, including feedback from ratings agencies, the antitrust and regulatory analysis and approval process, and the merger agreement and principal provisions still being negotiated therein. Representatives of
Barclays and Goldman Sachs then reviewed with the board of directors their respective preliminary financial analyses of the proposed transaction. Members of CVS Health&#146;s management then reviewed and discussed with the board of directors a
proposal, which is referred to in this joint proxy statement/prospectus as CVS Health&#146;s revised proposal, to (i)&nbsp;increase the consideration to be offered to Aetna shareholders to $203.00 per Aetna common share, which would be paid
approximately 70% in cash and 30% in shares of CVS Health common stock, with the stock portion of the consideration to be based on a fixed exchange ratio to be agreed before signing of the merger agreement, (ii)&nbsp;a termination fee of
$1.7&nbsp;billion payable by CVS Health in the event the transaction does not close because of the failure to obtain required regulatory approvals (which termination fee is referred to in this joint proxy statement/prospectus as the regulatory
termination fee) and (iii)&nbsp;the addition of two Aetna directors, including Mr.&nbsp;Bertolini, to the CVS Health board of directors upon the closing of the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later in the evening on November&nbsp;27, 2017, Mr.&nbsp;Merlo sent a letter to Mr.&nbsp;Bertolini setting forth the terms of CVS
Health&#146;s revised proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;28, 2017, the Aetna board of directors held a telephonic special meeting, which was
attended by Aetna&#146;s senior management and representatives of Simpson Thacher. At the meeting, management briefed the board of directors on the terms of CVS Health&#146;s revised proposal. Management updated the board of directors on the status
of negotiations with CVS Health on the terms and conditions of the merger agreement, including the regulatory termination fee, and discussions with CVS Health regarding the potential strategy and operating model for the combined company. The board
of directors then discussed (without members of Aetna&#146;s management present) CVS Health&#146;s revised proposal. At the conclusion of the meeting, management was authorized to seek a higher purchase price from CVS Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on November&nbsp;28, 2017, at the requests of the respective managements of Aetna and CVS Health, representatives of Lazard,
Allen&nbsp;&amp; Company and Evercore held an <FONT STYLE="white-space:nowrap">in-person</FONT> discussion with representatives of Barclays and Goldman Sachs to address a number of topics related to timing and next steps. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on November&nbsp;28, 2017, representatives of Aetna management and Davis Polk met with
representatives of CVS Health and Shearman to discuss and negotiate the remaining open terms of the merger agreement for the proposed transaction. During the course of these negotiations, representatives of Aetna proposed a regulatory termination
fee of $2.5&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;29, 2017, Mr.&nbsp;Denton met with Mr.&nbsp;Guertin, and Mr.&nbsp;Guertin made a revised
proposal, which included (i)&nbsp;a purchase price of $207.00 per Aetna common share, which would be paid approximately 70% in cash and 30% in shares of CVS Health common stock, with the stock portion of the consideration to be based on a fixed
exchange ratio to be agreed before signing of the merger agreement, (ii)&nbsp;the previously proposed regulatory termination fee of $2.5&nbsp;billion, (iii)&nbsp;the addition of three Aetna directors, including Mr.&nbsp;Bertolini, to the CVS Health
board of directors upon the closing of the transaction and (iv)&nbsp;certain agreements as to the maintenance of the &#147;Aetna&#148; brand and Aetna Foundation, Inc. for specified periods of time following the closing of the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later in the day on November&nbsp;29, 2017, Mr.&nbsp;Denton had a telephone conversation with Mr.&nbsp;Guertin, and Mr.&nbsp;Denton made a
revised proposal of a regulatory termination fee of $2.1&nbsp;billion, and informed Mr.&nbsp;Guertin that CVS Health would be willing to accept the other terms of the proposal made by Mr.&nbsp;Guertin earlier in the day. Mr.&nbsp;Guertin also
discussed with Mr.&nbsp;Denton Aetna&#146;s general expectations on the exchange ratio. Later in the day, at the direction of CVS Health management, a representative of Barclays advised a representative of Lazard that CVS Health&#146;s proposed
purchase price of $207.00 per Aetna common share consisted of $145.00 in cash and $62.00 in shares of CVS Health common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;30, 2017, at the requests of the respective managements of Aetna and CVS Health, representatives of Lazard, Allen&nbsp;&amp; Company and Evercore had a series of telephonic conversations with representatives of Barclays and Goldman
Sachs regarding the price per share of CVS Health common stock on which CVS Health&#146;s most recent proposal was based and the resulting exchange ratio for the stock portion of the purchase price. Also on November&nbsp;30, 2017, Mr.&nbsp;Guertin
and Mr.&nbsp;Denton had several telephonic conversations to discuss the exchange ratio, which was ultimately agreed, subject to the approval of Aetna&#146;s and CVS Health&#146;s respective boards of directors, to be 0.8378 shares of CVS Health
common stock per Aetna common share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the evening of November&nbsp;30, 2017, the CVS Health board of directors held a telephonic
special meeting that was attended by members of CVS Health&#146;s senior management and representatives of each of Barclays, Goldman Sachs and Shearman. At the meeting, Mr.&nbsp;Merlo provided an update on the discussions with Aetna concerning the
proposed transaction, including Mr.&nbsp;Merlo&#146;s discussions with Mr.&nbsp;Bertolini. Next, Mr.&nbsp;Denton, Mr.&nbsp;Moriarty and representatives of Shearman reviewed and discussed with the board of directors an update on the proposed terms of
the bridge financing being arranged for the acquisition, including the syndication thereof and fees payable in connection therewith to Barclays, Goldman Sachs and Bank of America, N.A. Mr.&nbsp;Moriarty and representatives of Shearman then
summarized for the board of directors information provided by Barclays and Goldman Sachs regarding their (and their respective affiliates&#146;) respective material relationships with CVS Health and Aetna. The board of directors also instructed CVS
Health&#146;s management to engage a third independent financial advisor to CVS Health to evaluate the fairness to CVS Health of the consideration to be paid in the merger. Mr.&nbsp;Moriarty then reviewed and discussed with the board of directors a
summary of the results of the parties&#146; negotiations with respect to the merger agreement as well as the remaining outstanding issues being negotiated, including with respect to employee compensation and benefits matters. Mr.&nbsp;Moriarty then
provided an updated review of the required regulatory approvals and related approval process. Finally, representatives of each of Barclays and Goldman Sachs reviewed with the board of directors their respective preliminary financial analyses of the
proposed transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also in the evening of November&nbsp;30, 2017, the Aetna board of directors held a special meeting, which was
attended by representatives of Evercore and Simpson Thacher. Mr.&nbsp;Bertolini updated the board of directors on the status of negotiations with CVS Health of the terms of the proposed transaction, including with respect to price, the regulatory
termination fee and CVS Health&#146;s agreement to the addition of three Aetna directors, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including Mr.&nbsp;Bertolini, to the CVS Health board of directors upon the closing of the transaction. Representatives of Simpson Thacher advised the board of directors regarding its fiduciary
duties in the context of exploring potential business combination transactions. Representatives of Evercore discussed with the board of directors their updated views on certain potential longer term risks that could affect the combined company.
During the discussions of the board of directors at this meeting, Mr.&nbsp;Bertolini expressed his view that the proposed transaction with CVS Health was in the best interests of Aetna and its shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2017, CVS Health&#146;s management retained Centerview as an additional financial advisor to CVS Health to evaluate the
fairness, from a financial point of view, to CVS Health of the consideration to be paid in the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2017, the
Aetna board of directors held a regularly scheduled meeting, which was attended by Aetna&#146;s senior management and representatives of Lazard, Allen&nbsp;&amp; Company, Davis Polk, Evercore and Simpson Thacher. The board of directors discussed
(without Mr.&nbsp;Bertolini or other members of Aetna&#146;s management, Lazard, Allen&nbsp;&amp; Company, Davis Polk, Evercore or Simpson Thacher present) certain aspects of the proposed transaction with CVS Health and other matters. Aetna&#146;s
management and representatives of Davis Polk and Simpson Thacher then joined the meeting, and the board of directors, management and their legal advisors discussed the key terms of the proposed transaction, including price and mix of consideration,
the strategic and financial rationale of the proposed transaction, including synergy opportunities, the merits and considerations of potential strategic alternatives, including Aetna remaining a stand-alone company, and the impact of potential
industry consolidation. Aetna management then reviewed with the board of directors the operational, financial and legal due diligence review of CVS Health conducted by Aetna, including with respect to certain litigation and regulatory matters.
Representatives of Davis Polk provided the board of directors with a summary of the key terms of the merger agreement and updated their antitrust analysis for the potential transaction. The board of directors also reviewed certain proposed matters
relating to communications and shareholder reaction in the event of the announcement of a potential transaction. Representatives of Lazard, Allen&nbsp;&amp; Company and Evercore then joined the meeting, and representatives of Lazard and
Allen&nbsp;&amp; Company discussed with the board of directors Lazard&#146;s and Allen&nbsp;&amp; Company&#146;s respective preliminary financial analyses. The board of directors directed management to continue to negotiate the terms of the
potential transaction, and determined to hold another meeting to continue its discussion of the proposed transaction on December&nbsp;3, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From December&nbsp;1, 2017 through December&nbsp;3, 2017, Davis Polk and Shearman held several telephonic discussions and continued to
exchange drafts of the merger agreement and finalized the remaining terms of the merger agreement and related documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the morning
on December&nbsp;3, 2017, the CVS Health board of directors held a telephonic special meeting that was attended by members of CVS Health&#146;s senior management and representatives of Centerview, Barclays, Goldman Sachs, Shearman and Dechert. At
the meeting, members of CVS Health&#146;s senior management and representatives of Shearman reviewed and discussed with the board of directors the key terms of the merger agreement and the changes to such terms since the board of directors&#146;
November&nbsp;30, 2017 meeting. Next, members of management discussed with the board of directors CVS Health&#146;s and Aetna&#146;s limited contacts in the prior two years with Centerview, none of which had involved the payment of any fees to
Centerview, following which the board of directors approved the engagement by CVS Health of Centerview as an additional financial advisor in connection with the proposed transaction. Representatives of Centerview then reviewed with the board of
directors Centerview&#146;s financial analysis of the proposed transaction and rendered to the board of directors an oral opinion, which was subsequently confirmed by delivery of a written opinion dated December&nbsp;3, 2017, that, as of such date
and based upon and subject to various assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken in preparing its opinion, the merger consideration to be paid by CVS Health in the merger
pursuant to the merger agreement was fair, from a financial point of view, to CVS Health. Representatives of each of Barclays and Goldman Sachs then reviewed with the board of directors their respective financial analyses of the proposed transaction
and rendered to the board of directors their respective oral opinions, which were subsequently confirmed by delivery of written </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opinions dated December&nbsp;3, 2017, that as of such date and based upon and subject to the qualifications, limitations, factors and assumptions set forth in the respective opinions, the merger
consideration to be paid by CVS Health in the merger was fair, from a financial point of view, to CVS Health. Also at the meeting, the board of directors and management reviewed the final terms of the bridge financing that had been arranged for the
acquisition. After discussion, including consideration of the factors described in the section &#147;&#151;CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of Directors that CVS Health Stockholders Approve the Stock
Issuance&#148; beginning on page 106 of this joint proxy statement/prospectus at this and prior meetings, the CVS Health board of directors unanimously (i)&nbsp;determined that the merger agreement and the transactions contemplated by the merger
agreement, including the merger and the stock issuance, are fair to and in the best interests of CVS Health and its stockholders, (ii)&nbsp;approved, adopted and declared advisable the merger agreement and the transactions contemplated by the merger
agreement, including the merger and the stock issuance, (iii)&nbsp;directed that the stock issuance be submitted to a vote at a meeting of CVS Health&#146;s stockholders and (iv)&nbsp;recommended the approval of the stock issuance by CVS
Health&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later in the morning on December&nbsp;3, 2017, the Aetna board of directors held a telephonic special
meeting, which was attended by Aetna&#146;s senior management and representatives of Lazard, Allen&nbsp;&amp; Company, Davis Polk, Evercore and Simpson Thacher. The board of directors, management and Aetna&#146;s advisors discussed the key terms of
the merger agreement and the changes to such terms since the board of directors&#146; December&nbsp;1, 2017 meeting. Also at this meeting, Lazard and Allen&nbsp;&amp; Company reviewed with the Aetna board of directors their respective financial
analyses of the merger consideration, and each separately rendered an oral opinion, confirmed by delivery by each of a written opinion dated December&nbsp;3, 2017, to the Aetna board of directors to the effect that, as of that date and based on and
subject to various assumptions, limitations and qualifications described in the opinion, the consideration to be paid to holders of Aetna common shares in the merger was fair, from a financial point of view, to such holders. After discussion,
including consideration of the factors described in the section &#147;&#151;Aetna&#146;s Reasons for the Merger; Recommendation of the Aetna Board of Directors that Aetna Shareholders Approve and Adopt the Merger Agreement&#148; beginning on page
101 of this joint proxy statement/prospectus at this and prior meetings, the Aetna board of directors unanimously (i)&nbsp;determined that the merger agreement and the transactions contemplated by the merger agreement, including the merger, are fair
to and in the best interests of Aetna and its shareholders, (ii)&nbsp;approved, adopted and declared advisable the merger agreement and the transactions contemplated by the merger agreement (including the merger), (iii) directed that the merger
agreement (including the merger) be submitted to a vote at a meeting of Aetna&#146;s shareholders and (iv)&nbsp;recommended the approval and adoption of the merger agreement (including the merger) by Aetna&#146;s shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">That evening, following the Aetna and CVS Health board of directors meetings, Aetna and CVS Health entered into the merger agreement, and
shortly thereafter issued a joint press release announcing the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_76"></A>Certain Relationships between CVS Health and
Aetna </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health, Aetna and their respective affiliates engage in transactions and enter into agreements with each other in the
ordinary course of business, including certain agreements pursuant to which CVS Health or its subsidiaries provide pharmacy benefit management services to Aetna. Aetna is CVS Health&#146;s largest client. In 2016, Aetna accounted for approximately
11% of CVS Health&#146;s consolidated net revenues. Except as described in this joint proxy statement/prospectus, there are and have been no past, present or proposed material contracts, arrangements, understandings, relationships, negotiations or
transactions during the current calendar year or the five immediately preceding calendar years, between CVS Health or its affiliates, on the one hand, and Aetna or its affiliates, on the other hand, concerning a merger, consolidation or acquisition,
a tender offer for or other acquisition of securities, the election of directors, or the sale or other transfer of a material amount of assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_77"></A>Aetna&#146;s Reasons for the Merger; Recommendation of the Aetna Board of
Directors that Aetna Shareholders Approve and Adopt the Merger Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating the merger agreement and the merger,
Aetna&#146;s board of directors consulted with Aetna&#146;s management and legal and financial advisors and, in reaching its decision to approve the merger agreement and the transactions contemplated by the merger agreement (including the merger)
and to recommend that Aetna&#146;s shareholders vote <B>&#147;FOR&#148;</B> the approval and adoption of the merger agreement (including the merger), Aetna&#146;s board of directors considered a variety of factors, including the following (which are
not necessarily in order of relative importance): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Strategic Factors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna believes that joining CVS Health and Aetna will improve the consumer health care experience by combining Aetna&#146;s health care
benefits and services with CVS Health&#146;s 9,700 retail locations, 1,100 clinics and integrated pharmacy capabilities with the goal of becoming the new, trusted front door to health care in the U.S. The combination of Aetna&#146;s businesses with
CVS Health&#146;s existing businesses is expected to result in a number of potential strategic benefits, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Enhanced consumer engagement</I></B><I>.</I> With nearly 70% of the U.S. population living within three miles of a CVS Health retail store, Aetna believes that its presence in CVS Health&#146;s retail locations
will provide an opportunity to better understand Aetna&#146;s members&#146; health goals, guide them through the health care system and help them achieve their best health, and will provide a seamless connection for patients to their providers, to
improve continuity of care. Aetna also believes its presence in retail locations will allow it to develop trusted relationships with consumers in their local communities, helping the combined company retain and grow membership, and, by doing so,
enabling the combined company to improve patients&#146; access to convenient care, facilitating preemptive care, medication adherence, and early intervention.</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Lower cost, higher quality care</I></B>. Aetna believes that the combined company will be able to deliver care at lower cost to consumers and customers through CVS Health&#146;s
<FONT STYLE="white-space:nowrap">in-store</FONT> clinics, which are currently significantly less expensive than traditional health care delivery settings. In addition, Aetna believes the combined company will have the ability to complement the <FONT
STYLE="white-space:nowrap">in-store</FONT> clinics and traditional health care delivery systems through interventions when consumers, members and patients are not in the traditional delivery system, which will enhance access to care. The combination
is also expected to align CVS Health&#146;s clinics and <FONT STYLE="white-space:nowrap">in-home</FONT> services with Aetna&#146;s provider networks and care management expertise, which Aetna believes will allow the combined company to better
address the social determinants that drive health care costs. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Integrated medical and pharmacy solutions</I></B>. The integration of CVS Health&#146;s pharmacy and pharmacy benefit management services and Aetna&#146;s clinical data, analytics and care management capabilities
is expected to improve medication adherence and care plan compliance while uncovering new ways to impact Aetna&#146;s members&#146; health. Aetna believes the combined solutions of CVS Health and Aetna can help offset the rising cost of prescription
drugs. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Medicare leadership</I></B>. The combination of Aetna&#146;s Medicare Advantage and Medicare Supplement assets with CVS Health&#146;s Medicare Part D excellence is expected to drive higher quality, lower costs and
a better, more convenient experience for seniors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Innovative Plan Designs</I></B>.<B> </B>By combining CVS Health&#146;s care delivery capabilities with Aetna&#146;s traditional strengths in care management, Aetna believes that the combined company will be able
to offer innovative plan designs, which will make it easier and cheaper for Aetna&#146;s members and plan sponsors to navigate the health care system. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Enhanced mobile capabilities</I></B>. Combining Aetna&#146;s clinical data and digital assets with CVS
Health&#146;s pharmacy data and mobile tools is expected to allow consumers to schedule appointments, manage medications, access their personal health data and communicate with health care professionals more
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
conveniently and efficiently, which Aetna believes will improve health outcomes, including by helping consumers adhere to their care plans. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Increased operating efficiency</I></B>. The merger is expected to create significant opportunities to increase the combined company&#146;s operating efficiency by simplifying processes and projected administrative
and other cost synergies, which Aetna believes could be $2.4&nbsp;billion per year by the fifth full year following completion of the merger, and which Aetna believes will further drive efficiencies and cost savings for consumers and customers.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Leadership and governance</I></B><B></B>.<B> </B>CVS Health has stated that it plans for members of the Aetna management team to play significant roles in the combined company and for Aetna to operate as a
stand-alone business unit within the combined company led by members of Aetna&#146;s current management team, and CVS Health has committed to maintain in accordance with the merger agreement the Aetna brand in the marketplace. Aetna believes these
commitments will in each case help to build on Aetna&#146;s distinguished history and position the combined company for growth. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Medicaid</I></B>. By utilizing CVS Health&#146;s pharmacy footprint and <FONT STYLE="white-space:nowrap">in-store</FONT> clinics, Aetna believes that the combined company will be able to better serve the Medicaid
population by improving their access to care at lower cost. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Factors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the strategic factors summarized above, Aetna&#146;s board of directors also considered the following factors in connection with
its evaluation of the merger: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the respective businesses, operations, management, financial condition, earnings, market reputation, competitive pressures, regulatory constraints and prospects of Aetna and CVS Health; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of Aetna&#146;s due diligence investigation of CVS Health and the reputation, business practices and experience of CVS Health and its management; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the historical trading prices of shares of CVS Health common stock and Aetna common shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the review by Aetna&#146;s board of directors with the assistance of Aetna&#146;s management and legal and financial advisors of the structure of the merger and the financial and other terms of the merger agreement;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trends and competitive developments in the retail and health care industries (including the pharmacy industry), including potential new entrants into such industries; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that CVS Health has obtained an executed debt commitment letter which provides for a bridge loan facility, the limited number and nature of the conditions to the debt financing and CVS Health&#146;s obligation
under the merger agreement to use its reasonable best efforts to obtain the debt financing at completion of the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Aetna&#146;s board of directors was unanimous in its determination to recommend the merger agreement for approval and adoption by Aetna&#146;s shareholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risks and uncertainties regarding then-pending tax reform proposals in the United States, including the potential costs to each of Aetna and CVS Health, the potential benefits to Aetna on a stand-alone basis and the
likelihood of any benefits being retained by Aetna in light of the competitive industries in which Aetna operates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that the merger agreement will be subject to the approval of Aetna&#146;s shareholders; </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Price and Structure </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the current and historical market prices for Aetna common shares, including the fact that the implied value of
the merger consideration of $207.94 per share (as of December&nbsp;1, 2017) represented an approximate premium of (i) 15% over the closing price per share of Aetna common shares on </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
December&nbsp;1, 2017 (the last trading day prior to the announcement of the merger agreement), (ii) 30% over the closing price per share of Aetna common shares on October&nbsp;25, 2017 (the last
trading day prior to reports in the news media of rumors of a transaction involving Aetna), (iii) 32% over the volume-weighted average closing price per share of Aetna common shares over the 30 days ended October&nbsp;25, 2017 and (iv) 62% over the
closing price per share of Aetna common shares on February&nbsp;15, 2017 (the trading day following the termination of Aetna&#146;s agreement to acquire Humana); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that, because holders of outstanding Aetna common shares as of immediately prior to completion of the merger are expected to hold approximately 22% of the outstanding CVS Health common stock immediately after
completion of the merger, Aetna shareholders are expected to have the opportunity to participate in the future performance of the combined company, including synergies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that approximately 70% of the merger consideration is payable in cash, which provides Aetna&#146;s shareholders with certainty of value upon completion of the merger; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that because the exchange ratio under the merger agreement is fixed (and will not be adjusted for fluctuations in the market price of Aetna common shares or CVS Health common stock), Aetna shareholders have
greater certainty as to the number of shares of CVS Health common stock to be received in the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Aetna&#146;s board of directors had carefully considered, with the assistance of Aetna&#146;s management and legal and financial advisors, various potential strategic alternatives available to Aetna,
including remaining an independent company or pursuing certain other alternative transactions, and had explored the possibility of potential strategic transactions with other companies (including Party X and Party Y), and the Aetna board of
directors&#146; belief that the transaction with CVS Health presented a more favorable opportunity for Aetna&#146;s shareholders than the potential value that might result from other potential strategic alternatives available to Aetna;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Aetna&#146;s board of directors had carefully considered, with the assistance of Aetna&#146;s management and legal and financial advisors, the potential consequences for Aetna if CVS Health were to pursue
certain strategic alternatives to the proposed transaction with Aetna, and the Aetna board of directors&#146; belief that Aetna&#146;s strategic alternatives may be more limited and less favorable in such circumstances; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that, notwithstanding the publicity surrounding a potential transaction between Aetna and CVS Health over more than a month prior to December&nbsp;3, 2017, Aetna had not received an acquisition proposal from
any third party (other than CVS Health); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the view of Aetna&#146;s board of directors, after review by the board of directors with the assistance of Aetna&#146;s legal advisors of the potential regulatory considerations of the transaction, that CVS Health will
successfully consummate the merger in a timely manner; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the debt commitment letter and the bridge loan facility thereunder, particularly in light of the then-current market for such commitments and facilities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Aetna&#146;s management was assisted in negotiations by Aetna&#146;s legal and financial advisors and that Aetna&#146;s board of directors was provided directly and regularly with perspectives on the
negotiations from Aetna&#146;s management and advisors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the separate opinions, each dated December&nbsp;3, 2017, of Lazard and Allen&nbsp;&amp; Company to Aetna&#146;s board of directors as to the fairness, from a financial point of view and as of such date, of the
consideration to be paid to holders of Aetna common shares in the merger, which opinions were based on and subject to the assumptions made, procedures followed, matters considered and limitations and qualifications on the review undertaken, as more
fully described in the section entitled &#147;&#151;Opinions of Aetna&#146;s Financial Advisors&#148; beginning on page 111 of this joint proxy statement/prospectus; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Terms of the Merger Agreement </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that CVS Health is required to take all actions necessary to obtain regulatory approvals for the transaction, including agreeing to divestitures if necessary, unless such actions would have or would reasonably
be expected to have, individually or in the aggregate, a regulatory material adverse effect on CVS Health or on Aetna, as more fully described in the section entitled &#147;Merger Agreement&#151; Reasonable Best Efforts Covenant&#148; beginning on
page 194 of this joint proxy statement/prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that, if the merger is not completed because CVS Health is unable to obtain certain regulatory approvals for the transaction, including the approval under the HSR Act or approval of state insurance and other
regulators, CVS Health will be required to pay Aetna a termination fee of $2.1&nbsp;billion;<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the limited ability of CVS Health&#146;s board of directors to change its recommendation that CVS Health&#146;s stockholders approve the stock issuance, and the fact that CVS Health will be required to pay Aetna a
termination fee of $2.1&nbsp;billion if (i)&nbsp;Aetna terminates the merger agreement as a result of (a)&nbsp;an adverse change of CVS Health&#146;s board of directors&#146; recommendation that CVS Health&#146;s stockholders approve the stock
issuance or (b)&nbsp;CVS Health&#146;s material breach of its &#147;no shop&#148; obligations or its obligation to call the CVS Health special meeting to approve the stock issuance, (ii)&nbsp;CVS Health terminates the merger agreement to enter into
a definitive agreement providing for an acquisition of CVS Health that is superior to the merger or (iii)&nbsp;(a) either party terminates the merger agreement as a result of the failure of CVS Health&#146;s stockholders to approve the stock
issuance, (b)&nbsp;a proposal for an acquisition of CVS Health was publicly announced and not withdrawn prior to the CVS Health special meeting and (c)&nbsp;CVS Health enters into or completes an alternative transaction within one year after such
termination; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the absence of a financing condition, and CVS Health&#146;s representations, warranties and covenants related to obtaining the financing to complete the merger; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna&#146;s ability, under certain circumstances, and subject to certain conditions, to furnish information to and to conduct negotiations with a third party that makes an unsolicited bona fide written proposal for a
business combination or acquisition of Aetna that is reasonably likely to lead to a proposal that is superior to the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Aetna&#146;s board of directors, subject to certain conditions, has the right to (i)&nbsp;change its recommendation of the transaction in response to a proposal to acquire Aetna that is superior to the
merger or an intervening event with respect to Aetna or (ii)&nbsp;terminate the merger agreement to enter into a definitive agreement providing for an acquisition of Aetna that is superior to the merger, in each case, if Aetna&#146;s board of
directors determines that failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties to Aetna&#146;s shareholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna&#146;s board of directors&#146; conclusion, after consultation with Aetna&#146;s advisors, that the deal protection provisions of the merger agreement were customary and reasonable for transactions of this type
and should not preclude or deter a willing and financially capable third party, were one to exist, from making a superior proposal for Aetna following the announcement of a transaction with CVS Health; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that the end date under the merger agreement of December&nbsp;3, 2018 (which may be extended by either party to March&nbsp;3, 2019 and by CVS Health to June&nbsp;3, 2019 under certain circumstances) allows for
sufficient time to complete the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Aetna may seek specific performance of CVS Health&#146;s obligations under the merger agreement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement under the merger agreement that (i)&nbsp;at completion of the merger, the CVS Health board of
directors will be expanded by three directors to include Mr.&nbsp;Bertolini and two members of the board of directors of Aetna who are jointly designated by Aetna and CVS Health and who meet CVS Health&#146;s independence criteria prior to
completion of the merger, (ii)&nbsp;for at least three years following </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
completion of the merger, CVS Health will preserve Aetna Foundation, Inc. in a manner consistent in all material respects with the past practice of Aetna, including by maintaining its name and
charitable mission, and (iii)&nbsp;for at least five years following completion of the merger, CVS Health will maintain &#147;Aetna&#148; as the primary brand for the insurance businesses of CVS Health and its subsidiaries. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Potentially Negative Factors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna&#146;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the merger, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that the exchange ratio with respect to the stock portion of the merger consideration is fixed, which could result in Aetna&#146;s shareholders being adversely affected by a decrease in the trading price of CVS
Health common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that the merger may not be completed despite the parties&#146; efforts or that completion of the merger may be delayed, even if the requisite approvals are obtained from Aetna shareholders and CVS Health
stockholders, including the possibility that conditions to the parties&#146; obligations to complete the merger may not be satisfied, and the potential resulting disruptions to Aetna&#146;s and CVS Health&#146;s respective businesses;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Aetna and CVS Health must obtain clearance under the HSR Act, as well as other approvals from state insurance and other regulators, in order to complete the merger, which approvals may not be obtained or
may be subject to conditions that CVS Health is not required to comply with; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the challenges inherent in the combination of two companies, including the risk that integration of the two companies may take more time and be more costly than anticipated, the risk that the cost savings, synergies and
other benefits expected to be obtained as a result of the merger might not be fully or timely realized, the risk that the combined company may not succeed in implementing a new retail health operating model or that consumers may not embrace the new
model, the risk of front store retail sales revenue pressures from competitors, the risk of pharmacy revenue pressures from competitors, the risk of the loss of pharmacy benefit management revenues from other managed care companies and the risk of
price/earnings multiple compression; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of time it could take to complete the regulatory approval process and the merger, the potential for diversion of management focus for an extended period and employee attrition, the potential inability to hire
new employees and the possible adverse effects of the announcement and pendency of the transaction on customers, providers, vendors, regulators and other business relationships, and the communities in which Aetna operates, in particular if the
merger is not completed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the restrictions under the terms of the merger agreement on the conduct of Aetna&#146;s business prior to completion of the merger, which could delay or prevent Aetna from undertaking material strategic opportunities
that might arise pending completion of the merger to the detriment of Aetna&#146;s shareholders, in particular if the merger is not completed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that the financial performance of Aetna and CVS Health might not meet the expectations of their respective managements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the limitations on Aetna&#146;s ability to solicit alternative proposals for an acquisition of Aetna; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that CVS Health does not have to complete the merger if CVS Health and Aetna would be required to take actions to obtain regulatory approvals that would have or would reasonably be expected to have,
individually or in the aggregate, a regulatory material adverse effect on CVS Health or on Aetna; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CVS Health&#146;s ability, under certain circumstances, and subject to certain conditions, to furnish information
to and to conduct negotiations with a third party that makes an unsolicited bona fide </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
written proposal for a business combination or acquisition of CVS Health that is reasonably likely to lead to a proposal that is superior to the merger; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that CVS Health&#146;s board of directors, subject to certain conditions, has the right to (i)&nbsp;change its recommendation of the stock issuance in response to a proposal to acquire CVS Health that is
superior to the merger or an intervening event with respect to CVS Health or (ii)&nbsp;terminate the merger agreement to enter into a definitive agreement providing for an acquisition of CVS Health that is superior to the merger, in each case, if
CVS Health&#146;s board of directors determines that failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Aetna will be required to pay CVS Health a termination fee of $2.1&nbsp;billion if the merger agreement is terminated under certain circumstances, including (i)&nbsp;a termination of the merger agreement
by CVS Health as a result of a change of Aetna&#146;s board of directors&#146; recommendation or (ii)&nbsp;a termination of the merger agreement by Aetna to enter into a definitive agreement providing for an acquisition of Aetna that is superior to
the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that the merger may not be completed, or that completion may be significantly delayed, for reasons beyond the control of Aetna, including the failure to satisfy certain conditions to closing, including
(i)&nbsp;the failure of CVS Health&#146;s stockholders to approve the stock issuance and (ii)&nbsp;the failure to obtain the required regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that certain of Aetna&#146;s directors and executive officers may receive certain benefits that are different from, and in addition to, those of Aetna&#146;s other shareholders (see &#147;Interests of
Aetna&#146;s Directors and Executive Officers in the Merger&#148; beginning on page 209 of this joint proxy statement/prospectus); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risks and uncertainties inherent in CVS Health&#146;s business and operations and in the regulatory environment, including the health care regulatory environment; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that the merger consideration will be taxable to Aetna&#146;s shareholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risks described in the section entitled &#147;Risk Factors&#148; beginning on page 62 of this joint proxy statement/prospectus. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion of the material factors considered by Aetna&#146;s board of directors in its consideration of the merger and the other
transactions contemplated by the merger agreement is not intended to be exhaustive, but does set forth the principal factors considered by Aetna&#146;s board of directors. In light of the number and wide variety of factors considered in connection
with the evaluation of the merger, and the complexity of these matters, Aetna&#146;s board of directors did not consider it practicable to, and did not attempt to, quantify, rank or otherwise assign relative weights or values to the specific factors
it considered in reaching its final decision to approve the merger and the other transactions contemplated by the merger agreement. Aetna&#146;s board of directors viewed its decision as based on all of the information available to it and the
factors presented to and considered by it, including its experience and history. In addition, individual directors may themselves have given different weight to different factors. The factors, potential risks and uncertainties contained in this
explanation of Aetna&#146;s reasons for the merger and other information presented in this section contain information that is forward-looking in nature and, therefore, should be read in light of the factors discussed in &#147;Cautionary Statement
Regarding Forward-Looking Statements&#148; beginning on page 72 of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AETNA&#146;S BOARD OF
DIRECTORS UNANIMOUSLY RECOMMENDS THAT AETNA SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL AND ADOPTION OF THE MERGER AGREEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_78">
</A>CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of Directors that CVS Health Stockholders Approve the Stock Issuance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating the merger agreement and the merger, CVS Health&#146;s board of directors consulted with CVS Health&#146;s management and legal
and financial advisors and, in reaching its decision to approve the merger </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement and the transactions contemplated by the merger agreement, including the stock issuance, and to recommend that CVS Health&#146;s stockholders vote &#147;FOR&#148; the approval of the
stock issuance, CVS Health&#146;s board of directors considered a variety of factors, including the following (which are not necessarily in order of relative importance): </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Strategic Factors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health believes that the acquisition of Aetna will complement its competitive strategy, which is built on a diversified set of core and
emerging businesses that enable it to better compete with more cost-effective products, pursue profitable growth across a range of opportunities and lead the transformation of the health care industry to a more consumer-focused marketplace. The
acquisition of Aetna and the combination of Aetna&#146;s businesses with CVS Health&#146;s businesses is expected to result in a number of strategic benefits, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">creating a leading health care platform with an unmatched suite of services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing high-touch connectivity to consumers as their primary health care resource in the community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improving quality of care through enhanced data integration and predictive analytics; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lowering the cost of health care through an integrated model anchored by CVS Health&#146;s lower cost health care delivery settings and Aetna&#146;s provider networks and care management expertise; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing a higher quality, more convenient health care experience for seniors at a lower cost through the combined company&#146;s Medicare assets; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">producing highly diversified, strong and stable cash flows; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing potential synergies of $750&nbsp;million in the second full year following closing and the potential for long-term opportunities for additional savings; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-single</FONT> digit accretion in the second full year following closing. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Factors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to the strategic factors summarized above, CVS Health&#146;s board of directors also considered the following factors in connection with its evaluation of the merger: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the respective businesses, operations, management, financial condition, earnings, market reputation, competitive pressures, regulatory constraints and prospects of CVS Health and Aetna; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of CVS Health&#146;s due diligence investigation of Aetna and the reputation, business practices and experience of Aetna and its management; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the historical trading prices of shares of CVS Health common stock and Aetna common shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the review by CVS Health&#146;s board of directors, in consultation with its legal, financial and other advisors, of the structure of the merger and the financial and other terms of the merger agreement;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trends and competitive developments in the industries in which CVS Health and Aetna operate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that the stock issuance will be subject to the approval of CVS Health&#146;s stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the range of other strategic alternatives available to CVS Health and CVS Health&#146;s board of directors&#146; belief that the transaction with Aetna presented a more favorable opportunity for CVS Health&#146;s
stockholders than the potential value that may result from other strategic alternatives available to CVS Health; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that CVS Health&#146;s board of directors had carefully considered, after consulting with CVS
Health&#146;s management and financial, legal and other advisors, the potential consequences for CVS </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Health if Aetna were to pursue certain strategic alternatives to the proposed transaction with CVS Health, and the CVS Health board of directors&#146; belief that CVS Health&#146;s strategic
alternatives may be more limited and less favorable in such circumstances; </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Price and Structure </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that because the exchange ratio under the merger agreement is fixed (and will not be adjusted for fluctuations in the market price of shares of CVS Health common stock or Aetna common shares), CVS Health has
greater certainty as to the number of shares of CVS Health common stock to be issued in the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the respective financial analyses of Barclays and Goldman Sachs and the respective opinions of each of Barclays and Goldman Sachs, rendered orally on December&nbsp;3, 2017 and subsequently confirmed in writing, to the
CVS Health board of directors that, as of such date and based upon and subject to the qualifications, limitations, factors and assumptions set forth in the respective opinions, the merger consideration to be paid by CVS Health in the merger was
fair, from a financial point of view, to CVS Health. See &#147;&#151;Opinions of CVS Health&#146;s Financial Advisors&#151;Opinion of Barclays Capital Inc.&#148; beginning on page 128 of this joint proxy statement/prospectus and &#147;&#151;Opinions
of CVS Health&#146;s Financial Advisors&#151;Opinion of Goldman Sachs&nbsp;&amp; Co. LLC&#148; beginning on page 132 of this joint proxy statement/prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the analyses of Centerview and the opinion of Centerview rendered to the CVS Health board of directors on December&nbsp;3, 2017, which was subsequently confirmed by delivery of a written opinion dated December&nbsp;3,
2017, that, as of such date and based upon and subject to the assumptions made, procedures followed, matters considered, and qualifications limitations upon the review undertaken by Centerview in preparing its opinion, the merger consideration to be
paid by CVS Health in the merger pursuant to the merger agreement was fair, from a financial point of view, to CVS Health. See &#147;&#151;Opinions of CVS Health&#146;s Financial Advisors&#151;Opinion of Centerview Partners LLC&#148; beginning on
page 145 of this joint proxy statement/prospectus; </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Other Factors </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the belief of the CVS Health board of directors, following consultation with CVS Health&#146;s management, and based in part upon the debt financing commitments that CVS Health obtained, that CVS Health will have the
necessary financing to pay the aggregate cash portion of the merger consideration and that CVS Health, following the merger, will be able to repay, service or refinance any indebtedness that is expected to form the interim or permanent financing for
the merger and, with respect to such indebtedness, to comply with applicable financial covenants, after its review and discussion of various factors, including (i)&nbsp;the terms of CVS Health&#146;s current indebtedness, (ii)&nbsp;the terms of
Aetna&#146;s current indebtedness and (iii)&nbsp;the expected terms of the proposed interim and permanent financing for the merger (including covenants, fees and interest); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the belief of the CVS Health board of directors, following consultation with CVS Health&#146;s management, that the financing commitments it had obtained to finance the aggregate cash portion of the merger consideration
were on attractive terms for CVS Health; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the belief of the CVS Health board of directors that CVS Health would maintain its investment grade credit rating after incurring the interim or permanent indebtedness necessary to finance the cash portion of the
merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the experience of CVS Health&#146;s management in integrating acquired companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expectation that members of Aetna&#146;s management team will play significant roles in the combined company; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Larry J. Merlo, CVS Health&#146;s President and Chief Executive Officer, will continue to lead the combined company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the requirement under the merger agreement that (i)&nbsp;for a period of at least five years following completion of the merger, CVS Health maintain &#147;Aetna&#148; as the primary brand for the insurance businesses of
the combined company, (ii)&nbsp;for a period of at least three years following completion of the merger, CVS Health preserve Aetna Foundation, Inc. in a manner consistent in all material respects with past practice, including by maintaining its name
and charitable mission, and (iii)&nbsp;at completion of the merger, the CVS Health board of directors will include three members of the board of directors of Aetna, including Mark T. Bertolini, Chairman and Chief Executive Officer of Aetna;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that, while CVS Health is obligated to use its reasonable best efforts to complete the merger, CVS Health is not obligated to take any actions or agree to any terms, conditions or limitations as a condition to,
or in connection with, obtaining any regulatory approvals required to complete the merger that would have or would reasonably be expected to have, individually or in the aggregate, a regulatory material adverse effect on CVS Health or Aetna;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health&#146;s ability, under circumstances described in the merger agreement, to provide information to and engage in discussions or negotiations with a third party that makes an unsolicited bona fide written
acquisition proposal; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of CVS Health&#146;s board of directors, subject to certain conditions, to change its recommendation in favor of the stock issuance in response to a superior proposal or an intervening event other than a
superior proposal, if CVS Health&#146;s board of directors determines that failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of CVS Health&#146;s board of directors, subject to certain conditions, to terminate the merger agreement to enter into a definitive agreement providing for a superior proposal; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the limited ability of Aetna&#146;s board of directors to change its recommendation that Aetna shareholders approve and adopt the merger agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that Aetna is required to pay CVS Health a termination fee of $2.1&nbsp;billion if the merger agreement is terminated under certain circumstances relating to an alternative acquisition proposal for Aetna; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that the end date under the merger agreement of December&nbsp;3, 2018 (which may be extended by either party to March&nbsp;3, 2019 and by CVS Health to June&nbsp;3, 2019 under certain circumstances) allows for
sufficient time to complete the merger. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s board of directors also considered a number of uncertainties and
risks in its deliberations concerning the merger, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that the merger may not be completed or may be delayed despite the parties&#146; efforts, including the possibility that conditions to the parties&#146; obligations to complete the merger may not be satisfied,
and the potential resulting disruptions to CVS Health&#146;s and Aetna&#146;s businesses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential length of the regulatory approval process and the period of time during which CVS Health may be subject to certain restrictions on the conduct of its businesses, which could prevent CVS Health from making
certain acquisitions or divestitures or otherwise pursuing certain business opportunities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility that governmental authorities might seek to require certain actions of CVS Health or Aetna or impose certain terms, conditions or limitations on CVS Health&#146;s or Aetna&#146;s businesses in connection
with granting approval of the merger or might otherwise seek to prevent or delay the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that CVS Health is required to pay Aetna a termination fee of $2.1&nbsp;billion if the merger agreement is terminated under certain circumstances (i)&nbsp;due to the failure to obtain the required regulatory
approvals for the merger or (ii)&nbsp;relating to an acquisition proposal for CVS Health; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that CVS Health has incurred and will continue to incur significant transaction fees and expenses in connection with the merger, regardless of whether it is completed; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the challenges inherent in the combination of two businesses of the size, scope and complexity of CVS Health and Aetna, including the potential for unforeseen difficulties in integrating operations and systems and
difficulties and costs of integrating or retaining employees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the challenges for CVS Health in developing the operational expertise to efficiently run a national diversified health care benefits company; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that the potential benefits of the merger may not be fully realized, including the possibility that expected synergies, cost savings and operating efficiencies expected to result from the merger may not be
realized to the extent expected, or at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk of diverting CVS Health management focus and resources from other strategic opportunities and operational matters, and potential disruption of CVS Health management associated with the merger and integrating
the companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna&#146;s ability, under circumstances described in the merger agreement, to provide information to and engage in discussions or negotiations with a third party that makes an unsolicited bona fide written acquisition
proposal; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of Aetna&#146;s board of directors, subject to certain conditions, to change its recommendation supporting the merger in response to a superior proposal or an intervening event other than a superior
proposal, if Aetna&#146;s board of directors determines that failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of Aetna&#146;s board of directors, subject to certain conditions, to terminate the merger agreement to enter into a definitive agreement providing for a superior proposal; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the absence of a financing condition in the merger agreement and Aetna&#146;s ability to specifically enforce CVS Health&#146;s obligations under the merger agreement whether or not CVS Health is able to maintain its
committed financing for the acquisition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential negative effects of the announcement and pendency of the merger on CVS Health&#146;s and Aetna&#146;s businesses, including stockholder and market reactions and relationships with employees, customers
(including pharmacy benefits manager clients), patients, providers, vendors, regulators and the communities in which they operate, including the risk that certain key members of senior management of CVS Health or Aetna might not choose to remain
with the combined company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dilution of existing shares of CVS Health common stock associated with the stock issuance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that the CVS Health stockholders do not approve the stock issuance proposal, which is a condition to completion of the merger; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk of litigation related to the transaction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risks and uncertainties regarding then-pending tax reform proposals in the United States, including the potential costs to each of Aetna and CVS Health, the potential benefits to CVS Health on a stand-alone basis
and the likelihood of any benefits being retained by CVS Health in light of the competitive industries in which CVS Health operates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">various other risks associated with the merger and the businesses of CVS Health, Aetna and the combined company described under &#147;Risk Factors,&#148; beginning on page 62 and the matters described under
&#147;Cautionary Note Regarding Forward-Looking Statements&#148; beginning on page 72 of this joint proxy statement/prospectus. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During its consideration of the merger, CVS Health&#146;s board of directors was also aware that certain of Aetna&#146;s directors and
executive officers may have interests in the merger that are different from or in addition to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
those of Aetna shareholders generally, as described in the section entitled &#147;Interests of Aetna&#146;s Directors and Executive Officers in the Merger&#148; beginning on page 209 of this
joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion of the material factors considered by CVS Health&#146;s board of directors in its
consideration of the merger and the other transactions contemplated by the merger agreement is not intended to be exhaustive, but does set forth the principal factors considered by CVS Health&#146;s board of directors. In light of the number and
wide variety of factors considered in connection with the evaluation of the merger, CVS Health&#146;s board of directors did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific
factors it considered in reaching its final decision. CVS Health&#146;s board of directors viewed its position as being based on all of the information available to it and the factors presented to and considered by it. However, some directors may
themselves have given different weight to different factors. The factors, potential risks and uncertainties contained in this explanation of CVS Health&#146;s reasons for the merger and other information presented in this section contain information
that is forward-looking in nature and, therefore, should be read in light of the factors discussed in &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; beginning on page 72 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE CVS HEALTH BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH STOCKHOLDERS VOTE &#147;FOR&#148; THE STOCK ISSUANCE. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_79"></A>Opinions of Aetna&#146;s Financial Advisors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of Lazard Fr&egrave;res&nbsp;&amp; Co. LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna has engaged Lazard as a financial advisor in connection with the proposed merger. In connection with this engagement, Aetna requested
that Lazard render an opinion to the Aetna board of directors as to the fairness, from a financial point of view, to the holders of Aetna common shares of the consideration to be paid to such holders in the merger. On December&nbsp;3, 2017, at a
meeting of the Aetna board of directors held to evaluate the merger, Lazard rendered an oral opinion, which was confirmed by delivery of a written opinion dated December&nbsp;3, 2017, to the Aetna board of directors to the effect that, as of that
date and based on and subject to the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken described in such opinion, the consideration to be paid to holders of Aetna common shares in
the merger was fair, from a financial point of view, to such holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of Lazard&#146;s written opinion, dated
December&nbsp;3, 2017, which describes the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken, is attached as Annex B and is incorporated by reference herein in its entirety.<B>
</B>The description of Lazard&#146;s opinion set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of Lazard&#146;s opinion. <B>Lazard&#146;s opinion was for the benefit of the Aetna board of
directors (in its capacity as such) in connection with its evaluation of the merger and did not address any terms or other aspects (other than the merger consideration to the extent expressly specified in Lazard&#146;s opinion) of the merger.
Lazard&#146;s opinion did not address the relative merits of the merger as compared to any other transaction or business strategy in which Aetna might engage or the merits of the underlying decision by Aetna to engage in the merger. Lazard&#146;s
opinion is not intended to and does not constitute a recommendation to any shareholder as to how such shareholder should vote or act with respect to the merger or any matter relating thereto. </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its opinion, Lazard: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">reviewed the financial terms and conditions of a draft, dated December&nbsp;2, 2017, of the merger agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed certain publicly available historical business and financial information relating to Aetna and CVS Health; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed various financial forecasts and other data prepared by Aetna<B> </B>relating to the business of Aetna,
financial forecasts and other data prepared by CVS Health<B> </B>and<B> </B>as extrapolated per Aetna </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
relating to the business of CVS Health, and<B> </B>the projected synergies and other benefits, including the amount and timing thereof, anticipated by the respective managements of Aetna and CVS
Health to be realized from the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">held discussions with members of the senior management of Aetna with respect to the businesses and prospects of Aetna and CVS Health, with members of the senior management of CVS Health with respect to the business and
prospects of CVS Health, and with members of the senior managements of Aetna and CVS Health with respect to the projected synergies and other benefits, including the amount and timing thereof, anticipated by the respective managements to be realized
from the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">reviewed public information with respect to certain other companies in lines of business Lazard believed to be generally relevant in evaluating the businesses of Aetna<B> </B>and CVS Health, respectively;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">reviewed the financial terms of certain business combinations involving companies in lines of business Lazard believed to be generally relevant in evaluating the business of Aetna; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed historical stock prices of Aetna common shares and shares of CVS Health common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed the potential pro forma financial impact of the merger on CVS Health based on the financial forecasts referred to above relating to Aetna, CVS Health and the projected synergies and other benefits anticipated
by the management of Aetna to be realized from the merger; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top">conducted such other financial studies, analyses and investigations as Lazard deemed appropriate. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard assumed and relied upon the accuracy and completeness of the foregoing information, without independent verification of such
information. Lazard did not conduct any independent valuation or appraisal of any of the assets or liabilities (contingent or otherwise) of Aetna or CVS Health or concerning the solvency or fair value of Aetna or CVS Health, and Lazard was not
furnished with any such valuation or appraisal. Lazard is not an actuary and Lazard&#146;s services did not include any actuarial determination or evaluation by Lazard or any attempt to evaluate actuarial assumptions or allowances for losses,
uncollectible accounts, claims or other matters and, accordingly, Lazard assumed, without independent analysis, the appropriateness of, and expressed no view or opinion as to, reserves. At Aetna&#146;s direction, for purposes of Lazard&#146;s
analysis, Lazard utilized the projected synergies and other benefits anticipated to be realized from the merger that were prepared by Aetna. With respect to the financial forecasts utilized in Lazard&#146;s analyses, including those related to
projected synergies and other benefits anticipated by the management of Aetna to be realized from the merger, Lazard assumed, with the consent of Aetna, that they were reasonably prepared on bases reflecting the best currently available estimates
and judgments as to the future financial performance of Aetna<B> </B>and CVS Health, respectively, and such synergies and other benefits. In addition, Lazard assumed, with the consent of Aetna, that such financial forecasts and projected synergies
and other benefits would be realized in the amounts and at the times contemplated thereby. Lazard assumed no responsibility for and expressed no view as to any such forecasts or the assumptions on which they were based. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Lazard&#146;s opinion was necessarily based on economic, monetary, market and other conditions as in effect on, and the information
made available to Lazard as of, the date of its opinion. Lazard assumed no responsibility for updating or revising its opinion based on circumstances or events occurring after the date of its opinion. Lazard did not express any opinion as to the
prices at which Aetna common shares or shares of CVS Health common stock may trade at any time subsequent to the announcement of the merger. In connection with Lazard&#146;s engagement, Lazard was not authorized to, and it did not, solicit
indications of interest from third parties regarding a potential transaction with Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering its opinion, Lazard assumed, with
the consent of Aetna, that the merger would be consummated on the terms described in the merger agreement, without any waiver or modification of any material terms or conditions. Representatives of Aetna advised Lazard, and Lazard assumed, that the
merger agreement, when executed, would conform to the draft reviewed by Lazard in all material respects. Lazard also assumed, with the consent of Aetna, that obtaining the necessary governmental, regulatory or third party approvals and consents for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the merger would not have an adverse effect on Aetna, CVS Health<B> </B>or the merger. Lazard did not express any opinion as to any tax or other consequences that might result from the merger,
nor does Lazard&#146;s opinion address any legal, tax, regulatory, actuarial or accounting matters, including, without limitation, the potential impact of U.S. health care and tax laws, regulations and governmental and legislative policies on Aetna,
CVS Health or the merger, as to which Lazard understood that Aetna obtained such advice as it deemed necessary from qualified professionals. Lazard expressed no view or opinion as to any terms or other aspects (other than the merger consideration<B>
</B>to the extent expressly specified in Lazard&#146;s opinion) of the merger, including, without limitation, the form or structure of the merger or any agreements or arrangements entered into in connection with, or contemplated by, the merger. In
addition, Lazard expressed no view or opinion as to the fairness of the amount or nature of, or any other aspects relating to, the compensation to any officers, directors or employees of any parties to the merger, or class of such persons, relative
to the merger consideration or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its opinion, Lazard performed a variety of financial and comparative
analyses, including those described below. The summary of the analyses below and certain factors considered is not a comprehensive description of all analyses undertaken or factors considered by Lazard. The preparation of a financial opinion or
analysis is a complex process involving various determinations as to the most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances and, therefore, a financial opinion and
analyses are not readily susceptible to summary description. Lazard arrived at its opinion based on the results of all analyses undertaken and assessed as a whole, and did not draw, in isolation, conclusions from or with regard to any one factor or
method of analysis. Accordingly, Lazard believes that the analyses and factors summarized below must be considered as a whole and in context. Lazard further believes that selecting portions of the analyses and factors or focusing on information
presented in tabular format, without considering all analyses and factors or the narrative description of the analyses and factors, could create a misleading or incomplete view of the processes underlying Lazard&#146;s analyses and opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In performing its financial analyses, Lazard considered industry performance, general business and economic, market and financial conditions
and other matters existing as of the date of its opinion, many of which are beyond the control of Aetna and CVS Health. No company, business or transaction reviewed is identical or directly comparable to Aetna, CVS Health or their respective
businesses or the merger and an evaluation of these analyses is not entirely mathematical; rather, the analyses involve complex considerations and judgments concerning financial and operating characteristics and other factors that could affect the
public trading, acquisition or other values of the companies, businesses or transactions reviewed. The estimates of the future performance of Aetna and CVS Health in or underlying Lazard&#146;s analyses are not necessarily indicative of actual
values or actual future results, which may be significantly more or less favorable than those estimates or those suggested by such analyses. These analyses were prepared solely as part of Lazard&#146;s analysis of the fairness, from a financial
point of view, of the merger consideration and were provided to the Aetna board of directors in connection with the delivery of Lazard&#146;s opinion. The analyses do not purport to be appraisals or to reflect the prices at which a company might
actually be sold or the prices at which any securities have traded or may trade at any time in the future. Accordingly, the assumptions and estimates used in, and the ranges of valuations resulting from, any particular analysis described below are
inherently subject to substantial uncertainty and should not be taken as the views of Lazard regarding the actual values of Aetna or CVS Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard did not recommend that any specific consideration constituted the only appropriate consideration in the merger. The type and amount of
consideration payable in the merger was determined through negotiations between Aetna and CVS Health, rather than by any financial advisor, and was approved by the Aetna board of directors. The decision to enter into the merger agreement was solely
that of the Aetna board of directors and the CVS Health board of directors. Lazard&#146;s opinion and analyses were only one of many factors considered by the Aetna board of directors in its evaluation of the proposed merger and the merger
consideration and should not be viewed as determinative of the views of the Aetna board of directors or management with respect to the merger or the consideration payable in the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Financial Analyses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary of the financial analyses described in this section entitled &#147;&#151;<I>Financial Analyses</I>&#148; is a summary of the
material financial analyses provided by Lazard in connection with its opinion, dated December&nbsp;3, 2017, to the Aetna board of directors. <B>The summary set forth below is not a comprehensive description of all analyses undertaken by Lazard in
connection with its opinion, nor does the order of the analyses in the summary below indicate that any analysis was given greater weight than any other analysis. The financial analyses summarized below include information presented in tabular
format. In order to fully understand the financial analyses performed by Lazard, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses performed by Lazard.
Considering the data set forth in the tables below without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the
financial analyses performed by Lazard. Future results may differ from those described and such differences may be material.</B> For purposes of the financial analyses described below in this section of this joint proxy statement/prospectus, the
term (i) &#147;implied per share merger consideration&#148; means approximately $207.94 per share, calculated as the (a)&nbsp;cash consideration of $145.00 per share and (b)&nbsp;implied value of the stock consideration of approximately $62.94 per
share based on a 0.8378x per share exchange ratio and an illustrative reference closing price for shares of CVS Health common stock of $75.12 per share as of December&nbsp;1, 2017, (ii) &#147;EBITDA&#148; means earnings before interest, income
taxes, depreciation and amortization, excluding certain <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">non-recurring</FONT> items, as applicable, and (iii) &#147;EPS&#148; means earnings per share, excluding
certain <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-recurring</FONT> or <FONT STYLE="white-space:nowrap">non-cash</FONT> items, as applicable. Financial data utilized for Aetna and CVS Health in the
financial analyses described below, to the extent based on internal financial forecasts and estimates of management, were based on financial forecasts and other data prepared by Aetna relating to the business of Aetna and financial forecasts and
other data prepared by CVS Health<B> </B>and<B> </B>as extrapolated per Aetna relating to the business of CVS Health, which are referred to for purposes of this section of this joint proxy statement/prospectus as the Aetna forecasts and the CVS
Health forecasts, respectively. Financial data of Aetna, when utilizing Aetna&#146;s closing share price on December&nbsp;1, 2017, were pro forma for Aetna&#146;s completed sale of its domestic group life insurance, group disability insurance and
absence management businesses based on internal data provided by the management of Aetna. Implied per share equity value reference ranges of Aetna and CVS Health reflected in the summaries of the financial analyses described below were rounded to
the nearest $1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Aetna Financial Analyses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis &#150; Perpetuity Growth Rate Methodology</I>. Lazard performed a discounted cash flow analysis of Aetna by
calculating, based on the Aetna forecasts, the estimated present value (as of December&nbsp;31, 2017) of the stand-alone unlevered, <FONT STYLE="white-space:nowrap">after-tax</FONT> free cash flows that Aetna was forecasted to generate during the
fiscal year ending December&nbsp;31, 2018 through the fiscal year ending December&nbsp;31, 2022. For purposes of this analysis, stock-based compensation was treated as a cash expense. Lazard calculated a range of estimated terminal values for Aetna
by applying a range of perpetuity growth rates of 2.0% to 3.0% to Aetna&#146;s stand-alone unlevered, <FONT STYLE="white-space:nowrap">after-tax</FONT> free cash flows during the fiscal year ending December&nbsp;31, 2022 (assuming, for purposes of
the terminal year, growth in risk-based capital contributions commensurate with premium revenue growth), which range of perpetuity growth rates was selected based on Lazard&#146;s professional judgment and taking into account, among other things,
the Aetna forecasts and trends in the overall economy generally and in the industries and sectors in which Aetna operates. The cash flows and range of terminal values were then discounted to present value (as of December&nbsp;31, 2017) using a
selected range of discount rates of 7.0% to 8.0% derived from a weighted average cost of capital calculation. This analysis indicated the following approximate implied per share equity value reference range for Aetna, as compared to the implied per
share merger consideration: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:102.05pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Reference Range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied&nbsp;Per&nbsp;Share</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Merger&nbsp;Consideration</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$152 &#150; $233</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$207.94</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis &#150; Exit Multiple Methodology</I>. Lazard performed a
discounted cash flow analysis of Aetna by calculating, based on the Aetna forecasts, the estimated present value (as of December&nbsp;31, 2017) of the stand-alone unlevered, <FONT STYLE="white-space:nowrap">after-tax</FONT> free cash flows that
Aetna was forecasted to generate during the fiscal year ending December&nbsp;31, 2018 through the fiscal year ending December&nbsp;31, 2022. For purposes of this analysis, stock-based compensation was treated as a cash expense. Lazard calculated a
range of estimated terminal values for Aetna by applying to Aetna&#146;s estimated EBITDA for the fiscal year ending December&nbsp;31, 2022 a range of EBITDA multiples of 10.0x to 11.0x selected based<B> </B>on Lazard&#146;s professional judgment
and taking into account, among other things, observed implied calendar year 2018 estimated EBITDA multiples for Aetna and the Aetna selected companies (as defined below under the heading &#147;&#151;<I>Selected Public Companies Analysis</I>&#148;)
noting, in particular, the calendar year 2018 estimated EBITDA multiples derived for Anthem, Inc. and Cigna Corporation. The cash flows and range of terminal values were then discounted to present value (as of December&nbsp;31, 2017) using a
selected range of discount rates of 7.0% to 8.0% derived from a weighted average cost of capital calculation. This analysis indicated the following approximate implied per share equity value reference range for Aetna, as compared to the implied per
share merger consideration: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:102.05pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Reference Range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied&nbsp;Per&nbsp;Share</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Merger&nbsp;Consideration</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$182 &#150; $208</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$207.94</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Public Companies Analysis</I>. <I></I>Lazard reviewed publicly available financial and stock
market information of Aetna and the following four selected large cap publicly traded managed care companies that, given business and financial characteristics, Lazard considered generally relevant for purposes of analysis, which are referred to for
purposes of this section of this joint proxy statement/prospectus as the Aetna selected companies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Anthem, Inc. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cigna Corporation </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Humana Inc. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">UnitedHealth Group Incorporated </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard reviewed, among other information, closing stock
prices as of, in the case of the Aetna selected companies, December&nbsp;1, 2017 (the last trading day prior to the date of the merger agreement) and, in the case of Aetna, December&nbsp;1, 2017 and October&nbsp;25, 2017 (the last trading day prior
to initial published reports regarding a potential acquisition of Aetna by CVS Health), as a multiple of calendar year 2018 estimated EPS. Lazard also reviewed enterprise values, calculated as fully diluted equity values based on closing stock
prices as of, in the case of the Aetna selected companies, December&nbsp;1, 2017 and, in the case of Aetna, December&nbsp;1, 2017 and October&nbsp;25, 2017, plus total debt, preferred stock and <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests (as applicable) and less unrestricted cash and cash equivalents and unconsolidated investments (as applicable), as a multiple of calendar year 2018 estimated EBITDA. Financial data of the Aetna selected companies were based on public
filings, publicly available Wall Street research analysts&#146; estimates and other publicly available information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard observed
overall low to high calendar year 2018 estimated EPS multiples and calendar year 2018 estimated EBITDA multiples for the Aetna selected companies based on closing stock prices on December&nbsp;1, 2017 of 18.0x to 21.4x (with a mean and a median of
19.6x) and 10.2x to 12.7x (with a mean and a median of 11.4x), respectively, noting, in particular, the calendar year 2018 estimated EPS multiples and calendar year 2018 estimated EBITDA multiples derived for Anthem, Inc. of 18.0x and 11.9x,
respectively, and the calendar year 2018 estimated EPS and calendar year 2018 estimated EBITDA multiples derived for Cigna Corporation of 18.3x and 10.9x, respectively. Lazard also noted that, based on closing prices for Aetna common shares on
December&nbsp;1, 2017 and October&nbsp;25, 2017 utilizing publicly available Wall Street research analysts&#146; estimates, the calendar year 2018 estimated EPS multiples observed for Aetna were 18.0x and 15.9x, respectively, and the calendar year
2018 estimated EBITDA multiples observed for Aetna were 10.7x and 9.8x, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard then applied selected ranges of calendar year 2018 estimated EPS and calendar year
2018 estimated EBITDA multiples derived from the Aetna selected companies of 17.0x to 19.0x and 10.0x to 12.0x, respectively, to corresponding data of Aetna utilizing the Aetna forecasts. This analysis indicated the following approximate implied per
share equity value reference ranges for Aetna, as compared to the implied per share merger consideration: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied&nbsp;Per Share Equity Value Reference
Ranges Based on:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied&nbsp;Per&nbsp;Share<BR>Merger&nbsp;Consideration</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Calendar&nbsp;Year&nbsp;2018&nbsp;Estimated</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EPS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Calendar&nbsp;Year&nbsp;2018&nbsp;Estimated</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$170 &#150; $190</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$163&nbsp;&#150;&nbsp;$200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$207.94</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Precedent Transactions Analysis. </I>Using publicly available information, Lazard reviewed
financial information relating to the following seven selected transactions involving target managed care organizations that, given business and financial characteristics, Lazard considered generally relevant for purposes of analysis, which are
referred to for purposes of this section of this joint proxy statement/prospectus as the Aetna selected transactions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Announced</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Acquiror</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Target</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">September 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Centene Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;New York State Catholic Health Plan, Inc. D/B/A Fidelis Care New
York</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">July 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Anthem, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Cigna Corporation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">July 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Aetna Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Humana Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">July 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Centene Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Health Net, Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">August 2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Aetna Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Coventry Health Care Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">July 2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;WellPoint, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Amerigroup Corporation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">October 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Cigna Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;HealthSpring, Inc.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard reviewed, among other information, transaction values of the Aetna selected transactions, calculated as
the enterprise values implied for the target companies based on the consideration paid or payable in the Aetna selected transactions, as a multiple, to the extent publicly available, of the target company&#146;s latest 12 months EBITDA as of the
applicable announcement date of such transaction. Financial data for the Aetna selected transactions were based on public filings, publicly available Wall Street research analysts&#146; estimates and other publicly available information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard observed overall low to high latest 12 months EBITDA multiples for the Aetna selected transactions of 8.0x to 16.2x (with a mean of
11.7x and a median of 12.6x and 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile multiples of 9.2x and 12.6x, respectively) noting, in particular, the latest 12 months
EBITDA multiples derived for the July 2015 Anthem, Inc./Cigna Corporation and the July 2015 Aetna Inc./Humana Inc. transactions of 12.5x and 12.6x, respectively. Lazard then applied a selected range of latest 12 months EBITDA multiples of 11.0x to
13.0x derived from the Aetna selected transactions to Aetna&#146;s calendar year 2017 estimated EBITDA utilizing the Aetna forecasts. This analysis indicated the following approximate implied per share equity value reference range for Aetna, as
compared to the implied per share merger consideration: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:102.05pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Reference Range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied&nbsp;Per&nbsp;Share</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Merger&nbsp;Consideration</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$170 &#150; $205</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$207.94</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>CVS Health Financial Analyses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis</I>. Lazard performed a discounted cash flow analysis of CVS Health by calculating, based on the CVS Health
forecasts, the estimated present value (as of December&nbsp;31, 2017) of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stand-alone unlevered, <FONT STYLE="white-space:nowrap">after-tax</FONT> free cash flows that CVS Health was forecasted to generate during the fiscal year ending December&nbsp;31, 2018 through
the fiscal year ending December&nbsp;31, 2022. For purposes of this analysis, stock-based compensation was treated as a cash expense. Lazard calculated a range of estimated terminal values for CVS Health by applying to CVS Health&#146;s estimated
EBITDA for the fiscal year ending December&nbsp;31, 2022 a range of EBITDA multiples of 9.0x to 10.0x selected based<B> </B>on Lazard&#146;s professional judgment and taking into account, among other things, observed implied calendar year 2018
estimated EBITDA multiples for the CVS Health selected companies (as defined below under the heading &#147;&#151;<I>Selected Public Companies Analysis</I>&#148;) and CVS Health. The cash flows and range of terminal values were then discounted to
present value (as of December&nbsp;31, 2017) using a selected range of discount rates of 6.0% to 7.0% derived from a weighted average cost of capital calculation. This analysis indicated the following approximate implied per share equity value
reference range for CVS Health, as compared to the per share closing price of CVS Health common stock on December&nbsp;1, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:102.05pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Reference Range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Per&nbsp;Share&nbsp;Closing&nbsp;Price<BR>of&nbsp;CVS&nbsp;Health&nbsp;Common</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Stock on December&nbsp;1,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2017</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$105 &#150; $122</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$75.12</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Public Companies Analysis</I>. <I></I>Lazard reviewed publicly available financial and stock
market information of CVS Health and the following seven selected publicly traded drug store companies, pharmacy benefit management services companies and mass merchant companies that, given certain business and financial characteristics, Lazard
considered generally relevant for purposes of analysis, consisting of two selected publicly traded drug store companies, which are referred to for purposes of this section of this joint proxy statement/prospectus as the selected drug store
companies; one pharmacy benefit management services company, which is referred to for purposes of this section of this joint proxy statement/prospectus as the selected PBM company; and four mass merchant companies, which are referred to for purposes
of this section of this joint proxy statement/prospectus as the selected mass merchant companies and, together with the selected drug store companies and the selected PBM company, as the CVS Health selected companies: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Selected Drug Store</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Companies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Selected PBM Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Selected Mass Merchant Companies</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Rite Aid Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Walgreens Boots Alliance, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Express Scripts Holding Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Costco Wholesale Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;The Kroger Co.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Target Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#149;&#8195;&#8194;&#8202;Wal-Mart</FONT> Stores, Inc.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard reviewed, among other information, closing stock prices as of December&nbsp;1, 2017 as a multiple, to
the extent meaningful, of calendar year 2018 estimated EPS. Lazard also reviewed enterprise values, calculated as fully diluted equity values based on closing stock prices on December&nbsp;1, 2017, plus total debt, preferred stock and <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interests (as applicable) and less cash and cash equivalents and unconsolidated investments (as applicable), as a multiple of calendar year 2018 estimated EBITDA. Financial data of the CVS Health
selected companies (pro forma for certain recent acquisitions or divestitures or the loss of certain commercial arrangements, as applicable) were based on public filings, publicly available Wall Street research analysts&#146; estimates and other
publicly available information and calendarized to a December&nbsp;31 <FONT STYLE="white-space:nowrap">year-end</FONT> when necessary. Financial data of CVS Health were pro forma for CVS Health&#146;s announced divestiture of RxCrossroads based on
publicly available information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall low to high calendar year 2018 estimated EPS multiples and calendar year 2018
estimated EBITDA multiples observed for the CVS Health selected companies were 8.5x to 28.1x and 6.5x to 13.9x, with overall low to high calendar year 2018 estimated EPS multiples and calendar year 2018 estimated EBITDA multiples observed for the
CVS Health selected companies as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selected drug store companies: low to high calendar year 2018 estimated EPS multiples and calendar year 2018 estimated EBITDA multiples of not meaningful (less than zero) to 12.5x and 6.8x to 8.4x, respectively;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selected PBM company: calendar year 2018 estimated EPS multiples utilizing publicly available Wall Street research analysts&#146; estimates both before and after taking into account the loss of a major commercial
arrangement of 8.5x and 12.1x, respectively, and calendar year 2018 estimated EBITDA multiples utilizing publicly available Wall Street research analysts&#146; estimates both before and after taking into account the loss of such commercial
arrangement of 6.5x and 9.0x, respectively; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selected mass merchant companies: low to high calendar year 2018 estimated EPS multiples and calendar year 2018 estimated EBITDA multiples of 13.0x to 28.1x and 6.5x to 13.9x, respectively. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard noted that the calendar year 2018 estimated EPS and calendar year 2018 estimated EBITDA multiples observed for CVS Health, utilizing
publicly available Wall Street research analysts&#146; estimates and based on CVS Health&#146;s closing stock price on December&nbsp;1, 2017, were 11.8x and 7.7x, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard then applied selected ranges of calendar year 2018 estimated EPS and calendar year 2018 estimated EBITDA multiples derived from the CVS
Health selected companies of 11.0x to 14.0x and 8.0x to 9.0x, respectively, to corresponding data of CVS Health utilizing the CVS Health forecasts. This analysis indicated the following approximate implied per share equity value reference ranges for
CVS Health, as compared to the per share closing price of CVS Health common stock on December&nbsp;1, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value Reference Ranges
Based on:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Per&nbsp;Share&nbsp;Closing&nbsp;Price</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">of CVS Health</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Common Stock on</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">December&nbsp;1, 2017</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Calendar Year 2018 Estimated</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EPS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Calendar&nbsp;Year&nbsp;2018&nbsp;Estimated</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$70 &#150; $89</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$80&nbsp;&#150;&nbsp;$92</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$75.12</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Certain Additional Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard observed certain additional information that was not considered part of its financial analyses for its opinion but was noted for
informational reference, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">undiscounted price targets for Aetna common shares and shares of CVS Health common stock as reflected in selected publicly available Wall Street research analysts&#146; reports prior to October&nbsp;25, 2017 (in the
case of Aetna) and prior to December&nbsp;1, 2017 (in the case of CVS Health), which indicated an overall low to high target share price range of $150 to $185 per share for Aetna common shares and an overall low to high target stock price range of
$73 to $97 per share for CVS Health common stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">historical trading prices of Aetna common shares and shares of CVS Health common stock during the <FONT STYLE="white-space:nowrap">52-week</FONT> period ended October&nbsp;25, 2017 (in the case of Aetna) and during the <FONT
STYLE="white-space:nowrap">52-week</FONT> period ended December&nbsp;1, 2017 (in the case of CVS Health), which indicated during the relevant periods low and high closing prices for Aetna common shares of approximately $105 and $163 per share,
respectively, and low and high closing prices for shares of CVS Health common stock of approximately $67 and $84, respectively. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Miscellaneous </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna selected Lazard as a financial advisor in connection with the merger based on, among other things, Lazard&#146;s reputation, experience
and familiarity with Aetna and the industries in which Aetna and CVS Health </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operate. Lazard, as part of its investment banking business, is regularly engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, private
placements and related financings, bankruptcy reorganizations and similar recapitalizations, negotiated underwritings, secondary distributions of listed and unlisted securities, and valuations for corporate and other purposes. In the ordinary
course, Lazard and its affiliates and employees may trade securities of Aetna, CVS Health<B> </B>and certain of their respective affiliates for their own accounts and for the accounts of their customers, may at any time hold a long or short position
in such securities, and may also trade and hold securities on behalf of Aetna, CVS Health and certain of their respective affiliates. The issuance of Lazard&#146;s opinion was approved by the Opinion Committee of Lazard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Lazard&#146;s financial advisory services, Aetna has agreed to pay Lazard an aggregate fee of $50<B></B>&nbsp;million, of which
$5&nbsp;million was payable upon delivery of Lazard&#146;s opinion and $45<B></B>&nbsp;million is contingent upon completion of the merger. Aetna also has agreed subject to certain limitations to reimburse Lazard&#146;s reasonable expenses and to
indemnify Lazard and related parties against certain liabilities, including liabilities under the federal securities laws, arising out of its engagement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard in the past provided certain investment banking services to Aetna and/or certain of its affiliates unrelated to the merger, for which
Lazard received compensation, including, during the <FONT STYLE="white-space:nowrap">two-year</FONT> period prior to the date of its opinion, having acted as a financial advisor to Aetna in connection with its potential acquisition of Humana (which
acquisition was not consummated), for which Lazard received from Aetna a fee of $5&nbsp;million upon delivery of its opinion to the Aetna board of directors in connection with such transaction. The financial advisory business of Lazard and its
affiliates did not provide services to CVS Health for which fees were received during the <FONT STYLE="white-space:nowrap">two-year</FONT> period prior to December&nbsp;3, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of Allen&nbsp;&amp; Company LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna also has engaged Allen&nbsp;&amp; Company as a financial advisor in connection with the proposed merger. In connection with this
engagement, Aetna requested that Allen&nbsp;&amp; Company render an opinion to the Aetna board of directors as to the fairness, from a financial point of view, to the holders of Aetna common shares of the consideration to be received by such holders
pursuant to the merger agreement. On December&nbsp;3, 2017, at a meeting of the Aetna board of directors held to evaluate the merger, Allen&nbsp;&amp; Company rendered an oral opinion, which was confirmed by delivery of a written opinion dated
December&nbsp;3, 2017, to the Aetna board of directors to the effect that, as of that date and based on and subject to the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken
described in such opinion, the consideration to be received by holders of Aetna common shares pursuant to the merger agreement was fair, from a financial point of view, to such holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of Allen&nbsp;&amp; Company&#146;s written opinion, dated December&nbsp;3, 2017, which describes the assumptions made,
procedures followed, matters considered and qualifications and limitations on the review undertaken, is attached as Annex C and is incorporated by reference herein in its entirety.<B> </B>The description of Allen&nbsp;&amp; Company&#146;s opinion
set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of Allen&nbsp;&amp; Company&#146;s opinion. <B>Allen</B><B></B><B>&nbsp;&amp; Company&#146;s opinion was intended for the benefit and use
of the Aetna board of directors (in its capacity as such) in connection with its evaluation of the merger consideration from a financial point of view and did not address any other terms, aspects or implications of the merger.
Allen</B><B></B><B>&nbsp;&amp; Company&#146;s opinion did not constitute a recommendation as to the course of action that Aetna (or the Aetna board of directors) should pursue in connection with the merger or otherwise address the merits of the
underlying decision by Aetna to engage in the merger, including in comparison to other strategies or transactions that might be available to Aetna or which Aetna might engage in or consider. Allen</B><B></B><B>&nbsp;&amp; Company&#146;s opinion does
not constitute advice or a recommendation to any shareholder as to how such shareholder should vote or act on any matter relating to the merger or otherwise. </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company&#146;s opinion reflected and gave effect to Allen&nbsp;&amp; Company&#146;s general familiarity with Aetna and CVS
Health as well as information that Allen&nbsp;&amp; Company received during the course of its assignment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including information provided by the managements of Aetna and CVS Health in the course of discussions relating to the merger as more fully described below. In arriving at its opinion,
Allen&nbsp;&amp; Company neither conducted a physical inspection of the properties or facilities of Aetna, CVS Health or any other entity nor made or obtained any evaluations or appraisals of the assets or liabilities (contingent, accrued,
derivative, <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet or otherwise) of Aetna, CVS Health or any other entity, or conducted any analysis concerning the solvency or fair value of Aetna, CVS Health or any other entity. Allen&nbsp;&amp;
Company is not an actuary and its services did not include any actuarial determination or evaluation by Allen&nbsp;&amp; Company or any attempt to evaluate actuarial assumptions or allowances for losses, uncollectible accounts, claims or other
matters and, accordingly, Allen&nbsp;&amp;&nbsp;Company assumed, without independent analysis, the appropriateness of, and expressed no opinion or view as to, reserves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In arriving at its opinion, Allen&nbsp;&amp; Company, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">reviewed the financial terms and conditions of the merger as reflected in a draft, dated December&nbsp;2, 2017, of the merger agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed certain publicly available historical business and financial information relating to Aetna and CVS Health, including public filings of Aetna and CVS Health and historical market prices for Aetna common shares
and shares of CVS Health common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed certain financial information relating to Aetna provided to or discussed with Allen&nbsp;&amp; Company by the management of Aetna, including certain internal financial forecasts, estimates and other financial
and operating data relating to Aetna prepared by the management of Aetna, which forecasts are referred to in this section of this joint proxy statement/prospectus as the Aetna forecasts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">reviewed certain financial information relating to CVS Health provided to or discussed with Allen&nbsp;&amp; Company by the managements of CVS Health and Aetna, including certain internal financial forecasts, estimates
and other financial and operating data relating to CVS Health prepared by the management of CVS Health and as extrapolated per the management of Aetna, which forecasts, as extrapolated, are referred to in this section of this joint proxy
statement/prospectus as the CVS Health forecasts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">held discussions with the managements of Aetna and CVS Health relating to the past and current operations, financial condition and prospects of Aetna and CVS Health; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">discussed with the managements of Aetna and CVS Health the strategic rationale for the merger and the potential synergies expected by such managements to result from the merger, including the timing and amount of, costs
to achieve, and capital expenditures associated with, such synergies, which are, collectively, referred to in this section of this joint proxy statement/prospectus as the synergies, and certain potential pro forma financial effects of the merger;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed certain publicly available information, including certain stock market data and financial information, relating to selected companies with businesses that Allen&nbsp;&amp; Company deemed generally
relevant in evaluating Aetna and CVS Health; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed certain publicly available financial information relating to selected transactions that Allen&nbsp;&amp; Company deemed generally relevant in evaluating the merger; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top">conducted such other financial analyses and investigations as Allen&nbsp;&amp; Company deemed necessary or appropriate for purposes of its opinion. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering its opinion, Allen&nbsp;&amp; Company relied upon and assumed, with Aetna&#146;s consent and without independent verification,
the accuracy and completeness of all of the financial, legal, regulatory, tax, accounting, actuarial and other information available to Allen&nbsp;&amp; Company from public sources, provided to or discussed with Allen&nbsp;&amp; Company by the
managements and/or other representatives of Aetna and CVS Health or otherwise reviewed by Allen&nbsp;&amp; Company. With respect to the Aetna forecasts and the synergies that Allen&nbsp;&amp; Company was
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directed to utilize for purposes of its analyses, Allen&nbsp;&amp; Company was advised by the management of Aetna, and Allen&nbsp;&amp; Company assumed, at the direction of Aetna, that such
financial forecasts, estimates and other financial and operating data were reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of such management as to, and were a reasonable basis upon which to
evaluate, the future financial and operating performance of Aetna, such synergies and the other matters covered thereby. With respect to the CVS Health forecasts (including, without limitation, extrapolations therefrom) that Allen&nbsp;&amp; Company
was directed to utilize for purposes of its analyses, Allen&nbsp;&amp; Company was advised by the managements of CVS Health and Aetna, as the case may be, and Allen&nbsp;&amp; Company assumed, at the direction of Aetna, that such financial
forecasts, estimates and other financial and operating data were reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of the respective managements of CVS Health and Aetna as to, and were a
reasonable basis upon which to evaluate, the future financial and operating performance of CVS Health and the other matters covered thereby. Allen&nbsp;&amp; Company also assumed, with the consent of Aetna, that the financial results, including,
without limitation, the synergies expected by the management of Aetna to result from the merger, reflected in the financial forecasts, estimates and other financial and operating data utilized in its analyses would be realized in the amounts and at
the times projected. Allen&nbsp;&amp; Company expressed no opinion or view as to any financial forecasts, estimates or other financial or operating data or the assumptions on which they were based. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company relied, at the direction of Aetna, upon the assessments of the managements of Aetna and CVS Health, as the case may
be, as to, among other things, (i)&nbsp;the potential impact on Aetna and CVS Health of certain market, cyclical, competitive and other trends and developments in and prospects for, and governmental, regulatory and legislative policies and matters
relating to or otherwise affecting, the health care industry and health care benefits sector thereof and the retail, pharmacy and pharmacy services industries, including, without limitation, laws and regulations relating to government subsidized
health care programs, capital requirements and reimbursement, (ii)&nbsp;existing and future contracts, agreements and arrangements relating to, and the ability to attract, retain and/or replace, key commercial relationships of, Aetna and CVS Health,
and (iii)&nbsp;the ability of CVS Health to integrate the operations of Aetna and CVS Health. Allen&nbsp;&amp; Company assumed, with the consent of Aetna, that there would be no developments with respect to any such matters that would have an
adverse effect on Aetna, CVS Health or the merger (including the contemplated benefits thereof) or that otherwise would be meaningful in any respect to its analyses or opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Allen&nbsp;&amp; Company&#146;s opinion was necessarily based on economic, monetary, market and other conditions as in effect on, and
the information made available to Allen&nbsp;&amp; Company as of, the date of its opinion. It should be understood that subsequent developments may affect the conclusion expressed in Allen&nbsp;&amp; Company&#146;s opinion and that Allen&nbsp;&amp;
Company assumed no responsibility for advising any person of any change in any matter affecting Allen&nbsp;&amp; Company&#146;s opinion or for updating or revising its opinion based on circumstances or events occurring after the date of its opinion.
As the Aetna board of directors was aware, the credit, financial and stock markets, and the industries in which Aetna and CVS Health operate, have experienced and continue to experience volatility and Allen&nbsp;&amp; Company expressed no opinion or
view as to any potential effects of such volatility on Aetna or CVS Health (or their respective businesses) or the merger (including the contemplated benefits thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Allen&nbsp;&amp; Company&#146;s engagement, Allen&nbsp;&amp; Company was not requested to, and it did not, solicit
third-party indications of interest with respect to the acquisition of all or a portion of Aetna. Allen&nbsp;&amp; Company did not express any opinion as to the fairness, financial or otherwise, of the amount, nature or any other aspect of any
compensation or other consideration payable to any officers, directors or employees of any party to the merger or any related entities, or any class of such persons or any other party, relative to the merger consideration or otherwise.
Allen&nbsp;&amp; Company expressed no opinion as to the actual value of shares of CVS Health common stock when issued in connection with the merger or the prices at which Aetna common shares or shares of CVS Health common stock (or any other
securities) may trade or otherwise be transferable at any time. In addition, Allen&nbsp;&amp; Company expressed no opinion or view as to any tax or other consequences that might result from the merger or otherwise, including, without limitation, the
potential impact of changes in U.S. health care </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and tax laws, regulations and governmental and legislative policies on Aetna, CVS Health or the merger (or the contemplated benefits thereof), nor did Allen&nbsp;&amp; Company express any opinion
or view as to, and Allen&nbsp;&amp; Company relied, at the direction of Aetna, upon the assessments of representatives of Aetna regarding, legal, regulatory, accounting, tax and actuarial matters relating to Aetna, CVS Health and the merger, as to
which Allen&nbsp;&amp; Company understood that Aetna obtained such advice as it deemed necessary from qualified professionals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company assumed, with the consent of Aetna, that the merger would be consummated in accordance with its terms and in
compliance with all applicable laws, documents and other requirements, without waiver, modification or amendment of any material term, condition or agreement, and that, in the course of obtaining the necessary governmental, regulatory or third party
approvals, consents, releases, waivers, decrees and agreements for the merger, no delay, limitation, restriction or condition, including any divestiture or other requirements or remedies, amendments or modifications, would be imposed or occur that
would have an adverse effect on Aetna, CVS Health or the merger (including the contemplated benefits thereof) or that otherwise would be meaningful in any respect to its analyses or opinion. Allen&nbsp;&amp; Company further assumed, with the consent
of Aetna, that the final executed merger agreement would not differ from the draft reviewed by Allen&nbsp;&amp; Company in any respect meaningful to Allen&nbsp;&amp; Company&#146;s analyses or opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company&#146;s opinion was limited to the fairness, from a financial point of view and as of its date, of the merger
consideration to be received by holders of Aetna common shares pursuant to the merger agreement, without regard to individual circumstances of holders of Aetna common shares that may distinguish such holders or the securities of Aetna held by such
holders, and Allen&nbsp;&amp; Company expressed no opinion or view with respect to any consideration received in connection with the merger by the holders of any other securities, creditors or other constituencies of any party. Allen&nbsp;&amp;
Company&#146;s opinion did not address any other terms, aspects or implications of the merger, including, without limitation, the form or structure of the merger or any terms, aspects or implications of any governance or other arrangements,
agreements or understandings entered into in connection with, related to or contemplated by the merger or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with
its opinion, Allen&nbsp;&amp; Company performed a variety of financial and comparative analyses, including those described below. The summary of the analyses below and certain factors considered is not a comprehensive description of all analyses
undertaken or factors considered by Allen&nbsp;&amp; Company. The preparation of a financial opinion or analysis is a complex process involving various determinations as to the most appropriate and relevant methods of financial analysis and the
application of those methods to the particular circumstances and, therefore, a financial opinion and analyses are not readily susceptible to summary description. Allen&nbsp;&amp; Company arrived at its opinion based on the results of all analyses
undertaken and assessed as a whole, and did not draw, in isolation, conclusions from or with regard to any one factor or method of analysis. Accordingly, Allen&nbsp;&amp; Company believes that the analyses and factors summarized below must be
considered as a whole and in context. Allen&nbsp;&amp; Company further believes that selecting portions of the analyses and factors or focusing on information presented in tabular format, without considering all analyses and factors or the narrative
description of the analyses and factors, could create a misleading or incomplete view of the processes underlying Allen&nbsp;&amp; Company&#146;s analyses and opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In performing its financial analyses, Allen&nbsp;&amp; Company considered industry performance, general business and economic, market and
financial conditions and other matters existing as of the date of its opinion, many of which are beyond the control of Aetna and CVS Health. No company, business or transaction reviewed is identical or directly comparable to Aetna, CVS Health or
their respective businesses or the merger and an evaluation of these analyses is not entirely mathematical; rather, the analyses involve complex considerations and judgments concerning financial and operating characteristics and other factors that
could affect the public trading, acquisition or other values of the companies, businesses or transactions reviewed. The estimates of the future performance of Aetna and CVS Health in or underlying Allen&nbsp;&amp; Company&#146;s analyses are not
necessarily indicative of actual values or actual future results, which may be significantly more or less favorable than those estimates or those suggested by such analyses. These analyses were prepared solely as part of Allen&nbsp;&amp;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s analysis of the fairness, from a financial point of view, of the merger consideration and were provided to the Aetna board of directors in connection with the delivery of
Allen&nbsp;&amp; Company&#146;s opinion. The analyses do not purport to be appraisals or to reflect the prices at which a company might actually be sold or the prices at which any securities have traded or may trade at any time in the future.
Accordingly, the assumptions and estimates used in, and the ranges of valuations resulting from, any particular analysis described below are inherently subject to substantial uncertainty and should not be taken as the views of Allen&nbsp;&amp;
Company regarding the actual values of Aetna or CVS Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company did not recommend that any specific consideration
constituted the only appropriate consideration in the merger. The type and amount of consideration payable in the merger was determined through negotiations between Aetna and CVS Health, rather than by any financial advisor, and was approved by the
Aetna board of directors. The decision to enter into the merger agreement was solely that of the Aetna board of directors and the CVS Health board of directors. Allen&nbsp;&amp; Company&#146;s opinion and analyses were only one of many factors
considered by the Aetna board of directors in its evaluation of the proposed merger and the merger consideration and should not be viewed as determinative of the views of the Aetna board of directors or management with respect to the merger or the
consideration payable in the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Financial Analyses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary of the financial analyses described in this section entitled &#147;&#151;<I>Financial Analyses</I>&#148; is a summary of the
material financial analyses provided by Allen&nbsp;&amp; Company in connection with its opinion, dated December&nbsp;3, 2017, to the Aetna board of directors. <B>The summary set forth below is not a comprehensive description of all analyses
undertaken by Allen</B><B></B><B>&nbsp;&amp; Company in connection with its opinion, nor does the order of the analyses in the summary below indicate that any analysis was given greater weight than any other analysis. The financial analyses
summarized below include information presented in tabular format. In order to fully understand the financial analyses performed by Allen</B><B></B><B>&nbsp;&amp; Company, the tables must be read together with the text of each summary. The tables
alone do not constitute a complete description of the financial analyses performed by Allen</B><B></B><B>&nbsp;&amp; Company. Considering the data set forth in the tables below without considering the full narrative description of the financial
analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses performed by Allen</B><B></B><B>&nbsp;&amp; Company. Future results may differ from those described
and such differences may be material.</B> For purposes of the financial analyses described below in this section of this joint proxy statement/prospectus, the term (i) &#147;implied per share merger consideration&#148; means approximately $207.94
per share, calculated as the (a)&nbsp;cash consideration of $145.00 per share and (b)&nbsp;implied value of the stock consideration of approximately $62.94 per share based on a 0.8378x per share exchange ratio and an illustrative reference closing
price for CVS Health common stock of $75.12 per share as of December&nbsp;1, 2017, (ii) &#147;EBITDA&#148; means earnings before interest, income taxes, depreciation and amortization, excluding certain
<FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">non-recurring</FONT> items, as applicable, and (iii) &#147;EPS&#148; means earnings per share, excluding certain <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT
STYLE="white-space:nowrap">non-recurring</FONT> or <FONT STYLE="white-space:nowrap">non-cash</FONT> items, as applicable. Financial data of Aetna, when utilizing Aetna&#146;s closing share price on December&nbsp;1, 2017, were pro forma for
Aetna&#146;s completed sale of its domestic group life insurance, group disability insurance and absence management businesses based on internal data provided by the management of Aetna. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Aetna Financial Analyses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis</I>. Allen&nbsp;&amp; Company performed a discounted cash flow analysis of Aetna by calculating, based on the
Aetna forecasts, the estimated present value (as of December&nbsp;1, 2017) of the stand-alone unlevered, <FONT STYLE="white-space:nowrap">after-tax</FONT> free cash flows that Aetna was forecasted to generate during the month ending
December&nbsp;31, 2017 through the full fiscal year ending December&nbsp;31, 2022. For purposes of this analysis, stock-based compensation was treated as a cash expense. Allen&nbsp;&amp; Company calculated a range of estimated terminal values for
Aetna by applying a range of perpetuity growth rates of 2.0% to 3.0% to Aetna&#146;s stand-alone unlevered, <FONT STYLE="white-space:nowrap">after-tax</FONT> free cash flows during the fiscal year ending December&nbsp;31, 2022 (assuming, for
purposes of the terminal year, growth in risk-based capital contributions commensurate with premium revenue growth), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which range of perpetuity growth rates was selected based on Allen &amp; Company&#146;s professional judgment and taking into account, among other things, the Aetna forecasts and trends in the
overall economy generally and in the industries and sectors in which Aetna operates. The cash flows and range of terminal values were then discounted to present value (as of December&nbsp;1, 2017) using a selected range of discount rates of 7.0% to
8.5% derived from a weighted average cost of capital calculation. This analysis indicated the following approximate implied per share equity value reference range for Aetna, as compared to the implied per share merger consideration: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:102.05pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Reference Range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied&nbsp;Per&nbsp;Share</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Merger&nbsp;Consideration</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$137 &#150; $231</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$207.94</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Public Companies Analysis</I>. <I></I>Allen&nbsp;&amp; Company reviewed publicly available
financial and stock market information of Aetna and the following four selected large cap publicly traded managed care companies that, given business and financial characteristics, Allen&nbsp;&amp; Company considered generally relevant for purposes
of analysis, which are referred to for purposes of this section of this joint proxy statement/prospectus as the Aetna selected companies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Anthem, Inc. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cigna Corporation </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Humana Inc. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">UnitedHealth Group Incorporated </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company reviewed, among other information,
closing stock prices as of, in the case of the Aetna selected companies, December&nbsp;1, 2017 (the last trading day prior to the date of the merger agreement) and, in the case of Aetna, October&nbsp;25,<B> </B>2017 (the last trading day prior to
initial published reports regarding a potential acquisition of Aetna by CVS Health) and December&nbsp;1, 2017, as a multiple of calendar year 2018 estimated EPS. Allen&nbsp;&amp; Company also reviewed enterprise values, calculated as fully diluted
equity values based on closing stock prices as of, in the case of the Aetna selected companies, December&nbsp;1, 2017 and, in the case of Aetna, October&nbsp;25,<B> </B>2017 and December&nbsp;1, 2017, plus total debt, preferred stock and <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interests (as applicable) and less unrestricted cash and cash equivalents and unconsolidated investments (as applicable), as a multiple of calendar year 2018 estimated EBITDA. Financial data of the
Aetna selected companies were based on public filings, publicly available Wall Street research analysts&#146; estimates and other publicly available information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall low to high calendar year 2018 estimated EPS multiples and calendar year 2018 estimated EBITDA multiples observed for the Aetna
selected companies based on closing stock prices on December&nbsp;1, 2017 were 18.0x to 21.4x (with a mean and a median of 19.6x) and 10.2x to 12.8x (with a mean of 11.4x and a median of 11.3x), respectively. Allen&nbsp;&amp; Company noted that the
calendar year 2018 estimated EPS multiples observed for Aetna, utilizing publicly available Wall Street research analysts&#146; estimates and the Aetna forecasts, were 15.9x and 16.0x, respectively (based on Aetna&#146;s closing share price on
October&nbsp;25, 2017), and 18.0x and 18.1x, respectively (based on Aetna&#146;s closing share price on December&nbsp;1, 2017). Allen&nbsp;&amp; Company also noted that the calendar year 2018 estimated EBITDA multiples observed for Aetna, utilizing
publicly available Wall Street research analysts&#146; estimates and the Aetna forecasts, were 9.6x and 10.2x, respectively (based on Aetna&#146;s closing share price on October&nbsp;25, 2017), and 10.6x and 11.0x, respectively (based on
Aetna&#146;s closing share price on December&nbsp;1, 2017). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company then applied selected ranges of calendar year 2018
estimated EPS and calendar year 2018 estimated EBITDA multiples derived from the Aetna selected companies of 18.0x to 20.0x and 10.0x to 12.0x, respectively, to corresponding data of Aetna utilizing the Aetna forecasts. This analysis indicated the
following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximate implied per share equity value reference ranges for Aetna, as compared to the implied per share merger consideration: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value Reference Ranges
Based on:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied&nbsp;Per&nbsp;Share<BR>Merger&nbsp;Consideration</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Calendar Year 2018 Estimated</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EPS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Calendar&nbsp;Year&nbsp;2018&nbsp;Estimated</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$180 &#150; $200</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$162&nbsp;&#150;&nbsp;$199</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$207.94</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Precedent Transactions Analysis. </I>Using publicly available information, Allen&nbsp;&amp;
Company reviewed financial information relating to the following seven selected transactions involving target managed care organizations that, given business and financial characteristics, Allen&nbsp;&amp; Company considered generally relevant for
purposes of analysis, which are referred to for purposes of this section of this joint proxy statement/prospectus as the Aetna selected transactions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Announced</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Acquiror</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Target</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">September 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Centene Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;New York State Catholic Health Plan, Inc. D/B/A Fidelis Care New
York</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">July 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Anthem, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Cigna Corporation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">July 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Aetna Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Humana Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">July 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Centene Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Health Net, Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">August 2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Aetna Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Coventry Health Care Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">July 2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;WellPoint, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Amerigroup Corporation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">October 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Cigna Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;HealthSpring, Inc.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company reviewed, among other information, transaction values of the Aetna selected
transactions, calculated as the enterprise values implied for the target companies based on the consideration paid or payable in the Aetna selected transactions, as a multiple, to the extent publicly available, of the target company&#146;s latest 12
months EBITDA and forward estimated EBITDA, as of the applicable announcement date of such transaction. Financial data for the Aetna selected transactions were based on public filings, publicly available Wall Street research analysts&#146; estimates
and other publicly available information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall low to high latest 12 months EBITDA multiples and forward estimated EBITDA
multiples observed for the Aetna selected transactions were 8.0x to 16.2x (with a mean of 11.7x and a median of 12.6x) and 7.2x to 12.3x (with a mean of 9.5x and a median of 9.8x), respectively. Allen&nbsp;&amp; Company then applied a selected range
of latest 12 months EBITDA multiples of 10.0x to 13.0x and forward estimated EBITDA multiples of 9.5x to 12.5x, in each case derived from the Aetna selected transactions, to Aetna&#146;s latest 12 months EBITDA (as of September&nbsp;30, 2017)
utilizing publicly available information and internal data provided by the management of Aetna and calendar year 2018 estimated EBITDA utilizing the Aetna forecasts. This analysis indicated the following approximate implied per share equity value
reference ranges for Aetna, as compared to the implied per share merger consideration: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value Reference Ranges
Based on:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied&nbsp;Per&nbsp;Share</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Merger&nbsp;Consideration</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Latest 12 Months</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Calendar Year 2018 Estimated</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$167 &#150; $224</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$153 &#150; $208</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$207.94</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shortly following the December&nbsp;3, 2017 meeting of the Aetna board of directors, Aetna discovered that in
calculating its latest 12 months EBITDA (as of September&nbsp;30, 2017) for its financial advisors, Aetna had inadvertently overstated the interest related to certain debt incurred in connection with the proposed Humana acquisition. Aetna confirmed
that the impact of the inclusion of the additional interest was immaterial and did not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affect any financial data provided to its financial advisors other than Aetna&#146;s latest 12 months EBITDA (as of September&nbsp;30, 2017). Applying the selected range of latest 12 months
EBITDA multiples referred to above to Aetna&#146;s corrected latest 12 months EBITDA (as of September&nbsp;30, 2017) would have indicated a lower approximate implied per share equity value reference range for Aetna derived from the analysis
described above of $161 to $216. The inclusion of the additional interest in the calculation of Aetna&#146;s latest 12 months EBITDA (as of September&nbsp;30, 2017) had no other impact on the financial analyses described in this section of the joint
proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>CVS Health Financial Analyses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis</I>. Allen&nbsp;&amp; Company performed a discounted cash flow analysis of CVS Health by calculating, based on
the CVS Health forecasts, the estimated present value (as of December&nbsp;1, 2017) of the stand-alone unlevered, <FONT STYLE="white-space:nowrap">after-tax</FONT> free cash flows that CVS Health was forecasted to generate during the month ending
December&nbsp;31, 2017 through the full fiscal year ending December&nbsp;31, 2022. For purposes of this analysis, stock-based compensation was treated as a cash expense. Allen&nbsp;&amp; Company calculated a range of estimated terminal values for
CVS Health by applying a range of perpetuity growth rates of 1.0% to 1.5% to CVS Health&#146;s stand-alone unlevered, <FONT STYLE="white-space:nowrap">after-tax</FONT> free cash flows during the fiscal year ending December&nbsp;31, 2022 (assuming,
for purposes of the terminal year, normalized depreciation, amortization, capital expenditures and sale-leaseback proceeds), which range of perpetuity growth rates was selected based on Allen &amp; Company&#146;s professional judgment and taking
into account, among other things, the CVS Health forecasts and trends in the overall economy generally and in the industries and sectors in which CVS Health operates. The cash flows and range of terminal values were then discounted to present value
(as of December&nbsp;1, 2017) using a selected range of discount rates of 6.0% to 7.5% derived from a weighted average cost of capital calculation. This analysis indicated the following approximate implied per share equity value reference range for
CVS Health, as compared to the per share closing price of CVS Health common stock on December&nbsp;1, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:102.05pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Reference Range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Per Share Closing Price</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">of CVS Health Common</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Stock on
December&nbsp;1,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2017</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$99 &#150; $149</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$75.12</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Public Companies Analysis</I>. <I></I>Allen&nbsp;&amp; Company reviewed publicly available
financial and stock market information of CVS Health and the following seven selected publicly traded drug store companies, pharmacy benefit management services companies and mass merchant companies that, given certain business and financial
characteristics, Allen&nbsp;&amp; Company considered generally relevant for purposes of analysis, which are referred to for purposes of this section of this joint proxy statement/prospectus as the CVS Health selected companies: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Costco Wholesale Corporation </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Express Scripts Holding Company </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Kroger Co. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Rite Aid Corporation </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Target Corporation </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Walgreens Boots Alliance, Inc. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Wal-Mart</FONT> Stores, Inc. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company
reviewed, among other information, closing stock prices as of, in the case of the CVS Health selected companies, December&nbsp;1, 2017 and, in the case of CVS Health, November&nbsp;29, 2017 (the last trading day prior to additional published reports
regarding a potential acquisition of Aetna by CVS Health) and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;1, 2017, as a multiple, to the extent meaningful, of calendar year 2018 estimated EPS. Allen&nbsp;&amp; Company also reviewed enterprise values, calculated as fully diluted equity
values based on closing stock prices as of, in the case of the CVS Health selected companies, December&nbsp;1, 2017 and, in the case of CVS Health, November&nbsp;29, 2017 and December&nbsp;1, 2017, plus total debt, preferred stock and <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interests (as applicable) and less cash and cash equivalents and unconsolidated investments (as applicable), as a multiple of calendar year 2018 estimated EBITDA. Financial data of the CVS Health
selected companies (pro forma for certain recent acquisitions or divestitures or the loss of certain commercial arrangements, as applicable) were based on public filings, publicly available Wall Street research analysts&#146; estimates and other
publicly available information and calendarized to a December&nbsp;31 <FONT STYLE="white-space:nowrap">year-end</FONT> when necessary. Financial data of CVS Health were pro forma for CVS Health&#146;s announced divestiture of RxCrossroads based on
publicly available information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall low to high calendar year 2018 estimated EPS multiples and calendar year 2018 estimated
EBITDA multiples observed for the CVS Health selected companies based on closing stock prices as of December&nbsp;1, 2017 were 12.5x to 27.8x (with a mean of 16.8x and a median of 13.5x) and 6.5x to 13.8x (with a mean of 8.7x and a median of 8.5x),
respectively. Allen&nbsp;&amp; Company noted that the calendar year 2018 estimated EPS multiples observed for CVS Health, utilizing publicly available Wall Street research analysts&#146; estimates and the CVS Health forecasts, were 11.6x and 11.6x,
respectively (based on CVS Health&#146;s closing stock price on November&nbsp;29, 2017), and 11.8x and 11.9x, respectively (based on CVS Health&#146;s closing stock price on December&nbsp;1, 2017). Allen&nbsp;&amp; Company also noted that the
calendar year 2018 estimated EBITDA multiples observed for CVS Health, utilizing publicly available Wall Street research analysts&#146; estimates and the CVS Health forecasts, were 7.6x and 7.4x, respectively (based on CVS Health&#146;s closing
stock price on November&nbsp;29, 2017), and 7.7x and 7.6x, respectively (based on CVS Health&#146;s closing stock price on December&nbsp;1, 2017). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company then applied selected ranges of calendar year 2018 estimated EPS and calendar year 2018 estimated EBITDA multiples
derived from the CVS Health selected companies of 11.0x to 14.0x and 8.0x to 9.0x, respectively, to corresponding data of CVS Health utilizing the CVS Health forecasts. This analysis indicated the following approximate implied per share equity value
reference ranges for CVS Health, as compared to the per share closing price of CVS Health common stock on December&nbsp;1, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Implied Per Share Equity Value Reference Ranges
Based on:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Per Share Closing Price</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">of CVS Health</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Common Stock on</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">December&nbsp;1, 2017</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Calendar Year 2018 Estimated</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EPS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Calendar Year 2018 Estimated</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$70 &#150; $89</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$81 &#150; $93</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$75.12</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Certain Additional Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company observed certain additional information that was not considered part of its financial analyses for its opinion but was
noted for informational reference, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">undiscounted price targets for Aetna common shares and shares of CVS Health common stock as reflected in selected publicly available Wall Street research analysts&#146; reports prior to October&nbsp;25, 2017 (in the
case of Aetna) and prior to December&nbsp;1, 2017 (in the case of CVS Health), which indicated an overall low to high target share price range of $150 to $185 per share for Aetna common shares and an overall low to high target stock price range of
$73 to $97 per share for CVS Health common stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">historical trading prices of Aetna common shares and shares of CVS Health common stock during the <FONT STYLE="white-space:nowrap">52-week</FONT> period ended October&nbsp;25, 2017 (in the case of Aetna) and during the <FONT
STYLE="white-space:nowrap">52-week</FONT> period ended December&nbsp;1, 2017 (in the case of CVS Health), which indicated during the relevant periods low and high closing prices for Aetna common shares of approximately $105 and $163 per share,
respectively, and low and high closing prices for shares of CVS Health common stock of approximately $67 and $84, respectively. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Miscellaneous </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna selected Allen&nbsp;&amp; Company as a financial advisor in connection with the merger based on, among other things, Allen&nbsp;&amp;
Company&#146;s reputation, experience and familiarity with Aetna and the industries in which Aetna and CVS Health operate. Allen&nbsp;&amp; Company, as part of its investment banking business, is regularly engaged in the valuation of businesses and
their securities in connection with mergers and acquisitions, private placements and related financings, bankruptcy reorganizations and similar recapitalizations, negotiated underwritings, secondary distributions of listed and unlisted securities,
and valuations for corporate and other purposes. In the ordinary course, Allen&nbsp;&amp; Company as a broker-dealer and certain of Allen&nbsp;&amp; Company&#146;s affiliates (including a senior member of the team assisting in providing
Allen&nbsp;&amp; Company&#146;s financial advisory services to Aetna in connection with the merger) and/or related entities have invested or may invest, hold long or short positions and may trade, either on a discretionary or <FONT
STYLE="white-space:nowrap">non-discretionary</FONT> basis, for their own account or for those of Allen&nbsp;&amp; Company&#146;s clients, in the debt and equity securities (or related derivative securities) of Aetna, CVS Health and/or their
respective affiliates. The issuance of Allen&nbsp;&amp; Company&#146;s opinion was approved by Allen&nbsp;&amp; Company&#146;s fairness opinion committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Allen&nbsp;&amp; Company&#146;s financial advisory services, Aetna has agreed to pay Allen&nbsp;&amp; Company an aggregate fee of
$50<B></B>&nbsp;million, of which $5&nbsp;million was payable upon delivery of Allen&nbsp;&amp; Company&#146;s opinion and $45<B></B>&nbsp;million is contingent upon completion of the merger. Aetna also has agreed subject to certain limitations to
reimburse Allen&nbsp;&amp; Company&#146;s reasonable expenses and to indemnify Allen&nbsp;&amp; Company and related parties against certain liabilities, including liabilities under the federal securities laws, arising out of its engagement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the Aetna board of directors was aware, Allen&nbsp;&amp; Company in the past has provided and in the future may provide, investment banking
services to Aetna and/or its affiliates unrelated to the merger, for which services Allen&nbsp;&amp; Company may receive compensation, including, during the <FONT STYLE="white-space:nowrap">two-year</FONT> period prior to December 3, 2017, acting or
having acted as financial advisor to Aetna in connection with certain potential transactions and strategic advisory matters, for which no fees were received. Allen&nbsp;&amp; Company and its affiliates did not provide financial advisory services to
CVS Health for which fees were received during the <FONT STYLE="white-space:nowrap">two-year</FONT> period prior to December&nbsp;
3, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_80"></A>Opinions of CVS Health&#146;s Financial Advisors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Opinions of Barclays Capital Inc. and Goldman Sachs&nbsp;&amp; Co. LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of Barclays Capital Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health engaged Barclays to act as its financial advisor with respect to the merger pursuant to an engagement letter dated
November&nbsp;30,&nbsp;2017. Barclays delivered its opinion to CVS Health&#146;s board of directors that, as of December&nbsp;3,&nbsp;2017 and based upon and subject to the qualifications, limitations, factors and assumptions set forth therein, the
merger consideration to be paid by CVS Health in the merger was fair, from a financial point of view, to CVS Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of
Barclays&#146; written opinion, dated as of December&nbsp;3,&nbsp;2017, is attached as Annex D to this joint proxy statement/prospectus. <B>Barclays&#146; written opinion sets forth, among other things, the assumptions made, procedures followed,
factors considered and limitations on the review undertaken by Barclays in connection with the opinion. You are encouraged to read the opinion carefully in its entirety. The following is a summary of Barclays&#146; opinion and the methodology that
Barclays used to render its opinion. This summary is qualified in its entirety by reference to the full text of the opinion.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays&#146; opinion, the issuance of which was approved by Barclays&#146; Valuation and Fairness Opinion Committee, is addressed to the
board of directors of CVS Health, addresses only the fairness, from a financial point of view, of the merger consideration to be paid by CVS Health in the merger and does not constitute a recommendation to any stockholder of CVS Health as to how
such stockholder should vote with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger or any other matter. Barclays was not requested to address, and its opinion does not in any manner address, CVS Health&#146;s underlying business decision to proceed with or effect the
merger, the likelihood of completion of the merger, or the relative merits of the merger as compared to any other transaction in which CVS Health may engage. In addition, Barclays expressed no opinion on, and its opinion does not in any manner
address, the fairness of the amount or the nature of any compensation to any officers, directors or employees of any parties to the merger, or any class of such persons, relative to the merger consideration to be paid by CVS Health in the merger. No
limitations were imposed by CVS Health&#146;s board of directors upon Barclays with respect to the investigations made or procedures followed by it in rendering its opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In arriving at its opinion, Barclays, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed the merger agreement and the specific terms of the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed publicly available information concerning CVS Health and Aetna that Barclays believed to be relevant to its analysis, including their respective Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31,&nbsp;2016 and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended September&nbsp;30, June&nbsp;30 and
March&nbsp;31,&nbsp;2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed financial and operating information with respect to the business, operations and prospects of CVS Health, including certain financial analyses, forecasts and projections of CVS Health prepared by
management of CVS Health, which are referred to for purposes of this section of this joint proxy statement/prospectus as the CVS Health forecasts, financial and operating information with respect to the business, operations and prospects of Aetna,
including certain financial analyses, forecasts and projections of Aetna prepared by management of CVS Health, which are referred to for purposes of this section of this joint proxy statement/prospectus as the adjusted Aetna forecasts, and certain
financial analyses, forecasts and projections of CVS Health on a pro forma basis giving effect to the merger prepared by the management of CVS Health, which are referred to for purposes of this section of this joint proxy statement/prospectus as the
CVS Health pro forma forecasts, in each case, as approved for Barclays&#146; and Goldman Sachs&#146; use by CVS Health, and financial and operating information with respect to the business, operations and prospects of Aetna prepared by management of
Aetna, which are referred to for purposes of this section of this joint proxy statement/prospectus as the Aetna forecasts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed the pro forma impact of the merger on the future financial performance of the combined company, including (i)&nbsp;certain financial and operating information with respect to the business,
operations and prospects of CVS Health on a pro forma basis giving effect to the merger, including the CVS Health pro forma forecasts and (ii)&nbsp;cost savings and operating synergies expected by the management of CVS Health to result from the
merger, which are referred to for purposes of this section of this joint proxy statement/prospectus as the expected synergies, in each case, as prepared and furnished to Barclays and Goldman Sachs by CVS Health and approved for Barclays&#146; and
Goldman Sachs&#146; use by CVS Health; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed the trading histories of shares of CVS Health common stock and Aetna common shares for the three years ending December&nbsp;1, 2017 and a comparison of those trading histories with those of other
companies that Barclays deemed relevant; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed a comparison of the historical financial results and present financial condition of CVS Health and Aetna with each other and with those of other companies that Barclays deemed relevant;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed a comparison of the financial terms of the merger as set forth in the merger agreement with the financial terms of certain other transactions that Barclays deemed relevant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed published estimates of independent research analysts with respect to the future financial performance and price targets of CVS Health and Aetna; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">had discussions with the managements of CVS Health and Aetna concerning Aetna&#146;s businesses, operations, assets, financial condition and prospects; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">had discussions with the management of CVS Health concerning CVS Health&#146;s businesses, operations, assets, financial condition and prospects; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">undertook such other studies, analyses and investigations as Barclays deemed appropriate. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
arriving at its opinion, Barclays assumed and relied upon the accuracy and completeness of the financial and other information used by Barclays without any independent verification of such information (and did not assume responsibility or liability
for any independent verification of such information). Barclays also relied upon the assurances of the management of CVS Health that they were not aware of any facts or circumstances that would make such information inaccurate or misleading in any
material respect. With respect to the CVS Health forecasts, upon the advice and at the instruction of CVS Health, Barclays assumed that such forecasts were reasonably prepared on a basis reflecting the best currently available estimates and
judgments of the management of CVS Health as to the future financial performance of CVS Health and that CVS Health would perform substantially in accordance with such forecasts. With respect to the Aetna forecasts, upon the advice and at the
instruction of CVS Health, Barclays assumed that such forecasts were reasonably prepared on a basis reflecting the best currently available estimates and judgments of the management of Aetna as to the future financial performance of Aetna. With
respect to the adjusted Aetna forecasts, upon the advice and at the instruction of CVS Health, Barclays assumed that such forecasts were reasonably prepared on a basis reflecting the best currently available estimates and judgments of the management
of CVS Health as to the future financial performance of Aetna and that Aetna would perform substantially in accordance with such forecasts. With respect to the CVS Health pro forma forecasts, upon the advice and at the instruction of CVS Health,
Barclays assumed that such forecasts were reasonably prepared on a basis reflecting the best currently available estimates and judgments of the management of CVS Health as to the future financial performance of CVS Health on a pro forma basis giving
effect to the merger, and that the pro forma company would perform substantially in accordance with such CVS Health pro forma forecasts. Furthermore, upon the advice and at the instruction of CVS Health, Barclays assumed that the amounts and timing
of the expected synergies were reasonable and that the expected synergies would be realized substantially in accordance with such estimates. In arriving at its opinion, Barclays assumed no responsibility for and expressed no view as to any such
forecasts or estimates or the assumptions on which they were based. In arriving at its opinion, Barclays did not conduct a physical inspection of the properties and facilities of CVS Health or Aetna and did not make or obtain any evaluations or
appraisals of the assets or liabilities of CVS Health or Aetna. Barclays is not an actuary, its services did not include any actuarial determination or evaluation by Barclays or any attempt to evaluate actuarial assumptions and Barclays has relied
on CVS Health&#146;s actuaries with respect to the adequacy of reserves for Aetna&#146;s insurance liabilities. Barclays&#146; opinion was necessarily based upon market, economic and other conditions as they existed on, and could be evaluated as of,
December&nbsp;3,&nbsp;2017. Barclays assumed no responsibility for updating or revising its opinion based on events or circumstances that may have occurred after December&nbsp;3,&nbsp;2017. Barclays expressed no opinion as to the prices at which the
Aetna common shares would trade following the announcement of the merger or the prices at which the shares of CVS Health common stock would trade following the announcement or completion of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays assumed the accuracy of the representations and warranties contained in the merger agreement and all the agreements related thereto.
Barclays also assumed, upon the advice and at the instruction of CVS Health, that all material governmental, regulatory and third party approvals, consents and releases for the merger would be obtained within the constraints contemplated by the
merger agreement and that the merger will be consummated in accordance with the terms of the agreement without waiver, modification or amendment of any material term, condition or agreement thereof. Barclays did not express any opinion as to any tax
or other consequences that might result from the merger, nor did Barclays&#146; opinion address any legal, tax, regulatory or accounting matters, as to which Barclays understood CVS Health had obtained such advice as it deemed necessary from
qualified professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays is an internationally recognized investment banking firm and, as part of its investment banking
activities, is regularly engaged in the valuation of businesses and their securities in connection with mergers and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquisitions, investments for passive and control purposes, negotiated underwritings, competitive bids, secondary distributions of listed and unlisted securities, private placements and
valuations for estate, corporate and other purposes. CVS Health&#146;s board of directors selected Barclays because of its familiarity with CVS Health and its qualifications, reputation and experience in the valuation of businesses and securities in
connection with mergers and acquisitions generally, as well as its substantial experience in transactions comparable to the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays is acting as financial advisor to CVS Health in connection with the merger. As compensation for its services in connection with the
merger, CVS Health has agreed to pay Barclays a transaction fee of $52&nbsp;million, $5&nbsp;million of which became payable upon the delivery of the Barclays opinion, and the remainder of which is contingent upon completion of the merger. The
opinion fee was not contingent upon the conclusion of Barclays&#146; opinion or completion of the merger. In addition, CVS Health has agreed to reimburse Barclays for its reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the merger and to indemnify Barclays for certain liabilities that may arise out of its engagement by CVS Health and
the rendering of Barclays&#146; opinion. Barclays and its affiliates have performed various investment banking and financial services for CVS Health, Aetna and their respective affiliates in the past, and expect to perform such services in the
future, and have received, and expect to receive, customary fees for such services. Specifically, in the past two years, Barclays and its affiliates have performed the following investment banking and financial services: (i)&nbsp;for CVS Health or
its affiliates, (A)&nbsp;acting as exclusive financial advisor to CVS Health in connection with the pending sale of its RxCrossroads reporting unit, (B)&nbsp;having acted as Joint Placement Agent on a $243&nbsp;million sale-leaseback private
placement in August 2017, (C) having acted as Joint Bookrunner and <FONT STYLE="white-space:nowrap">Co-Syndication</FONT> Agent on the refinancing of CVS Health&#146;s $1&nbsp;billion existing five-year revolving credit facility, (D)&nbsp;having
acted as Joint Bookrunner, Joint Lead Arranger and <FONT STYLE="white-space:nowrap">Co-Documentation</FONT> Agent on the issuance of a new $1&nbsp;billion revolving credit facility to CVS Health in May 2017, (E)&nbsp;having acted as Sole Bookrunner,
Sole Lead Arranger and Administrative Agent in the creation of a $2.5&nbsp;billion bilateral revolving credit facility for CVS Health in January 2017, (F) having acted as Sole Structuring Advisor and Joint Placement Agent on a $205&nbsp;million
sale-leaseback private placement by CVS Health in July 2016, (G) having acted as Joint Dealer Manager on a $3.1&nbsp;billion tender offer by CVS Health for senior notes in May 2016, (H) having acted as Joint Active Bookrunner on a $3.5&nbsp;billion
senior notes offering by CVS Health in May 2016, (I) having acted as exclusive financial advisor to CVS Health in the $1.9&nbsp;billion acquisition of Target Corporation&#146;s pharmacy and clinic businesses in December 2015 and (J)&nbsp;acting as a
tier 1 lender under certain of CVS Health&#146;s revolving credit facilities; and (ii)&nbsp;for Aetna or its affiliates, (A)&nbsp;having acted as exclusive financial advisor to Aetna in connection with the sale of its domestic group life insurance,
group disability insurance and absence management businesses to Hartford Life and Accident Insurance Company for $1.45&nbsp;billion in November 2017, (B)&nbsp;having acted as Senior <FONT STYLE="white-space:nowrap">Co-Manager</FONT> on a
$1&nbsp;billion bond offering by Aetna in August 2017, (C)&nbsp;having acted as Bridge Lender on a $13&nbsp;billion bridge loan and $3.2&nbsp;billion delayed-draw term loan to Aetna in June 2016, (D) having acted as Joint Book-Running Manager on a
$13&nbsp;billion bond offering by Aetna in June 2016 and (E)&nbsp;acting as a lender under Aetna&#146;s revolving credit facility. During the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;3, 2017, Barclays received
compensation for investment banking and financial services provided by its investment banking division to CVS Health and/or its affiliates of $23&nbsp;million. During the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;3,
2017, Barclays received compensation for investment banking and financial services provided by its investment banking division to Aetna and/or its affiliates of $28&nbsp;million. In addition, at the request of CVS Health, an affiliate of Barclays
(i)&nbsp;entered into financing commitments and agreements with other banks and financial institutions to provide CVS Health with a $49&nbsp;billion <FONT STYLE="white-space:nowrap">364-day</FONT> senior unsecured bridge facility and
(ii)&nbsp;entered into a first amendment to each of CVS Health&#146;s existing revolving credit facilities (consisting of (A)&nbsp;a $1.0&nbsp;billion, <FONT STYLE="white-space:nowrap">364-day</FONT> unsecured credit facility expiring on
May&nbsp;17, 2018, (B) a $1.25&nbsp;billion, five-year unsecured <FONT STYLE="white-space:nowrap">back-up</FONT> credit facility expiring on July&nbsp;24, 2019, (C) a $1.25&nbsp;billion, five-year unsecured backup credit facility expiring on
July&nbsp;1, 2020 and (D)&nbsp;a $1.0&nbsp;billion, five-year unsecured <FONT STYLE="white-space:nowrap">back-up</FONT> credit facility expiring on May&nbsp;18, 2022) with other banks and financial institutions party thereto. An affiliate of
Barclays acted as joint lead arranger and joint bookrunner and acts as one of the lenders and administrative agent, in each case, on a senior unsecured term loan facility in an aggregate principal amount of $5.0&nbsp;billion consisting of a
$3.0&nbsp;billion three-year tranche and a $2.0&nbsp;billion five-year tranche. An affiliate of Barclays may also act as active lead joint bookrunner with respect to a bond issuance by CVS Health. The actual amount of aggregate fees to be received
by Barclays and its affiliates in connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the debt financing for the merger will depend upon, among other things, the timing of reductions of the bridge loan commitments, the completion date of the merger, CVS Health&#146;s credit rating
and the issuance costs for such debt financing. CVS Health estimates that Barclays and its affiliates will in aggregate receive approximately $142&nbsp;million in fees in connection with the bridge loan facility, term loan facility and bond
issuance. This estimate is based on various assumptions, including, without limitation, that CVS Health will incur permanent debt financing in connection with the proposed transaction and will receive an investment grade credit rating from
Moody&#146;s and S&amp;P. Also, Barclays and its affiliates have executed various share repurchase, hedging, derivative and other securities transactions and provided other risk management and equity origination services for CVS Health and its
affiliates, as well as executed various hedging, derivative and other securities transactions and provided other risk management and equity origination services for Aetna and its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays and its affiliates engage in a wide range of businesses, including investment and commercial banking, lending, asset management and
other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> services. In the ordinary course of their businesses,&nbsp;Barclays and&nbsp;its affiliates may actively trade and effect transactions in the equity, debt and/or other
securities (and any derivatives thereof) and financial instruments (including loans and other obligations) of CVS Health and Aetna for their own accounts and for the accounts of their customers and, accordingly, may at any time hold long or short
positions and investments in such securities and financial instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed under &#147;Aetna Proposal I: Approval and Adoption
of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of Directors that CVS Health Stockholders Approve the Stock Issuance&#148;
beginning on page 106 of this joint proxy statement/prospectus, Barclays&#146; opinion to CVS Health&#146;s board of directors was one of many factors taken into consideration by the CVS Health board of directors in making its determination to
approve the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of Goldman Sachs&nbsp;&amp; Co. LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs delivered its opinion to CVS Health&#146;s board of directors that, as of December&nbsp;3, 2017 and based upon and subject to the
qualifications, limitations, factors and assumptions set forth therein, the merger consideration to be paid by CVS Health in the merger was fair, from a financial point of view, to CVS Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of the written opinion of Goldman Sachs &amp; Co. LLC, dated as of December&nbsp;3, 2017, is attached as Annex E to this joint
proxy statement/prospectus. <B>Goldman Sachs&#146; written opinion sets forth, among other things, the assumptions made, procedures followed, factors considered and limitations on the review undertaken by Goldman Sachs in connection with the
opinion. Goldman Sachs provided advisory services and its opinion for the information and assistance of CVS Health&#146;s board of directors in connection with its consideration of the merger.</B> The Goldman Sachs opinion is not a recommendation as
to how any holder of shares of CVS Health common stock or Aetna common shares should vote with respect to the merger or any other matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with rendering the opinion described above and performing its related financial analyses, Goldman Sachs reviewed, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the merger agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">annual reports to shareholders and Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of CVS Health and Aetna for each of the five years ended December&nbsp;31, 2016; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain interim reports to shareholders and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of CVS Health and Aetna; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain other communications from CVS Health and Aetna to their respective shareholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain publicly available research analyst reports for CVS Health and Aetna; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Aetna forecasts, the CVS Health forecasts, the adjusted Aetna forecasts and the CVS Health pro forma forecasts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expected synergies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs also held discussions with members of the senior
managements of CVS Health and Aetna regarding their assessment of the past and current business operations, financial condition and future prospects of Aetna and with the members of senior management of CVS Health regarding their assessment of the
past and current business operations, financial condition and future prospects of CVS Health and the strategic rationale for, and the potential benefits of, the merger; reviewed the reported price and trading activity for the shares of CVS Health
common stock and the Aetna common shares; compared certain financial and stock market information for CVS Health and Aetna with similar information for certain other companies the securities of which are publicly traded; reviewed the financial terms
of certain recent business combinations in the health insurance industry and in other industries; and performed such other studies and analyses, and considered such other factors, as it deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of rendering this opinion, Goldman Sachs, with CVS Health&#146;s consent, relied upon and assumed the accuracy and completeness
of all of the financial, legal, regulatory, tax, accounting and other information provided to, discussed with or reviewed by it, without assuming any responsibility for independent verification thereof. In that regard, Goldman Sachs assumed with CVS
Health&#146;s consent that the CVS Health forecasts, the adjusted Aetna forecasts, the CVS Health pro forma forecasts and the expected synergies were reasonably prepared on a basis reflecting the best currently available estimates and judgments of
the management of CVS Health. Goldman Sachs did not make an independent evaluation or appraisal of the assets and liabilities (including any contingent, derivative or other <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> assets and
liabilities) of CVS Health or Aetna or any of their respective subsidiaries and it was not furnished with any such evaluation or appraisal. Goldman Sachs is not an actuary and its services did not include any actuarial determination or evaluation by
Goldman Sachs or any attempt to evaluate actuarial assumptions, and Goldman Sachs has relied on CVS Health&#146;s actuaries with respect to reserve adequacy. In that regard, Goldman Sachs has made no analysis of, and expressed no opinion as to, the
adequacy of the loss and loss adjustments expenses reserves, the future policy benefit reserves, the long-term business provision and claims outstanding or the embedded value of CVS Health and Aetna. Goldman Sachs assumed that all governmental,
regulatory or other consents and approvals necessary for completion of the merger will be obtained without any adverse effect on CVS Health or Aetna or on the expected benefits of the merger in any way meaningful to its analysis. Goldman Sachs has
also assumed that the merger will be consummated on the terms set forth in the merger agreement, without the waiver or modification of any term or condition the effect of which would be in any way meaningful to its analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs&#146; opinion does not address the underlying business decision of CVS Health to engage in the merger or the relative merits of
the merger as compared to any strategic alternatives that may be available to CVS Health; nor does it address any legal, regulatory, tax or accounting matters. Goldman Sachs&#146; opinion addresses only the fairness from a financial point of view to
CVS Health, as of the date of the opinion, of the merger consideration to be paid by CVS Health in the merger. Goldman Sachs&#146; opinion does not express any view on, and does not address, any other term or aspect of the merger agreement or the
merger or any term or aspect of any other agreement or instrument contemplated by the merger agreement or entered into or amended in connection with the merger, including the fairness of the merger to, or any consideration received in connection
therewith by, the holders of any class of securities, creditors or other constituencies of CVS Health; nor as to the fairness of the amount or nature of any compensation to be paid or payable to any of the officers, directors or employees of CVS
Health or Aetna, or any class of such persons in connection with the merger, whether relative to the merger consideration to be paid by CVS Health in the merger or otherwise. Goldman Sachs&#146; opinion was necessarily based on economic, monetary,
market and other conditions, as in effect on, and the information made available to it as of, the date of the opinion, and Goldman Sachs assumed no responsibility for updating, revising or reaffirming its opinion based on circumstances, developments
or events occurring after the date of its opinion. In addition, Goldman Sachs does not express any opinion as to the prices at which shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of CVS Health common stock will trade at any time or as to the impact of the merger on the solvency or viability of CVS Health or Aetna or the ability of CVS Health or Aetna to pay their
respective obligations when they come due. Goldman Sachs&#146; opinion was approved by a fairness committee of Goldman Sachs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman
Sachs and its affiliates are engaged in advisory, underwriting and financing, principal investing, sales and trading, research, investment management and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and
services for various persons and entities. Goldman Sachs and its affiliates and employees, and funds or other entities they manage or in which they invest or have other economic interests or with which they
<FONT STYLE="white-space:nowrap">co-invest,</FONT> may at any time purchase, sell, hold or vote long or short positions and investments in securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments
of CVS Health, Aetna and any of their respective affiliates and third parties, or any currency or commodity that may be involved in the merger contemplated by the merger agreement for the accounts of Goldman Sachs and its affiliates and employees
and their customers. Goldman Sachs acted as financial advisor to CVS Health in connection with, and participated in certain of the negotiations leading to, the merger. At the request of CVS Health, an affiliate of Goldman Sachs (i)&nbsp;entered into
financing commitments and agreements with other banks and financial institutions to provide CVS Health with a $49&nbsp;billion <FONT STYLE="white-space:nowrap">364-day</FONT> senior unsecured bridge facility and (ii)&nbsp;entered into a first
amendment to each of CVS Health&#146;s existing revolving credit facilities (consisting of (A)&nbsp;a $1.0&nbsp;billion, <FONT STYLE="white-space:nowrap">364-day</FONT> unsecured credit facility expiring on May&nbsp;17, 2018, (B) a
$1.25&nbsp;billion, five-year unsecured <FONT STYLE="white-space:nowrap">back-up</FONT> credit facility expiring on July&nbsp;24, 2019, (C) a $1.25&nbsp;billion, five-year unsecured <FONT STYLE="white-space:nowrap">back-up</FONT> credit facility
expiring on July&nbsp;1, 2020 and (D)&nbsp;a $1.0&nbsp;billion, five-year unsecured <FONT STYLE="white-space:nowrap">back-up</FONT> credit facility expiring on May&nbsp;18, 2022) with other banks and financial institutions party thereto. An
affiliate of Goldman Sachs acted as joint lead arranger and joint bookrunner and acts as one of the lenders and administrative agent, in each case, on a senior unsecured term loan facility in an aggregate principal amount of $5.0&nbsp;billion
consisting of a $3.0&nbsp;billion three-year tranche and a $2.0&nbsp;billion five-year tranche. An affiliate of Goldman Sachs may also act as active lead joint bookrunner with respect to a bond issuance by CVS Health. The actual amount of aggregate
fees to be received by Goldman Sachs and its affiliates in connection with the debt financing for the merger will depend upon, among other things, the timing of reductions of the bridge loan commitments, the completion date of the merger, CVS
Health&#146;s credit rating and the issuance costs for such debt financing. CVS Health estimates that Goldman Sachs and its affiliates will in aggregate receive approximately $142&nbsp;million in fees in connection with the bridge loan facility,
term loan facility and bond issuance. This estimate is based on various assumptions, including, without limitation, that CVS Health will incur permanent debt financing in connection with the proposed transaction and will receive an investment grade
credit rating from Moody&#146;s and S&amp;P. Except as disclosed herein with respect to the contemplated transaction, during the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;3, 2017, the Investment Banking Division of
Goldman Sachs has not been engaged by CVS Health or its affiliates to provide financial advisory or underwriting services for which Goldman Sachs has received compensation. Goldman Sachs has provided certain investment banking services to Aetna and
its affiliates from time to time for which the Investment Banking Division of Goldman Sachs has received, and may receive, compensation, including having acted as lead bookrunner in the structuring of catastrophe bonds (aggregate principal amount
$200 million) by Vitality Re VII Limited, a vehicle linked to a portfolio of Aetna insurance products, in January 2016; as lead bookrunner in the structuring of catastrophe bonds (aggregate principal amount $200 million) by Vitality Re VIII Limited,
a vehicle linked to a portfolio of Aetna insurance products, in January 2017; and as <FONT STYLE="white-space:nowrap">co-manager</FONT> with respect to a $1&nbsp;billion bond offering by Aetna in August 2017. During the <FONT
STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;3, 2017, Goldman Sachs received compensation for financial advisory and/or underwriting services provided by its Investment Banking Division to Aetna and/or its affiliates of less
than $5&nbsp;million. Goldman Sachs may also in the future provide investment banking services to CVS Health, Aetna and their respective affiliates for which the Investment Banking Division of Goldman Sachs may receive compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of CVS Health selected Goldman Sachs as its financial advisor because it is an internationally recognized investment
banking firm that has substantial experience in transactions similar to the merger. Pursuant to a letter agreement dated November&nbsp;30, 2017, CVS Health engaged Goldman Sachs to act as its financial advisor in connection with the contemplated
merger. Pursuant to an engagement letter between CVS Health and Goldman Sachs, CVS Health has agreed to pay Goldman Sachs a transaction fee of $52&nbsp;million, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$5&nbsp;million of which became payable upon execution of the merger agreement, and the remainder of which is contingent upon completion of the merger. In addition, CVS Health has agreed to
reimburse Goldman Sachs for certain of its expenses, including attorneys&#146; fees and disbursements, and to indemnify Goldman Sachs and related persons against various liabilities, including certain liabilities under the federal securities laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed under &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock
Issuance&#151;CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of Directors that CVS Health Stockholders Approve the Stock Issuance&#148; beginning on page 106 of this joint proxy statement/prospectus, Goldman
Sachs&#146; opinion to CVS Health&#146;s board of directors was one of many factors taken into consideration by the CVS Health board of directors in making its determination to approve the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Material Financial Analyses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material financial analyses used by Barclays and Goldman Sachs in preparing their respective opinions to CVS
Health&#146;s board of directors. The following summary is not a complete description of the analyses and reviews underlying their opinions, nor does the order of analyses described represent relative importance or weight given to those analyses.
The preparation of a fairness opinion is a complex process and involves various determinations as to the most appropriate and relevant methods of financial and comparative analyses and the application of those methods to the particular
circumstances. Therefore, a fairness opinion is not readily susceptible to summary description. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with rendering their
respective opinions, Barclays and Goldman Sachs performed certain financial, comparative and other analyses as summarized below. In arriving at their respective opinions, Barclays and Goldman Sachs did not ascribe a specific range of values to Aetna
common shares or shares of CVS Health common stock but rather made their determinations as to fairness, from a financial point of view, to CVS Health of the merger consideration to be paid by CVS Health in the merger on the basis of various
financial and comparative analyses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In arriving at their respective opinions, Barclays and Goldman Sachs did not attribute any particular
weight to any single analysis or factor considered by them but rather made their determinations as to fairness on the basis of their experience and professional judgment after considering the results of all of their analyses and made qualitative
judgments as to the significance and relevance of each analysis and factor relative to all other analyses and factors performed and considered by them and in the context of the circumstances of the particular transaction. Accordingly, Barclays and
Goldman Sachs believe that their respective analyses must be considered as a whole, as considering any portion of such analyses and factors, without considering all analyses and factors as a whole, could create a misleading or incomplete view of the
process underlying their respective opinions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of their analyses and reviews, Barclays and Goldman Sachs made numerous
assumptions with respect to industry performance, general business, economic, market and financial conditions and other matters, many of which are beyond the control of CVS Health, Aetna or any other parties to the merger. No company, business or
transaction considered in Barclays&#146; or Goldman Sachs&#146; analyses and reviews is identical to CVS Health, Aetna or the proposed transaction, and an evaluation of the results of those analyses and reviews is not entirely mathematical. Rather,
the analyses and reviews involve complex considerations and judgments concerning financial and operating characteristics and other factors that could affect the acquisition, public trading or other values of the companies, businesses or transactions
considered in Barclays&#146; and Goldman Sachs&#146; analyses and reviews. None of CVS Health, Aetna, Barclays, Goldman Sachs or any other person assumes responsibility if future results are materially different from those discussed. Any estimates
or forecasts of future results contained in these analyses and reviews and the ranges of valuations resulting from any particular analysis or review are not necessarily indicative of actual values or predictive of future results or values, which may
be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of companies, businesses or securities do not purport to be appraisals or reflect the prices at which the companies,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
businesses or securities may actually be sold. Accordingly, the estimates used in, and the results derived from, Barclays&#146; and Goldman Sachs&#146; analyses and reviews are inherently subject
to substantial uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary of the financial analyses and reviews summarized below includes information presented in tabular
format. In order to fully understand the financial analyses and reviews used by Barclays and Goldman Sachs, the tables must be read together with the text of each summary, as the tables alone do not constitute a complete description of the financial
analyses and reviews. Considering the data in the tables below without considering the full description of the analyses and reviews, including the methodologies and assumptions underlying the analyses and reviews, could create a misleading or
incomplete view of Barclays&#146; and Goldman Sachs&#146; analyses and reviews. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before
December&nbsp;1, 2017, the last trading day before the public announcement of the transaction, and is not necessarily indicative of current market conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the merger were determined through <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations between CVS Health and
Aetna and were unanimously approved by CVS Health&#146;s board of directors. Barclays and Goldman Sachs provided advice to CVS Health during these negotiations. Barclays and Goldman Sachs did not recommend any specific form or amount of
consideration to the board of directors of CVS Health or that any specific form or amount of consideration constituted the only appropriate consideration for the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Selected Comparable Company Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to assess how the public market values shares of similar publicly traded companies and to provide a range of relative implied equity
values per Aetna common share by reference to those companies, Barclays reviewed and compared specific financial and operating data relating to Aetna with selected companies that Barclays, based on its experience in the managed care industry, deemed
comparable to Aetna. The selected comparable companies with respect to Aetna were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">UnitedHealth Group Incorporated </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Anthem, Inc. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cigna Corporation </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Humana Inc. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays calculated and compared various financial multiples and ratios of Aetna
and the selected comparable companies. As part of its selected comparable company analysis, Barclays calculated and analyzed each company&#146;s ratio of its stock price as of December&nbsp;1, 2017 to its projected adjusted earnings per share, which
is referred to for purposes of this section of this joint proxy statement/prospectus as a price to earnings ratio or P/E multiple. Where applicable, the P/E multiples were adjusted to account for certain events such as acquisitions and divestitures.
All of these calculations were performed and based on publicly available financial data (including Wall Street research, FactSet data and SEC filings) and closing prices as of December&nbsp;1, 2017, the last trading date prior to the delivery of
Barclays&#146; opinion, and the adjusted Aetna forecasts. The selected comparable company analysis provides an illustrative valuation of Aetna and the selected comparable companies in a stand-alone context and not in a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> context. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The high, mean, median and low
adjusted P/E multiples for calendar year 2018 observed for the selected companies were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2018E&nbsp;Adj.&nbsp;P/E&nbsp;Multiples</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>High</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">21.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mean</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19.6</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Median</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19.6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Low</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18.0</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays selected the comparable companies listed above because of similarities in one or
more business or operating characteristics with Aetna. However, because of the inherent differences between the business, operations and prospects of Aetna and those of the selected comparable companies, Barclays believed that it was inappropriate
to, and therefore did not, rely solely on the quantitative results of the selected comparable company analysis. Accordingly, Barclays also made qualitative judgments concerning differences between the business, financial and operating
characteristics and prospects of Aetna and the selected comparable companies that could affect the public trading values of each in order to provide a context in which to consider the results of the quantitative analysis. These qualitative judgments
related primarily to the differing sizes, growth prospects, profitability levels and degree of operational risk between Aetna and the companies included in the selected comparable company analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon these judgments and its experience, Barclays selected a range of 17.0x to 18.5x multiples of the projected 2018 adjusted earnings
per share, which is referred to for purposes of this section of this joint proxy statement/prospectus as EPS, for Aetna and applied such range to the projected 2018 adjusted EPS of $10.01 based on the adjusted Aetna forecasts to calculate a range,
rounded to the nearest $0.25, of implied equity values per Aetna common share as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="40%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:93.65pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Selected Adj. P/E
Multiples</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied&nbsp;Equity&nbsp;Value&nbsp;Per&nbsp;Share&nbsp;Reference&nbsp;Range</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">17.0x &#150; 18.5x</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$170.25&nbsp;&#150;&nbsp;$185.25</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Selected Precedent Transaction Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays and Goldman Sachs reviewed and compared the purchase prices and financial multiples paid in selected other managed care transactions
that Barclays and Goldman Sachs, based on their experience with merger and acquisition transactions, deemed relevant. Barclays and Goldman Sachs chose such transactions based on, among other things, the similarity of the applicable target companies
to Aetna with respect to the characteristics of their businesses. The selected transactions were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"><B>Announce&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Acquiror</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Target</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/24/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Anthem, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cigna Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/03/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aetna Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Humana Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/02/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Centene Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Health Net, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/08/12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amil Participa&ccedil;&otilde;es S.A.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">08/20/12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aetna Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Coventry Health Care, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/09/12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">WellPoint, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">AMERIGROUP Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/24/11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cigna Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HealthSpring, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">03/12/07</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sierra Health Services, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">09/27/05</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">WellPoint, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">WellChoice, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/06/05</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PacifiCare Health Systems, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/14/04</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Coventry Health Care, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Health Group Corp.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">04/26/04</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Oxford Health Plans, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/27/03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mid Atlantic Medical Services, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/27/03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Anthem, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wellpoint Health Networks Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">04/29/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Anthem, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Trigon Healthcare, Inc.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each transaction, Barclays and Goldman Sachs calculated the next-twelve-months P/E multiples based on
information they obtained from SEC filings, IBES estimates and FactSet data by comparing the transaction value per share at announcement to the target company&#146;s next-twelve-months EPS based on IBES consensus projections as of the one trading
day prior to announcement or, where applicable, prior to rumor or leak. For the transactions which included a stock component as part of the merger consideration, the transaction value per share at announcement was calculated by Barclays and Goldman
Sachs based upon the acquiror closing share price as of the one trading day prior to the date of announcement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The high, mean, median and low next-twelve-months P/E multiples observed for the selected
companies were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>High</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.3</TD>
<TD NOWRAP VALIGN="bottom">x&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mean</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Median</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Low</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 25th percentile and 75th percentile next-twelve-months P/E multiples, rounded to the nearest 0.5, observed
for the selected companies were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>25th Percentile</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>75th Percentile</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reasons for and the circumstances surrounding each of the selected precedent transactions analyzed were
diverse and there are inherent differences in the businesses, operations, financial conditions and prospects of Aetna and the companies included in the selected precedent transaction analysis. Based upon their professional judgment and experience,
Barclays selected a range of 19.0x to 22.0x next-twelve-months P/E multiples and applied such range to the projected next-twelve-months (as of December&nbsp;1, 2017) adjusted EPS of $10.00 based on the adjusted Aetna forecasts, and Goldman Sachs
selected a range of 15.0x to 21.5x next-twelve-months P/E multiples and applied such range to the projected next-twelve-months (as of September&nbsp;30, 2017) adjusted EPS of $9.97 based on the adjusted Aetna forecasts, in each case, to calculate a
range, rounded to the nearest $0.25, of implied equity values per Aetna common share as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Selected&nbsp;P/E&nbsp;Multiples</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied&nbsp;Equity&nbsp;Value&nbsp;Per&nbsp;Share&nbsp;Reference&nbsp;Range</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Barclays</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19.0x&nbsp;&#150;&nbsp;22.0x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$190.00&nbsp;&#150;&nbsp;$220.00</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Goldman Sachs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">15.0x &#150; 21.5x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$149.50&nbsp;&#150;&nbsp;$214.25</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Transaction Premium Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>Opinion of Barclays Capital Inc. and Goldman Sachs &amp; Co. LLC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays and Goldman Sachs reviewed and compared the premiums paid in selected other managed care transactions that Barclays and Goldman Sachs,
based on their experience with merger and acquisition transactions, deemed relevant. Barclays and Goldman Sachs chose such transactions based on, among other things, the similarity of the applicable target companies to Aetna with respect to the
characteristics of their businesses. The selected transactions were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="36%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"><B>Announce&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Acquiror</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Target</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/24/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Anthem, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cigna Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/03/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aetna Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Humana Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/02/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Centene Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Health Net, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/08/12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amil Participa&ccedil;&otilde;es S.A.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">08/20/12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aetna Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Coventry Health Care, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/09/12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">WellPoint, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">AMERIGROUP Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/24/11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cigna Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HealthSpring, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">03/12/07</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sierra Health Services, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">09/27/05</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">WellPoint, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">WellChoice, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">07/06/05</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PacifiCare Health Systems, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/14/04</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Coventry Health Care, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Health Group Corp.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">04/26/04</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Oxford Health Plans, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/27/03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UnitedHealth Group Incorporated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mid Atlantic Medical Services, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10/27/03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Anthem, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wellpoint Health Networks Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">04/29/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Anthem, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Trigon Healthcare, Inc.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each transaction, Barclays and Goldman Sachs calculated the premium per share paid by
the acquiror based on information they obtained from SEC filings, IBES estimates and FactSet data by comparing the transaction value per share at announcement to the target company&#146;s: (i)&nbsp;closing share price as of the one trading day prior
to announcement or, where applicable, prior to rumor or leak and (ii)&nbsp;historical high closing share price during the <FONT STYLE="white-space:nowrap">52-week</FONT> period ending the one trading day prior to announcement or, where applicable,
prior to rumor or leak. For the transactions which included a stock component as part of the merger consideration, the transaction value per share at announcement was calculated by Barclays and Goldman Sachs based upon the acquiror closing share
price as of the one trading day prior to the date of announcement. The high, mean, median and low premiums observed for the selected transactions were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Premiums</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">1-Day</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">52-Week&nbsp;High</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>High</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mean</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Median</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Low</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25.1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>Opinion of Goldman Sachs &amp; Co. LLC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reasons for and the circumstances surrounding each of the transactions analyzed in the transaction premium analysis were diverse and there
are inherent differences in the business, operations, financial conditions and prospects of Aetna and the companies included in the transaction premium analysis. Based upon its professional judgment and experience, Goldman Sachs selected a range of
18.0% to 27.0% premiums (based on the 25th and 75th percentiles from the above <FONT STYLE="white-space:nowrap">1-Day</FONT> analysis) to the closing price of Aetna common shares on the unaffected date to calculate a range, rounded to the nearest
$0.25, of implied equity values per Aetna common share as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="40%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:65.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Selected
Premiums</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied&nbsp;Equity&nbsp;Value&nbsp;Per&nbsp;Share&nbsp;Reference&nbsp;Range</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">18.0% &#150; 27.0%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$189.00&nbsp;&#150;&nbsp;$203.25</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays did not calculate implied equity values per Aetna common share as part of its transaction premium
analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Large Transactions Premiums Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using Thomson Reuters data as of December&nbsp;1, 2017, Goldman Sachs reviewed and analyzed the acquisition premiums for transactions announced
during the time period from January&nbsp;1, 2013 through December&nbsp;1, 2017 involving a public company based in the United States as the target where the disclosed enterprise value for the transaction was greater than $25&nbsp;billion. For the
entire period, Goldman Sachs calculated the median, 25th percentile and 75th percentile premiums of the price paid in the 25 transactions relative to the target&#146;s closing stock price one day prior to original announcement of the transaction as
determined by Thomson Reuters. This analysis indicated a median premium of 29.0% across the period. This analysis also indicated a 25th percentile premium of 18.2% and 75th percentile premium of 36.4% across the period. Using this analysis, Goldman
Sachs applied a reference range of premiums of 18.0% to 36.5% to the undisturbed closing price per Aetna common share of $160.12 as of the unaffected date and calculated a range, rounded to the nearest $0.25, of implied equity values per Aetna
common share as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="40%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:65.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Selected
Premiums</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied&nbsp;Equity&nbsp;Value&nbsp;Per&nbsp;Share&nbsp;Reference&nbsp;Range</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">18.0% &#150; 36.5%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$189.00&nbsp;&#150;&nbsp;$218.50</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>Opinion of Barclays Capital Inc. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to estimate the illustrative present values of shares of CVS Health common stock, Aetna common shares (excluding and including the
expected synergies) and shares of the combined company, Barclays performed a discounted cash flow analysis of each of CVS Health, Aetna and the combined company. A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discounted cash flow analysis is a traditional valuation methodology used to derive a valuation of a company by calculating the &#147;present value&#148; of estimated future cash flows of the
company. &#147;Present value&#148; refers to the current value of future cash flows or amounts and is obtained by discounting those future cash flows or amounts by a discount rate that takes into account macroeconomic assumptions and estimates of
risk, the opportunity cost of capital, expected returns and other appropriate factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis of Aetna
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays performed a discounted cash flow analysis of Aetna based on estimates of unlevered free cash flows of Aetna as reflected in
the adjusted Aetna forecasts to derive a range of implied present values per Aetna common share as of September&nbsp;30, 2017. Utilizing discount rates ranging from 6.5% to 7.5%, reflecting estimates of Aetna&#146;s weighted average cost of capital,
Barclays derived a range of implied enterprise values for Aetna by discounting to present value as of September&nbsp;30, 2017, (i) estimates of unlevered free cash flows of Aetna for the three months ending December&nbsp;31, 2017, which were
calculated using the adjusted Aetna forecasts and approved for Barclays&#146; use by CVS Health, and each of the fiscal years 2018 through 2022, as reflected in the adjusted Aetna forecasts, and (ii)&nbsp;a range of terminal values for Aetna derived
by applying perpetuity growth rates ranging from 2.0% to 3.0% to the estimated terminal unlevered free cash flow for Aetna calculated based upon the adjusted Aetna forecasts. Barclays derived such discount rates by application of the Capital Asset
Pricing Model, which requires certain company-specific inputs, including the company&#146;s target capital structure weightings, the cost of long-term debt, after-tax yield on permanent excess cash, if any, future applicable marginal cash tax rate
and a beta for the company, as well as certain financial metrics for the United States financial markets generally. The range of perpetuity growth rates was estimated by Barclays utilizing its professional judgment and experience, taking into
account the adjusted Aetna forecasts and market expectations regarding long term real growth of gross domestic product and inflation. Barclays then added the present value of the terminal value to the present values of the unlevered free cash flows
for the three months ending December&nbsp;31, 2017 and each of the fiscal years 2018 through 2022 and subtracted the assumed amount of Aetna&#146;s net debt (as of September&nbsp;30, 2017 and based on guidance from CVS Health management) to
calculate a range of equity values for Aetna. Barclays then divided this range of equity values by the number of fully diluted Aetna common shares based on data provided by CVS Health management to derive a range, rounded to the nearest $0.25, of
present values per Aetna common share as indicated in the table below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays also performed a discounted cash flow analysis of Aetna
including the expected synergies based on estimates of unlevered free cash flows of Aetna as reflected in and calculated using the adjusted Aetna forecasts and approved for Barclays&#146; use by CVS Health, and as reflected in the expected synergies
to derive a range of implied present values per Aetna common share including the expected synergies as of September&nbsp;30, 2017. Utilizing discount rates ranging from 6.5% to 7.5%, reflecting estimates of Aetna&#146;s weighted average cost of
capital, Barclays derived a range of implied values of the expected synergies by discounting to present value as of September&nbsp;30, 2017, (i) the expected synergies for each of the fiscal years 2018 through 2022 and (ii)&nbsp;a terminal value for
the expected synergies derived by applying a perpetuity growth rate of 1.5% to the estimated terminal year expected synergies. Barclays derived such discount rates by application of the Capital Asset Pricing Model, which requires certain
company-specific inputs, including the company&#146;s target capital structure weightings, the cost of long-term debt, after-tax yield on permanent excess cash, if any, future applicable marginal cash tax rate and a beta for the company, as well as
certain financial metrics for the United States financial markets generally. The perpetuity growth rate was estimated by Barclays utilizing its professional judgment and experience, taking into account the adjusted Aetna forecasts and market
expectations regarding long term real growth of gross domestic product and inflation. Barclays then added the low end of the range of present value expected synergies to the low end of the range of present value equity values of Aetna calculated
above and added the high end of the range of present value expected synergies to the high end of the range of present value equity values of Aetna calculated above to derive a present value equity value range including the expected synergies.
Barclays calculated a range of implied equity values per Aetna common share using the same </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
method described above. Barclays&#146; analysis implied a range, rounded to the nearest $0.25 and including the expected synergies, of present values per Aetna common share as indicated in the
table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Implied Equity Value Per Share Reference
Range</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Excluding Expected Synergies)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Including&nbsp;Expected&nbsp;Synergies)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$170.50 &#150; $263.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$191.50&nbsp;&#150;&nbsp;$288.75</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis of CVS Health </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays performed a discounted cash flow analysis of CVS Health based on estimates of unlevered free cash flows of CVS Health, which were
calculated using the CVS Health forecasts and approved for Barclays&#146; use by CVS Health, to derive a range of implied present values per share of CVS Health common stock as of September&nbsp;30, 2017. Utilizing discount rates ranging from 6.0%
to 7.0%, reflecting estimates of CVS Health&#146;s weighted average cost of capital, Barclays derived a range of implied enterprise values for CVS Health by discounting to present value as of September&nbsp;30, 2017, (i) estimates of unlevered free
cash flows of CVS Health for the three months ending December&nbsp;31, 2017 and each of the fiscal years 2018 through 2022, which were calculated using the CVS Health forecasts and approved for Barclays&#146; use by CVS Health, and (ii)&nbsp;a range
of terminal values for CVS Health derived by applying a range of terminal value multiples based on EBITDA for the fiscal year ending December&nbsp;31, 2022 of 6.5x to 9.5x to the estimated terminal EBITDA for CVS Health calculated based upon the CVS
Health forecasts. Barclays derived such discount rates by application of the Capital Asset Pricing Model, which requires certain company-specific inputs, including the company&#146;s target capital structure weightings, the cost of long-term debt,
after-tax yield on permanent excess cash, if any, future applicable marginal cash tax rate and a beta for the company, as well as certain financial metrics for the United States financial markets generally. In selecting the range of terminal value
multiples based on EBITDA for the fiscal year ending December&nbsp;31, 2022, Barclays made qualitative judgments based on its experience and professional judgment. Barclays then added the present value of the terminal value to the present values of
the unlevered free cash flows for the three months ending December&nbsp;31, 2017 and each of the fiscal years 2018 through 2022, and subtracted the assumed amount of CVS Health&#146;s net debt and the book value of minority interests (each as of
September&nbsp;30, 2017 and based on guidance from CVS Health management) to calculate a range of equity values for CVS Health. Barclays then divided this range of equity values by the number of fully diluted shares of CVS Health common stock based
on data provided by CVS Health management to derive a range of present values per share of CVS Health common stock as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:169.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Implied Equity Value Per
Share Reference Range</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$75.10 &#150; $112.93</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman"><I>Illustrative Pro Forma Combined Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To calculate the range of illustrative equity values of the combined company using the discounted cash flow method, Barclays (i)&nbsp;added the
low and high estimates in the range of estimated equity values of CVS Health calculated above to the low and high estimates in the range of estimated equity values of Aetna (excluding the expected synergies) calculated above, respectively,
(ii)&nbsp;calculated the range of illustrative values of the expected synergies using the same assumptions used for the expected synergies analysis above, except that Barclays used perpetuity growth rates ranging from 1.0% to 2.0%, and added the low
and high estimates in the range of estimated values of the expected synergies to the low and high estimated combined equity values calculated in (i), (iii) subtracted from this range of equity values the amount of new debt expected from the
transaction as based on guidance from CVS Health management, and finally, (iv)&nbsp;divided this range of equity values by the sum of the number of fully diluted shares of CVS Health common stock based on data provided by CVS Health management plus
the number of new shares of CVS Health common stock expected to be issued as part of the transaction based on data provided by CVS Health management. The range of perpetuity growth rates used with respect to the expected synergies was estimated by
Barclays utilizing its professional judgment and experience. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Barclays&#146; analysis implied a range of equity values per share of the common shares of the combined company as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:169.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Implied Equity Value Per
Share Reference Range</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$72.81 &#150; $128.31</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>Opinion of Goldman Sachs &amp; Co. LLC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis of Aetna </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs performed a discounted cash flow analysis of Aetna (excluding and including the expected synergies) based on estimates of
unlevered free cash flows of Aetna as reflected in the adjusted Aetna forecasts and, as applicable, the expected synergies, to derive a range of implied present values per Aetna common share as of September&nbsp;30, 2017. Utilizing discount rates
ranging from 6.5% to 7.5%, reflecting estimates of Aetna&#146;s weighted average cost of capital, Goldman Sachs derived a range of implied enterprise values for Aetna by discounting to present value as of September&nbsp;30, 2017, (i) estimates of
unlevered free cash flows of Aetna for the three months ending December&nbsp;31, 2017, which were calculated using the adjusted Aetna forecasts and approved for Goldman Sachs&#146; use by CVS Health, and each of the fiscal years 2018 through 2022,
as reflected in the adjusted Aetna forecasts (each excluding and including the expected synergies), and (ii)&nbsp;a range of terminal values for Aetna (excluding and including the expected synergies) derived by applying perpetuity growth rates
ranging from 1.5% to 2.5% to CVS Health&#146;s estimated terminal unlevered free cash flow for Aetna as reflected in the adjusted Aetna forecasts. Goldman Sachs derived such discount rates by application of the Capital Asset Pricing Model, which
requires certain company-specific inputs, including the company&#146;s target capital structure weightings, the cost of long-term debt, <FONT STYLE="white-space:nowrap">after-tax</FONT> yield on permanent excess cash, if any, future applicable
marginal cash tax rate and a beta for the company, as well as certain financial metrics for the United States financial markets generally. The range of perpetuity growth rates was estimated by Goldman Sachs utilizing its professional judgment and
experience, taking into account the adjusted Aetna forecasts and market expectations regarding long-term real growth of gross domestic product and inflation. Goldman Sachs then added the present value of each terminal value to the present values of
each of the unlevered free cash flows for the three months ending December&nbsp;31, 2017 and each of the fiscal years 2018 through 2022 and subtracted the assumed amount of Aetna&#146;s net debt (as of September&nbsp;30, 2017 and based on guidance
from CVS Health management) to calculate a range of equity values for Aetna (excluding and including the expected synergies). Goldman Sachs then divided these ranges of equity values by the number of fully diluted Aetna common shares based on data
provided by CVS Health management to derive ranges, rounded to the nearest $0.25, of present values per Aetna common share as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Implied Equity Value Per Share Reference
Range</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Excluding Expected Synergies)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Including&nbsp;Expected&nbsp;Synergies)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$159.50 &#150; $235.50</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$180.50&nbsp;&#150;&nbsp;$267.00</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis of CVS Health </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs performed a discounted cash flow analysis of CVS Health based on estimates of unlevered free cash flows of CVS Health, which were
calculated using the CVS Health forecasts and approved for Goldman Sachs&#146; use by CVS Health, to derive a range of implied present values per share for CVS Health as of September&nbsp;30, 2017. Utilizing discount rates ranging from 6.25% to
7.25%, reflecting estimates of CVS Health&#146;s weighted average cost of capital, Goldman Sachs derived a range of implied enterprise values for CVS Health by discounting to present value as of September&nbsp;30, 2017, (i) estimates of unlevered
free cash flows of CVS Health for the three months ending December&nbsp;31, 2017 and each of the fiscal years 2018 through 2022, which were calculated using the CVS Health forecasts and approved for Goldman Sachs&#146; use by CVS Health, and
(ii)&nbsp;a range of terminal values for CVS Health derived by applying perpetuity growth rates ranging from 0.5% to 1.5% to the estimated terminal unlevered free cash flow for CVS Health, which were calculated using the CVS Health forecasts and
approved for Goldman Sachs&#146; use by CVS Health. Goldman Sachs derived such discount rates by application of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Capital Asset Pricing Model, which requires certain company-specific inputs, including the company&#146;s target capital structure weightings, the cost of long-term debt, <FONT
STYLE="white-space:nowrap">after-tax</FONT> yield on permanent excess cash, if any, future applicable marginal cash tax rate and a beta for the company, as well as certain financial metrics for the United States financial markets generally. The
range of perpetuity growth rates was estimated by Goldman Sachs utilizing its professional judgment and experience, taking into account the CVS Health forecasts and market expectations regarding long-term real growth of gross domestic product and
inflation. Goldman Sachs then added the present value of the terminal value to the present values of the unlevered free cash flows for the three months ending December&nbsp;31, 2017 and each of the fiscal years 2018 through 2022 and subtracted the
assumed amount of CVS Health&#146;s net debt and the book value of minority interests (each as of September&nbsp;30, 2017 and based on guidance from CVS Health management) to calculate a range of equity values for CVS Health. Goldman Sachs then
divided this range of equity values by the number of fully diluted shares of CVS Health common stock based on data provided by CVS Health management to derive a range of present values per share of CVS Health common stock as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:169.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Implied Equity Value Per
Share Reference Range</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$80.30 &#150; $118.84</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman"><I>Illustrative Pro Forma Combined Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs performed a discounted cash flow analysis of the combined company based on estimates of unlevered free cash flows of the combined
company, which were calculated using the CVS Health pro&nbsp;forma forecasts and approved for Goldman Sachs&#146; use by CVS Health, and the expected synergies to derive a range of implied present values per share of the combined company as of
September&nbsp;30, 2017. Utilizing discount rates ranging from 6.25% to 7.25%, reflecting pro forma estimates of the weighted average cost of capital of the combined company following completion of the merger, Goldman Sachs derived a range of
implied enterprise values for the combined company by discounting to present value as of September&nbsp;30, 2018, (i) estimates of unlevered free cash flows and the expected synergies of the combined company for the three months ending
December&nbsp;31, 2018 and each of the fiscal years 2019 through 2022, which were calculated using the CVS Health pro&nbsp;forma forecasts and approved for Goldman Sachs&#146; use by CVS Health, and expected synergies and (ii)&nbsp;a range of
terminal values for the combined company derived by applying perpetuity growth rates ranging from 1.0% to 2.0% to the estimated terminal unlevered free cash flow and the expected synergies for the combined company, which were calculated using the
CVS Health pro forma forecasts and approved for Goldman Sachs&#146; use by CVS Health, and the expected synergies. Goldman Sachs derived such discount rates by application of the Capital Asset Pricing Model, which requires certain company-specific
inputs, including the company&#146;s target capital structure weightings, the cost of long-term debt, <FONT STYLE="white-space:nowrap">after-tax</FONT> yield on permanent excess cash, if any, future applicable marginal cash tax rate and a beta for
the company, as well as certain financial metrics for the United States financial markets generally. The range of perpetuity growth rates was estimated by Goldman Sachs utilizing its professional judgment and experience, taking into account the CVS
Health forecasts and adjusted Aetna forecasts and market expectations regarding long-term real growth of gross domestic product and inflation. Goldman Sachs then (i)&nbsp;added the present value (as of September&nbsp;30, 2018) of the terminal value
to the present values (as of September&nbsp;30, 2018) of the unlevered free cash flows and the expected synergies for the three months ending December&nbsp;31, 2018 and each of the fiscal years 2019 through 2022, (ii) added the total CVS Health
dividends and Aetna dividends expected to be paid between September&nbsp;30, 2017 and September&nbsp;30, 2018, as reflected in the CVS Health forecasts and the adjusted Aetna forecasts and (iii)&nbsp;subtracted the assumed amount of the combined
company&#146;s net debt and the book value of minority interests (each based on guidance from CVS Health management) to calculate a range of equity values for the combined company. Goldman Sachs then divided this range of equity values by the number
of pro forma fully diluted shares of common stock for the combined company based on data provided by CVS Health management. Goldman Sachs then discounted the equity values per share to September&nbsp;30, 2017 based on a cost of equity of 7.8% to
derive a range of present values per share of the common shares of the combined company as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:169.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Implied Equity Value Per
Share Reference Range</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">$76.40 &#150; $129.88</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Illustrative Future Share Price Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Barclays and Goldman Sachs performed an illustrative analysis of the illustrative future value per share of CVS Health common stock, which is
designed to provide an indication of the theoretical future value of a company&#146;s shares of common stock, both as a stand-alone entity and as the pro forma combined company, as a function of the stand-alone entity&#146;s and the pro forma
combined company&#146;s respective financial multiples. Goldman Sachs then performed an illustrative analysis of the implied present value of the illustrative future value per share of CVS Health common stock, which is designed to provide an
indication of the present value of a theoretical future value of a company&#146;s shares of common stock, both as a stand-alone entity and as the pro forma combined company. For the analysis of the illustrative future value per share of CVS Health
common stock, Barclays and Goldman Sachs used the CVS Health forecasts for each of the fiscal years 2018 to 2022 and the CVS Health pro forma forecasts and the expected synergies for each of the fiscal years 2019 to 2022. Barclays and Goldman Sachs
first calculated the implied future values per share of CVS Health common stock as of December&nbsp;31 for each of the fiscal years 2017 to 2021, by applying next-twelve-months adjusted P/E multiples ranging from 11.60x to 14.00x to
next-twelve-months adjusted EPS estimates for CVS Health as a stand-alone entity for each of the fiscal years 2017 to 2021, as reflected in the CVS Health forecasts. Barclays and Goldman Sachs then calculated the implied future values per share of
the common stock of the combined company as of December&nbsp;31 for each of the fiscal years 2018 to 2021, by applying next-twelve-months adjusted P/E multiples ranging from 11.60x to 15.00x to next-twelve-months adjusted EPS estimates for the
combined company for each of the fiscal years 2018 to 2021, as reflected in the CVS Health pro forma forecasts and the expected synergies. This range of illustrative adjusted P/E multiples was derived by Barclays and Goldman Sachs utilizing their
professional judgment and experience, taking into account current and historical trading data and the current adjusted P/E multiples for CVS Health and Aetna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Utilizing a discount rate of 7.80%, reflecting an estimate of the cost of equity for each of CVS Health and the combined company and derived
by application of the Capital Asset Pricing Model, which requires certain company-specific inputs, including a beta for the company, as well as certain financial metrics for the United States financial markets generally, Goldman Sachs then derived a
range of implied present values per share for CVS Health as a stand-alone entity and for the combined company by discounting to present value as of December&nbsp;1, 2017, (i) the implied values per share of CVS Health as a stand-alone entity and of
the combined company and (ii)&nbsp;the values of the dividends per share projected to be paid by each of the respective entities for each of the calendar years 2018 to 2021. Goldman Sachs then added the present value of the implied values per share
to the present values of the dividends to calculate the present value of the stock of each of CVS Health as a stand-alone entity and the pro forma combined company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the results of the analysis of the implied present value of the illustrative future value per share of CVS Health
common stock: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Present Value as of December&nbsp;1, 2017 of Stand-alone CVS Health Future Stock </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.00 x NTM Adj. P/E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.75 x NTM Adj. P/E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.60 x NTM Adj. P/E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Present Value as of December&nbsp;1, 2017 of Pro Forma Combined Company Future Stock </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.00 x NTM Adj. P/E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.75 x NTM Adj. P/E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.50 x NTM Adj. P/E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.60 x NTM Adj. P/E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of Centerview Partners LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;3, 2017, Centerview rendered to the board of directors of CVS Health its oral opinion, subsequently confirmed in a written
opinion dated such date, that, as of such date and based upon and subject to various assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, the
merger consideration to be paid by CVS Health in the merger pursuant to the merger agreement was fair, from a financial point of view, to CVS Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of Centerview&#146;s written opinion, dated December&nbsp;3, 2017, which describes the assumptions made, procedures followed,
matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, is attached as Annex F and is incorporated herein by reference. <B>The summary of the written opinion of Centerview set forth
below is qualified in its entirety by the full text of Centerview&#146;s written opinion attached as Annex F.</B> <B>Centerview&#146;s financial advisory services and opinion were provided for the information and assistance of the board of directors
of CVS Health (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the transaction, and Centerview&#146;s opinion only addressed the fairness, from a financial point of view, as
of the date of Centerview&#146;s written opinion, to CVS Health of the merger consideration to be paid by CVS Health in the merger pursuant to the merger agreement. Centerview&#146;s opinion</B> <B>did not address any other term or aspect of the
merger agreement or the transaction and does not constitute a recommendation to any stockholder of CVS Health or any other person as to how such stockholder or other person should vote with respect to the merger or otherwise act with respect to the
transaction or any other matter. </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The full text of Centerview&#146;s written opinion should be read carefully in its entirety for
a description of the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with rendering the opinion described above and performing its related financial analyses, Centerview reviewed, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a draft of the merger agreement dated December&nbsp;3, 2017, referred to in this summary of Centerview&#146;s opinion as the &#147;draft merger agreement&#148;; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of each of Aetna and CVS Health for the years ended December&nbsp;31, 2016, December&nbsp;31, 2015 and December&nbsp;31, 2014; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain interim reports to stockholders and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of each of Aetna and CVS Health; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain publicly available research analyst reports for each of Aetna and CVS Health; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain other communications from each of Aetna and CVS Health to their respective stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain internal information relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of Aetna furnished to Centerview by CVS Health for purposes of Centerview&#146;s analysis, which
is referred to in this section of this joint proxy statement/prospectus as the Aetna internal data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the adjusted Aetna projections (as defined in &#147;&#151;Unaudited Prospective Financial Information&#151;Adjusted Aetna Projections&#148; beginning on page 158 of this joint proxy statement/prospectus), as prepared by
management of CVS Health and furnished to Centerview by CVS Health for purposes of Centerview&#146;s analysis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain internal information relating to the business, operations, earnings, cash flow, assets, liabilities and
prospects of CVS Health, including the CVS Health management projections (as defined in &#147;&#151;Unaudited Prospective Financial Information&#151;CVS Health Management Projections&#148; beginning on page 159 of this joint proxy
statement/prospectus) and the CVS Health combined company </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
projections (as defined in &#147;&#151;Unaudited Prospective Financial Information&#151;CVS Health Combined Company Projections&#148; beginning on page 161 of this joint proxy
statement/prospectus), prepared by management of CVS Health and furnished to Centerview by CVS Health for purposes of Centerview&#146;s analysis, which are collectively referred to in this section of this joint proxy statement/prospectus as the CVS
Health internal data; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain cost savings and operating synergies projected by management of CVS Health to result from the transaction furnished to Centerview by CVS Health for purposes of Centerview&#146;s analysis, which are referred to
in this section of this joint proxy statement/prospectus as the synergies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview also participated in discussions with
members of the senior management and representatives of CVS Health regarding their assessment of the Aetna internal data, the adjusted Aetna projections, the CVS Health internal data (including, without limitation, the CVS Health management
projections and the CVS Health combined company projections) and the synergies, and the strategic rationale for the transaction. In addition, Centerview reviewed publicly available financial and stock market data, including valuation multiples, for
Aetna and CVS Health and compared that data with similar data for certain other companies, the securities of which are publicly traded, in lines of business that Centerview deemed relevant. Centerview also compared certain of the proposed financial
terms of the transaction with the financial terms, to the extent publicly available, of certain other transactions that Centerview deemed relevant, and conducted such other financial studies and analyses and took into account such other information
as Centerview deemed appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview assumed, without independent verification or any responsibility therefor, the accuracy and
completeness of the financial, legal, regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by Centerview for purposes of its opinion and, with the consent of CVS Health, Centerview relied upon such information
as being complete and accurate. In that regard, Centerview assumed, at the direction of CVS Health, that the Aetna internal data was reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of
Aetna as to the matters covered thereby and that the CVS Health internal data (including without limitation the, CVS Health management projections and the CVS Health combined company projections), the adjusted Aetna projections and the synergies
were reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of CVS Health as to the matters covered thereby, and Centerview relied, at the direction of CVS Health, on the Aetna internal data,
the adjusted Aetna projections, the CVS Health internal data (including, without limitation, the CVS Health management projections and CVS Health combined company projections) and the synergies for purposes of Centerview&#146;s analysis and opinion.
Centerview expressed no view or opinion as to the Aetna internal data, the adjusted Aetna projections, the CVS Health internal data (including, without limitation, the CVS Health management projections and the CVS Health combined company
projections), the synergies or the assumptions on which they were based. In addition, at the direction of CVS Health, Centerview did not make any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, <FONT
STYLE="white-space:nowrap">off-balance-sheet</FONT> or otherwise) of Aetna or CVS Health, nor was Centerview furnished with any such evaluation or appraisal, and Centerview was not asked to conduct, and did not conduct, a physical inspection of the
properties or assets of Aetna or CVS Health. Centerview is not an actuary and its services did not include any actuarial determination or evaluation by Centerview or any attempt to evaluate actuarial assumptions, and Centerview relied on the
actuaries of CVS Health with respect to reserve adequacy. In that regard, Centerview made no analysis of, and expressed no opinion as to, the adequacy of the loss and loss adjustments expenses reserves, the future policy benefit reserves, the
long-term business provision and claims outstanding or the embedded value of CVS Health and Aetna. Centerview assumed, at the direction of CVS Health, that the final executed merger agreement would not differ in any respect material to
Centerview&#146;s analysis or opinion from the draft merger agreement reviewed by Centerview. Centerview also assumed, at the direction of CVS Health, that the transaction will be consummated on the terms set forth in the merger agreement and in
accordance with all applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be material to Centerview&#146;s analysis or
Centerview&#146;s opinion, that the representations and warranties made by Aetna and CVS Health in the merger agreement were and would be true </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and correct in all respects material to Centerview&#146;s analysis and that, in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers
for the transaction, no delay, limitation, restriction, condition or other change, including any divestiture requirements or amendments or modifications, will be imposed, the effect of which would be material to Centerview&#146;s analysis or
Centerview&#146;s opinion. Centerview did not evaluate and did not express any opinion as to the solvency or fair value of Aetna or CVS Health, or the ability of Aetna or CVS Health to pay their respective obligations when they come due, or as to
the impact of the transaction on such matters, under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. Centerview is not a legal, regulatory, tax, actuarial or accounting advisor, and Centerview expressed no
opinion as to any legal, regulatory, tax, actuarial or accounting matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview&#146;s opinion expressed no view as to, and did not
address, the underlying business decision of CVS Health to proceed with or effect the transaction, or the relative merits of the transaction as compared to any alternative business strategies or transactions that might be available to CVS Health or
in which CVS Health might engage. Centerview&#146;s opinion was limited to and addressed only the fairness, from a financial point of view, as of the date of Centerview&#146;s written opinion, to CVS Health of the merger consideration to be paid by
CVS Health in the merger pursuant to the merger agreement. For purposes of its opinion, Centerview was not asked to, and Centerview did not, express any view on, and its opinion did not address, any other term or aspect of the merger agreement or
the transaction, including, without limitation, the structure or form of the transaction, or any other agreements or arrangements contemplated by the merger agreement or entered into in connection with or otherwise contemplated by the transaction,
including, without limitation, the fairness of the transaction or any other term or aspect of the transaction to, or any consideration to be received in connection therewith by, or the impact of the transaction on, the holders of any other class of
securities, creditors or other constituencies of CVS Health or any other party. In addition, Centerview expressed no view or opinion as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid
or payable to any of the officers, directors or employees of CVS Health or any party, or class of such persons in connection with the transaction, whether relative to the merger consideration to be paid by CVS Health in the merger pursuant to the
merger agreement or otherwise. Centerview&#146;s opinion related in part to the relative values of Aetna and CVS Health. Centerview&#146;s opinion was necessarily based on financial, economic, monetary, currency, market and other conditions and
circumstances as in effect on, and the information made available to Centerview as of, the date of Centerview&#146;s written opinion, and Centerview does not have any obligation or responsibility to update, revise or reaffirm its opinion based on
circumstances, developments or events occurring after the date of Centerview&#146; written opinion. Centerview&#146;s opinion expressed no view or opinion as to what the value of the shares of CVS Health common stock actually will be when issued
pursuant to the transaction or the prices at which the Aetna common shares or the shares of CVS Health common stock will trade or otherwise be transferable at any time, including following the announcement or consummation of the transaction.
Centerview&#146;s opinion does not constitute a recommendation to any stockholder of CVS Health or any other person as to how such stockholder or other person should vote with respect to the merger or otherwise act with respect to the transaction or
any other matter. Centerview&#146;s financial advisory services and its written opinion were provided for the information and assistance of the board of directors of CVS Health (in their capacity as directors and not in any other capacity) in
connection with and for purposes of its consideration of the transaction. The issuance of Centerview&#146;s opinion was approved by the Centerview Partners LLC Fairness Opinion Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Centerview Financial Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material financial analyses prepared and reviewed with the board of directors of CVS Health in connection
with Centerview&#146;s opinion, dated December&nbsp;3, 2017. <B>The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the opinion of, Centerview, nor
does the order of the financial analyses described represent the relative importance or weight given to those financial analyses by Centerview. Centerview may have deemed various assumptions more or less probable than other assumptions, so the
reference ranges resulting from any particular portion of the analyses summarized below should not be</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>taken to be Centerview&#146;s view of the actual value of Aetna or CVS Health. Some of the summaries of the financial analyses set forth below include information presented in tabular format.
In order to fully understand the financial analyses, the tables must be read together with the text of each summary, as the tables alone do not constitute a complete description of the financial analyses performed by Centerview. Considering the data
in the tables below without considering all financial analyses or factors or the full narrative description of such analyses or factors, including the methodologies and assumptions underlying such analyses or factors, could create a misleading or
incomplete view of the processes underlying Centerview&#146;s financial analyses and its opinion. </B>In performing its analyses, Centerview made numerous assumptions with respect to industry performance, general business and economic conditions and
other matters, many of which are beyond the control of Aetna, CVS Health or any other parties to the transaction. None of Aetna, CVS Health, Merger Sub, Centerview or any other person assumes responsibility if future results are materially different
from those discussed. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition,
analyses relating to the value of Aetna and CVS Health do not purport to be appraisals or reflect the prices at which Aetna or CVS Health may actually be sold. Accordingly, the assumptions and estimates used in, and the results derived from, the
financial analyses are inherently subject to substantial uncertainty. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before
December&nbsp;1, 2017 (the last trading day before the public announcement of the transaction) and is not necessarily indicative of current market conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Stand-alone Aetna Financial Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Comparable Public Company Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview reviewed and compared certain financial information, ratios and multiples for Aetna to corresponding financial information, ratios
and multiples for publicly traded companies in the managed care industry that Centerview deemed comparable, based on its experience and professional judgment, to Aetna, which selected publicly traded companies are referred to in this section of this
joint proxy statement/prospectus as the selected Aetna comparable companies. None of the companies that were selected based on these criteria were subsequently excluded in conducting this analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected Aetna comparable companies consisted of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:135.25pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Selected Aetna Comparable Companies</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United Health</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthem</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cigna</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Humana</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although none of the selected Aetna comparable companies is directly comparable to Aetna, these companies were
selected by Centerview, among other reasons, because they are publicly traded companies in the managed care industry with certain operational and financial characteristics, which, for purposes of its analyses, Centerview considered to be similar to
those of Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using publicly available information obtained from SEC filings, FactSet (a data source containing historical and
estimated financial data), publicly available Wall Street research and closing stock prices as of December&nbsp;1, 2017, as well as the adjusted Aetna projections, Centerview calculated, for each selected Aetna comparable company, and for Aetna (and
in the case of Aetna, an unaffected calculation was also prepared based on a market closing stock price immediately prior to October&nbsp;26, 2017, the first day on which news of the potential transaction was published), the following ratios and
multiples: (1)&nbsp;enterprise value (calculated as the market value of common equity (determined using the fully diluted equity value) plus the book value of debt and noncontrolling interests, less cash and cash equivalents held at the parent
company) as a multiple of 2017, 2018 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and 2019 calendar year estimated EBITDA, and (2)&nbsp;the price to earnings ratio for the 2017, 2018 and 2019 calendar years. Where applicable, the multiples were adjusted to account for certain
events such as pending acquisitions and divestitures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of this analysis for the Aetna comparable companies are summarized
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Minimum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Median</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EV / 2017E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EV / 2018E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EV / 2019E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017E Price / Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018E Price / Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019E Price / Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on its experience and professional judgment, for purposes of its analysis Centerview selected an
enterprise value to estimated 2018 EBITDA multiple reference range of 10.0x to 12.5x and a price to estimated 2018 earnings ratio reference range of 16.0x to 21.0x. In selecting these reference ranges, Centerview made qualitative judgments based on
its experience and professional judgment concerning differences between the business, financial and operating characteristics and prospects of Aetna and the selected Aetna comparable companies that could affect the public trading values in order to
provide a context in which to consider the results of the quantitative analysis. Applying these reference ranges to the adjusted Aetna projections, Centerview calculated the following implied ranges of values per share, rounded to the nearest $1.00,
of Aetna common stock: (1)&nbsp;based on Aetna&#146;s 2018 calendar year estimated adjusted EBITDA, Centerview calculated an implied range of approximately $159 to $206 per share of Aetna common stock and, (2)&nbsp;based on Aetna&#146;s 2018
calendar year estimated adjusted earnings per share, Centerview calculated an implied range of approximately $160 to $210 per share of Aetna common stock. Centerview then compared these ranges to the value of the merger consideration of $207.94 per
share implied by the closing price of shares of CVS Health common stock on December&nbsp;1, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Transactions Analysis
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview analyzed certain information relating to selected transactions announced since 2000 for which publicly disclosed
information is available in the managed care industry that Centerview deemed, based on its experience, expertise and knowledge of the managed care industry, to have operations, results, business mix or product profiles that, for purposes of
analysis, are similar to certain operations, results, business mix or product profiles of Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the transactions that were
selected based on these criteria were subsequently excluded in conducting this analysis. The selected transactions consisted of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:70.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Announcement Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Acquiror</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Target</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jul-15</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthem</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cigna (Terminated)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jul-15</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Humana (Terminated)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jul-15</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Centene Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Health Net</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Oct-12</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UnitedHealth Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AMIL Participa&ccedil;&otilde;es</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Aug-12</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Coventry Health Care</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jul-12</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WellPoint Health Networks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amerigroup</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Oct-11</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cigna</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HealthSpring</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Mar-07</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UnitedHealth Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sierra Health Services</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sep-05</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WellPoint Health Networks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WellChoice</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sep-05</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Blackstone Group and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HealthMarkets</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jul-05</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UnitedHealth Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pacificare Health Systems</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Oct-04</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Coventry Health Care</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Health Group</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="38%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:70.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Announcement Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Acquiror</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Target</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sep-04</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pacificare Health Systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">American Medical Security Group</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Apr-04</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UnitedHealth Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oxford Health Plans</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Oct-03</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthem</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WellPoint</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Oct-03</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UnitedHealth Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mid Atlantic Medical Services</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jun-03</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WellPoint Health Networks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cobalt Corporation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Apr-02</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthem</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trigon Healthcare</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Oct-01</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WellPoint Health Networks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RightCHOICE Managed Care</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Nov-00</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WellPoint Health Networks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cerulean Companies</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No company or transaction used in this analysis is directly comparable to Aetna or CVS Health or the
transaction. The companies included in the selected transactions are companies that were selected, among other reasons, because they have certain operational and financial characteristics that, for the purposes of its analysis, Centerview considered
to be similar to those of Aetna. The reasons for and the circumstances surrounding each of the selected transactions analyzed were diverse, and there are inherent differences in the business, operations, financial conditions and prospects of Aetna,
CVS Health and the companies included in the selected transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of this analysis are summarized below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Median</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Mean</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EV / LTM EBITDA Multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on its analysis of the relevant metrics for each of the selected companies, Centerview selected an
enterprise value to estimated LTM EBITDA multiple reference range of 11.0x to 13.5x. In selecting this reference range, Centerview made qualitative judgments based on its experience and professional judgment concerning differences between the
business, financial and operating characteristics and prospects of Aetna and the companies included in the selected transactions and other factors that could affect the public trading, acquisition or other values of such companies or Aetna.
Centerview applied this reference range to Aetna&#146;s estimated calendar year 2017 adjusted EBITDA, reflected in the adjusted Aetna projections, to calculate an illustrative range of implied values per share, rounded to the nearest $1.00, of Aetna
common stock as of December&nbsp;1, 2017 of approximately $166 to $210 per share of Aetna common stock. Centerview then compared the results of this analysis to the value of the merger consideration of $207.94 per share implied by the closing price
of shares of CVS Health common stock on December&nbsp;1, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview performed a discounted cash flow analysis of Aetna, which is a traditional valuation methodology used to derive a valuation of an
asset by calculating the &#147;present value&#148; of estimated future cash flows of the asset. &#147;Present value&#148; refers to the current value of future cash flows and is obtained by discounting those future cash flows by a discount rate that
takes into account macroeconomic assumptions and estimates of risk, the opportunity cost of capital, expected returns and other appropriate factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In performing this analysis, Centerview calculated the estimated present value of the unlevered free cash flows of Aetna reflected in the
adjusted Aetna projections for Q4 2017 and the years from 2018 through 2022. The terminal value of Aetna at the end of the forecast period was estimated by using perpetuity growth rates ranging from 2.0% to 3.0%. This range of perpetuity growth
rates was estimated by Centerview utilizing its professional judgment and experience, taking into<B> </B>account the adjusted Aetna projections and market expectations regarding long term real growth of gross domestic product and inflation. The
unlevered free cash flows and terminal values were then discounted to present value using discount rates ranging from 6.5% to 7.5%. This range of discount rates was determined based on Centerview&#146;s analysis of Aetna&#146;s weighted average cost
of capital. Based on its analysis, Centerview calculated a range of implied values per share of Aetna common stock, rounded to the nearest $1.00, of $170 to $263 per share. Centerview then compared the results of this analysis to the value of the
merger consideration of $207.94 per share implied by the closing price of shares of CVS Health common stock on December&nbsp;1, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview also performed a discounted cash flow analysis of Aetna inclusive of the
synergies expected by CVS Health to be realized in connection with the transaction. In performing this analysis, Centerview calculated the estimated present value of the expected annual <FONT STYLE="white-space:nowrap">after-tax</FONT> synergies,
net of the costs to achieve such synergies, referred to in this section of this joint proxy statement/prospectus as net synergies, for the period from 2018 through 2022. The terminal value of the net synergies at the end of the forecast period was
estimated by using perpetuity growth rates ranging from 2.0% to 3.0%, which range was selected using the methodologies and assumptions described above. The net synergies and terminal values were then discounted to present value using discount rates
ranging from 6.5% to 7.5%, which range was selected using the methodologies and assumptions described above. Based on the discounted cash flow analyses Centerview performed on Aetna and the synergies, Centerview calculated implied values per share
of Aetna common stock, including the synergies and rounded to the nearest $1.00, of $193 to $299 per share. Centerview then compared the results of this analysis to the value of the merger consideration of $207.94 per share implied by the closing
price of shares of CVS Health common stock on December&nbsp;1, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Factors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview noted for the board of directors of CVS Health certain additional factors solely for informational purposes, including, among other
things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Historical Stock Price Trading Analysis</I>. Centerview reviewed the stock price performance of Aetna common stock for the <FONT STYLE="white-space:nowrap">52-week</FONT> period prior to December&nbsp;1, 2017, the
last trading day before the public announcement of the transaction. Centerview noted that the range, rounded to the nearest $1.00, of low and high closing prices of Aetna common stock during the prior <FONT STYLE="white-space:nowrap">52-week</FONT>
period was $105.00 to $192.00, as compared to the merger consideration of $207.94 per share implied by the closing price of shares of CVS Health common stock on December&nbsp;1, 2017. Centerview also noted that the highest closing price of Aetna
common stock during the <FONT STYLE="white-space:nowrap">52-week</FONT> period prior to December&nbsp;1, 2017 but prior to the first day on which speculation of the transaction was published was $165. Centerview also noted that historical trading
price analysis is not a valuation methodology and that such analysis was presented for reference purposes only and not as a component of Centerview&#146;s fairness analyses. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Analyst Price Target Analysis</I>. Centerview reviewed stock price targets for Aetna common stock reflected in publicly available Wall Street research analyst reports. Centerview noted that the range of stock price
targets in such research analyst reports prior to the first day on which speculation of the transaction was published was between $150 and $185, and the range of stock price targets in such research analyst reports after the day on which speculation
of the transaction was published was between $165 and $200, as compared to the merger consideration of $207.94 per share implied by the closing price of shares of CVS Health common stock on December&nbsp;1, 2017. Centerview also noted that analyst
price targets are not a valuation methodology and that such analysis was presented for reference purposes only and not as a component of Centerview&#146;s fairness analyses. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Stand-alone CVS Health Financial Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Comparable Public Company Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview also reviewed and compared certain financial information, ratios and multiples for CVS Health to corresponding financial
information, ratios and multiples for publicly traded companies in the retail and pharmacy benefits management industries that Centerview deemed comparable, based on its experience and professional judgment, to CVS Health, which selected publicly
traded companies are referred to in this section of this joint proxy statement/prospectus as the selected CVS Health comparable companies. None of the companies that were selected based on these criteria were subsequently excluded in conducting this
analysis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected CVS Health comparable companies consisted of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:155.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Selected CVS Health Comparable
Companies</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walmart</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Walgreens Boots Alliance</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Express Scripts</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although none of the selected CVS Health comparable companies is directly comparable to CVS Health, these
companies were selected, among other reasons, because they are publicly traded companies with certain operational and financial characteristics, which, for purposes of its analyses, Centerview considered to be similar to those of CVS Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using publicly available information obtained from SEC filings, FactSet data, publicly available Wall Street research and closing stock prices
as of December&nbsp;1, 2017, Centerview calculated, for each selected CVS Health comparable company, and for CVS Health, the following ratios and multiples: (1)&nbsp;enterprise value (calculated as the market value of common equity (determined using
the fully diluted equity value) plus the book value of debt and noncontrolling interests, less cash and cash equivalents) as a multiple of 2017, 2018 and 2019 calendar year estimated EBITDA, and (2)&nbsp;the price to earnings ratio for the 2017,
2018 and 2019 calendar years. Where applicable, the multiples were adjusted to account for certain events such as pending acquisitions and divestitures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of this analysis for the CVS Health comparable companies are summarized below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Minimum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Median</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EV / 2017E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EV / 2018E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EV / 2019E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017E Price / Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018E Price / Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019E Price / Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on its experience and professional judgment, for purposes of its analysis Centerview selected an
enterprise value to estimated calendar year 2018 EBITDA multiple reference range of 7.5x to 9.0x and a price to estimated calendar year 2018 earnings ratio reference range of 10.0x to 15.0x. In selecting these reference ranges, Centerview made
qualitative judgments based on its experience and professional judgment concerning differences between the business, financial and operating characteristics and prospects of CVS Health and the selected CVS Health comparable companies that could
affect the public trading values in order to provide a context in which to consider the results of the quantitative analysis. Applying these reference ranges to the CVS Health management projections, Centerview calculated the following implied
ranges of values per share, rounded to the nearest $1.00, of CVS Health common stock: (1)&nbsp;based on CVS Health&#146;s 2018 calendar year estimated adjusted EBITDA, Centerview calculated an implied range of approximately $74 to $93 per share of
CVS Health common stock, and, based on CVS Health&#146;s 2018 calendar year estimated adjusted earnings per share, Centerview calculated an implied range of approximately $63 to $95 per share of CVS Health common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview also performed a discounted cash flow analysis of CVS Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In performing the discounted cash flow analysis, Centerview calculated the estimated present value of the unlevered free cash flows of CVS
Health reflected in the CVS Health management projections for Q4 2017 and the years from 2018 through 2022. The terminal value of CVS Health at the end of the forecast period was estimated by using perpetuity growth rates ranging from 0.5% to 1.5%.
This range of perpetuity growth rates was estimated by Centerview utilizing its professional judgment and experience, taking into account the CVS Health </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management projections and market expectations regarding long term real growth of gross domestic product and inflation. The unlevered free cash flows and terminal values were then discounted to
present value using discount rates ranging from 6.25% to 7.25%. This range of discount rates was determined based on Centerview&#146;s analysis of CVS Health&#146;s weighted average cost of capital. Based on its analysis, Centerview calculated a
range of implied values per share of CVS Health common stock, rounded to the nearest $1.00, of $80 to $119 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Factors
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview noted for the board of directors of CVS Health certain additional factors solely for informational purposes, including,
among other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Historical Stock Price Trading Analysis</I>. Centerview reviewed the stock price performance of CVS Health common stock for the <FONT STYLE="white-space:nowrap">52-week</FONT> period prior to December&nbsp;1, 2017
and noted that the range, rounded to the nearest $1.00, of low and high closing prices during this period was $66 to $85, as compared to the closing price of shares of CVS Health common stock on December&nbsp;1, 2017 of $75.12. Centerview also noted
that historical trading price analysis is not a valuation methodology and that such analysis was presented for reference purposes only and not as a component of Centerview&#146;s fairness analyses. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Analyst Price Target Analysis. </I>Centerview reviewed stock price targets for shares of CVS Health common stock reflected in publicly available Wall Street research analyst reports and noted that the range of stock
price targets in such research analyst reports was between $73 and $97, as compared to the closing price of shares of CVS Health common stock on December&nbsp;1, 2017 of $75.12. Centerview also noted that analyst price targets are not a valuation
methodology and that such analysis was presented for reference purposes only and not as a component of Centerview&#146;s fairness analyses. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Relative Value Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon a comparison of the range of implied equity values for each of Aetna and CVS Health calculated pursuant to the selected comparable
public companies analysis and discounted cash flow analysis described above, Centerview calculated ranges of implied exchange ratios for the transaction, on a cash adjusted basis with the Aetna equity value contribution reduced by cash consideration
of $145 per share. Centerview calculated these ratios on bases exclusive and inclusive of expected synergies resulting from the transaction. With respect to any given range of exchange ratios, the higher ratio assumes the highest implied value per
share of Aetna common stock divided by the highest implied value per share of CVS Health common stock, and the lower ratio assumes the lowest implied value per share of Aetna common stock divided by the lowest implied value per share of CVS Health
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview&#146;s analysis indicated the following implied ranges of exchange ratios on a basis exclusive of expected
synergies and on a basis inclusive of expected synergies (based upon a present value of the near term synergies equal to $9.4&nbsp;billion with <FONT STYLE="white-space:nowrap">50-75%</FONT> of the value of the synergies attributed to Aetna and the
remainder to CVS Health): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:80.60pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Valuation Methodology</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied&nbsp;Cash&nbsp;Adjusted&nbsp;Exchange&nbsp;Ratio</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Without Synergies</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selected Trading Comparables (EV / EBITDA)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1951x&nbsp;to&nbsp;0.6527x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selected Trading Comparables (2018E Price / Earnings)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2395x&nbsp;to&nbsp;0.6868x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discounted Cash Flow Analysis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3162x&nbsp;to&nbsp;0.9929x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>With Synergies</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selected Trading Comparables (EV / EBITDA)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3637x&nbsp;to&nbsp;0.8594x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selected Trading Comparables (2018E Price / Earnings)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4317x&nbsp;to&nbsp;0.8882x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discounted Cash Flow Analysis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4655x to 1.1485x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview compared the implied ranges of cash adjusted exchange ratios to the implied
transaction exchange ratio of 0.8378 shares of CVS Health common stock per share of Aetna common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of a financial opinion is a complex analytical process involving various determinations as to the most appropriate and relevant
methods of financial analysis and the application of those methods to the particular circumstances and, therefore, a financial opinion is not readily susceptible to summary description. In arriving at its opinion, Centerview did not draw, in
isolation, conclusions from or with regard to any factor or analysis that it considered. Rather, Centerview made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of the
analyses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview&#146;s financial analyses and opinion were only one of many factors taken into consideration by the board of
directors of CVS Health in its evaluation of the transaction. Consequently, the analyses described above should not be viewed as determinative of the views of the board of directors or management of CVS Health with respect to the merger
consideration or as to whether the board of directors of CVS Health would have been willing to determine that a different consideration was fair. The consideration for the transaction was determined through
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations between CVS Health and Aetna and was approved by the board of directors of CVS Health. Centerview provided advice to CVS Health during these negotiations. Centerview did not,
however recommend any specific amount of consideration to CVS Health or CVS Health&#146;s board of directors or that any specific amount of consideration constituted the only appropriate consideration for the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Centerview is a securities firm engaged directly and through affiliates and related persons in a number of investment banking, financial
advisory and merchant banking activities. In the past two years, Centerview has not been engaged on a fee paying basis to provide financial advisory or other services to CVS Health or Aetna, and has not received any compensation from CVS Health or
Aetna during such period. As was disclosed to the CVS Health board of directors prior to its approval of Centerview&#146;s engagement on the transaction, Centerview has from time to time in the past two years engaged in discussions with and provided
certain advisory services to CVS Health with respect to various potential strategic alternatives. However Centerview did not enter into any engagement letters with, or receive any compensation from, CVS Health with respect to any such matters. As
was disclosed to the CVS Health board of directors prior to its approval of Centerview&#146;s engagement on the transaction, Centerview has from time to time in the past two years engaged in discussions with and provided certain advisory services to
Aetna with respect to various potential strategic alternatives. However, Centerview did not enter into any engagement letters with, or receive any compensation from, Aetna with respect to any such matters. Centerview may provide investment banking
and other services to or with respect to CVS Health or Aetna or their respective affiliates in the future, for which Centerview may receive compensation. In addition, as was disclosed to the CVS Health board of directors prior to its approval of
Centerview&#146;s engagement on the transaction, David W. Dorman, Chairman of the Board of Directors of CVS Health, is a partner in the ultimate general partner and the manager of Centerview Capital Technology Fund (Delaware), L.P. and Centerview
Capital Technology <FONT STYLE="white-space:nowrap">Fund-A</FONT> (Delaware), L.P., together with a related employee fund (collectively referred to as Centerview Capital Technology in this summary of Centerview&#146;s opinion), which are growth
equity investment funds focused on the technology sector. Certain partners of Centerview Partners LLC (including the senior member of the Centerview team advising on the transaction) are partners (either directly or indirectly) in the ultimate
general partner and the manager of Centerview Capital Technology and serve on Centerview Capital Technology&#146;s investment committee. Centerview Partners LLC provides certain back office support to Centerview Capital Technology. Mr.&nbsp;Dorman
has no ownership interest in, and is not an employee of, Centerview Partners LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain (i)&nbsp;of Centerview&#146;s and its
affiliates&#146; directors, officers, members and employees, or family members of such persons, (ii)&nbsp;of Centerview&#146;s affiliates or related investment funds and (iii)&nbsp;investment funds or other persons in which any of the foregoing may
have financial interests or with which they may <FONT STYLE="white-space:nowrap">co-invest,</FONT> may at any time acquire, hold, sell or trade, in debt, equity and other securities or financial instruments (including
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
derivatives, bank loans or other obligations) of, or investments in, CVS Health, Aetna or any of their respective affiliates, or any other party that may be involved in the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of CVS Health selected Centerview as its financial advisor in connection with the transaction based on
Centerview&#146;s reputation and experience in the managed care and insurance industries. Centerview is an internationally recognized investment banking firm that has substantial experience in transactions similar to the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Centerview&#146;s services as the financial advisor to the board of directors of CVS Health, CVS Health paid Centerview an
aggregate fee of $12&nbsp;million upon the rendering of Centerview&#146;s opinion. In addition, CVS Health has agreed to reimburse certain of Centerview&#146;s expenses arising, and to indemnify Centerview against certain liabilities that may arise,
out of Centerview&#146;s engagement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_81"></A>Unaudited Prospective Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither CVS Health nor Aetna generally publishes its business plans and strategies or makes external disclosures of its anticipated financial
position or results of operations due to, among other reasons, the uncertainty of the underlying assumptions and estimates, other than, in each case, providing, from time to time, estimated ranges of certain expected financial results and
operational metrics for the current year and certain future years in their respective regular earnings press releases and other investor materials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aetna Projections </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with CVS Health&#146;s evaluation of the merger, Aetna made available on October&nbsp;29, 2017 to CVS Health, Goldman Sachs and Barclays, and on December&nbsp;1, 2017 to Centerview, certain financial forecasts and unaudited prospective financial
information relating to Aetna on a stand-alone basis, assuming Aetna would continue as an independent company, which are referred to in this joint proxy statement/prospectus as the Aetna management projections. The Aetna management projections also
were provided to each of Lazard, Allen&nbsp;&amp; Company and Evercore for their use and reliance in connection with their respective financial analyses and, as applicable, opinions in connection with the merger. The Aetna board of directors also
reviewed and considered the Aetna management projections at the meetings of the Aetna board of directors on October&nbsp;27, 2017, November&nbsp;14, 2017, November&nbsp;20, 2017, December&nbsp;1, 2017 and December&nbsp;3, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Aetna projections (as defined below) reflect numerous assumptions and estimates that Aetna made in good faith, including, without
limitation, (i)&nbsp;with respect to the projections of Aetna adjusted earnings per share, that Aetna, as a stand-alone company, would continue to repurchase its common shares in the ordinary course of business; (ii)&nbsp;that macroeconomic
conditions would remain stable, both in the U.S. and globally; (iii)&nbsp;that the Patient Protection and Affordable Care Act would not be repealed or defunded; (iv)&nbsp;that the interest rate environment would remain stable; (v)&nbsp;that
competitor pricing would remain rational; (vi)&nbsp;that commercial medical cost trends would be in line with recent experience; (vii)&nbsp;that the Medicare Advantage and managed Medicaid rate environments would remain stable; (viii)&nbsp;that
Medicare Advantage membership would grow in excess of industry growth and Medicaid membership would return to growth in 2019; (ix)&nbsp;that consumers would continue to take on greater decision-making and financial responsibility with respect to
their health care; (x)&nbsp;that providers would remain receptive to partnering with Aetna on value-based contracting to reduce the cost of care, improve quality and provide consumers with better health care experiences; (xi)&nbsp;that the annual
premium-based health insurer fee under the Patient Protection and Affordable Care Act (which is referred to in this joint proxy statement/prospectus as the HIF) returns in 2018 and applies to each year thereafter;&nbsp;(xii) that the tax laws,
including corporate tax rates, remain unchanged relative to such laws (including such rates) as in effect on October&nbsp;29, 2017; (xiii)&nbsp;that the sale of Aetna&#146;s domestic group life insurance, group disability insurance and absence
management businesses occurred; and (xiv)&nbsp;certain other matters referred to below under &#147;&#151;General&#148; beginning on page&nbsp;164 of this joint proxy statement/prospectus. The Aetna projections also assume that GAAP as in effect on
October&nbsp;29, 2017 applies throughout the projection period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a summary of the Aetna management projections: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(dollars in billions, except for per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna adjusted revenue (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna adjusted earnings (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna adjusted earnings per share (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Aetna adjusted revenue means total revenue excluding net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of Aetna&#146;s business nor reflect Aetna&#146;s underlying
business performance. Projected full-year 2017 Aetna adjusted revenue excludes from total revenue interest income on the proceeds of Aetna&#146;s June 2016 debt financing of $11&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax</FONT> and net
realized capital losses for the nine months ended September&nbsp;30, 2017 of $262&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax.</FONT> The interest income on the proceeds of Aetna&#146;s June 2016 debt financing was excluded from total
revenue because it neither relates to the ordinary course of Aetna&#146;s business nor reflects Aetna&#146;s underlying business performance. Net realized capital gains and losses arise from various types of transactions, primarily in the course of
managing a portfolio of assets that support the payment of liabilities. However, these transactions do not directly relate to the underwriting or servicing of products for customers and are not directly related to the core performance of
Aetna&#146;s business operations. Aetna will experience net realized capital gains or net realized capital losses subsequent to September&nbsp;30, 2017, however Aetna cannot project the amount of such future gains or losses. Therefore, Aetna has
assumed no net realized capital gains or losses after September&nbsp;30, 2017 for purposes of projecting total revenue, net income attributable to Aetna, which is referred to in this section of this joint proxy statement/prospectus as net income,
and income before income taxes for the years ending December&nbsp;31, 2017 to 2022. Aetna&#146;s annual net realized capital gains or losses ranged from a net realized capital loss of $65&nbsp;million to a net realized capital gain of
$86&nbsp;million during calendar years 2014 through 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Aetna adjusted earnings means net income, excluding amortization of other acquired intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of
Aetna&#146;s business nor reflect Aetna&#146;s underlying business performance. Projected full-year 2017 Aetna adjusted earnings exclude from projected full-year 2017 net income the loss on early extinguishment of long-term debt of $246&nbsp;million
<FONT STYLE="white-space:nowrap">pre-tax,</FONT> projected guaranty fund assessments related to the insolvency of Penn Treaty Network America Insurance Company and one of its affiliates, which are referred to in this joint proxy statement/prospectus
as the projected Penn Treaty-related guaranty fund assessments, of $231&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> transaction and integration-related costs (including termination costs) primarily related to the Humana transaction
of $1.2&nbsp;billion <FONT STYLE="white-space:nowrap">pre-tax,</FONT> the reduction of Aetna&#146;s reserve for anticipated future losses on discontinued products of $(109) million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> estimated
amortization of other acquired intangible assets of approximately $230&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> net realized capital losses for the nine months ended September&nbsp;30, 2017 of $262&nbsp;million <FONT
STYLE="white-space:nowrap">pre-tax,</FONT> other items, if any, that neither relate to the ordinary course of Aetna&#146;s business nor reflect Aetna&#146;s underlying business performance and the corresponding income tax benefit related to the
items excluded from net income discussed above of approximately $(800) million. Although the excluded items may recur, management believes that Aetna adjusted earnings and Aetna adjusted earnings per share provide a more useful comparison of
Aetna&#146;s underlying business performance from period to period. Amortization of other acquired intangible assets relates to Aetna&#146;s acquisition activities, however this amortization does not directly relate to the underwriting or servicing
of products for customers and is not directly related to the core performance of Aetna&#146;s business operations. Refer to note (1)&nbsp;above for a discussion of net realized capital gains and losses. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Aetna adjusted earnings per share means (i)&nbsp;Aetna adjusted earnings, as described in note (2)&nbsp;above, divided by (ii)&nbsp;the projected number of weighted average diluted Aetna common shares. Projected
full-year 2017 net income per share and Aetna adjusted earnings per share reflect a range of 334&nbsp;million to 335&nbsp;million weighted average diluted Aetna common shares. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Aetna adjusted revenue, Aetna adjusted earnings and Aetna adjusted earnings per share, as presented above in the Aetna management
projections, is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. Aetna prepared this information as part of its ordinary
course internal business and strategic planning process, and not for external disclosure. Aetna cannot project either the amount of any other items excluded from net income or total revenue for the years ending December&nbsp;31, 2018 through 2022 or
the amount of future net realized capital gains or losses; therefore Aetna cannot reconcile Aetna adjusted revenue, Aetna adjusted earnings or Aetna adjusted earnings per share to the respective most directly comparable financial measure calculated
and presented in accordance with GAAP for any of those periods. Projected amortization of other acquired intangible assets is approximately $200&nbsp;million, $190&nbsp;million, $180&nbsp;million, $155&nbsp;million and $155&nbsp;million <FONT
STYLE="white-space:nowrap">pre-tax,</FONT> respectively, for the years ending December&nbsp;31, 2018 through 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain other
unaudited prospective financial information relating to Aetna on a stand-alone basis, assuming Aetna would continue as an independent company, was calculated based on the Aetna management projections and provided to each of Lazard, Allen&nbsp;&amp;
Company and Evercore for their use and reliance in connection with their respective financial analyses and, as applicable, opinions in connection with the merger, including, in the case of the following unlevered free cash flow estimates,
Lazard&#146;s and Allen&nbsp;&amp; Company&#146;s respective discounted cash flow analyses as described under &#147;&#151;Opinions of Aetna&#146;s Financial Advisors&#151;Opinion of Lazard Fr&egrave;res&nbsp;&amp; Co. LLC&#151;Aetna Financial
Analyses&#151;Discounted Cash Flow Analysis&#148; and &#147;&#151;Opinions of Aetna&#146;s Financial Advisors&#151;Opinion of Allen&nbsp;&amp; Company LLC&#151;Aetna Financial Analyses&#151;Discounted Cash Flow Analysis&#148; beginning on
pages&nbsp;114 and 123, respectively, of this joint proxy statement/prospectus. This information is referred to in this joint proxy statement/prospectus as the supplemental Aetna projections, and together with the Aetna management projections, the
Aetna projections. The Aetna board of directors reviewed and considered the supplemental Aetna projections at the meetings of the Aetna board of directors on October&nbsp;27, 2017, November&nbsp;14, 2017, November&nbsp;20, 2017, December&nbsp;1,
2017 and December&nbsp;3, 2017. On October&nbsp;29, 2017, Aetna made available to CVS Health, Goldman Sachs and Barclays the supplemental Aetna projections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a summary of the supplemental Aetna projections: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(dollars in billions)<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna adjusted EBITDA (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna unlevered free cash flow (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Aetna adjusted EBITDA means income before income taxes, excluding interest expense, depreciation and amortization, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course
of Aetna&#146;s business nor reflect Aetna&#146;s underlying business performance. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Aetna unlevered free cash flow means net income, excluding: (i)&nbsp;net realized capital gains or losses, (ii)&nbsp;other items, if any, that neither relate to the ordinary course of Aetna&#146;s business nor reflect
Aetna&#146;s underlying business performance as described above, (iii)&nbsp;the corresponding income tax benefit or expense related to net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of
Aetna&#146;s business nor reflect Aetna&#146;s underlying business performance that are excluded from net income as described above; less (I)&nbsp;risk based capital contributions (distributions), (II) changes in Aetna Inc.&#146;s working capital, <FONT
STYLE="white-space:nowrap">(III)&nbsp;after-tax</FONT> pension plan contributions, <FONT STYLE="white-space:nowrap">(IV)&nbsp;after-tax</FONT> debt retirement premiums, (V)&nbsp;acquisitions and investments and
<FONT STYLE="white-space:nowrap">(VI)&nbsp;after-tax</FONT> Humana related termination fees; plus <FONT STYLE="white-space:nowrap">(a)&nbsp;after-tax</FONT> net interest, (b)&nbsp;other net cash flow adjustments and (c)&nbsp;capital projected to be
released due to the sale of Aetna&#146;s domestic group life insurance, group disability insurance and absence management businesses. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Aetna adjusted EBITDA and Aetna unlevered free cash flow, as presented above in the supplemental Aetna projections, is a <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance
with GAAP. Refer to the description above for a discussion of net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of Aetna&#146;s business nor reflect Aetna&#146;s underlying business performance
that were excluded from the relevant GAAP metric. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Projected full-year 2017 Aetna adjusted EBITDA excludes from projected full-year 2017 income
before income taxes the loss on early extinguishment of long-term debt of $246&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> the projected Penn Treaty-related guaranty fund assessments of $231&nbsp;million <FONT
STYLE="white-space:nowrap">pre-tax,</FONT> transaction and integration-related costs (including termination costs) primarily related to the Humana transaction of $1.2&nbsp;billion <FONT STYLE="white-space:nowrap">pre-tax,</FONT> the reduction of
Aetna&#146;s reserve for anticipated future losses on discontinued products of $(109) million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> net realized capital losses for the nine months ended September&nbsp;30, 2017 of $262&nbsp;million <FONT
STYLE="white-space:nowrap">pre-tax,</FONT> other items, if any, that neither relate to the ordinary course of Aetna&#146;s business nor reflect Aetna&#146;s underlying business performance, projected interest expense of approximately
$360&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax</FONT> and projected depreciation and amortization expense of approximately $655&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax.</FONT> Projected interest expense is approximately
$360&nbsp;million, $380&nbsp;million, $400&nbsp;million, $420&nbsp;million and $470&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> respectively, for the years ending December&nbsp;31, 2018 through 2022. Projected depreciation and
amortization is approximately $610&nbsp;million, $630&nbsp;million, $635&nbsp;million, $630&nbsp;million and $650&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> respectively, for the years ending December&nbsp;31, 2018 through 2022.
Aetna cannot project either the amount of any other items excluded from income before income taxes for the years ending December&nbsp;31, 2018 through 2022 or the amount of future net realized capital gains or losses; therefore Aetna cannot
reconcile Aetna adjusted EBITDA to the most directly comparable financial measure calculated and presented in accordance with GAAP for any of those periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Projected full-year 2017 Aetna unlevered free cash flow excludes from projected full-year 2017 net income the loss on early extinguishment of
long-term debt of $246&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> the projected Penn Treaty-related guaranty fund assessments of $231&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> transaction and
integration-related costs (including termination costs) primarily related to the Humana transaction of $1.2&nbsp;billion <FONT STYLE="white-space:nowrap">pre-tax,</FONT> the reduction of Aetna&#146;s reserve for anticipated future losses on
discontinued products of $(109) million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> net realized capital losses for the nine months ended September&nbsp;30, 2017 of $262&nbsp;million <FONT STYLE="white-space:nowrap">pre-tax,</FONT> other items,
if any, that neither relate to the ordinary course of Aetna&#146;s business nor reflect Aetna&#146;s underlying business performance, the corresponding income tax benefit related to net realized capital gains or losses and other items, if any, that
neither relate to the ordinary course of Aetna&#146;s business nor reflect Aetna&#146;s underlying business performance that are excluded from net income of approximately $(700) million; less risk based capital contributions of approximately
$60&nbsp;million, changes in Aetna Inc.&#146;s working capital of approximately $(60) million, <FONT STYLE="white-space:nowrap">after-tax</FONT> debt retirement premiums of approximately $(95) million, acquisitions and investments of approximately
$(30) million and <FONT STYLE="white-space:nowrap">after-tax</FONT> Humana related termination fees of approximately $(660) million; plus <FONT STYLE="white-space:nowrap">after-tax</FONT> net interest of approximately $230&nbsp;million, other net
cash flow adjustments of approximately $(215) million and capital projected to be released due to the sale of Aetna&#146;s domestic group life insurance, group disability insurance and absence management businesses of approximately
$975&nbsp;million. Projected risk based capital contributions are approximately $(15) million, $(1.1) billion, $(1.1) billion, $(1.1) billion and $(1.2) billion, respectively, for the years ending December&nbsp;31, 2018 through 2022. Projected
changes in Aetna Inc.&#146;s working capital are approximately $(50) million for each of the years ending December&nbsp;31, 2018 through 2022. Projected <FONT STYLE="white-space:nowrap">after-tax</FONT> pension plan contributions are approximately
$(40) million for each of the years ending December&nbsp;31, 2018 through 2022. Projected <FONT STYLE="white-space:nowrap">after-tax</FONT> net interest is approximately $235&nbsp;million, $250&nbsp;million, $260&nbsp;million, $270&nbsp;million and
$310&nbsp;million, respectively, for the years ending December&nbsp;31, 2018 through 2022. Projected other net cash flow adjustments are approximately $(15) million, $190&nbsp;million, $(80) million, $(100) million and $(120) million, respectively,
for the years ending December&nbsp;31, 2018 through 2022. Capital projected to be released due to the sale of Aetna&#146;s domestic group life insurance, group disability insurance and absence management businesses is approximately $400&nbsp;million
for each of the years ending December&nbsp;31, 2018 and 2019. Aetna cannot project either the amount of any other items excluded from net income for the years ending December&nbsp;31, 2018 through 2022 or the amount of future net realized capital
gains or losses; therefore Aetna cannot reconcile Aetna unlevered free cash flow to the most directly comparable financial measure calculated and presented in accordance with GAAP for any of those periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adjusted Aetna Projections </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with its evaluation of the merger and the preparation of the CVS Health combined company projections described below (see &#147;&#151;CVS Health Combined Company Projections&#148; beginning on page&nbsp;161 of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this joint proxy statement/prospectus), CVS Health made certain adjustments to the assumptions and estimates underlying the Aetna projections in light of, among other things, the due diligence
CVS Health conducted on Aetna, the potential impact of the transaction pursuant to the terms of the merger agreement and other effects of the transaction, and certain macroeconomic and industry trends. CVS Health&#146;s adjusted version of the Aetna
projections are referred to in this joint proxy statement/prospectus as the adjusted Aetna projections. The adjusted Aetna projections were made available by CVS Health to each of Barclays, Goldman Sachs and Centerview for purposes of their
respective financial analyses and opinions. CVS Health directed each of Barclays, Goldman Sachs and Centerview to use and rely upon (and each of Barclays, Goldman Sachs and Centerview accordingly used and relied upon) the adjusted Aetna projections
for purposes of their respective financial analyses and opinions (see &#147;&#151;Opinions of CVS Health&#146;s Financial Advisors&#148; beginning on page&nbsp;128 of this joint proxy statement/prospectus). The CVS Health board of directors also
reviewed and considered the adjusted Aetna projections in connection with its review of Barclays&#146; and Goldman Sachs&#146; respective financial analyses at the meeting of the CVS Health board of directors held on November&nbsp;30, 2017 and
Barclays&#146;, Goldman Sachs&#146; and Centerview&#146;s respective financial analyses and opinions at the meeting of the CVS Health board of directors held on December&nbsp;3, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a summary of the adjusted Aetna projections. While the adjusted Aetna projections reflect certain adjustments
made by CVS Health&#146;s management to the assumptions and estimates underlying the Aetna projections, the aggregate effect of these adjustments to such projections was not significant. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(dollars in billions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna adjusted revenue (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna adjusted earnings (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna adjusted EBITDA (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna unlevered free cash flow (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Each of Aetna adjusted revenue, Aetna adjusted earnings, Aetna adjusted EBITDA and Aetna unlevered free cash flow has the meaning set forth above under &#147;&#151;Aetna Projections&#148; beginning on page&nbsp;155 of
this joint proxy statement/prospectus. As further described above (see &#147;&#151;Aetna Projections&#148; beginning on page&nbsp;155 of this joint proxy statement/prospectus), Aetna adjusted revenue, Aetna adjusted earnings, Aetna adjusted EBITDA
and Aetna unlevered free cash flow, as presented above in the adjusted Aetna projections, are each a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. As further described above, <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP, and these measures cannot be reconciled to the respective most directly comparable financial measure
calculated and presented in accordance with GAAP for any of the periods presented. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adjusted Aetna projections were not
prepared with a view to public disclosure and are included in this joint proxy statement/prospectus only because such information was made available, in whole or in part, to Barclays, Goldman Sachs and Centerview for purposes of their respective
financial analyses and opinions (see &#147;&#151;Opinions of CVS Health&#146;s Financial Advisors&#148; beginning on page&nbsp;128 of this joint proxy statement/prospectus). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CVS Health Management Projections </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Aetna&#146;s evaluation of the merger, CVS Health made available to each of Aetna, Lazard, Allen&nbsp;&amp; Company and
Evercore certain financial forecasts and unaudited prospective financial information relating to CVS Health for the years ending December&nbsp;31, 2017 through December&nbsp;31, 2021 prepared by CVS Health management on a stand-alone basis, assuming
CVS Health would continue as an independent company, without giving effect to the merger, which are referred to in this joint proxy statement/prospectus as the CVS Health management projections. The CVS Health management projections for the years
ending December&nbsp;31, 2017 through December&nbsp;31, 2022 were provided to each of Barclays, Goldman Sachs and Centerview for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes of their respective financial analyses and opinions (see &#147;&#151;Opinions of CVS Health&#146;s Financial Advisors&#148; beginning on page&nbsp;128 of this joint proxy
statement/prospectus). CVS Health directed each of Barclays, Goldman Sachs and Centerview to use and rely upon (and each of Barclays, Goldman Sachs and Centerview accordingly used and relied upon) the CVS Health management projections for purposes
of their respective financial analyses and opinions. The CVS Health board of directors also reviewed and considered the CVS Health management projections at the meetings of the CVS Health board of directors held on November&nbsp;30, 2017 and
December&nbsp;3, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVS Health management projections reflect numerous assumptions and estimates that CVS Health made in good
faith, including, without limitation, (i)&nbsp;that macroeconomic conditions will remain stable, both in the U.S. and globally; (ii)&nbsp;that no major changes occur in U.S. policy, laws and regulations, including reform of the United States health
care system and tax laws; (iii)&nbsp;that gross margins in the pharmacy benefit management, retail pharmacy and long-term care pharmacy industries remain stable; (iv)&nbsp;that no new regulatory and business changes occur relating to CVS
Health&#146;s participation in Medicare Part D; (v)&nbsp;that no major changes in industry pricing benchmarks and drug pricing generally occur, (vi)&nbsp;that reimbursement pressure does not accelerate significantly; (vii) that the sale of CVS
Health&#146;s RxCrossroads business occurred and (viii)&nbsp;certain other matters referred to below under &#147;&#151;General&#148; beginning on page&nbsp;164 of this joint proxy statement/prospectus. The CVS Health management projections also
assume that GAAP as in effect on November&nbsp;7, 2017 applies throughout the projection period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a summary
of the CVS Health management projections: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022P&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(dollars in billions, except for per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">205.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">217.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">231.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">245.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health adjusted EBITDA (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health adjusted net income (3)(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health adjusted earnings per share (4)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The CVS Health management projections for 2022 were provided to each of Barclays, Goldman Sachs and Centerview for purposes of their respective financial analyses and opinions. The CVS Health management projections for
2022 were not provided to Aetna, Lazard, Allen &amp; Company or Evercore. Accordingly, the CVS Health management projections, as such term is used in the section below entitled &#147;&#151;Calculated CVS Health Projections&#148; beginning on page
162 of this joint proxy statement/prospectus, do not include the prospective financial information set forth under the column labeled 2022P in the table above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">CVS Health adjusted EBITDA is a non-GAAP financial measure defined as earnings before income tax provision, interest, depreciation and amortization (excluding the impact, when applicable, of acquisition-related
transaction and integration costs, charges in connection with store rationalization, goodwill impairments, losses on settlements of defined benefit pension plans and other items, if any, that neither relate to the ordinary course of CVS
Health&#146;s business nor reflect CVS Health&#146;s underlying business performance). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">CVS Health adjusted net income is a non-GAAP financial measure defined as income from continuing operations (excluding the impact, when applicable, of the amortization of intangible assets, acquisition-related
transaction and integration costs, charges in connection with store rationalization, goodwill impairments, losses on settlements of defined benefit pension plans and other items, if any, that neither relate to the ordinary course of CVS
Health&#146;s business nor reflect CVS Health&#146;s underlying business performance). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The respective financial analyses and opinions (see &#147;&#151;Opinion of Barclays Capital Inc.&#148; and
&#147;&#151;Opinion of Goldman Sachs &amp; Co. LLC&#148; beginning on pages 128 and 132, respectively, of this joint proxy statement/prospectus) of Barclays and Goldman Sachs utilized certain further adjustments to the CVS Health management
projections set forth in the table above related to the sale of RxCrossroads, which further adjustments were approved by management of CVS Health. These further adjustments had the impact of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
reducing CVS Health adjusted earnings per share by $0.02 per share for each of the years ending December&nbsp;31, 2018 through 2022. Accordingly, the CVS Health management projections for the
sections entitled &#147;&#151;Opinion of Barclays Capital Inc.&#148; and &#147;&#151;Opinion of Goldman Sachs &amp; Co. LLC&#148; beginning on pages 128 and 132, respectively, of this joint proxy statement/prospectus, utilize such further
adjustments. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">CVS Health adjusted earnings per share is a non-GAAP financial measure defined as (i)&nbsp;CVS Health adjusted net income as described in note&nbsp;(3) above, divided by (ii)&nbsp;the projected number of weighted
average diluted shares of CVS Health common stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health adjusted EBITDA, CVS Health adjusted net income and CVS
Health adjusted earnings per share, as presented above, are each a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. This information was not prepared for public disclosure. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT>
financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. Additionally, <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures as presented by CVS
Health may not be comparable to similarly titled measures reported by other companies. In the view of CVS Health&#146;s management, the CVS Health management projections were prepared on a reasonable basis based on the information available to CVS
Health&#146;s management at the time of their preparation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CVS Health Combined Company Projections </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its evaluation of the merger, CVS Health management made available to Barclays, Goldman Sachs and Centerview certain
financial forecasts and unaudited prospective financial information relating to CVS Health and Aetna as a combined company, giving effect to the merger, which is referred to in this joint proxy statement/prospectus as the CVS Health combined company
projections. The CVS Health combined company projections were provided to each of Barclays, Goldman Sachs and Centerview for purposes of their respective financial analyses and opinions. CVS Health directed each of Barclays, Goldman Sachs and
Centerview to use and rely upon (and each of Barclays, Goldman Sachs and Centerview accordingly used and relied upon) the CVS Health combined company projections for purposes of their respective financial analyses and opinions (see
&#147;&#151;Opinions of CVS Health&#146;s Financial Advisors&#148; beginning on page&nbsp;128 of this joint proxy statement/prospectus). The CVS Health board of directors also reviewed and considered the CVS Health combined company projections at
the meetings of the CVS Health board of directors held on November&nbsp;30, 2017 and December&nbsp;3, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CVS Health combined
company projections reflect numerous assumptions and estimates that CVS Health made in good faith in connection with the preparation of the adjusted Aetna projections and the CVS Health management projections as more fully described in
&#147;&#151;Adjusted Aetna Projections&#148; and &#147;&#151;CVS Health Management Projections&#148; beginning on pages&nbsp;158 and 159, respectively, of this joint proxy statement/prospectus. Additionally, the CVS Health combined company
projections reflect estimated synergies of $750&nbsp;million by the second full year following completion of the merger (which is assumed to be completed in the second half of 2018 for purposes of calculating the estimated synergies), which increase
by 5% per year thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a summary of the CVS Health combined company projections: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(dollars in billions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health combined company net revenue (1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">251.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">272.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">291.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">311.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">333.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health combined company adjusted EBITDA (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health combined company adjusted net income (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Does not include any intercompany revenue eliminations between CVS Health and Aetna. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">CVS Health combined company net revenue is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure that reflects the combination of CVS Health net revenue, a GAAP measure, with Aetna adjusted revenue, a <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measure defined above under &#147;&#151;Aetna Projections&#148; beginning on page&nbsp;155 of this joint proxy statement/prospectus. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">CVS Health combined company adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure defined as earnings before income tax provision, interest, depreciation and amortization (excluding the
impact, when applicable, of acquisition-related transaction and integration costs, charges in connection with store rationalization, goodwill impairments, losses on settlements of defined benefit pension plans, net realized capital gains or losses
and other items, if any, that neither relate to the ordinary course of the combined company&#146;s business nor reflect the combined company&#146;s underlying business performance). CVS Health combined company adjusted EBITDA reflects the estimated
synergies of $750&nbsp;million by the second full year following completion of the merger (which is assumed to be completed in the second half of 2018 for purposes of calculating the estimated synergies), which increase by 5% per year thereafter.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">CVS Health combined company adjusted net income is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure defined as income from continuing operations
(excluding<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>the impact, when applicable, of the amortization of intangible assets, acquisition-related transaction and integration costs, charges in connection with store rationalization, goodwill
impairments, losses on settlements of defined benefit pension plans, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the combined company&#146;s business nor reflect the combined
company&#146;s underlying business performance). CVS Health combined company adjusted net income reflects the estimated synergies of $750&nbsp;million by the second full year following completion of the merger (which is assumed to be completed in
the second half of 2018 for purposes of calculating the estimated synergies), which increase by 5% per year thereafter. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS
Health combined company net revenue, CVS Health combined company adjusted EBITDA and CVS Health combined company adjusted net income, as presented above, are each a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. This information
was prepared for use by CVS Health and Barclays, Goldman Sachs and Centerview for purposes of their respective financial analyses and opinions and not for public disclosure. Net realized capital gains and losses arise from various types of
transactions, primarily in the course of managing a portfolio of assets that support the payment of liabilities. However, these transactions do not directly relate to the core performance of CVS Health&#146;s business operations. CVS Health is not
able to project the amount of future net realized capital gains or losses or any other items excluded from CVS Health combined company net revenue, CVS Health combined company adjusted EBITDA or CVS Health combined company adjusted net income as
defined in the immediately preceding notes&nbsp;(2), (3) and (4), respectively (other than estimated amortization of other acquired intangible assets and projected transaction and integration-related costs), and CVS Health therefore cannot reconcile
CVS Health combined company net revenue, CVS Health combined company adjusted EBITDA or CVS Health combined company adjusted net income to the respective most directly comparable financial measure calculated and presented in accordance with GAAP. <FONT
STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. Additionally,
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures as presented by CVS Health may not be comparable to similarly titled measures reported by other companies. In the view of CVS Health&#146;s management, the CVS Health combined
company projections were prepared on a reasonable basis based on the information available to CVS Health&#146;s management at the time of their preparation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calculated CVS Health Projections </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain other unaudited prospective financial information relating to CVS Health on a stand-alone basis, assuming CVS Health would continue as
an independent company, was calculated by Aetna, based on the CVS Health management projections, and provided to each of Lazard, Allen&nbsp;&amp; Company and Evercore for their use and reliance in connection with their respective financial analyses
and, as applicable, opinions, in connection with the merger, including Lazard&#146;s and Allen&nbsp;&amp; Company&#146;s respective discounted cash flow analyses as described under &#147;&#151;Opinions of Aetna&#146;s Financial Advisors&#151;Opinion
of Lazard Fr&egrave;res&nbsp;&amp; Co. LLC&#151;CVS Health Financial Analyses&#151;Discounted Cash Flow Analysis&#148; and &#147;&#151;Opinions of Aetna&#146;s Financial Advisors&#151;Opinion of Allen&nbsp;&amp; Company LLC&#151;CVS Health Financial
Analyses&#151;Discounted Cash Flow Analysis&#148; beginning on pages&nbsp;116 and 126, respectively, of this joint proxy statement/prospectus. This information is referred to in this joint proxy statement/prospectus as the calculated CVS Health
projections and, together with the CVS Health management projections, the CVS Health projections. The Aetna board of directors reviewed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and considered the calculated CVS Health projections at the meetings of the Aetna board of directors on November&nbsp;14, 2017, December&nbsp;1, 2017 and December&nbsp;3, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a summary of the calculated CVS Health projections: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(dollars in billions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health unlevered free cash flow (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">CVS Health unlevered free cash flow means CVS Health adjusted EBITDA as defined above under &#147;&#151;CVS Health Management Projections&#148; beginning on page 159 of this joint proxy statement/prospectus, less
unlevered cash taxes, plus/minus change in working capital, less capital expenditures, plus sale-leaseback proceeds. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS
Health unlevered free cash flow, as presented above in the calculated CVS Health projections, is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures should not be
considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP, and this measure cannot be reconciled to the most directly comparable financial measure calculated and presented in accordance with
GAAP for any of the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Extrapolated CVS Health Projections </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in &#147;&#151;CVS Health Management Projections&#148; beginning on page&nbsp;159 of this joint proxy statement/prospectus and
&#147;&#151;Calculated CVS Health Projections&#148; beginning on page&nbsp;162 of this joint proxy statement/prospectus, the CVS Health projections provided to Aetna, Lazard, Allen&nbsp;&amp; Company and Evercore included projections only for years
2017 through 2021. In connection with its evaluation of the merger, Aetna extrapolated from the CVS Health projections, with reference to Wall Street research, an additional year of projections for CVS Health, referred to in this joint proxy
statement/prospectus as the extrapolated CVS Health projections. Aetna directed each of Lazard, Allen&nbsp;&amp; Company and Evercore to use and rely upon the extrapolated CVS Health projections for purposes of their respective financial analyses
and, as applicable, opinions, in connection with the merger (see &#147;&#151;Opinions of Aetna&#146;s Financial Advisors&#148; beginning on page&nbsp;111 of this joint proxy statement/prospectus). The Aetna board of directors also reviewed and
considered the extrapolated CVS Health projections at the meetings of the Aetna board of directors on November&nbsp;14, 2017, December&nbsp;1, 2017 and December&nbsp;3, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a summary of the extrapolated CVS Health projections: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022P</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(dollars&nbsp;in&nbsp;billions,&nbsp;except<BR>for per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">240.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health adjusted earnings per share (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health adjusted EBITDA (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Health unlevered free cash flow (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Each of CVS Health adjusted earnings per share and CVS Health adjusted EBITDA has the meaning set forth above under &#147;&#151;CVS Health Management Projections&#148; beginning on page&nbsp;159 of this joint proxy
statement/prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">CVS Health unlevered free cash flow has the meaning set forth above under &#147;&#151;Calculated CVS Health Projections&#148; beginning on page&nbsp;162 of this joint proxy statement/prospectus. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As further described above (see &#147;&#151;CVS Health Management Projections&#148; and
&#147;&#151;Calculated CVS Health Projections&#148; beginning on pages&nbsp;159 and 162, respectively, of this joint proxy statement/prospectus), CVS Health adjusted earnings per share, CVS Health adjusted EBITDA and CVS Health unlevered free cash
flow, as presented above in the extrapolated CVS Health projections, are each a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. As further described above, <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures
should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP, and these measures cannot be reconciled to the respective most directly comparable financial measure calculated and
presented in accordance with GAAP for any of the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summaries of the parties&#146; respective projections included above are provided to give CVS Health&#146;s stockholders and Aetna&#146;s
shareholders access to certain <FONT STYLE="white-space:nowrap">non-public</FONT> information that was made available to CVS Health, Aetna and their respective boards of directors and financial advisors in connection with the parties&#146;
evaluation of the merger. The parties&#146; projections were, in general, prepared solely for internal use and are subjective in many respects and thus subject to interpretation. While presented with numerical specificity, the parties&#146;
projections reflect numerous assumptions and estimates that the parties preparing such projections made in good faith at the time such projections were prepared with respect to industry performance, general business, economic, regulatory, market and
financial conditions and other future events, as well as matters specific to the applicable party. These assumptions are inherently uncertain, were made as of the date the parties&#146; projections were prepared, and may not be reflective of actual
results, either since the date such projections were prepared, now or in the future, in light of changed circumstances, economic conditions, or other developments. Some or all of the assumptions that have been made regarding, among other things, the
timing of certain occurrences or impacts, may have changed since the date the parties&#146; projections were prepared. For example, in December 2017 the Tax Cuts and Jobs Act of 2017 (which is referred to in this joint proxy statement/prospectus as
the TCJA) became effective, and in January 2018 the HIF was suspended for 2019. The parties&#146; projections were based on numerous variables and assumptions that are inherently uncertain and may be beyond the control of CVS Health or Aetna, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Important factors that may affect actual results and cause the parties&#146; projections not to be achieved include risks and
uncertainties relating to CVS Health&#146;s and Aetna&#146;s businesses (including their abilities to achieve their respective strategic goals, objectives and targets over applicable periods; industry conditions; the regulatory environment; general
business and economic conditions; and other factors described under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; beginning on pages&nbsp;62 and 72, respectively, of this joint proxy
statement/prospectus, as well as the risk factors with respect to CVS Health&#146;s and Aetna&#146;s respective businesses contained in their most recent SEC filings, which readers are urged to review, which may be found as described under
&#147;Where You Can Find More Information&#148; beginning on page&nbsp;254 of this joint proxy statement/prospectus). In addition, the parties&#146; projections cover multiple future years, and such information by its nature is less reliable in
predicting each successive year. The parties&#146; projections also do not take into account any circumstances or events occurring after the date on which they were prepared, and do not give effect to the transactions contemplated by the merger
agreement, including the merger, except that, as described above, the CVS Health combined company projections give effect to the completion of the merger. For example, the parties&#146; projections do not take into account the TCJA or the suspension
of the HIF for 2019. The parties&#146; projections also reflect assumptions as to certain business decisions that are subject to change. As a result, actual results may differ materially from those contained in the parties&#146; projections.
Accordingly, there can be no assurance that the parties&#146; projections will be realized or that actual results will not be significantly lower than projected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties&#146; projections were not prepared with a view toward complying with GAAP (including because certain metrics are <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> measures as discussed above), the published guidelines of the SEC regarding projections or the guidelines established by the American Institute of Certified Public Accountants for preparation and
presentation of prospective financial information. Neither CVS Health&#146;s nor Aetna&#146;s independent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registered public accounting firm, nor any other independent accountants, have compiled, examined or performed any procedures with respect to either party&#146;s projections, nor has any of them
expressed any opinion or any other form of assurance on either party&#146;s projections or the achievability of the results reflected in either party&#146;s projections, and none of them assumes any responsibility for, and each of them disclaims any
association with, either party&#146;s projections. The reports of CVS Health&#146;s and Aetna&#146;s independent registered public accounting firms incorporated by reference into this joint proxy statement/prospectus relate to CVS Health&#146;s and
Aetna&#146;s historical financial information, respectively, and no such report extends to either party&#146;s projections or should be read to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The inclusion of the parties&#146; respective projections in this joint proxy statement/prospectus should not be regarded as an indication
that any of CVS Health, Aetna or their respective affiliates, officers, directors, employees, advisors or other representatives considered either party&#146;s projections to be predictive of actual future events, and the parties&#146; respective
projections should not be relied on as such. None of CVS Health, Aetna or their respective affiliates, officers, employees, directors, advisors or other representatives can give you any assurance that actual results will not differ from the
parties&#146; respective projections, and none of CVS Health, Aetna or their respective affiliates, officers, employees or directors undertakes any obligation to update or otherwise revise or reconcile either party&#146;s projections to reflect
circumstances existing after the date the parties&#146; respective projections were prepared or to reflect the occurrence of future events even in the event that any or all of the assumptions underlying the parties&#146; respective projections are
not realized. Neither CVS Health nor Aetna intends to publicly update or make any other revision to either party&#146;s projections. None of CVS Health, Aetna or any of their respective affiliates, officers, employees, directors, advisors or other
representatives has made or makes any representation to any CVS Health stockholder, Aetna shareholder or any other person regarding CVS Health&#146;s or Aetna&#146;s ultimate performance compared to either party&#146;s projections or that the
results reflected therein will be achieved. Neither CVS Health nor Aetna has made any representation to the other, in the merger agreement or otherwise, concerning the parties&#146; respective projections. For the reasons described above, readers of
this joint proxy statement/prospectus are cautioned not to place undue, if any, reliance on either party&#146;s projections. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_82">
</A>Regulatory Approvals Required for the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health and Aetna have agreed to use their respective reasonable best efforts to obtain all regulatory approvals required to complete the
merger, which reasonable best efforts include contesting any proceeding brought by a governmental authority seeking to prohibit completion of the merger or seeking damages or to impose any terms or conditions in connection with the merger. In using
its reasonable best efforts, under the terms of the merger agreement, CVS Health is required to take all actions and do all things necessary, proper or advisable to complete the merger in connection with (i)&nbsp;the expiration or early termination
of the waiting period relating to the merger under the HSR Act, (ii)&nbsp;any other antitrust law or (iii)&nbsp;the required governmental authorizations, except that CVS Health is not required to take any action or agree to any term, condition or
limitation in connection with those matters if that action, term, condition or limitation would have or would reasonably be expected to have, individually or in the aggregate, a regulatory material adverse effect on CVS Health or on Aetna. See
&#147;The Merger Agreement&#151;Conditions to Completion of the Merger&#148; beginning on page&nbsp;181 of this joint proxy statement/prospectus. In addition, in connection with obtaining the regulatory approvals required to complete the merger,
(x)&nbsp;neither CVS Health nor Aetna is required to take any action that is not conditioned upon completion of the merger and (y)&nbsp;Aetna is not permitted to take any action or agree to any term or condition without CVS Health&#146;s consent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligation of each of CVS Health, Aetna and Merger Sub to effect the merger is conditioned upon, among other things, the expiration
or early termination of the applicable waiting period under the HSR Act and the required governmental authorizations having been made or obtained and being in full force and effect. See </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;The Merger Agreement&#151;Conditions to Completion of the Merger&#148; beginning on page&nbsp;181 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Department of Justice, Federal Trade Commission and Other U.S. Antitrust Authorities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the HSR Act, certain transactions, including the merger, may not be completed unless certain waiting period requirements have expired or
been terminated. The HSR Act provides that each party must file a <FONT STYLE="white-space:nowrap">pre-merger</FONT> notification with the FTC and the Antitrust Division of the DOJ. A transaction notifiable under the HSR Act may not be completed
until the expiration of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-calendar-day</FONT></FONT> waiting period following the parties&#146; filings of their respective HSR Act notification forms or the early termination of
that waiting period. The merger is being reviewed by the DOJ. If the DOJ issues a Request for Additional Information and Documentary Material prior to the expiration of the initial waiting period, the parties must observe a second <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-calendar-day</FONT></FONT> waiting period, which would begin to run only after both parties have substantially complied with the request for additional information, unless the waiting
period is terminated earlier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of CVS Health and Aetna filed its respective HSR Act notification and report with respect to the
merger on January&nbsp;2, 2018. On February&nbsp;1, 2018, CVS Health and Aetna each received a request for additional information, which is referred to in this joint proxy statement/prospectus as the second request, from the DOJ in connection with
the DOJ&#146;s review of the transactions contemplated by the merger agreement. Issuance of the second request extends the waiting period under the HSR Act until 30 days after both CVS Health and Aetna have substantially complied with the second
request or such later time as the parties may agree with the DOJ, unless the waiting period is terminated earlier by the DOJ. CVS Health and Aetna have been cooperating with the DOJ staff since shortly after the announcement of the merger agreement
and are continuing to cooperate with the DOJ staff in its review of the transactions contemplated by the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time
before or after the merger is completed, the DOJ could take action under the antitrust laws in opposition to the merger, including seeking to enjoin completion of the merger, condition approval of the merger upon the divestiture of assets of CVS
Health, Aetna or their respective subsidiaries or impose restrictions on CVS Health&#146;s post-merger operations. In addition, U.S. state attorneys general could take such action under the antitrust laws as they deem necessary or desirable in the
public interest including, without limitation, seeking to enjoin completion of the merger or permitting completion subject to regulatory concessions or conditions. Private parties also may seek to take legal action under the antitrust laws under
some circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Federal, State and Foreign Regulatory Approvals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to federal health care laws and regulations and, in some instances, the health care and insurance laws and regulations of certain
states, and pursuant to certain licenses and contracts of certain of Aetna&#146;s subsidiaries, applicable federal and state regulatory and governmental authorities must approve, or be notified of, CVS Health&#146;s acquisition of control of
Aetna&#146;s health maintenance organizations, insurance companies, pharmacy businesses and other regulated businesses or entities. To obtain these approvals and provide such notices, CVS Health, or the applicable CVS Health subsidiary, and in some
instances Aetna, or the applicable Aetna regulated entity, as the case may be, has filed and/or will file acquisition of control and/or material modification or other statements, notices or applications, as required by federal health care law or
regulation and the insurance and health care laws and regulations of each applicable state and country or the Aetna regulated entities&#146; licenses and contracts. In addition, certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental
authorities must approve, or be notified of, the merger, and CVS Health and/or Aetna and/or their respective subsidiaries will file all such statements, notices, or applications, as are required by the laws of applicable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> governmental authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Governmental Approvals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither CVS Health nor Aetna is aware of any material governmental approvals or actions that are required for completion of the merger other
than those described above. It is presently contemplated that if any such additional material governmental approvals or actions are required, those approvals or actions will be sought. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Timing; Challenges by Governmental and Other Entities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that any of the regulatory approvals described above will be obtained and, if obtained, there can be no assurance as
to the timing of any approvals, the ability to obtain the approvals on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
satisfactory terms or the absence of any litigation challenging such approvals. In addition, there can be no assurance that any of the governmental or other entities described above, including
the DOJ, U.S. state attorneys general, state insurance regulators and private parties, will not challenge the merger on antitrust or competition grounds and, if such a challenge is made, there can be no assurance as to its result. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain conditions, if the merger is not completed on or before the end date, either CVS Health or Aetna may terminate the merger
agreement. See &#147;The Merger Agreement&#151;Termination of the Merger Agreement&#148; beginning on page&nbsp;203 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_83"></A>No Appraisal or Dissenters&#146; Rights for Aetna Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;1571(b) of the PBCL, Aetna shareholders will not be entitled to appraisal or dissenters&#146; rights in connection
with the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_84"></A>Material U.S. Federal Income Tax Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following summary discusses the material U.S. federal income tax consequences of the merger to holders of Aetna common shares. This discussion is based on the Internal Revenue Code of 1986, as amended, which is referred to in this joint proxy
statement/prospectus as the Code, applicable Treasury regulations promulgated under the Code, administrative interpretations, and judicial decisions as in effect as of the date of this joint proxy statement/prospectus, all of which may change,
possibly with retroactive effect.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion addresses only the consequences of the exchange of Aetna common shares held as capital
assets within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). It does not address all aspects of U.S. federal income taxation that may be important to an Aetna shareholder in light of the Aetna
shareholder&#146;s particular circumstances, or to an Aetna shareholder that is subject to special rules, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a financial institution or insurance company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a dealer or broker in securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person whose functional currency is not the U.S. dollar; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a former citizen or former long-term resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a real estate investment trust; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an Aetna shareholder that holds its Aetna common shares through individual retirement or other <FONT STYLE="white-space:nowrap">tax-deferred</FONT> accounts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an Aetna shareholder that holds Aetna common shares as part of a hedge, appreciated financial position, straddle, or conversion or integrated transaction; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an Aetna shareholder that acquired Aetna common shares through the exercise of compensatory options or stock purchase plans or otherwise as compensation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;U.S. holder&#148; is a beneficial owner of Aetna common shares that is for U.S. federal income tax
purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States or any state therein or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (i)&nbsp;that is subject to the primary supervision of a court within the United States and all the substantial decisions of which are controlled by one or more U.S. persons or (ii)&nbsp;that has a valid
election in effect under applicable Treasury regulations to be treated as a U.S. person. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
<FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; is a beneficial owner of Aetna common shares that is neither a U.S. holder nor a partnership for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds Aetna common
shares, the U.S. federal income tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership. A partner of a partnership holding Aetna common shares should consult its tax
advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion of material U.S. federal income tax consequences is not a complete description of all potential U.S. federal
income tax consequences of the merger. This discussion does not address tax consequences that may vary with, or are contingent on, individual circumstances. In addition, it does not address any alternative minimum tax, any <FONT
STYLE="white-space:nowrap">non-income</FONT> tax or any <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> state or local tax consequences of the merger or the potential application of the Medicare contribution tax on net investment income.
<B>Accordingly, each Aetna shareholder should consult its tax advisor to determine the particular U.S. federal, state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income or other tax consequences to it of the merger. </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Federal Income Tax Consequences to U.S. Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The receipt of the merger consideration by U.S. holders pursuant to the merger will be a taxable transaction for U.S. federal income tax
purposes. In general, for U.S. federal income tax purposes, a U.S. holder will recognize taxable capital gain or loss in an amount equal to the difference, if any, between (i)&nbsp;the sum of (x)&nbsp;the amount of cash, including cash received in
lieu of fractional shares, received in the merger, and (y)&nbsp;the fair market value of the shares of CVS Health common stock received in the merger and (ii)&nbsp;such U.S. holder&#146;s adjusted tax basis in its Aetna common shares exchanged
therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. holder&#146;s holding period in the Aetna common shares surrendered in the merger is greater than one year as of the
date of the merger, the capital gain or loss will be long-term capital gain or loss. Long-term capital gains of certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> holders, including individuals, are generally subject to U.S. federal
income tax at preferential rates. The deductibility of a capital loss recognized in connection with the merger is subject to limitations under the Code. If a U.S. holder acquired different blocks of Aetna common shares at different times or
different prices, such U.S. holder must determine its adjusted tax basis and holding period separately with respect to each block of Aetna common shares that it holds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder&#146;s aggregate tax basis in CVS Health common stock received in the merger will equal the fair market value of the CVS Health
common stock as of the date of the merger. The holding period of the CVS Health common stock received in the merger will begin on the day after the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Federal Income Tax Consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The receipt of the merger consideration by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder pursuant to the merger will not be subject
to U.S. federal income tax unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain, if any, recognized by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is effectively connected with a trade or business of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United
States (and, if required by an applicable income tax treaty, is attributable to the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s permanent establishment in the United States); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual who is present in the United States for 183&nbsp;days or more in the taxable year of the merger and certain other conditions are met; or
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder owned, directly or under certain constructive ownership rules of the Code, more than 5% of the Aetna common shares at any time during the five-year period
preceding the merger, and Aetna is or has been a &#147;U.S. real property holding corporation&#148; within the meaning of Section&nbsp;897(c)(2) of the Code for U.S. federal income tax purposes at any time during the shorter of the five-year period
preceding the merger or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held the Aetna common shares. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax on a net income basis in the same manner as if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder were a U.S. holder (unless an applicable income tax treaty provides otherwise). Additionally, any gain described in the first bullet point above of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder that is a corporation also may be subject to an additional &#147;branch profits tax&#148; at a 30% rate (or lower rate provided by an applicable income tax treaty). A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the
second bullet point above will be subject to tax at a rate of 30% (or a lower rate provided by an applicable income tax treaty) on any capital gain realized, which may be offset by U.S.-source capital losses recognized in the same taxable year. If
the third bullet point above applies to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, capital gain recognized by such holder will be subject to tax at generally applicable U.S. federal income tax rates. Aetna believes that it has not
been a &#147;U.S. real property holding corporation&#148; for U.S. federal income tax purposes at any time during the five-year period preceding the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Backup Withholding and Information Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made in exchange for Aetna common shares (including cash paid in lieu of fractional shares) pursuant to the merger may be subject,
under certain circumstances, to information reporting and backup withholding (currently at a rate of 24%). To avoid backup withholding, a U.S. holder that does not otherwise establish an exemption should complete and return an IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-9,</FONT> certifying under penalties of perjury that such U.S. holder is a &#147;United States person&#148; (within the meaning of the Code), that the taxpayer identification number provided is correct and that
such U.S. holder is not subject to backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be subject to
information reporting and backup withholding (currently at a rate of 24%) on the merger consideration (including cash paid in lieu of fractional shares) received in exchange for Aetna common shares unless the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder establishes an exemption, for example, by completing the appropriate IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT> for the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, in
accordance with the instructions thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amount withheld under the backup withholding rules will be allowed as a refund or credit
against the U.S. federal income tax liability of an Aetna shareholder, provided the required information is timely furnished to the IRS. The IRS may impose a penalty upon an Aetna shareholder that fails to provide the correct taxpayer identification
number. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_85"></A>Accounting Treatment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will be accounted for as an acquisition of a business. CVS Health will record assets acquired and liabilities assumed from Aetna
primarily at their respective fair values at the date of completion of the merger. Any excess of the purchase price (as described under<I> Note 4. Estimate of Consideration Expected to be Transferred</I> under &#147;CVS Health and Aetna Unaudited
Pro Forma Condensed Combined Financial Statements&#148; beginning on page&nbsp;49 of this joint proxy statement/prospectus) over the net fair value of such assets and liabilities will be recorded as goodwill. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial condition and results of operations of CVS Health after completion of the merger will reflect Aetna&#146;s balances and results
after completion of the merger but will not be restated retroactively to reflect the historical financial condition or results of operations of Aetna. The earnings of CVS Health following completion of the merger will reflect acquisition accounting
adjustments, including the effect of changes in the carrying value for assets and liabilities on interest expense and amortization expense. Intangible assets with indefinite useful lives and goodwill will not be amortized but will be tested for
impairment at least annually, and all assets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including goodwill will be tested for impairment when certain indicators are present. If, in the future, CVS Health determines that tangible or intangible assets (including goodwill) are
impaired, CVS Health will record an impairment charge at that time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_86"></A>Listing of CVS Health Common Stock; Delisting and
Deregistration of Aetna Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application will be made to have the shares of CVS Health common stock to be issued in the
merger approved for listing on the NYSE, where shares of CVS Health common stock are currently traded. If the merger is completed, Aetna common shares will no longer be listed on the NYSE and will be deregistered under the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_87a"></A>Description of Debt Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with the merger, CVS Health has entered into a bridge facility commitment letter with the initial bridge commitment parties and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated (solely in its capacity as an arranger) pursuant
to which the initial bridge commitment parties have agreed to provide a <FONT STYLE="white-space:nowrap">364-day</FONT> senior unsecured bridge loan facility in an aggregate principal amount of up to $49.0&nbsp;billion. A copy of the bridge facility
commitment letter is filed as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed by CVS Health on December&nbsp;5, 2017, which is incorporated by reference into this joint proxy statement/prospectus. See
&#147;Where You Can Find More Information&#148; beginning on page&nbsp;254 of this joint proxy statement/prospectus. You are urged to read the bridge facility commitment letter in its entirety. On December&nbsp;15, 2017, CVS Health, the initial
bridge commitment parties and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated entered into the bridge joinder agreement with the additional bridge commitment parties. The bridge joinder agreement amends the bridge facility commitment
letter and reallocates the commitments of the initial bridge commitment parties to fund loans under the bridge facility among the initial bridge commitment parties and the additional bridge commitment parties. A copy of the bridge joinder agreement
is filed as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed by CVS Health on December&nbsp;19, 2017, which is incorporated by reference into this joint proxy statement/prospectus. You are urged to read the
bridge joinder agreement in its entirety. The bridge commitment parties&#146; obligation to fund the bridge facility is subject to several limited conditions as set forth in the bridge facility commitment letter, including, among others, completion
of the merger, the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of a material adverse effect (as defined in the bridge facility commitment letter) on Aetna, the accuracy in all material respects of certain representations and warranties
related to both CVS Health and Aetna, the absence of certain defaults by CVS Health, the delivery of certain financial statements of CVS Health and Aetna and other customary conditions to completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the merger, CVS Health also has entered into the term loan agreement with the term lenders pursuant to which the term
lenders have agreed to provide a senior unsecured term loan facility in an aggregate principal amount of $5.0&nbsp;billion consisting of a $3.0&nbsp;billion three-year tranche and a $2.0&nbsp;billion five-year tranche. A copy of the term loan
agreement is filed as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed by CVS Health on December 19, 2017, which is incorporated by reference into this joint proxy statement/prospectus. See &#147;Where You
Can Find More Information&#148; beginning on page&nbsp;254 of this joint proxy statement/prospectus. You are urged to read the term loan agreement in its entirety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the merger, CVS Health also has entered into a first amendment to each of its revolving credit agreements with the
revolving lenders pursuant to which the revolving lenders have agreed to (w)&nbsp;amend the net tangible assets test included in the covenant restricting the incurrence of debt by CVS Health&#146;s subsidiaries by (a)&nbsp;excluding any Aetna
existing indebtedness from indebtedness for purposes of determining compliance with the net tangible assets test, and (b)&nbsp;restricting the indebtedness that may be incurred by all of CVS Health&#146;s subsidiaries (excluding the Aetna existing
indebtedness and other indebtedness under capital leases incurred in connection with a sale and leaseback transaction) to an amount not exceeding $900.0&nbsp;million in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate, in each case, on and following completion of the merger until the date that CVS Health is in compliance with the net tangible assets test without giving effect to the exclusion set
forth in clause (a)&nbsp;above, (x) expressly permit completion of the merger under the acquisition covenant, (y)&nbsp;amend the financial covenant by (a)&nbsp;increasing the consolidated indebtedness to total capitalization ratio from 0.60:1.00 to
0.65:1.00 from completion of the merger through and including the fiscal quarter ending September&nbsp;30, 2019, and (b)&nbsp;excluding unsecured indebtedness in an aggregate principal amount not exceeding $49.0&nbsp;billion incurred by CVS Health
for the purpose of financing the merger (including all of the transaction costs, fees, commissions and expenses in connection therewith) and which is redeemable or prepayable if the merger is not consummated, from the calculation of consolidated
indebtedness and total capitalization, until the earliest of the occurrence of completion of the merger, the date that is 30 days following the termination of the merger agreement in accordance with its terms and August&nbsp;31, 2019, and
(z)&nbsp;increase the threshold amount of specified events of default to (a)&nbsp;prior to the later of (i)&nbsp;the termination or other expiration of the bridge facility commitment letter in accordance with its terms and (ii)&nbsp;the termination
or other expiration of the bridge facility if it is entered into, $250.0&nbsp;million, and (b)&nbsp;at all other times, $200.0&nbsp;million. Copies of the first amendments to the revolving credit agreements are filed as exhibits to the Current
Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed by CVS Health on December&nbsp;19, 2017, which is incorporated by reference into this joint proxy statement/prospectus. A summary of the terms of the revolving credit agreements may be
found in CVS Health&#146;s Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> filed on August&nbsp;5, 2014, August&nbsp;4, 2015 and August&nbsp;8, 2017, which summary is incorporated herein by reference. See &#147;Where You
Can Find More Information&#148; beginning on page&nbsp;254 of this joint proxy statement/prospectus. You are urged to read the revolving credit agreements, as amended by their respective first amendments, in their entirety. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Bridge Loan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the bridge facility commitment letter, the proceeds of the loans under the bridge facility will be available upon the
satisfaction of several limited conditions precedent on completion of the merger and, if drawn, will be used to finance, in part, the cash component of the merger consideration and to pay fees, commissions and expenses incurred in connection with
the merger. The loans under the bridge facility will mature on the 364th day after funding thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditions Precedent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The bridge commitment parties&#146; obligation to fund the loans under the bridge facility is subject to several limited conditions, including
completion of the merger, the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of a material adverse effect (as such term is defined in the bridge facility commitment letter) on Aetna, the accuracy in all material respects of certain
representations and warranties related to both CVS Health and Aetna, the absence of certain defaults by CVS Health, the delivery of certain financial statements of CVS Health and Aetna and other customary conditions to completion more fully set
forth in the bridge facility commitment letter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of CVS Health, borrowings under the bridge facility will bear interest at either a base rate or at the reserve adjusted
Eurodollar rate, plus, in each case, an applicable margin. The applicable margin will range initially from <FONT STYLE="white-space:nowrap">0.00-0.75%</FONT> with respect to base rate borrowings, and
<FONT STYLE="white-space:nowrap">0.875-1.75%</FONT> with respect to the reserve adjusted Eurodollar rate borrowings, based on the public ratings of CVS Health&#146;s senior unsecured <FONT STYLE="white-space:nowrap">non-credit</FONT> enhanced
long-term indebtedness for borrowed money, and subject to increase every 90-day period by 0.25%, beginning on the 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the closing of, and funding of the loans under, the bridge facility
(but subject to a 0.125% increase in the case of base rate borrowings for days 90 through 179 after such closing and funding in the event that the public ratings of CVS Health&#146;s senior unsecured
<FONT STYLE="white-space:nowrap">non-credit</FONT> enhanced long-term indebtedness for borrowed money is equal to or greater than A2 by Moody&#146;s and A by S&amp;P), based on how long the loans under the bridge facility are outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Base Rate Option </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest will be at the base rate plus an applicable margin based on the public ratings of CVS Health&#146;s senior unsecured <FONT
STYLE="white-space:nowrap">non-credit</FONT> enhanced long-term indebtedness for borrowed money, calculated on the basis of the actual number of days elapsed in a year of 365 or 366 days and payable quarterly in arrears. The base rate will be, for
any day, a fluctuating rate per annum equal to the highest of (i)&nbsp;the rate last quoted by <I>The Wall Street Journal</I> as the &#147;prime rate&#148; or, if <I>The Wall Street Journal</I> ceases to quote such rate, the highest rate per annum
published by the Federal Reserve Board as the &#147;bank prime loan&#148; rate or, if such rate is no longer quoted, any similar release by the Federal Reserve Board, (ii)&nbsp;the Federal Funds effective rate plus
<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">2</SUB> of 1.0% and (iii)&nbsp;the <FONT STYLE="white-space:nowrap">one-month</FONT> reserve adjusted Eurodollar Rate plus 1.0% (provided, that the reserve
adjusted Eurodollar Rate shall not be less than zero). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Eurodollar Rate Option </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest will be determined based on interest periods to be selected by CVS Health of one, two, three or six months or (if agreed by all
relevant lenders under the bridge facility) less than one month or twelve months and for each interest period will be at an annual rate equal to the London Interbank Offered Rate, which is referred to in this joint proxy statement/prospectus as
LIBOR, for deposits with a term equivalent to such interest period in U.S. dollars adjusted for applicable reserve requirements (such rate as so adjusted is referred to in this joint proxy statement/prospectus as the reserve adjusted Eurodollar
rate), plus the applicable margin based on the public ratings of CVS Health&#146;s senior unsecured <FONT STYLE="white-space:nowrap">non-credit</FONT> enhanced long-term indebtedness for borrowed money. Interest will be paid at the end of each
interest period (and at the end of every three months, in the case of interest periods longer than three months) and will be calculated on the basis of the actual number of days elapsed in a year of 360 days. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Covenants and Events of Default </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The bridge facility commitment letter provides that the definitive financing agreement documenting the bridge facility (if any), which is
referred to in this joint proxy statement/prospectus as the bridge credit agreement, shall contain covenants substantially similar to the covenants in the 2017 five-year revolving credit facility, which relate to the following subjects: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">legal existence; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payment of taxes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintenance of insurance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">condition of property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">observance of legal requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delivery of financial statements and other information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">records; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintenance of authorizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on liens; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on acquisitions and dispositions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on mergers and consolidations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on restricted payments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitation on upstream dividends by subsidiaries; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitation on negative pledges. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the bridge facility commitment letter provides that the bridge credit agreement
(if executed and delivered) shall include (x)&nbsp;a financial covenant requiring the ratio of consolidated indebtedness to total capitalization at each <FONT STYLE="white-space:nowrap">quarter-end</FONT> not to exceed 0.65:1.00 (defined and
calculated in a manner consistent with the 2017 five-year revolving credit facility), but with an exclusion for any indebtedness incurred by CVS Health to finance the merger until the earlier of (i)&nbsp;the closing date under the bridge facility
and (ii) 30 days following the termination of the merger agreement (in each case to the extent that such indebtedness is redeemable if the merger is not consummated), and (y)&nbsp;a covenant restricting the incurrence of debt by CVS Health&#146;s
subsidiaries to up to 15% of net tangible assets. In determining compliance with such test, (i)&nbsp;any Aetna existing indebtedness shall be excluded from indebtedness, and (ii)&nbsp;indebtedness that may be incurred by all of CVS Health&#146;s
subsidiaries (excluding the Aetna existing indebtedness and other indebtedness under capital leases incurred in connection with a sale and leaseback transaction) may not exceed $900.0&nbsp;million in the aggregate, in each case, on and following
completion of the merger until such date as CVS Health shall be in compliance with such test without giving effect to the exclusion in clause (i)&nbsp;of this sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The bridge facility commitment letter also provides that the bridge credit agreement (if executed and delivered) shall contain events of
default substantially similar to the events of default in the 2017 five-year revolving credit facility, limited to nonpayment of principal when due; nonpayment of interest or fees within five business days of due date; violation of covenants
(subject to a grace period of 30 days in the case of certain affirmative covenants); inaccuracy of representations and warranties in any material respect when made; payment default or default resulting in or permitting acceleration in respect of
indebtedness of $250.0&nbsp;million or more; bankruptcy or insolvency events; change in control; undischarged judgments in excess of $250.0&nbsp;million; and certain events under the Employee Retirement Income Security Act of 1974, as amended, which
is referred to in this joint proxy statement/prospectus as ERISA, with a threshold amount of $250.0&nbsp;million. In the event that any of the thresholds in the 2017 five-year revolving credit facility is, as of the closing date of, and funding of
the loans under, the bridge facility, less favorable to CVS Health, then the aforementioned $250.0&nbsp;million thresholds shall be deemed amended to match the thresholds in the 2017 five-year revolving credit facility. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term Loan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the term loan agreement, the proceeds of the term loans will be available upon the satisfaction of several limited
conditions precedent on completion of the merger and, if drawn, will be used to finance, in part, the cash component of the merger consideration and to pay fees, commissions and expenses incurred in connection with the merger. Borrowings under the
term loan agreement will be unsecured. The term loans are <FONT STYLE="white-space:nowrap">pre-payable</FONT> without premium or penalty (but subject to breakage costs, if applicable). The term loans under the $3.0&nbsp;billion three-year tranche do
not amortize. The term loans under the $2.0&nbsp;billion five-year tranche amortize in equal quarterly amounts equal to the percentage per three calendar months&#146; period of the aggregate principal amount of the five-year tranche loans made on
the date on which the term lenders are obligated to make loans under the term loan agreement, which is referred to in this joint proxy statement/prospectus as the term loan closing date, as follows: (i) 0% for each quarterly payment date occurring
after the term loan closing date, to, and including, the first anniversary of the term loan closing date, (ii) 1.25% for each quarterly payment date occurring after the first anniversary of the term loan closing date to, and including, the third
anniversary of the term loan closing date and (iii) 2.5% for each quarterly payment date occurring after the third anniversary of the term loan closing date to, and including, the fifth anniversary of the term loan closing date. The
$3.0&nbsp;billion tranche of the term loan facility will mature and be payable on the third anniversary of the term loan closing date. The $2.0&nbsp;billion tranche of the term loan facility will mature and be payable (to the extent not amortized)
on the fifth anniversary of the term loan closing date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditions Precedent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term lenders&#146; obligation to fund the term loans is subject to several limited conditions, including completion of the merger, the <FONT
STYLE="white-space:nowrap">non-occurrence</FONT> of a material adverse effect (as such term is defined in the term loan agreement) on Aetna, the accuracy in all material respects of certain representations and warranties related
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to both CVS Health and Aetna, the absence of certain defaults by CVS Health, the delivery of certain financial statements of CVS Health and Aetna and other customary conditions to completion more
fully set forth in the term loan agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of CVS Health, borrowings under the term loan agreement will bear interest at either a base rate or at the Eurodollar rate, plus,
in each case, an applicable margin. The applicable margin will range from <FONT STYLE="white-space:nowrap">0.00-0.875%</FONT> with respect to base rate borrowings, and <FONT STYLE="white-space:nowrap">0.875-1.875%</FONT> with respect to Eurodollar
rate borrowings, based on the public ratings of CVS Health&#146;s senior unsecured <FONT STYLE="white-space:nowrap">non-credit</FONT> enhanced long-term indebtedness for borrowed money. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Base Rate Option </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest will be at the base rate plus an applicable margin based on the public ratings of CVS Health&#146;s senior unsecured <FONT
STYLE="white-space:nowrap">non-credit</FONT> enhanced long-term indebtedness for borrowed money, calculated on the basis of the actual number of days elapsed in a year of 365 or 366 days and payable quarterly in arrears. The base rate will be, for
any day, a fluctuating rate per annum equal to the highest of (i)&nbsp;the rate last quoted by <I>The Wall Street Journal</I> as the &#147;prime rate&#148; or, if <I>The Wall Street Journal</I> ceases to quote such rate, the highest rate per annum
published by the Federal Reserve Board as the &#147;bank prime loan&#148; rate or, if such rate is no longer quoted, any similar release by the Federal Reserve Board, (ii)&nbsp;the Federal Funds effective rate plus 0.5% and (iii)&nbsp;the <FONT
STYLE="white-space:nowrap">one-month</FONT> LIBOR rate plus 1.0%, provided that the LIBOR rate shall never be less than zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Eurodollar Rate Option </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest will be determined based on interest periods to be selected by CVS Health of one, two, three or six months or (if agreed by all term
lenders) less than one month or twelve months and will be at an annual rate equal to LIBOR for deposits with a term equivalent to such interest period in U.S. dollars multiplied by the statutory reserve rate, plus the applicable margin based on the
public ratings of CVS Health&#146;s senior unsecured <FONT STYLE="white-space:nowrap">non-credit</FONT> enhanced long-term indebtedness for borrowed money. Interest will be paid at the end of each interest period (and at the end of every three
months, in the case of interest periods longer than three months) and will be calculated on the basis of the actual number of days elapsed in a year of 360 days. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Covenants and Events of Default </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term loan agreement contains covenants relating to the following subjects: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">legal existence; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payment of taxes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintenance of insurance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">condition of property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">observance of legal requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delivery of financial statements and other information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">records; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintenance of authorizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on liens; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on acquisitions and dispositions; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on mergers and consolidations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on restricted payments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitation on upstream dividends by subsidiaries; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitation on negative pledges. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the term loan agreement includes (x)&nbsp;a
financial covenant requiring the ratio of consolidated indebtedness to total capitalization (defined as the sum of consolidated indebtedness and shareholders&#146; equity determined in accordance with GAAP) at each
<FONT STYLE="white-space:nowrap">quarter-end</FONT> not to exceed 0.60:1.00; provided that (a)&nbsp;from the term loan closing date through and including the fiscal quarter ending September&nbsp;30, 2019, CVS Health will not permit its ratio of
consolidated indebtedness to total capitalization at the end of any fiscal quarter to exceed 0.65:1.00, and (b)&nbsp;until the earlier of (i)&nbsp;the occurrence of the term loan closing date and (ii)&nbsp;the date that is 30 days following the
termination of the merger agreement in accordance with its terms, consolidated indebtedness and total capitalization shall each be calculated exclusive of any unsecured indebtedness not exceeding $49.0&nbsp;billion issued or borrowed by CVS Health
for the purpose of financing the merger (including all of the transaction costs, fees, commissions and expenses in connection therewith) and which is redeemable or prepayable if the merger is not consummated, and (y)&nbsp;a covenant restricting the
incurrence of debt by CVS Health&#146;s subsidiaries to up to 15% of net tangible assets. In determining compliance with such net tangible assets test, (i)&nbsp;any Aetna existing indebtedness shall be excluded from indebtedness, and
(ii)&nbsp;indebtedness that may be incurred by all of CVS Health&#146;s subsidiaries (excluding the Aetna existing indebtedness and other indebtedness under capital leases incurred in connection with a sale and leaseback transaction) may not exceed
$900.0&nbsp;million in the aggregate, in each case, on and following completion of the merger until such date as CVS Health shall be in compliance with such test without giving effect to the exclusion in clause (i)&nbsp;of this sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term loan agreement also contains certain events of default, limited to nonpayment of principal when due; nonpayment of interest or fees
within five business days of due date; violation of covenants (subject to a grace period of 30 days in the case of certain affirmative covenants); inaccuracy of representations and warranties in any material respect when made; payment default or
default resulting in or permitting acceleration in respect of indebtedness of $250.0&nbsp;million or more; bankruptcy or insolvency events; change in control; undischarged judgments in excess of $250.0&nbsp;million; and certain events under ERISA
with a threshold amount of $250.0&nbsp;million. The aforementioned threshold amounts of $250.0&nbsp;million shall be applicable at all times prior to the later of (x)&nbsp;the termination or other expiration of the bridge facility commitment letter
in accordance with its terms and (y)&nbsp;the termination or other expiration of the bridge facility if it is entered into. At all other times, the aforementioned threshold amounts of $250.0&nbsp;million shall be reduced to $200.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revolving Credit Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the first amendments to each of the revolving credit agreements, the revolving lenders agreed to (w)&nbsp;amend the net tangible
assets test included in the covenant restricting the incurrence of debt by CVS Health&#146;s subsidiaries by (a)&nbsp;excluding any Aetna existing indebtedness from indebtedness for purposes of determining compliance with the net tangible assets
test, and (b)&nbsp;restricting the indebtedness that may be incurred by all of CVS Health&#146;s subsidiaries (excluding the Aetna existing indebtedness and other indebtedness under capital leases incurred in connection with a sale and leaseback
transaction) to an amount not exceeding $900.0&nbsp;million in the aggregate, in each case, on and following completion of the merger until the date that CVS Health is in compliance with the net tangible assets test without giving effect to the
exclusion set forth in clause (a)&nbsp;above, (x) expressly permit completion of the merger under the acquisition covenant, (y)&nbsp;amend the financial covenant by (a)&nbsp;increasing the consolidated indebtedness to total capitalization ratio from
0.60:1.00 to 0.65:1.00 from completion of the merger through and including the fiscal quarter ending September&nbsp;30, 2019, and (b)&nbsp;excluding unsecured indebtedness in an aggregate principal amount not exceeding $49.0&nbsp;billion incurred by
CVS Health for the purpose of financing the merger (including all of the transaction costs, fees, commissions and expenses in connection therewith) and which is redeemable or prepayable if the merger is not consummated, from the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
calculation of consolidated indebtedness and total capitalization, until the earliest of the occurrence of completion of the merger, the date that is 30 days following the termination of the
merger agreement in accordance with its terms and August&nbsp;31, 2019, and (z)&nbsp;increase the threshold amount of specified events of default to (a)&nbsp;prior to the later of (i)&nbsp;the termination or other expiration of the bridge facility
commitment letter in accordance with its terms and (ii)&nbsp;the termination or other expiration of the bridge facility if it is entered into, $250.0&nbsp;million, and (b)&nbsp;at all other times, $200.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditions Precedent </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
first amendments to each of the revolving credit agreements became effective on December&nbsp;15, 2017. The effectiveness of such amendments was subject only to the execution and delivery of such amendments by CVS Health, the applicable
administrative agent and the required lenders under each of the revolving credit agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="rom482402_87b"></A><B>Litigation Relating to the
Merger</B> </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February 8, 2018, seven complaints had been filed by purported Aetna shareholders challenging the merger. The first,
a putative class action complaint, was filed by Olivier Miramond in the United States District Court for the District of Connecticut and is captioned <I>Miramond v. Aetna, Inc., et al.</I>, case number 3:18-cv-00083. The second complaint, filed in
the United States District Court for the District of Connecticut by Shiva Stein individually, is captioned <I>Stein v. Aetna, Inc., et al</I>., case number 3:18-cv-00136. The third complaint, a putative class action, was filed by Robert Freedman in
the United States District Court for the Eastern District of Pennsylvania and is captioned <I>Freedman v. Aetna, Inc., et al</I>., case number 2:18-cv-00323. The fourth complaint, filed in the United States District Court for the District of
Connecticut by Luan Pham individually, is captioned <I>Pham v. Aetna, Inc., et al.</I>, case number 3:18-cv-00154. The fifth complaint, filed in the United States District Court for the Eastern District of Pennsylvania by Vladimir Gusinsky Rev.
Trust individually, is captioned <I>Vladimir Gusinsky Rev. Trust v. Aetna Inc. et al.</I>, case number 2:18-cv-00361. The sixth complaint, a putative class action complaint, was filed by Dr. Eli Inzlicht-Sprei in the United States District Court for
the District of Connecticut and is captioned <I>Inzlicht-Sprei v. Aetna, Inc., et al.</I>, case number 3:18-cv-00176. The seventh complaint, a putative class action complaint, was filed by Joel Rosenfeld in the United States District Court for the
District of Connecticut and is captioned <I>Rosenfeld v. Aetna, Inc., et al.,</I> case number 3:18-cv-00213. The complaints name as defendants Aetna and each member of Aetna&#146;s board of directors. In addition, the <I>Vladimir Gusinsky Rev.
Trust</I> complaint names CVS Health and Merger Sub as defendants. The complaints generally allege, among other things, that the merger consideration in the proposed transaction is unfair, inadequate and undervalues Aetna; that the defendants failed
to conduct a fair and reasonable sales process; that the merger agreement&#146;s deal protection provisions improperly deter other suitors from submitting a superior offer for Aetna; that Aetna&#146;s board of directors and executive officers are
conflicted because they have secured unique benefits for themselves from the proposed transaction not available to Aetna shareholders generally; and that the defendants authorized the filing of a materially incomplete and misleading registration
statement. Among other remedies, the complaints seek to enjoin the Aetna special meeting and the closing of the merger, as well as costs and attorneys&#146; fees. Defendants believe that the complaints are without merit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_88"></A>THE MERGER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms and conditions of the merger agreement. This summary may not contain all the information
about the merger agreement that is important to you. This summary is qualified in its entirety by reference to the merger agreement attached as Annex A to, and incorporated by reference into, this joint proxy statement/prospectus. You are encouraged
to read the merger agreement in its entirety because it is the legal document that governs the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Explanatory Note </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement and the summary of its terms in this joint proxy statement/prospectus have been included to provide information about the
terms and conditions of the merger agreement. The representations, warranties, covenants and agreements contained in the merger agreement were made by CVS Health, Aetna and Merger Sub as of specific dates and were qualified and subject to certain
limitations and exceptions agreed to by CVS Health, Aetna and Merger Sub in connection with negotiating the terms of the merger agreement. In particular, in your review of the representations and warranties contained in the merger agreement and
described in this summary, it is important to bear in mind that the representations and warranties were negotiated for the purpose of allocating contractual risk among the parties to the merger agreement rather than to establish matters as facts.
The representations and warranties also may be subject to a contractual standard of materiality or material adverse effect that is different from what may be viewed as material by stockholders or shareholders, as applicable, or other investors and
from the materiality standard applicable to reports and documents filed with the SEC and in some cases may be qualified by disclosures made by one party to the other, which are not reflected in the merger agreement. Moreover, information concerning
the subject matter of the representations and warranties, which do not purport to be accurate as of the date of this joint proxy statement/prospectus, may have changed since the date of the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the foregoing reasons, the representations, warranties, covenants and agreements and any descriptions of those provisions should be read
only in conjunction with the other information provided elsewhere in this joint proxy statement/prospectus or incorporated by reference into this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_89"></A>Structure of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides for the merger, in which Merger Sub will be merged with and into Aetna, with Aetna surviving the merger as a
wholly-owned subsidiary of CVS Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After completion of the merger, the articles of incorporation set forth as Exhibit A to the merger
agreement and the <FONT STYLE="white-space:nowrap">by-laws</FONT> of Merger Sub in effect immediately prior to completion of the merger will be the articles of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> respectively, of
Aetna, as the surviving corporation in the merger, in each case, until amended in accordance with applicable law and the articles of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> as applicable. After completion of the merger,
the directors of Merger Sub and the officers of Aetna immediately prior to completion of the merger will be the directors and officers, respectively, of Aetna, as the surviving corporation in the merger, in each case, until their successors are duly
elected or appointed and qualified in accordance with the surviving corporation&#146;s articles of incorporation, <FONT STYLE="white-space:nowrap">by-laws</FONT> and applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_90"></A>Completion and Effectiveness of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will be completed and become effective at such time as the statement of merger for the merger is duly filed with the Pennsylvania
Department of State (or at such later time as agreed to by Aetna and CVS Health and specified in the statement of merger for the merger). Unless another date and time are agreed to by CVS Health and Aetna, completion of the merger will occur on the
third business day following satisfaction or, to the extent permitted by applicable law, waiver, of the conditions to completion of the merger (other than those conditions that by their nature are to be satisfied at completion of the merger, but
subject to the satisfaction or, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the extent permitted by applicable law, waiver of such conditions at the time of completion) described under &#147;&#151;Conditions to Completion of the Merger&#148; beginning on page 181 of this
joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this joint proxy statement/prospectus, CVS Health and Aetna expect that the merger
will be completed in the second half of 2018. However, completion of the merger is subject to the satisfaction or, to the extent permitted by applicable law, waiver of the conditions to completion of the merger, which are summarized below. There can
be no assurances as to when, or if, the merger will occur. If the merger is not completed on or before the initial end date of December&nbsp;3, 2018, either CVS Health or Aetna may terminate the merger agreement, unless all conditions to completion
of the merger have been satisfied or waived on the initial end date other than the regulatory approvals condition, and either CVS Health or Aetna elects to extend the initial end date to March&nbsp;3, 2019, in which case, if the merger is not
completed on or before March&nbsp;3, 2019, either CVS Health or Aetna may terminate the merger agreement, unless all conditions to completion of the merger have been satisfied or waived on the extended end date other than the regulatory approvals
condition, and CVS Health elects to extend the extended end date to June&nbsp;3, 2019, in which case, if the merger is not completed on or before June&nbsp;3, 2019, either CVS Health or Aetna may terminate the merger agreement. The right to
terminate the merger agreement after the end date, or to extend the initial end date or extended end date, will not be available to CVS Health or Aetna, as applicable, if that party&#146;s breach of any provision of the merger agreement resulted in
the failure of the merger to be completed by the end date. See &#147;&#151;Conditions to Completion of the Merger&#148; and &#147;&#151;Termination of the Merger Agreement&#148; beginning on pages 181 and 203, respectively, of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_91"></A>Merger Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At completion of the merger, each Aetna common share outstanding immediately prior to completion of the merger, except for shares held by Aetna
as treasury stock or shares owned by CVS Health or by any subsidiary of Aetna or CVS Health, will be converted into the right to receive $145.00 in cash without interest thereon and 0.8378 of a share of CVS Health common stock (with cash payable in
lieu of any fractional shares as described under &#147;&#151;Fractional Shares&#148; beginning on page 178 of this joint proxy statement/prospectus). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, between the date of the merger agreement and completion of the merger, any change in the outstanding shares of capital stock of Aetna or
CVS Health occurs as a result of any reclassification, recapitalization, stock split (including reverse stock split), merger, combination, exchange or readjustment of shares, subdivision or other similar transaction, or any stock dividend thereon
with a record date during such period, the merger consideration and any other amounts payable pursuant to the merger agreement will be appropriately adjusted to eliminate the effect of such event thereon. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_92"></A>Fractional Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares of CVS Health common stock will be issued to any holder of Aetna common shares upon completion of the merger. Instead, all
fractional shares of CVS Health common stock that a holder of Aetna common shares would otherwise be entitled to receive as a result of the merger will be aggregated and, if a fractional share results from that aggregation, the holder will be
entitled to receive cash in an amount determined by multiplying that fraction by the CVS Health closing price in lieu of that fractional share. No interest will be paid or accrued on cash payable in lieu of fractional shares of CVS Health common
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_93"></A>No Appraisal or Dissenters&#146; Rights for Aetna Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;1571(b) of the PBCL, holders of Aetna common shares will not be entitled to appraisal or dissenters&#146; rights in
connection with the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_94"></A>Procedures for Surrendering Aetna Share Certificates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion of Aetna common shares into the right to receive the merger consideration will occur automatically at completion of the merger.
Prior to completion of the merger, CVS Health will appoint an exchange agent reasonably acceptable to Aetna and enter into an exchange agent agreement with the exchange agent reasonably acceptable to Aetna providing for the exchange agent to handle
the exchange of certificates or book-entry shares representing Aetna common shares for the merger consideration. As of completion of the merger, CVS Health will deposit or make available as needed the cash and shares of CVS Health common stock
comprising the merger consideration payable in respect of Aetna common shares. Promptly (but not later than two business days) after completion of the merger, CVS Health will, or will cause the exchange agent to, send a letter of transmittal to each
person who is a record holder of Aetna common shares at completion of the merger for use in the exchange and instructions explaining how to surrender Aetna share certificates or transfer uncertificated Aetna common shares to the exchange agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna shareholders who submit a properly completed letter of transmittal, together with their share certificates (in the case of certificated
shares) or other evidence of transfer requested by the exchange agent (in the case of book-entry shares), will receive the merger consideration into which the Aetna common shares were converted in the merger. The shares of CVS Health common stock
constituting part of the merger consideration will be delivered to Aetna shareholders in book-entry form unless a physical certificate is requested by an Aetna shareholder or otherwise required under applicable law. After completion of the merger,
each certificate that previously represented Aetna common shares and each uncertificated Aetna common share that previously was registered to a holder on Aetna&#146;s stock transfer books, except for shares held by Aetna as treasury stock or shares
owned by CVS Health or by any subsidiary of Aetna or CVS Health, will only represent the right to receive the merger consideration into which those Aetna common shares have been converted (and cash in lieu of any fractional shares of CVS Health
common stock as described under &#147;&#151;Fractional Shares&#148; beginning on page&nbsp;178 of this joint proxy statement/prospectus, and any dividends on the shares of CVS Health common stock into which such Aetna shares have been converted as
described below under &#147;&#151;Procedures for Surrendering Aetna Share Certificates&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither CVS Health nor Aetna will be
responsible for transfer or other similar taxes and fees incurred by holders of Aetna common shares in connection with the merger. Those taxes and fees, if any, will be the sole responsibility of such holders. In addition, if there is a transfer of
ownership of Aetna common shares that is not registered in the records of Aetna&#146;s transfer agent, payment of the merger consideration as described above (and cash in lieu of any fractional shares of CVS Health common stock as described under
&#147;&#151;Fractional Shares&#148; beginning on page&nbsp;178 of this joint proxy statement/prospectus, and any dividends on the shares of CVS Health common stock into which such Aetna shares have been converted as described below under
&#147;&#151;Procedures for Surrendering Aetna Share Certificates&#148;) will be made to a person other than the person in whose name the certificate or uncertificated share so surrendered is registered only if the certificate is properly endorsed or
otherwise is in proper form for transfer or the uncertificated share is properly transferred, and the person requesting the payment must pay to the exchange agent any transfer or other similar taxes required as a result of such payment or satisfy
the exchange agent that any transfer or other similar taxes have been paid or that no payment of those taxes is necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After
completion of the merger, CVS Health will not pay dividends with a record date on or after completion of the merger to any holder of any Aetna share certificates or uncertificated Aetna common shares on the shares of CVS Health common stock into
which such Aetna shares have been converted until such holder surrenders the Aetna share certificates or transfers the uncertificated Aetna common shares as described above. However, once those certificates or uncertificated Aetna common shares are
surrendered or transferred, as applicable, CVS Health will pay to such holder, without interest, any dividends on the shares of CVS Health common stock into which such Aetna shares have been converted with a record date on or after completion of the
merger that have been paid prior to such surrender or transfer, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_95"></A>Treatment of Aetna Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Aetna Stock Appreciation Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of completion of the merger, each outstanding vested Aetna stock appreciation right (including those Aetna stock appreciation rights that
vest by their terms as of completion of the merger), will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the excess, if any, of the equity award cash consideration over the applicable per share
exercise price of such Aetna stock appreciation right multiplied by the total number of Aetna common shares subject to such Aetna stock appreciation right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Aetna stock appreciation right that is not vested as of completion of the merger or that is granted after the date of the merger
agreement (to the extent permitted under the merger agreement), at completion of the merger, will be assumed by CVS Health and will become an assumed stock appreciation right representing the right to receive a payment in shares of CVS Health common
stock on the same terms and conditions, except that the number of shares of CVS Health common stock subject to the assumed stock appreciation right will equal the product of the number of Aetna common shares that were subject to such Aetna stock
appreciation right immediately prior to completion of the merger multiplied by the equity award exchange ratio, with such product rounded down to the nearest whole share of CVS Health common stock. The per share exercise price for each assumed stock
appreciation right will equal the exercise price per share of such Aetna stock appreciation right immediately prior to completion of the merger divided by the equity award exchange ratio, rounded up to the nearest whole cent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Aetna Restricted Stock Units and Performance Stock Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to completion of the merger, each outstanding Aetna RSU and each outstanding Aetna PSU that provides for accelerated vesting
upon completion of the merger will vest and will be converted into the right to receive, with respect to each Aetna common share underlying the Aetna RSU or Aetna PSU, the merger consideration, less applicable tax withholdings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Aetna RSU or Aetna PSU that is not converted into a right to receive the merger consideration or is granted after the date of the merger
agreement (to the extent permitted under the merger agreement) will be assumed by CVS Health and will be converted into a time-based restricted stock unit award covering the number of whole shares of CVS Health common stock equal to the product of
the number of Aetna common shares underlying such assumed Aetna RSU or Aetna PSU immediately prior to completion of the merger (with the performance of each Aetna PSU to be determined based on the applicable award agreement relating to such Aetna
PSU) multiplied by the equity award exchange ratio with such product rounded down to the nearest whole share of CVS Health common stock. Except as provided in the immediately preceding sentence, each assumed Aetna RSU or Aetna PSU will continue to
have, and be subject to, the same terms and conditions as applied to the corresponding Aetna RSU or Aetna PSU immediately prior to completion of the merger (including any terms and conditions relating to accelerated vesting upon a termination of the
holder&#146;s employment in connection with or following the merger). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_96"></A>Listing of CVS Health Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement obligates CVS Health to use its reasonable best efforts to cause the shares of CVS Health common stock to be issued in the
merger to be listed on the NYSE, subject to official notice of issuance, prior to completion of the merger. Approval for listing on the NYSE of the shares of CVS Health common stock issuable to Aetna shareholders in the merger, subject to official
notice of issuance, is a condition to the obligations of CVS Health and Aetna to complete the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_97"></A>Governance and Social
Matters Following Completion of the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Board of Directors of CVS Health</I>. CVS Health will take all necessary corporate
action to cause, effective at completion of the merger, the size of the board of directors of CVS Health to be increased by three and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vacancies created thereby to be filled by Mark T. Bertolini, the Chairman and Chief Executive Officer of Aetna, and two other individuals who are serving on the board of directors of Aetna
immediately prior to completion of the merger who meet CVS Health&#146;s independence criteria as in effect as of such time and who will be jointly designated by Aetna and CVS Health prior to completion of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Aetna Foundation</I>. The merger agreement provides that, for at least three years following completion of the merger, CVS Health will
preserve Aetna Foundation, Inc. in a manner consistent in all material respects with the past practice of Aetna, including by maintaining its name and charitable mission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Aetna&#148; Brand</I>. The merger agreement provides that, for at least five years following completion of the merger, CVS Health
will maintain &#147;Aetna&#148; as the primary brand for the insurance businesses of CVS Health and its subsidiaries (including Aetna and its subsidiaries). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_98"></A>Conditions to Completion of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mutual Conditions to Completion</I>. The obligation of each of CVS Health, Aetna and Merger Sub to complete the merger is subject to the
satisfaction (or, to the extent permitted by applicable law, waiver) of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval and adoption of the merger agreement by the affirmative vote of the holders of a majority of the outstanding Aetna common shares in accordance with Aetna&#146;s articles and the PBCL; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval of the stock issuance by a majority of all votes cast by holders of outstanding shares of CVS Health common stock in accordance with the rules of the NYSE; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the absence of any applicable law or order enacted, adopted or promulgated after the date of the merger agreement being in effect in the U.S. that enjoins, prevents or prohibits completion of the merger;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of the registration statement for the shares of CVS Health common stock to be issued in the merger (of which this joint proxy statement/prospectus forms a part) and the absence of any stop order
suspending that effectiveness or any proceedings for that purpose pending before the SEC; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval for listing on the NYSE of the shares of CVS Health common stock to be issued in the merger, subject to official notice of issuance. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Additional Conditions to Completion for the Benefit of CVS Health and Merger Sub</I>. In addition to the conditions to all parties&#146;
obligations, the obligation of each of CVS Health and Merger Sub to complete the merger is subject to the satisfaction (or, to the extent permitted by applicable law, waiver) of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">both (i)&nbsp;the expiration or early termination of any applicable waiting period relating to the merger under the HSR Act and (ii)&nbsp;the required governmental authorizations having been made or obtained and being
in full force and effect, in each case in this bullet, without the imposition of any term or condition that would have or would reasonably be expected to have, individually or in the aggregate, a regulatory material adverse effect on CVS Health or
Aetna (see &#147;&#151;Reasonable Best Efforts Covenant&#148; beginning on page 194 of this joint proxy statement/prospectus for the definition of regulatory material adverse effect); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the absence since the date of the merger agreement of any event, change, effect, development or occurrence that has had or would reasonably be expected to have, individually or in the aggregate, a material adverse
effect on Aetna (see &#147;&#151;Definition of &#145;Material Adverse Effect&#146;&#148; beginning on page&nbsp;184 of this joint proxy statement/prospectus for the definition of material adverse effect); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy (subject only to <I>de minimis</I> exceptions) as of the date of the merger agreement and as of completion of the merger (or, in the case of representations and warranties given as of another specific date,
as of that date) of certain representations and warranties made in the merger agreement by Aetna regarding its capitalization; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy in all material respects as of the date of the merger agreement and as of completion of the merger (or, in the case of representations and warranties given as of another specific date, as of that date) of
certain representations and warranties made in the merger agreement by Aetna regarding, among other matters, its corporate existence, its corporate authority relative to the merger agreement and the merger, fees payable to its financial advisors in
connection with the merger, its ownership of its subsidiaries, the receipt of opinions from its financial advisors and the inapplicability of certain antitakeover laws; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy of all other representations and warranties made in the merger agreement by Aetna (disregarding all qualifications and exceptions contained in such representations and warranties relating to materiality or
material adverse effect) as of the date of the merger agreement and as of completion of the merger (or, in the case of representations and warranties given as of another specified date, as of that date), except for any inaccuracies in such
representations and warranties that have not had and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Aetna; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance (or cure of any <FONT STYLE="white-space:nowrap">non-performance)</FONT> in all material respects by Aetna of the covenants and agreements required to be performed by it prior to completion of the merger;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of a certificate from an executive officer of Aetna confirming the satisfaction of the conditions described in the preceding five bullets. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Additional Conditions to Completion for the Benefit of Aetna</I>. In addition to the conditions to all parties&#146; obligations, the
obligation of Aetna to complete the merger is subject to the satisfaction (or, to the extent permitted by applicable law, waiver) of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expiration or early termination of any applicable waiting period relating to the merger under the HSR Act to the extent required under applicable law to complete the transactions contemplated by the merger
agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the required governmental authorizations having been made or obtained and being in full force and effect to the extent required under applicable law to complete the transactions contemplated by the merger agreement
(this condition, together with the preceding bullet, the corresponding conditions for the benefit of CVS Health and Merger Sub, and the condition for the benefit of Aetna, CVS Health and Merger Sub relating to the absence of any applicable law or
order enjoining, preventing or prohibiting completion of the merger, with respect to any applicable law or order relating to the governmental authorizations referred to in this condition, in the preceding bullet and in the corresponding conditions
for the benefit of CVS Health and Merger Sub, is referred to in this joint proxy statement/prospectus as the regulatory approvals condition); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the absence since the date of the merger agreement of any event, change, effect, development or occurrence that has had or would reasonably be expected to have, individually or in the aggregate, a material adverse
effect on CVS Health (see &#147;&#151;Definition of &#145;Material Adverse Effect&#146;&#148; beginning on page&nbsp;184 of this joint proxy statement/prospectus for the definition of material adverse effect); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy (subject only to <I>de minimis</I> exceptions) as of the date of the merger agreement and as of completion of the merger (or, in the case of representations and warranties given as of another specific date,
as of that date) of certain representations and warranties made in the merger agreement by CVS Health regarding its capitalization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy in all material respects as of the date of the merger agreement and as of completion of the merger (or, in the case of representations and warranties given as of another specific date, as of that date) of
certain representations and warranties made in the merger agreement by CVS Health regarding, among other matters, its corporate existence, its corporate authority relative to the merger agreement and the merger, fees payable to its financial
advisors in connection with the merger, its ownership of its subsidiaries, the opinions of its financial advisors and the inapplicability of certain antitakeover laws; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy of all other representations and warranties made in the merger agreement by CVS Health (disregarding all qualifications and exceptions contained in such representations and warranties relating to
materiality or material adverse effect) as of the date of the merger agreement and as of completion of the merger (or, in the case of representations and warranties given as of another specified date, as of that date), except for any inaccuracies in
such representations and warranties that have not had and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on CVS Health; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance (or cure of any <FONT STYLE="white-space:nowrap">non-performance)</FONT> in all material respects by CVS Health and Merger Sub of the covenants and agreements required to be performed by them prior to
completion of the merger; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of a certificate from an executive officer of CVS Health confirming the satisfaction of the conditions described in the preceding five bullets. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_99"></A>Representations and Warranties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement contains a number of representations and warranties made by both CVS Health and Aetna that are subject in some cases to
exceptions and qualifications (including exceptions that are not material to the party making the representations and warranties and its subsidiaries, taken as a whole, and exceptions that do not have, and would not reasonably be expected to have,
individually or in the aggregate, a material adverse effect on the party making the representations and warranties). See &#147;&#151;Definition of &#145;Material Adverse Effect&#146;&#148; beginning on page 184 of this joint proxy
statement/prospectus for the definition of material adverse effect. The representations and warranties in the merger agreement relate to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">corporate existence, good standing and qualification to conduct business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">due authorization, execution and validity of the merger agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">governmental and third-party consents necessary to complete the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">absence of any conflict with or violation or breach of organizational documents or any conflict with or violation or breach of agreements, laws or regulations as a result of the execution, delivery or performance of the
merger agreement and completion of the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">capitalization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subsidiaries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">SEC filings, the absence of material misstatements or omissions from such filings and compliance with the Sarbanes-Oxley Act of 2002; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information provided by the applicable party for inclusion in disclosure documents to be filed with the SEC in connection with the merger; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct of business in the ordinary course of business consistent with past practices and absence of changes that have had or would reasonably be expected to have, individually or in the aggregate, a material adverse
effect on the applicable party, in each case since December&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">absence of undisclosed material liabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with laws, court orders and permits; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employees, employee benefit plans and labor matters; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">intellectual property matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">environmental matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inapplicability of antitakeover statutes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of opinions from such party&#146;s financial advisors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fees payable to financial advisors in connection with the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no ownership of the other party&#146;s common stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no other representations and warranties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna also makes representations and warranties
relating to, among other things, statutory financial statements, loss reserves, capital or surplus maintenance of regulated subsidiaries, material contracts, properties, insurance matters and transactions with affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health also makes representations and warranties relating to, among other things, matters with respect to the debt commitment letter
regarding the financing for the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties in the merger agreement do not survive completion of the
merger. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;&#151;Explanatory Note&#148; beginning on page&nbsp;177 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_100"></A>Definition of &#147;Material Adverse Effect&#148; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the representations and warranties in the merger agreement are qualified by &#147;material adverse effect&#148; on the party making
such representations and warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the merger agreement, &#147;material adverse effect&#148; means, with respect to CVS
Health or Aetna, as the case may be, a material adverse effect on the financial condition, business or results of operations of that party and its subsidiaries, taken as a whole, except that no effect to the extent resulting from any of the
following events, changes, developments or occurrences will be taken into account in determining whether there has been a material adverse effect, or whether a material adverse effect would reasonably be expected to occur: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes in general United States or global economic conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes in conditions generally affecting the industry in which that party or any of its subsidiaries operate, including, in the case of Aetna, the health insurance or managed care industry (including, in the case
of Aetna, the Medicare Advantage managed care industry); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any decline, in and of itself, in the market price or trading volume of that party&#146;s common stock (but not any facts or occurrences giving rise to or contributing to that decline that are not otherwise excluded
from the definition of material adverse effect); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes in regulatory, legislative or political conditions or in securities, credit, financial, debt or other capital markets, in each case in the United States or any foreign jurisdiction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any failure, in and of itself, by that party to meet any internal or published projections, forecasts, estimates or predictions in respect of enrollments, revenues, earnings or other financial or operating metrics for
any period (but not any facts or occurrences giving rise to or contributing to that failure that are not otherwise excluded from the definition of material adverse effect); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the execution and delivery of the merger agreement, the public announcement or pendency of the merger agreement
or the merger, the taking of any action required or expressly contemplated by the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
merger agreement or the identity of, or any facts or circumstances relating to any other party to the merger agreement or that other party&#146;s subsidiaries, including the impact of any of the
foregoing on the relationships, contractual or otherwise, of that party or any of its subsidiaries with governmental authorities, customers, providers, suppliers, partners, officers or employees (except with respect to any representation or warranty
that is intended to address the consequences of the execution, delivery or performance of the merger agreement or completion of the transactions contemplated by the merger agreement); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any adoption, implementation, promulgation, repeal, modification, amendment, authoritative interpretation, change or proposal of any applicable law of or by any governmental authority; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes in United States generally accepted accounting principles or, in the case of Aetna, statutory accounting principles or actuarial standards of practice (or, in any of such cases, authoritative interpretations
thereof); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes in geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage, cyberattack or terrorism, or any escalation or worsening of any acts of war, sabotage, cyberattack or
terrorism threatened or underway as of the date of the merger agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any taking of any action at the written request of or with the consent of any other party to the merger agreement (but not any facts or occurrences resulting from that action that are not otherwise excluded from the
definition of material adverse effect); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any reduction in the credit rating of that party or any of its subsidiaries (but not any facts or occurrences giving rise to or contributing to that reduction that are not otherwise excluded from the definition of
material adverse effect); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any epidemic, plague, pandemic or other outbreak of illness or public health event, hurricane, earthquake, flood or other natural disasters, acts of God or any change resulting from weather conditions;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes to reimbursement rates or in methods or procedures for determining those rates, any changes to eligibility requirements or any other programmatic changes by any governmental authority, in each case whether
such changes are applicable nationally or to only certain geographic areas; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any claims, actions, suits or proceedings arising from allegations of a breach of fiduciary duty or violation of applicable law relating to the merger agreement or the merger; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except, in the case of the events, changes, developments or occurrences referred to in the first, second, fourth, seventh, eighth and thirteenth bullets in
the immediately preceding list, to the extent that those events, changes, developments or occurrences have a materially disproportionate adverse effect on that party and its subsidiaries, taken as a whole, relative to the adverse effect those
changes, developments or occurrences have on other companies operating in the industries in which that party or any of its subsidiaries operate (except that any such disproportionate effect on that party and its subsidiaries to the extent resulting
from the greater concentration of the businesses of that party and its subsidiaries in any particular industry or geography relative to other companies operating in the industries in which that party or any of its subsidiaries operate will not be
taken into account in determining whether there has been, or would reasonably be expected to be, a material adverse effect on that party and its subsidiaries). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_101"></A>Conduct of Business Pending the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, except (i)&nbsp;as required or expressly contemplated by the merger agreement, (ii)&nbsp;as required or prohibited by applicable
law or (iii)&nbsp;as set forth in the confidential disclosure schedules delivered to the other party concurrently with the execution of the merger agreement, unless the other party otherwise consents (which consent may not be unreasonably withheld,
conditioned or delayed), Aetna, CVS Health and their respective subsidiaries are required to conduct their business in the ordinary course of business consistent with past practice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and to use commercially reasonable efforts to preserve intact their respective business organizations and relationships with third parties and to keep available the services of their present
officers and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without limiting the generality of the foregoing, except (i)&nbsp;as required or expressly contemplated by the
merger agreement, (ii)&nbsp;as required or prohibited by applicable law or (iii)&nbsp;as set forth in Aetna&#146;s confidential disclosure schedule delivered to CVS Health concurrently with the execution of the merger agreement, unless CVS Health
otherwise consents (which consent generally may not be unreasonably withheld, conditioned or delayed) and subject to certain exceptions and qualifications described in the merger agreement, each of Aetna and each of its subsidiaries is not permitted
to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amend its organizational documents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">merge or consolidate with any other entity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire any assets, other than (i)&nbsp;acquisitions in an amount not to exceed $100.0&nbsp;million individually or $200.0&nbsp;million in the aggregate, taking into account the acquisitions set forth in Aetna&#146;s
confidential disclosure schedule delivered to CVS Health concurrently with the execution of the merger agreement, together with all capital contributions permitted under clause (ii)&nbsp;of the tenth bullet point in this list below,
(ii)&nbsp;securities under Aetna&#146;s investment portfolio consistent with Aetna&#146;s investment policy in effect as of the date of the merger agreement and (iii)&nbsp;certain intracompany transactions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adopt a plan of complete or partial liquidation, dissolution, recapitalization or restructuring; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">(i) split, combine or reclassify any shares of its capital stock, (ii)&nbsp;amend any term of any of its outstanding equity securities, (iii)&nbsp;declare or pay any dividend or make any other distribution in respect of
any shares of its capital stock or other securities, other than, in the case of Aetna, regular cash dividends in the ordinary course of business consistent with past practice in an amount not to exceed $0.50 per Aetna common share per quarter
(appropriately adjusted to reflect any stock dividends, subdivisions, splits, combinations or other similar events), and in the case of Aetna&#146;s subsidiaries, any dividends or other distributions to Aetna or any other wholly-owned subsidiary
thereof, or (iv)&nbsp;redeem, repurchase, cancel or otherwise acquire any securities of Aetna or any of its subsidiaries, other than certain repurchases in connection with the exercise of Aetna stock appreciation rights or the vesting and settlement
of Aetna RSUs or PSUs, in each case that are outstanding as of the date of the merger agreement or are granted after the date of the merger agreement to the extent permitted by the merger agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue, deliver or sell any shares of its capital stock or any securities convertible into or exercisable for, or any rights to acquire, any such capital stock or any such convertible securities, other than (i)&nbsp;the
issuance of Aetna common shares upon the exercise of Aetna stock appreciation rights or the vesting or settlement of Aetna RSUs or PSUs, in each case that are outstanding as of the date of the merger agreement in accordance with their then current
terms or granted after the date of the merger agreement to the extent permitted by the merger agreement, (ii)&nbsp;in connection with the exercise of rights to purchase Aetna common shares under Aetna&#146;s stock purchase plan in the offering
period for which participant payroll deductions commence during December 2017 to the extent permitted by the merger agreement (iii)&nbsp;in connection with certain intracompany transactions, (iv)&nbsp;the grant of Aetna equity awards to Aetna
employees in connection with Aetna&#146;s annual equity grant procedures or in connection with promotions or new hires, in each case, conducted in the ordinary course of business and consistent with past practice, including with respect to timing,
and subject to the limitations set forth in the merger agreement or (v)&nbsp;the grant of Aetna equity awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in the ordinary course of business consistent with past practice;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur any capital expenditures, other than as set forth in Aetna&#146;s confidential disclosure schedule delivered to CVS Health concurrently with the execution of the merger agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, lease, license or otherwise dispose of any assets, other than (i)&nbsp;in the ordinary course of business
consistent with past practice for fair market value in an amount not to exceed $30.0&nbsp;million in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
aggregate, (ii)&nbsp;dispositions of securities under Aetna&#146;s investment portfolio consistent with Aetna&#146;s investment policy in effect as of the date of the merger agreement or
(iii)&nbsp;certain intracompany transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell, assign, license, sublicense, abandon, allow to lapse, transfer or otherwise dispose of, or create or incur any lien (other than certain permitted liens) on, any intellectual property, other than in the ordinary
course of business (i)&nbsp;pursuant to <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses or (ii)&nbsp;for the purpose of disposing of obsolete or worthless assets; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any material loans, advances or capital contributions, other than (i)&nbsp;certain intracompany transactions, (ii)&nbsp;capital contributions required under the terms of contracts in effect as of the date of the
merger agreement in an amount not to exceed $200.0&nbsp;million in the aggregate, together with all acquisitions permitted under clause (i)&nbsp;of the third bullet point in this list above, (iii)&nbsp;extensions of loans or advances to providers in
the ordinary course of business consistent with past practice or (iv)&nbsp;extensions of loans or advances to business associates other than providers in the ordinary course of business consistent with past practice, so long as the amount of such
loans or advances to business associates other than providers outstanding at any time does not exceed $20.0&nbsp;million in the aggregate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur, assume, guarantee or repurchase any indebtedness for borrowed money, other than additional borrowings under Aetna&#146;s facilities set forth in Aetna&#146;s confidential disclosure schedule delivered to CVS
Health concurrently with the execution of the merger agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">create or incur any lien (except for certain permitted liens) on any material asset; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into, terminate, renew, extend or materially amend any material contract or waive any material right thereunder, other than in the ordinary course of business consistent with past practice; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminate, suspend or amend (i)&nbsp;any certificate of authority to conduct business as an insurance company or health maintenance organization issued by the applicable insurance or health regulatory governmental
authority or (ii)&nbsp;any other material permit, in each case in a manner material and adverse to Aetna and its subsidiaries, taken as a whole; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as required by applicable law or Aetna employee benefit plans or other contracts as in effect on the date
of the merger agreement, (i)&nbsp;grant any change in control, severance or termination pay to (or amend any existing arrangement with) any of Aetna&#146;s current or former directors, officers, employees or individual independent contractors other
than severance or termination pay in the ordinary course of business consistent with past practice for terminated employees in exchange for a general release of claims or other customary covenants, (ii)&nbsp;enter into any employment, deferred
compensation or other similar agreement (or any amendment to any such existing agreement) with any of Aetna&#146;s current or former directors, executive officers, employees or individual independent contractors, other than offer letters (and
related compensation arrangements set forth in such offer letters) with any newly hired directors, employees or individual independent contractors who are not considered to be executive officers and who are not members of the executive leadership
team that are entered into in the ordinary course of business consistent with past practice, (iii)&nbsp;establish, adopt or amend any Aetna employee plan or labor agreement, other than in the ordinary course of business consistent with past practice
(other than paying cash incentive awards for any fiscal years of Aetna ending prior to completion of the merger and establishing cash incentive program terms for any fiscal years of Aetna commencing prior to completion of the merger under
Aetna&#146;s existing incentive plans and arrangements in the ordinary course of business consistent with past practice, subject to the limitations set forth in clause (iv)) or any immaterial amendment that would not increase the cost to Aetna of
maintaining an employee plan, or (iv)&nbsp;increase the compensation, bonus opportunity or other benefits payable to any of Aetna&#146;s or its subsidiaries&#146; current or former directors, officers, employees or individual independent
contractors, other than (A)&nbsp;increases in base compensation and bonus opportunity to current directors, individual independent contractors or employees who are not considered to be executive officers and who are not members of the executive
leadership team in the ordinary course of business (1)&nbsp;consistent with past </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
practice or (2)&nbsp;in connection with a promotion or change in role and (B)&nbsp;increases in employee welfare benefits in the ordinary course of business consistent with past practice for
employees generally;<I> provided</I> that any base compensation increases will not in the aggregate exceed 3.0% of the aggregate base compensation levels of Aetna&#146;s directors and employees who are not considered to be executive officers and who
are not members of the executive leadership team (with base salary increases that had been approved by Aetna but not yet implemented and were disclosed to CVS Health as of the date of the merger agreement being excluded from the foregoing
limitation); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any material change in any method, principles or practice of financial or statutory accounting, except for any such change required by reason of, or advisable under, a change in United States generally accepted
accounting principles, statutory accounting principles, actuarial standards of practice or Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any material change in investment, hedging, underwriting or claims administration principles or practices or in methodologies for estimating and providing for medical costs and other liabilities, in each case with
respect to Aetna or certain of its material subsidiaries, except for any such change required by reason of a change in United States generally accepted accounting principles, applicable statutory accounting principles, actuarial standards of
practice or Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">(i) make or change any material tax election; (ii)&nbsp;change any annual tax accounting period; (iii)&nbsp;adopt or change any material method of tax accounting; (iv)&nbsp;enter into any material closing agreement with
respect to taxes; (v)&nbsp;settle or surrender any material tax claim, audit or assessment; or (vi)&nbsp;enter into any intercompany transaction within the meaning of Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-13</FONT> that (x)&nbsp;is outside the ordinary course of business and (y)&nbsp;results in a material amount of deferred income or gain that would be taken into account pursuant to Treasury
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-13(d)</FONT> as a result of the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">settle or compromise any proceeding, other than settlements or compromises (i)&nbsp;in the ordinary course of business consistent with past practice, including in connection with the processing and paying of claims to
members or providers or risk sharing arrangements with providers (it being understood and agreed that any individual settlement or compromise or any series of related settlements or compromises involving payments in excess of $25.0&nbsp;million,
other than any such settlements or compromises with providers that do not relate to sequestration matters, will not be deemed to be in the ordinary course of business) and (ii)&nbsp;involving only a monetary payment in an amount not to exceed
$10.0&nbsp;million individually or $30.0&nbsp;million in the aggregate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce in any material respect the budget or scope of Aetna&#146;s and its subsidiaries&#146; program for, or otherwise reduce in any material respect the resources or efforts specifically dedicated by Aetna and its
subsidiaries to&nbsp;the maintenance and improvement of their respective Medicare star ratings; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">agree, commit or propose to do any of the foregoing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without limiting the generality of the
first paragraph of this section (under &#147;&#151;Conduct of Business Pending the Merger&#148;), except (i)&nbsp;as required or expressly contemplated by the merger agreement, (ii)&nbsp;as required or prohibited by applicable law or (iii)&nbsp;as
set forth in CVS Health&#146;s confidential disclosure schedule delivered to Aetna concurrently with the execution of the merger agreement, unless Aetna otherwise consents (which consent may not be unreasonably withheld, conditioned or delayed) and
subject to certain exceptions and qualifications described in the merger agreement, each of CVS Health and each of its subsidiaries is not permitted to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amend CVS Health&#146;s organizational documents in a manner materially adverse to Aetna shareholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire any assets, other than (i)&nbsp;acquisitions in an amount not to exceed $2.0&nbsp;billion individually or $5.0&nbsp;billion in the aggregate, (ii)&nbsp;acquisitions of securities under CVS Health&#146;s
investment portfolio consistent with CVS Health&#146;s investment policy and (iii)&nbsp;certain intracompany transactions; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adopt a plan of complete or partial liquidation or dissolution with respect to CVS Health or Merger Sub; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">(i) split, combine or reclassify any shares of its capital stock, (ii)&nbsp;amend any term of any of its outstanding equity securities, (iii)&nbsp;declare or pay any dividend or make any other distribution in respect of
any shares of its capital stock or other securities, other than, in the case of CVS Health, regular cash dividends in the ordinary course of business consistent with past practice in an amount not to exceed $0.50 per share of CVS Health common stock
per quarter (appropriately adjusted to reflect any stock dividends, subdivisions, splits, combinations or other similar events), and in the case of CVS Health&#146;s subsidiaries, any dividends or other distributions to CVS Health or a wholly-owned
subsidiary thereof, or (iv)&nbsp;redeem, repurchase, cancel or otherwise acquire any securities of CVS Health or any of its subsidiaries, other than in the ordinary course of business consistent with past practice, including repurchases
(A)&nbsp;pursuant to accelerated share repurchase programs or agreements in the ordinary course of business consistent with past practice, and (B)&nbsp;in connection with the exercise or the vesting and settlement of CVS Health equity awards, in
each case in this clause (B)&nbsp;that are outstanding as of the date of the merger agreement or are granted after the date of the merger agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue, deliver or sell any shares of its capital stock or any securities convertible into or exercisable for, or any rights to acquire, any such capital stock or any such convertible securities, other than (i)&nbsp;the
issuance of shares of CVS Health common stock upon the exercise of CVS Health equity awards or other equity and equity-linked awards that are outstanding as of the date of the merger agreement or are granted after the date of the merger agreement,
(ii)&nbsp;in connection with certain intracompany transactions, (iii)&nbsp;the grant of CVS Health equity awards to employees, directors or individual independent contractors pursuant to CVS Health&#146;s equity compensation plans or (iv)&nbsp;the
stock issuance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell, lease, license or otherwise dispose of any assets, other than (i)&nbsp;dispositions in an amount not to exceed $3.0&nbsp;billion individually or $6.0&nbsp;billion in the aggregate, (ii)&nbsp;dispositions of
securities under CVS Health&#146;s investment portfolio consistent with CVS Health&#146;s investment policy or (iii)&nbsp;certain intracompany transactions; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">agree, commit or propose to do any of the foregoing. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_102"></A>Obligations to Call
Shareholders&#146; and Stockholders&#146; Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As promptly as practicable after the effectiveness of the registration statement on
Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this joint proxy statement/prospectus forms a part, each of Aetna and CVS Health has agreed to, in consultation with the other party, establish a record date for, duly call and give notice
of a meeting of its shareholders or stockholders, respectively, at which Aetna will seek the vote of its shareholders required to approve and adopt the merger agreement, and CVS Health will seek the vote of its stockholders required to approve the
stock issuance. The record date for the meeting of Aetna shareholders must be no later than ten days after the effectiveness of the registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this joint proxy
statement/prospectus forms a part, and the record date for the meeting of CVS Health stockholders must be the same as the record date for the meeting of Aetna shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as promptly as practicable after the effectiveness of the registration statement on Form
<FONT STYLE="white-space:nowrap">S-4,</FONT> of which this joint proxy statement/prospectus forms a part, each of Aetna and CVS Health has agreed to duly convene and hold the meeting of its shareholders or stockholders, respectively. The meeting of
Aetna shareholders must be held no later than 40 days after the record date for that meeting, and the meeting of CVS Health stockholders must be held on the same date and time as the meeting of Aetna shareholders. Subject to the rights of the Aetna
and CVS Health boards of directors to make an adverse recommendation change, as discussed under &#147;&#151;No Solicitation&#148; beginning on page 190 of this joint proxy statement/prospectus, each of Aetna and CVS Health has agreed to use its
reasonable best efforts to cause the required vote of its shareholders or stockholders, respectively, in connection with the merger to be received at the meeting of its shareholders or stockholders, respectively, and will comply with all legal
requirements applicable to such meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Aetna nor CVS Health may adjourn, postpone or otherwise delay the meeting of its
shareholders or stockholders, respectively, without the prior written consent of the other party. However, each party may, without the prior written consent of the other party, adjourn or postpone the meeting of its shareholders or stockholders,
respectively, after consultation with the other party, if that party believes in good faith that such adjournment or postponement is reasonably necessary to allow reasonable additional time to (i)&nbsp;solicit additional proxies necessary to obtain
the required vote of its shareholders or stockholders, respectively, in connection with the merger at such meeting, or (ii)&nbsp;distribute any supplement or amendment to this joint proxy statement/prospectus that its board of directors has
determined in good faith after consultation with outside legal counsel is necessary under applicable law and for such supplement or amendment to be reviewed by its shareholders or stockholders, as applicable, prior to such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the merger agreement is earlier terminated, Aetna&#146;s board of directors must submit the merger agreement for adoption at the
meeting of its shareholders called for such purpose, even if it changes its recommendation with respect to the merger agreement. Similarly, unless the merger agreement is earlier terminated in accordance with its terms, CVS Health&#146;s board of
directors must submit the stock issuance for approval at the meeting of its stockholders called for such purpose, even if it changes its recommendation with respect to the stock issuance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_103"></A>Obligations to Recommend the Approval and Adoption of the Merger Agreement and the Approval of the Stock Issuance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed under &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock
Issuance&#151;Aetna&#146;s Reasons for the Merger; Recommendation of the Aetna Board of Directors that Aetna Shareholders Approve and Adopt the Merger Agreement&#148; beginning on page&nbsp;101 of this joint proxy statement/prospectus, Aetna&#146;s
board of directors unanimously recommends that Aetna shareholders vote <B>&#147;FOR&#148;</B> the approval and adoption of the merger agreement. Aetna&#146;s board of directors, however, may (i)&nbsp;withdraw or qualify, amend or modify in a manner
adverse to CVS Health its recommendation that Aetna shareholders approve and adopt the merger agreement or (ii)&nbsp;recommend, adopt or approve an alternative acquisition proposal for Aetna, in each case, under specified circumstances as discussed
under &#147;&#151;No Solicitation&#148; beginning on page 190 of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, as discussed under
&#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of Directors that CVS Health
Stockholders Approve the Stock Issuance&#148; beginning on page 106 of this joint proxy statement/prospectus, CVS Health&#146;s board of directors unanimously recommends that CVS Health stockholders vote <B>&#147;FOR&#148;</B> the stock issuance.
CVS Health&#146;s board of directors, however, may (i)&nbsp;withdraw or qualify, amend or modify in a manner adverse to Aetna its recommendation that CVS Health stockholders approve the stock issuance or (ii)&nbsp;recommend, adopt or approve an
alternative acquisition proposal for CVS Health, in each case, under specified circumstances as discussed under &#147;&#151;No Solicitation&#148; beginning on page 190 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, unless the merger agreement has previously been terminated in accordance with its terms, the merger agreement must be submitted to
Aetna shareholders for adoption (even if Aetna&#146;s board of directors has made an adverse recommendation change, or if an acquisition proposal for Aetna has been publicly proposed or announced or otherwise submitted). Similarly, unless the merger
agreement has previously been terminated in accordance with its terms, the stock issuance must be submitted to CVS Health stockholders for approval (even if CVS Health&#146;s board of directors has made an adverse recommendation change, or if an
acquisition proposal for CVS Health has been publicly proposed or announced or otherwise submitted). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_104"></A>No Solicitation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the exceptions described below, each of Aetna and CVS Health has agreed not to, and to cause its subsidiaries not to, and
to use its reasonable best efforts to cause its and its subsidiaries&#146; officers, directors, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees, investment bankers, attorneys, accountants, consultants and other agents, advisors and representatives, which are collectively referred to in this joint proxy statement/prospectus as
representatives, not to, directly or indirectly, among other things: (i)&nbsp;solicit, initiate or take any action to knowingly facilitate or knowingly encourage the submission of any acquisition proposal (as defined below), (ii)&nbsp;enter into or
participate in any discussions or negotiations with, furnish any information relating to that party or any of its subsidiaries or afford access to the business, properties, assets, books or records of that party or any of its subsidiaries to,
otherwise cooperate in any way with, or knowingly assist, participate in, knowingly facilitate or knowingly encourage any effort by, any third party that such party knows is seeking to make, or has made, an acquisition proposal, (iii)(A) fail to
make or withdraw or qualify, amend or modify in a manner adverse to the other party (or fail to include in this joint proxy statement/prospectus) the recommendation of that party&#146;s board of directors that such party&#146;s shareholders vote in
favor of the approval and adoption of the merger agreement or such party&#146;s stockholders vote in favor of the approval of the stock issuance, as applicable, or (B)&nbsp;recommend, adopt or approve an acquisition proposal for such party (any of
the actions described in this clause (iii)&nbsp;are referred to in this joint proxy statement/prospectus as an adverse recommendation change), (iv)&nbsp;take any action to make any antitakeover laws and regulations of the Commonwealth of
Pennsylvania, including Subchapter F of Chapter 25 of the PBCL, in the case of Aetna, or of the State of Delaware, including Section&nbsp;203 of the Delaware General Corporation Law (which is referred to in this joint proxy statement/prospectus as
the DGCL), in the case of CVS Health, inapplicable to any third party or acquisition proposal, (v)&nbsp;in the case of CVS Health, approve any transaction (other than the transactions contemplated by the merger agreement) under, or any person
becoming a &#147;Related Person&#148; under Article Fifth of CVS Health&#146;s certificate of incorporation as in effect on the date of the merger agreement or take any other action to make any other antitakeover provision in CVS Health&#146;s
certificate of incorporation inapplicable to any third party or any acquisition proposal or (vi)&nbsp;fail to enforce or grant any waiver or release under any standstill or similar agreement with respect to any class of equity securities of that
party or any of its subsidiaries unless that party&#146;s board of directors determines after consulting with its outside legal counsel that the failure to waive such provision would be inconsistent with its fiduciary duties under applicable law
(except that the obligation not to fail to enforce any such standstill or similar agreement under this clause (vi)&nbsp;will apply with respect to known breaches of such agreements only). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, if at any time prior to the approval and adoption of the merger agreement by Aetna shareholders, in the case of Aetna, or at any time
prior to the approval of the stock issuance by CVS Health stockholders, in the case of CVS Health, Aetna or CVS Health, as applicable, receives a written acquisition proposal made after the date of the merger agreement which has not resulted from a
violation of the solicitation restrictions described in the first paragraph of this section (under &#147;&#151;No Solicitation&#148;), the board of directors of that party is permitted to, directly or indirectly through its representatives, and
subject to certain exceptions and qualifications described in the merger agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">contact the third party that has made such acquisition proposal in order to ascertain facts or clarify terms for the sole purpose of Aetna&#146;s or CVS Health&#146;s board of directors, as applicable, informing itself
about such acquisition proposal and such third party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) engage in negotiations or discussions with any third party that, subject to Aetna&#146;s or CVS Health&#146;s
compliance, as applicable, with the solicitation restrictions described in the first paragraph of this section (under &#147;&#151;No Solicitation&#148;), has made after the date of the merger agreement a superior proposal (as defined below in this
section) or an unsolicited written acquisition proposal that Aetna&#146;s or CVS Health&#146;s board of directors, as applicable, determines is reasonably likely to lead to a superior proposal, (ii)&nbsp;furnish to such third party and its
representatives and financing sources nonpublic information relating to Aetna or CVS Health, as applicable, or any of its subsidiaries pursuant to a confidentiality agreement between Aetna or CVS Health, as applicable, and such third party in
existence on or prior to the date of the merger agreement, or a confidentiality agreement with confidentiality terms in the aggregate no less favorable to Aetna or CVS Health, as applicable, than those contained in the confidentiality agreement
between Aetna and CVS Health, so long as all such nonpublic information (to the extent not previously provided or made available to the other party) is provided or made available to the other party substantially concurrently with the time it is
provided or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
made available to such third party and (iii)&nbsp;following receipt of a superior proposal after the date of the merger agreement, make an adverse recommendation change and/or terminate the
merger agreement to enter into a definitive agreement providing for such superior proposal and pay concurrently a termination fee to the other party (See &#147;The Merger Agreement&#151;Termination of the Merger Agreement&#148; beginning on page 203
of this joint proxy statement/prospectus); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make an adverse recommendation change involving or relating to an intervening event (as defined below). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna or CVS Health, as applicable, is only permitted to take the actions described in the second or third bullets above if that party&#146;s
board of directors determines in good faith, after consultation with that party&#146;s outside legal counsel and, in the case of the actions described in the second bullet above, financial advisor, that the failure to take such action would be
reasonably likely to be inconsistent with its fiduciary duties under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Aetna&#146;s or CVS Health&#146;s board
of directors, as applicable, is not permitted to take any of the actions described in the second bullet above unless that party has delivered to the other party written notice advising the other party that it intends to take such action, and Aetna
or CVS Health, as applicable, continues to advise the other party, on a current basis, after taking that action of the status and material terms of any discussions and negotiations with the applicable third party. Aetna or CVS Health, as applicable,
must also notify the other party promptly (but in no event later than 24 hours) after receipt by Aetna or CVS Health, as applicable (or any of its representatives), of any acquisition proposal, any indication that a third party is considering making
an acquisition proposal or any request for information relating to Aetna or CVS Health, as applicable, or any of its subsidiaries or for access to the business, properties, assets, books or records of Aetna or CVS Health, as applicable, or any of
its subsidiaries by any third party that, to the knowledge of Aetna or CVS Health, as applicable, or any member of its board of directors, is considering making, is reasonably likely to make or has made, an acquisition proposal. Aetna or CVS Health,
as applicable, must also keep the other party fully informed, on a current basis, of the status and details of any such acquisition proposal, indication or request (including any changes thereto) and must promptly (but in no event later than 24
hours after receipt) provide to the other party copies of all material correspondence and written materials sent or provided to Aetna or CVS Health, as applicable, or any of its subsidiaries that describes any terms or conditions of any acquisition
proposal (as well as written summaries of any material oral communications addressing such matters). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Aetna&#146;s or CVS
Health&#146;s board of directors, as applicable, is not permitted to make an adverse recommendation change involving or relating to a superior proposal or terminate the merger agreement in order to enter into a definitive agreement with respect to a
superior proposal, unless (i)&nbsp;Aetna or CVS Health, as applicable, promptly notifies the other party, in writing at least three business days before taking that action, that it intends to take that action, attaching the most current version of
any proposed agreement (or a detailed summary of all material terms and the identity of the offeror), (ii)&nbsp;if requested by the other party, during such three business day period, Aetna or CVS Health, as applicable, and its representatives have
discussed and negotiated in good faith with the other party regarding any proposal by the other party to amend the terms of the merger agreement in response to such superior proposal and (iii)&nbsp;after such three business day period, Aetna&#146;s
or CVS Health&#146;s board of directors, as applicable, determines in good faith, taking into account any proposal by the other party to amend the terms of the merger agreement, that such acquisition proposal continues to constitute a superior
proposal. Any amendment to the financial terms or other material terms of such superior proposal will require a new written notification from Aetna or CVS Health, as applicable, to the other party and will commence a new notice period under the
preceding sentence, except that such new notice period will be for two business days rather than three business days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna&#146;s or CVS
Health&#146;s board of directors, as applicable, is not permitted to make an adverse recommendation change involving or relating to an intervening event unless (i)&nbsp;Aetna or CVS Health, as applicable, has promptly notified the other party in
writing of its intention to take such action, (ii)&nbsp;Aetna or CVS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Health, as applicable, negotiates with the other party for three business days following such notice regarding revisions to the terms of the merger agreement proposed by the other party and
(iii)&nbsp;after such three business day period, Aetna&#146;s or CVS Health&#146;s board of directors, as applicable, determines in good faith, after consultation with its outside legal counsel, that the failure to take such action would be
reasonably likely to be inconsistent with its fiduciary duties under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Acquisition proposal&#148; means, with respect
to Aetna or CVS Health, any indication of interest, proposal or offer from any person or &#147;group&#148; (as defined in Section&nbsp;13(d) of the Exchange Act), other than the other party and its subsidiaries, relating to any (i)&nbsp;direct or
indirect acquisition (whether in a single transaction or a series of related transactions) of assets of Aetna or CVS Health, as applicable, or its subsidiaries (including securities of subsidiaries) equal to 20% or more of that party&#146;s
consolidated assets, or to which 20% or more of that party&#146;s revenues or earnings on a consolidated basis are attributable, (ii)&nbsp;direct or indirect acquisition or issuance (whether in a single transaction or a series of related
transactions) of 20% or more of any class of equity or voting securities of Aetna or CVS Health, as applicable, (iii)&nbsp;tender offer or exchange offer that, if completed, would result in any person or &#147;group&#148; (as defined in
Section&nbsp;13(d) of the Exchange Act), other than the other party and its subsidiaries, beneficially owning 20% or more of any class of equity or voting securities of Aetna or CVS Health, as applicable, or (iv)&nbsp;merger, consolidation, share
exchange, business combination, joint venture, reorganization, recapitalization, liquidation, dissolution or similar transaction involving Aetna or CVS Health, as applicable, under which any person or &#147;group&#148; (as defined in
Section&nbsp;13(d) of the Exchange Act), other than the other party and its subsidiaries, would acquire, directly or indirectly, (A)&nbsp;assets equal to 20% or more of CVS Health&#146;s or Aetna&#146;s consolidated assets, as applicable, or to
which 20% or more of that party&#146;s revenues or earnings on a consolidated basis are attributable or (B)&nbsp;beneficial ownership of 20% or more of any class of equity or voting securities of that party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Intervening event&#148; means, with respect to Aetna or CVS Health, any material event, change, effect, development or occurrence
occurring or arising after the date of the merger agreement that (i)&nbsp;was not known or reasonably foreseeable, or the material consequences of which were not known or reasonably foreseeable, in each case to that party&#146;s board of directors
or executive officers as of or prior to the date of the merger agreement and (ii)&nbsp;does not relate to or involve an acquisition proposal. However, in no event will any action taken by either party pursuant to the affirmative obligations
described under &#147;&#151;Reasonable Best Efforts Covenant&#148; beginning on page 194 of this joint proxy statement/prospectus, or the consequences of any such action, or any event, change, effect, development or occurrence that would fall within
any of the exceptions to the definition of &#147;material adverse effect&#148;, as such definition relates to the other party, as described under &#147;&#151;Definition of &#145;Material Adverse Effect&#146;&#148; beginning on page 184 of this joint
proxy statement/prospectus, be taken into account in determining whether there has been an intervening event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Superior
proposal&#148; means, with respect to Aetna or CVS Health, any written acquisition proposal which has not resulted from a violation of the solicitation restrictions described in the first paragraph of this section (under &#147;&#151;No
Solicitation&#148;) (with all references to &#147;20%&#148; in the definition of acquisition proposal being deemed to be references to &#147;50%&#148;) on terms that such party&#146;s board of directors determines in good faith, after consultation
with its financial advisor and outside legal counsel, and taking into account all the terms and conditions of the acquisition proposal that such party&#146;s board of directors considers to be appropriate (including the identity of the third party
making the acquisition proposal, the expected timing and likelihood of completion, any governmental or other approval requirements (including divestitures and entry into other commitments and
<FONT STYLE="white-space:nowrap">limitations),break-up</FONT> fees, expense reimbursement provisions, conditions to completion and availability of necessary financing), would result in a transaction (i)&nbsp;that if completed, is more favorable to
that party&#146;s shareholders or stockholders, respectively, from a financial point of view than the merger (taking into account any proposal by the other party to amend the terms of the merger agreement), (ii)&nbsp;that is reasonably capable of
being completed on the terms proposed, taking into account the identity of the person making the acquisition proposal, any approval requirements and all other financial, regulatory, legal and other aspects of such acquisition proposal and
(iii)&nbsp;for which financing, if a cash transaction (whether in whole or in part), is then fully </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committed in a manner comparable to CVS Health&#146;s and Merger Sub&#146;s financing (or which is reasonably determined to be available by that party&#146;s board of directors). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Aetna and CVS Health has agreed to, to cause its subsidiaries to, and to use its reasonable best efforts to cause its and its
subsidiaries&#146; respective representatives to, terminate any and all existing activities, discussions or negotiations, if any, with any third parties conducted prior to the date of the merger agreement with respect to any acquisition proposal,
and to use its reasonable best efforts to cause any such party (or its agents or advisors) in possession of confidential information about Aetna or CVS Health, as applicable, that was furnished by or on behalf of that party to return or destroy all
such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the merger agreement has previously been terminated in accordance with its terms, in no event may Aetna or CVS
Health, as applicable, or any of its subsidiaries (i)&nbsp;enter into any agreement in principle, letter of intent, term sheet, merger agreement, acquisition agreement, option agreement, joint venture agreement, partnership agreement or other
similar instrument constituting or relating to an acquisition proposal (other than a confidentiality agreement), (ii)&nbsp;except as required by applicable law or permitted under the merger agreement as described under this section, make, facilitate
or provide information in connection with any SEC or other filing in connection with the transactions contemplated by any acquisition proposal or (iii)&nbsp;seek any consents in connection with the transactions contemplated by any acquisition
proposal (even if Aetna&#146;s or CVS Health&#146;s board of directors, as applicable, has made an adverse recommendation change, or if an acquisition proposal for that party has been made). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_105"></A>Reasonable Best Efforts Covenant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health and Aetna have agreed to use their reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be
done, all things necessary, proper or advisable under applicable law to complete the merger and other transactions contemplated by the merger agreement as promptly as practicable, including preparing and filing as promptly as practicable all
necessary governmental or third-party filings, notices and other documents and obtaining as promptly as practicable and thereafter maintaining all consents, approvals, waivers, licenses, permits, variances, exemptions, franchises, clearances,
authorizations, acknowledgments, orders or other confirmations required to be obtained from any governmental authority or other third party that are necessary, proper or advisable to complete the merger, and complying with the terms and conditions
of each consent and approval and cooperating to the extent reasonable with the other parties to the merger agreement in their efforts to comply with their obligations under the merger agreement, including in seeking to obtain as promptly as
practicable any required consents and approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s and Aetna&#146;s obligation to use their respective reasonable best
efforts includes contesting (which includes contesting by litigation) any (i)&nbsp;action, suit, investigation or proceeding brought by any governmental authority in a federal, state or administrative court seeking to enjoin, restrain, prevent,
prohibit or make illegal completion of the merger or seeking damages or to impose any terms or conditions in connection with the merger or (ii)&nbsp;order that has been entered by a federal, state or administrative court that enjoins, restrains,
prevents, prohibits or makes illegal completion of the merger or imposes any damages, terms or conditions in connection with the merger. CVS Health&#146;s obligation to use its reasonable best efforts includes taking all actions and doing all things
necessary, proper or advisable under applicable law (including divestitures, hold separate arrangements, the termination, assignment, novation or modification of contracts (or portions thereof) or other business relationships, the acceptance of
restrictions on business operations, and the entry into other commitments and limitations) to obtain the following governmental approvals and authorizations required to complete the merger, so long as such actions would not have and would not
reasonably be expected to have, individually or in the aggregate, a regulatory material adverse effect on CVS Health or Aetna: (i)&nbsp;the expiration or early termination of any applicable waiting period relating to the merger under the HSR Act,
(ii)&nbsp;approvals in connection with any other applicable law that is designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or (iii)&nbsp;the required governmental
authorizations or any other approval from a governmental authority or otherwise (the matters described in clauses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(i)&nbsp;through (iii)&nbsp;are referred to in this joint proxy statement/prospectus as the specified regulatory matters). In no event are CVS Health or any of its subsidiaries required by the
merger agreement to take or cause to be taken any action (or refrain or cause to refrain from taking any action) or agree or cause to agree to any term, condition or limitation as a condition to, or in connection with the specified regulatory
matters, if such action (or refraining from such action), term, condition or limitation would have or would reasonably be expected to have, individually or in the aggregate, a regulatory material adverse effect on CVS Health or Aetna.
&#147;Regulatory material adverse effect&#148; means, with respect to CVS Health or Aetna, a material adverse effect on the financial condition, business, revenue or EBITDA (as defined in the merger agreement) of that party and its subsidiaries,
taken as a whole. For purposes of determining whether any action, term or condition would have or would reasonably be expected to have a regulatory material adverse effect on Aetna, Aetna and its subsidiaries will collectively be deemed to be a
company the size of (and with revenue and EBITDA equal to those of) CVS Health and its subsidiaries, taken as a whole (excluding, for the avoidance of doubt, Aetna and its subsidiaries). For purposes of determining whether any action, term or
condition would have or would reasonably be expected to have a regulatory material adverse effect on CVS Health or Aetna, impacts on CVS Health, Aetna or any of their respective subsidiaries will be aggregated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health will have principal responsibility for directing, devising, and implementing the strategy for obtaining any necessary approval of,
for responding to any request from, inquiry by, or investigation by (including directing the timing, nature, and substance of all such responses), and for leading all meetings and communications with any governmental authority that has authority to
enforce any antitrust law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, each of Aetna and CVS Health has agreed to, as promptly as practicable
following the date of the merger agreement, make all filings with all governmental authorities that may be or may become reasonably necessary, proper or advisable under the merger agreement or applicable law to complete the merger and the other
transactions contemplated by the merger agreement, including: (i)&nbsp;not later than 30 business days after the date of the merger agreement, CVS Health filing, or causing to be filed, &#147;Form A Statements&#148; or similar change of control
applications, with the insurance commissioners or regulators or departments of health or other governmental authorities in each jurisdiction where required by applicable law seeking approval of CVS Health&#146;s acquisition of control of each of
Aetna&#146;s regulated subsidiaries that would result from the merger; (ii)&nbsp;as promptly as practicable after the date of the merger agreement, CVS Health filing, or causing to be filed, any
<FONT STYLE="white-space:nowrap">pre-acquisition</FONT> notifications on &#147;Form E&#148; or similar market share notifications to be filed in each jurisdiction where required by applicable laws with respect to the merger and the other
transactions contemplated by the merger agreement; (iii)&nbsp;not later than 20 business days after the date of the merger agreement (unless the parties otherwise agree to another date), each of Aetna and CVS Health filing its respective
notification and report with the FTC and the DOJ with respect to the merger and the other transactions contemplated by the merger agreement and requesting early termination of the waiting period under the HSR Act, (iv)&nbsp;not later than 30
business days after the date of the merger agreement, Aetna and CVS Health filing any required notices to the U.S. Centers for Medicare&nbsp;&amp; Medicaid Services, referred to in this joint proxy statement/prospectus as CMS, with a separate notice
to the CMS Medicare Drug Benefit Group and Central and/or Regional Office Medicare Advantage and/or Part D plan manager, if applicable; and (v)&nbsp;promptly following the date of the merger agreement make any other filing that may be required under
any applicable law or by any governmental authority with jurisdiction over enforcement of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable
laws relating to the sharing of information, each of Aetna and CVS Health has agreed to, and to cause its subsidiaries to: (i)(A) as far in advance as practicable, notify the other party of and consult the other party with respect to any filing or
material or substantive communication or inquiry it or any of its affiliates intends to make with any governmental authority relating to the merger agreement, (B)&nbsp;prior to submitting any such filing or making any such communication or inquiry,
provide the other party and its counsel a reasonable opportunity to review, and consider in good faith the comments of the other party in connection with, any such filing, communication or inquiry, and (C)&nbsp;promptly after the submission of such
filing or making of such communication or inquiry, provide the other party and its counsel with a copy of any such filing, communication or inquiry or, if such communication or inquiry is made in oral form, a summary of any such oral communication
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or inquiry; (ii)&nbsp;as promptly as practicable after receipt, furnish the other party with a copy of any filing or material or substantive communication or inquiry it or any of its affiliates
receives from any governmental authority relating to the merger agreement; (iii)&nbsp;coordinate and cooperate fully with the other party in exchanging such information and providing such assistance as the other party may reasonably request in
connection with the obligations described in this section; and (iv)&nbsp;consult with the other party in connection with any inquiry, hearing, investigation or litigation by, or negotiations with, any governmental authority relating to the merger or
any filings with respect thereto under applicable law. Each of Aetna and CVS Health has agreed that neither it nor any of its representatives will participate in any material or substantive meeting or conference (including by telephone) with any
governmental authority, or any member of the staff of any governmental authority, in respect of any filing, proceeding, investigation (including the settlement of any investigation), litigation, or other inquiry regarding the merger unless that
party consults with the other party in advance and, to the extent permitted by such governmental authority, allows the other party to participate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health and Aetna have agreed not to, and to cause their respective subsidiaries not to, directly or indirectly, acquire, purchase, lease
or license (or agree to acquire, purchase, lease or license) any business, corporation, partnership, association or other business organization or division or part thereof, or any securities or collection of assets, if doing so would reasonably be
expected to: (i)&nbsp;impose any material delay in the obtaining of, or materially increase the risk of not obtaining, any consent or approval of any governmental authority necessary to complete the merger or any of the other transactions
contemplated by the merger agreement or the expiration or early termination of any applicable waiting period; (ii)&nbsp;materially increase the risk of any governmental authority entering an order prohibiting completion of the merger or any of the
other transactions contemplated by the merger agreement; (iii)&nbsp;materially increase the risk of not being able to remove any such order on appeal or otherwise; or (iv)&nbsp;otherwise prevent or materially delay completion of the merger or any of
the other transactions contemplated by the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this section, (i)&nbsp;CVS
Health, Aetna and their respective affiliates are not required to take any action that is not conditioned upon completion of the merger and (ii)&nbsp;Aetna and its affiliates are not permitted to agree to any obligation or other action relating to
the consents or approvals required in connection with the merger without CVS Health&#146;s prior consent (which consent may not be withheld, delayed or conditioned if doing so would be inconsistent with CVS Health&#146;s obligations described under
this section). In addition, Aetna will not voluntarily extend the waiting period under the HSR Act relating to the merger or enter into any agreement with a third party to not complete the merger without the consent of CVS Health. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_106"></A>Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CVS Health Obligations to Obtain Financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of CVS Health and Merger Sub has agreed to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary to
complete and obtain the debt financing for the merger, which is referred to in this joint proxy statement/prospectus as the debt financing, on substantially the terms and conditions described in the debt commitment letter, including
(i)&nbsp;negotiating and entering into definitive financing agreements on the terms and conditions contemplated by the debt commitment letter, which are referred to in this joint proxy statement/prospectus as the definitive financing agreements, (or
on other terms and conditions agreed by CVS Health, Aetna and CVS Health&#146;s financing sources, which are referred to in this joint proxy statement/prospectus as the financing sources) by completion of the merger and (ii)&nbsp;satisfying or
causing to be satisfied (or, if determined advisable by CVS Health, obtaining the waiver of) on a timely basis all conditions to obtaining the debt financing within CVS Health&#146;s control and complying or causing to be complied with all of its
obligations pursuant to the debt commitment letter and any of the definitive financing agreements to the extent the failure to comply with such obligations would adversely impact the timing of completion of the merger or the availability at
completion of the merger of sufficient aggregate proceeds of the debt financing to complete the transactions contemplated by the merger agreement. Upon satisfaction of all conditions to funding contained in the debt
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commitment letter, each of CVS Health and Merger Sub has agreed to use its reasonable best efforts to (i)&nbsp;cause the financing sources that are party to the debt commitment letter and the
definitive financing agreements, which are referred to in this joint proxy statement/prospectus as the financing sources, to fund the debt financing required to consummate the transactions contemplated by the merger agreement and to pay related fees
and expenses at completion of the merger (including by taking enforcement action to cause the financing sources to provide the debt financing) and (ii)&nbsp;enforce all of its rights under the debt commitment letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any portion of the financing contemplated by the debt commitment letter becomes unavailable and such portion is necessary to complete the
transactions contemplated by the merger agreement (except in accordance with the express terms set forth in the debt commitment letter or unless concurrently replaced on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-for-dollar</FONT></FONT> basis by commitments subject to substantially the same conditions as those set forth in the debt commitment letter from other financing sources or from
proceeds of other sources of financing or cash), CVS Health and Merger Sub must (i)&nbsp;use their reasonable best efforts to obtain alternative debt financing as promptly as practicable in an amount that will enable CVS Health and Merger Sub to
consummate the transactions contemplated by the merger agreement and that does not contain additional (or changes to the) conditions set forth in the debt commitment letter delivered to Aetna on or prior to the date of the merger agreement that, in
each case, could reasonably be expected to adversely affect the ability of CVS Health or Merger Sub to timely complete the transactions contemplated by the merger agreement and (ii)&nbsp;promptly notify Aetna of such unavailability and the reason
for such unavailability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health has agreed to give Aetna prompt notice of, among other things, (i)&nbsp;any material breach by any
party to the debt commitment letter or any of the definitive financing agreements of which it has become aware, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;any termination of the debt
commitment letter or any of the definitive financing agreements and (iii)&nbsp;the receipt of any notice or other communication from any financing source with respect to such financing source&#146;s failure or anticipated failure to fund its
commitments under the debt commitment letter or any of the definitive financing agreements, in the case of clauses (i)&nbsp;and (ii) above, to the extent such breach or termination could reasonably be expected to prevent or materially delay
completion of the merger or otherwise result in sufficient proceeds of the debt financing to consummate the transactions contemplated by the merger agreement not being available at completion of the merger. CVS Health has also agreed to keep Aetna
reasonably informed on a current basis of the status of its efforts to consummate the debt financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health and Merger Sub may not,
without Aetna&#146;s prior written consent, permit any amendment or modification to, or any waiver of any provision or remedy under, the debt commitment letter or any of the definitive financing agreements unless the terms of the debt commitment
letter or definitive financing agreements, in each case as so amended, modified or waived, are substantially similar to those in the debt commitment letter or definitive financing agreement prior to giving effect to such amendment, modification or
waiver (other than economic terms, which must be as good as or better for CVS Health and Merger Sub as those in the debt commitment letter or applicable definitive financing agreement(s) prior to giving effect to such amendment, modification or
waiver). However, in the case of amendments or modifications of the debt commitment letter or any of the definitive financing agreements, the foregoing will only apply if such amendment or modification (i)&nbsp;could reasonably be expected to
(A)&nbsp;adversely affect the ability or likelihood of CVS Health or Merger Sub timely consummating the transactions contemplated by the merger agreement or (B)&nbsp;make the timely funding of the debt financing or the satisfaction of the conditions
to obtaining the debt financing less likely to occur, (ii)&nbsp;reduces the aggregate amount of the debt financing or (iii)&nbsp;materially and adversely affects the ability of CVS Health or Merger Sub to enforce their rights against other parties
to the debt commitment letter. In any event, CVS Health may amend the debt commitment letter or any of the definitive financing agreements to (x)&nbsp;add lenders, arrangers, bookrunners, agents, managers or similar entities that have not executed
the debt commitment letter as of the date of the merger agreement and consent to the assignment after the date of the merger agreement of lending commitments under the debt commitment letter to other lenders, or (y)&nbsp;increase the aggregate
amount of the debt financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cooperation of Aetna </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna has agreed to, and to cause its subsidiaries to use its and their commercially reasonable efforts to provide such cooperation as may be
reasonably requested by CVS Health in connection with the arrangement of the debt financing (including any of the permanent financing referred to in the debt commitment letter), so long as such requested cooperation does not unreasonably interfere
with the ongoing operations of Aetna and its subsidiaries, including using commercially reasonable efforts to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as promptly as reasonably practicable, provide information (financial or otherwise) relating to Aetna to CVS Health and to the financing sources to the extent reasonably requested by CVS Health in connection with CVS
Health&#146;s preparation of customary offering or information documents to be used for completion of the debt financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cooperate and assist with the due diligence, rating agency process and marketing efforts of CVS Health, its representatives and the financing sources, including by participating in a reasonable number of meetings, due
diligence sessions and road shows, at times and at locations reasonably acceptable to Aetna; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonably assist CVS Health in the preparation of customary offering memoranda, rating agency presentations, lender and investor presentations, confidential information memoranda, financial statements, private
placement memoranda, prospectuses, filings with the SEC and other similar documents, including by delivering and consenting to the inclusion or incorporation in any SEC filing related to the debt financing or alternative financing of certain
financial statements of Aetna and providing all other historical financial and other information regarding Aetna reasonably necessary to permit CVS Health to prepare pro forma financial statements customary for the bank financing and the debt
securities offering contemplated by the debt financing or alternative financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make available, on a customary and reasonable basis and upon reasonable notice, appropriate personnel, including representatives of Aetna and its subsidiaries, documents and information relating to Aetna and its
subsidiaries, in each case, as may be reasonably requested by CVS Health or the financing sources or as may be requested by the SEC in connection with completion of the financing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide to CVS Health and the financing sources promptly, and in any event at least five business days prior to completion of the merger, all documentation and other information about Aetna and its affiliates required
by the financing sources or regulatory authorities with respect to the debt financing under applicable &#147;know your customer&#148; and anti-money laundering rules and regulations, including the PATRIOT Act, that is required under the debt
commitment letter to the extent such documentation and other information is requested in writing to Aetna at least 10 business days prior to completion of the merger; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain any necessary consents from Aetna&#146;s independent public accounting firm in connection with any filings with the SEC; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in connection with any securities offering contemplated as part of the debt financing or the alternative financing, (i)&nbsp;obtain customary comfort letters from Aetna&#146;s independent public accounting firm,
(ii)&nbsp;cause Aetna&#146;s independent public accounting firm to consent to the inclusion or incorporation of their audit reports with respect to the financial statements of Aetna provided in accordance with the obligation set forth in the third
bullet in the list above in any filing or registration statement of CVS Health with the SEC or any prospectus, offering memoranda, private placement memoranda, marketing material or similar documentation, including by providing customary
representation letters and (iii)&nbsp;cause Aetna&#146;s independent public accounting firm to cooperate with CVS Health and its representatives, including by participating in accounting due diligence sessions at times and at locations reasonably
acceptable to Aetna and its independent accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to customary confidentiality provisions, provide customary authorization letters to the financing sources authorizing the distribution of information to prospective lenders or investors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">deliver notices of prepayment and/or notices for termination of commitments within the time periods required by Aetna&#146;s existing credit facility and obtain customary payoff letters and instruments of discharge to
be delivered at completion of the merger to allow for the payoff, discharge and termination in full on such date of Aetna&#146;s existing credit facility; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonably assist with the preparation of the definitive documentation for the debt financing, including by providing information reasonably necessary for completion of any schedules thereto, in each case to the extent,
and solely to the extent, such materials relate to information concerning Aetna and its subsidiaries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide or cause to be provided any customary certificates, or other customary closing documents as may reasonably be requested in connection with the debt financing and the alternative financing; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">consent to the use of the trademarks, service marks and logos of Aetna or any of its subsidiaries in connection with the debt financing, so long as such trademarks, service marks and logos are used solely in a manner
that is not intended to or is reasonably likely to harm or disparage Aetna or any of its subsidiaries. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, (i)&nbsp;neither Aetna nor any of its subsidiaries will be required to pay any commitment or other similar fee or incur prior to completion of the merger any other liability or obligation in connection with the debt financing, unless CVS
Health reimburses or is required to reimburse or indemnify Aetna and its subsidiaries pursuant to the merger agreement or otherwise agrees to do so, (ii)&nbsp;none of Aetna, its subsidiaries or their respective officers, directors or employees will
be required to execute or enter into or perform any agreement with respect to the debt financing that is not contingent upon completion of the merger or that would be effective prior to completion of the merger (other than the authorization letters
contemplated by the eighth bullet in the list above) and for the avoidance of doubt, the boards of directors or other equivalent governing bodies of CVS Health, Merger Sub, and/or Aetna, as the surviving corporation in the merger, shall enter into
or provide any resolutions, consents, approvals or other closing arrangements on behalf of Aetna and its subsidiaries as may be required by the financing sources pursuant to the bridge facility commitment letter at, or as of, completion of the
merger, and (iii)&nbsp;nothing will obligate Aetna or any of its subsidiaries to provide, or cause to be provided, any legal opinion by its counsel, or to provide, or cause to be provided, any information or take, or cause to be taken, any action to
the extent it would reasonably be expected, in the reasonable judgment of Aetna, to result in a violation of applicable law or loss of any privilege. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that CVS Health will, promptly upon written request by Aetna, reimburse Aetna for all reasonable and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including reasonable attorneys&#146; fees) incurred by Aetna or any of its subsidiaries in satisfying its obligations described above in this
section. CVS Health and Merger Sub have also agreed to, on a joint and several basis, indemnify and hold harmless Aetna, its subsidiaries and their respective representatives from and against any and all losses, claims, damages, liabilities, costs,
reasonable attorneys&#146; fees, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of any thereof) suffered or incurred in connection
with any action taken by Aetna, any of or its subsidiaries or any of their respective representatives pursuant to the obligations described above (other than the use of any information provided by Aetna, any of its subsidiaries or any of their
respective representatives in writing for use in connection with the debt financing), except in the event such losses, claims, damages, liabilities, costs, reasonable attorneys&#146; fees, judgments, fines, penalties and amounts paid in settlement
are determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction to have arisen out of, or resulted from, the gross negligence or willful misconduct of Aetna, any of its subsidiaries or
any of their respective representatives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Compliance with Aetna&#146;s Existing Indentures </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna has agreed to use its reasonable best efforts to timely provide or cause to be provided, in accordance with the provisions of each
indenture governing its outstanding notes, to the trustee under each such indenture, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any notices, announcements, certificates or legal opinions required by each such indenture to be provided in connection with the merger prior to completion of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_107"></A>Proxy Statement and Registration Statement Covenant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As promptly as practicable after the date of the merger agreement, (i)&nbsp;Aetna and CVS Health have agreed to prepare and file with the SEC
this joint proxy statement/prospectus, and (ii)&nbsp;CVS Health has agreed to prepare and file with the SEC the registration statement of which this joint proxy statement/prospectus forms a part. Aetna and CVS Health have agreed that this joint
proxy statement/prospectus and the registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this joint proxy statement/prospectus forms a part, will comply as to form in all material respects with the applicable
provisions of the Exchange Act, the Securities Act and other applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Aetna and CVS Health will use its reasonable best
efforts to have this joint proxy statement/prospectus cleared by the SEC as promptly as practicable after its filing, and CVS Health will use its reasonable best efforts to have the registration statement of which this joint proxy
statement/prospectus forms a part declared effective under the Securities Act as promptly as practicable after its filing and to keep the registration statement effective for so long as is necessary to complete the merger. Each of Aetna and CVS
Health will, as promptly as practicable after the receipt thereof, provide the other party with copies of any written comments and advise the other party of any oral comments with respect to this joint proxy statement/prospectus or the registration
statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4,</FONT> of which this joint proxy statement/prospectus forms a part, received by such party from the SEC, and provide the other with copies of all substantive correspondence between it and
its representatives, on the one hand, and the SEC, on the other hand. Prior to filing the registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this joint proxy statement/prospectus forms a part, mailing this joint
proxy statement/prospectus or responding to any comments of the SEC with respect thereto, each of Aetna and CVS Health will provide the other party and its counsel a reasonable opportunity to review such document or response and consider in good
faith the comments of the other party in connection with any such document or response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time prior to the later of the approval
and adoption of the merger agreement by Aetna&#146;s shareholders and the approval of the stock issuance by CVS Health&#146;s stockholders, any information relating to Aetna or CVS Health, or any of their respective affiliates, officers or
directors, is discovered by Aetna or CVS Health that should be set forth in an amendment or supplement to either this joint proxy statement/prospectus or the registration statement of which it forms a part, so that either of such documents would not
include any misstatement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the party that discovers such information has agreed
to promptly notify the other parties to the merger agreement and the parties have agreed that an appropriate amendment or supplement describing such information will be promptly prepared and filed with the SEC and, to the extent required under
applicable law, disseminated to the shareholders of Aetna and the stockholders of CVS Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As promptly as practicable after the
effectiveness of the registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this joint proxy statement/prospectus forms a part, each of Aetna and CVS Health has agreed to cause this joint proxy statement/prospectus to
be mailed to its shareholders or stockholders, respectively. Except to the extent that Aetna&#146;s board of directors makes an adverse recommendation change as described under &#147;&#151;No Solicitation&#148; beginning on page 190 of this joint
proxy statement/prospectus, this joint proxy statement/prospectus will contain the recommendation of Aetna&#146;s board of directors that Aetna shareholders vote in favor of the approval and adoption of the merger agreement. Similarly, except to the
extent that the CVS Health board of directors makes an adverse recommendation change as described under &#147;&#151;No Solicitation&#148; beginning on page 190 of this joint proxy statement/prospectus, this joint proxy statement/prospectus will
contain the recommendation of CVS Health&#146;s board of directors that CVS Health stockholders vote in favor of approval of the stock issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_108"></A>Indemnification and Insurance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that, from and after completion of the merger, CVS Health will (and CVS Health will cause Aetna, as the surviving
corporation in the merger, to), to the fullest extent authorized or permitted by applicable law, (i)&nbsp;indemnify and hold harmless each present or former director, officer or employee of Aetna or any of its subsidiaries and each present or former
director, trustee, officer or employee of any other entity or benefit plan serving at the request or for the benefit of Aetna or any of its subsidiaries (which individuals are collectively referred to in this joint proxy statement/prospectus as
indemnified persons) from and against any losses, claims, damages, liabilities, costs, expenses (including reasonable attorneys&#146; fees and all other reasonable,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses), judgments, fines, penalties and amounts paid in settlement in connection with any threatened, asserted, pending or completed claim,
action, suit, proceeding, inquiry or investigation arising out of or pertaining to such indemnified person&#146;s duties or services as a director, officer or employee of Aetna or any of its subsidiaries, or a director, trustee, officer or employee
of any other entity or benefit plan serving at the request or for the benefit of Aetna or any of its subsidiaries at or prior to completion of the merger, and (ii)&nbsp;subject to certain conditions, promptly pay or advance to such indemnified
person any such expenses incurred by such indemnified person in defending, serving as a witness in or otherwise participating in any such claim, action, suit, proceeding, inquiry or investigation in advance of its final disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement also provides that, for a period of six years after completion of the merger, the organizational documents of Aetna, as
the surviving corporation in the merger, and its subsidiaries must contain provisions no less favorable with respect to indemnification, advancement of expenses and limitations on liability of directors and officers than were set forth in the
organizational documents of Aetna as of the date of the merger agreement. Such provisions may not be amended, repealed or otherwise modified for a period of six years after completion of the merger in any manner that would adversely affect the
rights thereunder of individuals who, at or prior to completion of the merger, were directors, officers or employees of Aetna or any of its subsidiaries, except to the extent any such modification is required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that, at Aetna&#146;s option and expense, prior to completion of the merger, Aetna may purchase and prepay the
premium for a <FONT STYLE="white-space:nowrap">six-year</FONT> &#147;tail&#148; insurance policy of at least the same coverage and amounts and containing other terms and conditions that are no less favorable to the directors, officers, employees,
agents and fiduciaries of Aetna and its subsidiaries as Aetna&#146;s directors&#146; and officers&#146; insurance coverage existing as of the date of the merger agreement, with a claims period of six years after completion of the merger for claims,
actions, suits, proceedings, inquiries and investigations arising from facts, acts, events or omissions that occurred at or prior to completion of the merger. However, the premium for such tail policy may not exceed 300% of the annual premium paid
by Aetna for its directors&#146; and officers&#146; insurance coverage existing as of the date of the merger agreement. If Aetna does not obtain such a tail policy prior to completion of the merger, CVS Health or Aetna, as the surviving corporation
in the merger, must obtain such a policy, except that the premium for such tail policy may not exceed the maximum premium referred to in the immediately preceding sentence. If the premium for such tail policy would exceed such maximum premium, CVS
Health or Aetna, as applicable, will only be required to obtain as much directors&#146; and officers&#146; insurance coverage as can be obtained by paying such maximum premium. CVS Health and Aetna, as the surviving corporation in the merger, will
cause any such tail policy to be maintained in full force and effect for its full term, and CVS Health will cause Aetna, as the surviving corporation in the merger, to honor its obligations thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_109"></A>Employee Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From completion of the merger through the later of the first anniversary of completion of the merger and May&nbsp;31, 2019, which period is
referred to in this joint proxy statement/prospectus as the benefits continuation period, CVS Health will provide to employees of Aetna and its subsidiaries who continue employment with Aetna (as the surviving corporation in the merger), CVS Health
or any of CVS Health&#146;s subsidiaries, which employees are referred to as continuing employees, base salary, bonus and other cash incentive compensation opportunities that are no less favorable than the base salary, bonus and other cash incentive
compensation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opportunities provided to such continuing employees immediately prior to completion of the merger, employee benefits (excluding equity compensation, defined benefit pension plan benefits,
retention or change in control payments or awards or any similar compensation or benefit) that are no less favorable in the aggregate than the employee benefits provided to such continuing employees immediately prior to completion of the merger, and
equity incentive awards with a target value no less favorable than the target value of the equity incentive awards provided to such continuing employees immediately prior to completion of the merger. Until the second anniversary of the completion of
the merger, CVS Health will provide the continuing employees with severance benefits in amounts and on terms and conditions that are no less favorable than those provided to such individuals immediately prior to completion of the merger, as set
forth in Aetna&#146;s severance pay plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to each employee benefit plan maintained by CVS Health or any of its subsidiaries
in which continuing employees become eligible to participate, CVS Health will waive all preexisting conditions, exclusions and waiting periods with respect to participation and coverage requirements, recognize continuing employees&#146; service
accrued (to the extent credited by Aetna or its subsidiaries) prior to completion of the merger for all purposes under such plans (except for the purposes of benefit accrual under any defined benefit pension plan) and if applicable, cause to be
credited, in any new Aetna plan that is a health plan in which continuing employees participate, any deductibles or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the continuing
employees and their beneficiaries and dependents during the portion of the calendar year in which completion of the merger occur prior to their participation in CVS Health&#146;s health plans to avoid any double counting during the year in which the
merger is completed of such deductibles or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to specified Aetna annual cash incentive plans, CVS Health will provide each participant who remains employed with the surviving
corporation through the end of the year during which the merger is completed, with an annual cash incentive award for the year during which the merger is completed. The amount of such annual cash incentive award will be determined as the sum of the
following: (i)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of the bonus with respect to the <FONT STYLE="white-space:nowrap">pre-closing</FONT> portion of the year the merger is completed, which will be determined based upon
actual performance through the date the merger is completed, as determined by Aetna in accordance with the applicable annual cash incentive plan plus (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of the bonus with respect to
the post-closing portion of the year during which the merger is completed, which bonus will be payable at the applicable annual cash incentive plan participant&#146;s target incentive level under such annual cash incentive plan. If a
participant&#146;s employment is terminated by CVS Health or the surviving corporation for any reason following the date on which the merger is completed and through the end of the year during which the merger is completed other than for cause (or
any voluntary termination of employment), the participant will be entitled to the prorated payment set forth in clause (i), plus an amount equal to the participant&#146;s target value <FONT STYLE="white-space:nowrap">pro-rated</FONT> by a ratio
equal to the quotient of the number of days worked between completion of the merger and the participant&#146;s termination date divided by 365. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna is permitted to establish a cash-based retention program providing for retention payments in an aggregate amount of up to
$70&nbsp;million, with the individual retention bonuses to be determined by the Chief Executive Officer of Aetna (in consultation with CVS Health). Certain retention bonus payments will be made upon completion of the merger and the remaining
payments will be made between the three- and twelve-month period following the date of completion of the merger, subject to the participant&#146;s continued employment with Aetna or its subsidiaries (or upon an earlier involuntary termination under
certain circumstances). Executive officers and members of the Aetna executive leadership team are excluded from participating in this retention program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_110"></A>Other Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement contains certain other covenants and agreements, including covenants and agreements requiring, among other things, and
subject to certain exceptions and qualifications described in the merger agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of Aetna and CVS Health to provide the other party and its representatives with reasonable access to such party&#146;s properties, books, contracts, records and information concerning its businesses, properties and
personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of Aetna and CVS Health to notify the other of any shareholder litigation against it or any of its directors or officers relating to the merger agreement or the merger, to give the other party the opportunity to
consult with it regarding the defense or settlement of any such shareholder litigation and, in the case of Aetna, not to settle any such shareholder litigation without CVS Health&#146;s prior consent (which consent may not be unreasonably withheld
or delayed); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of Aetna and CVS Health to coordinate the declaration, record dates for and payment of dividends in respect of their respective shares in order that holders of shares of CVS Health common stock and Aetna common
shares do not receive two dividends or fail to receive one dividend for any quarter in respect of Aetna common shares, on the one hand, and the shares of CVS Health common stock to be issued in the merger, on the other hand; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of Aetna and CVS Health to consult with each other before issuing any press release, making any public statement or making certain other public communications, in each case with respect to the merger agreement or
the merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of Aetna and CVS Health to cooperate with the other in taking all actions necessary to delist Aetna common shares from the NYSE and terminate its registration under the Exchange Act, in each case effective upon
completion of the merger; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of Aetna and CVS Health to notify the other of certain events. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_111"></A>Termination of the Merger Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement may be terminated at any time before completion of the merger, whether before or after Aetna shareholders have approved
and adopted the merger agreement or CVS Health stockholders have approved the stock issuance, in any of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by mutual written consent of CVS Health and Aetna; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by either CVS Health or Aetna, if: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the merger has not been completed on or before the initial end date of December&nbsp;3, 2018, unless all conditions to completion of the merger have been satisfied or waived on the initial end date other than the
regulatory approvals condition, and either CVS Health or Aetna elects to extend the initial end date to March&nbsp;3, 2019, in which case the merger agreement may be terminated by either CVS Health or Aetna if the merger has not been completed on or
before March&nbsp;3, 2019, unless all conditions to completion of the merger have been satisfied or waived on the extended end date other than the regulatory approvals condition, and CVS Health elects to extend the extended end date to June&nbsp;3,
2019, in which case the merger agreement may be terminated by either CVS Health or Aetna if the merger has not been completed on or before June&nbsp;3, 2019; provided, however, that the right to terminate the merger agreement after the end date, or
to extend the initial end date to March&nbsp;3, 2019 or extended end date to June&nbsp;3, 2019, will not be available to CVS Health or Aetna, as applicable, if that party&#146;s breach of any provision of the merger agreement resulted in the failure
of the merger to be completed by the end date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is in effect any applicable law or order enacted, adopted or promulgated after the date of the merger
agreement in the U.S. that enjoins, prevents or prohibits completion of the merger and, in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the case of any order, that order has become final and <FONT STYLE="white-space:nowrap">non-appealable.</FONT> However, the right to terminate the merger agreement in respect of any such
applicable law will not be available to any party that has failed to perform its obligations described under &#147;&#151;Reasonable Best Efforts Covenant&#148; beginning on page 194 of this joint proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna shareholders fail to approve and adopt the merger agreement upon a vote taken on a proposal to approve and adopt the merger agreement at the Aetna special meeting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health stockholders fail to approve the stock issuance upon a vote taken on a proposal to approve and adopt the merger agreement at the CVS Health special meeting; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there has been a breach of any representation or warranty or failure to perform any covenant or agreement on the part of the other party that would cause the other party to fail to satisfy the applicable condition to
completion of the merger related to accuracy of representations and warranties or performance of covenants and agreements, as applicable, and such breach or failure to perform either (i)&nbsp;is incapable of being cured by the end date or
(ii)&nbsp;has not been cured within 45 days following notice from the <FONT STYLE="white-space:nowrap">non-breaching</FONT> party of such breach or failure to perform. However, the right to terminate the merger agreement in respect of the inaccuracy
of any representation or warranty or the failure to perform any covenant or agreement will not be available to the other party if such party is then in breach of its representations, warranties, covenants or agreements as would cause the applicable
condition to completion of the merger related to accuracy of its representations and warranties or performance of its covenants and agreements not to be satisfied; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by CVS Health: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if Aetna&#146;s board of directors makes an adverse recommendation change or fails to publicly confirm its recommendation to Aetna shareholders in favor of adopting the merger agreement within seven business days after
a written request by CVS Health to do so; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if Aetna has breached in any material respect any of its obligations described under &#147;&#151;No Solicitation&#148; beginning on page 190 of this joint proxy statement/prospectus or its obligations to call and hold a
meeting of its shareholders for purposes of approving and adopting the merger agreement described under &#147;&#151;Obligations to Call Shareholders&#146; and Stockholders&#146; Meetings&#148; beginning on page 189 of this joint proxy
statement/prospectus (except where the breach is the result of an isolated action by a representative (other than a director or officer) of Aetna, the breach is not caused by or within the knowledge of, Aetna, Aetna has taken appropriate action to
remedy the breach and CVS Health is not significantly harmed by the breach); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the approval of the stock issuance by CVS Health stockholders, in order to enter into a definitive agreement providing for a superior proposal (which definitive agreement must be entered into concurrently with,
or immediately following, the termination of the merger agreement), provided that CVS Health concurrently pays to Aetna the applicable termination fee; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if CVS Health&#146;s board of directors makes an adverse recommendation change or fails to publicly confirm its recommendation to CVS Health stockholders in favor of approving the stock issuance within seven business
days after a written request by Aetna to do so; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if CVS Health has breached in any material respect any of its obligations described under &#147;&#151;No
Solicitation&#148; beginning on page 190 of this joint proxy statement/prospectus or its obligations to call and hold a meeting of its stockholders for purposes of approving the stock issuance described under &#147;&#151;Obligations to Call
Shareholders&#146; and Stockholders&#146; Meetings&#148; beginning on page 189 of this joint proxy statement/prospectus (except where the breach is the result of an isolated action by a representative (other than a director or officer) of CVS
Health, the breach is not caused by or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
within the knowledge of, CVS Health, CVS Health has taken appropriate action to remedy the breach and Aetna is not significantly harmed by the breach); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the approval and adoption of the merger agreement by Aetna shareholders, in order to enter into a definitive agreement providing for a superior proposal (which definitive agreement must be entered into
concurrently with, or immediately following, the termination of the merger agreement) provided that Aetna concurrently pays to CVS Health the applicable termination fee; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if (i)&nbsp;there is in effect any order in respect of the specified regulatory matters that has not become final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> and enjoins, prevents or prohibits completion
of the merger, (ii)&nbsp;within 30 days after the order taking effect, CVS Health has not instituted appropriate proceedings seeking to have the order terminated and (iii)&nbsp;CVS Health&#146;s failure to institute appropriate proceedings has not
been cured within 10 days following irrevocable written notice to CVS Health from Aetna of Aetna&#146;s intent to terminate the merger agreement in respect of such failure (which notice may not be given prior to the expiration of such <FONT
STYLE="white-space:nowrap">30-day</FONT> period and will not be effective if CVS Health institutes appropriate proceedings within such <FONT STYLE="white-space:nowrap">10-day</FONT> period). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger agreement is validly terminated, the merger agreement will become void and of no effect without liability of any party (or any
shareholder, stockholder or representative of any party) to any other party, except that certain designated provisions, including the provisions regarding termination fees, will survive termination. However, subject to the provisions described under
&#147;&#151;Exclusive Remedy&#148; beginning on page 207 of this joint proxy statement/prospectus, none of the parties to the merger agreement will be relieved or released from any liabilities or damages resulting from any fraud by any party or any
willful breach of any representation, warranty, covenant or agreement set forth in the merger agreement. For purposes of the merger agreement, the failure of CVS Health, for any reason, other than any material breach of the merger agreement by
Aetna, to pay the cash component of the merger consideration at completion of the merger will be deemed to constitute a willful breach of the merger agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_112"></A>Termination Fees and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Termination Fee Payable by Aetna </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna has agreed to pay CVS Health a termination fee of $2.1&nbsp;billion if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health terminates the merger agreement because Aetna&#146;s board of directors makes an adverse recommendation change or fails to publicly confirm its recommendation to Aetna shareholders in favor of approving and
adopting the merger agreement within seven business days after a written request by CVS Health to do so; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health terminates the merger agreement due to Aetna&#146;s breach in any material respect of any of its obligations described under &#147;&#151;No Solicitation&#148; beginning on page 190 of this joint proxy
statement/prospectus or its obligations to call and hold a meeting of its shareholders for purposes of approving and adopting the merger agreement described under &#147;&#151;Obligations to Call Shareholders&#146; and Stockholders&#146;
Meetings&#148; beginning on page 189 of this joint proxy statement/prospectus (in each case, except where the breach is the result of an isolated action by a representative (other than a director or officer) of Aetna, the breach is not caused by or
within the knowledge of, Aetna, Aetna has taken appropriate action to remedy the breach and CVS Health is not significantly harmed by the breach); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna terminates the merger agreement prior to the approval and adoption of the merger agreement by Aetna shareholders, in order to enter into a definitive agreement providing for a superior proposal (which definitive
agreement must be entered into concurrently with, or immediately following, the termination of the merger agreement); or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health or Aetna terminates the merger agreement due to Aetna shareholders&#146; failure to approve and adopt the merger agreement upon a vote taken on a proposal to approve and adopt the merger agreement at the
Aetna special meeting, and at or prior to the Aetna special meeting an acquisition proposal for Aetna (substituting references to 20% with references to 50% in the definition of acquisition proposal) is publicly disclosed or announced, and on or
prior to the first anniversary of such termination Aetna enters into a definitive agreement, or completes a transaction, relating to an acquisition proposal for Aetna. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Termination Fee Payable by CVS Health </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health has agreed to pay Aetna a termination fee of $2.1&nbsp;billion if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna terminates the merger agreement because CVS Health&#146;s board of directors makes an adverse recommendation change or fails to publicly confirm its recommendation to CVS Health stockholders in favor of approving
the stock issuance within seven business days after a written request by Aetna to do so; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna terminates the merger agreement due to CVS Health&#146;s breach in any material respect of any of its obligations described under &#147;&#151;No Solicitation&#148; beginning on page 190 of this joint proxy
statement/prospectus or its obligations to call and hold a meeting of its stockholders for purposes of approving the stock issuance described under &#147;&#151;Obligations to Call Shareholders&#146; and Stockholders&#146; Meetings&#148; beginning on
page 189 of this joint proxy statement/prospectus (in each case, except where the breach is the result of an isolated action by a representative (other than a director or officer) of CVS Health, the breach is not caused by or within the knowledge
of, CVS Health, CVS Health has taken appropriate action to remedy the breach and Aetna is not significantly harmed by the breach); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health terminates the merger agreement prior to obtaining the approval of the stock issuance by CVS Health stockholders, in order to enter into a definitive agreement providing for a superior proposal (which
definitive agreement must be entered into concurrently with, or immediately following, the termination of the merger agreement); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aetna or CVS Health terminates the merger agreement due to CVS Health stockholders&#146; failure to approve the stock issuance upon a vote taken on a proposal to approve the stock issuance at the CVS Health special
meeting, and at or prior to the CVS Health special meeting an acquisition proposal for CVS Health (substituting references to 20% with references to 50% in the definition of acquisition proposal) is publicly disclosed or announced, and on or prior
to the first anniversary of such termination CVS Health enters into a definitive agreement, or completes a transaction, relating to an acquisition proposal for CVS Health. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, CVS Health has agreed to pay Aetna a termination fee of $2.1&nbsp;billion if both (x)&nbsp;the merger agreement is terminated:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna or CVS Health because the merger has not been completed on or before the end date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna or CVS Health because there is in effect any applicable law or final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> order enacted, adopted or promulgated after the date of the merger agreement in
respect of the specified regulatory matters in the U.S. that enjoins, prevents or prohibits completion of the merger; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by Aetna because (i)&nbsp;there is in effect any order in respect of the specified regulatory matters that has not become final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> and enjoins, prevents or
prohibits completion of the merger, (ii)&nbsp;within 30 days after the order taking effect, CVS Health has not instituted appropriate proceedings seeking to have the order terminated and (iii)&nbsp;CVS Health&#146;s failure to institute appropriate
proceedings has not been cured within 10 days following irrevocable written notice to CVS Health from Aetna of Aetna&#146;s intent to terminate the merger agreement (which notice may not be given prior to the expiration of such <FONT
STYLE="white-space:nowrap">30-day</FONT> period and will not be effective if CVS Health institutes appropriate proceedings within such <FONT STYLE="white-space:nowrap">10-day</FONT> period); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and (y)&nbsp;at the time of termination of the merger agreement, all of the conditions to CVS Health&#146;s
and Merger Sub&#146;s obligation to complete the merger are satisfied or waived other than (i)&nbsp;the regulatory approvals condition, (ii)&nbsp;the condition requiring the absence of any applicable law or order being in effect in the U.S. that
enjoins, prevents or prohibits completion of the merger (but only if that condition is not satisfied solely due to any applicable law or order in respect of the specified regulatory matters) and (iii)&nbsp;those conditions that, by their nature,
cannot be satisfied until the date on which the merger is completed, but which conditions would be satisfied if completion of the merger were to occur on the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, CVS Health will have no obligation to pay the $2.1&nbsp;billion termination fee referred to above if the failure of the regulatory
approvals condition to be satisfied is caused by Aetna&#146;s willful breach of its obligations described under &#147;&#151;Reasonable Best Efforts Covenant&#148; beginning on page 194 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_113"></A>Exclusive Remedy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except in the case of fraud, if either party receives a termination fee in accordance with the provisions of the merger agreement, the receipt
of the termination fee (together with any applicable amounts referred to in the immediately following paragraph) will be the receiving party&#146;s sole and exclusive remedy against the paying party and its subsidiaries and their respective former,
current or future partners, shareholders, stockholders, managers, members, affiliates and representatives, and none of the paying party, any of its subsidiaries or any of their respective former, current or future partners, shareholders,
stockholders, managers, members, affiliates or representatives will have any further liability or obligation, in each case relating to or arising out of the merger agreement or the transactions contemplated by the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that a termination fee is not promptly paid by any party when due, the party failing to pay the termination fee is also required
to pay any costs and expenses (including reasonable legal fees and expenses) incurred by the other party in connection with legal action taken to enforce the merger agreement that results in a judgment for such amount against the party failing to
promptly pay such amount, together with interest on the unpaid fee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_114"></A>Other Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, the merger agreement provides that each of CVS Health and Aetna will pay its own costs and expenses in connection
with the transactions contemplated by the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_115"></A>Specific Performance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties to the merger agreement are entitled to an injunction or injunctions to prevent breaches of the merger agreement and to
specifically enforce the terms and provisions of the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_116"></A>Third-Party Beneficiaries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement is not intended to and does not confer upon any person other than the parties to the merger agreement any legal or
equitable rights or remedies, except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">from and after completion of the merger, the right of Aetna shareholders to receive the merger consideration and the right of holders of Aetna stock appreciation rights, Aetna RSUs and Aetna PSUs to receive the assumed
awards or other consideration described under the respective subsections under &#147;&#151;Treatment of Aetna Equity Awards&#148; beginning on page 180 of this joint proxy statement/prospectus; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the right of Aetna, on behalf of its shareholders, to seek equitable relief or pursue damages suffered by Aetna and its shareholders in the event of CVS Health&#146;s or Merger Sub&#146;s wrongful termination or willful
breach of the merger agreement; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the right of the indemnified persons to enforce the obligations described under &#147;&#151;Indemnification and Insurance&#148; beginning on page 201 of this joint proxy statement/prospectus; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the right of each of the financing sources to enforce certain provisions of the merger agreement relating to liability of the financing sources to Aetna and its affiliates prior to completion of the merger, the law
governing the merger agreement, the jurisdiction and venue for resolution of disputes involving the financing sources arising under the merger agreement, the waiver of jury trial by the parties to the merger agreements and amendments of those
provisions. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_117"></A>Amendments; Waivers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision of the merger agreement may be amended or waived before completion of the merger if the amendment or waiver is in writing and
signed, in the case of an amendment, by each party to the merger agreement or, in the case of a waiver, by each party against whom the waiver is to be effective, except that after approval and adoption of the merger agreement by Aetna shareholders
or approval of the stock issuance by CVS Health stockholders, the parties may not amend or waive any provision of the merger agreement if such amendment or waiver would require further approval of Aetna shareholders or CVS Health stockholders under
applicable law unless such approval has first been obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_118"></A>INTERESTS OF AETNA&#146;S DIRECTORS AND EXECUTIVE OFFICERS IN
THE MERGER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Aetna board of directors to approve and adopt the merger agreement, Aetna
shareholders should be aware that Aetna&#146;s directors and executive officers have interests in the merger that may be different from, or in addition to, the interests of Aetna shareholders generally. Aetna&#146;s board of directors was aware of
these interests and considered them, among other matters, in evaluating and negotiating the merger agreement, in reaching its decision to approve the merger agreement and the transactions contemplated by the merger agreement (including the merger),
and in recommending to Aetna shareholders that the merger agreement be approved and adopted. These interests include those described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the transactions contemplated by the merger agreement will constitute a change in control of Aetna under all of the Aetna
agreements and arrangements described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_119"></A>Continuing Board Service </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At completion of the merger, the size of the board of directors of CVS Health will be increased by three and the vacancies created thereby will
be filled by Mark T. Bertolini, the Chairman and Chief Executive Officer of Aetna, and two other individuals who are serving on the board of directors of Aetna immediately prior to completion of the merger who meet CVS Health&#146;s independence
criteria as in effect as of such time and who will be jointly designated by Aetna and CVS Health prior to completion of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
the date of this joint proxy statement/prospectus, CVS Health and Aetna have not made a determination as to which two additional members of the board of directors of Aetna will be designated to CVS Health&#146;s board of directors at completion of
the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_120"></A>Treatment of Outstanding Aetna Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is consummated, any then outstanding equity awards (including Aetna stock appreciation rights, Aetna RSUs and Aetna PSUs) granted
by Aetna to executive officers will be treated as described under &#147;The Merger Agreement&#151;Treatment of Aetna Equity Awards&#148; beginning on page 180 of this joint proxy statement/prospectus. If the merger is consummated, any Aetna RSUs
held by Aetna&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, including RSUs granted annually and any deferred stock units, will be settled in cash at a value equal to the fair market value of Aetna common shares on the
effective date of the merger pursuant to the terms of Aetna&#146;s 2010 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_121"></A>Vested Equity Interests of Aetna&#146;s Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Aetna&#146;s executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors currently holds equity awards that
have either vested or that are scheduled to vest before completion of the merger, assuming that completion of the merger occurs on December&nbsp;3, 2018, which is referred to in this section of this joint proxy statement/prospectus as the assumed
completion date of the merger. Aetna PSUs held by Aetna&#146;s executive officers that are based on 2015 &#150; 2017 performance will be earned at the actual performance level of 120% of target, and any other Aetna PSUs held by Aetna&#146;s
executive officers that are scheduled to vest before the completion of the merger will be earned in accordance with the terms of the applicable award agreements. For purposes of the quantifications in this section, the number of Aetna common shares
acquired by Aetna&#146;s executive officers for Aetna PSUs that are based on 2015 &#150; 2017 performance has been determined at a performance level of 120% of the target value, representing the actual performance for these units, and the number of
Aetna common shares acquired by Aetna&#146;s executive officers through the vesting of all other Aetna PSUs between the execution of the merger agreement and the assumed completion date of the merger has been determined assuming that all such other
Aetna PSUs vest at target level. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated values of the Aetna common shares held by Aetna&#146;s
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors and executive officers and outstanding Aetna equity awards that are vested or scheduled to vest before the assumed completion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date of the merger are quantified below. As previously described in this joint proxy statement/prospectus, the exchange ratio is fixed, which means that it will not change between now and the
date of completion of the merger, regardless of whether the market price of either shares of CVS Health common stock or Aetna common shares changes. Therefore, the value of the stock component of the merger consideration will depend on the market
price of shares of CVS Health common stock at the time Aetna shareholders receive shares of CVS Health common stock in the merger. For purposes of quantifying the estimated values in this section, the calculations were done using a value per Aetna
common share of $205.03, which is calculated based on the price of a share of CVS Health common stock of $71.65, which (consistent with the rules set forth for Item 402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K)</FONT> is the average
closing price of a share of CVS Health common stock over the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">five-business-day-period</FONT></FONT> following the first public announcement of the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of Aetna&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, the respective estimated value of the Aetna common
shares (whether held directly or indirectly), vested deferred stock units (as described below) and unvested annual Aetna RSUs that are scheduled to vest before the assumed completion date of the merger is: Mr.&nbsp;Aguirre ($4,460,939);
Mr.&nbsp;Clark ($8,691,684); Mrs.&nbsp;Cohen ($28,718,593); Dr.&nbsp;Coye ($4,966,393); Mr.&nbsp;Farah ($12,303,508); Mr.&nbsp;Garten ($7,599,232); Mrs.&nbsp;Hancock ($31,984,852); Mr.&nbsp;Harrington ($10,055,340); Mr.&nbsp;Ludwig ($11,918,714);
Dr.&nbsp;Newhouse ($17,061,070); and Senator Snowe ($855,673). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of Aetna&#146;s executive officers, the respective estimated
value of the Aetna common shares (whether held directly or indirectly) and Aetna equity awards that are currently vested or scheduled to vest before the assumed completion date of the merger (with the value of each vested Aetna stock appreciation
right calculated based on $205.03 minus the applicable per share exercise price for the Aetna stock appreciation right), and, in the case of Messrs. Bertolini and Soistman and Ms.&nbsp;McCarthy, vested deferred stock units (as described below) is:
Mr.&nbsp;Bertolini ($465,266,762); Mr.&nbsp;Guertin ($20,355,924); Mr.&nbsp;Loveman ($22,512,574); Ms.&nbsp;Lynch ($38,181,591); Mr.&nbsp;Sabatino ($10,317,584); Mr.&nbsp;Jelinek ($12,008,732); Ms.&nbsp;McCarthy ($42,293,601); Dr.&nbsp;Paz
($13,468,703); and Mr.&nbsp;Soistman ($26,510,383). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;25, 2018, Aetna announced that Mr.&nbsp;Loveman will be leaving
the company. Because Mr.&nbsp;Loveman&#146;s last day of employment and the terms of any additional agreement between him and Aetna have not been agreed upon as of the date of this joint proxy statement/prospectus, the values of
Mr.&nbsp;Loveman&#146;s equity interests and severance benefits have been calculated based on the terms of his arrangements as in effect as of the&nbsp;date of this joint proxy statement/prospectus in the same manner as Aetna&#146;s other named
executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_122"></A>Unvested Equity Interests of Aetna&#146;s Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed under the heading &#147;The Merger Agreement&#151;Treatment of Aetna Equity Awards,&#148; beginning on page 180 of this joint
proxy statement/prospectus, certain outstanding unvested Aetna equity awards, by their terms, automatically vest either immediately upon completion of the merger or upon an involuntary termination of employment (other than for cause) in connection
with completion of the merger. Aetna PSUs held by Aetna&#146;s executive officers will be earned either at target or higher actual performance as of the date of completion of the merger, depending on the applicable terms and the ability of Aetna to
determine actual performance as of completion of the merger. For purposes of the quantifications in this section, the number of Aetna common shares acquired by Aetna&#146;s executive officers through the vesting of Aetna PSUs upon completion of the
merger or upon an involuntary termination of employment (other than for cause) in connection with completion of the merger has been determined assuming that all Aetna PSUs vest at target level. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to Aetna&#146;s named executive officers, for the quantification of the equity awards that are expected to vest as of the assumed
completion date of the merger, including as a result of an assumed involuntary termination of employment (other than for cause) in connection with completion of the merger on that date (without taking into account any potential grants in the
ordinary course of business to the extent permitted under the merger agreement between the filing of this joint proxy statement/prospectus and the assumed completion date of the merger), see &#147;&#151;Quantification of Potential Payments to Aetna
Named Executive Officers in Connection with the Merger&#148; beginning on page 216 of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the four Aetna executive officers who are not named executive officers, the estimated
values of the unvested equity awards (including Aetna stock appreciation rights, Aetna RSUs and Aetna PSUs) held by each such executive officer that are expected to vest as of the assumed completion date of the merger, including as a result of an
assumed involuntary termination of employment (other than for cause) in connection with completion of the merger on that date (without taking into account any potential grants in the ordinary course of business to the extent permitted under the
merger agreement between the filing of this joint proxy statement/prospectus and the assumed completion date of the merger) (with the value of each unvested Aetna stock appreciation right calculated based on $205.03 minus the applicable per share
exercise price for the Aetna stock appreciation right) is as follows: Mr.&nbsp;Jelinek ($11,410,692); Ms.&nbsp;McCarthy ($2,181,439); Dr.&nbsp;Paz ($1,185,174) and Mr.&nbsp;Soistman ($2,566,842). For Ms.&nbsp;McCarthy, Dr.&nbsp;Paz and
Mr.&nbsp;Soistman, the amounts exclude the portion of awards the executive is entitled to receive as a result of reaching retirement eligibility under the award terms, regardless of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the unvested Aetna RSUs held by Aetna&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as of the date of this
joint proxy statement/prospectus will vest and be settled prior to the assumed completion date of the merger, and the value of these awards is included for each <FONT STYLE="white-space:nowrap">non-employee</FONT> director under &#147;Vested Equity
Interests of Aetna&#146;s Directors and Executive Officers&#148; above. At the close of business on February 5, 2018, the most recent practicable date for which such information was available, each of Aetna&#146;s
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors held Aetna RSUs with respect to 1,203 Aetna common shares. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_123">
</A>Deferred Compensation Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna maintains nonqualified deferred compensation arrangements for its <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. Such directors may defer all or any portion of their compensation for a given plan year. In the event of a change in control, a participating director will be entitled to a <FONT
STYLE="white-space:nowrap">lump-sum</FONT> cash payout of the entire cash and stock balances, with the cash payout of the stock balance determined using Aetna&#146;s fair market value on the effective date of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna also permits executives to defer up to 100% of their annual bonus and such amounts may be invested in either an interest account or a
stock unit account, at the executive&#146;s election. The arrangement pays out on a date selected by the executive at the time of deferral. Executives may also elect to defer vested RSU and PSU awards, and such amounts pay out according to the award
terms at the time of deferral. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The value of the vested deferred stock units for each <FONT STYLE="white-space:nowrap">non-employee</FONT>
director and Messrs. Bertolini and Soistman and Ms.&nbsp;McCarthy is included in the applicable amounts disclosed under &#147;Vested Equity Interests of Aetna&#146;s Directors and Executive Officers&#148; above. No other executive officer has
deferred amounts under this arrangement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_124"></A>Arrangements with CVS Health </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this joint proxy statement/prospectus, none of Aetna&#146;s executive officers has entered into any agreement with CVS Health
or any of its affiliates regarding employment or other compensation arrangements with the surviving corporation or one or more of its affiliates. Prior to or following completion of the merger, however, some or all of Aetna&#146;s executive officers
may discuss or enter into agreements with CVS Health or any of its affiliates regarding employment or other compensation arrangements with the surviving corporation or one or more of its affiliates. In addition, as described in more detail above, at
completion of the merger, Mr.&nbsp;Bertolini and two other individuals who are serving on the Aetna board of directors immediately prior to completion of the merger will fill newly created vacancies on the CVS Health board of directors and will
receive compensation in connection with their service on the same terms as other <FONT STYLE="white-space:nowrap">non-employee</FONT> directors of CVS Health. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_125"></A>Director and Officer Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors and executive officers of Aetna have rights to indemnification and directors&#146; and officers&#146; liability insurance that will
survive completion of the merger. See &#147;The Merger Agreement&#151;Indemnification and Insurance&#148; beginning on page 201 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_126"></A>Mr.&nbsp;Bertolini&#146;s Employment Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Bertolini is party to an employment agreement with Aetna that provides that all of his unvested equity-based compensation outstanding
at completion of the merger will become immediately vested, nonforfeitable and exercisable. In addition, he is entitled to receive certain benefits if his employment is involuntarily terminated by Aetna other than for Cause (as defined below) or due
to his death or disability, or terminated by Mr.&nbsp;Bertolini for Good Reason (as defined below), whether or not in connection with the merger, including: (i) 24 months of cash compensation, calculated as two times the sum of (a)
Mr.&nbsp;Bertolini&#146;s highest annual base salary in effect during the six months prior to his termination and (b) his target annual cash bonus opportunity (which equals 120% of his annual base salary then in effect) and (ii)&nbsp;a pro rata
portion of his target cash bonus opportunity for the year of termination (subject in certain circumstances to meeting applicable performance requirements). Such amounts are payable in equal installments over two years following
Mr.&nbsp;Bertolini&#146;s termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Mr.&nbsp;Bertolini&#146;s employment agreement, &#147;Cause&#148; means the
occurrence of any one or more of the following: (i)&nbsp;Mr.&nbsp;Bertolini&#146;s willful and continued failure to attempt in good faith to perform the duties of his position (other than as a result of incapacity due to physical or mental illness
or injury) which failure is not remedied within 15 business days of written notice from Aetna; (ii)&nbsp;Mr.&nbsp;Bertolini&#146;s material gross negligence or willful malfeasance in the performance of his duties under the employment agreement;
(iii)&nbsp;with respect to Aetna, Mr.&nbsp;Bertolini&#146;s commission of an act constituting fraud, embezzlement, or any other act constituting a felony; or (iv)&nbsp;Mr.&nbsp;Bertolini&#146;s commission of any act constituting a felony (other than
a speeding violation or by virtue of vicarious liability) which has or is likely to have a material adverse economic or reputational impact on Aetna; <I>provided</I> that, no act or failure to act shall be deemed &#147;willful&#148; unless effected
by Mr.&nbsp;Bertolini without reasonable belief that such action or failure to act was lawful and in the best interests of Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
Mr.&nbsp;Bertolini&#146;s employment agreement, &#147;Good Reason&#148; means, without Mr.&nbsp;Bertolini&#146;s express written consent, the occurrence of any one or more of the following: (i)&nbsp;a reduction by Aetna of Mr.&nbsp;Bertolini&#146;s
annual base salary in effect immediately prior thereto or target cash bonus opportunity, except in the event of a ratable reduction prior to a change in control (as defined in any plan in which Mr.&nbsp;Bertolini participates or in any award that
Mr.&nbsp;Bertolini has been given) affecting all senior officers of Aetna; (ii)&nbsp;within 24 months following a change in control (as defined in any plan in which Mr.&nbsp;Bertolini participates or in any award that Mr.&nbsp;Bertolini has been
given), a reduction in the level of Mr.&nbsp;Bertolini&#146;s long-term incentive plan opportunity from that afforded to him immediately prior to the change in control; (iii)&nbsp;any failure of a successor of Aetna to assume and agree to perform
Aetna&#146;s entire obligations under the employment agreement; <I>provided</I> that such successor has received at least 10 days&#146; written notice from Aetna or Mr.&nbsp;Bertolini of such requirements; (iv)&nbsp;a reporting relationship for
Mr.&nbsp;Bertolini other than to Aetna&#146;s Board of Directors; (v)&nbsp;any action or inaction by Aetna that constitutes a material breach of the terms of the employment agreement; (vi)&nbsp;removal of Mr.&nbsp;Bertolini as President, Chief
Executive Officer, or director of Aetna other than in connection with the termination of his employment for Cause, <I>provided</I>, however, that if the failure to be elected a director of Aetna by its shareholders is solely related to a regulatory
requirement prohibiting Aetna executives from serving on Aetna&#146;s Board of Directors, then such failure to be elected shall not constitute &#147;Good Reason&#148;; or (vii)&nbsp;following the appointment of Mr.&nbsp;Bertolini as Chairman, the
appointment of any other person to the position of executive Chairman, it being understood and agreed that the appointment by Aetna of a <FONT STYLE="white-space:nowrap">non-executive</FONT> Chairman shall not constitute &#147;Good Reason.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the quantification of Mr.&nbsp;Bertolini&#146;s severance benefits assuming a termination of employment following the merger, see
&#147;&#151;Quantification of Potential Payments to Aetna Named Executive Officers in Connection with the Merger&#148; beginning on page&nbsp;216 of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_127"></A>Ms.&nbsp;Lynch&#146;s Employment Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Lynch is party to an employment agreement with Aetna that provides that she is entitled to receive certain benefits if her employment
is involuntarily terminated by Aetna other than for Cause (as defined below) or due to her death or disability, or terminated by Ms.&nbsp;Lynch for Good Reason (as defined below), whether or not in connection with the merger, including: (i) 24
months of cash compensation, calculated as two times the sum of (a) Ms.&nbsp;Lynch&#146;s highest annual base salary in effect during the six months prior to her termination and (b) her target cash bonus opportunity for the year of termination of
employment (which equals at least 120% of her annual base salary) and (ii)&nbsp;a pro rata portion of her target cash bonus opportunity for the year of termination of employment (subject in certain circumstances to meeting applicable performance
requirements). Such amounts are payable in equal installments over two years following Ms.&nbsp;Lynch&#146;s termination of employment. In addition, upon a qualifying termination, Ms.&nbsp;Lynch will be treated as retirement eligible for purposes of
the vesting and exercise terms of all her outstanding equity awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Ms.&nbsp;Lynch&#146;s employment agreement, &#147;Cause&#148;
means the occurrence of any one or more of the following: (i)&nbsp;Ms.&nbsp;Lynch&#146;s willful and continued failure to attempt in good faith to perform the duties of her position (other than as a result of incapacity due to physical or mental
illness or injury) which failure is not remedied within 15 business days of written notice from Aetna; (ii)&nbsp;Ms.&nbsp;Lynch&#146;s material gross negligence or willful malfeasance in the performance of her duties under the employment agreement;
(iii)&nbsp;with respect to Aetna, Ms.&nbsp;Lynch&#146;s commission of an act constituting fraud, embezzlement, or any other act constituting a felony; or (iv)&nbsp;Ms.&nbsp;Lynch&#146;s commission of any act constituting a felony (other than a
speeding violation or by virtue of vicarious liability) which has or is likely to have a material adverse economic or reputational impact on Aetna; <I>provided</I> that, no act or failure to act shall be deemed &#147;willful&#148; unless effected by
Ms.&nbsp;Lynch without reasonable belief that such action or failure to act was lawful and in the best interests of Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
Ms.&nbsp;Lynch&#146;s employment agreement, &#147;Good Reason&#148; means, without Ms.&nbsp;Lynch&#146;s express written consent, the occurrence of any one or more of the following: (i)&nbsp;a reduction by Aetna of Ms.&nbsp;Lynch&#146;s annual base
salary or target annual cash bonus opportunity from the level in effect immediately prior thereto, except in the event of a ratable reduction affecting all senior officers of Aetna; (ii)&nbsp;any failure of a successor of Aetna to assume and agree
to perform Aetna&#146;s entire obligations under the employment agreement; <I>provided</I> that such successor has received at least 10 days&#146; written notice from Aetna or Ms.&nbsp;Lynch of the requirement to do so under the employment
agreement; (iii)&nbsp;Ms.&nbsp;Lynch reporting to any Aetna officer other than Aetna&#146;s Chief Executive Officer; (iv)&nbsp;removal of Ms.&nbsp;Lynch as President (other than in connection with a termination of Ms.&nbsp;Lynch&#146;s employment
for Cause); and (v)&nbsp;any action or inaction by Aetna that constitutes a material breach of the terms of the employment agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
the quantification of Ms.&nbsp;Lynch&#146;s severance benefits assuming a termination of employment following the merger, see &#147;&#151;Quantification of Potential Payments to Aetna Named Executive Officers in Connection with the Merger&#148;
beginning on page&nbsp;216 of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_128"></A>Letter Agreements with Other Named Executive Officers
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Messrs. Guertin, Loveman and Sabatino (Aetna&#146;s other named executive officers, as defined below) are parties to letter agreements
with Aetna that provide for annual base salary continuation for 52 weeks on certain terminations of employment by Aetna in lieu of amounts payable under any Aetna severance and salary continuation plan, whether or not in connection with the merger,
as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under his letter agreement, Mr.&nbsp;Guertin is entitled to receive salary continuation payments if he is
involuntarily terminated under circumstances that would call for severance pay benefits and/or salary continuation benefits under any Aetna severance and salary continuation plan.&nbsp;While his letter agreement provides for 52 weeks of base salary
continuation, due to his tenure with Aetna, Mr.&nbsp;Guertin is entitled to 68 weeks of base salary continuation under Aetna&#146;s Job Elimination Benefits Plan (assuming seven years of service at completion of the merger) upon a termination
following a change in control, and the tables below reflect this higher value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Loveman is entitled to receive such payments if Aetna terminates his employment for
reasons other than Cause or if he resigns because he is required to report to an Aetna officer other than Aetna&#146;s Chief Executive Officer. In the case of Mr.&nbsp;Loveman&#146;s letter agreement, &#147;Cause&#148; means Mr.&nbsp;Loveman&#146;s:
(i)&nbsp;willful failure to perform substantially his duties as an employee of Aetna (other than due to physical or mental illness) after reasonable notice from Aetna; (ii)&nbsp;engagement in serious misconduct that is injurious to Aetna, any
subsidiary or any affiliate, (iii)&nbsp;conviction of, or entrance of a plea of nolo contendere to, a crime that constitutes a felony; (iv)&nbsp;breach of any written covenant or agreement not to compete with Aetna, any subsidiary or any affiliate;
or (v)&nbsp;breach of his duty of loyalty to Aetna which includes, without limitation: (a)&nbsp;disclosure by him of confidential information pertaining to Aetna, any subsidiary or any affiliate; (b)&nbsp;harmful interference by him in the business
or operations of Aetna, any subsidiary or any affiliate; (c)&nbsp;an attempt by him to directly or indirectly induce any employee, insurance agent, insurance broker or broker-dealer of Aetna, any subsidiary or any affiliate to be employed or perform
services elsewhere; (d)&nbsp;an attempt by him, directly or indirectly, to solicit the trade of any customer or supplier, or prospective customer or supplier, of Aetna to do business other than with Aetna; or (e)&nbsp;any breach or violation of
Aetna&#146;s code of conduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Sabatino is currently entitled to receive such payments if he is terminated for reasons other than
Cause. In the case of Mr.&nbsp;Sabatino&#146;s letter agreement, &#147;Cause&#148; means: (i)&nbsp;his willful and material violation of any Aetna policies; (ii)&nbsp;his material and willful failure or refusal to perform any of his duties or
responsibilities to Aetna or any of its affiliates, in each case if and only if such failure or refusal is capable of cure and his failure or refusal is not cured within 10 days following his receipt of written notice from Aetna specifying such
failure or refusal; (iii)&nbsp;his failure to follow a lawful instruction of Aetna if and only if such failure is capable of cure and his failure is not cured within 10 days following his receipt of written notice from Aetna specifying such failure;
or (iv)&nbsp;his commission of an act constituting a fraud, embezzlement or other act constituting a felony. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the quantification of
severance benefits for Messrs. Guertin, Loveman and Sabatino assuming a termination of employment following the merger, see &#147;&#151;Quantification of Potential Payments to Aetna Named Executive Officers in Connection with the Merger&#148;
beginning on page&nbsp;216 of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_129"></A>Other Severance Arrangements with Executive Officers
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jelinek is party to a letter agreement with Aetna that provides, in lieu of amounts payable under any Aetna severance and
salary continuation benefits plan, that he is entitled to receive a cash severance amount equal to the sum of 52 weeks of his annual base salary and his target annual cash bonus opportunity for the year of termination if his employment is terminated
by Aetna other than for cause (which is undefined in the letter agreement) or if he terminates his employment for Good Reason (as defined below). Such amount is payable in equal installments over 52 weeks following Mr.&nbsp;Jelinek&#146;s
termination of employment. In addition, Mr. Jelinek will be paid a cash lump sum pro rated target bonus for active service during the year of termination within 45&nbsp;days following his termination of employment. In the case of
Mr.&nbsp;Jelinek&#146;s letter agreement, &#147;Good Reason&#148; means: (i)&nbsp;Mr.&nbsp;Jelinek no longer reports to the Chief Executive Officer of Aetna; (ii)&nbsp;a reduction by Aetna of his total annual target cash compensation from the level
in effect immediately prior thereto, except in the event of a ratable reduction affecting all senior officers of Aetna; or (iii)&nbsp;Mr.&nbsp;Jelinek&#146;s principal office location is required to be in a location other than the New York, NY
metropolitan area. In addition, the &#147;Good Reason&#148; provision for Mr.&nbsp;Jelinek was triggered when a prior acquisition did not close, and Mr.&nbsp;Jelinek may exercise this right until July&nbsp;31, 2018, <I>provided</I> that he may not
exercise this right without Aetna&#146;s consent prior to 120 days following the date he notifies Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr. Paz is party to a letter
agreement with Aetna that provides that he is entitled to receive base salary continuation if his employment is terminated by Aetna other than for cause (which is undefined in the letter agreement), whether or not in connection with the merger.
While his letter agreement provides for 52 weeks of base salary continuation, due to his tenure with Aetna, Dr.&nbsp;Paz is entitled to 56 weeks of base salary continuation under Aetna&#146;s Job Elimination Benefits Plan (assuming four years of
service at completion of the merger) upon a termination following a change in control, and the severance benefit amount below reflects this higher value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;McCarthy and Mr.&nbsp;Soistman are not parties to letter agreements with Aetna that
provide severance benefits, and instead are entitled to receive severance benefits under Aetna&#146;s Job Elimination Benefits Plan on certain terminations of employment by Aetna. Under the Job Elimination Benefits Plan, upon a termination following
a change in control, Ms.&nbsp;McCarthy is eligible to receive 100 weeks of base salary continuation (assuming 15 years of service at completion of the merger) and Mr.&nbsp;Soistman is eligible to receive 60 weeks of base salary continuation
(assuming five years of service at completion of the merger), based on their current pay levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon any termination of
employment, all executive officers will continue to receive Aetna-provided benefits for nine weeks, and may elect to continue coverage under Aetna&#146;s medical plan at employee rates for an additional two months thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming that all four of the executive officers who are not named executive officers experience a termination of employment immediately
following the assumed completion date of the merger that results in severance benefits pursuant to the letter agreements or Job Elimination Benefits Plan, as applicable, the aggregate severance benefits to be paid or provided (including the value of
continuing benefits) for each such executive officer would be as follows: Mr.&nbsp;Jelinek ($1,684,714); Ms.&nbsp;McCarthy ($1,271,309); Dr.&nbsp;Paz ($780,277); and Mr.&nbsp;Soistman ($905,902). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_130"></A>Restrictive Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of their equity award agreements, each executive officer is subject to
<FONT STYLE="white-space:nowrap">non-competition</FONT> restrictions for 12 months following termination of employment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> of customers and employees restrictions for 24 months following
termination of employment. These restrictions are as strict as, or stricter than, the restrictive covenants in any other agreements between Aetna and its executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_131"></A>Annual Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger agreement provides that, upon completion of the merger, Aetna will determine the performance under its annual incentive plans (as
defined in the merger agreement) through the date of completion and each participant will be eligible to earn (i) a pro-rated portion of his or her annual incentive plan bonus based on actual performance through the date of completion of the merger
and (ii) a pro-rated portion of the bonus with respect to the portion of the year following the date of completion of the merger based on the participant&#146;s target incentive level.&nbsp;Under the terms of Aetna&#146;s Amended and Restated 2001
Annual Incentive Plan, which is referred to in this joint proxy statement/prospectus as Aetna&#146;s 2001 Annual Incentive Plan, an executive officer whose employment is terminated for any reason other than for cause (or any voluntary termination of
employment) in connection with completion of the merger will remain eligible to receive the payments described above for the full calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming that the employment of all four of the executive officers who are not named executive officers is terminated immediately following
the assumed completion date of the merger, the aggregate value of the bonus paid for each such executive officer, assuming a target level of performance for the portion of the year prior to the date of completion of the merger, would be
approximately: Mr.&nbsp;Jelinek ($880,000); Ms.&nbsp;McCarthy ($594,000); Dr.&nbsp;Paz ($576,800); and Mr.&nbsp;Soistman ($781,000). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
information on the bonus paid for the named executive officers, see &#147;&#151;Quantification of Potential Payments to Aetna Named Executive Officers in Connection with the Merger&#148; beginning on page&nbsp;216 of this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_132"></A>280G Mitigation Payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to its authority under the merger agreement, and in order to mitigate the impact of Section&nbsp;4999 of the Code, Aetna&#146;s
compensation committee elected on December&nbsp;19, 2017 to accelerate to December&nbsp;27, 2017, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the vesting of certain Aetna RSUs and Aetna PSUs held by Messrs. Jelinek and Loveman and certain Aetna RSUs held by Mr.&nbsp;Sabatino. The accelerated Aetna RSUs and Aetna PSUs were originally
scheduled to vest during 2018. Because these equity awards would have vested prior to the assumed completion date of the merger under their original terms, they have been included in the amounts described under &#147;&#151;Vested Equity Interests of
Aetna&#146;s Directors and Executive Officers&#148; above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_133"></A>Quantification of Potential Payments to Aetna Named Executive
Officers in Connection with the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Item 402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> the
table below sets forth for each of Aetna&#146;s five named executive officers estimates of the amounts of compensation that are based on or otherwise relate to the merger and that will or may become payable to the named executive officer either
immediately at completion of the merger (i.e., on a &#147;single trigger&#148; basis) or on a qualifying termination of employment following the merger (i.e., on a &#147;double trigger&#148; basis). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of the disclosure in this joint proxy statement/prospectus, Aetna&#146;s named executive officers are determined in
accordance with Item 402(3)(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> with respect to Aetna&#146;s most recent annual proxy statement. Accordingly, the named executive officers are (i)&nbsp;Mark T. Bertolini, Chairman and Chief
Executive Officer (Aetna&#146;s Principal Executive Officer), (ii) Shawn M. Guertin, Executive Vice President, Chief Financial Officer and Chief Enterprise Risk Officer (Aetna&#146;s Principal Financial Officer), and (iii)&nbsp;Gary W. Loveman,
Executive Vice President, Consumer Health and Services, Karen S. Lynch, President, and Thomas J. Sabatino, Jr., Executive Vice President and General Counsel, who were each of Aetna&#146;s three other highest compensated executive officers serving at
December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;25, 2018, Aetna announced that Mr. Loveman will be leaving the company. Because
Mr.&nbsp;Loveman&#146;s last day of employment and the terms of any additional agreement between him and Aetna have not been agreed upon as of the date of this joint proxy statement/prospectus, the values of Mr. Loveman&#146;s equity interests and
severance benefits have been calculated based on the terms of his arrangements as in effect as of the&nbsp;date of this joint proxy statement/prospectus in the same manner as Aetna&#146;s other named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna shareholders are being asked to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the compensation
for these named executive officers specified in the table below (see &#147;Aetna Proposal III: Advisory Vote On Merger-Related Executive Compensation Arrangements&#148; beginning on page 220 of this joint proxy statement/prospectus). Because the
vote to approve such compensation is advisory only, it will not be binding on either Aetna or CVS Health. Accordingly, if the merger agreement is approved and adopted by Aetna&#146;s shareholders and the merger is completed, the compensation will be
payable regardless of the outcome of the vote to approve such compensation, subject only to the conditions applicable thereto, which are described in the footnotes to the table and above under &#147;Interests of Aetna&#146;s Directors and Executive
Officers in the Merger&#148; beginning on page 209 of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna continuously monitors its executive
compensation programs and, from time to time, has made modifications to ensure they are consistent with its philosophy and within the bounds of the competitive marketplace. Aetna believes that the potential cost of the change in control benefits
described in the table below is necessary to retain the employees needed to complete the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts indicated below are estimates of amounts that would be payable assuming that a
qualifying termination of each named executive officer&#146;s employment occurs immediately following the assumed completion date of the merger. These estimates are based on multiple assumptions that may not actually occur, including assumptions
described in this joint proxy statement/prospectus. Certain information is not currently available and thus is not included in the table below, such as equity grants in the ordinary course of business to the extent permitted under the merger
agreement between the filing of this joint proxy statement/prospectus and the assumed completion date of the merger, and, as a result, the actual amounts, if any, to be received by a named executive officer may differ in material respects from the
amounts set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Benefits(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark T. Bertolini</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,720,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,007,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,731,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn M. Guertin,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,690,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,669,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, CFO and Chief Enterprise Risk Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary W. Loveman,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,722,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,698,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,424,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Consumer Health and Services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen S. Lynch,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,216,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,864,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,084,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas J. Sabatino, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,094,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,598,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"><B>Cash</B>: The amount in this column and set forth below assumes termination by Aetna without &#147;cause&#148; or by the executive for &#147;good reason&#148; on the assumed completion date of the merger. The
following provides a summary of the cash severance amounts: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base Salary<BR>and<BR>Target<BR>Incentive(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><BR>Incentive<BR>Plan(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark T. Bertolini</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,280,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,440,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,720,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn M. Guertin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,072,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary W. Loveman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">820,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,722,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen S. Lynch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,098,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,117,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,216,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas J. Sabatino, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">For Mr. Bertolini and Ms. Lynch, the severance payment is based on 24 months of his or her cash compensation (calculated as annual base salary and target cash bonus opportunity). For Mr.&nbsp;Guertin, the severance
amount is based on 68 weeks of his annual base salary. For Messrs.&nbsp;Loveman and Sabatino, the severance payment is based on 52 weeks of his annual base salary. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Reflects each named executive officer&#146;s annual incentive plan bonus for the full year of closing pursuant to the terms of the 2001 Annual Incentive Plan, assuming a target level of performance for the portion of
the year prior to the date of completion of the merger. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Equity</B>: The amounts in this column reflect the value of the accelerated vesting of unvested equity awards
that would occur upon completion of the merger and upon a qualifying termination of employment within 24 months following completion of the merger. The assumed <FONT STYLE="white-space:nowrap">per-share</FONT> value of Aetna common shares for
purposes of determining the values in this column is $205.03. This value is calculated based on a price of a share of CVS Health common stock of $71.65, which, as required by Item 402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> is
the average closing price of a share of CVS Health common stock over the five business day period following the first public announcement of the merger agreement. For Mr.&nbsp;Bertolini, the amounts exclude the portion of awards he is entitled to
receive as a result of reaching retirement eligibility under the award terms, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
regardless of the merger. The following sets forth the applicable accelerated vesting amounts by type of award: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Aetna Stock<BR>Appreciation<BR>Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Aetna RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Aetna PSUs<BR>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark T. Bertolini</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,913,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,713,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,381,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,007,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn M. Guertin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,165,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,524,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,690,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary W. Loveman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,865,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,833,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,698,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen S. Lynch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,131,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,733,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,864,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas J. Sabatino, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,704,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,390,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,094,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Aetna PSUs held by Aetna&#146;s named executive officers will be earned either at target or higher actual performance as of the date of completion of the merger, depending on the applicable terms and the ability of
Aetna to determine actual performance as of completion of the merger. Because actual performance is not measurable at this time, this disclosure assumes target performance through the date of the applicable named executive officer&#146;s
termination. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"><B>Benefits</B>: The estimated amounts in this column reflect the value of the continuation of health, dental and vision insurance under the plans and programs in which the named executive officer currently participates
for a period of nine weeks following termination and the value of continued coverage under Aetna&#146;s medical plan at employee rates for an additional two months thereafter. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_134"></A>AETNA PROPOSAL II: ADJOURNMENT OF THE AETNA SPECIAL MEETING
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna shareholders are being asked to approve a proposal that will give Aetna&#146;s board of directors authority to adjourn the Aetna
special meeting one or more times if necessary to solicit additional proxies if there are not sufficient votes to approve and adopt the merger agreement at the time of the Aetna special meeting or any adjournment or postponement thereof. If this
proposal is approved, the Aetna special meeting could be adjourned to any date. Any determination of whether it is necessary to adjourn the Aetna special meeting (or any adjournment or postponement thereof) to solicit additional proxies will be made
solely by Aetna consistent with the terms of the merger agreement or with the consent of CVS Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Aetna special meeting is
adjourned, Aetna shareholders who have already submitted their proxies will be able to revoke them at any time prior to their use. If you sign and return a proxy and do not indicate how you wish to vote on any proposal, or if you indicate that you
wish to vote in favor of the approval and adoption of the merger agreement but do not indicate a choice on the Aetna adjournment proposal, your shares will be voted in favor of the Aetna adjournment proposal. But if you indicate that you wish to
vote against the approval and adoption of the merger agreement, your shares will only be voted in favor of the Aetna adjournment proposal if you indicate that you wish to vote in favor of that proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the votes cast at the Aetna special meeting by Aetna shareholders will be required to approve the Aetna
adjournment proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Aetna&#146;s board of directors unanimously recommends that Aetna shareholders vote &#147;FOR&#148; the Aetna
adjournment proposal. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_135"></A>AETNA PROPOSAL III: ADVISORY VOTE ON MERGER-RELATED EXECUTIVE
COMPENSATION ARRANGEMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna is providing its shareholders with the opportunity to cast an advisory
<FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote to approve the compensation that will or may be paid or provided by Aetna to its named executive officers in connection with the merger, as required by the Dodd-Frank Wall Street Reform and
Consumer Protection Act of 2010. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation that Aetna&#146;s named executive officers may be entitled to receive from Aetna in
connection with the merger is summarized in the table under &#147;Interests of Aetna&#146;s Directors and Executive Officers in the Merger&#151;Quantification of Potential Payments to Aetna Named Executive Officers in Connection with the
Merger&#148; beginning on page 216 of this joint proxy statement/prospectus. That summary includes all compensation and benefits that will or may be paid or provided by Aetna to its named executive officers in connection with the merger, including
as a result of a termination of employment in connection with the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna&#146;s board of directors encourages you to review
carefully the information regarding the compensation that will or may be paid or provided by Aetna to its named executive officers in connection with the merger disclosed in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna&#146;s board of directors unanimously recommends that the shareholders of Aetna approve the following resolution: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the shareholders of Aetna approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the
compensation that will or may be paid or provided by Aetna to its named executive officers in connection with the merger, as disclosed pursuant to Item 402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> in the Golden Parachute
Compensation table and the related narrative disclosures.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vote on the Aetna compensation advisory proposal is a vote separate
and apart from the vote on the approval and adoption of the merger agreement. Accordingly, you may vote for the approval and adoption of the merger agreement and vote against the Aetna compensation advisory proposal and vice versa. Because the vote
on the Aetna compensation advisory proposal is advisory only, it will not be binding on either Aetna or CVS Health. Accordingly, if the merger agreement is approved and adopted and the merger is completed, the compensation payments that are
contractually required to be paid by Aetna to its named executive officers will or may be paid, subject only to the conditions applicable thereto, regardless of the outcome of the advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote
of Aetna shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A majority of the votes cast affirmatively or negatively on the proposal at the Aetna special meeting will be
required to approve, on an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> basis, the Aetna compensation advisory proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Aetna&#146;s board of directors unanimously recommends that Aetna shareholders vote &#147;FOR&#148; the Aetna compensation advisory
proposal. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_136"></A>CVS HEALTH PROPOSAL II: ADJOURNMENT OF THE CVS HEALTH SPECIAL
MEETING </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health stockholders are being asked to approve a proposal that will give CVS Health&#146;s board of directors authority to
adjourn the CVS Health special meeting one or more times if necessary to solicit additional proxies if there are not sufficient votes at the time of the CVS Health special meeting, or any adjournment or postponement thereof, to approve the stock
issuance. If this proposal is approved, the CVS Health special meeting could be adjourned to any date. Any determination of whether it is necessary to adjourn the CVS Health special meeting (or any adjournment or postponement thereof) to solicit
additional proxies will be made solely by CVS Health consistent with the terms of the merger agreement or with the consent of Aetna. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
the CVS Health special meeting is adjourned, CVS Health stockholders who have already submitted their proxies will be able to revoke them at any time prior to their use. If you sign and return a proxy and do not indicate how you wish to vote on any
proposal, or if you indicate that you wish to vote in favor of the approval of the stock issuance but do not indicate a choice on the CVS Health adjournment proposal, your shares will be voted in favor of the CVS Health adjournment proposal. But if
you indicate that you wish to vote against the approval of the stock issuance, your shares will only be voted in favor of the CVS Health adjournment proposal if you indicate that you wish to vote in favor of that proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the votes cast at the CVS Health special meeting by CVS Health stockholders will be required to approve
the CVS Health adjournment proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVS Health&#146;s board of directors unanimously recommends that CVS Health stockholders vote
&#147;FOR&#148; the CVS Health adjournment proposal. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_137"></A>DESCRIPTION OF CVS HEALTH CAPITAL STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of the terms of CVS Health capital stock is a summary only and is qualified by reference to the relevant provisions
of Delaware law, CVS Health&#146;s certificate of incorporation and CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws.</FONT> Copies of CVS Health&#146;s certificate of incorporation and CVS Health&#146;s
<FONT STYLE="white-space:nowrap">by-laws</FONT> are incorporated by reference and will be sent to holders of Aetna common shares free of charge upon written or telephonic request. See &#147;Comparison of Stockholder Rights&#148; and &#147;Where You
Can Find More Information&#148; beginning on pages 225 and 254, respectively, of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_138"></A>Authorized Capital Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under CVS Health&#146;s certificate of incorporation as of February 5, 2018, the authorized capital stock of CVS Health consisted of
(i)&nbsp;3,200,000,000 shares of common stock, par value of $0.01 per share, (ii)&nbsp;120,619 shares of cumulative preferred stock, par value $0.01 per share, which is referred to in this joint proxy statement/prospectus as preferred stock, and
(iii)&nbsp;50,000,000 shares of preference stock, par value $1.00 per share, which is referred to in this joint proxy statement/prospectus as preference stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in CVS Health&#146;s certificate of incorporation or in a board resolution, shares purchased, redeemed by,
surrendered to or otherwise acquired by CVS Health assume the status of authorized but unissued shares, undesignated as to class or series, and may thereafter be reissued in the same manner as other authorized but unissued shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_139"></A>CVS Health Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of shares of CVS Health common stock are entitled to one vote per share on all matters voted on by stockholders, including
elections of directors. Except as otherwise required by law, or by the provisions of the preferred stock or the preference stock, or provided in any resolution adopted by the CVS Health board with respect to any subsequently created class or series
of CVS Health shares, the holders of the shares of CVS Health common stock exclusively possess all voting power. CVS Health&#146;s certificate of incorporation precludes cumulative voting in the election of directors. CVS Health&#146;s certificate
of incorporation provide for a majority vote standard for uncontested elections of directors, and a plurality of votes standard for contested elections of directors. Subject to any rights of any outstanding series of CVS Health preferred shares, the
holders of shares of CVS Health common stock (i)&nbsp;are entitled to such dividends as may be declared from time to time by the CVS Health board from funds available therefor, (ii)&nbsp;no dividends may be declared, paid, or set aside for payment
on shares of CVS Health common stock unless full cumulative dividends are paid on any outstanding CVS Health preference stock and any other CVS preferred stock issued and outstanding at such time that is designated to have such dividend preference
and (iii)&nbsp;upon dissolution are entitled to receive pro rata all assets of CVS Health available for distribution to such holders, subject to any liquidation preferences designated to any preferred stock or preference stock that may be issued and
outstanding at such time of liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of CVS Health common stock are listed on the NYSE under the symbol &#147;CVS.&#148;
The transfer agent and registrar for the shares of CVS Health common stock is Wells Fargo Shareowner Services, which is referred to in this joint proxy statement/prospectus as the CVS Health transfer agent and registrar. It is a condition to the
merger that the shares of CVS Health common stock issuable in the merger be approved for listing on the NYSE on or before the effective time of the merger, subject to official notice of issuance. If the merger is completed, Aetna common shares will
cease to be listed on the NYSE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_140"></A>No Preemptive Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s certificate of incorporation provides that no holder of any shares of CVS Health of any class or series may have any
preemptive right to purchase or subscribe to any shares of CVS Health or any security convertible into CVS Health shares of any class or series. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_141"></A>Book-Entry Shareholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certificates representing the shares of CVS Health common stock will not be issued unless requested in writing or otherwise required under
applicable law. Holders of record of shares of CVS Health common stock have credited to a book-entry account established for them by, and maintained at, the CVS Health transfer agent and registrar the number of shares of CVS Health common stock
owned by them. Each holder of record receives an ownership statement from the CVS Health transfer agent and registrar promptly following each transfer to or from such account. CVS Health stockholders may request the issuance of a certificate
representing the shares of CVS Health common stock owned of record by them by writing to the CVS Health transfer agent and registrar. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_142">
</A>CVS Preferred Stock and Preference Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February 5, 2018, the CVS Health record date, no shares of CVS Health preferred
stock or preference stock were issued and outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential Issuances of CVS Health Preferred Stock and Preference Stock
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February 5, 2018, CVS Health&#146;s certificate of incorporation authorized 120,619 shares of preferred stock, par value
$0.01 per share and 50,000,000 shares of preference stock, par value $1.00 per share. CVS Health&#146;s certificate of incorporation also authorizes the CVS Health board of directors to issue shares of preferred stock or preference stock, from time
to time, in such class or classes, and such series within any class, and such designations, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof as the board may
determine, including, for example, (i)&nbsp;the designation of the class or series; (ii)&nbsp;the number of shares of the class or series, which number the CVS Health board of directors may thereafter (except where otherwise provided in the
designation of any subsequently authorized class or series) increase or decrease (but not below the number of shares thereof then outstanding); (iii)&nbsp;whether dividends, if any, will be cumulative or noncumulative and the dividend rate of the
class or series; (iv)&nbsp;the dates on which dividends, if any, will be payable; (v)&nbsp;the redemption rights and price or prices, if any, for shares of the class or series; (vi)&nbsp;the terms and amounts of any sinking fund provided for the
purchase or redemption of shares of the class or series; (vii)&nbsp;the amounts payable on shares of the class or series in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of CVS Health;
(viii)&nbsp;whether the shares of the class or series will be convertible into shares of any other class or series, or any other security, of CVS Health or any other corporation, and, if so, the specification of such other class or series or such
other security, the conversion price or prices or rate or rates, any adjustments thereof, the date or dates as of which such shares will be convertible and all other terms and conditions upon which such conversion may be made; (ix)&nbsp;restrictions
on the issuance of shares of the same class or series or of any other class or series; and (x)&nbsp;the voting rights, if any, of the holders of such class or series. The authorized capital stock of CVS Health, including preferred stock, preference
stock and common stock, will be available for issuance without further action by CVS Health stockholders, unless such action is required by applicable law or the rules of any stock exchange or automated quotation system on which CVS Health&#146;s
securities may be listed or traded. If the approval of CVS Health stockholders is not so required, the CVS Health board of directors does not intend to seek stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the CVS Health board of directors has no intention at the present time of doing so, it could issue a class or series of CVS Health
preferred stock that could, depending on the terms of such class or series, impede completion of a merger, tender offer or other takeover attempt that some, or a majority, of CVS Health stockholders might believe to be in their best interests or in
which stockholders might receive a premium for their shares over the then-current market price of such shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential Issuances
of Rights to Purchase Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health does not currently have a stockholder rights plan, although the CVS Health board of
directors retains the right to adopt a new plan at a future date. CVS Health&#146;s certificate of incorporation grants the CVS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Health board of directors exclusive authority to create and issue rights entitling the holders thereof to purchase from CVS Health shares of capital stock or other securities and to elect to
repurchase, redeem, terminate or amend any such rights. The times at which and terms upon which such rights are to be issued, repurchased, redeemed, terminated or amended are to be determined exclusively by the CVS Health board of directors and set
forth in the contracts or instruments that evidence any such rights. The authority of the CVS Health board of directors with respect to such rights includes determining, for example, (i)&nbsp;the purchase price of the capital stock or other
securities or property to be purchased upon exercise of such rights; (ii)&nbsp;provisions relating to the times at which and the circumstances under which such rights may be exercised or sold or otherwise transferred, either together with or
separately from any other shares or other securities of CVS Health; (iii)&nbsp;provisions which adjust the number or exercise price of such rights or the amount or nature of the shares, other securities or other property receivable upon exercise of
such rights in the event of a combination, split or recapitalization of any shares of CVS Health, a change in ownership of CVS Health&#146;s shares or other securities or a reorganization, merger, consolidation, sale of assets or other occurrence
relating to CVS Health or any shares of CVS Health, and provisions restricting the ability of CVS Health to enter into any such transaction absent an assumption by the other party or parties thereto of the obligations of CVS Health under such
rights; (iv)&nbsp;provisions which deny the holder of a specified percentage of the outstanding securities of CVS Health the right to exercise such rights and/or cause such rights held by such holder to become void; (v)&nbsp;provisions which permit
CVS Health to redeem or exchange such rights; and (vi)&nbsp;the appointment of the rights agent with respect to such rights. This provision is intended to confirm the CVS Health board of directors exclusive authority to issue, repurchase, redeem,
terminate or amend share purchase rights or other rights to purchase shares or securities of CVS Health or any other corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s certificate of incorporation provides that stockholder action may be taken at an annual or special meeting of stockholders or
by written consent in lieu of a meeting, but only if such action is taken in accordance with the provisions of CVS Health&#146;s certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws.</FONT> Any person other than CVS Health
seeking to have the stockholders authorize or take corporate action by written consent without a meeting are required to deliver a written notice signed by holders of record of at least twenty-five percent (25%) of the voting power of the
outstanding capital stock of CVS Health entitled to express consent on the relevant action and request that a record date be fixed for such purpose. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_143">
</A>Provisions Relating to Amendments to CVS Health&#146;s Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-Laws</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, stockholders have the right to adopt, amend or repeal the certificate of incorporation and
<FONT STYLE="white-space:nowrap">by-laws</FONT> of a corporation. However, Delaware law requires that any amendment to CVS Health&#146;s certificate of incorporation also be approved by the board of directors. Under Delaware law, unless a higher
vote is required in a corporation&#146;s certificate of incorporation, amendments to the corporation&#146;s certificate of incorporation will be adopted upon receiving at a properly convened meeting the affirmative vote of a majority of the votes
cast by all stockholders entitled to vote thereon, and if any class or series is entitled to vote thereon as a class, the affirmative vote of a majority of the votes cast in each class vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> may be amended by the board of directors with respect to all
matters not exclusively reserved by law to the stockholders. Amendments to CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> may be adopted and approved by the affirmative vote of the holders of record of a majority of the
outstanding shares of stock of CVS Health entitled to vote cast at any annual or special meeting, or by the affirmative vote of a majority of the directors cast at any regular or special meeting at which a quorum is present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> the name of CVS Health can only be changed by a vote of at least
three fourths of the members of the board of directors of CVS Health and any amendment to such provision in CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> must also be approved by a vote of at least three fourths of the members of
the board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_144"></A>COMPARISON OF STOCKHOLDER RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of CVS Health stockholders are currently governed by Delaware law and CVS Health&#146;s certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws.</FONT> The rights of Aetna shareholders are currently governed by Pennsylvania law and Aetna&#146;s articles of incorporation and <FONT STYLE="white-space:nowrap">by-laws.</FONT> Following completion of the
merger, the rights of Aetna shareholders who become stockholders of CVS Health in the merger will be governed by Delaware law and CVS Health&#146;s certificate of incorporation and CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws.</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion summarizes the material differences between the current rights of Aetna shareholders and the current rights of
CVS Health stockholders. These differences arise in part from differences between Delaware law and Pennsylvania law. Additional differences arise from the governing instruments of the two companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although it is impracticable to compare all of the aspects in which Delaware law and Pennsylvania law and CVS Health&#146;s and Aetna&#146;s
governing instruments differ with respect to stockholder rights, the following discussion summarizes certain material differences between them. This summary is not intended to be complete, and it is qualified in its entirety by reference to Delaware
law, Pennsylvania law, CVS Health&#146;s certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> and Aetna&#146;s articles of incorporation and <FONT STYLE="white-space:nowrap">by-laws.</FONT> In addition, the identification
of some of the differences in the rights of these stockholders as material is not intended to indicate that other differences that are equally important do not exist. CVS Health and Aetna urge you to carefully read this entire joint proxy
statement/prospectus, the relevant provisions of Delaware law and Pennsylvania law and the other documents to which CVS Health and Aetna refer in this joint proxy statement/prospectus for a more complete understanding of the differences between the
rights of a CVS Health stockholder and the rights of an Aetna shareholder. CVS Health and Aetna have filed with the SEC their respective governing documents referenced in this comparison of stockholder rights and will send copies of these documents
to you, without charge, upon your written or telephonic request. See &#147;Where You Can Find More Information&#148; beginning on page 254 of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_145"></A>Material Differences in Stockholder Rights </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Authorized Capital Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">As of February 5, 2018, the authorized capital stock of CVS Health consists of (i)&nbsp;3,200,000,000 shares of common stock, par value $0.01 per share and (ii)&nbsp;120,619 shares of preferred stock, par value $0.01 per share
and (iii)&nbsp;50,000,000 shares of preference stock, par value $1.00 per share.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of February 5, 2018, the authorized capital stock of Aetna consists of (i) 2,520,137,562 common shares, par value $0.01 per share, (ii) 7,625,000 Class&nbsp;A voting preferred shares, par value $0.01 per share, and (iii)
468,891,771 undesignated shares, par value $0.01 per share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The CVS Health board of directors is authorized to issue shares of preferred stock, from time to time, in such class or classes, and such series within any class, and such designations, preferences and relative, participating,
optional or other special rights, and qualifications, limitations or restrictions thereof as the CVS Health board of directors may determine.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Aetna board of directors is authorized to provide for the issuance of shares of Aetna capital stock in one or more classes and series, including preferred shares, to establish the number of shares in each class and series, and
to fix the designations, powers, preferences and rights of each such class and series and the qualifications, limitations or restrictions thereof.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">As of February 5, 2018, there were outstanding (i)&nbsp;1,015,460,751 shares of CVS Health common stock (ii)&nbsp;no shares of CVS Health preferred stock and (iii)&nbsp;no shares of CVS Health preference stock.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of February 5, 2018, there were outstanding (i) 326,942,525 Aetna common shares and (ii)&nbsp;no Aetna Class&nbsp;A voting preferred shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Number of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CVS Health&#146;s board of directors currently has 12 members.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Aetna board of directors currently has 12 members.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Under CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> the number of directors constituting the whole board of directors is fixed by resolution of the board of directors and must consist of not fewer than three
nor more than 18 members.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> the Aetna board of directors must consist of not fewer than three nor more than 21 members.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delaware law permits classified boards of directors. CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> and CVS Health&#146;s certificate of incorporation do not provide for a classified board of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pennsylvania law permits classified boards of directors, but Aetna does not have one.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Election of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, directors are elected annually. CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> provide for a majority vote standard for uncontested elections of directors and a plurality of votes standard for
contested elections of directors. Under CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> a majority of votes cast means that the number of votes &#147;for&#148; a director&#146;s election must exceed fifty percent (50%) of the
votes cast with respect to that director&#146;s election. Votes &#147;against&#148; a director&#146;s election will count as votes cast, but &#147;abstentions&#148; and &#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;</FONT> will not
count as votes cast with respect to that director&#146;s election.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aetna&#146;s articles provide for a majority vote standard for uncontested elections of directors and a plurality of votes standard for contested elections of directors. Under Pennsylvania law and Aetna&#146;s articles, if an
incumbent director nominee does not receive a majority of the votes cast in an uncontested election, the incumbent director will continue to serve on the board of directors until his or her successor is elected and qualified. To address this
situation, Aetna&#146;s corporate governance guidelines require any incumbent nominee for director in an uncontested election who receives more &#147;against&#148; votes than &#147;for&#148; votes to promptly submit his or her resignation for
consideration by the Aetna board of directors&#146; nominating committee.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Removal of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, directors may be removed with or without cause by the affirmative vote of holders of a majority of all the shares of stock outstanding and entitled to vote for the election of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pennsylvania law provides that, unless otherwise provided in a <FONT STYLE="white-space:nowrap">by-law</FONT> adopted by the shareholders, in the absence of cumulative voting or a classified board of directors, any director may be
removed with or without cause by a vote of</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shareholders entitled to elect directors. Aetna does not have such a <FONT STYLE="white-space:nowrap">by-law,</FONT> cumulative voting or a classified board of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Voting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law and CVS Health&#146;s certificate of incorporation, each holder of CVS Health common stock is entitled to one vote per share of CVS Health common stock.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Aetna&#146;s articles, each holder of Aetna common shares is entitled to one vote per Aetna common share, and each holder of an Aetna Class&nbsp;A voting preferred share is entitled to 100 votes per Aetna Class&nbsp;A voting
preferred share. The holders of Aetna common shares and Aetna Class&nbsp;A voting preferred shares vote together as a single class on all matters submitted to a vote of Aetna shareholders. No Aetna Class&nbsp;A voting preferred shares are currently
outstanding.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cumulative Voting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, CVS Health stockholders are not entitled to cumulative voting unless it is expressly provided for in the certificate of incorporation. CVS Health&#146;s certificate of incorporation does not provide for
cumulative voting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pennsylvania law allows for cumulative voting, but Aetna&#146;s articles expressly preclude it in the election of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vacancies on the Board of Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law and CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> vacancies in the CVS Health board of directors, from any cause whatsoever, including vacancies created by an increase in the number of
directors, shall be filled by the vote of a majority of the remaining directors, even if less than a quorum.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> vacancies on the board of directors may be filled by a majority vote of the remaining directors, regardless of how the vacancy was created. Shareholders may fill
vacancies on the board of directors, regardless of how the vacancy was created, only if and when authorized by resolution of the Aetna board of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Special Meeting of the Board of Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under CVS Health&#146;s certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> special meetings of the CVS Health board of directors may be called only by the chairman of the CVS Health board of directors,
the chief executive officer or by <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors then in office.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> special meetings of the board of directors may be called by the Chairman of the board of directors, the President, the Lead Director or not less than <FONT
STYLE="white-space:nowrap">one-third</FONT> of the directors then in office.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stockholder Action by Written Consent</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law and CVS Health&#146;s certificate of incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Aetna&#146;s articles, shareholder action may only be taken at an annual</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">and <FONT STYLE="white-space:nowrap">by-laws,</FONT> any action that could be taken at a stockholder meeting can be taken without a meeting, upon the written consent of the holders of the outstanding stock having at least the
minimum number of votes that would have been necessary to authorize the action at a meeting at which all shares entitled to vote were present and voted. Under CVS Health&#146;s certificate of incorporation and
<FONT STYLE="white-space:nowrap">by-laws,</FONT> any stockholder of record seeking to have the stockholders authorize or take corporate action by written consent must, by written notice to the secretary, request the CVS Health board of directors to
fix a record date to determine the stockholders entitled to consent to corporate action in writing without a meeting. The CVS Health board of directors must promptly, but in all events within ten days after the date on which such a request is
received, adopt a resolution fixing the record date, which date may not be more than ten days after the date upon which the resolution fixing the record date is adopted by the CVS Health board of directors. If no record date is fixed by the CVS
Health board of directors within such period, the record date will be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to CVS Health.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">or special meeting and not by written consent.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Amendment to Certificate of Incorporation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, an amendment to CVS Health&#146;s certificate of incorporation generally requires (i)&nbsp;the approval of the CVS Health board of directors, (ii)&nbsp;the approval of a majority of the voting power of the
outstanding stock entitled to vote upon the proposed amendment and (iii)&nbsp;the approval of the holders of a majority of the outstanding stock of each class entitled to vote thereon as a class, if any. Under CVS Health&#146;s certificate of
incorporation, CVS Health reserves the right to amend its certificate of incorporation in any manner permitted by Delaware law and, with the sole exception of the rights and powers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Pennsylvania law, unless a greater vote is required by Aetna&#146;s articles, an amendment to Aetna&#146;s articles can be proposed by a resolution by Aetna&#146;s board of directors and then approved by an affirmative vote of
a majority of the votes cast by all shareholders entitled to vote thereon and the affirmative vote of a majority of the votes cast in any required class vote, except for amendments on certain specified matters that do not require shareholder
approval. Aetna&#146;s articles require that an amendment changing the vote required to approve a fundamental or extraordinary corporate transaction</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">conferred under the provision of the certificate of incorporation with respect to liability of directors for breaches of fiduciary duties, all rights and powers conferred herein on CVS Health&#146;s stockholders, directors and
officers, if any, are subject to such reserved power.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">described below under &#147;&#151;Stockholder Vote on Fundamental or Extraordinary Corporate Transactions&#148; beginning on page 245 of this joint proxy statement/prospectus must be approved by the affirmative vote of at least a
majority of the votes that all voting shareholders are entitled to cast and by any required class vote.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Amendment of <FONT STYLE="white-space:nowrap">By-laws</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law and CVS Health&#146;s certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> may be amended by the affirmative vote of
the holders of record of a majority of the outstanding shares of stock of CVS Health entitled to vote cast at any annual or special meeting, or by the affirmative vote of a majority of the directors cast at any regular or special meeting at which a
quorum is present; however, also under CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> the name of the corporation can only be changed by a vote of 3/4 of the members of the CVS Health board of directors and any amendment to such
provision in CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> must also be approved by a vote of 3/4 of the members of the CVS Health board of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> the <FONT STYLE="white-space:nowrap">by-laws</FONT> may be amended by either (i)&nbsp;the affirmative vote of a majority of the votes cast by all shareholders
entitled to vote thereon, voting as a single class, and, if any shareholders are entitled to vote thereon as a class, upon receiving the affirmative vote of a majority of the votes cast by the shareholders entitled to a vote as a class, at a meeting
of the shareholders in the call for which written notice of the proposed action has been given, or (ii)&nbsp;with respect to those matters that are not by statute committed exclusively to the shareholders and alterations of the size of the board of
directors to less than three or more than 21, and regardless of whether the shareholders have previously adopted or approved the <FONT STYLE="white-space:nowrap">by-law</FONT> being amended or repealed, by the affirmative vote of a majority of the
directors then in office, upon written notice to each director of the action proposed to be taken.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Special Stockholder Meetings</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law and CVS Health&#146;s certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> a special meeting of the stockholders may be called (i)&nbsp;by the CVS Health board of directors, the
chairman of the CVS Health board of directors or the chief executive officer of CVS Health or (ii)&nbsp;by the secretary of CVS Health upon written request from holders of record of at least 25% of the voting power of the outstanding capital stock
of CVS Health entitled to vote on the matter or matters to be brought before the proposed special meeting, filed with the secretary of CVS Health and otherwise in accordance with the <FONT STYLE="white-space:nowrap">by-laws.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Aetna&#146;s articles and <FONT STYLE="white-space:nowrap">by-laws,</FONT> a special meeting of the Aetna shareholders may be called by
holders of at least 25% of the votes that all voting shareholders, voting as a single class, are entitled to cast, or by the President, the Chairman or the board of directors.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In order to request a special meeting, holders of at least 25% of the votes that all
voting shareholders, voting as a single class, are entitled to cast must submit a written petition that sets forth: (i)&nbsp;a brief description of the business to be conducted at the special meeting, and the reasons
for</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> a special meeting request to the secretary must be signed and dated by each stockholder of record (or a duly authorized agent of such stockholder)
requesting the special meeting, and must include (i)&nbsp;a statement of the specific purpose or purposes of the special meeting, (ii) (a)&nbsp;if the reason for the special meeting is to nominate a director, all information relating to such person
that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including such person&#146;s written consent to being named in the
proxy statement as a nominee and to serving as a director if elected), (b)&nbsp;as to any other business that the stockholder proposes to bring before the special meeting, a brief description of the business desired to be brought before the special
meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend these <FONT STYLE="white-space:nowrap">by-laws,</FONT> the language of
the proposed amendment), the reasons for conducting such business at the special meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made, (iii)&nbsp;an
acknowledgement by the requesting stockholders and the beneficial owners, if any, on whose behalf the special meeting request are being made that a disposition of shares of the corporation&#146;s capital stock owned of record or beneficially as of
the date on which the special meeting request in respect of such shares is delivered to the secretary that is made at any time prior to the special meeting will constitute a revocation of such special meeting request with respect to such disposed
shares, and (iv)&nbsp;documentary evidence that the</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">conducting the business at a special meeting; (ii)&nbsp;the name(s) of any director nominee(s), if any; (iii)&nbsp;the name and address of (A)&nbsp;each requesting shareholder who has signed the special meeting request and
(B)&nbsp;each beneficial owner, if any, on whose behalf the special meeting request is made; (iv)&nbsp;evidence of the class and number of shares of capital stock of Aetna that are held of record and/or beneficially owned by each requesting
shareholder, including without limitation documentary evidence that the requesting shareholders in the aggregate beneficially owned shares of capital stock of Aetna entitled to cast in the aggregate at least the requisite percentage of votes at the
close of business on the date of the special meeting request, provided, however, that if any requesting shareholder is not the beneficial owner of the shares of capital stock of Aetna listed as owned by such requesting shareholder on such special
meeting request, then to be valid, the special meeting request must also include documentary evidence that the beneficial owner on whose behalf the special meeting request is made beneficially owned the identified shares at the close of business on
the date of such special meeting request; (v)&nbsp;a description of any material interest of each requesting shareholder (and each beneficial owner, if any, of identified shares on whose behalf a special meeting request is made) in the business
specified in the special meeting request; (vi)&nbsp;a description of any agreement, arrangement or understanding (including without limitation, regardless of the form of settlement, any derivatives, long or short positions, profit interests or
similar rights, hedging transactions and borrowed or loaned shares) that has been entered into by or on behalf of, or any other agreement,</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">requesting stockholders own at least 25% of the outstanding capital stock as of the date of such written request to the secretary; provided,
however, that if the requesting stockholders are not the beneficial owners of the shares representing the requisite percentage, then to be valid, the special meeting request must also include documentary evidence (within ten business days after the
date on which the special meeting request are delivered to the secretary) that the beneficial owners on whose behalf the special meeting request are made beneficially own the requisite percentage as of the date on which such special meeting request
are delivered to the secretary. In addition, the requesting stockholders and the beneficial owners, if any, on whose behalf the special meeting request are being made will promptly provide any other information reasonably requested by CVS
Health.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A special meeting requested by stockholders will not be held if
(i)&nbsp;the special meeting request does not comply with the procedures set forth in CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> (ii)&nbsp;the special meeting request relates to an item of business that is not a proper
subject for stockholder action under applicable law, (iii)&nbsp;the special meeting request is received by CVS Health during the period commencing 90 days prior to the first anniversary of the date of the immediately preceding annual meeting and
ending on the date of the next annual meeting, (iv)&nbsp;an annual or special meeting of stockholders that included an identical or substantially similar item of business was held not more than 120 days before the special meeting request was
received by the secretary, (v)&nbsp;the CVS Health board of directors has called or calls for an annual or special meeting of stockholders to be held within 90 days after the special</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">arrangement or understanding that has been made, the effect or intent of which is to create or mitigate loss to, to manage risk or benefit of
share price changes for, or to increase or decrease the voting power of, any requesting shareholder or any requesting beneficial owner with respect to the voting securities of Aetna; (vii)&nbsp;a representation that the requesting shareholder
intends to appear in person or by proxy at the requested special meeting to bring the business specified in the special meeting request before such special meeting; (viii)&nbsp;a representation as to whether any requesting shareholder or any such
beneficial owner intends (or is part of a group that intends) to solicit proxies from shareholders in support of such proposal, nomination or nominations; (ix)&nbsp;any other information relating to such requesting shareholder, beneficial owner, if
any, or director nominee or other proposed business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with the solicitation of proxies in support of such proposal or director nominee
pursuant to Section&nbsp;14 of the Exchange Act; and (x)&nbsp;such other information relating to any proposed item of business as Aetna may reasonably require, including without limitation to determine whether such proposed item of business is a
proper matter for shareholder action.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Aetna&#146;s <FONT
STYLE="white-space:nowrap">by-laws,</FONT> each special meeting request must include or be accompanied by an agreement by each requesting shareholder and each requesting beneficial owner, if any, to notify Aetna&#146;s corporate secretary promptly
in the event of any decrease in the number of shares of capital stock of Aetna held by such requesting shareholder or requesting beneficial owner following the delivery of the</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">meeting request is received by the secretary and the business to be conducted at such meeting includes an identical or substantially similar
item of business or (vi)&nbsp;the special meeting request was made in a manner that involved a violation of Regulation 14A under the Exchange Act or other applicable law.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> the nomination, election or removal of directors are deemed to be similar
business with respect to all items of business involving the nomination, election or removal of directors, changing the size of the CVS Health board of directors and filling of vacancies and/or newly created directorships resulting from any increase
in the authorized number of directors.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">With respect to the stockholder giving the
notice and the beneficial owner, if any, on whose behalf the proposal is made, CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that the following information be included: (i)&nbsp;the name and address, as they appear on CVS
Health&#146;s books, of such stockholder and any such beneficial owner; (ii)&nbsp;the class or series and number of shares of capital stock of CVS Health which are held of record or are beneficially owned by such stockholder and by any such
beneficial owner; (iii)&nbsp;a description of any agreement, arrangement or understanding between or among such stockholder and any such beneficial owner, any of their respective affiliates or associates, and any other person or persons (including
their names) in connection with the proposal of such nomination or other business; (iv)&nbsp;a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, convertible
securities, stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">special meeting request and prior to the requested special meeting, and an acknowledgment that any such decrease will be deemed to be a
revocation of the special meeting request by such requesting shareholder or requesting beneficial owner to the extent of such reduction. Any requesting shareholder also may revoke his, her or its special meeting request at any time prior to the
requested special meeting by written revocation delivered to Aetna&#146;s corporate secretary.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No later than 10 calendar days after the record date for the special meeting, each requesting shareholder and each requesting beneficial owner, if any, must
supplement the information required by Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> to disclose such information as of such record date.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> a special meeting requested by a shareholder will not be held if (A)&nbsp;the special
meeting request does not comply with Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> (B)&nbsp;the special meeting request relates to an item of business that is not a proper subject for shareholder action under applicable law,
(C)&nbsp;the special meeting request is received by Aetna&#146;s corporate secretary during the period commencing 90 calendar days prior to the first anniversary of the date of the immediately preceding annual meeting of shareholders and ending on
the date of the next annual meeting of shareholders, (D)&nbsp;an annual or special meeting of shareholders that included an identical or substantially similar item of business was held not more than 120 calendar days before the special meeting
request was received by Aetna&#146;s corporate secretary, (E)&nbsp;Aetna&#146;s board of directors has called or calls an annual or special meeting of shareholders to be held within 90 calendar days after
the</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">appreciation or similar rights, hedging transactions and borrowed or loaned shares) that has been entered into by or on behalf of, or any
other agreement, arrangement or understanding that has been made, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, such stockholder or any such
beneficial owner (including any affiliate of such stockholder or any such beneficial owner) or any such nominee with respect to CVS Health&#146;s securities; (v)&nbsp;a representation that the stockholder is a holder of record of stock of CVS Health
entitled to vote at such meeting and intends to appear in person or by proxy at the special meeting to bring such nomination or other business before the special meeting; and (vi)&nbsp;a representation as to whether such stockholder or any such
beneficial owner intends or is part of a group that intends to (a)&nbsp;deliver a proxy statement and/or form of proxy to holders of at least the percentage of the voting power of CVS Health&#146;s outstanding capital stock required to approve or
adopt the proposal or to elect each such nominee and/or (b)&nbsp;otherwise to solicit proxies from stockholders in support of such proposal or nomination.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In determining whether a special meeting of stockholders has been requested by the record holders of shares representing in the aggregate at least the
requisite percentage, multiple special meeting requests delivered to the secretary will be considered together only if: (i)&nbsp;each special meeting request identifies substantially the same purpose or purposes of the special meeting and
substantially the same matters proposed to be acted on at the special meeting (in each case as determined in good faith by the CVS Health board of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">special meeting request is received by Aetna&#146;s corporate secretary and the business to be conducted at such meeting includes similar business, or (F)&nbsp;the special meeting request was made in a manner that involved a
violation of the Exchange Act or other applicable law. For purposes of Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> the nomination, election or removal of directors will be deemed to be similar business with respect to all items of
business involving the nomination, election or removal of directors, changing the size of the board of directors and filling of vacancies on the board of directors, including without limitation vacancies resulting from any increase in the number of
directors designated by the board of directors.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">directors) and (ii)&nbsp;such special meeting requests have been dated and delivered to the secretary within 60 days of the earliest dated
special meeting request. A requesting stockholder may revoke a special meeting request at any time by written revocation delivered to the secretary and if, following such revocation, there are outstanding
<FONT STYLE="white-space:nowrap">un-revoked</FONT> requests from requesting stockholders holding less than the requisite percentage, the CVS Health board of directors may, in its discretion, cancel the special meeting. If none of the requesting
stockholders appears or sends a duly authorized agent to present the business to be presented for consideration that was specified in the special meeting request, the corporation need not present such business for a vote at such special meeting.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Special meetings must be held at such date and time as may be fixed by the CVS Health
board of directors in accordance with CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws;</FONT> provided, however, that in the case of a special meeting requested by stockholders, the date of any such special meeting must not be more than
90 days after a special meeting request that satisfies the requirements of CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> is received by the secretary.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Notice of Stockholder Meetings</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law and CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> written notice of each stockholders&#146; meeting must be mailed at least 10 days but not more than 60 days before the date of the meeting.
Delaware law requires notice of a meeting to vote on a merger agreement, a sale, lease or exchange of all or substantially all assets, a conversion to another form of entity or a transfer, domestication or conveyance to a foreign jurisdiction to be
given at least 20 days before the date of such meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> written notice of each meeting of shareholders must be given not less than 10 calendar days before the date of the
meeting.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stockholder Nominations of Persons for Election as Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> generally permit stockholders to nominate persons for election as directors
if the stockholder intending to make such nomination gives timely notice thereof in writing in proper form to CVS Health&#146;s secretary. If stockholders call a special meeting for the purpose of electing directors, they must comply with the
procedures described above under &#147;&#151;Special Stockholder Meetings&#148; beginning on page 229 of this joint proxy statement/prospectus.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> to be timely, a stockholder&#146;s notice must be delivered to, or mailed and
received, at CVS Health&#146;s principal office not less than 90 days nor more than 120 days prior to first anniversary of the preceding year&#146;s annual meeting of stockholders; provided, however, that in the event that the date of the annual
meeting is advanced more than 30 days prior to such anniversary date or delayed more than 70 days after such anniversary date, or if no annual meeting was held in the preceding year, then to be timely such notice must be received by CVS Health no
earlier than the close of business on the 120th day prior to such annual meeting and no later than close of business on the later of (x)&nbsp;the 90th day prior to such annual meeting or (y)&nbsp;the 10th day following the day on which public
announcement of the date of such meeting is first made by CVS Health. In no event will the public announcement of an adjournment or postponement of an annual meeting of stockholders commence a new time period (or extend any time period) for the
giving of a stockholder&#146;s notice as described above.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s <FONT
STYLE="white-space:nowrap">by-laws</FONT> also include proxy access provisions which provide that a stockholder, or a group of up to 20 stockholders, owning at least 3% of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> generally permit shareholders to nominate persons for election as directors if
the shareholder intending to make such nomination gives timely notice thereof in writing in proper form. If shareholders call a special meeting for the purpose of electing directors, they must comply with the procedures described above under
&#147;&#151;Special Stockholder Meetings&#148; beginning on page 229 of this joint proxy statement/prospectus.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be timely, a shareholder&#146;s notice must be received by Aetna&#146;s corporate secretary not later than 90 calendar days prior to the date such annual
meeting is to be held, provided that the notice will be considered timely if it is received not later than the close of business on the 10th calendar day following the day on which public disclosure of the date of such meeting was made.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be in proper form, the notice must set forth: (i)&nbsp;as to each person whom the
shareholder proposes to nominate for election or <FONT STYLE="white-space:nowrap">re-election</FONT> as a director, (a)&nbsp;the name, age, business address and residence address of the person, (b)&nbsp;the principal occupation or employment of the
person, (c)&nbsp;the class and number of Aetna shares beneficially owned by the person and (d)&nbsp;any other information relating to the person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise
required, in each case pursuant to Section&nbsp;14 of the Exchange Act and the rules and regulations thereunder; and (ii)&nbsp;as to the shareholder giving the notice, (a)&nbsp;the name and address of the shareholder and (b)&nbsp;evidence of the
class and number of Aetna shares that are beneficially owned by the shareholder.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A
special meeting request for the nomination of any director to Aetna&#146;s</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Company&#146;s outstanding common stock continuously for at least three years to nominate and include in the Company&#146;s proxy
materials director nominees constituting up to the greater of two individuals or 20% of the CVS Health board of directors, provided that the stockholders and the nominees satisfy the requirements specified in the
<FONT STYLE="white-space:nowrap">by-laws.</FONT></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A stockholder notice under the
proxy access provisions of CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> must include: (i)&nbsp;the written consent of each stockholder nominee to being named in the corporation&#146;s proxy materials as a nominee and to serving
as a director if elected; (ii)&nbsp;a copy of the Schedule 14N that has been or concurrently is filed with the SEC under Exchange Act Rule <FONT STYLE="white-space:nowrap">14a-18;</FONT> (iii)&nbsp;a description of all direct and indirect
compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships, between or among the eligible stockholder and its affiliates and associates, or others acting in
concert therewith, on the one hand, and each stockholder nominee, and each stockholder nominee&#146;s respective affiliates and associates, or others acting in concert therewith, on the other hand, including, without limitation all information that
would be required to be disclosed pursuant to Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> if the eligible stockholder making the nomination or on whose behalf the nomination is made, or any affiliate or associate thereof or
person acting in concert therewith, were the &#147;registrant&#148; for the purposes of Item 404 and the stockholder nominee were a director or executive officer of such registrant; (iv)&nbsp;the information specified for stockholder notices
described above under &#147;&#151;Special Stockholder Meetings&#148; on page 229 of this joint proxy statement/prospectus;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">board of directors must comply with the requirements set forth in Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> which are described in greater detail in the section titled &#147;&#151;Special Stockholder
Meetings&#148; beginning on page 229 of this joint proxy/prospectus.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">and (v)&nbsp;the written agreement of the eligible stockholder (or in the case of a group, each stockholder or beneficial owner whose shares are aggregated for purposes of constituting an eligible stockholder) addressed to the
corporation, which written agreement will include the eligible stockholder&#146;s: (a)&nbsp;disclosure of, and certification as to, the number of shares it owns and has owned continuously for at least three years as of the date of the stockholder
notice and agreement to continue to own such shares through the annual meeting of stockholders, which information must also be included in the Schedule 14N filed by the eligible stockholder with the SEC; (b)&nbsp;agreement to provide within five
business days of the record date of the annual meeting of stockholders, (1)&nbsp;the information required for stockholder notices under CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> and (2)&nbsp;written statements from the record
holder and intermediaries verifying the eligible stockholder&#146;s continuous ownership of the required shares, in each case, through and as of the record date; (c)&nbsp;representation and warranty that it (1)&nbsp;acquired the required shares in
the ordinary course of business and not with the intent to change or influence control at the corporation, and does not presently have any such intent, (2)&nbsp;has not nominated and will not nominate for election to the CVS Health board of
directors at the annual meeting of stockholders any person other than the stockholder nominee(s) being nominated pursuant to the proxy access provisions of the <FONT STYLE="white-space:nowrap">by-laws,</FONT> (3)&nbsp;has not engaged and will not
engage in, and has not been and will not be a participant (as defined in Item 4 of Schedule 14A under the Exchange Act) in, a solicitation within the meaning of Rule <FONT STYLE="white-space:nowrap">14a-1(l)</FONT> under the Exchange Act, in support
of the election of any individual as a director at the annual meeting of stockholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">other than its stockholder nominee(s) or a nominee of the CVS Health board of directors, and (4)&nbsp;will not distribute any form of proxy for the annual meeting of stockholders other than the form distributed by the corporation;
(d)&nbsp;agreement to (1)&nbsp;assume all liability stemming from any legal or regulatory violation arising out of the eligible stockholder&#146;s communications with the holders of CVS Health common stock or out of the information that the eligible
stockholder provided to CVS Health, (2)&nbsp;indemnify and hold harmless (jointly with all other group members, in the case of a group member) CVS Health and each of its directors, officers and employees individually against any liability, loss,
damages, expenses or other costs (including attorney&#146;s fees) in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the corporation or any of its directors, officers or
employees arising out of any nomination submitted by the eligible stockholder, (3)&nbsp;comply with all laws, rules, regulations and listing standards applicable to any solicitation in connection with the annual meeting of stockholders,
(4)&nbsp;file all applicable materials with the SEC, regardless of whether any such filing is required under Regulation 14A of the Exchange Act, or whether any exemption from filing is available for such materials thereunder, (5)&nbsp;provide to CVS
Health prior to the annual meeting of stockholders such additional information as necessary or reasonably requested by CVS Health, and (6)&nbsp;provide a statement of whether or not the eligible stockholder intends to maintain ownership of the
required shares for at least one year following the annual meeting, which statement must also be included in the Schedule 14N filed with the SEC; (e)&nbsp;in the case of a nomination by a group of</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">stockholders or beneficial owners that together is an eligible stockholder, the applicable written agreement (or another agreement or
instrument) must include a designation by all group members of one group member that is authorized to act on behalf of all such members with respect to the nomination and matters related thereto, including withdrawal of the nomination; and
(f)&nbsp;agreement to immediately notify CVS Health if the eligible stockholder ceases to own any of the required shares prior to the date of the applicable annual meeting of stockholders; <I>provided, however,</I> that this maximum number must be
reduced by (1)&nbsp;any stockholder nominee whose name was submitted for inclusion in CVS Health&#146;s proxy materials but either is subsequently withdrawn or that the CVS Health board of directors decides to nominate as a nominee to the CVS Health
board of directors, (2)&nbsp;any director candidate who had been a stockholder nominee at any of the preceding two annual meetings of stockholders and whose reelection at the upcoming annual meeting of stockholders is being recommended by the CVS
Health board of directors, (3)&nbsp;any director candidate for which CVS Health has received one or more valid shareholder notices (whether or not subsequently withdrawn) nominating director candidates, other than any such director referred to in
this clause&nbsp;(3) who at the time of such annual meeting will have served as director continuously, as a nominee of the CVS Health board of directors, for at least two annual terms, but only to the extent the maximum number after such reduction
with respect to this clause&nbsp;(3) equals or exceeds one, and</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(4)&nbsp;any director candidate who will be included in CVS Health&#146;s proxy materials
with respect to such annual meeting as an unopposed (by CVS Health) nominee pursuant to any</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">agreement, arrangement or other understanding with any stockholder or group of stockholders (other than any such agreement, arrangement or
understanding entered into in connection with an acquisition of shares of capital stock of CVS Health, by such stockholder or group of stockholders, from CVS Health), other than any such director referred to in this clause&nbsp;(4) who at the time
of such annual meeting will have served as a director continuously, as a nominee of the CVS Health board of directors, for at least annual terms, but only to the extent the maximum number after such reduction with respect to this clause&nbsp;(4)
equals or exceeds one.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">To be timely under these proxy access provisions of CVS
Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> the stockholder notice must be delivered to, or mailed and received by, the secretary at the principal office of CVS Health not earlier than the close of business on the 150th day nor
earlier than the close of business on the 120th day prior to the first anniversary of the date (as stated in CVS Health&#146;s proxy statement) the definitive proxy statement was first sent to stockholders in connection with the preceding
year&#146;s annual meeting of stockholders; provided, however, that in the event that the date of the annual meeting is advanced more than 30 days prior to the anniversary date of the preceding year&#146;s annual meeting or delayed more than 70 days
after such anniversary date, or if no annual meeting was held in the preceding year, then to be timely the stockholder notice must be received by CVS Health no earlier than the close of business on the 150th day prior to such annual meeting and no
later than the close of business on the later of (x)&nbsp;the 120th day prior to such annual meeting and (y)&nbsp;the 10th day following the day on which public</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">announcement of the date of such meeting is first made by CVS Health. The public announcement of an adjournment or postponement of an annual
meeting of stockholders will not commence a new time period (or extend any time period) for the giving of a stockholder notice in accordance with the proxy access provisions of CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws.</FONT></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> no person will
be eligible for election as a director of CVS Health unless nominated (i)&nbsp;by or at the direction of the CVS Health board of directors or (ii)&nbsp;by a stockholder who complies with the advance notice provisions summarized above.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stockholder Proposals (other than Nomination of Persons for Election as Directors)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that at an annual meeting of stockholders only such business will
be conducted, and only such proposals will be acted upon, as are properly brought before the annual meeting of stockholders (i)&nbsp;by, or at the direction of, the CVS Health board of directors or (ii)&nbsp;by a stockholder of CVS Health who
complies with the procedures set forth in CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws.</FONT> For business or a proposal to be properly brought before an annual meeting of stockholders by a stockholder, the stockholder must have given
timely notice thereof in writing to the secretary of CVS Health.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A special meeting
request for any item of business other than the nomination of any director to CVS Health&#146;s board of directors must comply with the requirements set forth in CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> which are described
in greater detail in the section titled &#147;Comparison of Stockholder Rights&#151;Special Stockholder Meetings&#148; beginning on page 229 of this joint proxy/prospectus.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> generally permit shareholders to bring business before an annual meeting of
shareholders if the shareholder intending to bring such business gives timely notice thereof in writing in proper form.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be timely, a shareholder&#146;s notice must be delivered to Aetna&#146;s corporate secretary not later than 90 calendar days prior to the date the annual
meeting is to be held, provided that the notice will be considered timely if it is received not later than the close of business on the 10th calendar day following the day on which public disclosure of the date of such meeting was made.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">To be in proper form, the notice must include as to each matter the shareholder
proposes to bring before the annual meeting (i)&nbsp;a brief description of the business desired to be brought before the annual meeting and the reasons for conducting the business at the annual meeting, (ii)&nbsp;the name and address of the
shareholder, (iii)&nbsp;evidence of the class and number of Aetna shares that are beneficially</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Notwithstanding the foregoing, none of the procedures described in the paragraphs above will be interpreted or construed to require the inclusion of information about any such proposal in any proxy statement distributed by, at the
direction of, or on behalf of, the CVS Health board of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">owned by the shareholder and (iv)&nbsp;any material interest of the shareholder in such business.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A special meeting request for any item of business other than the nomination of any
director to Aetna&#146;s board of directors must comply with the requirements set forth in Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> which are described in greater detail in the section titled &#147;Comparison of Stockholder
Rights&#151;Special Stockholder Meetings&#148; beginning on page 229 of this joint proxy/prospectus.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Limitation of Liability of Directors and Officers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delaware law provides that a corporation may limit or eliminate a director&#146;s personal liability for monetary damages to the corporation
or its stockholders for breach of fiduciary duty as a director, except for liability for: (i)&nbsp;any breach of the director&#146;s duty of loyalty to such corporation or its stockholders; (ii)&nbsp;acts or omissions not in good faith or which
involve intentional misconduct or a knowing violation of law; (iii)&nbsp;willful or negligent violation of provisions of Delaware law governing payment of dividends and stock purchases or redemptions; (iv)&nbsp;any transaction from which the
director derived an improper personal benefit; or (v)&nbsp;any act or omission before the adoption of such a provision in the certificate of incorporation.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under CVS Health&#146;s certificate of incorporation, directors are not personally liable to CVS Health or its stockholders for monetary damages for breach of
fiduciary duty as a director as a director to the fullest extent permitted by Delaware law.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna&#146;s articles provide that no directors or officers of Aetna will have personal liability to Aetna or its shareholders for monetary
damages (other than under criminal statutes and under federal, state and local laws imposing liability on directors for the payment of taxes) unless the person&#146;s conduct constitutes self-dealing, willful misconduct or recklessness.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">If Pennsylvania law is amended to authorize corporate action further eliminating or
limiting the personal liability of directors or officers, the liability of directors or officers of Aetna will be eliminated or limited to the fullest extent permitted by Pennsylvania law, as amended.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Indemnification of Directors, Officers Employees and Agents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under CVS Health&#146;s certificate of incorporation, CVS Health will indemnify and hold harmless to the fullest extent permitted by Delaware law, any person (and the heirs,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Aetna&#146;s articles, Aetna will indemnify its directors and officers and advance expenses (upon receipt of an undertaking by or on behalf of such director or officer to repay
such</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">executors or administrators of such person) who was or is a party or is threatened to be made a party to, or is involved in any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director or officer of CVS Health or is or was serving at the request of CVS Health as a
director or officer of another corporation, partnership, joint venture, trust or other enterprise. The right to indemnification conferred in CVS Health&#146;s certificate of incorporation also includes the right to be paid by CVS Health the expenses
incurred in connection with any such proceeding in advance of its final disposition to the fullest extent authorized by Delaware law. The right to indemnification conferred in CVS Health&#146;s certificate of incorporation is a contract right.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Additionally, under CVS Health&#146;s certificate of incorporation, CVS Health&#146;s
board of directors provides indemnification to such of the employees and agents of CVS Health to such extent and to such effect as the CVS Health board of directors determines to be appropriate and authorized by Delaware law.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">expenses if it is ultimately determined that such director or officer is not entitled to be indemnified by Aetna), to the fullest extent permitted by Pennsylvania law (except that Aetna is not obligated to indemnify or advance with
respect to claims initiated by the director or officer) and permit, by action of Aetna&#146;s board of directors, indemnification and advancement of expenses to its employees and agents as determined by the Aetna board of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Appraisal Rights or Dissenters&#146; Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, stockholders of a Delaware corporation have the right in certain mergers or consolidations to which the corporation is a party, to demand payment for the fair value of their shares pursuant to, and in compliance
with procedures set forth in Section&nbsp;262 of the DGCL, except in connection with a merger or consolidation with respect to shares (i)&nbsp;listed on a national securities exchange or held of record by more than 2,000 holders and (ii)&nbsp;for
which, pursuant to the plan of merger or consolidation, stockholders will receive only (a)&nbsp;shares or depository</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Pennsylvania law, unless the articles or <FONT STYLE="white-space:nowrap">by-laws</FONT> provide otherwise, shareholders of a
Pennsylvania corporation generally are not entitled to dissenters&#146; rights if the shares that would otherwise give rise to such rights are (i)&nbsp;listed on a national securities exchange or (ii)&nbsp;held beneficially or of record by more than
2,000 persons.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Neither Aetna&#146;s articles nor Aetna&#146;s <FONT
STYLE="white-space:nowrap">by-laws</FONT> contain provisions in this regard.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">receipts of another corporation which at the date the merger or consolidation is completed will be either listed on a national securities
exchange or held of record by more than 2,000 holders, (b)&nbsp;shares of stock or depositary receipts of the surviving corporation in the merger or consolidation, (c)&nbsp;cash in lieu of fractional shares or (d)&nbsp;any combination of the
foregoing. Delaware law also provides that, subject to certain exceptions, stockholders of a surviving corporation do not have appraisal rights in connection with a plan of merger if the merger did not require for its approval the vote of the
surviving corporation&#146;s stockholders. Delaware law permits the certificate of incorporation of a Delaware corporation to provide for appraisal rights in mergers or consolidations in which appraisal rights are not otherwise available and in
connection with amendments to the certificate of incorporation and sales of all or substantially all assets. CVS Health&#146;s certificate of incorporation contains no provisions giving rise to appraisal rights in such transactions.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Additionally, pursuant to Section&nbsp;262 of the DGCL, if immediately before a merger
or consolidation the shares of a class or series of stock of a corporation as to which appraisal rights are available were listed on a national securities exchange, the Delaware Court of Chancery must dismiss an appraisal proceeding as to all
stockholders who assert appraisal rights unless (i)&nbsp;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, or (ii)&nbsp;the value of the consideration provided in the
merger or consolidation for such total number of shares seeking appraisal exceeds $1&nbsp;million, or (iii)&nbsp;the merger was approved pursuant to Section&nbsp;253 or Section&nbsp;267 of the DGCL.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest will accrue thereafter as provided herein only upon
the sum of (1)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&nbsp;interest theretofore accrued, unless paid at that time.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dividends and Stock Repurchases</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under CVS Health&#146;s certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> subject to the preferential rights of any holders of outstanding preferred stock or preference stock, holders of CVS Health
common stock are entitled to receive, to the extent permitted by law, such dividends as the CVS Health board of directors may declare from time to time from funds available therefor.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subject to any rights of any outstanding series of Aetna shares senior to the Aetna common shares, the holders of Aetna common shares are entitled to such dividends as may be declared from time to time by the Aetna board of
directors from funds available therefor.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stockholder Vote on Fundamental or Extraordinary Corporate Transactions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a sale, lease or exchange of all or substantially all of a corporation&#146;s assets, an amendment to CVS Health&#146;s
certificate of incorporation, a merger or consolidation of a corporation with another corporation or a dissolution of a corporation generally requires the affirmative vote of CVS Health&#146;s board of directors and, with limited exceptions, the
affirmative vote of a majority of the aggregate voting power of the outstanding stock entitled to vote on the transaction.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">With respect to transactions with related persons (persons who own at least 10% of the outstanding capital stock of CVS Health, CVS Health&#146;s certificate
of incorporation provides that a majority of outstanding shares (excluding those owned by the related person) is required to approve such business combination transaction with a related person, unless (i)&nbsp;such</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Pennsylvania law, except in certain limited circumstances where a vote of shareholders is not required, or unless a higher vote is
required in a corporation&#146;s articles of incorporation, a plan of merger, a plan of asset transfer providing for the sale of all or substantially all of the assets of a corporation, a plan of interest exchange, division or voluntary dissolution
will be adopted upon receiving at a properly convened meeting the affirmative vote of a majority of the votes cast by all shareholders entitled to vote thereon and the affirmative vote of a majority of the votes cast in any required class vote.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Aetna&#146;s articles provide that any merger, interest exchange or division, or a sale
of all or substantially all of its assets may be adopted only upon receiving the affirmative vote of at least a majority of the votes that all</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">transaction is approved by a majority of continuing directors (directors of CVS Health who are not the related person, or an affiliate or associate thereof (or a representative or nominee of the related person or such affiliate or
associate), that is involved in the relevant business combination and (a)&nbsp;who was a member of the CVS Health board of directors immediately prior to the time that such related person became a related person or (b)&nbsp;whose initial election as
a director of CVS Health was recommended by the affirmative vote of a least a majority of the continuing directors then in office, provided that, in either such case, such continuing director has continued in office after becoming a continuing
director) or (ii)&nbsp;certain fair price requirements are met.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">voting shareholders, voting as a single class, are entitled to cast thereon and, in addition, the affirmative vote of such number or proportion of shares of any class or series of Aetna&#146;s capital stock as are then-required by
the express terms of such class or series.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>State Anti-Takeover Provisions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CVS Health has not opted out of Section&nbsp;203 of the DGCL, which provides that, if a person acquires 15% or more of the outstanding voting stock of a Delaware corporation, thereby becoming an &#147;interested stockholder&#148;,
that person may not engage in certain &#147;business combinations&#148; with the corporation, including mergers, purchases and sales of 10% or more of its assets, stock purchases and other transactions pursuant to which the percentage of the
corporation&#146;s stock owned by the interested stockholder increases (other than on a pro rata basis) or pursuant to which the interested stockholder receives a financial benefit from the corporation, for a period of three years after becoming an
interested stockholder unless one of the following exceptions applies: (i)&nbsp;the CVS Health board of directors approved the acquisition of stock pursuant to which the person became an interested stockholder or the transaction that resulted in the
person becoming an interested stockholder prior to the time that the person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Aetna&#146;s articles, Aetna has expressly opted out of the protection provided pursuant to Subchapter G of Chapter 25 of the PBCL,
which would otherwise block the voting rights of an acquiring person who makes or proposes to make a control-share acquisition, which is defined as increasing ownership in the corporation above certain thresholds. In opting out of Subchapter G of
Chapter 25 of the PBCL, Aetna also opted out of Subchapter I of Chapter 25 (providing for a minimum severance payment to certain employees terminated within two years of the approval of a control-share acquisition) and Subchapter J of Chapter 25
(prohibiting, in connection with certain &#147;control-share acquisitions,&#148; the abrogation of certain labor contracts, if any, prior to their stated date of expiration).</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Aetna has opted out of Subchapter H of Chapter 25 of the PBCL, which would otherwise
enable Aetna to recover certain profits from the sale of shares by shareholders who hold or</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">became an interested stockholder; (ii)&nbsp;upon consummation of the transaction that resulted in the person becoming an interested stockholder such person owned at least 85% of the outstanding voting stock of the corporation,
excluding, for purposes of determining the voting stock outstanding, voting stock owned by directors who are also officers and certain employee stock plans; or (iii)&nbsp;the transaction is approved by the CVS Health board of directors and by the
affirmative vote of <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder. An &#147;interested stockholder&#148; also includes the affiliates and associates of a 15% or
more owner and any affiliate or associate of the corporation who was the owner of 15% or more of the outstanding voting stock within the three-year period prior to determine whether a person is an interested stockholder.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">will hold 20% of the voting power of Aetna or who have evidenced an intent to acquire control of Aetna.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna has opted out of Subchapter E of Chapter 25 of the PBCL, which would otherwise
subject persons who acquire at least 20% of the voting power in a &#147;control transaction&#148; to an obligation to pay objecting shareholders fair value for their shares (including a proportionate amount of any control premium), determined as
provided in Section&nbsp;2547 of the PBCL.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Aetna has not opted out of Subchapter F
of Chapter 25 of the PBCL (which Subchapter is referred to in this section of this joint proxy statement/prospectus as Subchapter F), which applies to a transaction between a publicly traded corporation and an interested shareholder (defined
generally to be any beneficial owner of 20% or more of the corporation&#146;s voting shares). Subchapter F prohibits such a corporation from engaging in a &#147;business combination&#148; (as defined in the PBCL) with an &#147;interested
shareholder&#148; (as defined in the PBCL) unless (i)&nbsp;the board of directors of such corporation gives approval to the proposed transaction or gives approval to the interested shareholder&#146;s acquisition of shares that gave such person
beneficial ownership of 20% of the shares entitled to vote in an election of directors of such corporation, in either case prior to the date on which the shareholder first becomes an interested shareholder (which date is referred to in this section
of this joint proxy statement/prospectus as the share acquisition date), (ii) the interested shareholder owns at least 80% of the shares of such corporation entitled to vote in an election of directors and, no earlier than three months after such
interested shareholder reaches such 80% level, the holders of a majority of the</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">remaining shares approve the proposed transaction and shareholders receive a minimum &#147;fair price&#148; for their shares (as set forth in the PBCL) in the transaction and the other conditions of Subchapter F are met,
(iii)&nbsp;holders of all outstanding common shares approve the transaction, (iv)&nbsp;no earlier than five years after the share acquisition date, a majority of the shares held by shareholders other than the interested shareholder and entitled to
vote in an election of directors approve the transaction, or (v)&nbsp;no earlier than five years after the share acquisition date, a majority of all the shares approve the transaction, all shareholders receive a minimum &#147;fair price&#148; for
their shares (as set forth in the PBCL) and the other conditions of Subchapter F are met.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholder Rights Plan</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Delaware law does not include a statutory provision expressly authorizing stockholder rights plans, such rights plans have generally
been found to be authorized by Delaware law and have been upheld by Delaware courts where they are adopted in response to a reasonably perceived threat to CVS Health and its stockholders, and maintaining such rights plans in response to such threat
has been found to be reasonable in relation to the threat posed.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health does
not currently have a stockholder rights plan, but CVS Health&#146;s board of directors has the power under Delaware law and its certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> to adopt a stockholder rights plan in
the future, subject to its fiduciary duties.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s <FONT
STYLE="white-space:nowrap">by-laws</FONT> provide that, unless ratified by the stockholders of CVS Health, any stockholder rights plan (i)&nbsp;requires the approval of 3/4 of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pennsylvania law expressly authorizes a corporation to adopt a shareholder rights plan.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Aetna currently has no shareholder rights plan. While Aetna has no present intention to
adopt a shareholder rights plan, the Aetna board of directors retains the right to adopt such a plan at a future date pursuant to its exclusive authority to create and issue rights entitling the holders thereof to purchase from Aetna shares of
capital stock or other securities and to elect to repurchase, redeem, terminate or amend any such rights.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the CVS Health board of directors and (ii)&nbsp;expires if not so amended no later than one year following the later of the date of its adoption and the date of its last such amendment.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Preemptive Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, stockholders of a corporation do not have preemptive rights to subscribe for or purchase any additional issue of stock or
to any security convertible into such stock, unless such right is expressly included in the certificate of incorporation.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s certificate of incorporation does not provide holders of shares of CVS Health capital stock with preemptive rights.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aetna&#146;s articles provide that no holder of any class or series of Aetna capital stock will have any preemptive right to purchase or subscribe for any shares of Aetna or any security convertible into Aetna shares of any class or
series.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Duties of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the standards of conduct for directors of corporations are not statutory but are based on fiduciary duty principles developed by the Delaware courts. Generally, directors of Delaware corporations are subject to a
duty of loyalty and a duty of care. The duty of loyalty requires directors to act with the sole purpose of advancing the best interests of the corporation and its stockholders and the duty of care requires directors in managing the
corporation&#146;s affairs to use the level of care that ordinarily careful and prudent persons would use in similar circumstances. Directors owe fiduciary duties of loyalty and care to the corporation and its stockholders. Fiduciary duties are not
owed to <FONT STYLE="white-space:nowrap">non-stockholder</FONT> constituencies such as customers and employees.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Pennsylvania law, the standard of conduct for directors is governed by statute and case law. Pennsylvania law requires that a director
of a Pennsylvania corporation perform his or her duties: (i)&nbsp;in good faith, (ii)&nbsp;in a manner he or she reasonably believes to be in the best interests of the corporation, and (iii)&nbsp;with such care, including reasonable inquiry, skill
and diligence, as a person of ordinary prudence would use under similar circumstances.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In discharging their duties, directors may, in considering the best interests of their corporation, consider, among other things, to the extent they deem
appropriate: (a)&nbsp;the effects of any action upon any or all groups affected by the action, including shareholders, employees, suppliers, customers and creditors of the corporation, and upon communities in which offices or other establishments of
the corporation are located; (b)&nbsp;the short-term and long-term interests of the corporation; (c)&nbsp;the resources, intent and conduct (past, stated and potential) of any person seeking to acquire control of the corporation; and (d)&nbsp;all
other pertinent factors. In considering the</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholder Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna Shareholder Rights</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">best interests of the corporation or the effects of any action, directors are not required to regard any corporate interest or the interests of the shareholders, or any other group affected by the action, as a dominant or
controlling factor.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_146"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of CVS Health common stock to be issued to Aetna shareholders pursuant to the merger has been passed upon by
Shearman&nbsp;&amp; Sterling LLP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_147"></A>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of CVS Health incorporated by reference in CVS Health&#146;s Annual Report <FONT
STYLE="white-space:nowrap">(Form&nbsp;10-K)</FONT> for the year ended December&nbsp;31, 2016, and the effectiveness of CVS Health&#146;s internal control over financial reporting as of December&nbsp;31, 2016, have been audited by Ernst&nbsp;&amp;
Young LLP, an independent registered public accounting firm, as set forth in their reports thereon, incorporated by reference therein, and incorporated by reference herein. Such consolidated financial statements and CVS Health management&#146;s
assessment of the effectiveness of internal control over financial reporting as of December&nbsp;31, 2016 are incorporated by reference herein in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the unaudited condensed consolidated interim financial information of CVS Health as of and for the three-month periods
ended March&nbsp;31, 2017 and 2016, as of and for the three and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2017 and 2016, and as of and for the three and nine-month periods ended September&nbsp;30, 2017 and 2016,
incorporated by reference into this joint proxy statement/prospectus, Ernst&nbsp;&amp; Young LLP reported that they have applied limited procedures in accordance with professional standards for a review of such information. However, their separate
reports dated May&nbsp;2, 2017, August&nbsp;8, 2017 and November&nbsp;6, 2017, included in CVS Health&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2017, June&nbsp;30, 2017 and
September&nbsp;30, 2017, respectively, and incorporated by reference herein, state that they did not audit and they do not express an opinion on that interim financial information. Accordingly, the degree of reliance on their reports on such
information should be restricted in light of the limited nature of the review procedures applied. Ernst&nbsp;&amp; Young LLP is not subject to the liability provisions of Section&nbsp;11 of the Securities Act for their reports on the unaudited
interim financial information because those reports are not &#147;reports&#148; or &#147;parts&#148; of the registration statement prepared or certified by Ernst&nbsp;&amp; Young LLP within the meaning of Sections 7 and 11 of the&nbsp;Securities
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements and schedule of Aetna Inc. and its subsidiaries as of December&nbsp;31, 2016 and 2015, and for
each of the years in the three-year period ended December&nbsp;31, 2016, and Aetna&#146;s management&#146;s assessment of the effectiveness of Aetna&#146;s internal control over financial reporting as of December&nbsp;31, 2016, have been
incorporated by reference into this joint proxy statement/prospectus in reliance on the reports of KPMG LLP, which is referred to in this joint proxy statement/prospectus as KPMG, an independent registered public accounting firm, incorporated by
reference herein, and upon the authority of said firm as experts in accounting and auditing. With respect to the unaudited interim consolidated financial information of Aetna Inc. and its subsidiaries for the periods ended March&nbsp;31, 2017,
June&nbsp;30, 2017, and September&nbsp;30, 2017, incorporated by reference into this joint proxy statement/prospectus, KPMG has reported that they applied limited procedures in accordance with professional standards for a review of such information.
However, KPMG&#146;s separate reports included in Aetna&#146;s quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarterly periods ended March&nbsp;31, 2017, June&nbsp;30, 2017, and September&nbsp;30, 2017, and
incorporated by reference herein, state that KPMG did not audit and they do not express an opinion on that interim financial information. Accordingly, the degree of reliance on KPMG&#146;s reports on such information should be restricted in light of
the limited nature of the review procedures applied. KPMG is not subject to the liability provisions of Section&nbsp;11 of the Securities Act for their reports on the unaudited interim financial information because those reports are not
&#147;reports&#148; or &#147;parts&#148; of the registration statement prepared or certified by the accountants within the meaning of Sections 7 and 11 of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_148"></A>FUTURE STOCKHOLDER PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_149"></A>CVS Health </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health will hold an annual meeting of stockholders in 2018, which is referred to in this joint proxy statement/prospectus as the CVS Health
2018 annual meeting, regardless of whether the merger has been completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any stockholder proposals intended to be presented at the CVS
Health 2018 annual meeting and considered for inclusion in CVS Health&#146;s proxy materials must have been received by CVS Health&#146;s corporate secretary no later than the close of business Eastern Time on December&nbsp;1, 2017. Such proposals
must have been sent to: Corporate Secretary, CVS Health Corporation, One CVS Drive, Woonsocket, RI 02895. Such proposals also needed to comply with the SEC&#146;s rules and regulations, namely Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under
the Exchange Act, regarding the inclusion of stockholder proposals in CVS Health-sponsored proxy materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for a CVS Health
stockholder proposal to be raised from the floor during the CVS Health 2018 annual meeting instead of being submitted for inclusion in CVS Health&#146;s proxy statement, the stockholder&#146;s written notice must be received by CVS Health&#146;s
corporate secretary no earlier than the close of business Eastern Time on January&nbsp;10, 2018 and no later than the close of business Eastern Time on February&nbsp;9, 2018 and must contain the information required by CVS Health&#146;s <FONT
STYLE="white-space:nowrap">by-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may contact CVS Health&#146;s corporate secretary at CVS Health&#146;s headquarters, One
CVS Drive, Woonsocket, RI 02895, for a copy of the relevant provisions of CVS Health&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> regarding the requirements for making stockholder proposals and nominating director candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom482402_150"></A>Aetna </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
merger is not completed by the expected date of Aetna&#146;s 2018 annual meeting of shareholders, Aetna plans to hold such annual meeting. Any shareholder proposals intended to be presented at the Aetna 2018 annual meeting and considered for
inclusion in Aetna&#146;s proxy materials, should such annual meeting be held, must have been received by Aetna&#146;s corporate secretary no later than the close of business Eastern Time on December&nbsp;8, 2017. Such proposals must have been sent
to: Corporate Secretary, Aetna Inc., 151 Farmington Avenue, RW61, Hartford, CT 06156. Such proposals also needed to comply with the SEC&#146;s rules and regulations, namely Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act,
regarding the inclusion of shareholder proposals in Aetna-sponsored proxy materials. Shareholder proposals failing to comply with the procedures of Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act will be excluded. If the
scheduled date of Aetna&#146;s 2018 annual meeting of shareholders is changed by more than 30 days, shareholders will be informed of the new meeting date and the revised date by which shareholder proposals must be received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for an Aetna shareholder proposal to be raised from the floor during the Aetna 2018 annual meeting instead of being submitted for
inclusion in Aetna&#146;s proxy statement, the shareholder&#146;s written notice must be received by Aetna&#146;s corporate secretary at least 90 calendar days before the date of the Aetna 2018 annual meeting and must contain the information
required by Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aetna shareholders may propose director candidates for
consideration by the nominating committee of Aetna&#146;s board of directors. In addition, Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws</FONT> permit shareholders to nominate directors for consideration at an Aetna meeting of shareholders
at which one or more directors are to be elected. In order to nominate a director candidate at the Aetna 2018 annual meeting, should such annual meeting be held, the shareholder&#146;s written request must be received by Aetna&#146;s corporate
secretary at least 90 calendar days before the date of the Aetna 2018 annual meeting and must contain the information required by Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also contact Aetna&#146;s corporate secretary at Aetna&#146;s headquarters, 151 Farmington Avenue, RW61, Hartford, CT 06156 for a copy
of the relevant provisions of the Aetna <FONT STYLE="white-space:nowrap">by-laws</FONT> regarding the requirements for making shareholder proposals and nominating director candidates. You can also visit Aetna&#146;s website and download a copy of
Aetna&#146;s <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_151"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health has filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> to register with the SEC the shares of CVS
Health common stock to be issued to Aetna shareholders in connection with the merger. This joint proxy statement/prospectus is a part of that registration statement and constitutes a prospectus of CVS Health in addition to being proxy statements of
CVS Health and Aetna for their respective special meetings. The registration statement, including the attached exhibits and schedules, contains additional relevant information about CVS Health and the shares of CVS Health common stock. The rules and
regulations of the SEC allow CVS Health and Aetna to omit certain information included in the registration statement from this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health and Aetna file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy
this information at the SEC&#146;s Public Reference Room, 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the operation of the Public Reference Room. The SEC also maintains a website that
contains reports, proxy statements and other information about CVS Health and Aetna. The address of that site is http://www.sec.gov. The reports and other information filed by CVS Health and Aetna with the SEC are also available at their respective
websites, which are http://www.cvshealth.com and http://www.aetna.com. Information on these websites is not part of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows CVS Health and Aetna to &#147;incorporate by reference&#148; information into this joint proxy statement/prospectus. This means
that important information can be disclosed to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this joint proxy statement/prospectus, except for any
information superseded by information in this joint proxy statement/prospectus or in later filed documents incorporated by reference into this joint proxy statement/prospectus. This joint proxy statement/prospectus incorporates by reference the
documents set forth below that CVS Health and Aetna have, respectively, previously filed with the SEC and any additional documents that either company may file with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act between the
date of this joint proxy statement/prospectus and the respective dates of the Aetna and CVS Health special meetings (other than, in each case, those documents, or the portions of those documents or exhibits thereto, deemed to be furnished and not
filed in accordance with SEC rules). These documents contain important information about CVS Health and Aetna and their respective financial performance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health SEC Filings<BR>(File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Period</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fiscal year ended December&nbsp;31, 2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fiscal quarters ended March&nbsp;31, 2017, June&nbsp;30, 2017 and September&nbsp;30, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proxy Statement on Schedule 14A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Filed on March&nbsp;31, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Filed on March&nbsp;2, 2017, May&nbsp;12, 2017, December&nbsp;4, 2017, December&nbsp;5, 2017, December&nbsp;19, 2017, February&nbsp;1, 2018 and February&nbsp;6, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any description of shares of CVS Health common stock contained in a registration statement filed
pursuant to the Exchange Act and any amendment or report filed for the purpose of updating such description</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aetna SEC Filings<BR>(File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-16095)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Period</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fiscal year ended December&nbsp;31, 2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fiscal quarters ended March&nbsp;31, 2017, June&nbsp;30, 2017, and September&nbsp;30, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proxy Statement on Schedule 14A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Filed on April&nbsp;7, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Filed on January&nbsp;26, 2017, February&nbsp;14, 2017 (excluding information furnished under Item 7.01), February&nbsp;22, 2017, February&nbsp;27, 2017, March&nbsp;21, 2017, May&nbsp;24, 2017, August&nbsp;10, 2017,
October&nbsp;2, 2017, October&nbsp;23, 2017, October&nbsp;26, 2017, November&nbsp;1, 2017, December&nbsp;4, 2017, December&nbsp;6, 2017, December&nbsp;22, 2017, January&nbsp;25, 2018 and February 1, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any description of Aetna common shares contained in a registration statement filed pursuant to the
Exchange Act and any amendment or report filed for the purpose of updating such description</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health has supplied all information contained in or incorporated by reference into this joint proxy
statement/prospectus relating to CVS Health, as well as all pro forma financial information, and Aetna has supplied all such information relating to Aetna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Documents incorporated by reference are available from CVS Health or Aetna, as the case may be, without charge, excluding any exhibits to
those documents, unless the exhibit is specifically incorporated by reference into this joint proxy statement/prospectus. Aetna shareholders or CVS Health stockholders, as applicable, may obtain these documents incorporated by reference by
requesting them in writing or by telephone from the appropriate party at the following addresses and telephone numbers: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CVS Health
Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One CVS Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Woonsocket, RI 02895 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention:
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (800) <FONT STYLE="white-space:nowrap">201-0938</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 Farmington Avenue
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hartford, CT 06156 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention:
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: <FONT STYLE="white-space:nowrap">(860)&nbsp;273-2402</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>To obtain timely delivery of the documents, you must request them no later than five business days before the date of the applicable
special meeting. Therefore, if you would like to request documents from CVS Health, please do so by March 6, 2018 in order to receive them before the CVS Health special meeting. If you would like to request documents from Aetna, please do so by
March 6, 2018 in order to receive them before the Aetna special meeting. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or
incorporated by reference into this joint proxy statement/prospectus to vote on the approval and adoption of the merger agreement, the Aetna adjournment proposal, the Aetna compensation advisory proposal, the approval of the stock issuance and the
CVS Health adjournment proposal. Neither CVS Health nor Aetna has authorized anyone to provide you with information that is different from what is contained in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are in a jurisdiction where offers to exchange or sell, or solicitations of offers to exchange or purchase, the securities offered by
this joint proxy statement/prospectus or solicitations of proxies are unlawful, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this joint proxy statement/prospectus does not extend to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus is dated February 9, 2018. You should not assume that the information in it is accurate as of any date
other than that date, and neither its mailing to Aetna shareholders or CVS Health stockholders nor the issuance of shares of CVS Health common stock in the merger will create any implication to the contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="ii482402_anxacov"></A><A NAME="rom482402_153"></A>Annex<A NAME="rom482402_152"></A> A </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>CONFIDENTIAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>EXECUTION&nbsp;VERSION</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>dated as of </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;3, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>among </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH
CORPORATION, </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HUDSON MERGER SUB CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AETNA INC.
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;1.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;1.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Other Definitional and Interpretative Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CLOSING; THE MERGER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.03.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conversion of Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.04.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Surrender and Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.05.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Dissenters Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.06.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Company Equity Awards; Company ESPP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.07.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Adjustments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.08.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fractional Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.09.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Withholding Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lost Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;2.11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;III</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ORGANIZATIONAL DOCUMENTS; DIRECTORS AND OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;3.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Articles of Incorporation and Bylaws of the Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;3.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Directors and Officers of the Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;IV</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Existence and Power</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Authorization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.03.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Governmental Authorization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.04.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Non-contravention</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.05.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.06.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.07.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SEC Filings and the Sarbanes-Oxley Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.08.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Financial Statements and Financial Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.09.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Disclosure Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Statutory Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Reserves</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Capital or Surplus Maintenance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.13.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Absence of Certain Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.14.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Undisclosed Material Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.15.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.16.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.17.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Compliance with Applicable Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.18.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.19.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.20.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employees and Employee Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.21.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.22.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.23.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Properties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.24.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.25.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.26.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.27.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Antitakeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.28.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Opinions of Financial Advisors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.29.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Finders&#146; Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.30.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Ownership of Parent Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;4.31.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Other Company Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;V</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">REPRESENTATIONS AND WARRANTIES OF PARENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Existence and Power</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Authorization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.03.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Governmental Authorization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.04.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Non-contravention</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.05.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.06.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.07.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SEC Filings and the Sarbanes-Oxley Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.08.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Financial Statements and Financial Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.09.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Disclosure Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-46</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Absence of Certain Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Undisclosed Material Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.13.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.14.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Compliance with Applicable Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.15.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.16.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employees and Employee Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.17.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.18.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.19.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.20.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Antitakeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.21.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Opinions of Financial Advisors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.22.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Finders&#146;&nbsp;Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.23.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Ownership of Company Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.24.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;5.25.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Other Parent Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;VI</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">COVENANTS OF THE COMPANY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conduct of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-54</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Solicitation by the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.03.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Financing Assistance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.04.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indentures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;6.05.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">280G Calculation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;VII</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">COVENANTS OF PARENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conduct of Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Solicitation by Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.03.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Obligations of Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.04.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director and Officer Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.05.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employee Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;7.06.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;VIII</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">COVENANTS OF PARENT AND THE COMPANY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Access to Information; Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Reasonable Best Efforts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.03.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Certain Filings; SEC Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.04.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shareholder and Stockholder Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.05.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Public Announcements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.06.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notices of Certain Events</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.07.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section 16 Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.08.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Transaction Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.09.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Exchange Delisting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Governance and Social Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;8.12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">State Takeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;IX</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CONDITIONS TO THE MERGER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conditions to the Obligations of Each Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conditions&nbsp;to&nbsp;the&nbsp;Obligations&nbsp;of&nbsp;Parent&nbsp;and&nbsp;Merger&nbsp;Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;9.03.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conditions to the Obligations of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;10.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-82</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;10.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;10.03.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Termination Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ARTICLE&nbsp;XI</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">MISCELLANEOUS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.01.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.02.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.03.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amendments and Waivers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.04.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.05.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Disclosure Schedule References and SEC Document References</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.06.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Binding Effect; Benefit; Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.07.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.08.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jurisdiction/Venue</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.09.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">WAIVER OF JURY TRIAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Counterparts; Effectiveness</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;11.13.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Specific Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>EXHIBITS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Exhibit A - Articles of Incorporation of Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AGREEMENT AND PLAN OF MERGER (this &#147;<U>Agreement</U>&#148;), dated as of December&nbsp;3, 2017, among CVS Health Corporation, a Delaware
corporation (&#147;<U>Parent</U>&#148;), Hudson Merger Sub Corp., a Pennsylvania corporation and a wholly owned Subsidiary of Parent (&#147;<U>Merger Sub</U>&#148;), and Aetna Inc., a Pennsylvania corporation (the &#147;<U>Company</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of the Company has unanimously (i)&nbsp;determined that this Agreement and the transactions contemplated
hereby (including the Merger) are fair to and in the best interests of the Company and its shareholders, (ii)&nbsp;approved, adopted and declared advisable this Agreement and the transactions contemplated hereby (including the Merger),
(iii)&nbsp;directed that this Agreement (including the Merger) be submitted to a vote at a meeting of the Company&#146;s shareholders, and (iv)&nbsp;recommended the approval and adoption of this Agreement (including the Merger) by the Company&#146;s
shareholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of Parent has unanimously (i)&nbsp;determined that this Agreement and the transactions
contemplated hereby (including the Parent Share Issuance) are fair to and in the best interests of Parent&#146;s stockholders, (ii)&nbsp;approved, adopted and declared advisable this Agreement and the transactions contemplated hereby (including the
Parent Share Issuance), (iii)&nbsp;directed that the Parent Share Issuance be submitted to a vote at a meeting of Parent&#146;s stockholders, and (iv)&nbsp;recommended the approval of the Parent Share Issuance by Parent&#146;s stockholders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of Merger Sub has unanimously (i)&nbsp;approved, adopted and declared advisable this Agreement and the
transactions contemplated hereby (including the Merger), and (ii)&nbsp;directed that this Agreement be submitted for approval and adoption by the sole shareholder of Merger Sub; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, Parent and Merger Sub desire to make certain representations, warranties, covenants and agreements specified in this
Agreement in connection with the Merger and to prescribe certain conditions to the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the
foregoing and the representations, warranties, covenants and agreements contained in this Agreement, the parties agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_1">
</A>Section&nbsp;1.01. <U>Definitions</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) As used in this Agreement, the following terms have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>1933 Act</U>&#148; means the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>1934 Act</U>&#148; means the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under
common control with such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Antitrust Laws</U>&#148; shall mean the Sherman Act of 1890, the Clayton Act of 1914, the
Federal Trade Commission Act of 1914, the HSR Act and all other federal, state and foreign Applicable Laws in effect from time to time that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of
monopolization or restraint of trade. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Applicable Law(s)</U>&#148; means, with respect to any Person, any federal, state
or local law (statutory, common or otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, executive order, Order or other similar requirement (including any federal, state or local directive or other requirement that
relates to Medicare or Medicaid) enacted, adopted, promulgated or applied by a Governmental Authority that is binding upon or applicable to such Person, as the same may be amended from time to time unless expressly specified otherwise in this
Agreement. References to &#147;Applicable Law&#148; or &#147;Applicable Laws&#148; shall be deemed to include Health Care Laws, any applicable Insurance Law and Antitrust Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ASOPs</U>&#148; means actuarial standards of practice promulgated by the Actuarial Standards Board for use by actuaries when
providing professional services in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Benefits Continuation Period</U>&#148; means the period from the Closing
Date through the later of (i)&nbsp;the first anniversary of the Closing Date and (ii)&nbsp;May 31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148;
means a day, other than Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by Applicable Law to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CMS</U>&#148; means the Centers for Medicare&nbsp;&amp; Medicaid Services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Acquisition Proposal</U>&#148; means any indication of interest, proposal or offer from any Person or Group, other than
Parent and its Subsidiaries, relating to any (i)&nbsp;direct or indirect acquisition (whether in a single transaction or a series of related transactions) of assets of the Company or its Subsidiaries (including securities of Subsidiaries) equal to
20% or more of the consolidated assets of the Company, or to which 20% or more of the revenues or earnings of the Company on a consolidated basis are attributable, (ii)&nbsp;direct or indirect acquisition or issuance (whether in a single transaction
or a series of related transactions) of 20% or more of any class of equity or voting securities of the Company, (iii)&nbsp;tender offer or exchange offer that, if consummated, would result in such Person or Group beneficially owning 20% or more of
any class of equity or voting securities of the Company, or (iv)&nbsp;merger, consolidation, share exchange, business combination, joint venture, reorganization, recapitalization, liquidation, dissolution or similar transaction involving the
Company, under which such Person or Group would acquire, directly or indirectly, (A)&nbsp;assets equal to 20% or more of the consolidated assets of the Company, or to which 20% or more of the revenues or earnings of the Company on a consolidated
basis are attributable, or (B)&nbsp;beneficial ownership of 20% or more of any class of equity or voting securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Balance Sheet</U>&#148; means the consolidated balance sheet of the Company and its Subsidiaries as of December&nbsp;31,
2016, and the footnotes to such consolidated balance sheet, in each case set forth in the Company&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Balance Sheet Date</U>&#148; means December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Common Stock</U>&#148; means the common shares, $0.01 par value, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Disclosure Schedule</U>&#148; means the Company Disclosure Schedule delivered to Parent on the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Employee Plan</U>&#148; means any (i) &#147;employee benefit plan&#148; as defined in Section&nbsp;3(3) of ERISA,
(ii)&nbsp;compensation, employment, consulting, severance, termination protection, change in control, transaction bonus, retention or similar plan, agreement, arrangement, program or policy, or (iii)&nbsp;other plan, agreement, arrangement, program
or policy providing for compensation, bonuses, profit-sharing, equity or equity-based compensation or other forms of incentive or deferred compensation, vacation benefits, insurance (including any self-insured arrangement), medical, dental, vision,
prescription or fringe benefits, life insurance, relocation or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expatriate benefits, perquisites, disability or sick leave benefits, employee assistance program, workers&#146; compensation, supplemental unemployment benefits or post-employment or retirement
benefits (including compensation, pension, health, medical or insurance benefits), in each case whether or not written (x)&nbsp;that is sponsored, maintained, administered, contributed to or entered into by the Company or any of its Subsidiaries for
the current or future benefit of any director, officer, employee or individual independent contractor (including any former director, officer, employee or individual independent contractor) of the Company or any of its Subsidiaries or (y)&nbsp;for
which the Company or any of its Subsidiaries has any direct or indirect liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity Awards</U>&#148; means Company
Stock Appreciation Rights, Company RSU Awards and Company PSU Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Intellectual Property</U>&#148; means the Owned
Intellectual Property and the Licensed Intellectual Property, in each case, of the Company and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company
Material Adverse Effect</U>&#148;<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>means a material adverse effect on the financial condition, business or results of operations of the Company and its Subsidiaries, taken as a whole;
<I>provided</I> that no event, change, effect, development or occurrence to the extent resulting from, arising out of, or relating to any of the following shall be deemed to constitute, or shall be taken into account in determining whether there has
been, a Company Material Adverse Effect, or whether a Company Material Adverse Effect would reasonably be expected to occur: (i)&nbsp;any changes in general United States or global economic conditions, (ii)&nbsp;any changes in conditions generally
affecting the health insurance or managed care industry (including the Medicare Advantage managed care industry) or any other industry in which the Company or any of its Subsidiaries operate, (iii)&nbsp;any decline, in and of itself, in the market
price or trading volume of the Company Common Stock (it being understood and agreed that the foregoing shall not preclude Parent from asserting that any facts or occurrences giving rise to or contributing to such decline that are not otherwise
excluded from the definition of Company Material Adverse Effect should be deemed to constitute, or be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect), (iv) any
changes in regulatory, legislative or political conditions or in securities, credit, financial, debt or other capital markets, in each case in the United States or any foreign jurisdiction, (v)&nbsp;any failure, in and of itself, by the Company or
any of its Subsidiaries to meet any internal or published projections, forecasts, estimates or predictions in respect of enrollments, revenues, earnings or other financial or operating metrics for any period (it being understood and agreed that the
foregoing shall not preclude Parent from asserting that any facts or occurrences giving rise to or contributing to such failure that are not otherwise excluded from the definition of Company Material Adverse Effect should be deemed to constitute, or
be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect), (vi) the execution and delivery of this Agreement, the public announcement or the pendency of this Agreement or
the Merger, the taking of any action required or expressly contemplated by this Agreement or the identity of, or any facts or circumstances relating to Parent or any of its Subsidiaries, including the impact of any of the foregoing on the
relationships, contractual or otherwise, of the Company or any of its Subsidiaries with Governmental Authorities, customers, Providers, suppliers, partners, officers or employees (it being understood and agreed that the foregoing shall not apply
with respect to any representation or warranty that is intended to address the consequences of the execution, delivery or performance of this Agreement or the consummation of the transactions contemplated hereby), (vii)&nbsp;any adoption,
implementation, promulgation, repeal, modification, amendment, authoritative interpretation, change or proposal of any Applicable Law of or by any Governmental Authority, (viii)&nbsp;any changes in GAAP, SAP or ASOPs (or authoritative
interpretations thereof), (ix) any changes in geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage, cyberattack or terrorism, or any escalation or worsening of any such acts of war, sabotage, cyberattack or
terrorism threatened or underway as of the date of this Agreement, (x)&nbsp;any taking of any action at the written request of or with the consent of Parent (it being understood and agreed that, with respect to any action taken with such consent,
the foregoing shall not preclude Parent from asserting that any facts or occurrences resulting from such action that are not otherwise excluded from the definition of Company Material Adverse Effect should be deemed to constitute, or be taken into
account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect), (xi) any reduction in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
credit rating of the Company or any of its Subsidiaries (it being understood and agreed that the foregoing shall not preclude Parent from asserting that any facts or occurrences giving rise to or
contributing to such reduction that are not otherwise excluded from the definition of Company Material Adverse Effect should be deemed to constitute, or be taken into account in determining whether there has been, or would reasonably be expected to
be, a Company Material Adverse Effect), (xii) any epidemic, plague, pandemic or other outbreak of illness or public health event, hurricane, earthquake, flood or other natural disasters, acts of God or any change resulting from weather conditions,
(xiii)&nbsp;any changes to reimbursement rates or in methods or procedures for determining such rates, any changes to eligibility requirements or any other programmatic changes by any Governmental Authority, in each case, whether such changes are
applicable nationally or to only certain geographic areas, or (xiv)&nbsp;any claims, actions, suits or proceedings arising from allegations of a breach of fiduciary duty or violation of Applicable Law relating to this Agreement or the Merger, except
in the case of each of clauses (i), (ii), (iv), (vii), (viii) or (xiii), to the extent that any such event, change, effect, development or occurrence has a materially disproportionate adverse effect on the Company and its Subsidiaries, taken as a
whole, relative to the adverse effect such event, change, effect, development or occurrence has on other companies operating in the industries in which the Company and its Subsidiaries operate (it being understood and agreed that any such
disproportionate effect on the Company and its Subsidiaries to the extent resulting from the greater concentration of the businesses of the Company and its Subsidiaries in any particular industry or geography relative to other companies operating in
the industries in which the Company and its Subsidiaries operate shall not be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Stock Plans</U>&#148; means the Aetna Inc. 2016 Employee Stock Purchase Plan, the Amended Aetna Inc. 2010 Stock Incentive
Plan, the Aetna Inc. 2010 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Plan, the Aetna Inc. 2000 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Plan, and the Amended and Restated Aetna Inc.
2000 Stock Incentive Plan, in each case, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Consent</U>&#148; means any consent, approval, waiver,
license, permit, variance, exemption, franchise, clearance, authorization, acknowledgment, Order or other confirmation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; means any contract, agreement, obligation, understanding or instrument, lease or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Credit Agreement</U>&#148; means the Five-Year Credit Agreement, dated as of March&nbsp;27, 2012, among the Company, the several
banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, Bank of America, N.A., and Citibank, N.A., as <FONT STYLE="white-space:nowrap">Co-Syndication</FONT> Agents, Wells Fargo
Bank, National Association and U.S. Bank, N.A., as Documentation Agents, and J.P. Morgan Securities Inc., Citigroup Global Markets, Inc. and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, as Joint Lead Arrangers and Joint Bookrunners.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Delaware Law</U>&#148; means the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Law</U>&#148; means any Applicable Law relating to (i)&nbsp;the protection, preservation or restoration of the
environment (including air, surface water, groundwater, drinking water supply, surface land, subsurface land, plant and animal life or any other natural resource), or (ii)&nbsp;the exposure to, or the use, storage, recycling, treatment, generation,
transportation, processing, handling, labeling, production, release or disposal of Hazardous Substances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental
Permits</U>&#148; means all permits, licenses, franchises, consents (including consents required by Contract), variances, exemptions, orders, certificates, approvals and other similar authorizations of Governmental Authorities required by
Environmental Law and affecting, or relating to, the business of the Company or any of its Subsidiaries, or the business of Parent or any of its Subsidiaries, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity Award Exchange Ratio</U>&#148; means the sum of (i)&nbsp;the Share Consideration, <I>plus</I> (ii)&nbsp;the quotient of
(x)&nbsp;the Cash Consideration <I>divided by</I> (y)&nbsp;the Parent Stock Price, rounded to the nearest one thousandth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA</U>&#148; means the Employee Retirement Income Security Act of 1974. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA Affiliate</U>&#148; means, with respect to any entity, any other entity that, together with such entity, would be treated as a
single employer under Section&nbsp;414 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Filing</U>&#148; means any registration, petition, statement, application,
schedule, form, declaration, notice, notification, report, submission or other filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Financing Sources</U>&#148; means the
Persons that have entered or will enter into commitment letters or agreements with Parent in connection with the Debt Financing (including any Persons providing Alternative Financing and including, for purposes of
<U>Section</U><U></U><U>&nbsp;6.03(a)</U>, any Persons providing any permanent financing referred to in the Debt Commitment Letters) and any joinder agreements, indentures or credit agreements entered into pursuant thereto, including the agents,
arrangers, lenders and other entities that have committed to provide or arrange all or part of the Debt Financing, and their respective Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means United States generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Government Sponsored Health Care Programs</U>&#148; means (i)&nbsp;the Medicare program established under and governed by the
applicable provisions of Title XVIII of the Social Security Act, the regulations promulgated thereunder and any <FONT STYLE="white-space:nowrap">sub-regulatory</FONT> guidance issued, (ii)&nbsp;the Medicaid program governed by the applicable
provisions of Title XIX of the Social Security Act, the regulations promulgated thereunder, as well as any state&#146;s Applicable Laws implementing the Medicaid program, (iii)&nbsp;the Federal Employees Health Benefit Program, and (iv)&nbsp;any
other state or federal health care program or plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Authority</U>&#148; means any transnational, domestic or
foreign federal, state or local governmental, regulatory or administrative authority, department, court, agency, commission or official, including any political subdivision thereof, or any <FONT STYLE="white-space:nowrap">non-governmental</FONT>
self-regulatory agency, commission or authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Group</U>&#148; means a &#147;group&#148; as defined in Section&nbsp;13(d) of
the 1934 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Hazardous Substance</U>&#148; means any substance, material or waste that is listed, defined, designated or
classified as hazardous, toxic, radioactive, dangerous or a &#147;pollutant&#148; or &#147;contaminant&#148; or words of similar meaning under any Applicable Law relating to the environment or natural resources or that is otherwise regulated by any
Governmental Authority with jurisdiction over the environment or natural resources, including petroleum or any derivative or byproduct thereof, radon, radioactive material, asbestos or asbestos-containing material, urea formaldehyde, foam insulation
or polychlorinated biphenyls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Health Care Laws</U>&#148; means all Applicable Laws relating to: (i)&nbsp;the licensure,
certification, qualification or authority to transact business in connection with the provision of, payment for, or arrangement of, health care services, health benefits or health insurance, including Applicable Laws that regulate Providers, managed
care, third party payors and Persons bearing the financial risk for, or providing administrative or other functions in connection with, the provision of, payment for or arrangement of health care services and, including all Applicable Laws relating
to Health Care Programs pursuant to which any Regulated Subsidiary of the Company or Parent, as applicable, is required to be licensed or authorized to transact business; (ii)&nbsp;health care or insurance fraud or abuse, including the solicitation
or acceptance of improper incentives involving persons operating in the health care industry, patient referrals or Provider incentives generally, including the following statutes: the Federal anti-kickback law (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7b),</FONT> the Stark Law (42 U.S.C. &#167; 1395nn), the Federal False Claims Act (31 U.S.C. &#167;&#167; 3729, et seq.), the Federal Civil Monetary Penalties Law (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the Federal Program Fraud Civil Remedies Act (31 U.S.C. &#167; 3801 et seq.) and the Federal Health Care Fraud Law (18 U.S.C. &#167; 1347); (iii)&nbsp;the provision of administrative, management or
other services related to any Health Care Programs, including the administration of health care claims or benefits or processing or payment for health care items and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services, treatment or supplies furnished by Providers, including the provision of the services of third party administrators, utilization review agents and Persons performing quality assurance,
credentialing or coordination of benefits; (iv)&nbsp;the licensure, certification, qualification or authority to transact business in connection with the provision of, or payment for, pharmacy services, along with the requirements of the U.S. Drug
Enforcement Administration in connection therewith, including 21 U.S.C. &#167; 801 et. seq., commonly referred to as the &#147;Controlled Substances Act&#148; and any similar state laws governing the prescribing or dispensing of controlled
substances; (v)&nbsp;the Consolidated Omnibus Budget Reconciliation Act of 1985; (vi)&nbsp;ERISA; (vii)&nbsp;the Medicare Prescription Drug, Improvement, and Modernization Act of 2003; (viii)&nbsp;the Medicare Improvements for Patients and Providers
Act of 2008; (ix)&nbsp;privacy, security, integrity, accuracy, transmission, storage or other protection of information about or belonging to actual or prospective participants in the Company&#146;s Health Care Programs or other lines of business,
including the Health Insurance Portability and Accountability Act of 1996 (Pub. L. <FONT STYLE="white-space:nowrap">No.&nbsp;104-191),</FONT> as amended by the Health Information Technology for Economic and Clinical Health Act (Pub. L. <FONT
STYLE="white-space:nowrap">No.&nbsp;111-5),</FONT> including any other Applicable Laws relating to medical information; (x)&nbsp;the Patient Protection and Affordable Care Act (Pub. L. <FONT STYLE="white-space:nowrap">111-148)</FONT> as amended by
the Health Care and Education Reconciliation Act of 2010 (Pub. L. <FONT STYLE="white-space:nowrap">111-152);</FONT> (xi)&nbsp;the claims made or promotional or marketing efforts undertaken by the Company or any of its Subsidiaries with respect to
prescription drugs or controlled substances; (xii)&nbsp;42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a(a)(5),</FONT> 42 C.F.R. &#167; 1003.101, commonly referred to as the &#147;Beneficiary Inducement Law&#148;; (xiii)&nbsp;the U.S. Food
and Drug Administration; (xiv)&nbsp;restricting the corporate practice of medicine or fee splitting by licensed healthcare professionals; (xv)&nbsp;the practice of pharmacy, the operation of pharmacies, the wholesale distribution, dispensing,
labeling, packaging, repackaging, advertising, adulteration or compounding of drug products or controlled substances;&nbsp;(xvi) the provision of pharmacy benefit management, utilization review and healthcare discount card programs and services;
(xvii)&nbsp;federal or state laws related to billing or claims for reimbursement for health care items and services submitted to any third party payor; (xviii)&nbsp;healthcare risk sharing products, services and arrangements; and (xix)&nbsp;any
state unfair and deceptive trade acts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Health Care Programs</U>&#148; means all lines of business, programs and types of
services offered by the Company or any of its Subsidiaries or Parent or any of its Subsidiaries that involve or relate to providing, arranging to provide, reimbursing, or otherwise administering health care services, as applicable, including
Government Sponsored Health Care Programs, commercial risk (individual, small group, large group), workers compensation, the Federal Employees Health Benefits Program (FEHBP), the Children&#146;s Health Insurance Program (CHIP), TRICARE,
administrative services only (ASO) and network rental, including self-funded group health plans.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HSR Act</U>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Insurance Laws</U>&#148; means all state and federal laws, regulations, subregulatory guidance, bulletins, licensure standards,
permits, approvals, or other requirements applicable to the provision of, payment for, or arrangement of any type of insurance coverage, including health insurance, life insurance, disability insurance, long term care insurance, critical illness
insurance, specific disease insurance, travel insurance, travel health insurance, reinsurance, home insurance, renters insurance, vehicle insurance, and liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; means any and all of the following, whether or not registered, and all rights therein, arising in the
United States or any other jurisdiction throughout the world: (i)&nbsp;trademarks, service marks, trade names, Internet domain names, Internet account names (including social networking and media names) and other indicia of origin, together with all
goodwill associated therewith or symbolized thereby, and all registrations and applications relating to the foregoing; (ii)&nbsp;patents and pending patent applications, and all divisions, continuations, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues and reexaminations, and any extensions thereof; (iii)&nbsp;registered and unregistered copyrights (including those in Software), all registrations and applications to register
the same, and all renewals, extensions, reversions and restorations thereof; (iv)&nbsp;trade secrets and rights in confidential technology and information, <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, processes, formulae,
algorithms, models and methodologies; (v)&nbsp;rights in Software; and (vi)&nbsp;other similar types of proprietary rights or intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>IT Assets</U>&#148; means any and all computers, Software, firmware, middleware,
servers, workstations, routers, hubs, switches, data communications lines and other information technology equipment, and all associated documentation, owned by, or licensed or leased to, the Company or any of its Subsidiaries, or Parent or any of
its Subsidiaries, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>knowledge</U>&#148; of any Person that is not an individual means the actual knowledge of those
executive officers of the Company or Parent, as the case may be, set forth in Section&nbsp;1.01 of the Company Disclosure Schedule or Section&nbsp;1.01 of the Parent Disclosure Schedule, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensed Intellectual Property</U>&#148; means any and all Intellectual Property owned by a Third Party and licensed or sublicensed
to the Company or any of its Subsidiaries, or Parent or any of its Subsidiaries, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; means, with
respect to any property or asset, any mortgage, lien, license, pledge, charge, security interest, encumbrance or other adverse claim of any kind in respect of such property or asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Major Subsidiary</U>&#148; means, with respect to any Person, each Subsidiary of such Person that is a &#147;significant
subsidiary&#148; (as defined in Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> of such Person or a Regulated Subsidiary of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; means any order, writ, decree, judgment, award, injunction, ruling, settlement or stipulation issued, promulgated,
made, rendered or entered into by or with any Governmental Authority or arbitrator (in each case, whether temporary, preliminary or permanent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Owned Intellectual Property</U>&#148; means any and all Intellectual Property owned or purported to be owned by the Company or any of
its Subsidiaries, or Parent or any of its Subsidiaries, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Acquisition Proposal</U>&#148; means any
indication of interest, proposal or offer from any Person or Group, other than the Company and its Subsidiaries, relating to any (i)&nbsp;direct or indirect acquisition (whether in a single transaction or a series of related transactions) of assets
of Parent or its Subsidiaries (including securities of Subsidiaries) equal to 20% or more of the consolidated assets of Parent, or to which 20% or more of the revenues or earnings of Parent on a consolidated basis are attributable, (ii)&nbsp;direct
or indirect acquisition or issuance (whether in a single transaction or a series of related transactions) of 20% or more of any class of equity or voting securities of Parent, (iii)&nbsp;tender offer or exchange offer that, if consummated, would
result in such Person or Group beneficially owning 20% or more of any class of equity or voting securities of Parent, or (iv)&nbsp;merger, consolidation, share exchange, business combination, joint venture, reorganization, recapitalization,
liquidation, dissolution or similar transaction involving Parent, under which such Person or Group would acquire, directly or indirectly, (A)&nbsp;assets equal to 20% or more of the consolidated assets of Parent, or to which 20% or more of the
revenues or earnings of Parent on a consolidated basis are attributable, or (B)&nbsp;beneficial ownership of 20% or more of any class of equity or voting securities of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Balance Sheet</U>&#148; means the consolidated balance sheet of Parent and its Subsidiaries as of December&nbsp;31, 2016, and
the footnotes to such consolidated balance sheet, in each case set forth in Parent&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Balance Sheet Date</U>&#148; means December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Common Stock</U>&#148; means the common stock, $0.01 par value, of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Disclosure Schedule</U>&#148; means the Parent Disclosure Schedule delivered to the Company on the date of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Employee Plan</U>&#148; means any (i) &#147;employee benefit plan&#148; as defined in Section&nbsp;3(3) of ERISA,
(ii)&nbsp;compensation, employment, consulting, severance, termination protection, change in control, transaction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bonus, retention or similar plan, agreement, arrangement, program or policy or (iii)&nbsp;other plan, agreement, arrangement, program or policy providing for compensation, bonuses,
profit-sharing, equity or equity-based compensation or other forms of incentive or deferred compensation, vacation benefits, insurance (including any self-insured arrangement), medical, dental, vision, prescription or fringe benefits, life
insurance, relocation or expatriate benefits, perquisites, disability or sick leave benefits, employee assistance program, workers&#146; compensation, supplemental unemployment benefits or post-employment or retirement benefits (including
compensation, pension, health, medical or insurance benefits), in each case whether or not written (x)&nbsp;that is sponsored, maintained, administered, contributed to or entered into by Parent or any of its Subsidiaries for the current or future
benefit of any director, officer, employee or individual independent contractor (including any former director, officer, employee or individual independent contractor) of Parent or any of its Subsidiaries or (y)&nbsp;for which Parent or any of its
Subsidiaries has any direct or indirect liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Intellectual Property</U>&#148; means the Owned Intellectual Property
and the Licensed Intellectual Property, in each case, of Parent and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Material Adverse Effect</U>&#148;<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>means a material adverse effect on the financial condition, business or results of operations of Parent and its Subsidiaries, taken as a whole; <I>provided</I> that no event, change, effect,
development or occurrence to the extent resulting from, arising out of, or relating to any of the following shall be deemed to constitute, or shall be taken into account in determining whether there has been, a Parent Material Adverse Effect, or
whether a Parent Material Adverse Effect would reasonably be expected to occur: (i)&nbsp;any changes in general United States or global economic conditions, (ii)&nbsp;any changes in conditions generally affecting any industry in which Parent or any
of its Subsidiaries operate, (iii)&nbsp;any decline, in and of itself, in the market price or trading volume of Parent Common Stock (it being understood and agreed that the foregoing shall not preclude the Company from asserting that any facts or
occurrences giving rise to or contributing to such decline that are not otherwise excluded from the definition of Parent Material Adverse Effect should be deemed to constitute, or be taken into account in determining whether there has been, or would
reasonably be expected to be, a Parent Material Adverse Effect), (iv) any changes in regulatory, legislative or political conditions or in securities, credit, financial, debt or other capital markets, in each case in the United States or any foreign
jurisdiction, (v)&nbsp;any failure, in and of itself, by Parent or any of its Subsidiaries to meet any internal or published projections, forecasts, estimates or predictions in respect of enrollments, revenues, earnings or other financial or
operating metrics for any period (it being understood and agreed that the foregoing shall not preclude the Company from asserting that any facts or occurrences giving rise to or contributing to such failure that are not otherwise excluded from the
definition of Parent Material Adverse Effect should be deemed to constitute, or be taken into account in determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse Effect), (vi) the execution and delivery of
this Agreement, the public announcement or the pendency of this Agreement or the Merger, the taking of any action required or expressly contemplated by this Agreement or the identity of, or any facts or circumstances relating to the Company or any
of its Subsidiaries, including the impact of any of the foregoing on the relationships, contractual or otherwise, of Parent or any of its Subsidiaries with Governmental Authorities, customers, Providers, suppliers, partners, officers or employees
(it being understood and agreed that the foregoing shall not apply with respect to any representation or warranty that is intended to address the consequences of the execution, delivery or performance of this Agreement or the consummation of the
transactions contemplated hereby), (vii)&nbsp;any adoption, implementation, promulgation, repeal, modification, amendment, authoritative interpretation, change or proposal of any Applicable Law of or by any Governmental Authority, (viii)&nbsp;any
changes in GAAP (or authoritative interpretations thereof), (ix)&nbsp;any changes in geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage, cyberattack or terrorism, or any escalation or worsening of any such
acts of war, sabotage, cyberattack or terrorism threatened or underway as of the date of this Agreement, (x) any taking of any action at the written request of or with the consent of the Company (it being understood and agreed that, with respect to
any action taken with such consent, the foregoing shall not preclude the Company from asserting that any facts or occurrences resulting from such action that are not otherwise excluded from the definition of Parent Material Adverse Effect should be
deemed to constitute, or be taken into account in determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse Effect), (xi) any reduction in the credit rating of Parent or any of its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiaries (it being understood and agreed that the foregoing shall not preclude the Company from asserting that any facts or occurrences giving rise to or contributing to such reduction that
are not otherwise excluded from the definition of Parent Material Adverse Effect should be deemed to constitute, or be taken into account in determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse
Effect), (xii) any epidemic, plague, pandemic or other outbreak of illness or public health event, hurricane, earthquake, flood or other natural disasters, acts of God or any change resulting from weather conditions, (xiii)&nbsp;any changes to
reimbursement rates or in methods or procedures for determining such rates, any changes to eligibility requirements or any other programmatic changes by any Governmental Authority, in each case, whether such changes are applicable nationally or to
only certain geographic areas, or (xiv)&nbsp;any claims, actions, suits or proceedings arising from allegations of a breach of fiduciary duty or violation of Applicable Law relating to this Agreement or the Merger, except in the case of each of
clauses (i), (ii), (iv), (vii), (viii) or (xiii), to the extent that any such event, change, effect, development or occurrence has a materially disproportionate adverse effect on Parent and its Subsidiaries, taken as a whole, relative to the adverse
effect such event, change, effect, development or occurrence has on other companies operating in the industries in which Parent and its Subsidiaries operate (it being understood and agreed that any such disproportionate effect on Parent and its
Subsidiaries to the extent resulting from the greater concentration of the businesses of Parent and its Subsidiaries in any particular industry or geography relative to other companies operating in the industries in which Parent and its Subsidiaries
operate shall not be taken into account in determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse Effect). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Stock Price</U>&#148; means the average of the volume weighted averages of the trading prices of Parent Common Stock on the
NYSE (as reported by Bloomberg L.P. or, if not reported therein, in another authoritative source mutually selected by Parent and the Company in good faith) on each of the five&nbsp;(5) consecutive trading days ending on the trading day that is two
(2)&nbsp;trading days prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PBGC</U>&#148; means the Pension Benefit Guaranty Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Lien</U>&#148; means (i)&nbsp;any Liens for Taxes not yet due and payable or which are being contested in good faith by
appropriate proceedings and with respect to which adequate reserves have been established in accordance with GAAP or SAP, as applicable, (ii)&nbsp;carriers&#146;, warehousemen&#146;s, mechanics&#146;, materialmen&#146;s, repairmen&#146;s or other
similar liens, (iii)&nbsp;pledges or deposits in connection with workers&#146; compensation, unemployment insurance and other social security legislation, (iv)&nbsp;gaps in the chain of title evident from the records of the applicable Governmental
Authority maintaining such records, easements, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rights-of-way,</FONT></FONT> covenants, restrictions and other encumbrances of record as of the date of this Agreement,
(v)&nbsp;easements, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rights-of-way,</FONT></FONT> covenants, restrictions and other encumbrances incurred in the ordinary course of business that do not, in any case, materially
detract from the value or the use of the property subject thereto, (vi)&nbsp;statutory landlords&#146; liens and liens granted to landlords under any lease, <FONT STYLE="white-space:nowrap">(vii)&nbsp;non-exclusive</FONT> licenses to Intellectual
Property granted in the ordinary course of business, (viii)&nbsp;any purchase money security interests, equipment leases or similar financing arrangements, (ix)&nbsp;any Liens which are disclosed on the Company Balance Sheet (in the case of Liens
applicable to the Company or any of its Subsidiaries) or the Parent Balance Sheet (in the case of Liens applicable to Parent or any of its Subsidiaries), or the notes thereto, or (x)&nbsp;any Liens that are not material to the Company and its
Subsidiaries or Parent and its Subsidiaries, as applicable, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any individual,
corporation, partnership, limited liability company, association, trust or other entity or organization, including a government or political subdivision or an agency or instrumentality of such government or political subdivision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Providers</U>&#148; means all physicians, physician groups, medical groups, and other groups of health care practitioners,
independent practice associations and other provider networks, dentists, optometrists, pharmacies and pharmacists, radiologists, radiology centers, laboratories, mental health professionals, community health centers, clinics, surgicenters,
accountable care organizations, chiropractors, physical therapists, nurses, nurse practitioners, physician&#146;s assistants, hospitals, skilled nursing facilities, extended care facilities, other health care
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or services facilities, durable medical equipment suppliers, home health agencies, alcoholism or drug abuse centers and any other specialty, ancillary or allied health professional or facility.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulated Subsidiary</U>&#148; means any Subsidiary of the Company or Parent, as applicable, that is licensed in one or more
jurisdictions as an insurance company, health maintenance organization (including a single healthcare service plan), managed care organization, healthcare service plan, specialized healthcare service plan, healthcare service corporation, pharmacy,
dental maintenance organization, dental plan organization, prepaid dental plan, third party administrator and/or utilization review agent, broker or agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SAP</U>&#148; means, as to any insurance company or health maintenance organization conducting an insurance business, the statutory
accounting practices prescribed or permitted by Applicable Law or Governmental Authorities seated in the jurisdiction where such insurance company or health maintenance organization is domiciled and responsible for the regulation thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sarbanes-Oxley Act</U>&#148; means the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Severance Pay Plan</U>&#148; means the severance plan set forth on Section&nbsp;7.05(a) of the Company Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Social Security Act</U>&#148; means the Social Security Act of 1935. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Software</U>&#148; means all (i)&nbsp;computer programs and other software including any and all software implementations of
algorithms, models, methodologies, assemblers, applets, compilers, development tools, design tools and user interfaces, whether in source code or object code form, (ii)&nbsp;databases and compilations, including all data and collections of data,
whether machine readable or otherwise, and (iii)&nbsp;updates, upgrades, modifications, improvements, enhancements, derivative works, new versions, new releases and corrections to or based on any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means, with respect to any Person, any entity of which securities or other ownership interests having ordinary
voting power to elect a majority of the board of directors or other persons performing similar functions are directly or indirectly owned by such Person. For purposes of this Agreement, a Subsidiary shall be considered a &#147;wholly owned
Subsidiary&#148; of a Person as long as such Person directly or indirectly owns all of the securities or other ownership interests (excluding any securities or other ownership interests held by an individual director or officer required to hold such
securities or other ownership interests pursuant to Applicable Law) of such Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax</U>&#148; means any income, gross
receipts, franchise, sales, use, ad valorem, property, payroll, withholding, excise, severance, transfer, employment, estimated, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT> minimum, value added, stamp, occupation, premium,
environmental or windfall profits taxes, and any other taxes, charges, fees, levies, imposts, customs, duties, licenses or other assessments, together with any interest, penalties and additions to tax (including penalties for failure to file or late
filing of any tax return, report or other filing, and any interest in respect of such penalties, additions to tax or additional amounts imposed by any federal, state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other Taxing
Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Return</U>&#148; means any report, return, document, statement, declaration or other information or filing
required to be supplied to any Taxing Authority with respect to Taxes, including information returns, claims for refunds, any documents with respect to or accompanying payments of estimated Taxes or with respect to or accompanying requests for the
extension of time in which to file any such report, return, document, declaration or other information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Sharing Agreement</U>&#148; means any existing agreement binding any Person or
any of its Subsidiaries that provides for the allocation, apportionment, sharing or assignment of any Tax liability or benefit, or the transfer or assignment of income, revenues, receipts, or gains for the purpose of determining any Person&#146;s
Tax liability, other than (i)&nbsp;agreements entered into in the ordinary course of business that do not have as a principal purpose addressing Tax matters, (ii)&nbsp;financing agreements that do not have as a principal purpose addressing Tax
matters and (iii)&nbsp;leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxing Authority</U>&#148; means any Governmental Authority responsible for the imposition or
collection of any tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Third Party</U>&#148; means any Person or Group, other than the Company, Parent, any of their respective
Affiliates or the Representatives of any such Persons acting in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Treasury Regulations</U>&#148; means the Treasury
regulations promulgated by the United States Department of Treasury under the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Willful Breach</U>&#148; means a material
breach of this Agreement that is the consequence of an act or omission by a party with the actual knowledge that the taking of such act or failure to take such action would be a material breach of this Agreement or as otherwise contemplated by the
last sentence of <U>Section</U><U></U><U>&nbsp;7.06(b)</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Each of the following terms is defined in the Section set forth opposite such term: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2001 Indenture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.04</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2007 Indenture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.04</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affected Employee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.05(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alternative Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.06</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.05(d)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed Performance Unit Award</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.06(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed Restricted Unit Award</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.06(a)(ii)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed Stock Appreciation Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.06(c)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bankruptcy and Equity Exceptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.02(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.03(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.03(a)(iv)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Claim Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.01</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.01</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Additional Amounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.03(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Adverse Recommendation Change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.02(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Approval Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.02(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Board Recommendation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.02(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Class&nbsp;A Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.05(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company ESPP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.06(d)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company ESPP Offering Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.06(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Insurance Policies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.25</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Intervening Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.02(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Material Contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.18(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.04</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Organizational Documents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.01</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Permits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.16</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company PSU Award</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.06(b)(i)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Record Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Registered IP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.22(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Required Governmental Authorizations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.03</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company RSU Award</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.06(a)(i)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company SEC Documents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.07(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.05(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Shareholder Approval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Shareholder Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.04(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Statutory Filings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Stock Appreciation Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.06(c)(i)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Superior Proposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.02(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Termination Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.03(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt Commitment Letter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt Commitment Letters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D&amp;O Claim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D&amp;O Indemnified Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.04(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D&amp;O Indemnifying Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.02(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">End Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.01(b)(i)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Award Cash Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.06(c)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Agent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.04(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Agent Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.04(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.03(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excluded Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.03(a)(i)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.04</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incentive Plan Participant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.05(d)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.04</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">internal controls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.07(f)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Proxy Statement/Prospectus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.03(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.23</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maximum Premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.02(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.03(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Sub</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Company Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.05(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NYSE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.03</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Additional Amounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.03(e)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Adverse Recommendation Change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Approval Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.02(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Board Recommendation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.02(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Equity Awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.05(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Intervening Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.02(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Organizational Documents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.01</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Permits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.13</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Preference Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.05(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.05(a)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Registered IP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.18(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Required Governmental Authorizations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.03</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Restricted Stock Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.05(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent SEC Documents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.07(b)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.05(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Share Issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.02(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.05(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Stockholder Approval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.02(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Stockholder Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Superior Proposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.02(f)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parent Termination Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.03(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pennsylvania Department of State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.02(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pennsylvania Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">principal executive officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.07(e)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">principal financial officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.07(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registration Statement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.03(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulation <FONT STYLE="white-space:nowrap">S-K</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.14</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulation <FONT STYLE="white-space:nowrap">S-X</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.01(m)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory Material Adverse Effect</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.02(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory Termination Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.03(c)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representatives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S&amp;S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.01</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.03(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statement of Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.02(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surviving Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.02(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surviving Corporation Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.03(a)(iii)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction Litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.08</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Uncertificated Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.03(a)(iv)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_2"></A>Section&nbsp;1.02. <U>Other Definitional and Interpretative Provisions</U>. The
following rules of interpretation shall apply to this Agreement: (i)&nbsp;the words &#147;hereof&#148;, &#147;hereby&#148;, &#147;herein&#148; and &#147;hereunder&#148; and words of like import used in this Agreement shall refer to this Agreement as
a whole and not to any particular provision of this Agreement; (ii)&nbsp;the table of contents and captions in this Agreement are included for convenience of reference only and shall be ignored in the construction or interpretation hereof;
(iii)&nbsp;references to Articles, Sections and Exhibits are to Articles, Sections and Exhibits of this Agreement unless otherwise specified; (iv)&nbsp;all Exhibits and schedules annexed to this Agreement or referred to in this Agreement, including
the Company Disclosure Schedule and the Parent Disclosure Schedule, are incorporated in and made a part of this Agreement as if set forth in full in this Agreement; (v)&nbsp;any capitalized term used in any Exhibit, the Company Disclosure Schedule
or the Parent Disclosure Schedule but not otherwise defined therein shall have the meaning set forth in this Agreement; (vi)&nbsp;any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, and
references to any gender shall include all genders; (vii)&nbsp;whenever the words &#147;include&#148;, &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without
limitation&#148;, whether or not they are in fact followed by those words or words of like import; (viii) &#147;writing&#148;, &#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing words (including
electronic media) in a visible form; (ix)&nbsp;references to any Applicable Law shall be deemed to refer to such Applicable Law as amended from time to time and to any rules or regulations promulgated thereunder; (x)&nbsp;references to any Contract
are to that Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof; <I>provided</I> that with respect to any Contract listed on any schedule hereto, all such amendments, modifications or
supplements (other than such amendments, modifications or supplements that are immaterial) must also be listed in the appropriate schedule; (xi)&nbsp;references to any Person include the successors and permitted assigns of that Person;
(xii)&nbsp;references &#147;from&#148; or &#147;through&#148; any date mean, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unless otherwise specified, &#147;from and including&#148; or &#147;through and including&#148;, respectively; (xiii)&nbsp;references to &#147;dollars&#148; and &#147;$&#148; means U.S. dollars;
(xiv)&nbsp;the term &#147;made available&#148; and words of similar import mean that the relevant documents, instruments or materials were (A)&nbsp;posted and made available to the other party on the Intralinks/Project Tree due diligence data site,
with respect to the Company, or on the Merrill Datasite/Project Hudson due diligence data site, with respect to Parent, as applicable, maintained by such party in connection with the transactions contemplated hereby, in each case, prior to the date
hereof; (B)&nbsp;provided via electronic mail or in person prior to the date hereof (including materials provided to or reviewed by outside counsel); or (C)&nbsp;filed or furnished to the SEC prior to the date hereof; (xv)&nbsp;the word
&#147;extent&#148; in the phrase &#147;to the extent&#148; shall mean the degree to which a subject or other theory extends and such phrase shall not mean &#147;if&#148;; and (xvi)&nbsp;the parties hereto have participated jointly in the negotiation
and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the parties hereto and no presumption or burden of proof shall arise favoring or
disfavoring any party by virtue of the authorship of any provision of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CLOSING; THE MERGER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_3">
</A>Section&nbsp;2.01. <U>Closing</U>.<I> </I>The closing of the Merger (the &#147;<U>Closing</U>&#148;) shall take place in New York City at the offices of Shearman&nbsp;&amp; Sterling LLP (&#147;<U>S&amp;S</U>&#148;), 599 Lexington Avenue, New
York, New York, 10022 at 10:00 a.m., Eastern time, on the third (3rd) Business Day after the date the conditions set forth in <U>Article</U><U></U><U>&nbsp;IX</U> (other than conditions that by their nature are to be satisfied at the Closing, but
subject to the satisfaction or, to the extent permitted by Applicable Law, waiver of such conditions by the party or parties entitled to the benefit thereof at the Closing) have been satisfied or, to the extent permitted by Applicable Law, waived by
the party or parties entitled to the benefit thereof, or at such other place, at such other time or on such other date as Parent and the Company may mutually agree (the date on which the Closing occurs, the &#147;<U>Closing Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_4"></A>Section&nbsp;2.02. <U>The Merger</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) At the Closing, the Company shall file a statement of merger (the &#147;<U>Statement of Merger</U>&#148;) with the Department of State of
the Commonwealth of Pennsylvania (the &#147;<U>Pennsylvania Department of State</U>&#148;) and make all other filings or recordings required by Title 15 of the Pennsylvania Consolidated Statutes (&#147;<U>Pennsylvania Law</U>&#148;) in connection
with the Merger. The Merger shall become effective at such time (the &#147;<U>Effective Time</U>&#148;) as the Statement of Merger is duly filed with the Pennsylvania Department of State (or at such later time as Parent and the Company shall agree
and is specified in the Statement of Merger). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At the Effective Time, Merger Sub shall be merged (the &#147;<U>Merger</U>&#148;) with
and into the Company in accordance with Pennsylvania Law, whereupon the separate existence of Merger Sub shall cease, and the Company shall be the surviving corporation (the &#147;<U>Surviving Corporation</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) From and after the Effective Time, the Surviving Corporation shall possess all the rights, powers, privileges and franchises and be
subject to all of the obligations, liabilities, restrictions and disabilities of the Company and Merger Sub, all as provided under Pennsylvania Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_5"></A>Section&nbsp;2.03. <U>Conversion of Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Sub, the Company or the holders of the
Company Common Stock: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) other than shares of Company Common Stock to be cancelled pursuant to
<U>Section</U><U></U><U>&nbsp;2.03(a)(ii)</U> (collectively, the &#147;<U>Excluded Shares</U>&#148;), each share of Company Common Stock outstanding immediately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
prior to the Effective Time shall be converted into the right to receive (i)&nbsp;0.8378 (the &#147;<U>Exchange Ratio</U>&#148;) fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Parent Common Stock (the &#147;<U>Share Consideration</U>&#148;) and (ii)&nbsp;$145.00 in cash without interest thereon (the &#147;<U>Cash Consideration</U>&#148; and, together with
the Share Consideration, the &#147;<U>Merger Consideration</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) each share of Company Common Stock held by the
Company as treasury stock or owned by Parent or any of its Subsidiaries immediately prior to the Effective Time (other than any such shares owned by Parent or any of its Subsidiaries in a fiduciary, representative or other capacity on behalf of
other Persons, whether or not held in a separate account) shall be cancelled, and no consideration shall be paid with respect thereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) each share of common stock of Merger Sub outstanding immediately prior to the Effective Time shall be converted into and
become one share of common stock, par value $0.01 per share, of the Surviving Corporation with the same rights, powers and privileges as the shares so converted and shall constitute the only outstanding shares of capital stock of the Surviving
Corporation (the &#147;<U>Surviving Corporation Common Stock</U>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) all outstanding shares of Company Common
Stock shall no longer be outstanding and shall automatically be cancelled and retired and shall cease to exist, and (x)&nbsp;each share of Company Common Stock that was immediately prior to the Effective Time represented by a certificate (each, a
&#147;<U>Certificate</U>&#148;) and (y)&nbsp;each uncertificated share of Company Common Stock (an &#147;<U>Uncertificated Share</U>&#148;) which immediately prior to the Effective Time was registered to a holder on the stock transfer books of the
Company shall (other than with respect to Excluded Shares) thereafter represent only the right to receive (A)&nbsp;the Merger Consideration and (B)&nbsp;with respect to the Share Consideration, the right to receive (1)&nbsp;any dividends or other
distributions pursuant to <U>Section</U><U></U><U>&nbsp;2.04(f)</U> and (2)&nbsp;any cash in lieu of any fractional shares of Parent Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;2.08</U>, in each case to be issued or paid in accordance
with <U>Section</U><U></U><U>&nbsp;2.04</U>, without interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_6"></A>Section&nbsp;2.04. <U>Surrender and
Payment</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to the Effective Time, Parent shall appoint a commercial bank or trust company reasonably acceptable to the
Company (the &#147;<U>Exchange Agent</U>&#148;) and enter into an exchange agent agreement with the Exchange Agent reasonably acceptable to the Company (the &#147;<U>Exchange Agent Agreement</U>&#148;) for the purpose of exchanging
(i)&nbsp;Certificates or (ii)&nbsp;Uncertificated Shares for the Merger Consideration payable in respect of the shares of Company Common Stock. As of the Effective Time, Parent shall deposit with the Exchange Agent, for the benefit of the holders of
shares of Company Common Stock, for exchange in accordance with this <U>Section</U><U></U><U>&nbsp;2.04</U> through the Exchange Agent, (x)&nbsp;certificates (or evidence of shares in book-entry form) representing the shares of Parent Common Stock
issuable pursuant to <U>Section</U><U></U><U>&nbsp;2.03(a)(i)</U> in exchange for outstanding shares of Company Common Stock and (y)&nbsp;cash sufficient to pay the aggregate Cash Consideration payable pursuant to
<U>Section</U><U></U><U>&nbsp;2.03(a)(i)</U>. Parent agrees to make available, directly or indirectly, to the Exchange Agent from time to time as needed additional cash and/or shares of Parent Common Stock sufficient to pay any dividends or other
distributions to which such holders are entitled pursuant to <U>Section</U><U></U><U>&nbsp;2.04(f)</U> and cash in lieu of any fractional share of Parent Common Stock to which such holder is entitled pursuant to
<U>Section</U><U></U><U>&nbsp;2.08</U>. Promptly after the Effective Time (and in no event more than two (2)&nbsp;Business Days following the Closing Date), Parent shall send, or shall cause the Exchange Agent to send, to each holder of shares of
Company Common Stock at the Effective Time a letter of transmittal and instructions (which shall be in a form reasonably acceptable to the Company and substantially finalized prior to the Effective Time and which shall specify that delivery shall be
effected, and risk of loss and title shall pass, only upon proper delivery of the Certificates or transfer of the Uncertificated Shares to the Exchange Agent) for use in such exchange. All certificates (or evidence of shares in book-entry form) and
cash deposited with the Exchange Agent pursuant to this <U>Section</U><U></U><U>&nbsp;2.04</U> shall be referred to in this Agreement as the &#147;<U>Exchange Fund</U>.&#148; Parent shall cause the Exchange Agent to deliver the Merger Consideration
contemplated to be issued or paid pursuant to this <U>Article</U><U></U><U>&nbsp;II</U> out of the Exchange Fund. The Exchange Fund shall not be used for any other purpose. The Exchange Agent shall invest any cash included in the Exchange Fund as
directed by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parent; <I>provided</I> that such cash shall only be invested in the manner provided in the Exchange Agent Agreement; and <I>provided</I>,<I> further</I>, that no such investment or losses
thereon shall affect the Merger Consideration payable to holders of Company Common Stock entitled to receive such consideration or cash in lieu of fractional interests; <I>provided</I>,<I> further</I>, that to the extent necessary to pay the Merger
Consideration, Parent shall promptly cause to be provided additional funds to the Exchange Agent for the benefit of holders of Company Common Stock entitled to receive such consideration in the amount of any such losses. Any interest and other
income resulting from such investments shall be the property of, and paid to, Parent upon termination of the Exchange Fund. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each
holder of shares of Company Common Stock that have been converted into the right to receive the Merger Consideration shall be entitled to receive, upon (i)&nbsp;surrender to the Exchange Agent of a Certificate, together with a properly completed
letter of transmittal, or (ii)&nbsp;receipt of an &#147;agent&#146;s message&#148; by the Exchange Agent (or such other evidence, if any, of transfer as the Exchange Agent may reasonably request) in the case of a book-entry transfer of
Uncertificated Shares, in respect of each share of the Company Common Stock represented by such Certificate or Uncertificated Share (A)&nbsp;the Merger Consideration and (B)&nbsp;cash in lieu of any fractional shares of Parent Common Stock and any
dividends and distributions with respect to the Share Consideration as contemplated by <U>Section</U><U></U><U>&nbsp;2.08</U> and <U>Section</U><U></U><U>&nbsp;2.04(f)</U>. The shares of Parent Common Stock constituting part of such Merger
Consideration, at Parent&#146;s option, shall be in uncertificated book-entry form, unless a physical certificate is requested by a holder of shares of Company Common Stock or is otherwise required under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If any portion of the Merger Consideration (or cash in lieu of any fractional shares of Parent Common Stock or any dividends and
distributions with respect to the Share Consideration as contemplated by <U>Section</U><U></U><U>&nbsp;2.08</U> or <U>Section</U><U></U><U>&nbsp;2.04(f)</U>) is to be paid to a Person other than the Person in whose name the surrendered Certificate
or the transferred Uncertificated Share is registered, it shall be a condition to such payment that (i)&nbsp;either such Certificate shall be properly endorsed or shall otherwise be in proper form for transfer or such Uncertificated Share shall be
properly transferred and (ii)&nbsp;the Person requesting such payment shall pay to the Exchange Agent any transfer or similar Taxes required as a result of such payment to a Person other than the registered holder of such Certificate or
Uncertificated Share or establish to the satisfaction of the Exchange Agent that such transfer or similar Taxes have been paid or are not payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Upon the Effective Time, there shall be no further registration of transfers of shares of Company Common Stock thereafter on the records
of the Company. If, after the Effective Time, Certificates or Uncertificated Shares are presented to Parent, the Surviving Corporation or the Exchange Agent for any reason, they shall be cancelled and exchanged for the Merger Consideration (and cash
in lieu of any fractional shares of Parent Common Stock and any dividends and distributions with respect to the Share Consideration as contemplated by <U>Section</U><U></U><U>&nbsp;2.08</U> and <U>Section</U><U></U><U>&nbsp;2.04(f)</U>) with respect
thereto in accordance with the procedures set forth in, or as otherwise contemplated by, this <U>Article</U><U></U><U>&nbsp;II</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
Any portion of the Exchange Fund that remains unclaimed by the holders of shares of Company Common Stock twelve (12)&nbsp;months following the Closing Date shall be delivered to Parent or as otherwise instructed by Parent, and any such holder who
has not exchanged shares of Company Common Stock for the Merger Consideration in accordance with this <U>Section</U><U></U><U>&nbsp;2.04</U> prior to that time shall thereafter look only to Parent for payment of the Merger Consideration (and cash in
lieu of any fractional shares of Parent Common Stock and any dividends and distributions with respect to the Share Consideration as contemplated by <U>Section</U><U></U><U>&nbsp;2.08</U> and <U>Section</U><U></U><U>&nbsp;2.04(f)</U>), without any
interest thereon. Notwithstanding the foregoing, Parent and its Subsidiaries (including the Surviving Corporation and its Subsidiaries) shall not be liable to any holder of shares of Company Common Stock for any amounts properly paid to a public
official in compliance with applicable abandoned property, escheat or similar laws. Any amounts remaining unclaimed by holders of shares of Company Common Stock immediately prior to such time when the amounts would otherwise escheat to or become
property of any Governmental Authority shall become, to the extent permitted by Applicable Law, the property of Parent free and clear of any claims or interest of any Person previously entitled thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Following the surrender of any Certificates or the transfer of any Uncertificated Shares
as provided in this <U>Section</U><U></U><U>&nbsp;2.04</U>, Parent shall pay, or cause to be paid, without interest, to the Person in whose name the shares of Parent Common Stock constituting the Share Consideration have been registered, (i)&nbsp;in
connection with the payment of the Share Consideration, (x)&nbsp;the amount of any cash payable in lieu of fractional shares to which such Person is entitled pursuant to <U>Section</U><U></U><U>&nbsp;2.08</U>, and (y)&nbsp;the aggregate amount of
all dividends or other distributions payable with respect to such shares of Parent Common Stock with a record date on or after the Effective Time that were paid prior to the time of such surrender or transfer, and (ii)&nbsp;at the appropriate
payment date after the payment of the Merger Consideration, the amount of all dividends or other distributions payable with respect to whole shares of Parent Common Stock constituting the Share Consideration with a record date on or after the
Effective Time and prior to the time of such surrender or transfer and with a payment date subsequent to the time of such surrender or transfer. No dividends or other distributions with respect to shares of Parent Common Stock constituting the Share
Consideration, and no cash payment in lieu of fractional shares pursuant to <U>Section</U><U></U><U>&nbsp;2.08</U>, shall be paid to the holder of any Certificates not surrendered or of any Uncertificated Shares not transferred until such
Certificates or Uncertificated Shares are surrendered or transferred, as the case may be, as provided in this <U>Section</U><U></U><U>&nbsp;2.04</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The payment of any transfer, documentary, sales, use, stamp, registration, value added and other Taxes and fees (including any penalties
and interest) incurred solely by a holder of Company Common Stock in connection with the Merger, and the filing of any related Tax Returns and other documentation with respect to such Taxes and fees, shall be the sole responsibility of such holder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_7"></A>Section&nbsp;2.05. <U>No Dissenters Rights</U>. In accordance with Section&nbsp;1571(b) of Pennsylvania Law,
the Merger will not entitle any holder of Company Common Stock to any dissenters rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_8"></A>Section&nbsp;2.06.
<U>Company Equity Awards</U><U>; Company ESPP</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Company Restricted Stock Units</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Immediately prior to the Effective Time, with respect to each restricted stock unit award with respect to shares of Company
Common Stock outstanding under any Company Stock Plan that (x)&nbsp;vests solely based on the passage of time (each, a &#147;<U>Company RSU Award</U>&#148;) and (y)&nbsp;pursuant to its terms as in effect as of the date hereof, provides for
automatic accelerated vesting upon the consummation of the transactions contemplated by this Agreement, the restrictions and vesting conditions applicable to such Company RSU Award shall lapse and each such Company RSU Award shall, by virtue of the
Merger and without any action on the part of the holder thereof, be converted as of the Effective Time into the right to receive, with respect to each share of Company Common Stock underlying such Company RSU Award, the Merger Consideration, less
applicable Tax withholdings, which shall be paid or provided by Parent as soon as practicable following the Closing Date, but in no event later than five (5)&nbsp;Business Days following the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) With respect to each Company RSU Award that (x)&nbsp;is not converted into a right to receive the Merger Consideration in
accordance with <U>Section</U><U></U><U>&nbsp;2.06(a)(i)</U> or (y)&nbsp;is granted after the date hereof to the extent permitted under <U>Section</U><U></U><U>&nbsp;6.01(d)</U>,<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>at the Effective
Time, such Company RSU Award shall, by virtue of the Merger and without further action on the part of the holder thereof, be assumed by Parent and shall be converted into a restricted unit award (each, an &#147;<U>Assumed Restricted Unit
Award</U>&#148;), except that each Assumed Restricted Unit Award shall cover that number of whole shares of Parent Common Stock equal to the product of the number of shares of Company Common Stock underlying such Company RSU Award immediately prior
to the Effective Time <I>multiplied </I>by the Equity Award Exchange Ratio, with the result rounded down to the nearest whole number of shares of Parent Common Stock. Except as provided in this <U>Section</U><U></U><U>&nbsp;2.06(a)(ii)</U>, each
Assumed Restricted Unit Award shall continue to have, and shall be subject to, the same terms and conditions as applied to the corresponding Company RSU Award immediately prior to the Effective Time (including any terms and conditions relating to
accelerated vesting upon a termination of the holder&#146;s employment in connection with or following the Merger). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Company Performance Stock Units</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Immediately prior to the Effective Time, with respect to each stock unit award with respect to shares of Company Common
Stock outstanding under any Company Stock Plan that (x)&nbsp;vests based on the achievement of performance goals (each, a &#147;<U>Company PSU Award</U>&#148;) and (y)&nbsp;pursuant to its terms as in effect as of the date hereof, provides for
automatic accelerated vesting upon the consummation of the transactions contemplated by this Agreement, the restrictions and vesting conditions applicable to such Company PSU Award shall lapse and each such Company PSU Award shall, by virtue of the
Merger and without any action on the part of the holder thereof, be converted as of the Effective Time into the right to receive, with respect to each share of Company Common Stock underlying such Company PSU Award (determined assuming the
achievement of target level performance), the Merger Consideration, less applicable Tax withholdings, which shall be paid or provided by Parent as soon as practicable following the Closing Date, but in no event later than five (5)&nbsp;Business Days
following the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) With respect to each Company PSU Award that (x)&nbsp;is not converted into a right to
receive Merger Consideration in accordance with <U>Section</U><U></U><U>&nbsp;2.06(b)(i)</U> or (y)&nbsp;is granted after the date hereof to the extent permitted under <U>Section</U><U></U><U>&nbsp;6.01(d)</U>, at the Effective Time, such Company
PSU Award shall, by virtue of the Merger and without further action on the part of the holder thereof, be assumed by Parent and shall be converted into a time-vesting restricted unit award (each, an &#147;<U>Assumed Performance Unit
Award</U>&#148;), except that each Assumed Performance Unit Award shall cover that number of whole shares of Parent Common Stock equal to the product of the number of shares of Company Common Stock underlying such Company PSU Award immediately prior
to the Effective Time (determined in accordance with the applicable award agreement) <I>multiplied </I>by the Equity Award Exchange Ratio, with the result rounded down to the nearest whole number of shares of Parent Common Stock. Except as provided
in this <U>Section</U><U></U><U>&nbsp;2.06(b)(ii)</U>, each Assumed Performance Unit Award shall continue to have, and shall be subject to, the same terms and conditions as applied to the corresponding Company PSU Award immediately prior to the
Effective Time (including any terms and conditions relating to accelerated vesting upon a termination of the holder&#146;s employment in connection with or following the Merger). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Company Stock Appreciation Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) At the Effective Time, each stock appreciation right representing the right to receive a payment in shares of Company
Common Stock under any Company Stock Plan that is outstanding and unexercised immediately prior to the Effective Time (each, a &#147;<U>Company Stock Appreciation Right</U>&#148;) that is vested or that, pursuant to its terms as in effect as of the
date hereof, would become vested as of the Effective Time, with a per share exercise price less than the Equity Award Cash Consideration, shall be cancelled and converted into the right to receive an amount in cash, without interest, equal to the
product of (A)&nbsp;the excess, if any, of (1)&nbsp;the sum of (x)&nbsp;the Cash Consideration <I>plus</I> (y)&nbsp;the value equal to the product of the Parent Stock Price <I>multiplied</I> by the Exchange Ratio (the sum of the amounts in clauses
(x)&nbsp;and (y), the &#147;<U>Equity Award Cash Consideration</U>&#148;) over (2)&nbsp;the applicable per share exercise price of such Company Stock Appreciation Right <I>multiplied </I>by (B)&nbsp;the total number of shares of Company Common Stock
subject to such Company Stock Appreciation Right. At the Effective Time, each Company Stock Appreciation Right that is vested or that, pursuant to its terms as in effect as of the date hereof, would become vested as of the Effective Time, with a per
share exercise price greater than or equal to the Equity Award Cash Consideration, shall be cancelled for no consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Each Company Stock Appreciation Right that (x)&nbsp;is not cancelled in accordance with
<U>Section</U><U></U><U>&nbsp;2.06(c)(i)</U> or (y)&nbsp;is granted after the date hereof to the extent permitted under <U>Section</U><U></U><U>&nbsp;6.01(d)</U>, at the Effective Time shall, by virtue of the Merger and without further action on the
part of the holder thereof, be assumed by Parent and become, as of the Effective Time, a stock appreciation right (an &#147;<U>Assumed Stock Appreciation Right</U>&#148;) representing the right to receive a payment in shares of Parent Common Stock,
on the same terms and conditions (including applicable vesting, exercise and expiration provisions) as applied to each such Company Stock Appreciation Right immediately prior to the Effective Time, shares of Parent Common Stock, except that
(A)&nbsp;the number of shares of Parent Common Stock, rounded down to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
nearest whole share, subject to such Assumed Stock Appreciation Right shall equal the product of (x)&nbsp;the number of shares of Company Common Stock that were subject to such Company Stock
Appreciation Right immediately prior to the Effective Time, <I>multiplied </I>by (y)&nbsp;the Equity Award Exchange Ratio, and (B)&nbsp;the per share exercise price, rounded up to the nearest whole cent, shall equal the quotient of (1)&nbsp;the
exercise price per share of Company Common Stock at which such Company Stock Appreciation Right was exercisable immediately prior to the Effective Time, divided by (2)&nbsp;the Equity Award Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Company ESPP</U>. As soon as practicable following the date of this Agreement, the Company shall take all actions with respect to the
Aetna Inc. 2016 Employee Stock Purchase Plan (the &#147;<U>Company ESPP</U>&#148;) that are necessary to provide that: (i)&nbsp;with respect to the offering period for which participant payroll deductions commence during December 2017 (the
&#147;<U>Company ESPP Offering Period</U>&#148;), (A)&nbsp;no participant may elect to participate in the Company ESPP after the date of this Agreement, (B)&nbsp;no participant may increase the percentage amount of his or her payroll deduction
election from that in effect on the date of this Agreement for such Company ESPP Offering Period; and (C)&nbsp;such Company ESPP Offering Period shall terminate at the earlier of (x)&nbsp;the scheduled purchase date for such Company ESPP Offering
Period and (y)&nbsp;immediately prior to the Effective Time; (ii)&nbsp;each participant&#146;s accumulated payroll deduction shall be used to purchase shares of Company Common Stock in accordance with the terms of the Company ESPP on the earlier of
(x)&nbsp;the scheduled purchase date for such Company ESPP Offering Period and (y)&nbsp;immediately prior to the Effective Time; (iii)&nbsp;no additional offering periods shall commence thereafter; and (iv)&nbsp;subject to the consummation of the
Merger, the Company ESPP shall terminate, effective at the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Reservation of Shares</U>. As soon as practicable
following the Closing Date (but in no event more than five (5)&nbsp;Business Days following the Closing Date), Parent shall file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (or any successor form) with respect to the
issuance of the shares of Parent Common Stock subject to the Assumed Restricted Unit Awards, Assumed Performance Unit Awards and Assumed Stock Appreciation Rights and shall use its reasonable best efforts to maintain the effectiveness of such
registration statement or registration statements (and maintain the current status of the prospectus or prospectuses contained therein) for so long as the Assumed Restricted Unit Awards, Assumed Performance Unit Awards and Assumed Stock Appreciation
Rights remain outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Board Actions</U>. Prior to the Effective Time, the Board of Directors of the Company (and/or the
compensation committee (or equivalent committee) of the Board of Directors of the Company) and the Board of Directors of Parent (and/or the Management Planning and Development Committee of the Board of Directors of Parent) shall adopt such
resolutions as are necessary to give effect to the transactions contemplated by this <U>Section</U><U></U><U>&nbsp;
2.06</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_9"></A>Section&nbsp;2.07. <U>Adjustments</U>. Without limiting or affecting any of the provisions of
<U>Section</U><U></U><U>&nbsp;6.01</U> or <U>Section</U><U></U><U>&nbsp;7.01</U>, if, during the period between the date of this Agreement and the Effective Time, any change in the outstanding shares of capital stock of the Company or Parent shall
occur as a result of any reclassification, recapitalization, stock split (including reverse stock split), merger, combination, exchange or readjustment of shares, subdivision or other similar transaction, or any stock dividend thereon with a record
date during such period, the Merger Consideration and any other amounts payable pursuant to this Agreement shall be appropriately adjusted to eliminate the effect of such event on the Merger Consideration or any such other amounts payable pursuant
to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_10"></A>Section&nbsp;2.08. <U>Fractional Shares</U>. Notwithstanding anything in this Agreement to
the contrary, no fractional shares of Parent Common Stock shall be issued in the Merger. All fractional shares of Parent Common Stock that a holder of shares of Company Common Stock would otherwise be entitled to receive as a result of the Merger
shall be aggregated and, if a fractional share results from such aggregation, such holder shall be entitled to receive, in lieu thereof, an amount in cash, without interest, determined by multiplying the Parent Stock Price by the fraction of a share
of Parent Common Stock to which such holder would otherwise have been entitled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_11"></A>Section&nbsp;2.09. <U>Withholding Rights</U>. Each of the
Exchange Agent, Parent and the Surviving Corporation shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this Agreement such amounts as it is required to deduct and withhold with respect to the making of
such payment under any provision of any Applicable Law, including federal, state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax law. If the Exchange Agent, Parent or the Surviving Corporation, as the case may be, so withholds and
pays over all amounts so withheld to the appropriate Taxing Authority within the period required under Applicable Law, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which the
Exchange Agent, Parent or the Surviving Corporation, as the case may be, made such deduction and withholding. Parent shall pay, or shall cause to be paid, all amounts so deducted or withheld by Parent or the Surviving Corporation to the appropriate
Taxing Authority within the period required under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_12"></A>Section&nbsp;2.10. <U>Lost
Certificates</U>. If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if reasonably required by the Surviving
Corporation, the posting by such Person of a customary bond issued for lost, stolen or destroyed stock certificates, in such reasonable amount as the Surviving Corporation may direct, as indemnity against any claim that may be made against the
Surviving Corporation, with respect to such Certificate, the Exchange Agent will issue, in exchange for such lost, stolen or destroyed Certificate, the Merger Consideration to be paid in respect of the shares of Company Common Stock represented by
such Certificate, as contemplated by this <U>Article</U><U></U><U>&nbsp;II</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_13"></A>Section&nbsp;2.11. <U>Further
Assurances</U>. At and after the Effective Time, the officers and directors of the Surviving Corporation shall be authorized to execute and deliver, in the name and on behalf of the Company, any of its Subsidiaries or Merger Sub, any deeds, bills of
sale, assignments or assurances and to take and do, in the name and on behalf of the Company, any of its Subsidiaries or Merger Sub, any other actions and things to vest, perfect or confirm of record or otherwise in the Surviving Corporation any and
all right, title and interest in, to and under any of the rights, properties or assets of the Company acquired or to be acquired by the Surviving Corporation as a result of, or in connection with, the Merger. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORGANIZATIONAL DOCUMENTS; DIRECTORS AND OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_14"></A>Section&nbsp;3.01. <U>Articles of Incorporation and Bylaws of the </U><U>Surviving Corporation</U>. At the
Effective Time, the articles of incorporation of the Company shall be amended so that it reads in its entirety as set forth on Exhibit A. From and after the Effective Time, the articles of incorporation of the Company as so amended shall be the
articles of incorporation of the Surviving Corporation until thereafter amended as provided therein or by Applicable Law. The bylaws of Merger Sub, as in effect immediately prior to the Effective Time, shall be the bylaws of the Surviving
Corporation from and after the Effective Time until thereafter amended as provided therein, in the articles of incorporation of the Surviving Corporation or by Applicable Law, except that the name of the corporation reflected therein shall be
&#147;Aetna Inc.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_15"></A>Section&nbsp;3.02. <U>Directors and Officers of the </U><U>Surviving Corporation</U>.
From and after the Effective Time, until their respective successors are duly elected or appointed and qualified in accordance with Applicable Law, (i)&nbsp;the directors of Merger Sub immediately prior to the Effective Time shall be the directors
of the Surviving Corporation and (ii)&nbsp;the officers of the Company immediately prior to the Effective Time shall be the officers of the Surviving Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to <U>Section</U><U></U><U>&nbsp;11.05</U>, except (i)&nbsp;other than with respect to the representations and warranties in
<U>Section</U><U></U><U>&nbsp;4.01</U>, <U>Section</U><U></U><U>&nbsp;4.02</U>, <U>Section</U><U></U><U>&nbsp;4.05</U>, <U>Section</U><U></U><U>&nbsp;4.06</U>, <U>Section</U><U></U><U>&nbsp;4.27</U>, Section&nbsp;4.28 and Section&nbsp;4.29, as
disclosed in any publicly available Company SEC Document filed after December&nbsp;31, 2016 and before the date of this Agreement or in the Company&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2015 or in the Company&#146;s proxy statement for the 2016 annual meeting of the Company&#146;s shareholders or (ii)&nbsp;as set forth in the Company Disclosure Schedule, the Company represents and warrants to Parent that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_16"></A>Section&nbsp;4.01. <U>Corporate Existence and Power</U>. The Company is a corporation duly incorporated and validly
subsisting under the laws of the Commonwealth of Pennsylvania. The Company has all corporate powers required to own or lease all of its properties or assets and to carry on its business as now conducted. The Company is duly qualified to do business
and is in good standing in each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified has not had and would not reasonably be expected to have, individually or in the aggregate, a Company
Material Adverse Effect. Prior to the date of this Agreement, the Company has made available to Parent true and complete copies of the articles of incorporation and bylaws of the Company as in effect on the date of this Agreement (the
&#147;<U>Company Organizational Documents</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_17"></A>Section&nbsp;4.02. <U>Corporate Authorization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the transactions
contemplated by this Agreement are within the corporate powers of the Company and, except for the Company Shareholder Approval, have been duly authorized by all necessary corporate action on the part of the Company. The affirmative vote of the
holders of at least a majority of the outstanding shares of Company Common Stock approving and adopting this Agreement is the only vote of the holders of any of the Company&#146;s capital stock necessary in connection with the consummation of the
Merger (the &#147;<U>Company Shareholder Approval</U>&#148;). This Agreement has been duly executed and delivered by the Company and (assuming due authorization, execution and delivery by Parent and Merger Sub) constitutes a valid and binding
agreement of the Company enforceable against the Company in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors&#146; rights and remedies generally, and subject, as
to enforceability, to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity) (collectively, the &#147;<U>Bankruptcy and Equity Exceptions</U>&#148;)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At a meeting duly called and held, the Board of Directors of the Company unanimously adopted resolutions (i)&nbsp;determining that this
Agreement and the transactions contemplated hereby (including the Merger) are fair to and in the best interests of the Company and its shareholders, (ii)&nbsp;approving, adopting and declaring advisable this Agreement and the transactions
contemplated hereby (including the Merger), (iii)&nbsp;directing that this Agreement be submitted to a vote at a meeting of the Company&#146;s shareholders, and (iv)&nbsp;recommending approval and adoption of this Agreement (including the Merger) by
the Company&#146;s shareholders (such recommendation, the &#147;<U>Company Board Recommendation</U>&#148;). Except as permitted by <U>Section</U><U></U><U>&nbsp;6.02</U>, the Board of Directors of the Company has not subsequently rescinded, modified
or withdrawn any of the foregoing resolutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_18"></A>Section&nbsp;4.03. <U>Governmental Authorization</U>. The
execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the transactions contemplated hereby require no action by or in respect of, Consents of, or Filing with, any Governmental Authority other
than (i)&nbsp;the filing of the Statement of Merger with the Pennsylvania Department of State and appropriate documents with the relevant authorities of other states in which the Company is qualified to do business, (ii)&nbsp;compliance with any
applicable requirements of the HSR Act, (iii)&nbsp;compliance with any applicable requirements of the 1933 Act, the 1934 Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and any other applicable U.S. state or federal securities laws or pursuant to the rules of the New York Stock Exchange (the &#147;<U>NYSE</U>&#148;), (iv)&nbsp;Consents of, and Filings with, the
state insurance departments, federal and state departments of health and other Consents and Filings required under the Health Care Laws, Government Sponsored Health Care Programs or Insurance Laws that are listed on Section&nbsp;4.03 of the Company
Disclosure Schedule (the Consents and Filings required under or in connection with this clause&nbsp;(iv), collectively, the &#147;<U>Company Required Governmental Authorizations</U>&#148;), and (v)&nbsp;any other actions, Consents or Filings the
absence of which has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_19"></A>Section&nbsp;4.04. <U><FONT STYLE="white-space:nowrap">Non-contravention</FONT></U>. The execution, delivery and
performance by the Company of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i)&nbsp;contravene, conflict with, or result in any violation or breach of any provision of the Company Organizational
Documents, (ii)&nbsp;assuming compliance with the matters referred to in <U>Section</U><U></U><U>&nbsp;4.03</U> and receipt of the Company Shareholder Approval, contravene, conflict with or result in any violation or breach of any provision of any
Applicable Law, (iii)&nbsp;assuming compliance with the matters referred to in <U>Section</U><U></U><U>&nbsp;4.03</U> and receipt of the Company Shareholder Approval, require any Consent or other action by any Person under, constitute a default, or
an event that, with or without notice or lapse of time or both, would constitute a default, under, or cause or permit the termination, cancellation, acceleration or other change of any right or obligation or the loss of any benefit to which the
Company or any of its Subsidiaries is entitled under, any provision of any Contract binding upon the Company or any of its Subsidiaries or any governmental Consents (including Consents required by Contract) affecting, or relating in any way to, the
assets or business of the Company and its Subsidiaries, or (iv)&nbsp;result in the creation or imposition of any Lien on any asset of the Company or any of its Subsidiaries, with such exceptions, in the case of each of clauses (ii)&nbsp;through
(iv), as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_20">
</A>Section&nbsp;4.05. <U>Capitalization</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Under the Company&#146;s Articles of Incorporation, the total number of shares of all
classes that the Company has the authority to issue is 2,996,654,333. As of the date of this Agreement, the Company&#146;s authorized capital stock consists of (x) 7,625,000 Class&nbsp;A Voting Preferred Shares (&#147;<U>Company
Class</U><U></U><U>&nbsp;A Preferred Shares</U>&#148;), (y) 2,520,137,562 shares of Company Common Stock and (z) 468,891,771 shares undesignated as to class or series. As of the Closing Date, 2,520,137,562 shares (less any shares purchased by,
redeemed by, surrendered to or otherwise acquired by the Company after the date of this Agreement and prior to the Closing Date, which shares will become undesignated) will be designated as Company Common Stock. As of November&nbsp;30, 2017, there
were outstanding (i)&nbsp;326,172,331 shares of Company Common Stock, (ii)&nbsp;no Company Class&nbsp;A Preferred Shares, (iii)&nbsp;Company Stock Appreciation Rights (including any Company Stock Appreciation Rights subject to performance conditions
that settle into Company Common Stock) with respect to an aggregate of 7,594,264 shares of Company Common Stock (of which Company Stock Appreciation Rights with respect to 3,727,241 shares of Company Common Stock were exercisable), (iv)&nbsp;886,715
Company PSU Awards and 1,422,112 Company RSU Awards under the Company&#146;s equity compensation plans and (v)&nbsp;unexercised rights to purchase approximately 51,000 shares of Company Common Stock under the Company ESPP in the current Company ESPP
Offering Period. Except as set forth in this <U>Section</U><U></U><U>&nbsp;4.05(a)</U> and for changes since November&nbsp;30, 2017 resulting from (A)&nbsp;the exercise or vesting and settlement of Company Equity Awards outstanding on such date or
issued after such date, or (B)&nbsp;the issuance of Company Equity Awards after such date, there are no issued, reserved for issuance or outstanding (i)&nbsp;shares of capital stock or other voting securities of, or other ownership interest in, the
Company, (ii)&nbsp;securities of the Company convertible into or exchangeable for shares of capital stock or other voting securities of, or other ownership interests in, the Company, (iii)&nbsp;warrants, calls, options or other rights to acquire
from the Company, or other obligations of the Company to issue, any capital stock or other voting securities of, or other ownership interests in, or securities convertible into or exchangeable for capital stock or other voting securities of, or
other ownership interests in, the Company, or (iv)&nbsp;restricted shares, stock appreciation rights, performance units, contingent value rights, &#147;phantom&#148; stock or similar securities or rights issued by or with the approval of the Company
that are derivative of, or provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
economic benefits based, directly or indirectly, on the value or price of, any capital stock or other voting securities of, or other ownership interests in, the Company (the items in clauses
(i)&nbsp;through (iv) being referred to collectively as the &#147;<U>Company Securities</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All outstanding shares of capital
stock of the Company have been, and all shares that may be issued pursuant to any employee stock option or other compensation plan or arrangement will be, when issued in accordance with the respective terms thereof, duly authorized and validly
issued, fully paid and nonassessable and free of preemptive rights. No Subsidiary of the Company owns any shares of capital stock of the Company (other than any such shares owned by Subsidiaries of the Company in a fiduciary, representative or other
capacity on behalf of other Persons, whether or not held in a separate account). Section&nbsp;4.05(b) of the Company Disclosure Schedule sets forth a true and complete list, as of November&nbsp;28, 2017, of all outstanding Company Equity Awards,
including with respect to each such equity award, the holder, date of grant, vesting schedule, whether the award provides for accelerated vesting upon the consummation of the transactions contemplated by this Agreement, whether subject to
performance conditions, number of shares of Company Common Stock subject to such award, the amount of any accrued but unpaid dividend equivalent rights relating to such award and, for Company Stock Appreciation Rights, the applicable exercise price
and expiration date. There are no outstanding bonds, debentures, notes or other indebtedness of the Company having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which shareholders
of the Company may vote. There are no outstanding obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any Company Securities. Neither the Company nor any of its Subsidiaries is a party to any agreement
with respect to the voting of any Company Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_21"></A>Section&nbsp;4.06. <U>Subsidiaries</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Major Subsidiary of the Company is a corporation or other entity duly incorporated or organized, validly existing and in good
standing under the laws of its jurisdiction of incorporation or organization and has all corporate or other organizational powers, as applicable, required to carry on its business as now conducted, except for those jurisdictions where failure to be
so organized, validly existing and in good standing or to have such power has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. Each such Major Subsidiary is duly qualified to
do business and is in good standing in each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified has not had and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect. Section&nbsp;4.06(a) of the Company Disclosure Schedule sets forth a true and complete list of each Major Subsidiary of the Company as of the date of this Agreement, its jurisdiction of incorporation or
organization, and, if a Regulated Subsidiary of the Company, each jurisdiction where it is licensed by the state department of insurance, state department of health or other applicable state agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding capital stock or other voting securities of, or ownership interests in, each Subsidiary of the Company are owned by
the Company, directly or indirectly, free and clear of any Lien. There are no issued, reserved for issuance or outstanding (i)&nbsp;securities of the Company or any of its Subsidiaries convertible into or exchangeable for shares of capital stock or
other voting securities of, or other ownership interests in, any Subsidiary of the Company, (ii)&nbsp;warrants, calls, options or other rights to acquire from the Company or any of its Subsidiaries, or other obligations of the Company or any of its
Subsidiaries to issue, any capital stock or other voting securities of, or other ownership interests in, or any securities convertible into or exchangeable for any capital stock or other voting securities of, or other ownership interests in, any
Subsidiary of the Company, or (iii)&nbsp;restricted shares, stock appreciation rights, performance units, contingent value rights, &#147;phantom&#148; stock or similar securities or rights issued by or with the approval of the Company or any of its
Subsidiaries that are derivative of, or provide economic benefits based, directly or indirectly, on the value or price of, any capital stock or other voting securities of, or other ownership interests in, any Subsidiary of the Company. There are no
outstanding obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any securities described in the foregoing clauses (i)&nbsp;through (iii) of this <U>Section</U><U></U><U>&nbsp;4.06(b)</U>. Except for the
capital stock or other voting securities of, or other ownership interests in, its Subsidiaries and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
publicly traded securities held for investment which do not exceed 5% of the outstanding securities of any entity, the Company does not own, directly or indirectly, any capital stock or other
voting securities of, or other ownership interests in, any Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_22"></A>Section&nbsp;4.07. <U>SEC Filings and the
Sarbanes-Oxley Act</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company has timely filed with or furnished to the SEC all reports, schedules, forms, statements,
prospectuses, registration statements and other documents required to be filed with or furnished to the SEC by the Company since January&nbsp;1, 2015. No Subsidiary of the Company is required to file any report, schedule, form, statement,
prospectus, registration statement or other document with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As of its filing date, each report, schedule, form, statement,
prospectus, registration statement and other document filed with or furnished to the SEC by the Company since January&nbsp;1, 2015 (collectively, together with any exhibits and schedules thereto and other information incorporated therein, the
&#147;<U>Company SEC Documents</U>&#148;) filed prior to the date of this Agreement complied, and each Company SEC Document filed subsequent to the date of this Agreement (assuming, in the case of the Joint Proxy Statement/Prospectus, that the
representation and warranty set forth in <U>Section</U><U></U><U>&nbsp;5.09</U> is true and correct) will comply, in all material respects with the applicable requirements of the NYSE, the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act, as the
case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As of its filing date (or, if amended or superseded by a filing prior to the date of this Agreement, on the date of such
amended or superseding filing), each Company SEC Document filed prior to the date of this Agreement did not, and each Company SEC Document filed subsequent to the date of this Agreement (assuming, in the case of the Joint Proxy Statement/Prospectus,
that the representation and warranty set forth in <U>Section</U><U></U><U>&nbsp;5.09</U> is true and correct) will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company is, and since January&nbsp;1, 2015 has
been, in compliance in all material respects with (i)&nbsp;the applicable provisions of the Sarbanes-Oxley Act and (ii)&nbsp;the applicable listing and corporate governance rules and regulations of the NYSE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company and its Subsidiaries have established and maintain disclosure controls and procedures (as defined in Rule <FONT
STYLE="white-space:nowrap">13a-15</FONT> under the 1934 Act). Such disclosure controls and procedures are designed to ensure that material information relating to the Company, including its consolidated Subsidiaries, is made known to the
Company&#146;s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the 1934 Act are being prepared. Such disclosure controls
and procedures are effective in timely alerting the Company&#146;s principal executive officer and principal financial officer to material information required to be included in the Company&#146;s periodic and current reports required under the 1934
Act. For purposes of this Agreement, &#147;<U>principal executive officer</U>&#148; and &#147;<U>principal financial officer</U>&#148; shall have the meanings given to such terms in the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company and its Subsidiaries have established and maintain a system of internal control over financial reporting (as defined in Rule <FONT
STYLE="white-space:nowrap">13a-15</FONT> under the 1934 Act) (&#147;<U>internal controls</U>&#148;). Such internal controls are sufficient to provide reasonable assurance regarding the reliability of the Company&#146;s financial reporting and the
preparation of the Company&#146;s financial statements for external purposes in accordance with GAAP. The Company&#146;s principal executive officer and principal financial officer have disclosed, based on their most recent evaluation of such
internal controls prior to the date of this Agreement, to the Company&#146;s auditors and the audit committee of the Board of Directors of the Company (x)&nbsp;all significant deficiencies and material weaknesses in the design or operation of
internal controls which are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information and (y)&nbsp;any fraud, whether or not material, that involves management or other employees
who have a significant role in internal controls. The Company has made available to Parent prior to the date of this Agreement a true and complete summary of any disclosure of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the type described in the preceding sentence made by management to the Company&#146;s auditors and audit committee since January&nbsp;1, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Since January&nbsp;1, 2015, each of the principal executive officer and principal financial officer of the Company (or each former
principal executive officer and principal financial officer of the Company, as applicable) has made all certifications required by Rules <FONT STYLE="white-space:nowrap">13a-14</FONT> and <FONT STYLE="white-space:nowrap">15d-14</FONT> under the 1934
Act and Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC and the NYSE, and the statements contained in any such certifications are true and complete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_23"></A>Section&nbsp;4.08. <U>Financial Statements and Financial Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The audited consolidated financial statements and unaudited consolidated interim financial statements of the Company included or
incorporated by reference in the Company SEC Documents present fairly in all material respects, in conformity with GAAP applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto), the consolidated
financial position of the Company and its Subsidiaries as of the dates thereof and their consolidated results of operations and cash flows for the periods then ended (subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT>
audit adjustments in the case of any unaudited interim financial statements). Such consolidated financial statements have been prepared from, and are in accordance with, the books and records of the Company and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) From January&nbsp;1, 2015 to the date of this Agreement, the Company has not received written notice from the SEC or any other
Governmental Authority indicating that any of its accounting policies or practices are or may be the subject of any review, inquiry, investigation or challenge by the SEC or any other Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_24"></A>Section&nbsp;4.09. <U>Disclosure Documents</U>. The information relating to the Company and its Subsidiaries that
is provided by the Company, any of its Subsidiaries or any of their respective Representatives for inclusion or incorporation by reference in the Registration Statement or the Joint Proxy Statement/Prospectus will not (i)&nbsp;in the case of the
Registration Statement, at the time the Registration Statement or any amendment or supplement thereto becomes effective and at the time of the Company Shareholder Meeting and the Parent Stockholder Meeting, and (ii)&nbsp;in the case of the Joint
Proxy Statement/Prospectus, at the time the Joint Proxy Statement/Prospectus or any amendment or supplement thereto is first mailed to the shareholders of the Company and the stockholders of Parent and at the time of the Company Shareholder Meeting
and the Parent Stockholder Meeting, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_25"></A>Section&nbsp;4.10. <U>Statutory Financial Statements</U>. The audited statutory financial statements for the
year ended December&nbsp;31, 2016, and the unaudited statutory financial statements for the quarters ended March&nbsp;31, 2017, June&nbsp;30, 2017 and September&nbsp;30, 2017 filed by the Company&#146;s Regulated Subsidiaries that are licensed as
insurance companies or health maintenance organizations prior to the date hereof with the applicable Governmental Authorities (the &#147;<U>Company Statutory Filings</U>&#148;) and the respective statements of assets, liabilities, capital and
surplus, revenues and expenses and cash flows included or incorporated therein (i)&nbsp;were prepared from the books and records of the applicable Regulated Subsidiary, (ii)&nbsp;present fairly in all material respects the statutory financial
condition and results of operations of the applicable Regulated Subsidiary as of the date and for the periods then ended (subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments in the case of any interim
statements), and (iii)&nbsp;were prepared in all material respects in accordance with SAP applied on a consistent basis (except as may be indicated in the notes thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_26"></A>Section&nbsp;4.11. <U>Reserves</U>. The loss reserves and other actuarial amounts of the Regulated Subsidiaries of
the Company as of December&nbsp;31, 2016 recorded in the Company Statutory Filings: (i)&nbsp;were determined in all material respects in accordance with ASOPs in effect on that date (except as may be indicated in the notes thereto), (ii)&nbsp;were
computed on the basis of methodologies consistent in all material respects with those used in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
computing the corresponding reserves in the prior fiscal year (except as may be indicated in the notes thereto) and (iii)&nbsp;include provisions for all actuarial reserves that were required at
that time to be established in accordance with Applicable Laws based on facts known to the Company as of such date; <I>provided</I> that, notwithstanding the foregoing, it is acknowledged and agreed by Parent and Merger Sub that with respect to the
adequacy or sufficiency of the reserves of the Company or any of the Company&#146;s Regulated Subsidiaries, the Company is not making any representation or warranty in this Agreement, and nothing contained in this Agreement or any other agreement,
document or instrument to be delivered in connection with this Agreement is intended or shall be construed to be a representation or warranty of the Company in respect of the adequacy or sufficiency of the reserves of the Company or any of the
Company&#146;s Regulated Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_27"></A>Section&nbsp;4.12. <U>Capital or Surplus Maintenance</U>. As of the
date of this Agreement, no Regulated Subsidiary of the Company is subject to any requirement imposed by a Governmental Authority to maintain capital or surplus amounts or levels or is subject to any restriction on the payment of dividends or other
distributions on its shares of capital stock, except for any such requirements or restrictions under Applicable Laws of general application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_28"></A>Section&nbsp;4.13. <U>Absence of Certain Changes</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Since the Company Balance Sheet Date through the date of this Agreement, (i)&nbsp;the business of the Company and its Subsidiaries has
been conducted in all material respects in the ordinary course of business consistent with past practice and (ii)&nbsp;there has not been any event, change, effect, development or occurrence that has had or would reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Since the Company Balance Sheet Date through the date of this
Agreement, there has not been any action taken by the Company or any of its Subsidiaries that, if taken during the period from the date of this Agreement through the Effective Time without Parent&#146;s consent, would constitute a breach of
<U>Section</U><U></U><U>&nbsp;6.01</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_29"></A>Section&nbsp;4.14. <U>No Undisclosed Material Liabilities</U>. There
are no liabilities or obligations of the Company or any of its Subsidiaries of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise, other than (i)&nbsp;liabilities or obligations disclosed and provided
for in the Company Balance Sheet or in the notes thereto, (ii)&nbsp;liabilities or obligations incurred in the ordinary course of business consistent with past practice since the Company Balance Sheet Date, (iii)&nbsp;liabilities arising in
connection with the transactions contemplated hereby, and (iv)&nbsp;other liabilities or obligations that have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. There are no <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements of any type pursuant to any off-balance sheet arrangement required to be disclosed pursuant to Item 303(a)(4) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated
under the 1933 Act (&#147;<U>Regulation <FONT STYLE="white-space:nowrap">S-K</FONT></U>&#148;) that have not been so described in the Company SEC Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_30"></A>Section&nbsp;4.15. <U>Litigation</U>. There is no claim, action, suit, investigation or proceeding pending or, to
the knowledge of the Company, threatened against or affecting the Company, any of its Subsidiaries, any present or former officers, directors or employees of the Company or any of its Subsidiaries in their respective capacities as such, or any of
the respective properties of the Company or any of its Subsidiaries, before (or, in the case of threatened claims, actions, suits, investigations or proceedings, that would be before) any arbitrator or Governmental Authority, that has had or would
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect or that in any manner challenges or seeks to prevent, enjoin, alter or materially delay the Merger or any of the other transactions contemplated
hereby. There is no Order outstanding or threatened against or affecting the Company, any of its Subsidiaries, any present or former officers, directors or employees of the Company or any of its Subsidiaries in their respective capacities as such,
or any of the respective properties of any of the Company or any of its Subsidiaries, that has had or would reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect or that would prevent, enjoin, alter or
materially delay the Merger or any of the other transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_31"></A>Section&nbsp;4.16. <U>Permits</U>. Except as has not had and
would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company and each of its Subsidiaries hold all governmental licenses and Consents necessary for the operation of its respective
businesses (the &#147;<U>Company Permits</U>&#148;). The Company and each of its Subsidiaries is and since January&nbsp;1, 2015, has been in compliance with the terms of the Company Permits, except for failures to comply that have not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. There is no claim, action, suit, investigation or proceeding pending, or, to the knowledge of the Company, threatened that seeks, or, to the
knowledge of the Company, any existing condition, situation or set of circumstances that would reasonably be expected to result in, the revocation, cancellation, termination, <FONT STYLE="white-space:nowrap">non-renewal</FONT> or adverse
modification of any Company Permit except where such revocation, cancellation, termination, <FONT STYLE="white-space:nowrap">non-renewal</FONT> or adverse modification has not had and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_32"></A>Section&nbsp;4.17. <U>Compliance with Applicable Laws</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and each of its Subsidiaries is, and since January&nbsp;1, 2015 has been, in compliance with all Applicable Laws, except for
failures to comply that have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Since January&nbsp;1, 2015, neither the Company nor any of its Subsidiaries has entered into any agreement or settlement with any
Governmental Authority with respect to any actual or alleged violation of any Applicable Law, except for agreements and settlements that have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material
Adverse Effect. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, none of the Company or any of its Subsidiaries is, to the knowledge of the Company, subject to
an ongoing investigation by a Governmental Authority or has received any written notice, citation, suspension, revocation, limitation, warning, or request for repayment or refund issued by a Governmental Authority which alleges or asserts that the
Company or any of its Subsidiaries has violated any Applicable Laws or which requires or seeks to adjust, modify or alter the Company&#146;s or any of its Subsidiaries&#146; operations, activities, services or financial condition that has not been
fully and finally resolved without further liability to the Company and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Since January&nbsp;1, 2015, each Regulated
Subsidiary of the Company has filed all Company Statutory Filings and all other material Filings (including Filings with respect to premium rates, rating plans, policy terms and other terms established or used by any Subsidiaries of the Company),
together with any amendments required to be made with respect thereto, that it was required to file with any Governmental Authority, including CMS, state insurance departments, state departments of health, other applicable state Medicaid
authorities, and any other agencies with jurisdiction over the Health Care Programs and including Filings that it was required to file under the Patient Protection and Affordable Care Act (Pub. L. <FONT STYLE="white-space:nowrap">111-148)</FONT> as
amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. <FONT STYLE="white-space:nowrap">111-152),</FONT> except where the failure to make such Company Statutory Filings and other Filings has not had and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as has not had and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company and its Subsidiaries have adopted and implemented policies, procedures or programs reasonably designed to assure that their respective directors,
officers, employees, agents, brokers, producers, contractors, vendors, field marketing organizations, Third Party marketing organizations and similar entities with which they do business are in compliance with all Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) With respect to participation in Government Sponsored Health Care Programs, except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect, each of the Regulated Subsidiaries of the Company that participates in such a Government Sponsored Health Care Program (i)&nbsp;meets the requirements for participation in,
and receipt of payment from, the Government </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sponsored Health Care Programs in which such Regulated Subsidiary currently participates, and (ii)&nbsp;is a party to one or more valid agreements with the appropriate Governmental Authority,
including CMS or applicable state entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Since January&nbsp;1, 2015, except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect, none of the Company, any of its Subsidiaries or any director, officer or employee of the Company or any of its Subsidiaries has been or is currently suspended, excluded or
debarred from contracting with the federal or any state government or from participating in any Government Sponsored Health Care Program or subject to an investigation or proceeding by any Governmental Authority that could result in such suspension,
exclusion or debarment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Since January&nbsp;1, 2015, except as has not had and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect, none of the Company or any of its Subsidiaries (i)&nbsp;has been assessed a civil monetary penalty under Section&nbsp;1128A of the Social Security Act, (ii)&nbsp;has been excluded from
participation in any federal health care program or state health care program (as such terms are defined by the Social Security Act), (iii)&nbsp;has been convicted of any criminal offense relating to the delivery of any item or service under a
federal health care program, or (iv)&nbsp;has been or is a party to or subject to any action or proceeding concerning any of the matters described in the foregoing clauses (i)&nbsp;through (iii) of this <U>Section</U><U></U><U>&nbsp;4.17(g)</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_33"></A>Section&nbsp;4.18. <U>Material Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;4.18(a) of the Company Disclosure Schedule sets forth a list as of the date of this Agreement of each of the following
Contracts to which the Company or any of its Subsidiaries is a party or by which it is bound (each such Contract listed or required to be so listed, and each of the following Contracts to which the Company or any of its Subsidiaries becomes a party
or by which it becomes bound after the date of this Agreement, a &#147;<U>Company Material Contract</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
(A)&nbsp;the 25 largest Contracts of the Company and its Subsidiaries, taken as a whole, with Providers, (B)&nbsp;the 25 largest service vendor Contracts of the Company and its Subsidiaries, taken as a whole, and (C)&nbsp;the 15 largest commercial
customer Contracts of the Company and its Subsidiaries, in each of (A)&nbsp;through (C) measured in terms of payments made or received (as applicable) by the Company and its Subsidiaries, taken as a whole, during the twelve (12)-month period ended
December&nbsp;31, 2016; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any Medicaid, Medicare, CHIP or TRICARE Contract or any national Office of Personnel
Management Contract with a Governmental Authority; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any Contracts of the Company and its Subsidiaries with brokers,
agents, or producers for which payments made by the Company and its Subsidiaries during the twelve (12)-month period ended December&nbsp;31, 2016 exceeded $10,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) any Contract or policy for reinsurance ceded to or assumed from a Third Party involving payments in excess of $7,500,000
in any fiscal year; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) any pharmacy benefit management agreement with any entity other than Parent or one of its
Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) any Contracts between the Company and its Subsidiaries with a pharmaceutical manufacturer involving
payments during the twelve (12)-month period ended December&nbsp;31, 2016 in excess of (A) $30,000,000 in the case of Contracts for formulary or pharmacy rebates or (B) $10,000,000 in the case of all other such Contracts; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) any Contract that (A)&nbsp;limits or purports to limit, in any material respect, the freedom of the Company or any of its
Subsidiaries to engage or compete in any line of business or with any Person or in any area or that would so limit or purport to limit, in any material respect, the freedom of Parent, the Company or any of their respective Affiliates after the
Effective Time or (B)&nbsp;contains exclusivity or &#147;most </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
favored nation&#148; obligations or restrictions or other provisions restricting or purporting to restrict the ability of the Company or any of its Subsidiaries to contract or establish prices
for health care or other services, to sell products directly or indirectly through third parties or to solicit any potential employee, Provider or customer that would so restrict or purport to restrict Parent or any of its Affiliates after the
Effective Time in any material respect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) any Contract reasonably expected to result in payments made or received by
the Company and its Subsidiaries in excess of $50,000,000 in any year and for which the execution, delivery and performance by the Company of this Agreement or the consummation of the transactions contemplated hereby would require any consent or
other action by any Person (including notice by the Company) thereunder, constitute a default, or an event that, with or without notice or lapse of time or both, would constitute a default, thereunder, or cause or permit the termination,
cancellation, acceleration or other change of any right or obligation (including triggering of a price adjustment, right of renegotiation or other remedy) or the loss of any benefit to which the Company or any of its Subsidiaries is entitled
thereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) promissory notes, loan agreements, indentures, evidences of indebtedness or other instruments providing
for or relating to the lending of money, (A)&nbsp;if as borrower or guarantor, in excess of $25,000,000, and (B)&nbsp;if as lender, in excess of $5,000,000 (in each case, other than (1)&nbsp;any such Contract, as lender, with any Provider, as
borrower, so long as such Contract was entered into in the ordinary course of business consistent with past practice, or (2)&nbsp;any such Contracts among the Company and its wholly owned Subsidiaries or among the Company&#146;s wholly owned
Subsidiaries); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) any Contract restricting the payment of dividends or the making of distributions to shareholders or the
repurchase of stock or other equity; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) any collective bargaining agreements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) any material joint venture, profit-sharing, partnership or other similar agreements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) other than with respect to any transactions involving investments in securities under the Company&#146;s investment
portfolio consistent with the Company&#146;s investment policy in effect as of the date hereof, any Contracts or series of related Contracts relating to the pending acquisition or disposition of the assets or securities of any Person or any business
for a price in excess of $15,000,000 (in each case, whether by merger, sale of stock, sale of assets or otherwise); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv)
any lease or sublease for real or personal property for which annual rental payments made by the Company and its Subsidiaries during the twelve (12)&nbsp;month period ended December&nbsp;31, 2016 or expected to be made by the Company and its
Subsidiaries during the twelve (12)&nbsp;month period ending December&nbsp;31, 2017 are greater than $1,500,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) all
material Contracts pursuant to which the Company or any of its Subsidiaries (A)&nbsp;receives or is granted any license or sublicense to, or covenant not to be sued under, any Intellectual Property (other than licenses to Software that is
commercially available on <FONT STYLE="white-space:nowrap">non-discriminatory</FONT> pricing terms) or (B)&nbsp;grants any license or sublicense to, or covenant not to be sued under, any Intellectual Property (other than immaterial, <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted in the ordinary course of business); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) any Contracts
or other transactions with any (A)&nbsp;executive officer or director of the Company, (B)&nbsp;record or, to the knowledge of the Company, beneficial owner of five percent (5%) or more of the voting securities of the Company, or (C)&nbsp;affiliate
(as such term is defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the 1934 Act) or &#147;associates&#148; (or members of any of their &#147;immediate family&#148;) (as such terms are respectively defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> and Rule <FONT STYLE="white-space:nowrap">16a-1</FONT> of the 1934 Act) of any such executive officer, director or beneficial owner; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) any other Contract required to be filed by the Company pursuant to Item 601(b)(10) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All of the Company Material Contracts are, subject to the Bankruptcy and Equity Exceptions,
(i)&nbsp;valid and binding obligations of the Company or a Subsidiary of the Company (as the case may be) and, to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
knowledge of the Company, each of the other parties thereto, and (ii)&nbsp;in full force and effect and enforceable in accordance with their respective terms against the Company or its
Subsidiaries (as the case may be) and, to the knowledge of the Company, each of the other parties thereto (except for such Company Material Contracts that are terminated after the date of this Agreement in accordance with their respective terms),
except where the failure to be valid and binding obligations and in full force and effect and enforceable has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the knowledge
of the Company, no Person is seeking to terminate or challenging the validity or enforceability of any Company Material Contract, except such terminations or challenges which have not had and would not reasonably be expected to have, individually or
in the aggregate, a Company Material Adverse Effect. Neither the Company nor any of its Subsidiaries, nor to the knowledge of the Company, any of the other parties thereto has violated any provision of, or committed or failed to perform any act
which (with or without notice, lapse of time or both) would constitute a default under any provision of, and neither the Company nor any of its Subsidiaries has received written notice that it has violated or defaulted under, any Company Material
Contract, except for those violations and defaults (or potential defaults) which have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Section&nbsp;4.18(c) of the Company Disclosure Schedule sets forth a true and complete list as of the date of this Agreement of each
executory contract, offer or other undertaking that is outside of the ordinary course of business consistent with past practice executed by the Company or any of its Subsidiaries that, if accepted or executed and delivered by the applicable Third
Party would constitute a Company Material Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_34"></A>Section&nbsp;4.19. <U>Taxes</U>. Except as has not had
and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All Tax Returns
required by Applicable Law to be filed with any Taxing Authority by, or on behalf of, the Company or any of its Subsidiaries have been filed when due (giving effect to all extensions) in accordance with all Applicable Law, and all such Tax Returns
are true and complete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company and each of its Subsidiaries has paid (or has had paid on its behalf) or has withheld and remitted
to the appropriate Taxing Authority all Taxes due and payable, or (i)&nbsp;where payment is not yet due, has established (or has had established on its behalf and for its sole benefit and recourse) in accordance with GAAP or SAP, as applicable, an
adequate accrual or (ii)&nbsp;where payment is being contested in good faith pursuant to appropriate procedures, has established (or has had established on its behalf and for its sole benefit and recourse) in accordance with GAAP or SAP, as
applicable, an adequate reserve, in each case for all Taxes through the end of the last period for which the Company and its Subsidiaries ordinarily record items on their respective books and records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) (i)&nbsp;All federal income Tax Returns of the affiliated group of which the Company is the common parent through the Tax year ended
December&nbsp;31, 2015 have been examined and closed or are Tax Returns with respect to which the applicable period for assessment under Applicable Law, after giving effect to extensions or waivers, has expired, and (ii)&nbsp;neither the Company nor
any of its Subsidiaries (or any member of any affiliated, consolidated, combined or unitary group of which the Company or any of its Subsidiaries is or has been a member) has granted any extension or waiver of the limitation period applicable to the
assessment or collection of any federal income Tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) There is no claim, action, suit, proceeding or investigation (including an audit)
pending or, to the Company&#146;s knowledge, threatened in writing against or with respect to the Company or its Subsidiaries in respect of any Tax or Tax asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) There are no requests for rulings or determinations in respect of any Tax or Tax asset pending between the Company or any of its
Subsidiaries and any Taxing Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) During the two (2)-year period ending on the date of this Agreement, the Company was not
a distributing corporation or a controlled corporation in a transaction purported or intended to be a <FONT STYLE="white-space:nowrap">spin-off</FONT> governed by Section&nbsp;355 or Section&nbsp;361 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) There are no Liens for Taxes (other than Permitted Liens) upon any of the assets of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) No claim has been made in writing by any Taxing Authority in a jurisdiction where the Company and/or the Company&#146;s Subsidiaries do
not file Tax Returns that the Company or any of its Subsidiaries is or may be subject to taxation by, or required to file any Tax Return in, that jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) None of the Company or its Subsidiaries has &#147;participated&#148; in a &#147;listed transaction&#148; within the meaning of Treasury
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Neither the Company nor any of its Subsidiaries
(i)&nbsp;has been a member of an affiliated, consolidated, combined or unitary group other than one of which the Company or any of its Subsidiaries was the common parent, (ii)&nbsp;is party to any Tax Sharing Agreement (other than any such agreement
solely between the Company and its Subsidiaries), or (iii)&nbsp;has any liability for the Taxes of any Person (other than the Company or any of its Subsidiaries) under Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> law) or any Tax Sharing Agreement or as a transferee or successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_35"></A>Section&nbsp;4.20. <U>Employees and Employee Benefit Plans</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;4.20 of the Company Disclosure Schedule sets forth a true and complete list as of the date of this Agreement of each material
Company Employee Plan and each Company Employee Plan that is subject to ERISA. For each material Company Employee Plan and each Company Employee Plan that is subject to ERISA, the Company has made available to Parent a copy of such plan (or a
description, if such plan is not written) and all amendments thereto and material written interpretations thereof, together with a copy of (if applicable) (i)&nbsp;each trust, insurance or other funding arrangement, (ii)&nbsp;each summary plan
description and summary of material modifications, (iii)&nbsp;the most recently filed Internal Revenue Service Forms 5500, (iv)&nbsp;the most recent favorable determination or opinion letter from the Internal Revenue Service, (v)&nbsp;the most
recently prepared actuarial reports and financial statements in connection with each such Company Employee Plan, (vi)&nbsp;all documents and correspondence relating thereto received from or provided to the Department of Labor, the PBGC, the Internal
Revenue Service or any other Governmental Authority during the past year, and (vii)&nbsp;all current employee handbooks, manuals and policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither the Company nor any of its ERISA Affiliates (nor any predecessor of any such entity) sponsors, maintains, administers or
contributes to (or has any obligation to contribute to), or has since January&nbsp;1, 2011, sponsored, maintained, administered or contributed to (or had any obligation to contribute to), any plan subject to Title IV of ERISA, including any
multiemployer plan, as defined in Section&nbsp;3(37) of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, each Company Employee Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has received a favorable determination or opinion letter from the Internal Revenue
Service or has applied to the Internal Revenue Service for such a letter within the applicable remedial amendment period or such period has not expired and, to the knowledge of the Company, no circumstances exist that would reasonably be expected to
result in any such letter being revoked or not being reissued or a penalty under the Internal Revenue Service Closing Agreement Program if discovered during an Internal Revenue Service audit or investigation. Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, each trust created under any such Company Employee Plan is exempt from tax under Section&nbsp;501(a) of the Code and has been so exempt since its
creation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as has not had and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect, since January&nbsp;1, 2015, each Company Employee Plan has been maintained in compliance with its terms and all Applicable Law, including ERISA and the Code. Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, no claim (other than routine claims for benefits), action, suit, investigation or proceeding (including an audit) is pending against or involves or,
to the Company&#146;s knowledge, is threatened against or reasonably expected to involve, any Company Employee Plan before any court or arbitrator or any Governmental Authority, including the Internal Revenue Service, the Department of Labor or the
PBGC. To the knowledge of the Company, since January&nbsp;1, 2015, no events have occurred with respect to any Company Employee Plan that would reasonably be expected to result in the assessment of any excise taxes or penalties against the Company
or any of its Subsidiaries, except for events that have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) With respect to each director, officer, employee or independent contractor (including each former director, officer, employee or
independent contractor) of the Company or any of its Subsidiaries, the consummation of the transactions contemplated by this Agreement will not, either alone or together with any other event: (i)&nbsp;entitle any such individual to any payment or
benefit, including any bonus, retention, severance, retirement or job security payment or benefit, (ii)&nbsp;accelerate the time of payment or vesting or trigger any payment or funding (through a grantor trust or otherwise) of compensation or
benefits under, or increase the amount payable or trigger any other obligation under, any Company Employee Plan or (iii)&nbsp;limit or restrict the right of the Company or any of its Subsidiaries or, after the Closing, Parent to merge, amend or
terminate any Company Employee Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of its Subsidiaries has any current or projected liability for, and
no Company Employee Plan provides or promises, any post- employment or post-retirement medical, dental, disability, hospitalization, life or similar benefits (whether insured or self-insured) to any director, officer, employee or individual
independent contractor (including any former director, officer, employee or individual independent contractor) of the Company or any of its Subsidiaries (other than coverage mandated by Applicable Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) There has been no amendment to, written interpretation of or announcement (whether or not written) by the Company or any of its Affiliates
relating to, or making a change in employee participation or coverage under, any Company Employee Plan that would materially increase the expense of maintaining such plan above the level of expense incurred in respect thereof for the fiscal year
ended on the Company Balance Sheet Date, except as required in order to comply with Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, no Company Employee Plan or other compensation benefit or arrangement, individually or collectively, would reasonably be expected to result in
the payment of any amount that would not be deductible under Section&nbsp;280G of the Code. Neither the Company nor any of its Subsidiaries has any obligation to <FONT STYLE="white-space:nowrap">gross-up,</FONT> indemnify or otherwise reimburse any
Person for any tax incurred by such Person, including under Section&nbsp;409A or 4999 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each Company Employee Plan, and
any award thereunder, that is or forms part of a &#147;nonqualified deferred compensation plan&#148; within the meaning of Section&nbsp;409A of the Code has been timely amended (if applicable) to comply and has been operated in compliance with, and
the Company and its Subsidiaries have complied in practice and operation with, all applicable requirements of Section&nbsp;409A of the Code in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) With respect to any Company Employee Plan covered by Subtitle B, Part 4 of Title I of ERISA or Section&nbsp;4975 of the Code, no <FONT
STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction has occurred that has caused or would reasonably be expected to cause the Company or any of its Subsidiaries to incur any material liability under ERISA or the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_36"></A>Section&nbsp;4.21. <U>Labor Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as has not had or would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
the Company and its Subsidiaries are, and since January&nbsp;1, 2015 have been, in compliance with all Applicable Laws relating to labor and employment, including those relating to labor management relations, wages, hours, overtime, employee
classification, discrimination, sexual harassment, civil rights, affirmative action, work authorization, immigration, safety and health, information privacy and security, workers compensation, continuation coverage under group health plans, wage
payment and the payment and withholding of taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither the Company nor any of its Subsidiaries is, or since January&nbsp;1, 2015
has been, a party to or subject to, or is currently negotiating in connection with entering into, any collective bargaining agreement, and, to the Company&#146;s knowledge, there has not been any organizational campaign, card solicitation, petition
or other unionization activity seeking recognition of a collective bargaining unit relating to any director, officer, employee or individual independent contractor of the Company or any of its Subsidiaries. Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, there are no unfair labor practice complaints pending or, to the Company&#146;s knowledge, threatened against the Company or any of its Subsidiaries
before the National Labor Relations Board or any other Governmental Authority or any current union representation questions involving any director, officer, employee or individual independent contractor (including any former director, officer,
employee or individual independent contractor) of the Company or any of its Subsidiaries with respect to the Company or its Subsidiaries. There is no labor strike, slowdown, stoppage, picketing, interruption of work or lockout pending or, to the
Company&#146;s knowledge, threatened against or affecting the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_37"></A>Section&nbsp;4.22. <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;4.22(a) of the Company Disclosure Schedule sets forth a list as of the date of this Agreement of all registrations (including
patents and domain name registrations) and applications for registration for Owned Intellectual Property that is Company Intellectual Property (the &#147;<U>Company Registered IP</U>&#148;). Except as has not had and would not reasonably be expected
to have, individually or in the aggregate, a Company Material Adverse Effect, none of the Company Registered IP has lapsed, expired, been abandoned or been adjudged invalid or unenforceable, and, to the knowledge of the Company, all Company
Registered IP is valid, enforceable and subsisting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except as has not had and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect, (i)&nbsp;the Company and its Subsidiaries are the sole and exclusive owners of all Owned Intellectual Property included in the Company Intellectual Property and hold all of their right, title
and interest in and to all of the Company Intellectual Property free and clear of all Liens (other than <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted by the Company or one of its Subsidiaries in the ordinary course of
business), (ii)&nbsp;to the knowledge of the Company, the Company&#146;s Owned Intellectual Property and the Company&#146;s Licensed Intellectual Property constitutes all of the Intellectual Property necessary to, or used or held for use in, the
conduct of the respective businesses of the Company and its Subsidiaries as currently conducted, and (iii)&nbsp;to the knowledge of the Company, there exist no material restrictions on the use of any of the Company&#146;s Owned Intellectual
Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material
Adverse Effect, (i)&nbsp;to the knowledge of the Company, neither the Company nor any of its Subsidiaries nor the conduct of their respective businesses has infringed, misappropriated, diluted or otherwise violated any Intellectual Property rights
of any Third Party, (ii)&nbsp;there is no claim, action, suit, investigation or proceeding pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries (A)&nbsp;alleging that the Company or any
of its Subsidiaries has infringed, misappropriated, diluted or otherwise violated any Intellectual Property rights of any Third Party or (B)&nbsp;based upon, or challenging or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seeking to deny or restrict, the rights of the Company or any of its Subsidiaries in any of the Company Intellectual Property, and (iii)&nbsp;to the knowledge of the Company, no Third Party has
infringed, misappropriated, diluted or otherwise violated any Company Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i)&nbsp;the Company and its Subsidiaries have provided reasonable notice of its privacy and personal data collection and use policies on its
websites and other customer and public communications and the Company and its Subsidiaries have complied with such policies and all Applicable Laws relating to (A)&nbsp;the privacy of the users of the Company&#146;s and its Subsidiaries&#146;
respective products, services and websites and (B)&nbsp;the collection, use, storage and disclosure of any personally-identifiable information (including personal health information) and other data or information collected or stored by the Company
or any of its Subsidiaries, (ii)&nbsp;there is no claim, action, suit, investigation or proceeding pending or, to the knowledge of the Company, threatened against the Company or any of its Subsidiaries alleging any violation of such policies or
Applicable Laws, (iii)&nbsp;neither this Agreement nor the consummation of the transactions contemplated hereby will violate any such policy, and (iv)&nbsp;the Company and its Subsidiaries have taken commercially reasonable steps consistent with
normal industry practice to protect the types of information referred to in this <U>Section</U><U></U><U>&nbsp;4.22(d)</U> against loss and unauthorized access, use, modification, disclosure or other misuse, and, to the knowledge of the Company,
there has been no unauthorized access, use, modification, disclosure or other misuse of such data or information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Except as has not
had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i)&nbsp;the Company&#146;s IT Assets operate in accordance with their specifications and related documentation and perform in a
manner that permits the Company and its Subsidiaries to conduct their respective businesses as currently conducted, (ii)&nbsp;the Company and its Subsidiaries take commercially reasonable actions, consistent with current industry standards, to
protect the confidentiality, integrity and security of the Company&#146;s IT Assets (and all information and transactions stored or contained therein or transmitted thereby) against any unauthorized use, access, interruption, modification or
corruption, including the implementation of commercially reasonable data backup, disaster avoidance and recovery procedures and business continuity procedures, and (iii)&nbsp;there has been no unauthorized use, access, interruption, modification or
corruption of the Company&#146;s IT Assets (or any information or transactions stored or contained therein or transmitted thereby). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_38">
</A>Section&nbsp;4.23. <U>Properties</U>. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i)&nbsp;the Company and each of its Subsidiaries has good, valid and
marketable fee simple title to, or valid leasehold interests in, as the case may be, each parcel of real property of the Company or any of its Subsidiaries, free and clear of all Liens, except for Permitted Liens, (ii)&nbsp;each lease, sublease or
license (each, a &#147;<U>Lease</U>&#148;) under which the Company or any of its Subsidiaries leases, subleases or licenses any real property is, subject to the Bankruptcy and Equity Exceptions, a valid and binding obligation of the Company or a
Subsidiary of the Company (as the case may be) and, to the knowledge of the Company, each of the other parties thereto, and in full force and effect and enforceable in accordance with its terms against the Company or its Subsidiaries (as the case
may be) and, to the knowledge of the Company, each of the other parties thereto (except for such Leases that are terminated after the date of this Agreement in accordance with their respective terms), (iii)&nbsp;neither the Company nor any of its
Subsidiaries, nor, to the knowledge of the Company, any of the other parties thereto has violated or committed or failed to perform any act which (with or without notice, lapse of time or both) would constitute a default under any provision of any
Lease, and (iv)&nbsp;neither the Company nor any of its Subsidiaries has received written notice that it has violated or defaulted under any Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_39"></A>Section&nbsp;4.24. <U>Environmental Matters</U>. Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) no notice, notification, demand, request for information,
citation, summons or order has been received, no complaint has been filed, no penalty has been assessed, and no claim, action, suit, proceeding or investigation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including a review) is pending or, to the knowledge of the Company, threatened by any Governmental Authority or other Person relating to the Company or any of its Subsidiaries that relates to,
or arises under, any Environmental Law, Environmental Permit or Hazardous Substance; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Company and its Subsidiaries are, and since
January&nbsp;1, 2015 have been, in compliance with all Environmental Laws and all Environmental Permits and hold all applicable Environmental Permits; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) there are no liabilities or obligations of the Company or any of its Subsidiaries of any kind whatsoever, whether accrued, contingent,
absolute, determined, determinable or otherwise arising under or relating to any Environmental Law, Environmental Permit or Hazardous Substance and there is no existing condition, situation or set of circumstances that could reasonably be expected
to result in any such liability or obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_40"></A>Section&nbsp;4.25. <U>Insurance</U>. The Company has made
available to Parent, prior to the date of this Agreement, a list and summaries of all material insurance policies and fidelity bonds for which the Company or any of its Subsidiaries is a policyholder or which covers the business, operations,
employees, officers, directors or assets of the Company or any of its Subsidiaries (the &#147;<U>Company Insurance Policies</U>&#148;). The Company and its Subsidiaries maintain insurance coverage with reputable insurers in such amounts and covering
such risks as the Company reasonably believes, based on past experience, is adequate for the businesses and operations of the Company and its Subsidiaries (taking into account the cost and availability of such insurance). Except as has not had and
would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company Insurance Policies (i)&nbsp;are sufficient for compliance by the Company and its Subsidiaries with all Company Material
Contracts and (ii)&nbsp;will not terminate or lapse by their terms by reason of the consummation of the transactions contemplated by this Agreement. Section&nbsp;4.25 of the Company Disclosure Schedule sets forth the amount per annum the Company
paid in its last full fiscal year ending prior to the date of this Agreement for the Company&#146;s existing directors&#146; and officers&#146; insurance policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_41"></A>Section&nbsp;4.26. <U>Transactions with Affiliates</U>. To the knowledge of the Company and as of the date of this
Agreement, since January&nbsp;1, 2015, there have been no transactions, or series of related transactions, agreements, arrangements or understandings in effect, nor are there any currently proposed transactions, or series of related transactions,
agreements, arrangements or understandings, that would be required to be disclosed under Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> that have not been otherwise disclosed in the Company SEC Documents filed prior to the date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_42"></A>Section&nbsp;4.27. <U>Antitakeover Statutes</U>. Assuming the representation and warranty set forth
in <U>Section</U><U></U><U>&nbsp;5.23</U> is true and correct, neither the restrictions set forth in Subchapter F of Chapter 25 of Pennsylvania Law nor any other &#147;control share acquisition,&#148; &#147;fair price,&#148; &#147;moratorium&#148;
or other antitakeover laws enacted under U.S. state or federal laws apply to this Agreement or any of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_43"></A>Section&nbsp;4.28. <U>Opinions of Financial Advisor</U><U>s</U>. The Board of Directors of the Company has
received the separate opinions of each of Lazard Fr&egrave;res&nbsp;&amp; Co. LLC and Allen&nbsp;&amp; Company LLC, financial advisors to the Company, to the effect that, as of the date of such opinion and based upon and subject to the various
assumptions, limitations, qualifications and other matters set forth therein, the Merger Consideration to be paid to the holders of Company Common Stock pursuant to this Agreement is fair, from a financial point of view, to such holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_44"></A>Section&nbsp;4.29. <U>Finders</U><U>&#146;</U><U> Fees</U>. Except for Lazard Fr&egrave;res&nbsp;&amp; Co. LLC,
Allen&nbsp;&amp; Company LLC and Evercore Group L.L.C., a copy of each of whose engagement agreements has been provided to Parent prior to the date of this Agreement, there is no investment banker, broker, finder or other intermediary that has been
retained by or is authorized to act on behalf of the Company or any of its Subsidiaries who might be entitled to any fee or commission from the Company or any of its Affiliates in connection with the transactions contemplated by this Agreement. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_45"></A>Section&nbsp;4.30. <U>No Ownership of Parent Common Stock</U>.
Neither the Company nor any of its Subsidiaries beneficially owns, directly or indirectly, any shares of Parent Common Stock or other securities convertible into, exchangeable for or exercisable for shares of Parent Common Stock, and neither the
Company nor any of its Subsidiaries has any rights to acquire any shares of Parent Common Stock (other than any such securities owned by the Company or any of its Subsidiaries in a fiduciary, representative or other capacity on behalf of other
Persons, whether or not held in a separate account). There are no voting trusts or other agreements or understandings to which the Company or any of its Subsidiaries is a party with respect to the voting of the capital stock or other equity interest
of Parent or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_46"></A>Section&nbsp;4.31. <U>No Other Company Representations and
Warranties</U>. Except for the representations and warranties made by the Company in this <U>Article</U><U></U><U>&nbsp;IV</U> (as qualified by the applicable items disclosed in the Company Disclosure Schedule in accordance with
<U>Section</U><U></U><U>&nbsp;11.05</U> and the introduction to this <U>Article</U><U></U><U>&nbsp;IV</U>), neither the Company nor any other Person makes or has made any representation or warranty, expressed or implied, at law or in equity, with
respect to or on behalf of the Company or its Subsidiaries, their businesses, operations, assets, liabilities, financial condition, results of operations, future operating or financial results, estimates, projections, forecasts, plans or prospects
(including the reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or completeness of any information regarding the Company or its Subsidiaries or any other matter furnished or
provided to Parent or made available to Parent in any &#147;data rooms,&#148; &#147;virtual data rooms,&#148; management presentations or in any other form in expectation of, or in connection with, this Agreement or the transactions contemplated
hereby. The Company and its Subsidiaries disclaim any other representations or warranties, whether made by the Company or any of its Subsidiaries or any of their respective Affiliates or Representatives. Without limiting the generality of the
foregoing, except for the representations and warranties made by the Company in this <U>Article</U><U></U><U>&nbsp;IV</U> (as qualified by the applicable items disclosed in the Company Disclosure Schedule in accordance with
<U>Section</U><U></U><U>&nbsp;11.05</U> and the introduction to this <U>Article</U><U></U><U>&nbsp;IV</U>), neither the Company nor any other Person makes or has made any representation or warranty, expressed or implied, at law or in equity, with
respect to or on behalf of the Company or its Subsidiaries with respect to (a)&nbsp;the adequacy or sufficiency of reserves, (b)&nbsp;the effect of the adequacy or sufficiency of reserves on any line item, asset, liability or equity amount on any
financial or other document, (c)&nbsp;whether or not reserves were determined in accordance with any actuarial, statutory, regulatory or other standard, or (d)&nbsp;the collectability of any amounts under any reinsurance Contract. The Company
acknowledges and agrees that, except for the representations and warranties made by Parent in <U>Article</U><U></U><U>&nbsp;V</U> (as qualified by the applicable items disclosed in the Parent Disclosure Schedule in accordance with
<U>Section</U><U></U><U>&nbsp;11.05</U> and the introduction to <U>Article</U><U></U><U>&nbsp;V</U>), neither Parent nor any other Person is making or has made any representations or warranty, expressed or implied, at law or in equity, with respect
to or on behalf of Parent or its Subsidiaries, their businesses, operations, assets, liabilities, financial condition, results of operations, future operating or financial results, estimates, projections, forecasts, plans or prospects (including the
reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or completeness of any information regarding Parent or its Subsidiaries or any other matter furnished or provided to Parent or
made available to the Company in any &#147;data rooms,&#148; &#147;virtual data rooms,&#148; management presentations or in any other form in expectation of, or in connection with, this Agreement, or the transactions contemplated hereby or thereby.
The Company specifically disclaims that it is relying upon or has relied upon any such other representations or warranties that may have been made by any Person, and acknowledges and agrees that Parent and its Affiliates have specifically disclaimed
and do hereby specifically disclaim any such other representations and warranties. Notwithstanding the foregoing, this <U>Section</U><U></U><U>&nbsp;4.31</U> shall not limit Parent&#146;s, Merger Sub&#146;s or the Company&#146;s remedies in the case
of fraud. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF PARENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to <U>Section</U><U></U><U>&nbsp;11.05</U>, except (i)&nbsp;other than with respect to the representations and warranties in
<U>Section</U><U></U><U>&nbsp;5.01</U>, <U>Section</U><U></U><U>&nbsp;5.02</U>, <U>Section</U><U></U><U>&nbsp;5.05</U>, <U>Section</U><U></U><U>&nbsp;5.06</U>, <U>Section</U><U></U><U>&nbsp;5.20</U>, <U>Section</U><U></U><U>&nbsp;5.21</U> and
<U>Section</U><U></U><U>&nbsp;5.22</U>, as disclosed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in any publicly available Parent SEC Document filed after December&nbsp;31, 2016 and before the date of this Agreement or in Parent&#146;s annual report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2015 or in Parent&#146;s proxy statement for the 2016 annual meeting of Parent&#146;s stockholders or (ii)&nbsp;as set forth in the Parent Disclosure Schedule,
Parent represents and warrants to the Company that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_47"></A>Section&nbsp;5.01. <U>Corporate Existence and Power</U>.
Parent is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and Merger Sub is a corporation duly incorporated and validly subsisting under the laws of the Commonwealth of Pennsylvania.
Each of Parent and Merger Sub has all corporate powers required to own or lease all of its properties or assets and to carry on its business as now conducted. Each of Parent and Merger Sub is duly qualified to do business and is in good standing in
each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. As
of the date hereof, Parent indirectly owns all of the outstanding shares of capital stock of Merger Sub. Prior to the date of this Agreement, Parent has made available to the Company true and complete copies of the certificate of incorporation and
bylaws of Parent and the articles of incorporation and bylaws of Merger Sub, as in effect on the date of this Agreement (the &#147;<U>Parent Organizational Documents</U>&#148;). Since the date of its formation, Merger Sub has not engaged in any
activities other than in connection with or as contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_48"></A>Section&nbsp;5.02.
<U>Corporate Authorization</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The execution, delivery and performance by each of Parent and Merger Sub of this Agreement and the
consummation by Parent and Merger Sub of the transactions contemplated by this Agreement are within the corporate powers of each of Parent and Merger Sub and, except for the Parent Stockholder Approval and the required approval of the shareholder of
Merger Sub in connection with the consummation of the Merger, have been duly authorized by all necessary corporate action on the part of Parent and Merger Sub. The affirmative vote of a majority of all votes cast by holders of outstanding shares of
Parent Common Stock at a duly called and held meeting of Parent&#146;s stockholders at which a quorum is present approving the issuance of shares of Parent Common Stock in connection with the Merger (the &#147;<U>Parent Share Issuance</U>&#148;) is
the only vote of the holders of any of Parent&#146;s capital stock necessary in connection with the consummation of the Merger (the &#147;<U>Parent Stockholder Approval</U>&#148;). This Agreement has been duly executed and delivered by each of
Parent and Merger Sub and (assuming due authorization, execution and delivery by the Company) constitutes a valid and binding agreement of each of Parent and Merger Sub enforceable against Parent and Merger Sub in accordance with its terms (subject
to the Bankruptcy and Equity Exceptions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At a meeting duly called and held, the Board of Directors of Parent unanimously adopted
resolutions (i)&nbsp;determining that this Agreement and the transactions contemplated hereby (including the Parent Share Issuance) are fair to and in the best interests of Parent&#146;s stockholders, (ii)&nbsp;approving, adopting and declaring
advisable this Agreement and the transactions contemplated hereby (including the Parent Share Issuance), (iii)&nbsp;directing that the approval of the Parent Share Issuance be submitted to a vote at a meeting of Parent&#146;s stockholders and
(iv)&nbsp;recommending approval of the Parent Share Issuance by Parent&#146;s stockholders (such recommendation, the &#147;<U>Parent Board Recommendation</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Board of Directors of Merger Sub has unanimously adopted resolutions (i)&nbsp;determining that this Agreement and the transactions
contemplated hereby (including the Merger) are fair to and in the best interests of Merger Sub and its shareholder, (ii)&nbsp;approving, adopting and declaring advisable this Agreement and the transactions contemplated hereby (including the Merger),
(iii)&nbsp;directing that this Agreement be submitted to a vote of Merger Sub&#146;s shareholder and (iv)&nbsp;recommending approval and adoption of this Agreement by Merger Sub&#146;s shareholder. Except as permitted by
<U>Section</U><U></U><U>&nbsp;7.02</U>, the Board of Directors of each of Parent and Merger Sub has not subsequently rescinded, modified or withdrawn any of the foregoing resolutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_49"></A>Section&nbsp;5.03. <U>Governmental Authorization</U>. The execution, delivery and performance by each of Parent
and Merger Sub of this Agreement and the consummation by each of Parent and Merger Sub of the transactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated hereby require no action by or in respect of, Consents of, or Filing with, any Governmental Authority other than (i)&nbsp;the filing of the Statement of Merger with the Pennsylvania
Department of State and appropriate documents with the relevant authorities of other states in which Parent or Merger Sub is qualified to do business, (ii)&nbsp;compliance with any applicable requirements of the HSR Act, (iii)&nbsp;compliance with
any applicable requirements of the 1933 Act, the 1934 Act and any other applicable U.S. state or federal securities laws or pursuant to the rules of the NYSE, (iv)&nbsp;Consents of, and Filings with, the state insurance departments, federal and
state departments of health and other Consents and Filings required under the Health Care Laws, Government Sponsored Health Care Programs or Insurance Laws that are listed on Section&nbsp;5.03 of the Parent Disclosure Schedule (the Consents and
Filings required under or in connection with this clause&nbsp;(iv), collectively, the &#147;<U>Parent Required Governmental Authorizations</U>&#148;), and (v)&nbsp;any other actions, Consents or Filings the absence of which has not had and would not
reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_50"></A>Section&nbsp;5.04. <U><FONT STYLE="white-space:nowrap">Non-contravention</FONT></U>. The execution, delivery and
performance by each of Parent and Merger Sub of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i)&nbsp;contravene, conflict with, or result in any violation or breach of any provision of the Parent
Organizational Documents, (ii)&nbsp;assuming compliance with the matters referred to in <U>Section</U><U></U><U>&nbsp;5.03</U> and receipt of the Parent Stockholder Approval, contravene, conflict with or result in any violation or breach of any
provision of any Applicable Law, (iii)&nbsp;assuming compliance with the matters referred to in <U>Section</U><U></U><U>&nbsp;5.03</U> and receipt of the Parent Stockholder Approval, require any Consent or other action by any Person under,
constitute a default, or an event that, with or without notice or lapse of time or both, would constitute a default, under, or cause or permit the termination, cancellation, acceleration or other change of any right or obligation or the loss of any
benefit to which Parent or any of its Subsidiaries is entitled under, any provision of any Contract binding upon Parent or any of its Subsidiaries or any governmental Consents (including Consents required by Contract) affecting, or relating in any
way to, the assets or business of Parent and its Subsidiaries, or (iv)&nbsp;result in the creation or imposition of any Lien on any asset of Parent or any of its Subsidiaries, with such exceptions, in the case of each of clauses (ii)&nbsp;through
(iv), as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_51">
</A>Section&nbsp;5.05. <U>Capitalization</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Parent consists of (i)&nbsp;3,200,000,000 shares of
Parent Common Stock, (ii)&nbsp;120,619 shares of cumulative preferred stock, par value $0.01 per share (&#147;<U>Parent Preferred Stock</U>&#148;) and (iii)&nbsp;50,000,000 shares of preference stock, par value $1.00 per share (&#147;<U>Parent
Preference Stock</U>&#148;). As of November&nbsp;30, 2017, there were outstanding (i)&nbsp;1,013,088,658 shares of Parent Common Stock, (ii)&nbsp;no shares of Parent Preferred Stock, (iii)&nbsp;no shares of Parent Preference Stock, (iv)&nbsp;options
to purchase shares of Parent Common Stock (&#147;<U>Parent Stock Options</U>&#148;) with respect to an aggregate of 20,940,443 shares of Parent Common Stock (of which, Parent Stock Options with respect to 11,604,106 shares of Parent Common Stock
were exercisable), (v)&nbsp;5,577,549 restricted stock units under Parent&#146;s equity compensation plans, assuming target performance levels for any performance-based restricted stock units (&#147;<U>Parent Restricted Stock Units</U>&#148;) and
(vi)&nbsp;865,100 shares of Parent Common Stock subject to long-term incentive plan awards, at target performance levels (together with Parent Stock Options, Parent Restricted Stock Units and any other equity or equity-linked awards granted after
November&nbsp;30, 2017, &#147;<U>Parent Equity Awards</U>&#148;). The shares of Parent Common Stock to be issued as part of the Merger Consideration have been duly authorized and, when issued and delivered in accordance with the terms of this
Agreement, will have been validly issued and will be fully paid and nonassessable and the issuance thereof will be free of preemptive right. Parent directly or indirectly owns all of the issued and outstanding capital stock of Merger Sub. Except as
set forth in this <U>Section</U><U></U><U>&nbsp;5.05(a)</U> and for changes since November&nbsp;30, 2017 resulting from (x)&nbsp;the exercise or vesting and settlement of Parent Equity Awards outstanding on such date or issued after such date, or
(y)&nbsp;the issuance of Parent Equity Awards after such date, there are no issued, reserved for issuance or outstanding (A)&nbsp;shares of capital stock or other voting securities of, or other ownership interest in, Parent, (B)&nbsp;securities of
Parent convertible into or exchangeable for shares of capital stock or other voting securities of, or other ownership interests in, Parent, (C)&nbsp;warrants, calls, options or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other rights to acquire from Parent, or other obligations of Parent to issue, any capital stock or other voting securities of, or other ownership interests in, or securities convertible into or
exchangeable for capital stock or other voting securities of, or other ownership interests in, Parent, or (D)&nbsp;restricted shares, stock appreciation rights, performance units, contingent value rights, &#147;phantom&#148; stock or similar
securities or rights issued by or with the approval of Parent that are derivative of, or provide economic benefits based, directly or indirectly, on the value or price of, any capital stock or other voting securities of, or other ownership interests
in, Parent (the items in clauses (A)&nbsp;through (D) being referred to collectively as the &#147;<U>Parent Securities</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
All outstanding shares of capital stock of Parent have been, and all shares that may be issued pursuant to any employee stock option or other compensation plan or arrangement will be, when issued in accordance with the respective terms thereof, duly
authorized and validly issued, fully paid and nonassessable and free of preemptive rights. No Subsidiary of Parent owns any shares of capital stock of Parent (other than any such shares owned by Subsidiaries of Parent in a fiduciary, representative
or other capacity on behalf of other Persons, whether or not held in a separate account). There are no outstanding bonds, debentures, notes or other indebtedness of Parent having the right to vote (or convertible into, or exchangeable for,
securities having the right to vote) on any matters on which stockholders of Parent may vote. There are no outstanding obligations of Parent or any of its Subsidiaries to repurchase, redeem or otherwise acquire any Parent Securities. Neither Parent
nor any of its Subsidiaries is a party to any agreement with respect to the voting of any Parent Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_52"></A>Section&nbsp;5.06. <U>Subsidiaries</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Major Subsidiary of Parent is a corporation or other entity duly incorporated or organized, validly existing and in good standing
under the laws of its jurisdiction of incorporation or organization and has all corporate or other organizational powers, as applicable, required to carry on its business as now conducted, except for those jurisdictions where failure to be so
organized, validly existing and in good standing or to have such power has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. Each such Major Subsidiary is duly qualified to do
business and is in good standing in each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified has not had and would not reasonably be expected to have, individually or in the aggregate,
a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding capital stock or other voting securities of, or ownership interests in, each
Subsidiary of Parent are owned by Parent, directly or indirectly, free and clear of any Lien. There are no issued, reserved for issuance or outstanding (i)&nbsp;securities of Parent or any of its Subsidiaries convertible into or exchangeable for
shares of capital stock or other voting securities of, or other ownership interests in, any Subsidiary of Parent, (ii)&nbsp;warrants, calls, options or other rights to acquire from Parent or any of its Subsidiaries, or other obligations of Parent or
any of its Subsidiaries to issue, any capital stock or other voting securities of, or other ownership interests in, or any securities convertible into or exchangeable for any capital stock or other voting securities of, or other ownership interests
in, any Subsidiary of Parent or (iii)&nbsp;restricted shares, stock appreciation rights, performance units, contingent value rights, &#147;phantom&#148; stock or similar securities or rights issued by or with the approval of Parent or any of its
Subsidiaries that are derivative of, or provide economic benefits based, directly or indirectly, on the value or price of, any capital stock or other voting securities of, or other ownership interests in, any Subsidiary of Parent. There are no
outstanding obligations of Parent or any of its Subsidiaries to repurchase, redeem or otherwise acquire any securities described in the foregoing clauses (i)&nbsp;through (iii) of this <U>Section</U><U></U><U>&nbsp;5.06(b)</U>. Except for the
capital stock or other voting securities of, or other ownership interests in, its Subsidiaries and publicly traded securities held for investment which do not exceed 5% of the outstanding securities of any entity, Parent does not own, directly or
indirectly, any capital stock or other voting securities of, or other ownership interests in, any Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_53"></A>Section&nbsp;5.07. <U>SEC Filings and the Sarbanes-Oxley Act</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Parent has timely filed with or furnished to the SEC all reports, schedules, forms, statements, prospectuses, registration statements and
other documents required to be filed with or furnished to the SEC by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parent since January&nbsp;1, 2015. No Subsidiary of Parent is required to file any report, schedule, form, statement, prospectus, registration statement or other document with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As of its filing date, each report, schedule, form, statement, prospectus, registration statement and other document filed with or
furnished to the SEC by Parent since January&nbsp;1, 2015 (collectively, together with any exhibits and schedules thereto and other information incorporated therein, the &#147;<U>Parent SEC Documents</U>&#148;) filed prior to the date of this
Agreement complied, and each Parent SEC Document filed subsequent to the date of this Agreement (assuming, in the case of each of the Registration Statement and the Joint Proxy Statement/Prospectus, that the representation and warranty set forth in
<U>Section</U><U></U><U>&nbsp;4.09</U> is true and correct) will comply, in all material respects with the applicable requirements of the NYSE, the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As of its filing date (or, if amended or superseded by a filing prior to the date of this Agreement, on the date of such amended or
superseding filing), each Parent SEC Document filed prior to the date of this Agreement did not, and each Parent SEC Document filed subsequent to the date of this Agreement (assuming, in the case of each of the Registration Statement and the Joint
Proxy Statement/Prospectus, that the representation and warranty set forth in <U>Section</U><U></U><U>&nbsp;4.09</U> is true and correct) will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Parent is, and since
January&nbsp;1, 2015 has been, in compliance in all material respects with (i)&nbsp;the applicable provisions of the Sarbanes-Oxley Act and (ii)&nbsp;the applicable listing and corporate governance rules and regulations of the NYSE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Parent and its Subsidiaries have established and maintain disclosure controls and procedures (as defined in Rule <FONT
STYLE="white-space:nowrap">13a-15</FONT> under the 1934 Act). Such disclosure controls and procedures are designed to ensure that material information relating to Parent, including its consolidated Subsidiaries, is made known to Parent&#146;s
principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the 1934 Act are being prepared. Such disclosure controls and procedures
are effective in timely alerting Parent&#146;s principal executive officer and principal financial officer to material information required to be included in Parent&#146;s periodic and current reports required under the 1934 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Parent and its Subsidiaries have established and maintain a system of internal controls. Such internal controls are sufficient to provide
reasonable assurance regarding the reliability of Parent&#146;s financial reporting and the preparation of Parent&#146;s financial statements for external purposes in accordance with GAAP. Parent&#146;s principal executive officer and principal
financial officer have disclosed, based on their most recent evaluation of internal controls prior to the date of this Agreement, to Parent&#146;s auditors and the audit committee of the Board of Directors of Parent (x)&nbsp;all significant
deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect Parent&#146;s ability to record, process, summarize and report financial information and (y)&nbsp;any fraud, whether
or not material, that involves management or other employees who have a significant role in internal controls. Parent has made available to the Company prior to the date of this Agreement a true and complete summary of any disclosure of the type
described in the preceding sentence made by management to Parent&#146;s auditors and audit committee since January&nbsp;1, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
Since January&nbsp;1, 2015, each of the principal executive officer and principal financial officer of Parent (or each former principal executive officer and principal financial officer of Parent, as applicable) has made all certifications required
by Rules <FONT STYLE="white-space:nowrap">13a-14</FONT> and <FONT STYLE="white-space:nowrap">15d-14</FONT> under the 1934 Act and Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC and the
NYSE, and the statements contained in any such certifications are true and complete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_54"></A>Section&nbsp;5.08.
<U>Financial Statements and Financial Matters</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The audited consolidated financial statements and unaudited condensed consolidated
interim financial statements of Parent included or incorporated by reference in the Parent SEC Documents present fairly in all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material respects, in conformity with GAAP applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto), the consolidated financial position of
Parent and its Subsidiaries as of the dates thereof and their consolidated results of operations and cash flows for the periods then ended (subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments in the
case of any unaudited interim financial statements). Such consolidated financial statements have been prepared from, and are in accordance with, the books and records of Parent and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) From January&nbsp;1, 2015 to the date of this Agreement, Parent has not received written notice from the SEC or any other Governmental
Authority indicating that any of its accounting policies or practices are or may be the subject of any review, inquiry, investigation or challenge by the SEC or any other Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_55"></A>Section&nbsp;5.09. <U>Disclosure Documents</U>. The information relating to Parent and its Subsidiaries that is
provided by Parent, any of its Subsidiaries or any of their respective Representatives for inclusion or incorporation by reference in the Registration Statement or the Joint Proxy Statement/Prospectus will not (i)&nbsp;in the case of the
Registration Statement, at the time the Registration Statement or any amendment or supplement thereto becomes effective and at the time of the Company Shareholder Meeting and the Parent Stockholder Meeting, and (ii)&nbsp;in the case of the Joint
Proxy Statement/Prospectus, at the time the Joint Proxy Statement/Prospectus or any amendment or supplement thereto is first mailed to the shareholders of the Company and the stockholders of Parent and at the time of the Company Shareholder Meeting
and Parent Stockholder Meeting, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_56"></A>Section&nbsp;5.10. <U>Absence of Certain Changes</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Since the Parent Balance Sheet Date through the date of this Agreement, (i)&nbsp;the business of Parent and its Subsidiaries has been
conducted in all material respects in the ordinary course of business consistent with past practice and (ii)&nbsp;there has not been any event, change, effect, development or occurrence that has had or would reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Since the Parent Balance Sheet Date through the date of this
Agreement, there has not been any action taken by Parent or any of its Subsidiaries that, if taken during the period from the date of this Agreement through the Effective Time without the Company&#146;s consent, would constitute a breach of
<U>Section</U><U></U><U>&nbsp;7.01</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_57"></A>Section&nbsp;5.11. <U>No Undisclosed Material Liabilities</U>. There
are no liabilities or obligations of Parent or any of its Subsidiaries of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise, other than (i)&nbsp;liabilities or obligations disclosed and provided for in
the Parent Balance Sheet or in the notes thereto, (ii)&nbsp;liabilities or obligations incurred in the ordinary course of business consistent with past practice since the Parent Balance Sheet Date, (iii)&nbsp;liabilities arising in connection with
the transactions contemplated hereby, and (iv)&nbsp;other liabilities or obligations that have not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. There are no <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements of any type pursuant to any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangement required to be disclosed pursuant to Item 303(a)(4) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> that have not been so described in the Parent SEC Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_58"></A>Section&nbsp;5.12. <U>Litigation</U>. There is no claim, action, suit, investigation or proceeding pending or, to
the knowledge of Parent, threatened against or affecting Parent, any of its Subsidiaries, any present or former officers, directors or employees of Parent or any of its Subsidiaries in their respective capacities as such or any of the respective
properties of Parent or any of its Subsidiaries, before (or, in the case of threatened claims, actions, suits, investigations or proceedings, that would be before) any arbitrator or Governmental Authority, that has had or would reasonably be
expected to have, individually or in the aggregate, a Parent Material Adverse Effect or that in any manner challenges or seeks to prevent, enjoin, alter or materially delay the Merger or any of the other transactions contemplated hereby. There is no
Order outstanding or threatened against or affecting Parent, any of its Subsidiaries, any present or former officers, directors or employees of Parent or any of its Subsidiaries in their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respective capacities as such or any of the respective properties of any of Parent or any of its Subsidiaries, that has had or would reasonably be expected to have, individually or in the
aggregate, a Parent Material Adverse Effect or that would prevent, enjoin, alter or materially delay the Merger or any of the other transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_59"></A>Section&nbsp;5.13. <U>Permits</U>. Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, Parent and each of its Subsidiaries hold all governmental licenses and Consents necessary for the operation of its respective businesses (the &#147;<U>Parent Permits</U>&#148;).
Parent and each of its Subsidiaries is and since January&nbsp;1, 2015, has been in compliance with the terms of the Parent Permits, except for failures to comply that have not had and would not reasonably be expected to have, individually or in the
aggregate, a Parent Material Adverse Effect. There is no claim, action, suit, investigation or proceeding pending, or, to the knowledge of Parent, threatened that seeks, or, to the knowledge of Parent, any existing condition, situation or set of
circumstances that would reasonably be expected to result in, the revocation, cancellation, termination, <FONT STYLE="white-space:nowrap">non-renewal</FONT> or adverse modification of any Parent Permit except where such revocation, cancellation,
termination, <FONT STYLE="white-space:nowrap">non-renewal</FONT> or adverse modification has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_60"></A>Section&nbsp;5.14. <U>Compliance with Applicable Laws</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Parent and each of its Subsidiaries is, and since January&nbsp;1, 2015 has been, in compliance with all Applicable Laws, except for
failures to comply that have not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Since January&nbsp;1, 2015, neither Parent nor any of its Subsidiaries has entered into any agreement or settlement with any Governmental
Authority with respect to any actual or alleged violation of any Applicable Law, except for agreements and settlements that have not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse
Effect. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, none of Parent or any of its Subsidiaries is, to the knowledge of Parent, subject to an ongoing
investigation by a Governmental Authority or has received any written notice, citation, suspension, revocation, limitation, warning, or request for repayment or refund issued by a Governmental Authority which alleges or asserts that Parent or any of
its Subsidiaries has violated any Applicable Laws or which requires or seeks to adjust, modify or alter Parent&#146;s or any of its Subsidiaries&#146; operations, activities, services or financial condition that has not been fully and finally
resolved without further liability to Parent and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Since January&nbsp;1, 2015, each Regulated Subsidiary of Parent
has filed all material Filings (including Filings with respect to premium rates, rating plans, policy terms and other terms established or used by any Subsidiaries of Parent), together with any amendments required to be made with respect thereto,
that it was required to file with any Governmental Authority, including CMS, state insurance departments, state departments of health, other applicable state Medicaid authorities, and any other agencies with jurisdiction over the Health Care
Programs and including Filings that it was required to file under the Patient Protection and Affordable Care Act (Pub. L. <FONT STYLE="white-space:nowrap">111-148)</FONT> as amended by the Health Care and Education Reconciliation Act of 2010 (Pub.
L. <FONT STYLE="white-space:nowrap">111-152),</FONT> except where the failure to make such Filings has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
Parent and its Subsidiaries have adopted and implemented policies, procedures or programs reasonably designed to assure that their respective directors, officers, employees, agents, brokers, producers, contractors, vendors, field marketing
organizations, Third Party marketing organizations and similar entities with which they do business are in compliance with all Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) With respect to participation in Government Sponsored Health Care Programs, except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Parent Material Adverse Effect, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each of the Subsidiaries of Parent that participates in such a Government Sponsored Health Care Program (i)&nbsp;meets the requirements for participation in, and receipt of payment from, the
Government Sponsored Health Care Programs in which such Subsidiary currently participates and (ii)&nbsp;is a party to one or more valid agreements with the appropriate Governmental Authority, including CMS or applicable state entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Since January&nbsp;1, 2015, except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent
Material Adverse Effect, none of Parent, any of its Subsidiaries, or any director, officer or employee of Parent or any of its Subsidiaries has been or is currently suspended, excluded or debarred from contracting with the federal or any state
government or from participating in any Government Sponsored Health Care Program or subject to an investigation or proceeding by any Governmental Authority that could result in such suspension, exclusion or debarment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Since January&nbsp;1, 2015, except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent
Material Adverse Effect, none of Parent or any of its Subsidiaries (i)&nbsp;has been assessed a civil monetary penalty under Section&nbsp;1128A of the Social Security Act, (ii)&nbsp;has been excluded from participation in any federal health care
program or state health care program (as such terms are defined by the Social Security Act), (iii) has been convicted of any criminal offense relating to the delivery of any item or service under a federal health care program or (iv)&nbsp;has been
or is a party to or subject to any action or proceeding concerning any of the matters described in the foregoing clauses (i)&nbsp;through (iii) of this <U>Section</U><U></U><U>&nbsp;5.14(g)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_61"></A>Section&nbsp;5.15. <U>Taxes</U>. Except as has not had and would not reasonably be expected to have, individually
or in the aggregate, a Parent Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All Tax Returns required by Applicable Law to be filed with any Taxing
Authority by, or on behalf of, Parent or any of its Subsidiaries have been filed when due (giving effect to all extensions) in accordance with all Applicable Law, and all such Tax Returns are true and complete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Parent and each of its Subsidiaries has paid (or has had paid on its behalf) or has withheld and remitted to the appropriate Taxing
Authority all Taxes due and payable, or (i)&nbsp;where payment is not yet due, has established (or has had established on its behalf and for its sole benefit and recourse) in accordance with GAAP an adequate accrual or (ii)&nbsp;where payment is
being contested in good faith pursuant to appropriate procedures, has established (or has had established on its behalf and for its sole benefit and recourse) in accordance with GAAP an adequate reserve, in each case for all Taxes through the end of
the last period for which Parent and its Subsidiaries ordinarily record items on their respective books and records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) (i)&nbsp;All
federal income Tax Returns of the affiliated group of which Parent is the common parent through the Tax year ended December&nbsp;31, 2015 have been examined and closed or are Tax Returns with respect to which the applicable period for assessment
under Applicable Law, after giving effect to extensions or waivers, has expired, and (ii)&nbsp;neither Parent nor any of its Subsidiaries (or any member of any affiliated, consolidated, combined or unitary group of which Parent or any of its
Subsidiaries is or has been a member) has granted any extension or waiver of the limitation period applicable to the assessment or collection of any federal income Tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) There is no claim, action, suit, proceeding or investigation (including an audit) pending or, to Parent&#146;s knowledge, threatened in
writing against or with respect to Parent or its Subsidiaries in respect of any Tax or Tax asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) There are no requests for rulings
or determinations in respect of any Tax or Tax asset pending between Parent or any of its Subsidiaries and any Taxing Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
During the two (2)-year period ending on the date of this Agreement, Parent was not a distributing corporation or a controlled corporation in a transaction purported or intended to be a <FONT STYLE="white-space:nowrap">spin-off</FONT> governed by
Section&nbsp;355 or Section&nbsp;361 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) There are no Liens for Taxes (other than Permitted Liens) upon any of the assets of
Parent or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) No claim has been made in writing by any Taxing Authority in a jurisdiction where Parent and/or
Parent&#146;s Subsidiaries do not file Tax Returns that Parent or any of its Subsidiaries is or may be subject to taxation by, or required to file any Tax Return in, that jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) None of Parent or its Subsidiaries has &#147;participated&#148; in a &#147;listed transaction&#148; within the meaning of Treasury
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Neither Parent nor any of its Subsidiaries
(i)&nbsp;has been a member of an affiliated, consolidated, combined or unitary group other than one of which Parent or any of its Subsidiaries was the common parent, (ii)&nbsp;is party to any Tax Sharing Agreement (other than any such agreement
solely between Parent and its Subsidiaries), or (iii)&nbsp;has any liability for the Taxes of any Person (other than Parent or any of its Subsidiaries) under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any
similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> law) or any Tax Sharing Agreement or as a transferee or successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_62"></A>Section&nbsp;5.16. <U>Employees and Employee Benefit Plans</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither Parent nor any of its ERISA Affiliates (nor any predecessor of any such entity) sponsors, maintains, administers or contributes to
(or has any obligation to contribute to), or has since January&nbsp;1, 2011, sponsored, maintained, administered or contributed to (or had any obligation to contribute to), any plan subject to Title IV of ERISA, including any multiemployer plan, as
defined in Section&nbsp;3(37) of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except as has not had and would not reasonably be expected to have, individually or in the
aggregate, a Parent Material Adverse Effect, each Parent Employee Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has received a favorable determination or opinion letter from the Internal Revenue Service or has applied
to the Internal Revenue Service for such a letter within the applicable remedial amendment period or such period has not expired and, to the knowledge of Parent, no circumstances exist that would reasonably be expected to result in any such letter
being revoked or not being reissued or a penalty under the Internal Revenue Service Closing Agreement Program if discovered during an Internal Revenue Service audit or investigation. Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Parent Material Adverse Effect, each trust created under any such Parent Employee Plan is exempt from tax under Section&nbsp;501(a) of the Code and has been so exempt since its creation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
since January&nbsp;1, 2015, each Parent Employee Plan has been maintained in compliance with its terms and all Applicable Law, including ERISA and the Code. Except as has not had and would not reasonably be expected to have, individually or in the
aggregate, a Parent Material Adverse Effect, no claim (other than routine claims for benefits), action, suit, investigation or proceeding (including an audit) is pending against or involves or, to Parent&#146;s knowledge, is threatened against or
reasonably expected to involve, any Parent Employee Plan before any court or arbitrator or any Governmental Authority, including the Internal Revenue Service, the Department of Labor or the PBGC. To the knowledge of Parent, since January&nbsp;1,
2015, no events have occurred with respect to any Parent Employee Plan that would reasonably be expected to result in the assessment of any excise taxes or penalties against Parent or any of its Subsidiaries, except for events that have not had and
would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Neither Parent nor any
of its Subsidiaries has any current or projected liability for, and no Parent Employee Plan provides or promises, any post-employment or post-retirement medical, dental, disability, hospitalization, life or similar benefits (whether insured or
self-insured) to any director, officer, employee or individual independent contractor (including any former director, officer, employee or individual independent contractor) of Parent or any of its Subsidiaries (other than coverage mandated by
Applicable Law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) There has been no amendment to, written interpretation of or announcement (whether or
not written) by Parent or any of its Affiliates relating to, or making a change in employee participation or coverage under, any Parent Employee Plan that would materially increase the expense of maintaining such plan above the level of expense
incurred in respect thereof for the fiscal year ended on the Parent Balance Sheet Date, except as required in order to comply with Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_63"></A>Section&nbsp;5.17. <U>Labor Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as has not had or would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
Parent and its Subsidiaries are, and since January&nbsp;1, 2015 have been, in compliance with all Applicable Laws relating to labor and employment, including those relating to labor management relations, wages, hours, overtime, employee
classification, discrimination, sexual harassment, civil rights, affirmative action, work authorization, immigration, safety and health, information privacy and security, workers compensation, continuation coverage under group health plans, wage
payment and the payment and withholding of taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither Parent nor any of its Subsidiaries is, or since January&nbsp;1, 2015 has
been, a party to or subject to, or is currently negotiating in connection with entering into, any collective bargaining agreement, and, to Parent&#146;s knowledge, there has not been any organizational campaign, card solicitation, petition or other
unionization activity seeking recognition of a collective bargaining unit relating to any director, officer, employee or individual independent contractor of Parent of any of its Subsidiaries. Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Parent Material Adverse Effect, there are no unfair labor practice complaints pending or, to Parent&#146;s knowledge, threatened against Parent or any of its Subsidiaries before the National
Labor Relations Board or any other Governmental Authority or any current union representation questions involving any director, officer, employee or individual independent contractor (including any former director, officer, employee or individual
independent contractor) of Parent or any of its Subsidiaries with respect to Parent or its Subsidiaries. There is no labor strike, slowdown, stoppage, picketing, interruption of work or lockout pending or, to Parent&#146;s knowledge, threatened
against or affecting Parent or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_64"></A>Section&nbsp;5.18. <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
none of the registrations (including patents and domain name registrations) and applications for registration for Owned Intellectual Property that is Parent Intellectual Property (the &#147;<U>Parent Registered IP</U>&#148;) has lapsed, expired,
been abandoned or been adjudged invalid or unenforceable, and, to the knowledge of Parent, all Parent Registered IP is valid, enforceable and subsisting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
(i)&nbsp;Parent and its Subsidiaries are the sole and exclusive owners of all Owned Intellectual Property included in the Parent Intellectual Property and hold all of their right, title and interest in and to all of the Parent Intellectual Property
free and clear of all Liens (other than <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted by Parent or one of its Subsidiaries in the ordinary course of business), (ii)&nbsp;to the knowledge of Parent, Parent&#146;s Owned
Intellectual Property and Parent&#146;s Licensed Intellectual Property constitutes all of the Intellectual Property necessary to, or used or held for use in, the conduct of the respective businesses of Parent and its Subsidiaries as currently
conducted, and (iii)&nbsp;to the knowledge of Parent, there exist no material restrictions on the use of any of Parent&#146;s Owned Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
(i)&nbsp;to the knowledge of Parent, neither Parent nor any of its Subsidiaries nor the conduct of their respective businesses has infringed, misappropriated, diluted or otherwise violated any Intellectual Property rights of any Third Party,
(ii)&nbsp;there is no claim, action, suit, investigation or proceeding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pending or, to the knowledge of Parent, threatened against or affecting Parent or any of its Subsidiaries (A)&nbsp;alleging that Parent or any of its Subsidiaries has infringed, misappropriated,
diluted or otherwise violated any Intellectual Property rights of any Third Party or (B)&nbsp;based upon, or challenging or seeking to deny or restrict, the rights of Parent or any of its Subsidiaries in any of Parent Intellectual Property, and
(iii)&nbsp;to the knowledge of Parent, no Third Party has infringed, misappropriated, diluted or otherwise violated any Parent Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
(i)&nbsp;Parent and its Subsidiaries have provided reasonable notice of its privacy and personal data collection and use policies on its websites and other customer and public communications and Parent and its Subsidiaries have complied with such
policies and all Applicable Laws relating to (A)&nbsp;the privacy of the users of Parent&#146;s and its Subsidiaries&#146; respective products, services and websites and (B)&nbsp;the collection, use, storage and disclosure of any
personally-identifiable information (including personal health information) and other data or information collected or stored by Parent or any of its Subsidiaries, (ii)&nbsp;there is no claim, action, suit, investigation or proceeding pending or, to
the knowledge of Parent, threatened against Parent or any of its Subsidiaries alleging any violation of such policies or Applicable Laws, (iii)&nbsp;neither this Agreement nor the consummation of the transactions contemplated hereby will violate any
such policy, and (iv)&nbsp;Parent and its Subsidiaries have taken commercially reasonable steps consistent with normal industry practice to protect the types of information referred to in this <U>Section</U><U></U><U>&nbsp;5.18(d)</U> against loss
and unauthorized access, use, modification, disclosure or other misuse and, to the knowledge of Parent, there has been no unauthorized access, use, modification, disclosure or other misuse of such data or information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
(i)&nbsp;Parent&#146;s IT Assets operate in accordance with their specifications and related documentation and perform in a manner that permits Parent and its Subsidiaries to conduct their respective businesses as currently conducted,
(ii)&nbsp;Parent and its Subsidiaries take commercially reasonable actions, consistent with current industry standards, to protect the confidentiality, integrity and security of Parent&#146;s IT Assets (and all information and transactions stored or
contained therein or transmitted thereby) against any unauthorized use, access, interruption, modification or corruption, including the implementation of commercially reasonable data backup, disaster avoidance and recovery procedures and business
continuity procedures, and (iii)&nbsp;there has been no unauthorized use, access, interruption, modification or corruption of Parent&#146;s IT Assets (or any information or transactions stored or contained therein or transmitted thereby). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_65"></A>Section&nbsp;5.19. <U>Environmental Matters</U>. Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Parent Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) no notice, notification, demand, request for information,
citation, summons or order has been received, no complaint has been filed, no penalty has been assessed, and no claim, action, suit, proceeding or investigation (including a review) is pending or, to the knowledge of Parent, threatened by any
Governmental Authority or other Person relating to Parent or any of its Subsidiaries that relates to, or arises under, any Environmental Law, Environmental Permit or Hazardous Substance; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Parent and its Subsidiaries are, and since January&nbsp;1, 2015 have been, in compliance with all Environmental Laws and all Environmental
Permits and hold all applicable Environmental Permits; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) there are no liabilities or obligations of Parent or any of its
Subsidiaries of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise arising under or relating to any Environmental Law, Environmental Permit or Hazardous Substance and there is no existing condition,
situation or set of circumstances that could reasonably be expected to result in any such liability or obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_66">
</A>Section&nbsp;5.20. <U>Antitakeover Statutes</U>. Assuming the representations and warranties set forth in <U>Sections 4.27</U> and <U>4.30</U> are true and correct, no &#147;control share acquisition,&#148; &#147;fair price,&#148;
&#147;moratorium&#148; or other antitakeover laws enacted under U.S. state or federal laws apply to this Agreement or any of the transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_67"></A>Section&nbsp;5.21. <U>Opinions of Financial Advisor</U><U>s</U>.
The Board of Directors of Parent has received separate opinions of each of Barclays Capital Inc., Goldman Sachs&nbsp;&amp; Co. LLC, and Centerview Partners LLC, financial advisors to Parent, to the effect that, as of the date of such opinions and
based upon and subject to the limitations, qualifications and assumptions set forth therein, the Merger Consideration to be paid by Parent pursuant to this Agreement is fair, from a financial point of view, to Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_68"></A>Section&nbsp;5.22. <U>Finders</U><U>&#146;</U><U> Fees</U>. Except for Barclays Capital Inc., Goldman,
Sachs&nbsp;&amp; Co., and Centerview Partners LLC, there is no investment banker, broker, finder or other intermediary that has been retained by or is authorized to act on behalf of Parent or any of its Subsidiaries who might be entitled to any fee
or commission from Parent or any of its Affiliates in connection with the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_69">
</A>Section&nbsp;5.23. <U>No Ownership of Company Common Stock</U>. Neither Parent nor any of its Subsidiaries beneficially owns, directly or indirectly, any shares of Company Common Stock or other securities convertible into, exchangeable for or
exercisable for shares of Company Common Stock, and neither Parent nor any of its Subsidiaries has any rights to acquire any shares of Company Common Stock (other than any such securities owned by Parent or any of its Subsidiaries in a fiduciary,
representative or other capacity on behalf of other Persons, whether or not held in a separate account). There are no voting trusts or other agreements or understandings to which Parent or any of its Subsidiaries is a party with respect to the
voting of the capital stock or other equity interest of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_70"></A>Section&nbsp;5.24. <U>Financing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Parent has delivered to the Company a complete and correct copy of a fully executed commitment letter from the Financing Sources
(including all exhibits, schedules, and annexes to such letters as and to the extent delivered to the Company on or prior to the date of this Agreement, the &#147;<U>Debt Commitment Letter</U>&#148;), pursuant to which the Financing Sources have
committed, upon the terms and subject to the conditions set forth therein, to provide the debt financing described therein in connection with the transactions contemplated hereby. The Debt Commitment Letter and any other debt commitment letter
(including any replacement of the Debt Commitment Letter in connection with any Alternative Financing) executed in accordance with <U>Section</U><U></U><U>&nbsp;7.06</U>, as replaced, amended, supplemented, modified or waived in accordance with
<U>Section</U><U></U><U>&nbsp;7.06</U>, including all exhibits, schedules, and annexes to such letters, are hereinafter referred to together as the &#147;<U>Debt Commitment Letters</U>&#148;. The financing contemplated pursuant to the Debt
Commitment Letters is hereinafter referred to as the &#147;<U>Debt Financing</U>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As of the date of this Agreement, the Debt
Commitment Letters are in full force and effect and are legal, valid and binding obligations of Parent, and to the knowledge of Parent, the other parties thereto, and enforceable in accordance with their respective terms against Parent, and to the
knowledge of Parent, each of the other parties thereto, subject to the Bankruptcy and Equity Exceptions. All commitment fees required to be paid under the Debt Commitment Letters have been paid in full or will be duly paid in full as and when due,
and Parent and Merger Sub have otherwise satisfied all of the other items and conditions required to be satisfied by them, and within their control, pursuant to the terms of the Debt Commitment Letters on or prior to the date of this Agreement. None
of the Debt Commitment Letters have been amended, modified or terminated on or prior to the date of this Agreement, and no Debt Commitment Letter will be amended, modified or terminated by Parent or Merger Sub except as consistent with
<U>Section</U><U></U><U>&nbsp;7.06</U>. As of the date of this Agreement, assuming the accuracy of the Company&#146;s representations and warranties set forth in this Agreement, no event has occurred which, with or without notice, lapse of time or
both, would constitute a breach or default by Parent or Merger Sub under any Debt Commitment Letter. None of Parent or Merger Sub is, as of the date of this Agreement, aware of any fact, occurrence or condition that makes any of the representations
or warranties of Parent or Merger Sub set forth in any Debt Commitment Letter inaccurate (assuming the accuracy of the Company&#146;s representations and warranties set forth in this Agreement) in any material respect, that would cause the
commitments provided in the Debt Commitment Letter to be terminated or ineffective or any of the conditions contained therein not to be met. The consummation of the Debt Financing is subject to no conditions precedent other than those expressly set
forth in the copies of the Debt Commitment Letters delivered to the Company, and there are no contingencies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that would permit the Financing Sources to reduce the total amount of the Debt Financing other than those expressly set forth in the copies of the Debt Commitment Letters delivered to the
Company. Except for fee letters relating to fees with respect to the Debt Financing (redacted copies of which, removing only fee amounts, market &#147;flex&#148; provisions and certain other terms (none of which would adversely affect the amounts,
availability, timing or conditionality of the Debt Financing), have been provided to the Company on or prior to the date of this Agreement) and any engagement letters or fee discount letters related to the permanent financing referred to in the Debt
Commitment Letters, there are no side letters or other agreements, contracts or arrangements to which Parent or Merger Sub or any of their respective Affiliates are a party related to the funding of the Debt Financing, other than as expressly set
forth in the Debt Commitment Letters delivered to the Company on or prior to the date of this Agreement. As of the date of this Agreement, assuming no breach by the Company of its representations and warranties under this Agreement (and cooperation
and assistance by the Company as required by the terms of this Agreement) and no breach or default by the Company of its obligations under this Agreement (in either case such that the conditions set forth in <U>Section</U><U></U><U>&nbsp;9.01</U> or
<U>Section</U><U></U><U>&nbsp;9.02</U> would fail to be satisfied), and based upon facts and events known by Parent as of the date of this Agreement, none of Parent or Merger Sub have any reason to believe that any of the conditions to the Debt
Financing will not be satisfied or that the Debt Financing will not be available to Parent or Merger Sub as contemplated in the Debt Commitment Letters on or prior to the Closing Date. Subject to the terms and conditions of the Debt Commitment
Letters, the aggregate proceeds of the Debt Financing, together with cash or cash equivalents held by Parent and the other sources of funds referenced in the copies of the Debt Commitment Letters delivered to the Company on or prior to the date of
this Agreement, as of the Effective Time, will be sufficient to enable Parent to pay in cash all amounts required to be paid by it in cash in connection with the transactions contemplated hereby, including the Merger Consideration and all payments,
fees and expenses payable by it related to or arising out of the consummation of the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_71">
</A>Section&nbsp;5.25. <U>No Other Parent Representations and Warranties</U>. Except for the representations and warranties made by Parent in this <U>Article</U><U></U><U>&nbsp;V</U> (as qualified by the applicable items disclosed in the Parent
Disclosure Schedule in accordance with <U>Section</U><U></U><U>&nbsp;11.05</U> and the introduction to this <U>Article</U><U></U><U>&nbsp;V</U>), neither Parent nor any other Person makes or has made any representation or warranty, expressed or
implied, at law or in equity, with respect to or on behalf of Parent or its Subsidiaries, their businesses, operations, assets, liabilities, financial condition, results of operations, future operating or financial results, estimates, projections,
forecasts, plans or prospects (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or completeness of any information regarding Parent or its Subsidiaries or any
other matter furnished or provided to the Company or made available to the Company in any &#147;data rooms,&#148; &#147;virtual data rooms,&#148; management presentations or in any other form in expectation of, or in connection with, this Agreement
or the transactions contemplated hereby. Parent and its Subsidiaries disclaim any other representations or warranties, whether made by Parent or any of its Subsidiaries or any of their respective Affiliates or Representatives. Without limiting the
generality of the foregoing, except for the representations and warranties made by Parent in this <U>Article</U><U></U><U>&nbsp;V</U> (as qualified by the applicable items disclosed in the Parent Disclosure Schedule in accordance with
<U>Section</U><U></U><U>&nbsp;11.05</U> and the introduction to this <U>Article</U><U></U><U>&nbsp;V</U>), neither Parent nor any other Person makes or has made any representation or warranty, expressed or implied, at law or in equity, with respect
to or on behalf of Parent or its Subsidiaries with respect to (a)&nbsp;the adequacy or sufficiency of reserves, (b)&nbsp;the effect of the adequacy or sufficiency of reserves on any line item, asset, liability or equity amount on any financial or
other document, (c)&nbsp;whether or not reserves were determined in accordance with any actuarial, statutory, regulatory or other standard, or (d)&nbsp;the collectability of any amounts under any reinsurance Contract. Parent acknowledges and agrees
that, except for the representations and warranties made by the Company in <U>Article</U><U></U><U>&nbsp;IV</U> (as qualified by the applicable items disclosed in the Company Disclosure Schedule in accordance with
<U>Section</U><U></U><U>&nbsp;11.05</U> and the introduction to <U>Article</U><U></U><U>&nbsp;IV</U>), neither the Company nor any other Person is making or has made any representations or warranty, expressed or implied, at law or in equity, with
respect to or on behalf of the Company or its Subsidiaries, their businesses, operations, assets, liabilities, financial condition, results of operations, future operating or financial results, estimates, projections, forecasts, plans or prospects
(including the reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or completeness of any information regarding the Company or its Subsidiaries or any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other matter furnished or provided to Parent or made available to Parent in any &#147;data rooms,&#148; &#147;virtual data rooms,&#148; management presentations or in any other form in
expectation of, or in connection with, this Agreement, or the transactions contemplated hereby or thereby. Parent specifically disclaims that it is relying upon or has relied upon any such other representations or warranties that may have been made
by any Person, and acknowledges and agrees that the Company and its Affiliates have specifically disclaimed and do hereby specifically disclaim any such other representations and warranties. Notwithstanding the foregoing, this
<U>Section</U><U></U><U>&nbsp;5.25</U> shall not limit Parent&#146;s, Merger Sub&#146;s or the Company&#146;s remedies in the case of fraud. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_72">
</A>Section&nbsp;6.01. <U>Conduct of the Company</U>. From the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement, except (x)&nbsp;as prohibited or required by Applicable Law, (y)&nbsp;as set forth
in Section&nbsp;6.01 of the Company Disclosure Schedule, or (z)&nbsp;as otherwise required or expressly contemplated by this Agreement, unless Parent shall otherwise consent (which consent shall not be unreasonably withheld, conditioned or delayed),
the Company shall, and shall cause each of its Subsidiaries to, conduct its business in the ordinary course of business consistent with past practice and use its commercially reasonable efforts to preserve intact its business organization and
relationships with customers, members, suppliers, Providers, licensors, licensees and other Third Parties and keep available the services of its present officers and employees; <I>provided</I> that (i)&nbsp;no action by the Company or any of its
Subsidiaries permitted by an exception to any of <U>Section</U><U></U><U>&nbsp;6.01(a)</U> through <U>Section</U><U></U><U>&nbsp;6.01(q)</U> will be a breach of this sentence and (ii)&nbsp;the Company&#146;s or any of its Subsidiaries&#146; failure
to take any action prohibited by any of <U>Section</U><U></U><U>&nbsp;6.01(a)</U> through <U>Section</U><U></U><U>&nbsp;6.01(q)</U> will not be a breach of this sentence. Without limiting the generality of the foregoing, except (x)&nbsp;as
prohibited or required by Applicable Law, (y)&nbsp;as set forth in Section&nbsp;6.01 of the Company Disclosure Schedule, or (z)&nbsp;as otherwise required or expressly contemplated by this Agreement, without Parent&#146;s prior written consent
(which consent shall not be unreasonably withheld, conditioned or delayed (other than with respect to <U>Section</U><U></U><U>&nbsp;6.01(a)</U>, <U>Section</U><U></U><U>&nbsp;6.01(c)</U> or <U>Section</U><U></U><U>&nbsp;6.01(d)</U>), the Company
shall not, and shall cause each of its Subsidiaries not to:<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) adopt or propose any change to its articles of incorporation,
bylaws or other organizational documents (whether by merger, consolidation or otherwise) (including the Company Organizational Documents); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i)&nbsp;merge or consolidate with any other Person, (ii)&nbsp;acquire (including by merger, consolidation, or acquisition of stock or
assets) any interest in any corporation, partnership, other business organization or any division thereof or any assets, securities or property, other than (A)&nbsp;acquisitions of assets, securities or property in an amount not to exceed
$100,000,000 individually or $200,000,000 in the aggregate for all such acquisitions taking into account the acquisitions listed on Section&nbsp;6.01(b) of the Company Disclosure Schedule, together with all capital contributions permitted by
<U>Section</U><U></U><U>&nbsp;6.01(h)(i)(B)</U>, (B)&nbsp;acquisitions of securities under the Company&#146;s investment portfolio consistent with the Company&#146;s investment policy in effect as of the date hereof and (C)&nbsp;transactions
(1)&nbsp;solely among the Company and one or more of its wholly owned Subsidiaries or (2)&nbsp;solely among the Company&#146;s wholly owned Subsidiaries, or (iii)&nbsp;adopt a plan of complete or partial liquidation, dissolution, recapitalization or
restructuring; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) (i)&nbsp;split, combine or reclassify any shares of its capital stock (other than transactions (1)&nbsp;solely among
the Company and one or more of its wholly owned Subsidiaries or (2)&nbsp;solely among the Company&#146;s wholly owned Subsidiaries), (ii)&nbsp;amend any term or alter any rights of any of its outstanding equity securities, (iii)&nbsp;declare, set
aside or pay any dividend or make any other distribution (whether in cash, stock, property or any combination thereof) in respect of any shares of its capital stock or other securities, other than (A)&nbsp;in the case of the Company, regular cash
dividends in the ordinary course of business consistent with past practice in an amount not to exceed $0.50 per share of Company Common Stock per quarter (appropriately adjusted to reflect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any stock dividends, subdivisions, splits, combinations or other similar events relating to Company Common Stock), or (B)&nbsp;dividends or distributions by a Subsidiary of the Company to the
Company or a wholly owned Subsidiary of the Company, or (iv)&nbsp;redeem, repurchase, cancel or otherwise acquire or offer to redeem, repurchase, or otherwise acquire any of its securities or any securities of any Subsidiary of the Company, other
than&nbsp;repurchases of shares of Company Common Stock in connection with the exercise of Company Stock Appreciation Rights or the vesting or settlement of Company RSU Awards or&nbsp;Company PSU Awards (including in satisfaction of any amounts
required to be deducted or withheld under Applicable Law), in each case outstanding as of the date of this Agreement in accordance with the present terms of such Company Equity Awards or granted after the date of this Agreement to the extent
permitted by this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) issue, deliver or sell, or authorize the issuance, delivery or sale of, any shares of its capital stock
or any securities convertible into or exercisable for, or any rights, warrants or options to acquire, any such capital stock or any such convertible securities, other than (i)&nbsp;the issuance of any shares of Company Common Stock upon the exercise
of Company Stock Appreciation Rights or the vesting or settlement of Company RSU Awards or Company PSU Awards, in each case outstanding as of the date of this Agreement in accordance with the present terms of such Company Equity Awards or granted
after the date of this Agreement to the extent permitted by this Agreement, (ii)&nbsp;in connection with the exercise of rights to purchase shares of Company Common Stock under the Company ESPP in the Company ESPP Offering Period as permitted by
<U>Section</U><U></U><U>&nbsp;2.06(d)</U>, (iii)&nbsp;with respect to capital stock or securities of any Subsidiary of the Company, in connection with transactions (A)&nbsp;solely among the Company and one or more of its wholly owned Subsidiaries or
(B)&nbsp;solely among the Company&#146;s wholly owned Subsidiaries, (iv)&nbsp;the grant of Company Equity Awards to employees of the Company or any of its Subsidiaries in connection with the Company&#146;s annual equity award grant procedures or in
connection with promotions or new hires, in each case, conducted in the ordinary course of business and consistent with past practice, including with respect to timing; <I>provided</I> that any such grants issued under this clause&nbsp;(iv) shall be
subject to the limitations set forth in Section&nbsp;6.01(d)(iv) of the Company Disclosure Schedule, or (v)&nbsp;the grant of Company Equity Awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in the ordinary course of business,
consistent with past practice; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) authorize, make or incur any capital expenditures or obligations or liabilities in connection
therewith, other than as set forth in Section&nbsp;6.01(e) of the Company Disclosure Schedule; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) sell, lease, license or otherwise
dispose of any Subsidiary or any division thereof or of the Company or any assets, securities or property, other than (i)&nbsp;in the ordinary course of business consistent with past practice for fair market value in an amount not to exceed
$30,000,000 in the aggregate, (ii)&nbsp;dispositions of securities under the Company&#146;s investment portfolio consistent with the Company&#146;s investment policy in effect as of the date hereof, or (iii)&nbsp;transactions (A)&nbsp;solely among
the Company and one or more of its wholly owned Subsidiaries or (B)&nbsp;solely among the Company&#146;s wholly owned Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
sell, assign, license, sublicense, abandon, allow to lapse, transfer or otherwise dispose of, or create or incur any Lien (other than a Permitted Lien) on, any Owned Intellectual Property or Licensed Intellectual Property, other than in the ordinary
course of business consistent with past practice (i)&nbsp;pursuant to <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses or (ii)&nbsp;for the purpose of disposing of obsolete or worthless assets; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) (i)&nbsp;make any material loans, advances or capital contributions to any other Person, other than (A)&nbsp;loans, advances or capital
contributions (1)&nbsp;by the Company to one or more of its wholly owned Subsidiaries or (2)&nbsp;by any Subsidiary of the Company to the Company or any wholly owned Subsidiary of the Company, (B)&nbsp;capital contributions required under the terms
of Contracts in effect as of the date hereof in an amount not to exceed $200,000,000 in the aggregate for all such capital contributions, together with all acquisitions permitted by <U>Section</U><U></U><U>&nbsp;6.01(b)(ii)(A)</U>,
(C)&nbsp;extensions of loans or advances to Providers in the ordinary course of business consistent with past practice or (D)&nbsp;extensions of loans or advances to business associates other than Providers in the ordinary course of business
consistent with past practice, so long as the amount of such loans and advances to business associates other than Providers outstanding at any time does not exceed $20,000,000 in the aggregate (it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
being understood and agreed that upon repayment of any loan or advance permitted by this clause&nbsp;(D), the amount of such repayment shall be available for future loans or advances pursuant to
this clause&nbsp;(D), subject to the foregoing restriction on the aggregate amount of all such loans or advances that may be outstanding at any time) or (ii)&nbsp;incur, assume, guarantee or repurchase any indebtedness for borrowed money, other than
additional borrowings under the facilities set forth in Section&nbsp;6.01(h) of the Company Disclosure Schedule (<I>provided</I> that all such indebtedness for borrowed money permitted to be incurred in this clause&nbsp;(ii) must be prepayable at
any time by the Company without penalty); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) create or incur any Lien (except for a Permitted Lien) on any material asset; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) (i)&nbsp;enter into any Company Material Contract (including by amendment of any Contract that is not a Company Material Contract such
that such Contract becomes a Company Material Contract), other than in the ordinary course of business consistent with past practice (except that no Company Material Contract pursuant to clause (vii)&nbsp;of <U>Section</U><U></U><U>&nbsp;4.18(a)</U>
shall be entered into), or (ii)&nbsp;terminate, renew, extend or amend in any material respect any Company Material Contract or waive any material right thereunder, other than in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) terminate, suspend, abrogate, amend or modify (i)&nbsp;any certificate of authority to conduct business as an insurance company or health
maintenance organization issued by the applicable insurance or health regulatory Governmental Authority or (ii)&nbsp;any other material Company Permit, in each case of (i)&nbsp;and (ii) in a manner material and adverse to the Company and its
Subsidiaries, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) except as required by Applicable Law or Company Employee Plans or other contracts as in effect as of
the date hereof, (i)&nbsp;grant any change in control, severance or termination pay to (or amend any existing arrangement with) any of their respective directors, officers, employees or individual independent contractors (including former directors,
officers, employees or individual independent contractors) other than severance or termination pay in the ordinary course of business consistent with past practice for terminated employees in exchange for a general release of claims or other
customary covenants, (ii)&nbsp;enter into any employment, deferred compensation or other similar agreement (or any amendment to any such existing agreement) with any of their respective current or former directors, executive officers (as defined in
the 1934 Act), employees or individual independent contractors, other than offer letters (and related compensation arrangements set forth in such offer letters) with any newly hired directors, employees or individual independent contractors of the
Company who are not considered to be executive officers (as defined in the 1934 Act) and who are not members of the executive leadership team that are entered into in the ordinary course of business consistent with past practice,
(iii)&nbsp;establish, adopt or amend any Company Employee Plan or labor agreement, other than in the ordinary course of business consistent with past practice (<I>provided</I>, for the avoidance of doubt, that this clause&nbsp;(iii) shall not
prohibit the Company from paying cash incentive awards for any fiscal years of the Company ending prior to the Closing and establishing cash incentive program terms for any fiscal years of the Company commencing prior to the Closing under its
existing incentive plans and arrangements in the ordinary course of business consistent with past practice, subject to the limitations set forth in clause&nbsp;(iv) below) or any immaterial amendment that would not increase the cost to the Company
or any of its Subsidiaries of maintaining such Company Employee Plan, or (iv)&nbsp;increase the compensation, bonus opportunity or other benefits payable to any of their respective directors, officers, employees or individual independent contractors
(including former directors, officers, employees or individual independent contractors), other than (A)&nbsp;increases in base compensation and bonus opportunity to current directors, individual independent contractors or employees who are not
considered to be executive officers (as defined in the 1934 Act) and who are not members of the executive leadership team in the ordinary course of business (1)&nbsp;consistent with past practice or (2)&nbsp;in connection with a promotion or change
in role (it being understood that the amount of bonus actually paid may be higher or lower than prior years based on actual performance and such payment shall not be considered an increase) and (B)&nbsp;increases in employee welfare benefits in the
ordinary course of business consistent with past practice for employees generally; <I>provided</I> that any such base compensation increases shall not in the aggregate exceed 3.0% of the aggregate base compensation levels as of the date hereof of
the Company&#146;s directors and employees who are not considered to be executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officers (as defined in the 1934 Act) and who are not members of the executive leadership team (with those base salary increases previously disclosed to Parent, which were approved in the
ordinary course of business consistent with past practice prior to the date hereof but are not yet effective as of the date hereof, to be excluded from being counted against such limitation); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) make any material change in any method of financial or statutory accounting or financial or statutory accounting principles or practice,
except for any such change required by reason of (or, in the reasonable good-faith judgment of the Company, advisable under) a change in GAAP, SAP, ASOP or Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the 1934 Act
(&#147;<U>Regulation <FONT STYLE="white-space:nowrap">S-X</FONT></U>&#148;), as approved by its independent public accountants; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) make
any material change in investment, hedging, underwriting or claims administration principles or practices or in methodologies for estimating and providing for medical costs and other liabilities, in each case with respect to the Company or any of
its &#147;significant subsidiaries&#148; (as defined in Rule 102(w) of Regulation <FONT STYLE="white-space:nowrap">S-X),</FONT> except, to the extent applicable, for any such changes required by reason of a change in GAAP, SAP, ASOP or Regulation <FONT
STYLE="white-space:nowrap">S-X,</FONT> as approved by its independent public accountants; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) (i)&nbsp;make or change any material Tax
election; (ii)&nbsp;change any annual Tax accounting period; (iii)&nbsp;adopt or change any material method of Tax accounting; (iv)&nbsp;enter into any material closing agreement with respect to Taxes; (v)&nbsp;settle or surrender any material Tax
claim, audit or assessment; or (vi)&nbsp;enter into any intercompany transaction within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-13</FONT> that (x)&nbsp;is outside the ordinary course of business and
(y) results in a material amount of deferred income or gain that would be taken into account pursuant to Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-13(d)</FONT> as a result of the Merger; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) settle or compromise, or propose to settle or compromise, any claim, action, suit, investigation or proceeding involving or against the
Company or any of its Subsidiaries, other than (i)&nbsp;in the ordinary course of business consistent with past practice, including in connection with the processing and paying of claims to members or Providers or risk sharing arrangements with
Providers (<I>provided</I> that any individual settlement or compromise or any series of related settlements or compromises involving payments by the Company and its Subsidiaries in excess of $25,000,000, other than any such settlements or
compromises with Providers that do not relate to sequestration matters, shall not be deemed to be in the ordinary course of business), or (ii)&nbsp;involving only a monetary payment by the Company or any of its Subsidiaries in an amount not to
exceed $10,000,000 individually or $30,000,000 in the aggregate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) reduce in any material respect the budget or scope of the
Company&#146;s and its Subsidiaries&#146; program for, or otherwise reduce in any material respect the resources or efforts specifically dedicated by the Company and its Subsidiaries to, the maintenance and improvement of their respective Medicare
star ratings; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) agree, commit or propose to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_73"></A>Section&nbsp;6.02. <U>No Solicitation by the Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) From the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement, except as otherwise set
forth in this <U>Section</U><U></U><U>&nbsp;6.02</U>, the Company shall not, and shall cause its Subsidiaries not to, and shall use its reasonable best efforts to cause its and its Subsidiaries&#146; officers, directors, employees, investment
bankers, attorneys, accountants, consultants and other agents, advisors and representatives (collectively, &#147;<U>Representatives</U>&#148;) not to, directly or indirectly, (i)&nbsp;solicit, initiate or take any action to knowingly facilitate or
knowingly encourage the submission of any Company Acquisition Proposal, (ii)&nbsp;enter into or participate in any discussions or negotiations with, furnish any information relating to the Company or any of its Subsidiaries or afford access to the
business, properties, assets, books or records of the Company or any of its Subsidiaries to, otherwise cooperate in any way with, or knowingly assist, participate in, knowingly facilitate or knowingly encourage any effort by, any Third Party that
the Company knows is seeking to make, or has made, a Company Acquisition Proposal, (iii)&nbsp;(A)&nbsp;fail to make or withdraw or qualify, amend or modify in any manner </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse to Parent, the Company Board Recommendation, (B)&nbsp;fail to include the Company Board Recommendation in the Joint Proxy Statement/Prospectus or (C)&nbsp;recommend, adopt or approve or
publicly propose to recommend, adopt or approve any Company Acquisition Proposal (any of the foregoing in this clause&nbsp;(iii), a &#147;<U>Company Adverse Recommendation Change</U>&#148;), (iv)&nbsp;take any action to make any
&#147;moratorium,&#148; &#147;control share acquisition,&#148; &#147;fair price,&#148; &#147;supermajority,&#148; &#147;affiliate transactions&#148; or &#147;business combination statute or regulation&#148; or other similar anti-takeover laws and
regulations of the Commonwealth of Pennsylvania, including Subchapter F of Chapter 25 of Pennsylvania Law, inapplicable to any Third Party or any Company Acquisition Proposal or (v)&nbsp;fail to enforce or grant any waiver or release under any
standstill or similar agreement with respect to any class of equity securities of the Company or any of its Subsidiaries unless the Board of Directors of the Company determines after consulting with its outside legal counsel that the failure to
waive such provision would be inconsistent with its fiduciary duties under Applicable Law (<I>provided</I> that the obligation not to fail to enforce any such standstill or similar agreement under this <U>Section</U><U></U><U>&nbsp;6.02(a)(v)</U>
shall apply with respect to known breaches of such agreements only). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing, if at any time prior to the
receipt of the Company Shareholder Approval (the &#147;<U>Company Approval Time</U>&#148;) (and in no event after the Company Approval Time), the Board of Directors of the Company receives a <I>bona fide</I> written Company Acquisition Proposal made
after the date hereof which has not resulted from a violation of this <U>Section</U><U></U><U>&nbsp;6.02</U>, the Board of Directors of the Company, directly or indirectly through its Representatives, may (x)&nbsp;contact the Third Party that has
made such Company Acquisition Proposal in order to ascertain facts or clarify terms for the sole purpose of the Board of Directors of the Company informing itself about such Company Acquisition Proposal and such Third Party and (y)&nbsp;subject to
compliance with this <U>Section</U><U></U><U>&nbsp;6.02(b)</U>, <U>Section</U><U></U><U>&nbsp;6.02(c)</U> and <U>Section</U><U></U><U>&nbsp;6.02(e)</U>, (i)&nbsp;engage in negotiations or discussions with any Third Party that, subject to the
Company&#146;s compliance with <U>Section</U><U></U><U>&nbsp;6.02(a)</U>, has made after the date of this Agreement a Company Superior Proposal or an unsolicited <I>bona fide</I> written Company Acquisition Proposal that the Board of Directors of
the Company determines in good faith, after consultation with its financial advisor and outside legal counsel, is reasonably likely to lead to a Company Superior Proposal, (ii)&nbsp;furnish to such Third Party and its Representatives and financing
sources nonpublic information relating to the Company or any of its Subsidiaries pursuant to (x)&nbsp;a confidentiality agreement between the Company and such Third Party in existence on or prior to the date hereof or (y)&nbsp;a confidentiality
agreement with confidentiality terms in the aggregate no less favorable to the Company than those contained in the Confidentiality Agreement, a copy of which shall be provided, promptly after its execution, to Parent for informational purposes;
<I>provided</I> that all such <FONT STYLE="white-space:nowrap">non-public</FONT> information (to the extent that such information has not been previously provided or made available to Parent) is provided or made available to Parent, as the case may
be, substantially concurrently with the time it is provided or made available to such Third Party, and (iii)&nbsp;following receipt of a Company Superior Proposal after the date of this Agreement, (A)&nbsp;make a Company Adverse Recommendation
Change and/or (B)&nbsp;terminate this Agreement to enter into a definitive agreement providing for such Company Superior Proposal in accordance with <U>Section</U><U></U><U>&nbsp;10.01(d)(v)</U>, but in each case referred to in the foregoing clauses
(i)&nbsp;through (iii) only if the Board of Directors of the Company determines in good faith, after consultation with the Company&#146;s outside legal counsel and financial advisor, that the failure to take such action would be reasonably likely to
be inconsistent with its fiduciary duties under Applicable Law. Nothing contained herein shall prevent the Board of Directors of the Company from (x)&nbsp;complying with Rule <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> under the 1934 Act with
regard to a Company Acquisition Proposal, so long as any action taken or statement made to so comply is consistent with this <U>Section</U><U></U><U>&nbsp;6.02</U>; or (y)&nbsp;making any required disclosure to the shareholders of the Company if the
Board of Directors of the Company determines in good faith, after consultation with its outside legal counsel, that the failure to take such action would be reasonably likely to be inconsistent with Applicable Law; <I>provided</I> that any Company
Adverse Recommendation Change involving or relating to a Company Acquisition Proposal may only be made in accordance with the provisions of this <U>Section</U><U></U><U>&nbsp;6.02(b)</U>, <U>Section</U><U></U><U>&nbsp;6.02(c)</U> and
<U>Section</U><U></U><U>&nbsp;6.02(e)</U>. For the avoidance of doubt, a &#147;stop, look and listen&#148; disclosure or similar communication of the type contemplated by Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> under the 1934 Act shall
not be a Company Adverse Recommendation Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In addition to the requirements set forth in
<U>Section</U><U></U><U>&nbsp;6.02(b)</U>, the Board of Directors of the Company shall not take any of the actions referred to in clauses (i)&nbsp;through (iii) of <U>Section</U><U></U><U>&nbsp;6.02(b)</U> unless the Company shall
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have first delivered to Parent written notice advising Parent that the Company intends to take such action, and the Company shall continue to advise Parent, on a current basis, after taking such
action of the status and material terms of any discussions and negotiations with the applicable Third Party. In addition, the Company shall notify Parent promptly (but in no event later than twenty-four (24)&nbsp;hours) after receipt by the Company
(or any of its Representatives) of any Company Acquisition Proposal, any indication that a Third Party is considering making a Company Acquisition Proposal or any request for information relating to the Company or any of its Subsidiaries or for
access to the business, properties, assets, books or records of the Company or any of its Subsidiaries by any Third Party that, to the knowledge of the Company or any member of its Board of Directors, is considering making, is reasonably likely to
make or has made, a Company Acquisition Proposal, which notice shall be provided in writing and shall identify the Third Party making, and the material terms and conditions of, any such Company Acquisition Proposal, indication or request (including
any material changes thereto). The Company shall keep Parent fully informed, on a current basis, of the status and details of any such Company Acquisition Proposal, indication or request (including any changes thereto) and shall promptly (but in no
event later than twenty-four (24)&nbsp;hours after receipt) provide to Parent copies of all material correspondence and written materials sent or provided to the Company or any of its Subsidiaries that describes any terms or conditions of any
Company Acquisition Proposal (as well as written summaries of any material oral communications addressing such matters). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
Notwithstanding anything in this Agreement to the contrary, at any time prior to the Company Approval Time (and in no event after the Company Approval Time), the Board of Directors of the Company may effect a Company Adverse Recommendation Change
involving or relating to a Company Intervening Event if the Board of Directors of the Company determines in good faith, after consultation with its outside legal counsel, that the failure to take such action would be reasonably likely to be
inconsistent with its fiduciary duties under Applicable Law; <I>provided</I> that (i)&nbsp;the Company shall (A)&nbsp;promptly notify Parent in writing of its intention to take such action and (B)&nbsp;negotiate in good faith with Parent for three
(3)&nbsp;Business Days following such notice regarding revisions to the terms of this Agreement proposed by Parent, and (ii)&nbsp;the Board of Directors of the Company shall not effect any Company Adverse Recommendation Change involving or relating
to a Company Intervening Event unless, after the three (3)&nbsp;Business Day period described in the foregoing clause (B), the Board of Directors of the Company determines in good faith, after consultation with its outside legal counsel, that the
failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Without
limiting or affecting <U>Section</U><U></U><U>&nbsp;6.02(a)</U>, <U>Section</U><U></U><U>&nbsp;6.02(b)</U> or <U>Section</U><U></U><U>&nbsp;6.02(c)</U>, the Board of Directors of the Company shall not make a Company Adverse Recommendation Change
involving or relating to a Company Superior Proposal or terminate this Agreement in order to enter into a definitive agreement with respect to a Company Superior Proposal unless (i)&nbsp;the Company promptly notifies Parent, in writing at least
three (3)&nbsp;Business Days before taking such action, that the Company intends to take such action, which notice attaches the most current version of any proposed agreement or a detailed summary of all material terms of such Company Superior
Proposal and the identity of the offeror, (ii)&nbsp;if requested by Parent, during such three (3)&nbsp;Business Day period, the Company and its Representatives have discussed and negotiated in good faith with Parent regarding any proposal by Parent
to amend the terms of this Agreement in response to such Company Superior Proposal and (iii)&nbsp;after such three (3)&nbsp;Business Day period, the Board of Directors of the Company determines in good faith, taking into account any proposal by
Parent to amend the terms of this Agreement, that such Company Acquisition Proposal continues to constitute a Company Superior Proposal (it being understood and agreed that in the event of any amendment to the financial terms or other material terms
of any such Company Superior Proposal, a new written notification from the Company consistent with that described in clause (i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.02(e)</U> shall be required, and a new notice period under clause
(i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.02(e)</U> shall commence, during which notice period the Company shall be required to comply with the requirements of this <U>Section</U><U></U><U>&nbsp;6.02(e)</U> anew, except that such new notice
period shall be for two (2)&nbsp;Business Days (as opposed to three (3)&nbsp;Business Days)). After delivery of such written notice pursuant to the immediately preceding sentence, the Company shall promptly keep Parent informed of all material
developments affecting the material terms of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any such Company Superior Proposal (and the Company shall provide Parent with copies of any additional written materials received that relate to such Company Superior Proposal). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Company Superior Proposal</U>&#148; means any <I>bona fide</I>, written Company Acquisition Proposal (other than a Company
Acquisition Proposal which has resulted from a violation of this <U>Section</U><U></U><U>&nbsp;6.02</U>) (with all references to &#147;20%&#148; in the definition of Company Acquisition Proposal being deemed to be references to &#147;50%&#148;) on
terms that the Board of Directors of the Company determines in good faith, after consultation with its financial advisor and outside legal counsel, and taking into account all the terms and conditions of the Company Acquisition Proposal that the
Board of Directors of the Company considers to be appropriate (including the identity of the Person making the Company Acquisition Proposal and the expected timing and likelihood of consummation, any governmental or other approval requirements
(including divestitures and entry into other commitments and limitations), <FONT STYLE="white-space:nowrap">break-up</FONT> fees, expense reimbursement provisions, conditions to consummation and availability of necessary financing), would result in
a transaction (i)&nbsp;that, if consummated, is more favorable to the Company&#146;s shareholders from a financial point of view than the Merger (taking into account any proposal by Parent to amend the terms of this Agreement), (ii)&nbsp;that is
reasonably capable of being completed on the terms proposed, taking into account the identity of the Person making the Company Acquisition Proposal, any approval requirements and all other financial, regulatory, legal and other aspects of such
Company Acquisition Proposal and (iii)&nbsp;for which financing, if a cash transaction (whether in whole or in part), is then fully committed in a manner comparable to Parent&#146;s and Merger Sub&#146;s financing (or which is reasonably determined
to be available by the Board of Directors of the Company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Company Intervening Event</U>&#148; means any material event,
change, effect, development or occurrence occurring or arising after the date of this Agreement that (i)&nbsp;was not known or reasonably foreseeable, or the material consequences of which were not known or reasonably foreseeable, in each case to
the Board of Directors or executive officers of the Company as of or prior to the date of this Agreement, and (ii)&nbsp;does not relate to or involve any Company Acquisition Proposal; <I>provided</I> that (A)&nbsp;in no event shall any action taken
by either party pursuant to the affirmative covenants set forth in <U>Section</U><U></U><U>&nbsp;8.02</U>, or the consequences of any such action, constitute, be deemed to contribute to or otherwise be taken into account in determining whether there
has been a Company Intervening Event, and (B)&nbsp;in no event shall any event, change, effect, development or occurrence that would fall within any of the exceptions to the definition of &#147;Parent Material Adverse Effect&#148; constitute, be
deemed to contribute to or otherwise be taken into account in determining whether there has been a Company Intervening Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The
Company shall, and shall cause its Subsidiaries to, and shall use its reasonable best efforts to cause its and its Subsidiaries&#146; respective Representatives to, cease immediately and cause to be terminated any and all existing activities,
discussions or negotiations, if any, with any Third Party conducted prior to the date of this Agreement with respect to any Company Acquisition Proposal and shall use its reasonable best efforts to cause any such party (or its agents or advisors) in
possession of confidential information about the Company that was furnished by or on behalf of the Company to return or destroy all such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Notwithstanding (i)&nbsp;any Company Adverse Recommendation Change, (ii)&nbsp;the making of any Company Acquisition Proposal or
(iii)&nbsp;anything in this Agreement to the contrary, until termination of this Agreement (x)&nbsp;in no event may the Company or any of its Subsidiaries (A)&nbsp;enter into any agreement in principle, letter of intent, term sheet, merger
agreement, acquisition agreement, option agreement, joint venture agreement, partnership agreement or other similar instrument constituting or relating to a Company Acquisition Proposal (other than a confidentiality agreement), (B)&nbsp;except as
required by Applicable Law or permitted pursuant to the remainder of this <U>Section</U><U></U><U>&nbsp;6.02</U>, make, facilitate or provide information in connection with any SEC or other Filings in connection with the transactions contemplated by
any Company Acquisition Proposal or (C)&nbsp;seek any Consents in connection with the transactions contemplated by any Company Acquisition Proposal and (y)&nbsp;the Company shall otherwise remain subject to all of its obligations under this
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_74"></A>Section&nbsp;6.03. <U>Financing Assistance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to the Closing, the Company shall, and shall cause its Subsidiaries to use its and their commercially reasonable efforts to provide
such cooperation as may be reasonably requested by Parent in connection with the arrangement of the Debt Financing (which term shall include, for purposes of this <U>Section</U><U></U><U>&nbsp;6.03(a)</U>, any of the permanent financing referred to
in the Debt Commitment Letters) (<I>provided</I> that such requested cooperation does not unreasonably interfere with the ongoing operations of the Company and its Subsidiaries). Without limiting the generality of the foregoing sentence, prior to
the Closing, the Company shall, and shall cause its Subsidiaries to use its and their commercially reasonable efforts to: (i)&nbsp;as promptly as reasonably practicable provide information (financial or otherwise) relating to the Company to Parent
and to the Financing Sources (including information to be used in the preparation of an information package regarding the business, operations, financial condition, financial projections and prospects of Parent and the Company customary or
reasonably necessary for the completion of such financing) to the extent reasonably requested by Parent in connection with Parent&#146;s preparation of customary offering or information documents to be used for the completion of the Debt Financing,
(ii)&nbsp;cooperate and assist with the due diligence, rating agency processes and marketing efforts of Parent, its Representatives and the Financing Sources, including participating in a reasonable number of meetings, due diligence sessions and
road shows, at times and at locations reasonably acceptable to the Company, (iii)&nbsp;reasonably assist Parent in preparing customary offering memoranda, rating agency presentations, lender and investor presentations, confidential information
memoranda, financial statements, private placement memoranda, prospectuses, filings with the SEC and other similar documents, including delivery and consenting to the inclusion or incorporation in any SEC filing related to the Debt Financing or the
Alternative Financing of (A)&nbsp;audited consolidated balance sheets and related audited statements of income, comprehensive income, shareholders&#146; equity and cash flows of the Company for each of the three fiscal years most recently ended more
than 60 days prior to the Closing Date (and audit reports for such financial statements shall not be subject to any &#147;going concern&#148; qualifications), (B)&nbsp;unaudited consolidated balance sheets and related unaudited statements of income,
comprehensive income, shareholders&#146; equity and cash flows of the Company for each subsequent fiscal quarter ended more than 40 days prior to the Closing Date and (C)&nbsp;all other historical financial and other information regarding the
Company reasonably necessary to permit Parent to prepare pro forma financial statements customary for the bank financing and the debt securities offering contemplated by the Debt Financing or the Alternative Financing, (iv)&nbsp;make available, on a
customary and reasonable basis and upon reasonable notice, appropriate personnel, including Representatives of the Company and its Subsidiaries, documents and information relating to the Company and its Subsidiaries, in each case, as may be
reasonably requested by Parent, the Financing Sources, or as may be requested by the SEC in connection with the completion of the financing, (v)&nbsp;provide to Parent and the Financing Sources promptly, and in any event at least five
(5)&nbsp;Business Days prior to the Closing Date, all documentation and other information about the Company and its Affiliates required by the Financing Sources or regulatory authorities with respect to the Debt Financing under applicable &#147;know
your customer&#148; and anti-money laundering rules and regulations, including the PATRIOT Act, that is required under the Debt Commitment Letters to the extent such documentation and other information is requested in writing to the Company at least
10 Business Days prior to the Closing Date, (vi)&nbsp;obtain any necessary consents from the Company&#146;s independent public accounting firm in connection with any filings with the SEC, (vii)&nbsp;in connection with any securities offering
contemplated as part of the Debt Financing or the Alternative Financing, (A)&nbsp;obtain customary comfort letters from the Company&#146;s independent public accounting firm, (B)&nbsp;cause the Company&#146;s independent public accounting firm to
consent to the inclusion or incorporation of their audit reports with respect to the financial statements of the Company provided pursuant to <U>Section</U><U></U><U>&nbsp;6.03(a)(iii)</U> in any filing or registration statement of Parent with the
SEC or any prospectus, offering memoranda, private placement memoranda, marketing material or similar documentation, including by providing customary representation letters and (C)&nbsp;cause the Company&#146;s independent public accounting firm to
cooperate with Parent and its Representatives, including by participating in accounting due diligence sessions at times and at locations reasonably acceptable to the Company and its independent accounting firm, (viii)&nbsp;subject to customary
confidentiality provisions, provide customary authorization letters to the Financing Sources authorizing the distribution of information to prospective lenders or investors, (ix)&nbsp;deliver notices of prepayment and/or notices for termination of
commitments within the time periods required by the Credit Agreement and obtain customary payoff letters and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
instruments of discharge to be delivered at Closing to allow for the payoff, discharge and termination in full on the Closing Date of the Credit Agreement, (x)&nbsp;reasonably assist with the
preparation of the definitive documentation for the Debt Financing, including by providing information reasonably necessary for the completion of any schedules thereto, in each case to the extent, and solely to the extent, such materials relate to
information concerning the Company and its Subsidiaries, (xi)&nbsp;provide or cause to be provided any customary certificates, or other customary closing documents as may reasonably be requested in connection with the Debt Financing and the
Alternative Financing and (xii)&nbsp;consent to the use of the trademarks, service marks and logos of the Company or any of its Subsidiaries in connection with the Debt Financing; <I>provided</I> that such trademarks, service marks and logos are
used solely in a manner that is not intended to or is reasonably likely to harm or disparage the Company or any of its Subsidiaries. Notwithstanding the foregoing, (1)&nbsp;neither the Company nor any of its Subsidiaries shall be required to pay any
commitment or other similar fee or incur prior to the Closing any other liability or obligation in connection with the Debt Financing, unless Parent reimburses or is required to reimburse or indemnify the Company and its Subsidiaries pursuant to
this Agreement or otherwise agrees to do so, (2)&nbsp;none of the Company, its Subsidiaries or their respective officers, directors or employees shall be required to execute or enter into or perform any agreement with respect to the Debt Financing
that is not contingent upon the Closing occurring or that would be effective prior to the Closing (other than authorization letters contemplated by clause (viii)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.03(a)</U> and for the avoidance of doubt,
the boards of directors or other equivalent governing bodies of Parent, Merger Sub, and/or the Surviving Corporation shall enter into or provide any resolutions, consents, approvals or other closing arrangements on behalf of the Company and its
Subsidiaries as may be required by the Financing Sources pursuant to the Debt Commitment Letter at, or as of, the Closing), and (3)&nbsp;nothing shall obligate the Company or any of its Subsidiaries to provide, or cause to be provided, any legal
opinion by its counsel, or to provide, or cause to be provided, any information or take, or cause to be taken, any action to the extent it would reasonably be expected, in the reasonable judgment of the Company, to result in a violation of
Applicable Law or loss of any privilege. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Parent shall, promptly upon written request by the Company, reimburse the Company for all
reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including reasonable attorneys&#146; fees) incurred by the Company or any of its Subsidiaries in satisfying
its obligations under this <U>Section</U><U></U><U>&nbsp;6.03</U>. Parent and Merger Sub shall, on a joint and several basis, indemnify and hold harmless the Company and its Subsidiaries and their respective Representatives from and against any and
all losses, claims, damages, liabilities, costs, reasonable attorneys&#146; fees, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of
any thereof) suffered or incurred in connection with any action taken by the Company, any of its Subsidiaries or any of their respective Representatives pursuant to this <U>Section</U><U></U><U>&nbsp;6.03</U> (other than the use of any information
provided by the Company, any of its Subsidiaries or any of their respective Representatives in writing for use in connection with the Debt Financing), except in the event such losses, claims, damages, liabilities, costs, reasonable attorneys&#146;
fees, judgments, fines, penalties and amounts paid in settlement are determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction to have arisen out of, or resulted from, the gross
negligence or willful misconduct of the Company, any of its Subsidiaries or any of their respective Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_75">
</A>Section&nbsp;6.04. <U>Indenture</U><U>s</U>. The Company shall use its reasonable best efforts to timely provide or cause to be provided, in accordance with the provisions of the Company&#146;s indenture, dated March&nbsp;2, 2001 (the
&#147;<U>2001 Indenture</U>&#148;), relating to the Company&#146;s Floating Rate Senior Notes due December 2017, 1.7% Senior Notes due June 2018, 2.2% Senior Notes due March 2019, 4.125% Senior Notes due June 2021, 2.75% Senior Notes due November
2022, 2.8% Senior Notes due June 2023, 3.5% Senior Notes due November 2024, 6.625% Senior Notes due June 2036, 6.75% Senior Notes due December 2037, 4.5% Senior Notes due May 2042, 4.125% Senior Notes due November 2042, 4.75% Senior Notes due March
2044 and 3.875% Senior Notes due June 2047 (collectively, the &#147;<U>Company Notes</U>&#148;) and the provisions of the indenture, dated as of March&nbsp;20, 2007 (the &#147;<U>2007 Indenture</U>&#148;, and together with the 2001 Indenture, the
&#147;<U>Indentures</U>&#148;), entered into by Coventry Health Care, Inc., a subsidiary of the Company, for the issuance by it of 5.45% Senior Notes due June 2021 (together with the Company Notes, the &#147;<U>Existing Notes</U>&#148;), to the
trustee under each of the Indentures, any notices, announcements, certificates or legal opinions required by the applicable Indenture to be provided in connection with the Merger </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to the Effective Time. Parent and its counsel shall be given a reasonable opportunity to review and comment on any such notice, announcement, certificate or legal opinion, in each case
before such document is provided to such a trustee, and the Company shall give reasonable and good faith consideration to any comments made by Parent and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_76"></A>Section&nbsp;6.05. <U>280G Calculation</U>. As soon as practicable, but in no event later than thirty
(30)&nbsp;Business Days after the date hereof, the Company will make available to Parent true and correct copies of preliminary Section&nbsp;280G calculations (based on the assumptions set forth in the applicable calculations) with respect to each
&#147;disqualified individual&#148; (within the meaning of Section&nbsp;280G of the Code and determined as of the date of this Agreement). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;VII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS OF PARENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parent agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_77">
</A>Section&nbsp;7.01. <U>Conduct of Parent</U>. From the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement, (A)&nbsp;except (x) as prohibited or required by Applicable Law, (y)&nbsp;as set forth in
<U>Section</U><U></U><U>&nbsp;7.01</U> of the Parent Disclosure Schedule, or (z)&nbsp;as otherwise required or expressly contemplated by this Agreement, unless the Company shall otherwise consent (which consent shall not be unreasonably withheld,
conditioned or delayed), Parent shall, and shall cause each of its Subsidiaries to, conduct its business in the ordinary course of business consistent with past practice and use its commercially reasonable efforts to preserve intact its business
organization and relationships with customers, members, suppliers, Providers, licensors, licensees and other Third Parties and keep available the services of its present officers and employees; <I>provided</I> that (i)&nbsp;no action by Parent or
any of its Subsidiaries permitted by an exception to any of <U>Section</U><U></U><U>&nbsp;7.01(a)</U> through <U>Section</U><U></U><U>&nbsp;7.01(e)</U> will be a breach of this sentence and (ii)&nbsp;Parent&#146;s or any of its Subsidiaries&#146;
failure to take any action prohibited by any of <U>Section</U><U></U><U>&nbsp;7.01(a)</U> through <U>Section</U><U></U><U>&nbsp;7.01(e)</U> will not be a breach of this sentence and (B)&nbsp;Parent shall, and shall cause each of its Subsidiaries to,
conduct its business in accordance with the restriction set forth in Section&nbsp;7.01(B) of the Parent Disclosure Schedule. Without limiting the generality of the foregoing, except (x)&nbsp;as prohibited or required by Applicable Law, (y)&nbsp;as
set forth in Section&nbsp;7.01 of the Parent Disclosure Schedule or (z)&nbsp;as otherwise required or expressly contemplated by this Agreement, without the Company&#146;s prior written consent (which consent shall not be unreasonably withheld,
conditioned or delayed), Parent shall not, and shall cause each of its Subsidiaries not to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) adopt or propose any change to the Parent
Organizational Documents in a manner that would be materially adverse to the Company&#146;s shareholders (whether by merger, consolidation or otherwise); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i)&nbsp;acquire (including by merger, consolidation or acquisition of stock or assets) any interest in any corporation, partnership,
other business organization or any division thereof or any assets, securities or property, other than (A)&nbsp;acquisitions of any of the foregoing in an amount not to exceed $2,000,000,000 individually or $5,000,000,000 in the aggregate,
(B)&nbsp;acquisitions of securities under Parent&#146;s investment portfolio consistent with Parent&#146;s investment policy and (C)&nbsp;transactions (1)&nbsp;solely among Parent and one or more of its wholly owned Subsidiaries or (2)&nbsp;solely
among Parent&#146;s wholly owned Subsidiaries, or (ii)&nbsp;adopt a plan of complete or partial liquidation or dissolution with respect to Parent or Merger Sub; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) (i)&nbsp;split, combine or reclassify any shares of its capital stock (other than transactions (1)&nbsp;solely among Parent and one or
more of its wholly owned Subsidiaries or (2)&nbsp;solely among Parent&#146;s wholly owned Subsidiaries), (ii)&nbsp;amend any term or alter any rights of any of its outstanding equity securities, (iii)&nbsp;declare, set aside or pay any dividend or
make any other distribution (whether in cash, stock, property or any combination thereof) in respect of any shares of its capital stock or other securities, other than (A)&nbsp;in the case of Parent, regular cash dividends in the ordinary course of
business, consistent with past practice, in an amount not to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exceed $0.50 per share of Parent Common Stock per quarter (appropriately adjusted to reflect any stock dividends, subdivisions, splits, combinations or other similar events relating to Parent
Common Stock),<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>or (B)&nbsp;dividends or distributions by a Subsidiary of Parent to Parent or a wholly owned Subsidiary of Parent, or (iv)&nbsp;redeem, repurchase, cancel or otherwise acquire or
offer to redeem, repurchase, or otherwise acquire any of its securities or any securities of any Subsidiary of Parent, other than in the ordinary course of business, consistent with past practice, including repurchases of shares of Parent Common
Stock (A)&nbsp;pursuant to accelerated share repurchase programs or agreements in the ordinary course of business, consistent with past practice, and (B)&nbsp;in connection with the exercise or the vesting and settlement of Parent Equity Awards
(including in satisfaction of any amounts required to be deducted or withheld under Applicable Law), in each case in this clause&nbsp;(B) outstanding as of the date of this Agreement in accordance with the present terms of such Parent Equity Awards
or granted after the date of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) issue, deliver or sell, or authorize the issuance, delivery or sale of, any shares of
its capital stock or any securities convertible into or exercisable for, or any rights, warrants or options to acquire, any such capital stock or any such convertible securities, other than (i)&nbsp;the issuance of any shares of Parent Common Stock
upon the exercise of Parent Equity Awards or other equity and equity-linked awards that are outstanding on the date of this Agreement or are granted after the date of this Agreement, (ii)&nbsp;with respect to capital stock or securities of any
Subsidiary of Parent, in connection with transactions (A)&nbsp;solely among Parent and one or more of its wholly owned Subsidiaries or (B)&nbsp;solely among Parent&#146;s wholly owned Subsidiaries, (iii)&nbsp;the grant of Parent Equity Awards or
other equity and equity-linked awards to employees, directors or individual independent contractors of Parent or any of its Subsidiaries pursuant to Parent&#146;s equity compensation plans, or (iv)&nbsp;in connection with the Parent Share Issuance;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) sell, lease, license or otherwise dispose of any Subsidiary or any division thereof or of Parent or any assets, securities or
property, other than (i)&nbsp;dispositions of any of the foregoing in an amount not to exceed $3,000,000,000 individually or $6,000,000,000 in the aggregate, (ii)&nbsp;dispositions of securities under Parent&#146;s investment portfolio consistent
with Parent&#146;s investment policy or (iii)&nbsp;transactions (A)&nbsp;solely among Parent and one or more of its wholly owned Subsidiaries or (B)&nbsp;solely among Parent&#146;s wholly owned Subsidiaries; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) agree, commit or propose to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_78"></A>Section&nbsp;7.02. <U>No Solicitation by Parent</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) From the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement, except as otherwise set
forth in this <U>Section</U><U></U><U>&nbsp;7.02</U>, Parent shall not, and shall cause its Subsidiaries not to, and shall use its reasonable best efforts to cause its and its Subsidiaries&#146; Representatives not to, directly or indirectly,
(i)&nbsp;solicit, initiate or take any action to knowingly facilitate or knowingly encourage the submission of any Parent Acquisition Proposal, (ii)&nbsp;enter into or participate in any discussions or negotiations with, furnish any information
relating to Parent or any of its Subsidiaries or afford access to the business, properties, assets, books or records of Parent or any of its Subsidiaries to, otherwise cooperate in any way with, or knowingly assist, participate in, knowingly
facilitate or knowingly encourage any effort by, any Third Party that Parent knows is seeking to make, or has made, a Parent Acquisition Proposal, (iii)&nbsp;(A)&nbsp;fail to make or withdraw or qualify, amend or modify in any manner adverse to the
Company, the Parent Board Recommendation, (B)&nbsp;fail to include the Parent Board Recommendation in the Joint Proxy Statement/Prospectus or (C)&nbsp;recommend, adopt or approve or publicly propose to recommend, adopt or approve any Parent
Acquisition Proposal (any of the foregoing in this clause&nbsp;(iii), a &#147;<U>Parent Adverse Recommendation Change</U>&#148;), (iv)&nbsp;take any action to make any &#147;moratorium,&#148; &#147;control share acquisition,&#148; &#147;fair
price,&#148; &#147;supermajority,&#148; &#147;affiliate transactions&#148; or &#147;business combination statute or regulation&#148; or other similar anti-takeover laws and regulations of the State of Delaware, including Section&nbsp;203 of Delaware
Law, inapplicable to any Third Party or any Parent Acquisition Proposal, (v)&nbsp;approve any transaction (other than transactions contemplated by this Agreement) under, or any Person becoming a &#147;Related Person&#148; under, the Fifth Article of
the certificate of incorporation of Parent as in effect on the date hereof, (vi)&nbsp;take any action to make any other antitakeover provision in the certificate of incorporation of Parent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inapplicable to any Third Party or any Parent Acquisition Proposal or (vii)&nbsp;fail to enforce or grant any waiver or release under any standstill or similar agreement with respect to any class
of equity securities of Parent or any of its Subsidiaries unless the Board of Directors of Parent determines after consulting with its outside legal counsel that the failure to waive such provision would be inconsistent with its fiduciary duties
under Applicable Law (<I>provided</I> that the obligation not to fail to enforce any such standstill or similar agreement under this <U>Section</U><U></U><U>&nbsp;7.02(a)(vii)</U> shall apply with respect to known breaches of such agreements only).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing, if at any time prior to the receipt of the Parent Stockholder Approval (the &#147;<U>Parent Approval
Time</U>&#148;) (and in no event after the Parent Approval Time), the Board of Directors of Parent receives a <I>bona fide</I> written Parent Acquisition Proposal made after the date hereof which has not resulted from a violation of this
<U>Section</U><U></U><U>&nbsp;7.02</U>, the Board of Directors of Parent, directly or indirectly through its Representatives, may (x)&nbsp;contact the Third Party that has made such Parent Acquisition Proposal in order to ascertain facts or clarify
terms for the sole purpose of the Board of Directors of Parent informing itself about such Parent Acquisition Proposal and such Third Party and (y)&nbsp;subject to compliance with this <U>Section</U><U></U><U>&nbsp;7.02(b)</U>,
<U>Section</U><U></U><U>&nbsp;7.02(c)</U> and <U>Section</U><U></U><U>&nbsp;7.02(e)</U>, (i)&nbsp;engage in negotiations or discussions with any Third Party that, subject to Parent&#146;s compliance with <U>Section</U><U></U><U>&nbsp;7.02(a)</U>,
has made after the date of this Agreement a Parent Superior Proposal or an unsolicited <I>bona fide</I> written Parent Acquisition Proposal that the Board of Directors of Parent determines in good faith, after consultation with its financial advisor
and outside legal counsel, is reasonably likely to lead to a Parent Superior Proposal, (ii)&nbsp;furnish to such Third Party and its Representatives and financing sources nonpublic information relating to Parent or any of its Subsidiaries pursuant
to (x)&nbsp;a confidentiality agreement between Parent and such Third Party in existence on or prior to the date hereof or (y)&nbsp;a confidentiality agreement with confidentiality terms in the aggregate no less favorable to Parent than those
contained in the Confidentiality Agreement, a copy of which shall be provided, promptly after its execution, to the Company for informational purposes; <I>provided</I> that all such <FONT STYLE="white-space:nowrap">non-public</FONT> information (to
the extent that such information has not been previously provided or made available to the Company) is provided or made available to the Company, as the case may be, substantially concurrently with the time it is provided or made available to such
Third Party and (iii)&nbsp;following receipt of a Parent Superior Proposal after the date of this Agreement, (A)&nbsp;make a Parent Adverse Recommendation Change and/or (B)&nbsp;terminate this Agreement to enter into a definitive agreement providing
for such Parent Superior Proposal in accordance with <U>Section</U><U></U><U>&nbsp;10.01(c)(iv)</U>, but in each case referred to in the foregoing clauses (i)&nbsp;through (iii) only if the Board of Directors of Parent determines in good faith,
after consultation with Parent&#146;s outside legal counsel and financial advisor, that the failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law. Nothing contained herein shall
prevent the Board of Directors of Parent from (x)&nbsp;complying with Rule <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> under the 1934 Act with regard to a Parent Acquisition Proposal, so long as any action taken or statement made to so comply
is consistent with this <U>Section</U><U></U><U>&nbsp;7.02</U>; or (y)&nbsp;making any required disclosure to the stockholders of Parent if the Board of Directors of Parent determines in good faith, after consultation with its outside legal counsel,
that the failure to take such action would be reasonably likely to be inconsistent with Applicable Law; <I>provided</I> that any Parent Adverse Recommendation Change involving or relating to a Parent Acquisition Proposal may only be made in
accordance with the provisions of this <U>Section</U><U></U><U>&nbsp;7.02(b)</U>, <U>Section</U><U></U><U>&nbsp;7.02(c)</U> and <U>Section</U><U></U><U>&nbsp;7.02(e)</U>. For the avoidance of doubt, a &#147;stop, look and listen&#148; disclosure or
similar communication of the type contemplated by Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> under the 1934 Act shall not be a Parent Adverse Recommendation Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In addition to the requirements set forth in <U>Section</U><U></U><U>&nbsp;7.02(b)</U>, the Board of Directors of Parent shall not take
any of the actions referred to in clauses (i)&nbsp;through (iii) of <U>Section</U><U></U><U>&nbsp;7.02(b)</U> unless Parent shall have first delivered to the Company written notice advising the Company that Parent intends to take such action, and
Parent shall continue to advise the Company, on a current basis, after taking such action of the status and material terms of any discussions and negotiations with the applicable Third Party. In addition, Parent shall notify the Company promptly
(but in no event later than twenty-four (24)&nbsp;hours) after receipt by Parent (or any of its Representatives) of any Parent Acquisition Proposal, any indication that a Third Party is considering making a Parent Acquisition Proposal or any request
for information relating to Parent or any of its Subsidiaries or for access to the business, properties, assets, books or records of Parent or any of its Subsidiaries by any Third Party that, to the knowledge of Parent or any member of its Board of
Directors, is considering making, is reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
likely to make or has made, a Parent Acquisition Proposal, which notice shall be provided in writing and shall identify the Third Party making, and the material terms and conditions of, any such
Parent Acquisition Proposal, indication or request (including any material changes thereto). Parent shall keep the Company fully informed, on a current basis, of the status and details of any such Parent Acquisition Proposal, indication or request
(including any changes thereto) and shall promptly (but in no event later than twenty-four (24)&nbsp;hours after receipt) provide to the Company copies of all material correspondence and written materials sent or provided to Parent or any of its
Subsidiaries that describes any terms or conditions of any Parent Acquisition Proposal (as well as written summaries of any material oral communications addressing such matters). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything in this Agreement to the contrary, at any time prior to the Parent Approval Time (and in no event after the
Parent Approval Time), the Board of Directors of Parent may effect a Parent Adverse Recommendation Change involving or relating to a Parent Intervening Event if the Board of Directors of Parent determines in good faith, after consultation with its
outside legal counsel, that the failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law; <I>provided</I> that (i)&nbsp;Parent shall (A)&nbsp;promptly notify the Company in writing of
its intention to take such action and (B)&nbsp;negotiate in good faith with the Company for three (3)&nbsp;Business Days following such notice regarding revisions to the terms of this Agreement proposed by the Company, and (ii)&nbsp;the Board of
Directors of Parent shall not effect any Parent Adverse Recommendation Change involving or relating to a Parent Intervening Event unless, after the three (3)&nbsp;Business Day period described in the foregoing clause (B), the Board of Directors of
Parent determines in good faith, after consultation with its outside legal counsel, that the failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Without limiting or affecting <U>Section</U><U></U><U>&nbsp;7.02(a)</U>, <U>Section</U><U></U><U>&nbsp;7.02(b)</U> or
<U>Section</U><U></U><U>&nbsp;7.02(c)</U>, the Board of Directors of Parent shall not make a Parent Adverse Recommendation Change involving or relating to a Parent Superior Proposal or terminate this Agreement in order to enter into a definitive
agreement with respect to a Parent Superior Proposal unless (i)&nbsp;Parent promptly notifies the Company, in writing at least three (3)&nbsp;Business Days before taking such action, that Parent intends to take such action, which notice attaches the
most current version of any proposed agreement or a detailed summary of all material terms of such Parent Superior Proposal and the identity of the offeror, (ii)&nbsp;if requested by the Company, during such three (3)&nbsp;Business Day period,
Parent and its Representatives have discussed and negotiated in good faith with the Company regarding any proposal by the Company to amend the terms of this Agreement in response to such Parent Superior Proposal and (iii)&nbsp;after such three
(3)&nbsp;Business Day period, the Board of Directors of Parent determines in good faith, taking into account any proposal by the Company to amend the terms of this Agreement, that such Parent Acquisition Proposal continues to constitute a Parent
Superior Proposal (it being understood and agreed that in the event of any amendment to the financial terms or other material terms of any such Parent Superior Proposal, a new written notification from Parent consistent with that described in clause
(i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;7.02(e)</U> shall be required, and a new notice period under clause (i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;7.02(e)</U> shall commence, during which notice period Parent shall be required to
comply with the requirements of this <U>Section</U><U></U><U>&nbsp;7.02(e)</U> anew, except that such new notice period shall be for two (2)&nbsp;Business Days (as opposed to three (3)&nbsp;Business Days)). After delivery of such written notice
pursuant to the immediately preceding sentence, Parent shall promptly keep the Company informed of all material developments affecting the material terms of any such Parent Superior Proposal (and Parent shall provide the Company with copies of any
additional written materials received that relate to such Parent Superior Proposal). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Parent Superior Proposal</U>&#148;
means any <I>bona fide</I>, written Parent Acquisition Proposal (other than a Parent Acquisition Proposal which has resulted from a violation of this <U>Section</U><U></U><U>&nbsp;7.02</U>) (with all references to &#147;20%&#148; in the definition
of Parent Acquisition Proposal being deemed to be references to &#147;50%&#148;) on terms that the Board of Directors of Parent determines in good faith, after consultation with its financial advisor and outside legal counsel, and taking into
account all the terms and conditions of the Parent Acquisition Proposal that the Board of Directors of Parent considers to be appropriate (including the identity of the Person making the Parent Acquisition Proposal and the expected timing and
likelihood of consummation, any governmental or other approval requirements (including divestitures and entry into other commitments and limitations), <FONT STYLE="white-space:nowrap">break-up</FONT> fees,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expense reimbursement provisions, conditions to consummation and availability of necessary financing), would result in a transaction (i)&nbsp;that, if consummated, is more favorable to
Parent&#146;s stockholders from a financial point of view than the Merger (taking into account any proposal by the Company to amend the terms of this Agreement), (ii)&nbsp;that is reasonably capable of being completed on the terms proposed, taking
into account the identity of the Person making the Parent Acquisition Proposal, any approval requirements and all other financial, regulatory, legal and other aspects of such Parent Acquisition Proposal and (iii)&nbsp;for which financing, if a cash
transaction (whether in whole or in part), is then fully committed in a manner comparable to Parent&#146;s and Merger Sub&#146;s financing (or which is reasonably determined to be available by the Board of Directors of Parent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Parent Intervening Event</U>&#148; means any material event, change, effect, development or occurrence occurring or arising after
the date of this Agreement that (i)&nbsp;was not known or reasonably foreseeable, or the material consequences of which were not known or reasonably foreseeable, in each case to the Board of Directors or executive officers of Parent as of or prior
to the date of this Agreement, and (ii)&nbsp;does not relate to or involve any Parent Acquisition Proposal; <I>provided</I> that (A)&nbsp;in no event shall any action taken by either party pursuant to the affirmative covenants set forth in
<U>Section</U><U></U><U>&nbsp;8.02</U>, or the consequences of any such action, constitute, be deemed to contribute to or otherwise be taken into account in determining whether there has been a Parent Intervening Event, and (B)&nbsp;in no event
shall any event, change, effect, development or occurrence that would fall within any of the exceptions to the definition of &#147;Company Material Adverse Effect&#148; constitute, be deemed to contribute to or otherwise be taken into account in
determining whether there has been a Parent Intervening Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Parent shall, and shall cause its Subsidiaries to, and shall use its
reasonable best efforts to cause its and its Subsidiaries&#146; respective Representatives to, cease immediately and cause to be terminated any and all existing activities, discussions or negotiations, if any, with any Third Party conducted prior to
the date of this Agreement with respect to any Parent Acquisition Proposal and shall use its reasonable best efforts to cause any such party (or its agents or advisors) in possession of confidential information about Parent that was furnished by or
on behalf of Parent to return or destroy all such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Notwithstanding (i)&nbsp;any Parent Adverse Recommendation Change,
(ii)&nbsp;the making of any Parent Acquisition Proposal or (iii)&nbsp;anything in this Agreement to the contrary, until termination of this Agreement (x)&nbsp;in no event may Parent or any of its Subsidiaries (A)&nbsp;enter into any agreement in
principle, letter of intent, term sheet, merger agreement, acquisition agreement, option agreement, joint venture agreement, partnership agreement or other similar instrument constituting or relating to a Parent Acquisition Proposal (other than a
confidentiality agreement), (B)&nbsp;except as required by Applicable Law or permitted pursuant to the remainder of this <U>Section</U><U></U><U>&nbsp;7.02</U>, make, facilitate or provide information in connection with any SEC or other Filings in
connection with the transactions contemplated by any Parent Acquisition Proposal or (C)&nbsp;seek any Consents in connection with the transactions contemplated by any Parent Acquisition Proposal and (y)&nbsp;Parent shall otherwise remain subject to
all of its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_79"></A>Section&nbsp;7.03. <U>Obligations of Merger Sub</U>. Until the
Effective Time, Parent shall at all times be the direct or indirect owner of all of the outstanding shares of capital stock of Merger Sub. Parent shall take all action necessary to cause Merger Sub to perform its obligations under this Agreement and
to consummate the Merger on the terms and conditions set forth in this Agreement. Promptly following the execution of this Agreement, Parent shall cause the sole shareholder of Merger Sub to execute and deliver a written consent adopting this
Agreement in accordance with Pennsylvania Law and provide copies of such written consent to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_80"></A>Section&nbsp;7.04. <U>Director and Officer Liability</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Without limiting any additional rights that any director, officer or employee may have under any indemnification agreement or under the
Company Organizational Documents or similar organizational documents of the Company&#146;s Subsidiaries, from and after the Effective Time, Parent shall, and shall cause the Surviving Corporation or any applicable Subsidiary thereof (collectively,
the &#147;<U>D&amp;O Indemnifying Parties</U>&#148;), to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the fullest extent each such D&amp;O Indemnifying Party is so authorized or permitted by Applicable Law, as now or hereafter in effect, to: (i)&nbsp;indemnify and hold harmless each person who is
at the date hereof, was previously or during the period from the date hereof through the date of the Effective Time will be serving as a director, officer or employee of the Company or any of its Subsidiaries or, at the request or for the benefit of
the Company or any of its Subsidiaries, as a director, trustee, officer or employee of any other entity or any benefit plan maintained by the Company or any of its Subsidiaries (collectively, the &#147;<U>D&amp;O Indemnified Parties</U>&#148;), as
now or hereafter in effect, in connection with any D&amp;O Claim and any losses, claims, damages, liabilities, costs, Claim Expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges
paid or payable in connection with or in respect of any thereof) relating to or resulting from such D&amp;O Claim; and (ii)&nbsp;promptly pay on behalf of or, within ten (10)&nbsp;Business Days after any request for advancement by a D&amp;O
Indemnified Party, advance to such D&amp;O Indemnified Party, any Claim Expenses incurred in defending, serving as a witness with respect to or otherwise participating with respect to any D&amp;O Claim in advance of the final disposition of such
D&amp;O Claim, including payment on behalf of or advancement to the D&amp;O Indemnified Party of any Claim Expenses incurred by such D&amp;O Indemnified Party in connection with enforcing any rights with respect to such indemnification and/or
advancement, in each case without the requirement of any bond or other security, but subject to the D&amp;O Indemnifying Party&#146;s receipt of a written undertaking by or on behalf of such D&amp;O Indemnified Party to repay such Claim Expenses if
it is ultimately determined under Applicable Law that such D&amp;O Indemnified Party is not entitled to be indemnified. The indemnification and advancement obligations of the Surviving Corporation pursuant to this
<U>Section</U><U></U><U>&nbsp;7.04(a)</U> shall extend to acts or omissions occurring at or before the Effective Time, and any D&amp;O Claim relating thereto (including with respect to any acts, facts, events or omissions occurring in connection
with the approval of this Agreement, the Merger and the consummation of the other transactions contemplated by this Agreement, including the consideration and approval thereof and the process undertaken in connection therewith and any D&amp;O Claim
relating thereto), and all rights to indemnification and advancement conferred hereunder shall continue as to a person who has ceased to be a director, officer or employee of the Company or any of its Subsidiaries after the date hereof and shall
inure to the benefit of such Person&#146;s heirs, successors, executors and personal and legal representatives. As used in this <U>Section</U><U></U><U>&nbsp;7.04</U>: (x) the term &#147;<U>D&amp;O Claim</U>&#148; means any threatened, asserted,
pending or completed claim, action, suit, proceeding, inquiry or investigation, whether instituted by any party hereto, any Governmental Authority or any other Person, whether civil, criminal, administrative, investigative or other, including any
arbitration or other alternative dispute resolution mechanism, arising out of or pertaining to matters that relate to such D&amp;O Indemnified Party&#146;s duties or service (A)&nbsp;as a director, officer or employee of the Company or the
applicable Subsidiary thereof at or prior to the Effective Time (including with respect to any acts, facts, events or omissions occurring in connection with the approval of this Agreement, the Merger and/or the consummation of the other transactions
contemplated by this Agreement, including the consideration and approval thereof and the process undertaken in connection therewith and any D&amp;O Claim relating thereto) or (B)&nbsp;as a director, trustee, officer or employee of any other entity
or any benefit plan maintained by the Company or any of its Subsidiaries (for which such D&amp;O Indemnified Party is or was serving at the request or for the benefit of the Company or any of its Subsidiaries) at or prior to the Effective Time; and
(y)&nbsp;the term &#147;<U>Claim Expenses</U>&#148; means reasonable attorneys&#146; fees and all other reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, expenses and obligations
(including experts&#146; fees, travel expenses, court costs, retainers, transcript fees, legal research, duplicating, printing and binding costs, as well as telecommunications, postage and courier charges) paid or incurred in connection with
investigating, defending, being a witness in or participating in (including on appeal), or preparing to investigate, defend, be a witness in or participate in (including on appeal), any D&amp;O Claim for which indemnification is authorized pursuant
to this <U>Section</U><U></U><U>&nbsp;7.04(a)</U>, including any action relating to a claim for indemnification or advancement brought by a D&amp;O Indemnified Party. No D&amp;O Indemnifying Party shall settle, compromise or consent to the entry of
any judgment in any actual or threatened D&amp;O Claim in respect of which indemnification has been sought by such D&amp;O Indemnified Party hereunder unless such settlement, compromise or judgment includes an unconditional release of such D&amp;O
Indemnified Party from all liability arising out of such D&amp;O Claim, or such D&amp;O Indemnified Party otherwise consents thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
Without limiting the foregoing, Parent agrees that all rights to indemnification, advancement of expenses and exculpation from liabilities for acts or omissions occurring at or prior to the Effective Time now existing in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
favor of the current or former directors, officers or employees of the Company or any of its Subsidiaries as provided in the Company Organizational Documents, similar organizational documents of
the Company&#146;s Subsidiaries and indemnification agreements of the Company and its Subsidiaries shall survive the Merger and shall continue in full force and effect in accordance with their terms. For a period of six (6)&nbsp;years from the
Effective Time, the organizational documents of the Surviving Corporation and its Subsidiaries shall contain provisions no less favorable with respect to indemnification, advancement of expenses and limitations on liability of directors and officers
than are set forth in the Company Organizational Documents, which provisions shall not be amended, repealed or otherwise modified for a period of six (6)&nbsp;years from the Effective Time in any manner that would affect adversely the rights
thereunder of individuals who, at or prior to the Effective Time, were directors, officers or employees of the Company or any of its Subsidiaries, unless such modification shall be required by Applicable Law and then only to the minimum extent
required by Applicable Law. At the Company&#146;s option and expense, prior to the Effective Time, the Company may purchase (and pay in full the aggregate premium for) a six (6)-year prepaid &#147;tail&#148; insurance policy (which policy by its
express terms shall survive the Merger) of at least the same coverage and amounts and containing terms and conditions that are no less favorable to the directors, officers, employees, agents or fiduciaries of the Company or any of its Subsidiaries
as the Company&#146;s and its Subsidiaries&#146; existing directors&#146; and officers&#146; insurance policy or policies with a claims period of six (6)&nbsp;years from the Effective Time for D&amp;O Claims arising from facts, acts, events or
omissions that occurred on or prior to the Effective Time; <I>provided</I> that the premium for such tail policy shall not exceed three hundred percent (300%) of the aggregate annual amounts currently paid by the Company and its Subsidiaries for
such insurance (such amount being the &#147;<U>Maximum Premium</U>&#148;). If the Company fails to obtain such tail policy prior to the Effective Time, Parent or the Surviving Corporation shall obtain such a tail policy; <I>provided</I> that the
premium for such tail policy shall not exceed the Maximum Premium; and <I>provided</I>, <I>further</I>, that if such tail policy cannot be obtained or can be obtained only by paying aggregate annual premiums in excess of the Maximum Premium, Parent,
the Company or the Surviving Corporation shall only be required to obtain as much coverage as can be obtained by paying an annual premium equal to the Maximum Premium. Parent and the Surviving Corporation shall cause any such policy (whether
obtained by Parent, the Company or the Surviving Corporation) to be maintained in full force and effect, for its full term, and Parent shall cause the Surviving Corporation to honor all its obligations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If any of Parent or the Surviving Corporation or any of their respective successors or assigns (i)&nbsp;consolidates with or merges with
or into any other Person and shall not be the continuing or surviving company, partnership or other Person of such consolidation or merger or (ii)&nbsp;liquidates, dissolves or <FONT STYLE="white-space:nowrap">winds-up,</FONT> or transfers or
conveys all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Corporation, as applicable, assume the obligations
set forth in this <U>Section</U><U></U><U>&nbsp;7.04</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_81"></A>Section&nbsp;7.05. <U>Employee Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During the Benefits Continuation Period, the Surviving Corporation shall provide, and Parent shall cause the Surviving Corporation to
provide, to each individual who is employed by the Company or any of its Subsidiaries immediately prior to the Effective Time and continues as an employee of the Surviving Corporation, Parent or any of Parent&#146;s Subsidiaries (including
Subsidiaries of the Surviving Corporation) during all or a portion of the Benefits Continuation Period (each, an &#147;<U>Affected Employee</U>&#148;) (x)&nbsp;base salary, bonus and other cash incentive compensation opportunities that are no less
favorable than the base salary, bonus and other cash incentive compensation opportunities provided to such Affected Employee immediately prior to the Effective Time, (y)&nbsp;employee benefits no less favorable in the aggregate than the employee
benefits provided to such Affected Employee under the Company Employee Plans immediately prior to the Effective Time, <I>provided</I> that, for purposes of determining that such employee benefits are no less favorable in the aggregate, equity
incentive awards, defined benefit pension plan benefits, retention or change in control payments or awards or any similar compensation or benefit, shall not be taken into account, and (z)&nbsp;equity incentive awards with a target value no less
favorable than the target value of the equity incentive awards provided to such Affected Employee immediately prior to the Effective Time. Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;7.05(a)</U>, for the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period from the Closing Date through the second anniversary of the Closing Date, each individual who is employed by the Company or any of its Subsidiaries immediately prior to the Effective Time
shall be provided with severance benefits in amounts and on terms and conditions that are no less favorable than those provided to such individual immediately prior to the Effective Time, as set forth in the Company&#146;s Severance Pay Plan as
amended in accordance with Section&nbsp;6.01(l) of the Company Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) With respect to any employee benefit plan in
which any Affected Employee first becomes eligible to participate on or after the Effective Time (the &#147;<U>New Company Plans</U>&#148;), Parent shall: (i)&nbsp;waive all <FONT STYLE="white-space:nowrap">pre-existing</FONT> conditions, exclusions
and waiting periods with respect to participation and coverage requirements applicable to such Affected Employee under any New Company Plan that is a health and welfare plan in which such Affected Employee may be eligible to participate after the
Effective Time, (ii)&nbsp;recognize service of all Affected Employees (to the extent credited by the Company or its Subsidiaries) accrued prior to the Effective Time for all purposes under (but not for the purposes of benefit accrual under any
defined benefit pension plan) any New Company Plan in which any such Affected Employee may be eligible to participate after the Effective Time; <I>provided</I>,<I> however</I>, that in no event shall any credit be given to the extent it would result
in the duplication of benefits for the same period of service and (iii)&nbsp;if applicable, cause to be credited, in any New Company Plan that is a health plan in which Affected Employees participate, any deductibles or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by such Affected Employees and their beneficiaries and dependents during the portion of the calendar year in which the Closing Date occurs
prior to their participation in Parent&#146;s health plans with the objective that there be no double counting during the year in which the Effective Time occurs of such deductibles or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including through adjustments to health savings accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For the avoidance of doubt, for purposes of any Company Employee Plan containing a definition of &#147;change in control&#148; or
&#147;change of control&#148; (or language having a similar meaning), the Closing shall be deemed to constitute a &#147;change in control&#148; or &#147;change of control&#148; (or language having a similar meaning). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Parent agrees that, with respect to the annual cash incentive plans set forth on Section&nbsp;7.05(d) of the Company Disclosure Schedule
(the &#147;<U>Annual Incentive Plans</U>&#148;), it shall, or shall cause the Surviving Corporation to, provide each participant in an Annual Incentive Plan (each an &#147;<U>Incentive Plan Participant</U>&#148;) who remains employed with the
Surviving Corporation through the end of the year during which the Closing occurs, with an annual cash incentive award for the year during which the Closing occurs, the amount of which shall be determined as the sum of the following: (i)&nbsp;a <FONT
STYLE="white-space:nowrap">pro-rated</FONT> portion of the bonus with respect to the portion of the year of the Closing that occurs prior to the Closing, which bonus shall be determined based upon actual performance through and including the Closing
Date, as determined by the Company in accordance with the applicable Annual Incentive Plan <I>plus</I> (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of the bonus with respect to the portion of the year of the Closing that
occurs after the Closing, which bonus shall be at the applicable Incentive Plan Participant&#146;s target incentive level under such Annual Incentive Plan; <I>provided</I> that, if an Incentive Plan Participant&#146;s employment is terminated by
Parent or the Surviving Corporation or any Subsidiary of Parent or the Surviving Corporation for any reason following the Closing Date and through the end of the year during which the Closing occurs (other than for &#147;cause&#148; (as defined in
Section&nbsp;7.05(d) of the Company Disclosure Schedule) or, for the avoidance of doubt, any voluntary termination of employment), such Incentive Plan Participant shall be entitled to the sum of (A)&nbsp;the prorated payment set forth in
clause&nbsp;(i) above <I>plus</I> (B)&nbsp;an amount equal to the Incentive Plan Participant&#146;s target value prorated by a ratio equal to the quotient of the number of days worked between the Closing Date and the Incentive Plan
Participant&#146;s termination date <I>divided by</I> 365, and such total amount shall be paid as soon as practicable following such termination of employment; and <I>provided</I>,<I> further</I>, that in no event shall payment of any amounts under
the Annual Incentive Plans (or any <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion thereof) pursuant to this <U>Section</U><U></U><U>&nbsp;7.05(d)</U> result in the duplication of payments to any Incentive Plan Participant under any other
incentive, severance or other similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Nothing contained in this <U>Section</U><U></U><U>&nbsp;7.05</U> or elsewhere in
this Agreement, express or implied (i)&nbsp;shall cause either Parent or any of its Affiliates to be obligated to continue to employ any Person, including any Affected Employees, for any period of time following the Effective Time, (ii)&nbsp;shall
prevent Parent or its Affiliates from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revising, amending or terminating any Company Employee Plan or any other employee benefit plan, program or policy in effect from time to time, (iii)&nbsp;shall be construed as an amendment of any
Company Employee Plan, Parent Employee Plan or (iv)&nbsp;shall create any third-party beneficiary rights in any director, officer, employee or individual Person, including any present or former employee, officer, director or individual independent
contractor of the Company or any of its Subsidiaries (including any beneficiary or dependent of such individual). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_82">
</A>Section&nbsp;7.06. <U>Financing</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent and Merger Sub shall take, or shall cause to be taken, all actions and do, or
cause to be done, all things necessary to arrange the Debt Financing on the terms and conditions described in the Debt Commitment Letters, including: (i)&nbsp;to negotiate and enter into the definitive agreements with respect thereto on the terms
and conditions contained in the Debt Commitment Letters (including, as necessary, the &#147;flex&#148; provisions contained in any related fee letter) (or on other terms and conditions agreed by Parent, the Company and the Financing Sources) by the
Closing Date, and (ii)&nbsp;to satisfy or cause to be satisfied (or, if determined advisable by Parent, obtain the waiver of) on a timely basis all conditions to obtaining the Debt Financing within Parent&#146;s control and to comply or cause to be
complied with all of its obligations pursuant to the Debt Commitment Letters and the definitive agreements related thereto to the extent the failure to comply with such obligations would adversely impact the timing of the Closing or the availability
at Closing of sufficient aggregate proceeds of the Debt Financing to consummate the transactions contemplated by this Agreement. In the event that all conditions to funding the commitments contained in the Debt Commitment Letters have been
satisfied, each of Parent and Merger Sub shall use its reasonable best efforts to cause the Financing Sources to fund the Debt Financing required to consummate the transactions contemplated by this Agreement and to pay related fees and expenses on
the Closing Date (including by taking enforcement action to cause the Financing Sources to provide the Debt Financing). Each of Parent and Merger Sub shall use its reasonable best efforts to enforce all of its rights under the Debt Commitment
Letters. Parent shall give the Company prompt notice of any material breach by any party to the Debt Commitment Letters or the definitive agreements related thereto of which Parent has become aware or any termination of any of the Debt Commitment
Letters or such definitive agreements, to the extent such breach or termination could reasonably be expected to prevent or materially delay the Closing or otherwise result in sufficient proceeds of the Debt Financing to consummate the transactions
contemplated by this Agreement not being available at the Closing. In the event that any portion of the Debt Financing becomes unavailable and such portion is necessary to consummate the transactions contemplated by this Agreement (except in
accordance with the express terms set forth in the Debt Commitment Letters or unless concurrently replaced on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-for-dollar</FONT></FONT> basis by commitments subject to
substantially the same conditions as those set forth in the Debt Commitment Letter from other financing sources or from proceeds of other sources of financing or cash), Parent and Merger Sub shall (1)&nbsp;use their reasonable best efforts to
obtain, as promptly as practicable following the occurrence of such event, alternative debt financing for any such portion from alternative debt sources (&#147;<U>Alternative Financing</U>&#148;) in an amount that will enable Parent and Merger Sub
to consummate the transactions contemplated by this Agreement and that does not contain additional (or changes to the) conditions set forth in the Debt Commitment Letter delivered to the Company on or prior to the date of this Agreement that, in
each case, could reasonably be expected to adversely affect the ability of Parent or Merger Sub to timely consummate the transactions contemplated by this Agreement and (2)&nbsp;promptly notify the Company of such unavailability and the reason
therefor. If obtained, Parent shall deliver to the Company true and complete copies of all agreements (including redacted copies of engagement and fee letters, removing only fee amounts, market &#147;flex&#148; provisions and certain other terms
(none of which concern or would adversely affect the amounts, availability, timing or conditionality of the Debt Financing)) pursuant to which any such alternative source shall have committed to provide Parent or the Surviving Corporation with
Alternative Financing. Parent and Merger Sub shall not, without the Company&#146;s prior written consent, permit any amendment or modification to, or any waiver of any provision or remedy under, any Debt Commitment Letter or any definitive
agreements related thereto unless the terms of such Debt Commitment Letter or definitive agreements related thereto, in each case as so amended, modified or waived, are substantially similar to those in such Debt Commitment Letter or definitive
agreement related thereto, prior to giving effect to such amendment, modification or waiver (other than economic terms, which shall be as good as or better for Parent and Merger Sub than those in the Debt Commitment Letter
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or definitive agreement relating thereto prior to giving effect to such amendment, modification or waiver); <I>provided</I> that, in the case of amendments or modifications of any Debt Commitment
Letter or a definitive agreement relating thereto, the foregoing shall only apply if such amendment or modification (x)&nbsp;could reasonably be expected to (I)&nbsp;adversely affect the ability or likelihood of Parent or Merger Sub timely
consummating the transactions contemplated by this Agreement or (II)&nbsp;make the timely funding of the Debt Financing or the satisfaction of the conditions to obtaining the Debt Financing less likely to occur, (y)&nbsp;reduces the aggregate amount
of the Debt Financing or (z)&nbsp;materially and adversely affects the ability of Parent or Merger Sub to enforce their rights against other parties to the Debt Commitment Letters, it being understood and agreed that in any event, Parent may amend
the Debt Commitment Letters or the definitive agreements relating thereto to (x)&nbsp;add lenders, arrangers, bookrunners, agents, managers or similar entities that have not executed the Debt Commitment Letters as of the date of this Agreement and
consent to the assignment after the date of this Agreement of lending commitments under the Debt Commitment Letters to other lenders, or (y)&nbsp;increase the aggregate amount of the Debt Financing. Parent shall provide the Company with prompt
written notice of the receipt of any notice or other communication from any Financing Source with respect to such Financing Source&#146;s failure or anticipated failure to fund its commitments under any Debt Commitment Letters or definitive
agreement in connection therewith. Parent shall keep the Company reasonably informed on a current basis of the status of its efforts to consummate the Debt Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything contained in this Agreement to the contrary, Parent expressly acknowledges and agrees that Parent&#146;s and
Merger Sub&#146;s obligations hereunder are not conditioned in any manner upon Parent or Merger Sub obtaining any financing. The failure, for any reason, other than as a result of any material breach of this Agreement by the Company, of Parent and
Merger Sub to have sufficient cash available on the date that the Closing is required to occur pursuant to <U>Section</U><U></U><U>&nbsp;2.01</U> hereof, and/or the failure to pay the aggregate Cash Consideration on the date that the Closing is
required to occur pursuant to <U>Section</U><U></U><U>&nbsp;2.01</U> hereof, shall constitute a Willful Breach of this Agreement by Parent and Merger Sub. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS OF PARENT AND THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereto agree that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_83">
</A>Section&nbsp;8.01. <U>Access to Information; Confidentiality</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon reasonable notice and subject to Applicable Law, each of
the Company and Parent shall, and each shall cause its Subsidiaries to, afford to the other party and its Representatives, reasonable access, during normal business hours during the period from the date of this Agreement to the earlier of the
Effective Time or the termination of this Agreement, to all of its properties, books, contracts and records, and, during such period, each of the Company and Parent shall, and each shall cause its Subsidiaries to, make available to the other party
all other information concerning its businesses, properties and personnel as the other may reasonably request, and instruct its Representatives to reasonably cooperate with the other party in its investigation. All information furnished pursuant to
this Agreement shall be subject to the confidentiality agreement, dated as of June&nbsp;7, 2017, between Parent and the Company, as supplemented by that certain Clean Team Confidentiality Agreement, dated October&nbsp;31, 2017, between Parent and
the Company, and the Joint Defense Agreement, effective as of October&nbsp;18, 2017, between Parent and the Company (collectively, the &#147;<U>Confidentiality Agreement</U>&#148;). No information or knowledge obtained in any investigation pursuant
to this <U>Section</U><U></U><U>&nbsp;8.01</U> shall affect or be deemed to modify any representation or warranty made by the Company or Parent pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;8.01</U>, <U>Section</U><U></U><U>&nbsp;8.02</U> or
<U>Section</U><U></U><U>&nbsp;8.03</U>, none of the Company, Parent or any of their respective Subsidiaries shall be required to provide access to its properties, books, contracts, records or personnel if such access would unreasonably disrupt its
operations, or provide access </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to or to disclose information where such access or disclosure would jeopardize the attorney-client privilege of such party or any of its Subsidiaries or contravene any Applicable Law, fiduciary
duty or binding agreement entered into prior to the date of this Agreement; <I>provided </I>that each of the Company and Parent shall, and each shall cause its Subsidiaries to, use reasonable best efforts to make appropriate substitute disclosure
arrangements under circumstances in which such restrictions apply (including redacting such information (i)&nbsp;to remove references concerning valuation, (ii)&nbsp;as necessary to comply with contractual arrangements in effect on or after the date
hereof and (iii)&nbsp;as necessary to address reasonable attorney-client or other privilege or confidentiality concerns); <I>provided</I>,<I> however</I>, that in no event shall either party have access to individual performance or evaluation
records, medical histories or other similar information that, in the reasonable opinion of the applicable party, is sensitive or the disclosure of which would reasonably be expected to subject such party or any of its Subsidiaries to risk of
liability. Each of the Company and Parent may, as each deems advisable and necessary, reasonably designate any competitively sensitive material provided to the other under this <U>Section</U><U></U><U>&nbsp;8.01</U> or
<U>Section</U><U></U><U>&nbsp;8.02</U> as &#147;Outside Counsel Only Material.&#148; Such materials and the information contained therein shall be given only to the outside counsel of the recipient and, subject to any additional confidentiality or
joint defense agreement the parties may mutually propose and enter into, will not be disclosed by such outside counsel to employees, officers or directors of the recipient unless express permission is obtained in advance from the source of the
materials (the Company or Parent, as the case may be) or its legal counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_84"></A>Section&nbsp;8.02. <U>Reasonable
Best Efforts</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions of this Agreement, including <U>Section</U><U></U><U>&nbsp;8.02(b)</U>, each of
the Company and Parent shall, and each shall cause its Subsidiaries to, use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under
Applicable Law to consummate the Merger and other transactions contemplated hereby as promptly as practicable, (x)&nbsp;including (i)&nbsp;preparing and filing as promptly as practicable with any Governmental Authority or other Third Party all
documentation to effect all necessary Filings, (ii)&nbsp;obtaining as promptly as practicable and thereafter maintaining all Consents required to be obtained from any Governmental Authority or other Third Party that are necessary, proper or
advisable to consummate the Merger or other transactions contemplated hereby, and complying with the terms and conditions of each Consent and (iii)&nbsp;cooperating to the extent reasonable with the other parties hereto in their efforts to comply
with their obligations under this Agreement, including in seeking to obtain as promptly as practicable any required Consents and (y)&nbsp;which includes contesting (which includes by litigation) any (i)&nbsp;action, suit, investigation or proceeding
brought by any Governmental Authority in a federal, state or administrative court seeking to enjoin, restrain, prevent, prohibit or make illegal consummation of the Merger or other transactions contemplated hereby or seeking damages or to impose any
terms or conditions in connection with the Merger or (ii)&nbsp;Order that has been entered by a federal, state or administrative court that enjoins, restrains, prevents, prohibits or makes illegal consummation of the Merger or other transactions
contemplated hereby or imposes any damages, terms or conditions in connection with the Merger or other transactions contemplated hereby. The parties understand and agree that Parent&#146;s obligation to use its reasonable best efforts set forth in
this <U>Section</U><U></U><U>&nbsp;8.02(a)</U> includes taking all actions and doing all things necessary, proper or advisable under Applicable Law (including divestitures, hold separate arrangements, the termination, assignment, novation or
modification of Contracts (or portions thereof) or other business relationships, the acceptance of restrictions on business operations and the entry into other commitments and limitations) to obtain the governmental approvals described in clauses
(x), (y) and (z)&nbsp;of the first sentence of <U>Section</U><U></U><U>&nbsp;8.02(b)</U> to consummate the Merger and the other transactions contemplated hereby, so long as such actions would not have and would not reasonably be expected to have,
individually or in the aggregate, a Regulatory Material Adverse Effect on Parent or on the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding
<U>Section</U><U></U><U>&nbsp;8.02(a)</U> or anything else in this Agreement to the contrary, nothing in this Agreement will obligate or require Parent, Merger Sub or any of their respective Subsidiaries to take or cause to be taken any action (or
refrain or cause to refrain from taking any action) or agree or cause to agree to any term, condition or limitation (including, in each case, any of the actions or items referred to in the last sentence of <U>Section</U><U></U><U>&nbsp;8.02(a)</U>)
as a condition to, or in connection with, (x)&nbsp;the expiration or termination of any applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
waiting period relating to the Merger under the HSR Act, (y)&nbsp;any other Antitrust Law or (z)&nbsp;obtaining any Parent Required Governmental Authorization or Company Required Governmental
Authorization or any other Consent from a Governmental Authority or otherwise, in each case if such action (or refraining from such action), term, condition or limitation would have or would reasonably be expected to have, individually or in the
aggregate, a Regulatory Material Adverse Effect on Parent or on the Company. &#147;<U>Regulatory Material Adverse Effect</U>&#148; means, with respect to any Person, a material adverse effect on the financial condition, business, revenue or EBITDA
of such Person and its Subsidiaries, taken as a whole; <I>provided</I> that, for purposes of determining whether any action, term or condition would have or would reasonably be expected to have a Regulatory Material Adverse Effect on the Company,
the Company and its Subsidiaries will collectively be deemed to be a company the size of (and with revenue and EBITDA equal to those of) Parent and its Subsidiaries, taken as a whole (excluding, for the avoidance of doubt, the Company and its
Subsidiaries); <I>provided</I>,<I> further</I>, that, for purposes of determining whether any action, term or condition would have or would reasonably be expected to have a Regulatory Material Adverse Effect on Parent or on the Company, impacts on
Parent, the Company or any of their respective Subsidiaries will be aggregated. &#147;<U>EBITDA</U>&#148; means, with respect to any Person, the sum of (1)&nbsp;consolidated net income, determined in accordance with GAAP, <I>plus</I>
(2)&nbsp;without duplication and to the extent deducted in determining such consolidated net income, the sum of (I)&nbsp;consolidated interest expense, (II)&nbsp;consolidated income tax expense and (III)&nbsp;all amounts attributed to depreciation
or amortization, in each case of such Person and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Neither the Company nor Parent shall, and each shall cause its
Subsidiaries not to, directly or indirectly (whether by merger, consolidation or otherwise), acquire, purchase, lease or license (or agree to acquire, purchase, lease or license) any business, corporation, partnership, association or other business
organization or division or part thereof, or any securities or collection of assets, if doing so would reasonably be expected to: (i)&nbsp;impose any material delay in the obtaining of, or materially increase the risk of not obtaining, any Consent
of any Governmental Authority necessary to consummate the Merger or any of the other transactions contemplated hereby or the expiration or termination of any applicable waiting period; (ii)&nbsp;materially increase the risk of any Governmental
Authority entering an Order prohibiting the consummation of the Merger or any of the other transactions contemplated hereby; (iii)&nbsp;materially increase the risk of not being able to remove any such Order on appeal or otherwise; or
(iv)&nbsp;otherwise prevent or materially delay the consummation of the Merger or any of the other transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
Parent shall have principal responsibility for directing, devising, and implementing the strategy for obtaining any necessary approval of, for responding to any request from, inquiry by, or investigation by (including directing the timing, nature,
and substance of all such responses), and for leading all meetings and communications with any Governmental Authority that has authority to enforce any Antitrust Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) In furtherance and not in limitation of the foregoing, each of the Company and Parent shall, and each shall cause its Subsidiaries to, as
promptly as practicable following the date of this Agreement, make all Filings with all Governmental Authorities that may be or may become reasonably necessary, proper or advisable under this Agreement or Applicable Law to consummate and make
effective the Merger and the other transactions contemplated hereby, including: (i)&nbsp;not later than thirty (30)&nbsp;Business Days following the date of this Agreement, Parent filing, or causing to be filed, &#147;Form A Statements&#148; or
similar change of control applications, with the insurance commissioners or regulators or departments of health or other Governmental Authorities in each jurisdiction where required by Applicable Law, seeking approval of Parent&#146;s acquisition of
control of each of the Regulated Subsidiaries which results from the Merger; (ii)&nbsp;as promptly as practicable following the date of this Agreement, Parent filing, or causing to be filed, any
<FONT STYLE="white-space:nowrap">pre-acquisition</FONT> notifications on &#147;Form E&#148; or similar market share notifications to be filed in each jurisdiction where required by Applicable Laws with respect to the Merger and the other
transactions contemplated hereby; (iii)&nbsp;not later than twenty (20)&nbsp;Business Days following the date of this Agreement (unless the parties otherwise agree to another time period), the Company and Parent each making an appropriate Filing of
a notification and report form pursuant to the HSR Act with the Federal Trade Commission and the Antitrust Division of the United States Department of Justice with respect to the Merger and the other transactions contemplated hereby and requesting
early termination of the waiting period under the HSR </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Act; (iv)&nbsp;the Company and Parent each making any other Filing that may be required under any other Antitrust Laws or by any Governmental Authority having antitrust jurisdiction under
Applicable Law; (v)&nbsp;not later than thirty (30)&nbsp;Business Days following the date of this Agreement, the Company and Parent filing any required notices to CMS, with a separate notice to the CMS Medicare Drug Benefit Group and Central Office
Medicare Advantage plan manager, if applicable; and (vi)&nbsp;the Company and Parent each promptly following the date hereof making any other Filing that may be required under any Health Care Laws, Insurance Laws or other Applicable Laws or by any
Governmental Authority with jurisdiction over enforcement of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) To the extent permitted by Applicable Law, the
Company and Parent shall, as promptly as practicable, (i)&nbsp;upon the reasonable request of the other party, furnish to such party and, upon any reasonable request from a Governmental Authority, furnish to such Governmental Authority, any
information or documentation concerning themselves, their Affiliates, directors, officers and shareholders or stockholders, as applicable, information or documentation concerning the Merger and the other transactions contemplated hereby and such
other matters as may be requested and (ii)&nbsp;make available their respective Representatives to each other and, upon reasonable request, any Governmental Authority, in connection with (A)&nbsp;the preparation of any Filing made by or on their
behalf to any Governmental Authority in connection with the Merger or the other transactions contemplated hereby or (B)&nbsp;any Governmental Authority investigation, review or approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Subject to Applicable Laws relating to the sharing of information and the terms and conditions of the Confidentiality Agreement and all
other agreements entered into by the parties to this Agreement, each of the Company and Parent shall, and each shall cause its Subsidiaries to: (i)&nbsp;(A)&nbsp;as far in advance as practicable, notify the other party of and consult the other party
with respect to any Filing or material or substantive communication or inquiry it or any of its Affiliates intends to make with any Governmental Authority relating to the matters that are the subject of this Agreement, (B)&nbsp;prior to submitting
any such Filing or making any such communication or inquiry, the submitting or making party shall provide the other party and its counsel a reasonable opportunity to review, and shall consider in good faith the comments of the other party in
connection with any such Filing, communication or inquiry, and (C)&nbsp;promptly following the submission of such Filing or making of such communication or inquiry, provide the other party and its counsel with a copy of any such Filing,
communication or inquiry or, if such communication or inquiry is made in oral form, a summary of any such oral communication or inquiry; (ii)&nbsp;as promptly as practicable following receipt, furnish the other party with a copy of any Filing or, if
in written form, material or substantive communication or inquiry, it or any of its Affiliates receives from any Governmental Authority relating to matters that are the subject of this Agreement; <I>provided</I> that, if any such communication or
inquiry is not in written form, the receiving party shall provide the other party with a written summary of such communication or inquiry; (iii)&nbsp;coordinate and cooperate fully with the other party in exchanging such information and providing
such assistance as the other party may reasonably request in connection with this <U>Section</U><U></U><U>&nbsp;8.02</U>; and (iv)&nbsp;consult with each other in connection with any inquiry, hearing, investigation or litigation by, or negotiations
with, any Governmental Authority relating to the transactions contemplated hereby or any Filings with respect thereto under Applicable Law, including the scheduling of, and strategic planning for, any meetings with any Governmental Authority
relating thereto. None of the Company, Parent or their respective Representatives shall agree to participate in any material or substantive meeting or conference (including by telephone) with any Governmental Authority, or any member of the staff of
any Governmental Authority, in respect of any Filing, proceeding, investigation (including the settlement of any investigation), litigation or other inquiry regarding the Merger unless it consults with the other party in advance and, to the extent
permitted by such Governmental Authority, allows the other party to participate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Notwithstanding anything in this Agreement to the
contrary, in no event shall (i)&nbsp;Parent or any of its Affiliates or the Company or any of its Affiliates be required to agree to take or enter into any action which is not conditioned upon the Closing, or (ii)&nbsp;the Company or any of its
Affiliates agree to any obligation, restriction, requirement, limitation, qualification, condition, remedy or other action relating to Consents required to be obtained by the parties or their respective Subsidiaries in connection with the Merger
without the prior written consent of Parent (which consent shall not be withheld, delayed or conditioned if doing so would be inconsistent with Parent&#146;s obligations under this <U>Section</U><U></U><U>&nbsp;8.02</U>). The Company further
covenants and agrees not to voluntarily </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extend any waiting period associated with any Consent of any Governmental Authority (including under the HSR Act) or enter into any agreement with any Governmental Authority or other Third Party
not to consummate the Merger and the other transactions contemplated hereby, except with the prior written consent of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_85">
</A>Section&nbsp;8.03. <U>Certain Filings; SEC Matters</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable following the date of this Agreement,
(i)&nbsp;the Company and Parent shall jointly prepare and file with the SEC a proxy statement relating to the Company Shareholder Meeting and the Parent Stockholder Meeting (together with all amendments and supplements thereto, the &#147;<U>Joint
Proxy Statement/Prospectus</U>&#148;) in preliminary form, and (ii)&nbsp;Parent shall prepare and file with the SEC a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> which shall include the Joint Proxy Statement/Prospectus
(together with all amendments and supplements thereto, the &#147;<U>Registration Statement</U>&#148;) relating to the registration of the shares of Parent Common Stock to be issued to the shareholders of the Company pursuant to the Parent Share
Issuance. The Joint Proxy Statement/Prospectus and Registration Statement shall comply as to form in all material respects with the applicable provisions of the 1933 Act and the 1934 Act and other Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each of the Company and Parent shall use its reasonable best efforts to have the Joint Proxy Statement/Prospectus cleared by the SEC as
promptly as practicable after its filing, and Parent shall use its reasonable best efforts to have the Registration Statement declared effective under the 1933 Act as promptly as practicable after its filing and keep the Registration Statement
effective for so long as necessary to consummate the Merger. Each of the Company and Parent shall, as promptly as practicable after the receipt thereof, provide the other party with copies of any written comments and advise the other party of any
oral comments with respect to the Joint Proxy Statement/Prospectus and the Registration Statement received by such party from the SEC, including any request from the SEC for amendments or supplements to the Joint Proxy Statement/Prospectus and the
Registration Statement, and shall provide the other with copies of all material or substantive correspondence between it and its Representatives, on the one hand, and the SEC, on the other hand. Notwithstanding the foregoing, prior to filing the
Registration Statement or mailing the Joint Proxy Statement/Prospectus or responding to any comments of the SEC with respect thereto, each of the Company and Parent shall provide the other party and its counsel a reasonable opportunity to review
such document or response (including the proposed final version of such document or response) and consider in good faith the comments of the other party in connection with any such document or response. None of the Company, Parent or any of their
respective Representatives shall agree to participate in any material or substantive meeting or conference (including by telephone) with the SEC, or any member of the staff thereof, in respect of the Registration Statement or the Joint Proxy
Statement/Prospectus unless it consults with the other party in advance and, to the extent permitted by the SEC, allows the other party to participate. Parent shall advise the Company, promptly after receipt of notice thereof, of the time of
effectiveness of the Registration Statement, and the issuance of any stop order relating thereto or the suspension of the qualification of shares of Parent Common Stock for offering or sale in any jurisdiction, and each of the Company and Parent
shall use its reasonable best efforts to have any such stop order or suspension lifted, reversed or otherwise terminated. Each of the Company and Parent shall use its reasonable best efforts to take any other action required to be taken by it under
the 1933 Act, the 1934 Act, Delaware Law (solely in the case of Parent), Pennsylvania Law (solely in the case of the Company) and the rules of the NYSE in connection with the filing and distribution of the Joint Proxy Statement/Prospectus and the
Registration Statement, and the solicitation of proxies from the shareholders of the Company and the stockholders of Parent thereunder. Subject to <U>Section</U><U></U><U>&nbsp;6.02</U>, the Joint Proxy Statement/Prospectus shall include the Company
Board Recommendation, and, subject to <U>Section</U><U></U><U>&nbsp;7.02</U>, the Joint Proxy Statement/Prospectus shall include the Parent Board Recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Parent shall use its reasonable best efforts to take, or cause to be taken, all actions, and to do or cause to be done all things,
necessary, proper or advisable under Applicable Laws and the rules and policies of the NYSE and the SEC to enable the listing of the Parent Common Stock being registered pursuant to the Registration Statement on the NYSE no later than the Effective
Time, subject to official notice of issuance. Parent shall also use its reasonable best efforts to obtain all necessary state securities law or &#147;blue sky&#148; permits and approvals required to carry out the transactions contemplated by this
Agreement (<I>provided</I> that in no event shall Parent be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to qualify to do business in any jurisdiction in which it is not now so qualified or file a general consent to service of process). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each of the Company and Parent shall, upon request, furnish to the other all information concerning itself, its Subsidiaries, directors,
officers and (to the extent reasonably available to the applicable party) shareholders or stockholders (as applicable) and such other matters as may be reasonably necessary or advisable in connection with any statement, Filing, notice or application
made by or on behalf of the Company, Parent or any of their respective Subsidiaries, to the SEC or the NYSE in connection with the Merger and the other transactions contemplated by this Agreement, including the Registration Statement and the Joint
Proxy Statement/Prospectus. In addition, each of the Company and Parent shall use its reasonable best efforts to provide information concerning it necessary to enable the Company and Parent to prepare required pro forma financial statements and
related footnotes in connection with the preparation of the Registration Statement and/or the Joint Proxy Statement/Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If at
any time prior to the later of the Company Approval Time and the Parent Approval Time, any information relating to the Company or Parent, or any of their respective Affiliates, officers or directors, should be discovered by the Company or Parent
that should be set forth in an amendment or supplement to either of the Registration Statement or the Joint Proxy Statement/Prospectus, so that either of such documents would not include any misstatement of a material fact or omit to state any
material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the party that discovers such information shall promptly notify the other party hereto and an appropriate amendment or
supplement describing such information shall promptly be prepared and filed with the SEC and, to the extent required under Applicable Law, disseminated to the shareholders of the Company and the stockholders of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_86"></A>Section&nbsp;8.04. <U>Shareholder and Stockholder Meetings</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable following the effectiveness of the Registration Statement, the Company shall, in consultation with Parent, in
accordance with Applicable Law and the Company Organizational Documents, (i)&nbsp;establish a record date (the &#147;<U>Company Record Date</U>&#148;) for, duly call and give notice of a meeting of the shareholders of the Company entitled to vote on
the Merger (the &#147;<U>Company Shareholder Meeting</U>&#148;) at which meeting the Company shall seek the Company Shareholder Approval, which record date shall be no later than ten (10)&nbsp;days after the date on which the Registration Statement
is declared effective under the 1933 Act, (ii)&nbsp;cause the Joint Proxy Statement/Prospectus (and all other proxy materials for the Company Shareholder Meeting) to be mailed to its shareholders and (iii)&nbsp;within forty (40)&nbsp;days after the
Company Record Date, duly convene and hold the Company Shareholder Meeting. Subject to <U>Section</U><U></U><U>&nbsp;6.02</U>, the Company shall use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done
all things, necessary, proper or advisable on its part to cause the Company Shareholder Approval to be received at the Company Shareholder Meeting or any adjournment or postponement thereof, and shall comply with all legal requirements applicable to
the Company Shareholder Meeting. The Company shall not, without the prior written consent of Parent, adjourn, postpone or otherwise delay the Company Shareholder Meeting; <I>provided</I> that the Company may, without the prior written consent of
Parent, adjourn or postpone the Company Shareholder Meeting, after consultation with Parent, if the Company believes in good faith that such adjournment or postponement is reasonably necessary to allow reasonable additional time to (x)&nbsp;solicit
additional proxies necessary to obtain the Company Shareholder Approval, or (y)&nbsp;distribute any supplement or amendment to the Joint Proxy Statement/Prospectus that the Board of Directors of the Company has determined in good faith after
consultation with outside legal counsel is necessary under Applicable Law and for such supplement or amendment to be reviewed by the Company&#146;s shareholders prior to the Company Shareholder Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As promptly as practicable following the effectiveness of the Registration Statement, Parent shall, in consultation with the Company, in
accordance with Applicable Law and the Parent Organizational Documents, (i)&nbsp;establish a record date (which date shall be the same as the Company Record Date) for, duly call and give notice of a meeting of the stockholders of Parent entitled to
vote on the Parent Share Issuance (the &#147;<U>Parent</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Stockholder Meeting</U>&#148;) at which meeting Parent shall seek the Parent Stockholder Approval, (ii)&nbsp;cause the Joint Proxy Statement/Prospectus (and all other proxy materials for the
Parent Stockholder Meeting) to be mailed to its stockholders and (iii)&nbsp;duly convene and hold the Parent Stockholder Meeting on the same date and at the same time as the Company Shareholder Meeting. Subject to
<U>Section</U><U></U><U>&nbsp;7.02</U>, Parent shall use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, necessary, proper or advisable on its part to cause the Parent Stockholder
Approval to be received at the Parent Stockholder Meeting or any adjournment or postponement thereof, and shall comply with all legal requirements applicable to the Parent Stockholder Meeting. Parent shall not, without the prior written consent of
the Company, adjourn, postpone or otherwise delay the Parent Stockholder Meeting; <I>provided</I> that Parent may, without the prior written consent of the Company, adjourn or postpone the Parent Stockholder Meeting, after consultation with the
Company, if Parent believes in good faith that such adjournment or postponement is reasonably necessary to allow reasonable additional time to (x)&nbsp;solicit additional proxies necessary to obtain the Parent Stockholder Approval, or
(y)&nbsp;distribute any supplement or amendment to the Joint Proxy Statement/Prospectus that the Board of Directors of Parent has determined in good faith after consultation with outside legal counsel is necessary under Applicable Law and for such
supplement or amendment to be reviewed by Parent&#146;s stockholders prior to the Parent Stockholder Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding
(x)&nbsp;any Company Adverse Recommendation Change or Parent Adverse Recommendation Change, (y)&nbsp;the public proposal or announcement or other submission to the Company or any of its Representatives of a Company Acquisition Proposal or the public
proposal or announcement or other submission to Parent or any of its Representatives of a Parent Acquisition Proposal or (z)&nbsp;anything in this Agreement to the contrary, unless this Agreement is terminated in accordance with its terms, the
obligations of the Company and Parent under <U>Section</U><U></U><U>&nbsp;8.03</U> and this <U>Section</U><U></U><U>&nbsp;8.04</U> shall continue in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_87"></A>Section&nbsp;8.05. <U>Public Announcements</U>. The initial press release concerning this Agreement and the
transactions contemplated hereby shall be a joint press release to be reasonably agreed upon by the Company and Parent. Following such initial press release, Parent and the Company shall consult with each other before issuing any additional press
release, making any other public statement or scheduling any press conference, conference call or meeting with investors or analysts with respect to this Agreement or the transactions contemplated hereby and, except as may be required by Applicable
Law or any listing agreement with or rule of any national securities exchange or association, shall not issue any such press release, make any such other public statement or schedule any such press conference, conference call or meeting before such
consultation (and, to the extent applicable, shall provide copies of any such press release, statement or agreement (or any scripts for any conference calls) to the other party and shall consider in good faith the comments of the other party);
<I>provided</I> that the restrictions set forth in this <U>Section</U><U></U><U>&nbsp;8.05</U> shall not apply to any release or public statement (a)&nbsp;made or proposed to be made by the Company in compliance with
<U>Section</U><U></U><U>&nbsp;6.02</U> with respect to the matters contemplated by <U>Section</U><U></U><U>&nbsp;6.02</U>, (b)&nbsp;made or proposed to be made by Parent in compliance with <U>Section</U><U></U><U>&nbsp;7.02</U> with respect to the
matters contemplated by <U>Section</U><U></U><U>&nbsp;7.02</U> or (c)&nbsp;in connection with any dispute between the parties regarding this Agreement, the Merger or the other transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_88"></A>Section&nbsp;8.06. <U>Notices of Certain Events</U>. Each of the Company and Parent shall promptly advise the
other of (a)&nbsp;any notice or other material communication from any Person alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this Agreement; (b)&nbsp;any notice or other
communication from any Governmental Authority in connection with the transactions contemplated by this Agreement; (c)&nbsp;any actions, suits, claims, investigations or proceedings commenced or, to its knowledge, threatened against, relating to or
involving or otherwise affecting the Company or any of its Subsidiaries or Parent or any of its Subsidiaries, as the case may be, that, if pending on the date of this Agreement, would have been required to have been disclosed pursuant to any Section
of this Agreement or that relate to the consummation of the transactions contemplated by this Agreement; (d)&nbsp;any change or event that has had or would be reasonably likely to have, individually or in the aggregate, a Company Material Adverse
Effect, in the case of the Company, or a Parent Material Adverse Effect, in the case of Parent; or (e)&nbsp;any change or event that it believes would or would be reasonably likely to cause or constitute a material breach of any of its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representations, warranties or covenants contained in this Agreement; <I>provided</I> that a failure to comply with this <U>Section</U><U></U><U>&nbsp;8.06</U> shall not constitute the failure of
any condition set forth in <U>Article</U><U></U><U>&nbsp;IX</U> to be satisfied unless the underlying change or event would independently result in the failure of a condition set forth in <U>Article</U><U></U><U>&nbsp;IX</U> to be satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_89"></A>Section&nbsp;8.07. <U>Section 16 Matters</U>. Prior to the Effective Time, Parent and the Company shall take all
such steps as may be required (to the extent permitted under Applicable Law) to cause any dispositions of Company Common Stock (including derivative securities with respect to Company Common Stock) or acquisitions of Parent Common Stock (including
derivative securities with respect to Parent Common Stock) resulting from the transactions contemplated by this Agreement by each individual who is subject to the reporting requirements of Section&nbsp;16(a) of the 1934 Act with respect to the
Company, or will become subject to such reporting requirements with respect to Parent, to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the 1934 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_90"></A>Section&nbsp;8.08. <U>Transaction Litigation</U>. Each of the Company and Parent shall promptly notify the other
of any shareholder or stockholder (as applicable) demands, litigations, arbitrations or other similar claims, actions, suits or proceedings (including derivative claims) commenced against it and/or its respective directors or officers relating to
this Agreement or any of the transactions contemplated hereby or any matters relating thereto (collectively, &#147;<U>Transaction Litigation</U>&#148;) and shall keep the other party informed regarding any Transaction Litigation. Each of the Company
and Parent shall cooperate with the other in the defense or settlement of any Transaction Litigation and shall give the other party the opportunity to consult with it regarding the defense or settlement of such Transaction Litigation and shall give
the other party&#146;s advice due consideration with respect to such Transaction Litigation. Prior to the Effective Time, none of the Company or any of its Subsidiaries shall settle or offer to settle any Transaction Litigation without the prior
written consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_91"></A>Section&nbsp;8.09. <U>Stock Exchange Delisting</U>. Each of the Company and Parent agrees to cooperate with the
other party in taking, or causing to be taken, all actions necessary to delist the Company Common Stock from the NYSE and terminate its registration under the 1934 Act; <I>provided</I> that such delisting and termination shall not be effective until
the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_92"></A>Section&nbsp;8.10. <U>Dividends</U>. Each of the Company and Parent shall coordinate with
the other regarding the declaration and payment of dividends in respect of Company Common Stock and Parent Common Stock and the record dates and payment dates relating thereto, it being the intention of the Company and Parent that no holder of
Company Common Stock or Parent Common Stock shall receive two dividends, or fail to receive one dividend, for any single calendar quarter with respect to its shares of Company Common Stock, on the one hand, and shares of Parent Common Stock any
holder of Company Common Stock receives pursuant to the Merger, on the other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_93"></A>Section&nbsp;8.11.
<U>Governance and Social Matters</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Parent shall take all necessary corporate action to cause, effective at the Effective Time,
(i)&nbsp;the number of members of the Board of Directors of Parent to be increased by three (3)&nbsp;and (ii) the vacancies created by the foregoing clause (i)&nbsp;to be filled by Mark T. Bertolini, the Chairman and Chief Executive Officer of the
Company, and two other individuals who are serving on the Board of Directors of the Company immediately prior to the Effective Time, who are jointly designated by the Company and Parent prior to the Closing and who meet Parent&#146;s independence
criteria as in effect as of such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For at least three years following the Closing, Parent shall preserve Aetna Foundation, Inc.
in a manner consistent in all material respects with the past practice of the Company, including by maintaining its name as &#147;Aetna Foundation&#148; and its charitable mission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For at least five years following the Closing, Parent shall maintain &#147;Aetna&#148; as the primary brand for the insurance businesses
of Parent and its Subsidiaries (including the Surviving Corporation and its Subsidiaries). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_94"></A>Section&nbsp;8.12. <U>State Takeover Statutes</U>. Each of
Parent, Merger Sub and the Company shall (a)&nbsp;take all action necessary so that no &#147;moratorium,&#148; &#147;control share acquisition,&#148; &#147;fair price,&#148; &#147;supermajority,&#148; &#147;affiliate transactions&#148; or
&#147;business combination statute or regulation&#148; or other similar state anti-takeover laws or regulations, or any similar provision of the Company Organizational Documents or the Parent Organizational Documents, as applicable, is or becomes
applicable to the Merger or any of the other transactions contemplated hereby, and (b)&nbsp;if any such anti-takeover law, regulation or provision is or becomes applicable to the Merger or any other transactions contemplated hereby, cooperate and
grant such approvals and take such actions as are reasonably necessary so that the transactions contemplated hereby may be consummated as promptly as practicable on the terms contemplated hereby and otherwise act to eliminate or minimize the effects
of such statute or regulation on the transactions contemplated hereby. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_95"></A>Section&nbsp;9.01. <U>Conditions to the Obligations of Each Party</U>. The obligations of the Company, Parent and
Merger Sub to consummate the Merger are subject to the satisfaction (or, to the extent permitted by Applicable Law, waiver) of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Company Shareholder Approval shall have been obtained in accordance with Pennsylvania Law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Parent Stockholder Approval shall have been obtained in accordance with the rules of the NYSE; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) no Applicable Law enacted, adopted or promulgated after the date hereof shall be in effect in the U.S. that enjoins, prevents or prohibits
the consummation of the Merger; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the Registration Statement shall have been declared effective, no stop order suspending the
effectiveness of the Registration Statement shall be in effect, and no proceedings for such purpose shall be pending before the SEC; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the shares of Parent Common Stock to be issued in the Parent Share Issuance shall have been approved for listing on the NYSE, subject to
official notice of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_96"></A>Section&nbsp;9.02. <U>Conditions to the Obligations of Parent</U><U> and Merger
Sub</U>. The obligations of Parent and Merger Sub to consummate the Merger are subject to the satisfaction (or, to the extent permitted by Applicable Law, waiver by Parent) of the following further conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Company shall have performed (or any <FONT STYLE="white-space:nowrap">non-performance</FONT> shall have been cured), in all material
respects, all of its obligations hereunder required to be performed by it prior to the Effective Time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i)&nbsp;the representations
and warranties of the Company contained in <U>Section</U><U></U><U>&nbsp;4.05(a)</U> shall be true and correct, subject only to <I>de minimis</I> exceptions, at and as of the date of this Agreement and at and as of the Closing as if made at and as
of the Closing (or, if such representations and warranties are given as of another specific date, at and as of such date); (ii)&nbsp;the representations and warranties of the Company contained in <U>Section</U><U></U><U>&nbsp;4.01</U> (other than
the third sentence thereof), <U>Section</U><U></U><U>&nbsp;4.02</U>, <U>Section</U><U></U><U>&nbsp;4.04(i)</U>, <U>Section</U><U></U><U>&nbsp;4.06(b)</U> ((x)&nbsp;other than the last sentence thereof and (y)&nbsp;solely with respect to the Major
Subsidiaries of the Company), <U>Section</U><U></U><U>&nbsp;4.27</U>, <U>Section</U><U></U><U>&nbsp;4.28</U> and <U>Section</U><U></U><U>&nbsp;4.29</U> shall be true and correct in all material respects at and as of the date of this Agreement and at
and as of the Closing as if made at and as of the Closing (or, if such representations and warranties are given as of another specific date, at and as of such date); and (iii)&nbsp;the other representations and warranties of the Company contained in
this Agreement, disregarding all qualifications and exceptions contained therein relating to materiality or Company Material Adverse Effect, shall be true and correct at and as of the date of this Agreement and at and as of the Closing as if made at
and as of the Closing (or, if such representations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
warranties are given as of another specific date, at and as of such date), except, in the case of this clause&nbsp;(iii) only, where the failure of such representations and warranties to be true
and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) since the date of this Agreement, there shall not have occurred any event, change, effect, development or occurrence that has had or would
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) both (i)&nbsp;the early
termination or expiration of the waiting period required under the HSR Act shall have occurred and (ii)&nbsp;the Company Required Governmental Authorizations and the Parent Required Governmental Authorizations set forth in Section&nbsp;9.02(d) of
the Parent Disclosure Schedule, in each case in this clause (d), with respect to the consummation of the Merger, shall have been made or obtained, as applicable, and shall be in full force and effect and, in each case in this clause&nbsp;(d), shall
not impose any term or condition that would have or would reasonably be expected to have, individually or in the aggregate, a Regulatory Material Adverse Effect on Parent or the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Parent shall have received a certificate from an executive officer of the Company confirming the satisfaction of the conditions set forth
in <U>Sections 9.02(a)</U>, <U>9.02(b)</U> and <U>9.02(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_97"></A>Section&nbsp;9.03. <U>Conditions to the
Obligations of the Company</U>. The obligations of the Company to consummate the Merger are subject to the satisfaction (or, to the extent permitted by Applicable Law, waiver by the Company) of the following further conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) each of Parent and Merger Sub shall have performed (or any <FONT STYLE="white-space:nowrap">non-performance</FONT> shall have been cured),
in all material respects, all of its obligations hereunder required to be performed by it prior to the Effective Time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i)&nbsp;the
representations and warranties of Parent contained in <U>Section</U><U></U><U>&nbsp;5.05(a)</U> shall be true and correct, subject only to <I>de minimis</I> exceptions, at and as of the date of this Agreement and at and as of the Closing as if made
at and as of the Closing (or, if such representations and warranties are given as of another specific date, at and as of such date); (ii)&nbsp;the representations and warranties of Parent contained in <U>Section</U><U></U><U>&nbsp;5.01</U> (other
than the third sentence thereof), <U>Section</U><U></U><U>&nbsp;5.02</U>, <U>Section</U><U></U><U>&nbsp;5.04(i)</U>, <U>Section</U><U></U><U>&nbsp;5.06(b)</U> ((x)&nbsp;other than the last sentence thereof and (y)&nbsp;solely with respect to the
Major Subsidiaries of Parent), <U>Section</U><U></U><U>&nbsp;5.20</U>, <U>Section</U><U></U><U>&nbsp;5.21</U> and <U>Section</U><U></U><U>&nbsp;5.22</U> shall be true and correct in all material respects at and as of the date of this Agreement and
at and as of the Closing as if made at and as of the Closing (or, if such representations and warranties are given as of another specific date, at and as of such date); and (iii)&nbsp;the other representations and warranties of Parent contained in
this Agreement, disregarding all qualifications and exceptions contained therein relating to materiality or Parent Material Adverse Effect, shall be true and correct at and as of the date of this Agreement and at and as of the Closing as if made at
and as of the Closing (or, if such representations and warranties are given as of another specific date, at and as of such date), except, in the case of this clause&nbsp;(iii) only, where the failure of such representations and warranties to be true
and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) since the date of this Agreement, there shall not have occurred any event, change, effect, development or occurrence that has had or would
reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) both (i)&nbsp;the early
termination or expiration of the waiting period required under the HSR Act shall have occurred, and (ii)&nbsp;the Company Required Governmental Authorizations and the Parent Required Governmental Authorizations set forth in Section&nbsp;9.03(d) of
the Company Disclosure Schedule, in each case in this clause (d), to the extent required under Applicable Law to consummate the transactions contemplated hereby at Closing, shall have been made or obtained, as applicable, and shall be in full force
and effect; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the Company shall have received a certificate from an executive officer of Parent confirming the satisfaction of the
conditions set forth in <U>Section</U><U></U><U>&nbsp;9.03(a)</U>, <U>Section</U><U></U><U>&nbsp;9.03(b)</U> and <U>Section</U><U></U><U>&nbsp;9.03(c)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;X </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_98">
</A>Section&nbsp;10.01. <U>Termination</U>. This Agreement may be terminated and the Merger and the other transactions contemplated hereby may be abandoned at any time prior to the Effective Time (notwithstanding receipt of the Company Shareholder
Approval or the Parent Stockholder Approval): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) by mutual written agreement of the Company and Parent; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) by either the Company or Parent, if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Merger has not been consummated on or before December 3, 2018 (as such date may be extended pursuant to the following
proviso, the &#147;<U>End Date</U>&#148;); <I>provided</I> that, (A)&nbsp;if on such date, the conditions to the Closing set forth in <U>Section</U><U></U><U>&nbsp;9.02(d)</U>, <U>Section</U><U></U><U>&nbsp;9.03(d)</U>, or
<U>Section</U><U></U><U>&nbsp;9.01(c)</U> (if the Applicable Law relates to the matters referenced in <U>Section</U><U></U><U>&nbsp;9.02(d)</U> or <U>Section</U><U></U><U>&nbsp;9.03(d)</U>) shall not have been satisfied, but all other conditions to
the Closing shall have been satisfied (or in the case of conditions that by their terms are to be satisfied at the Closing, shall be capable of being satisfied on such date) or waived, then the End Date shall be extended to March&nbsp;3, 2019, if
either the Company or Parent notifies the other party in writing on or prior to December&nbsp;3, 2018 of its election to extend the End Date to March&nbsp;3, 2019 and (B)&nbsp;if on March&nbsp;3, 2019, the conditions to the Closing set forth in
<U>Section</U><U></U><U>&nbsp;9.02(d)</U>, <U>Section</U><U></U><U>&nbsp;9.03(d)</U>, or <U>Section</U><U></U><U>&nbsp;9.01(c)</U> (if the Applicable Law relates to the matters referenced in <U>Section</U><U></U><U>&nbsp;9.02(d)</U> or
<U>Section</U><U></U><U>&nbsp;9.03(d)</U>) shall not have been satisfied, but all other conditions to the Closing shall have been satisfied (or in the case of conditions that by their terms are to be satisfied at the Closing, shall be capable of
being satisfied on such date) or waived, then the End Date shall be further extended to June&nbsp;3, 2019, if Parent notifies the Company in writing on or prior to March&nbsp;3, 2019 of its election to extend the End Date to June&nbsp;3, 2019;
<I>provided</I> that the right to terminate this Agreement or extend the End Date pursuant to this <U>Section</U><U></U><U>&nbsp;10.01(b)(i)</U> shall not be available to any party whose breach of any provision of this Agreement results in the
failure of the Merger to be consummated by such time; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) there shall be in effect any Applicable Law enacted, adopted or
promulgated after the date hereof in the U.S. that enjoins, prevents or prohibits the consummation of the Merger and, if such Applicable Law is an Order, such Order shall have become final and <FONT STYLE="white-space:nowrap">non-appealable;</FONT>
<I>provided</I> that the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;10.01(b)(ii)</U> shall not be available to any party who has failed to perform fully its obligations under
<U>Section</U><U></U><U>&nbsp;8.02</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the Company Shareholder Approval shall not have been obtained upon a vote
taken thereon at the Company Shareholder Meeting (including any adjournment or postponement thereof); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) the Parent
Stockholder Approval shall not have been obtained upon a vote taken thereon at the Parent Stockholder Meeting (including any adjournment or postponement thereof); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) by Parent, if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) (A)&nbsp;a Company Adverse Recommendation Change shall have occurred or (B)&nbsp;the Board of Directors of the Company
shall have failed to publicly confirm the Company Board Recommendation within seven (7)&nbsp;Business Days after a written request by Parent that it do so; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a breach of any representation or warranty or failure to perform any covenant or agreement on the part of the Company set
forth in this Agreement shall have occurred that would cause any condition set forth in <U>Section</U><U></U><U>&nbsp;9.02(a)</U> or <U>Section</U><U></U><U>&nbsp;9.02(b)</U> not to be satisfied, and such breach or failure to perform (A)&nbsp;is
incapable of being cured by the End Date or (B)&nbsp;has not been cured by the Company within forty-five (45)&nbsp;days following written notice to the Company from Parent of such breach or failure to perform, but only so long as Parent is not then
in breach of its representations, warranties, covenants or agreements set forth in this Agreement, which breach by Parent would cause any condition set forth in <U>Section</U><U></U><U>&nbsp;9.03(a)</U> or <U>Section</U><U></U><U>&nbsp;9.03(b)</U>
not to be satisfied; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the Company shall have breached any of its obligations under
<U>Section</U><U></U><U>&nbsp;6.02</U> or <U>8.04</U> in any material respect, other than in the case where (w)&nbsp;such breach is a result of an isolated action by a Representative of the Company (other than a director or officer of the Company),
(x) such breach was not caused by, or within the knowledge of, the Company, (y)&nbsp;the Company takes appropriate actions to remedy such breach upon discovery thereof, and (z)&nbsp;Parent is not significantly harmed as a result thereof;
<I>provided</I> that in no event shall Parent be entitled to terminate this Agreement on the basis of any breach of <U>Section</U><U></U><U>&nbsp;8.04</U> following the receipt of the Company Shareholder Approval; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) prior to obtaining the Parent Stockholder Approval, in order to enter into a definitive agreement providing for a Parent
Superior Proposal (which definitive agreement must be entered into concurrently with, or immediately following, the termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;10.01(c)(iv)</U>) in accordance with, and subject to the
terms and conditions of, <U>Section</U><U></U><U>&nbsp;7.02</U>; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) by the Company, if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) (A)&nbsp;a Parent Adverse Recommendation Change shall have occurred, or (B)&nbsp;the Board of Directors of Parent shall
have failed to publicly confirm the Parent Board Recommendation within seven (7)&nbsp;Business Days after a written request by the Company that it do so; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if a breach of any representation or warranty or failure to perform any covenant or agreement on the part of Parent or
Merger Sub set forth in this Agreement shall have occurred that would cause any condition set forth in <U>Section</U><U></U><U>&nbsp;9.03(a)</U> or <U>Section</U><U></U><U>&nbsp;9.03(b)</U> not to be satisfied, and such breach or failure to perform
(A)&nbsp;is incapable of being cured by the End Date or (B)&nbsp;has not been cured by Parent or Merger Sub, as applicable, within forty-five (45)&nbsp;days following written notice to Parent from the Company of such breach or failure to perform,
but only so long as the Company is not then in breach of its representations, warranties, covenants or agreements set forth in this Agreement, which breach by the Company would cause any condition set forth in
<U>Section</U><U></U><U>&nbsp;9.02(a)</U> or <U>Section</U><U></U><U>&nbsp;9.02(b)</U> not to be satisfied; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Parent
shall have breached any of its obligations under <U>Section</U><U></U><U>&nbsp;7.02</U> or <U>8.04</U> in any material respect, other than in the case where (w)&nbsp;such breach is a result of an isolated action by a Representative of Parent (other
than a director or officer of Parent), (x) such breach was not caused by, or within the knowledge of, Parent, (y)&nbsp;Parent takes appropriate actions to remedy such breach upon discovery thereof, and (z)&nbsp;the Company is not significantly
harmed as a result thereof; <I>provided</I> that in no event shall the Company be entitled to terminate this Agreement on the basis of any breach of <U>Section</U><U></U><U>&nbsp;8.04</U> following the receipt of the Parent Stockholder Approval;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) if (A)&nbsp;there shall be in effect any Order in respect of the matters contemplated by clauses (x), (y) and/or
(z)&nbsp;of the first sentence of <U>Section</U><U></U><U>&nbsp;8.02(b)</U> that shall not have become final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> and that enjoins, restrains, prevents, prohibits or makes illegal the
consummation of the Merger, (B)&nbsp;within thirty (30)&nbsp;days after such Order first being in effect, Parent shall not have instituted appropriate proceedings seeking to have such Order vacated, lifted, reversed, overturned or terminated and
(C)&nbsp;such failure to institute appropriate proceedings shall not have been cured by Parent within ten (10)&nbsp;days following irrevocable written notice to Parent from the Company of the Company&#146;s intent to terminate this Agreement
pursuant to this <U>Section</U><U></U><U>&nbsp;10.01(d)(iv)</U> in respect of such failure (which notice may not be given prior to the expiration of such thirty <FONT STYLE="white-space:nowrap">(30)-day</FONT> period and, for the avoidance of doubt,
shall not be effective if Parent institutes such appropriate proceedings within such ten <FONT STYLE="white-space:nowrap">(10)-day</FONT> period); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) prior to obtaining the Company Shareholder Approval, in order to enter into a definitive agreement providing for a Company
Superior Proposal (which definitive agreement must be entered into concurrently with, or immediately following, the termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;10.01(d)(v)</U>) in accordance with, and subject to the
terms and conditions of, <U>Section</U><U></U><U>&nbsp;6.02</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The party desiring to terminate this Agreement pursuant to this
<U>Section</U><U></U><U>&nbsp;10.01</U> (other than pursuant to <U>Section</U><U></U><U>&nbsp;10.01(a)</U>) shall give written notice of such termination to the other party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_99"></A>Section&nbsp;10.02. <U>Effect of Termination</U>. If this
Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;10.01</U>, this Agreement shall become void and of no effect without liability of any party (or any shareholder, stockholder or Representative of such party) to the other party
hereto, except as provided in <U>Section</U><U></U><U>&nbsp;10.03</U>; <I>provided</I> that, subject to <U>Section</U><U></U><U>&nbsp;10.03(e)</U>, neither Parent nor the Company shall be released from any liabilities or damages arising out of any
(i)&nbsp;fraud by any party, (ii)&nbsp;the Willful Breach by any party of any representation or warranty on the part of such party set forth in this Agreement or (iii)&nbsp;the Willful Breach of any covenant or agreement set forth in this Agreement.
The provisions of <U>Section</U><U></U><U>&nbsp;6.03(b)</U>, this <U>Section</U><U></U><U>&nbsp;10.02</U>, <U>Section</U><U></U><U>&nbsp;10.03</U> and <U>Article</U><U></U><U>&nbsp;XI</U> (other than <U>Section</U><U></U><U>&nbsp;11.13</U>) shall
survive any termination hereof pursuant to <U>Section</U><U></U><U>&nbsp;10.01</U>. In addition, the termination of this Agreement shall not affect the parties&#146; respective obligations under the Confidentiality Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_100"></A>Section&nbsp;10.03. <U>Termination Fees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If this Agreement is terminated: (i)&nbsp;by Parent pursuant to<U> Section</U><U></U><U>&nbsp;10.01(c)(i)</U> or <U>10.01(c)(iii)</U>;
(ii) by the Company pursuant to <U>Section</U><U></U><U>&nbsp;10.01(d)(v)</U>; or (iii)&nbsp;by the Company or Parent pursuant to <U>Section</U><U></U><U>&nbsp;10.01(b)(iii)</U>, and in the case of clause (iii)&nbsp;of this sentence: (I)&nbsp;at or
prior to the Company Shareholder Meeting a Company Acquisition Proposal shall have been publicly disclosed or announced; and (II)&nbsp;on or prior to the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) anniversary of such
termination of this Agreement: (1)&nbsp;a transaction relating to a Company Acquisition Proposal is consummated; or (2)&nbsp;a definitive agreement relating to a Company Acquisition Proposal is entered into by the Company, then, in the case of each
of the foregoing clauses (i)&nbsp;through (iii), the Company shall pay to Parent, in cash at the time specified in the following sentence, a fee in the amount of $2,100,000,000<B> </B>(the &#147;<U>Company Termination Fee</U>&#148;). The Company
Termination Fee shall be paid as follows: (x)&nbsp;in the case of clause (i)&nbsp;of the preceding sentence, within three (3)&nbsp;Business Days after the date of termination of this Agreement; (y)&nbsp;in the case of clause (ii)&nbsp;of the
preceding sentence, in advance of or concurrently with such termination; and (z)&nbsp;in the case of clause (iii)&nbsp;of the preceding sentence, within three (3)&nbsp;Business Days after the earlier of the consummation of the applicable transaction
and the date upon which the definitive agreement is entered into. &#147;Company Acquisition Proposal&#148; for purposes of the foregoing clause (iii)(II) of this <U>Section</U><U></U><U>&nbsp;10.03(a)</U> shall have the meaning assigned thereto in
the definition thereof set forth in <U>Section</U><U></U><U>&nbsp;1.01</U>, except that references in the definition to &#147;20%&#148; shall be replaced by &#147;50%.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If this Agreement is terminated: (i)&nbsp;by the Company pursuant to <U>Section</U><U></U><U>&nbsp;10.01(d)(i)</U> or
<U>10.01(d)(iii)</U>; (ii) by Parent pursuant to <U>Section</U><U></U><U>&nbsp;10.01(c)(iv)</U>; or (iii)&nbsp;by the Company or Parent pursuant to <U>Section</U><U></U><U>&nbsp;10.01(b)(iv)</U>, and in the case of clause (iii)&nbsp;of this
sentence: (I)&nbsp;at or prior to the Parent Stockholder Meeting a Parent Acquisition Proposal shall have been publicly disclosed or announced; and (II)&nbsp;on or prior to the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)
anniversary of such termination of this Agreement: (1)&nbsp;a transaction relating to a Parent Acquisition Proposal is consummated; or (2)&nbsp;a definitive agreement relating to a Parent Acquisition Proposal is entered into by Parent, then, in the
case of each of the foregoing clauses (i)&nbsp;through (iii), Parent shall pay to the Company, in cash at the time specified in the following sentence, a fee in the amount of $2,100,000,000 (the &#147;<U>Parent Termination Fee</U>&#148;). The Parent
Termination Fee shall be paid as follows: (x)&nbsp;in the case of clause (i)&nbsp;of the preceding sentence, within three (3)&nbsp;Business Days after the date of termination of this Agreement; (y)&nbsp;in the case of clause (ii)&nbsp;of the
preceding sentence, in advance of or concurrently with such termination; and (z)&nbsp;in the case of clause (iii)&nbsp;of the preceding sentence, within three (3)&nbsp;Business Days after the earlier of the consummation of the applicable transaction
and the date upon which the definitive agreement is entered into. &#147;<U>Parent Acquisition Proposal</U>&#148; for purposes of the foregoing clause (iii)(II) of this <U>Section</U><U></U><U>&nbsp;10.03(b)</U> shall have the meaning assigned
thereto in the definition thereof set forth in <U>Section</U><U></U><U>&nbsp;1.01</U> except that references in the definition to &#147;20%&#148; shall be replaced by &#147;50%.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In the event this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;10.01(b)(i)</U>,
<U>Section</U><U></U><U>&nbsp;10.01(b)(ii)</U> (solely in respect of any Applicable Law in respect of the matters contemplated by clauses (x), (y) and/or (z)&nbsp;of the first sentence of <U>Section</U><U></U><U>&nbsp;8.02(b)</U>) or
<U>Section</U><U></U><U>&nbsp;10.01(d)(iv)</U> and, at the time of such termination, (A)&nbsp;the condition set forth in <U>Section</U><U></U><U>&nbsp;9.02(d)</U> has not been satisfied and (B)&nbsp;the conditions set forth in
<U>Section</U><U></U><U>&nbsp;9.01</U> (other than the condition set forth in <U>Section</U><U></U><U>&nbsp;9.01(c)</U> solely in respect of any Applicable Law in respect of the matters </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated by clauses (x), (y) and/or (z)&nbsp;of the first sentence of <U>Section</U><U></U><U>&nbsp;8.02(b)</U>) and <U>Section</U><U></U><U>&nbsp;9.02</U> (other than the condition set forth
in <U>Section</U><U></U><U>&nbsp;9.02(d)</U>) have been satisfied (or in the case of conditions that by their nature are to be satisfied at the Closing, are capable of being satisfied if the Closing were to occur on the date of such termination) or
waived, then Parent shall pay or cause to be paid a fee in the amount of $2,100,000,000 (the &#147;<U>Regulatory Termination Fee</U>&#148;) to the Company as promptly as reasonably practicable (and in any event within five&nbsp;(5) Business Days
following such termination); <I>provided</I> that no Regulatory Termination Fee shall be payable by Parent pursuant to this <U>Section</U><U></U><U>&nbsp;10.03(c)</U> if the failure of the condition set forth in
<U>Section</U><U></U><U>&nbsp;9.02(d)</U> to be satisfied is caused by the Company&#146;s Willful Breach of <U>Section</U><U></U><U>&nbsp;8.02</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Any payment of the Company Termination Fee, the Parent Termination Fee or the Regulatory Termination Fee shall be made by wire transfer of
immediately available funds to an account designated in writing by Parent or the Company, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The parties agree and
understand that (x)&nbsp;in no event shall the Company be required to pay the Company Termination Fee on more than one occasion, and in no event shall Parent be required to pay either the Parent Termination Fee or the Regulatory Termination Fee on
more than one occasion, or more than one of the Parent Termination Fee or the Regulatory Termination Fee under any circumstances, and (y)&nbsp;in no event shall Parent be entitled, pursuant to this <U>Section</U><U></U><U>&nbsp;10.03</U>, to receive
an amount greater than the Company Termination Fee and any applicable additional amounts pursuant the last two sentences of this <U>Section</U><U></U><U>&nbsp;10.03(e)</U> (&#147;<U>Parent Additional Amounts</U>&#148;), and in no event shall the
Company be entitled, pursuant to this <U>Section</U><U></U><U>&nbsp;10.03</U>, to receive an amount greater than the Parent Termination Fee or the Regulatory Termination Fee, as applicable, and any applicable additional amounts pursuant to
<U>Section</U><U></U><U>&nbsp;6.03(b)</U> or the last two sentences of this <U>Section</U><U></U><U>&nbsp;10.03(e)</U> (collectively, &#147;<U>Company Additional Amounts</U>&#148;). Notwithstanding anything to the contrary in this Agreement, except
in the case of fraud, (i)&nbsp;if Parent receives the Company Termination Fee and any applicable Parent Additional Amounts from the Company pursuant to this <U>Section</U><U></U><U>&nbsp;10.03</U>, or if the Company receives the Parent Termination
Fee or the Regulatory Termination Fee and any applicable Company Additional Amounts from Parent pursuant to this <U>Section</U><U></U><U>&nbsp;10.03</U>, such payment shall be the sole and exclusive remedy of the receiving party against the paying
party and its Subsidiaries and their respective former, current or future partners, shareholders, stockholders, managers, members, Affiliates and Representatives, and none of the paying party, any of its Subsidiaries or any of their respective
former, current or future partners, shareholders, stockholders, managers, members, Affiliates or Representatives shall have any further liability or obligation, in each case relating to or arising out of this Agreement or the transactions
contemplated hereby, and (ii)&nbsp;if (A)&nbsp;Parent or Merger Sub receive any payments from the Company in respect of any breach of this Agreement and thereafter Parent receives the Company Termination Fee pursuant to this
<U>Section</U><U></U><U>&nbsp;10.03</U> or (B)&nbsp;the Company receives any payments from Parent or Merger Sub in respect of any breach of this Agreement and thereafter the Company receives the Parent Termination Fee or the Regulatory Termination
Fee pursuant to this <U>Section</U><U></U><U>&nbsp;10.03</U>, the amount of such Company Termination Fee, Parent Termination Fee or Regulatory Termination Fee, as applicable, shall be reduced by the aggregate amount of such payments made by the
party paying the Company Termination Fee, Parent Termination Fee or Regulatory Termination Fee, as applicable, in respect of any such breaches. The parties acknowledge that the agreements contained in this <U>Section</U><U></U><U>&nbsp;10.03</U> are
an integral part of the transactions contemplated hereby, that, without these agreements, the parties would not enter into this Agreement and that any amounts payable pursuant to this <U>Section</U><U></U><U>&nbsp;10.03</U> do not constitute a
penalty. Accordingly, if any party fails to promptly pay any amount due pursuant to this <U>Section</U><U></U><U>&nbsp;10.03</U>, such party shall also pay any costs and expenses (including reasonable legal fees and expenses) incurred by the party
entitled to such payment in connection with a legal action to enforce this Agreement that results in a judgment for such amount against the party failing to promptly pay such amount. Any amount not paid when due pursuant to this
<U>Section</U><U></U><U>&nbsp;10.03</U> shall bear interest from the date such amount is due until the date paid at a rate equal to the prime rate as published in <I>The Wall Street Journal, Eastern Edition</I> in effect on the date of such payment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) None of the Financing Sources shall have any liability to the Company or any Person that is an Affiliate of the Company prior to
giving effect to the Merger relating to or arising out of this Agreement or the Debt Financing, whether at law, or equity, in contract, in tort or otherwise, and neither the Company nor any Person </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that is an Affiliate of the Company prior to giving effect to the Merger shall have any rights or claims directly against any of the Financing Sources hereunder or thereunder. For the avoidance
of any doubt, the foregoing shall not impair, supplement, or otherwise modify any of the commitments and other obligations that the Financing Sources have under the Debt Commitment Letters to Parent and/or Merger Sub or any of the rights of Parent
and/or Merger Sub against any of the Financing Sources under the Debt Commitment Letters. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_101">
</A>Section&nbsp;11.01. <U>Notices</U>. All notices, requests and other communications to any party hereunder shall be in writing (including facsimile transmission) and shall be given, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aetna
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">151 Farmington Avenue, RC6A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Hartford,
<FONT STYLE="font-family:Times New Roman; font-size:10pt">&nbsp;</FONT><FONT STYLE="font-family:Times New Roman; font-size:15pt">&nbsp;</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt">Connecticut 06156 </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Facsimile: &nbsp;(860) <FONT STYLE="white-space:nowrap">273-8340</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10017 </P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">H. Oliver Smith</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John A. Bick</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Harold Birnbaum</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">701-5800</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">oliver.smith@davispolk.com</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">john.bick@davispolk.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">harold.birnbaum@davispolk.com</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to Parent, Merger Sub and, post-closing, the Surviving Corporation, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One CVS
Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Woonsocket, Rhode Island 02895 </P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(401) <FONT STYLE="white-space:nowrap">770-3663</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Shearman&nbsp;&amp; Sterling LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10022 </P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Creighton O&#146;M. Condon</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert M. Katz</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Daniel Litowitz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">848-7179</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CCondon@shearman.com</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RKatz@shearman.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Daniel.Litowitz@shearman.com</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address or facsimile number as such party may hereafter specify for the purpose by notice
to the other parties hereto. All such notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. on a Business Day. Otherwise, any such notice, request or
communication shall be deemed to have been received on the next succeeding Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_102"></A>Section&nbsp;11.02.
<U>Survival</U>. The representations, warranties, covenants and agreements contained in this Agreement and in any certificate or other writing delivered pursuant hereto shall not survive the Effective Time, except for the covenants and agreements
set forth in <U>Article</U><U></U><U>&nbsp;II</U>, <U>Section</U><U></U><U>&nbsp;7.04</U>, <U>Section</U><U></U><U>&nbsp;7.05</U>, <U>Section</U><U></U><U>&nbsp;8.11</U> and this <U>Article</U><U></U><U>&nbsp;XI</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_103"></A>Section&nbsp;11.03. <U>Amendments and Waivers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Any provision of this Agreement may be amended or waived prior to the Effective Time if, but only if, such amendment or waiver is in
writing and is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against whom the waiver is to be effective; <I>provided</I> that, after the Company Shareholder Approval or the Parent
Stockholder Approval has been obtained, there shall be no amendment or waiver that would require the further approval of the shareholders of the Company or the stockholders of Parent under Applicable Law without such approval having first been
obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary in this Agreement, the provisions in <U>Section</U><U></U><U>&nbsp;10.03(f)</U>,
this <U>Section</U><U></U><U>&nbsp;11.03(b)</U>, <U>Section</U><U></U><U>&nbsp;11.06(a)</U>, <U>Section</U><U></U><U>&nbsp;11.07</U>, <U>Section</U><U></U><U>&nbsp;11.08(b)</U> or <U>Section</U><U></U><U>&nbsp;11.09</U> may not be amended in a
manner that is material and adverse to the Financing Sources without the prior written consent of the applicable Financing Source. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No
failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other
right, power or privilege. The rights and remedies provided in this Agreement shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_104"></A>Section&nbsp;11.04. <U>Expenses</U>. Except as otherwise provided in this Agreement, all costs and expenses
incurred in connection with this Agreement shall be paid by the party incurring such cost or expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_105"></A>Section&nbsp;11.05. <U>Disclosure Schedule References and SEC Document References</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The parties hereto agree that each section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule, as
applicable, shall be deemed to qualify the corresponding section or subsection of this Agreement, irrespective of whether or not any particular section or subsection of this Agreement specifically refers to the Company Disclosure Schedule or the
Parent Disclosure Schedule, as applicable. The parties hereto further agree that (other than with respect to any items disclosed in Section&nbsp;4.18(a) of the Company Disclosure Schedule, for which an explicit reference in any other section shall
be required in order to apply to such other section) disclosure of any item, matter or event in any particular section or subsection of either the Company Disclosure Schedule or the Parent Disclosure Schedule shall be deemed disclosure with respect
to any other section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule, as applicable, to which the relevance of such disclosure would be reasonably apparent, notwithstanding the omission of a cross-reference to such
other section or subsections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The parties hereto agree that in no event shall any disclosure contained in any part of any Company SEC
Document or Parent SEC Document entitled &#147;Risk Factors&#148;, &#147;Forward-Looking Statements&#148;, &#147;Cautionary Statement Regarding Forward-Looking Statements&#148;, &#147;Special Note on Forward Looking Statements&#148; or &#147;Forward
Looking Information&#148; or containing a description or explanation of &#147;Forward-Looking Statements&#148; or any other disclosures in any Company SEC Document or Parent SEC Document that are cautionary, predictive or forward-looking in nature
be deemed to be an exception to (or a disclosure for purposes of) any representations and warranties of any party contained in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_106"></A>Section&nbsp;11.06. <U>Binding Effect; Benefit; Assignment</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The provisions of this Agreement shall be binding upon and shall inure solely to the benefit of the parties hereto, except for:
(i)&nbsp;only following the Effective Time, the right of the Company&#146;s shareholders and holders of Company Equity Awards, as applicable, to receive (x)&nbsp;the Merger Consideration in respect of shares of Company Common Stock pursuant to
<U>Section</U><U></U><U>&nbsp;2.03</U>, (y)&nbsp;the Merger Consideration, Assumed Restricted Unit Award, Assumed Performance Unit Award or Assumed Stock Appreciation Right payable in respect of Company RSU Awards pursuant to
<U>Section</U><U></U><U>&nbsp;2.06(a)</U>, Company PSU Awards pursuant to <U>Section</U><U></U><U>&nbsp;2.06(b)</U> and Company Stock Appreciation Rights pursuant to <U>Section</U><U></U><U>&nbsp;2.06(c)</U> and (z)&nbsp;the excess of the Equity
Award Cash Consideration over the applicable per share exercise price in respect of Company Stock Appreciation Rights pursuant to <U>Section</U><U></U><U>&nbsp;2.06(c)</U>, (ii)&nbsp;the right of the Company on behalf of its shareholders to seek
equitable relief or to pursue damages suffered by the Company and its shareholders (including claims for damages based on loss of the economic benefit of the Merger to the Company&#146;s shareholders (taking into consideration relevant matters,
including other combination opportunities and the time value of money)) in the event of the wrongful termination of this Agreement or Willful Breach of this Agreement by Parent or Merger Sub (whether or not this Agreement has been terminated
pursuant to <U>Section</U><U></U><U>&nbsp;10.01</U>), which right is hereby expressly acknowledged and agreed by Parent and Merger Sub, (iii)&nbsp;the right of the D&amp;O Indemnified Parties to enforce the provisions of
<U>Section</U><U></U><U>&nbsp;7.04</U> only and (iv)&nbsp;the right of each of the Financing Sources as an express third-party beneficiary of <U>Section</U><U></U><U>&nbsp;10.03(f)</U>, <U>Section</U><U></U><U>&nbsp;11.03(b)</U>, this
<U>Section</U><U></U><U>&nbsp;11.06(a)</U>, <U>Section</U><U></U><U>&nbsp;11.07</U>, <U>Section</U><U></U><U>&nbsp;11.08(b)</U> and <U>Section</U><U></U><U>&nbsp;11.09</U>. The third-party beneficiary rights referenced in clause (ii)&nbsp;of the
preceding sentence may be exercised only by the Company (on behalf of its shareholders as their agent) through actions expressly approved by the Board of Directors of the Company, and no shareholder of the Company, whether purporting to act in its
capacity as a shareholder or purporting to assert any right (derivatively or otherwise) on behalf of the Company, shall have any right or ability to exercise or cause the exercise of any such right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the prior written
consent of each other party hereto, except that Parent may transfer or assign its rights and obligations under this Agreement, in whole or from time to time in part, to any Person after the Closing, and Merger Sub may transfer or assign its rights
and obligations under this Agreement, in whole or from time to time in part, to any other wholly owned Subsidiary of Parent, which Subsidiary shall be a Pennsylvania corporation; <I>provided</I> that such transfer or assignment shall not
(i)&nbsp;relieve Parent or Merger Sub of its obligations hereunder or enlarge, alter or change any obligation of any other party hereto or due to Parent or Merger Sub or (ii)&nbsp;materially delay the consummation of the Merger or any of the other
transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_107"></A>Section&nbsp;11.07. <U>Governing Law</U>. Other than the provisions of
this Agreement related to the Merger that are exclusively governed by Pennsylvania Law, this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law rules of such
state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_108"></A>Section&nbsp;11.08. <U>Jurisdiction/Venue</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each of the parties hereto (i)&nbsp;irrevocably consents to the service of the summons and complaint and any other process in any action
or proceeding relating to the transactions contemplated hereby, on behalf of itself or its property, in accordance with <U>Section</U><U></U><U>&nbsp;11.01</U> or in such other manner as may be permitted by Applicable Law, and nothing in this
<U>Section</U><U></U><U>&nbsp;11.08</U> shall affect the right of any party to serve legal process in any other manner permitted by Applicable Law, (ii)&nbsp;irrevocably and unconditionally consents and submits itself and its property in any action
or proceeding to the exclusive general jurisdiction of the Delaware Court of Chancery and any state appellate court therefrom within the State of Delaware (or, only if the Delaware Court of Chancery declines to accept jurisdiction over a particular
matter, any federal court within the State of Delaware) in the event any dispute arises out of this Agreement or the transactions contemplated hereby, or for recognition and enforcement of any judgment in respect thereof, (iii)&nbsp;agrees that it
shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, (iv)&nbsp;agrees that any actions or proceedings arising in connection with this Agreement or the transactions contemplated
hereby shall be brought, tried and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determined only in the Delaware Court of Chancery (or, only if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any federal court within the State of
Delaware), (v)&nbsp;waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the
same and (vi)&nbsp;agrees that it shall not bring any action relating to this Agreement or the transactions contemplated hereby in any court other than the aforesaid courts. Each of Parent, Merger Sub and the Company agrees that a final judgment in
any action or proceeding in such court as provided above shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything herein to the contrary, the parties hereto acknowledge and irrevocably agree (i)&nbsp;that any action or
proceeding, whether in law or in equity, whether in contract or tort or otherwise, involving the Financing Sources arising out of or related to the transactions contemplated hereby, the Debt Financing or the performance of services thereunder or
related thereto shall be subject to the exclusive jurisdiction of any state or federal court sitting in the Borough of Manhattan, New York, New York, and any appellate court thereof and each party hereto submits for itself and its property with
respect to any such action or proceeding to the exclusive jurisdiction of such court and (ii)&nbsp;that any such action or proceeding shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to the
conflicts of law rules of such State that would result in the application of the laws of any other State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_109"></A>Section&nbsp;11.09. <U>WAIVER OF JURY TRIAL</U>. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH
MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY
OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE MERGER OR THE OTHER TRANSACTIONS CONTEMPLATED HEREBY (INCLUDING WITH RESPECT TO THE FINANCING SOURCES). EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i)&nbsp;NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii)&nbsp;EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS
WAIVER, (iii)&nbsp;EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (iv)&nbsp;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION</U><U></U><U>&nbsp;11.09</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_110"></A>Section&nbsp;11.10. <U>Counterparts; Effectiveness</U>. This Agreement may be signed in any number of
counterparts, including by facsimile or by email with .pdf attachments, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each
party hereto shall have received a counterpart hereof signed and delivered (by electronic communication, facsimile or otherwise) by all of the other parties hereto. Until and unless each party has received a counterpart hereof signed by the other
party hereto, this Agreement shall have no effect, and no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_111"></A>Section&nbsp;11.11. <U>Entire Agreement</U>. This Agreement and the Confidentiality Agreement constitute the
entire agreement between the parties with respect to the subject matter thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_112"></A>Section&nbsp;11.12. <U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is
held by a court of competent jurisdiction or other Governmental Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in
no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determination, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that
the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa482402_113"></A>Section&nbsp;11.13. <U>Specific Performance</U>. The parties acknowledge and agree that irreparable harm would
occur and that the parties would not have any adequate remedy at law (i)&nbsp;for any breach of the provisions of this Agreement or (ii)&nbsp;in the event that any of the provisions of this Agreement were not performed in accordance with their
specific terms. It is accordingly agreed that, except where this Agreement is terminated in accordance with <U>Section</U><U></U><U>&nbsp;10.01</U>, the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement
and to specifically enforce the terms and provisions of this Agreement (including <U>Section</U><U></U><U>&nbsp;7.06</U>), without proof of actual damages, and each party further agrees to waive any requirement for the securing or posting of any
bond in connection with such remedy. The parties further agree that (x)&nbsp;by seeking the remedies provided for in this <U>Section</U><U></U><U>&nbsp;11.13</U>, a party shall not in any respect waive its right to seek any other form of relief that
may be available to a party under this Agreement, including, subject to <U>Section</U><U></U><U>&nbsp;10.03(e)</U>, monetary damages in the event that this Agreement has been terminated or in the event that the remedies provided for in this
<U>Section</U><U></U><U>&nbsp;11.13</U> are not available or otherwise are not granted, and (y)&nbsp;nothing contained in this <U>Section</U><U></U><U>&nbsp;11.13</U> shall require any party to institute any proceeding for (or limit any party&#146;s
right to institute any proceeding for) specific performance under this <U>Section</U><U></U><U>&nbsp;11.13</U> before exercising any termination right under <U>Section</U><U></U><U>&nbsp;10.01</U> (and pursuing damages after such termination), nor
shall the commencement of any action pursuant to this <U>Section</U><U></U><U>&nbsp;11.13</U> or anything contained in this <U>Section</U><U></U><U>&nbsp;11.13</U> restrict or limit any party&#146;s right to terminate this Agreement in accordance
with the terms of <U>Section</U><U></U><U>&nbsp;10.01</U> or pursue any other remedies under this Agreement that may be available then or thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank; signature pages follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by
their respective authorized officers as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CVS HEALTH CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas M. Moriarty</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Thomas M. Moriarty</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Chief Policy and External Affairs Officer, and General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HUDSON MERGER SUB CORP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas S. Moffatt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Thomas S. Moffatt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AETNA INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Shawn M. Guertin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Shawn M. Guertin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Chief Financial Officer and Chief Enterprise Risk Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Agreement and Plan of Merger] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AETNA INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(A Pennsylvania Corporation) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Second Amended and Restated Articles of Incorporation amends and restates the existing Amended and Restated Articles of Incorporation of
the Corporation and has been duly adopted by the Board of Directors of the Corporation by unanimous written consent in lieu of a meeting in accordance with Section&nbsp;1727(b) of the Pennsylvania Business Corporation Law of 1988, as amended and by
the shareholders of the Corporation by unanimous written consent in lieu of a meeting in accordance with Section&nbsp;1766 of the Pennsylvania Business Corporation Law of 1988, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These Second Amended and Restated Articles of Incorporation supersede the original articles of incorporation of the Corporation, and all
amendments thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Articles of Incorporation of Aetna Inc., as amended hereby, shall, upon the effectiveness hereof, read in its
entirety, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Name</U></B><B>.</B> The name of the corporation is Aetna Inc. (the &#147;<U>Corporation</U>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Registered Office</U></B><B>.</B> The address of the Corporation&#146;s registered office in the Commonwealth of
Pennsylvania is the Corporation&#146;s principal office at 1425 Union Meeting Road, Blue Bell, PA 19422 (which is located in Montgomery County). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Incorporation</U></B><B>.</B> The Corporation is incorporated under the provisions of the Pennsylvania Business Corporation
Law of 1988, as amended (the &#147;<U>PA BCL</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>Purpose</U></B>. The purpose of the Corporation shall be to
engage in any lawful act and activity for which corporations may be organized and incorporated under the PA BCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. <U>Authorized
Capital</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>5.1.</B> <B><U>Authorized Shares</U></B><B>.</B> The aggregate number of shares of stock that the Corporation shall
have authority to issue is 100 Common Shares, par value $0.01 (&#147;<U>Common Stock</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>5.2.</B> <B><U>Common
Stock</U></B><B>.</B> The following is a statement of the designations, preferences, qualifications, limitations, restrictions and special or relative rights granted or imposed upon the shares of Common Stock of the Corporation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.2.1.</B> <B><U>Dividends</U></B><B>.</B> Holders of Common Stock shall be entitled to receive ratably such dividends (payable in cash,
stock or otherwise) as may be declared by the board of directors of the Corporation (the &#147;<U>Board of Directors</U>&#148;) on Common Stock out of funds legally available for the payment thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.2.2.</B> <B><U>Distribution of Assets</U></B><B>. </B>In the event of the voluntary or involuntary liquidation, dissolution or winding
up of the Corporation, the holders of Common Stock will be entitled to receive pro rata all of the remaining assets of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.2.3.</B> <B><U>Voting Rights</U></B><B>. </B>The holders of Common Stock shall have
the general right to vote for all purposes, including the election of directors, as provided by law. Each holder of Common Stock shall be entitled to one vote for each share thereof held. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>Bylaws</U></B><B>. </B>In furtherance and not in limitation of the powers conferred by law, the Board of Directors is
authorized to adopt, amend or repeal the bylaws of the Corporation (the &#147;<U>Bylaws</U>&#148;), except as otherwise specifically provided therein, subject to the powers of the shareholders of the Corporation to amend or repeal any bylaws adopted
by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Number; Election of Directors</U></B><B>. </B>The<B> </B>Board of Directors shall consist of
at least one director, or such other number of directors as determined in accordance with the Bylaws of the Corporation. Unless and except to the extent that the Bylaws shall so require, the election of directors of the Corporation need not be by
written ballot. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. <U>Indemnification</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.1.</B> <B><U>Indemnification</U></B><B>.</B> The Corporation shall indemnify any person who was or is a party or is threatened to be made
a party to any threatened, pending or completed action or proceeding, including without limitation actions by or in the right of the Corporation, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or
was a director or officer of the Corporation, or is or was serving while a director or officer of the Corporation at the request of the Corporation as a director, officer, employee, agent, fiduciary or other representative of another corporation
(for profit or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit),</FONT></FONT> limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise, against all liabilities,
expenses (including without limitation attorneys&#146; fees), judgments, fines, excise taxes and amounts paid in settlement in connection with such action or proceeding unless the act or failure to act by such person giving rise to the claim for
indemnification is determined by a court to have constituted willful misconduct or recklessness. The Corporation shall have the power to indemnify employees and agents of the Corporation on the same basis as provided above in this <U>Article
8.1</U>, and to advance expenses to employees and agents on the same basis as provided in <U>Article 8.2</U>, as the Board of Directors may from time to time determine or authorize. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.2.</B> <B><U>Advancement of Expenses</U></B><B>.</B> Expenses (including without limitation attorneys&#146; fees) incurred by any person
who was or is an officer or director of the Corporation in defending any action or proceeding referred to in <U>Article 8.1</U> shall automatically be paid by the Corporation, without the need for action by the Board of Directors, in advance of the
final disposition of the action or proceeding upon receipt of an undertaking by or on behalf of such person to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.3.</B> <B><U>Exception</U></B><B>.</B> Notwithstanding anything in this <U>Article 8</U> to the contrary, the Corporation shall not be
obligated to indemnify any person under <U>Article 8.1</U> or advance expenses under <U>Article 8.2</U> with respect to proceedings, claims or actions commenced by such person, other than mandatory counterclaims and affirmative defenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.4.</B> <B><U>Interpretation</U></B><B>.</B> The indemnification and advancement of expenses provided by or pursuant to this <U>Article
8</U> shall not be deemed exclusive of any other rights to which any person seeking indemnification or advancement of expenses may be entitled under any insurance policy, agreement, vote of shareholders or directors, or otherwise, both as to actions
in such person&#146;s official capacity and as to actions in another capacity while holding an office, and shall continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors and
administrators of such person. If the PA BCL is amended to permit a Pennsylvania corporation to provide greater rights to indemnification and advancement of expenses for its directors and officers than the express terms of this <U>Article 8</U>,
this <U>Article 8</U> shall be construed to provide for such greater rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.5.</B> <B><U>Contract</U></B><B>.</B> The duties of the
Corporation to indemnify and to advance expenses to a director or officer as provided in this <U>Article 8</U> shall be in the nature of a contract between the Corporation and each such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
person, and no amendment or repeal of any provision of this <U>Article 8</U> shall alter, to the detriment of such person, the right of such person to the advancement of expenses or
indemnification related to a claim based on an act or failure to act that took place prior to such amendment or repeal or the termination of the service of the person as a director or officer, whichever is earlier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B><U>Limitation of Directors&#146; Liability</U></B><B>. </B>No person who is or was a director of the Corporation shall be
personally liable, as such, for monetary damages (other than under criminal statutes and under federal, state and local laws imposing liability on directors for the payment of taxes) unless the person&#146;s conduct constitutes self-dealing, willful
misconduct or recklessness. No amendment or repeal of this <U>Article 9</U> shall apply to or have any effect on the liability or alleged liability of any person who is or was a director of the Corporation for or with respect to any acts or
omissions of the director occurring prior to the effective date of such amendment or repeal. If the PA BCL is amended to permit a Pennsylvania corporation to provide greater protection from personal liability for its directors than the express terms
of this <U>Article 9</U>, this <U>Article 9</U> shall be construed to provide for such greater protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B><U>Limitation of
Officers&#146; Liability</U></B><B>. </B>No person who is or was an officer of the Corporation shall be personally liable, as such, for monetary damages (other than under criminal statutes and under federal, state and local laws imposing liability
on officers for the payment of taxes) unless the person&#146;s conduct constitutes self-dealing, willful misconduct or recklessness. No amendment or repeal of this <U>Article 10</U> shall apply to or have any effect on the liability or alleged
liability of any person who is or was an officer of the Corporation for or with respect to any acts or omissions of the officer occurring prior to the effective date of such amendment or repeal. If the PA BCL is amended to permit a Pennsylvania
corporation to provide greater protection from personal liability for its officers than the express terms of this <U>Article 10</U>, this <U>Article 10</U> shall be construed to provide for such greater protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><U>Right to Amend</U></B><B>. </B>Except as otherwise provided herein or by applicable law, the Corporation reserves the right
to amend or repeal any provision contained in this Second Amended and Restated Articles of Incorporation as the same may from time to time be in effect, in the manner now or hereafter prescribed by law, and all rights, preferences and privileges
conferred on shareholders hereunder are subject to such reservation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF OMITTED SCHEDULES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a list of all schedules to the merger agreement, which have been omitted pursuant to Item 601(b)(2) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> CVS Health hereby agrees to furnish supplementally a copy of any such schedule to the SEC upon request. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company
Disclosure Schedule </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Knowledge Parties</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Company Required Governmental Authorizations</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.05</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Capitalization</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.06</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Subsidiaries</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.07</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SEC Filings and the Sarbanes-Oxley Act</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Financial Statements and Financial Matters</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Statutory Financial Statements</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Capital or Surplus Maintenance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Absence of Certain Changes</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Undisclosed Material Liabilities</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Litigation</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Permits</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Compliance with Applicable Laws</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Material Contracts</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Taxes</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employees and Employee Benefit Plans</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Labor Matters</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Intellectual Property</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.23</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Properties</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Environmental Matters</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.25</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Insurance</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conduct of the Company</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.05(a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Severance Pay Plan</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.05(d)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Annual Incentive Plans</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.03(d)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Certain Company Required Governmental Authorizations</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Parent Disclosure Schedule </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Knowledge Persons</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.03</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Governmental Authorization</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.04</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.05</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Capitalization</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.06</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Subsidiaries</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Financial Statements and Financial Matters</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Taxes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employees and Employee Benefit Plans</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Labor Matters</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conduct of Parent</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.02(d)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Certain Parent Required Governmental Authorizations</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom482402_154"></A>Annex B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Opinion of Lazard Fr&egrave;res&nbsp;&amp; Co. LLC </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:65%; font-size:10pt; font-family:Times New Roman">December&nbsp;3, 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">151 Farmington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford, Connecticut 06156 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Members of the Board: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We understand that Aetna Inc., a Pennsylvania corporation (&#147;Aetna&#148;), CVS Health Corporation, a Delaware<B> </B>corporation
(&#147;CVS&#148;), and Hudson Merger Sub Corp., a Pennsylvania corporation and wholly owned subsidiary of CVS (&#147;Merger Sub&#148;),<B> </B>propose to enter into an Agreement and Plan of Merger (the &#147;Agreement&#148;) pursuant to which CVS
will acquire Aetna (the &#147;Transaction&#148;). Pursuant to the Agreement, Merger Sub will be merged with and into Aetna and each outstanding common share, par value $0.01 per share, of Aetna (&#147;Aetna Common Shares&#148;) will be converted
into the right to receive (i) $145.00<B> </B>in cash (the &#147;Cash Consideration&#148;) and (ii) 0.8378<B> </B>of a share of the common stock, par value $0.01 per share, of CVS (&#147;CVS Common Stock&#148;) (such number of shares so issuable, the
&#147;Stock Consideration&#148; and, together with the Cash Consideration, the &#147;Consideration&#148;). The terms and conditions of the Transaction are more fully set forth in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have requested our opinion as of the date hereof as to the fairness, from a financial point of view, to holders of Aetna Common Shares of
the Consideration to be paid to such holders in the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">Reviewed the financial terms and conditions of a draft, dated December&nbsp;2, 2017, of the Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">Reviewed certain publicly available historical business and financial information relating to Aetna and CVS; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">Reviewed various financial forecasts and other data prepared by Aetna<B> </B>relating to the business of Aetna, financial forecasts and other data prepared by CVS<B> </B>and<B> </B>as extrapolated per Aetna relating to
the business of CVS, and<B> </B>the projected synergies and other benefits, including the amount and timing thereof, anticipated by the respective managements of Aetna and CVS to be realized from the Transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">Held discussions with members of the senior management of Aetna with respect to the businesses and prospects of Aetna and CVS, with members of the senior management of CVS with respect to the business and prospects of
CVS, and with members of the senior managements of Aetna and CVS with respect to the projected synergies and other benefits, including the amount and timing thereof, anticipated by the respective managements to be realized from the Transaction;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">Reviewed public information with respect to certain other companies in lines of business we believe to be generally relevant in evaluating the businesses of Aetna<B> </B>and CVS, respectively; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">Reviewed the financial terms of certain business combinations involving companies in lines of business we believe to be generally relevant in evaluating the business of Aetna; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">Reviewed historical stock prices of Aetna Common Shares and CVS Common Stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">Reviewed the potential pro forma financial impact of the Transaction on CVS based on the financial forecasts referred to above relating to Aetna, CVS and the projected synergies and other benefits anticipated by the
management of Aetna to be realized from the Transaction;<B> </B>and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top">Conducted such other financial studies, analyses and investigations as we deemed appropriate. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 3, 2017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page<B> </B>
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assumed and
relied upon the accuracy and completeness of the foregoing information, without independent verification of such information. We have not conducted any independent valuation or appraisal of any of the assets or liabilities (contingent or otherwise)
of Aetna or CVS or concerning the solvency or fair value of Aetna or CVS, and we have not been furnished with any such valuation or appraisal. We are not actuaries and our services did not include any actuarial determination or evaluation by us or
any attempt to evaluate actuarial assumptions or allowances for losses, uncollectible accounts, claims or other matters and, accordingly, we have assumed, without independent analysis, the appropriateness of, and express no view or opinion as to,
reserves. At your direction, for purposes of our analysis, we have utilized the projected synergies and other benefits anticipated to be realized from the Transaction that were prepared by Aetna. With respect to the financial forecasts utilized in
our analyses, including those related to projected synergies and other benefits anticipated by the management of Aetna to be realized from the Transaction, we have assumed, with the consent of Aetna, that they have been reasonably prepared on bases
reflecting the best currently available estimates and judgments as to the future financial performance of Aetna<B> </B>and CVS, respectively,<B> </B>and such synergies and other benefits. In addition, we have assumed, with the consent of Aetna, that
such financial forecasts and projected synergies and other benefits will be realized in the amounts and at the times contemplated thereby. We assume no responsibility for and express no view as to any such forecasts or the assumptions on which they
are based. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our opinion is necessarily based on economic, monetary, market and other conditions as in effect on, and the
information made available to us as of, the date hereof. We assume no responsibility for updating or revising our opinion based on circumstances or events occurring after the date hereof. We do not express any opinion as to the prices at which Aetna
Common Shares or shares of CVS Common Stock may trade at any time subsequent to the announcement of the Transaction. In connection with our engagement, we were not authorized to, and we did not, solicit indications of interest from third parties
regarding a potential transaction with Aetna. In addition, our opinion does not address the relative merits of the Transaction as compared to any other transaction or business strategy in which Aetna might engage or the merits of the underlying
decision by Aetna to engage in the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering our opinion, we have assumed, with the consent of Aetna, that the
Transaction will be consummated on the terms described in the Agreement, without any waiver or modification of any material terms or conditions. Representatives of Aetna have advised us, and we have assumed, that the Agreement, when executed, will
conform to the draft reviewed by us in all material respects. We also have assumed, with the consent of Aetna, that obtaining the necessary governmental, regulatory or third party approvals and consents for the Transaction will not have an adverse
effect on Aetna, CVS<B> </B>or the Transaction. We do not express any opinion as to any tax or other consequences that might result from the Transaction, nor does our opinion address any legal, tax, regulatory, actuarial or accounting matters,
including, without limitation, the potential impact of U.S. healthcare and tax laws, regulations and governmental and legislative policies on Aetna, CVS or the Transaction, as to which we understand that Aetna obtained such advice as it deemed
necessary from qualified professionals. We express no view or opinion as to any terms or other aspects (other than the Consideration<B> </B>to the extent expressly specified herein) of the Transaction, including, without limitation, the form or
structure of the Transaction or any agreements or arrangements entered into in connection with, or contemplated by, the Transaction. In addition, we express no view or opinion as to the fairness of the amount or nature of, or any other aspects
relating to, the compensation to any officers, directors or employees of any parties to the Transaction, or class of such persons, relative to the Consideration or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lazard Fr&egrave;res&nbsp;&amp; Co. LLC (&#147;Lazard&#148;) is acting as financial advisor to Aetna in connection with the Transaction and
will receive a fee for such services, a portion of which is payable upon the rendering of this opinion and the principal portion of which is contingent upon the closing of the Transaction. We in the past have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 3, 2017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page<B> </B>
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided certain investment banking
services to Aetna and/or certain of its affiliates unrelated to the Transaction, for which we have received compensation, including, during the past two years, having acted as a financial advisor to Aetna in connection with its potential acquisition
of Humana Inc. (which acquisition was not consummated). In addition, in the ordinary course, Lazard and its affiliates and employees may trade securities of Aetna, CVS<B> </B>and certain of their respective affiliates for their own accounts and for
the accounts of their customers, may at any time hold a long or short position in such securities, and may also trade and hold securities on behalf of Aetna, CVS and certain of their respective affiliates. The issuance of this opinion was approved
by the Opinion Committee of Lazard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our engagement and the opinion expressed herein are for the benefit of the Board of Directors of
Aetna (in its capacity as such) and our opinion is rendered to the Board of Directors of Aetna in connection with its evaluation of the Transaction. Our opinion is not intended to and does not constitute a recommendation to any shareholder as to how
such shareholder should vote or act with respect to the Transaction or any matter relating thereto.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on and subject to the
foregoing, we are of the opinion that, as of the date hereof, the Consideration to be paid to holders of Aetna<B> </B>Common Shares<B> </B>in the Transaction is fair, from a financial point of view, to such holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Lazard Fr&egrave;res&nbsp;&amp; Co. LLC </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">LAZARD FRERES&nbsp;&amp; CO. LLC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom482402_155"></A>Annex C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Opinion of Allen&nbsp;&amp; Company LLC </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">December&nbsp;3, 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">151 Farmington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford, Connecticut 06156 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We understand that Aetna Inc., a Pennsylvania corporation (&#147;<U>Aetna</U>&#148;), CVS Health Corporation, a Delaware corporation
(&#147;<U>CVS</U>&#148;), and Hudson<B> </B>Merger Sub Corp., a Pennsylvania corporation and a wholly owned subsidiary of CVS (&#147;<U>Merger Sub</U>&#148;), propose to enter into an Agreement and Plan of Merger (the &#147;<U>Agreement</U>&#148;)
pursuant to which Merger Sub will be merged with and into Aetna (the &#147;<U>Merger</U>&#148;) and each outstanding common share, par value $0.01 per share, of Aetna (&#147;<U>Aetna Common Shares</U>&#148;) will be converted into the right to
receive (i) $145.00<B> </B>in cash (the &#147;<U>Cash Consideration</U>&#148;) and (ii) 0.8378<B> </B>of a<B> </B>share (such number of shares, the &#147;<U>Stock Consideration</U>&#148; and, together with the Cash Consideration, the &#147;<U>Merger
Consideration</U>&#148;) of the common stock, par value $0.01 per share, of CVS (&#147;<U>CVS Common Stock</U>&#148;). The terms and conditions of the Merger are more fully set forth in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company LLC (&#147;<U>Allen</U><U></U><U>&nbsp;&amp; Company</U>&#148;) has acted as a financial advisor to Aetna in
connection with the proposed Merger and has been asked to render an opinion to the Board of Directors of Aetna (the &#147;<U>Board</U>&#148;) as to the fairness, from a financial point of view, to the holders of Aetna Common Shares of the Merger
Consideration to be received by such holders pursuant to the Agreement. For such services, Aetna has agreed to pay to Allen&nbsp;&amp; Company cash fees, of which a portion is payable upon the delivery of this opinion (the &#147;<U>Opinion
Fee</U>&#148;) and the principal portion is contingent upon consummation of the Merger. No portion of the Opinion Fee is contingent upon either the conclusion expressed in this opinion or successful consummation of the Merger. Aetna also has agreed
to reimburse Allen&nbsp;&amp; Company&#146;s reasonable expenses and to indemnify Allen&nbsp;&amp; Company and related parties against certain liabilities arising out of our engagement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allen&nbsp;&amp; Company, as part of our investment banking business, is regularly engaged in the valuation of businesses and their securities
in connection with mergers and acquisitions, private placements and related financings, bankruptcy reorganizations and similar recapitalizations, negotiated underwritings, secondary distributions of listed and unlisted securities, and valuations for
corporate and other purposes. As the Board is aware, Allen&nbsp;&amp; Company in the past has provided, currently is providing and in the future may provide, investment banking services to Aetna and/or its affiliates unrelated to the Merger, for
which services Allen&nbsp;&amp; Company may receive compensation, including, during the <FONT STYLE="white-space:nowrap">two-year</FONT> period prior to the date hereof, acting or having acted as financial advisor to Aetna in connection with certain
potential transactions and strategic advisory matters. In the ordinary course, Allen&nbsp;&amp; Company as a broker-dealer and certain of Allen&nbsp;&amp; Company&#146;s affiliates (including a senior member of the team assisting in providing
Allen&nbsp;&amp; Company&#146;s financial advisory services to Aetna in connection with the Merger) and/or related entities have invested or may invest, hold long or short positions and may trade, either on a discretionary or <FONT
STYLE="white-space:nowrap">non-discretionary</FONT> basis, for their own account or for those of Allen &amp; Company&#146;s clients, in the debt and equity securities (or related derivative securities) of Aetna, CVS and/or their respective
affiliates. The issuance of this opinion has been approved by Allen&nbsp;&amp; Company&#146;s fairness opinion committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion as
expressed herein reflects and gives effect to our general familiarity with Aetna and CVS as well as information that we received during the course of this assignment, including information provided by the managements of Aetna and CVS in the course
of discussions relating to the Merger as more fully described </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 3, 2017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">below. In arriving at our opinion, we
neither conducted a physical inspection of the properties or facilities of Aetna, CVS or any other entity nor made or obtained any evaluations or appraisals of the assets or liabilities (contingent, accrued, derivative, <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet or otherwise) of Aetna, CVS or any other entity, or conducted any analysis concerning the solvency or fair value of Aetna, CVS or any other entity. We are not actuaries and our services did not
include any actuarial determination or evaluation by us or any attempt to evaluate actuarial assumptions or allowances for losses, uncollectible accounts, claims or other matters and, accordingly, we have assumed, without independent analysis, the
appropriateness of, and express no opinion or view as to, reserves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In arriving at our opinion, we have, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">reviewed the financial terms and conditions of the Merger as reflected in a draft, dated December&nbsp;2, 2017, of the Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed certain publicly available historical business and financial information relating to Aetna and CVS, including public filings of Aetna and CVS and historical market prices for Aetna Common Shares and CVS Common
Stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed certain financial information relating to Aetna provided to or discussed with us by the management of Aetna, including certain internal financial forecasts, estimates and other financial and operating data
relating to Aetna prepared by the management of Aetna (such forecasts, the &#147;<U>Aetna Forecasts</U>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">reviewed certain financial information relating to CVS provided to or discussed with us by the managements of CVS and Aetna, including certain internal financial forecasts, estimates and other financial and operating
data relating to CVS prepared by the management of CVS and as extrapolated per the management of Aetna (such forecasts, as extrapolated, the &#147;<U>CVS Forecasts</U>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">held discussions with the managements of Aetna and CVS relating to the past and current operations, financial condition and prospects of Aetna and CVS; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">discussed with the managements of Aetna and CVS the strategic rationale for the Merger and the potential synergies expected by such managements to result from the Merger, including the timing and amount of, costs to
achieve, and capital expenditures associated with, such synergies (collectively, the &#147;<U>Synergies</U>&#148;), and certain potential pro forma financial effects of the Merger; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed certain publicly available information, including certain stock market data and financial information, relating to selected companies with businesses that we deemed generally relevant in evaluating
Aetna and CVS; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">reviewed and analyzed certain publicly available financial information relating to selected transactions that we deemed generally relevant in evaluating the Merger; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top">conducted such other financial analyses and investigations as we deemed necessary or appropriate for purposes of the opinion expressed herein. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering our opinion, we have relied upon and assumed, with your consent and without independent verification, the accuracy and
completeness of all of the financial, legal, regulatory, tax, accounting, actuarial and other information available to us from public sources, provided to or discussed with us by the managements and/or other representatives of Aetna and CVS or
otherwise reviewed by us. With respect to the Aetna Forecasts and the Synergies that we have been directed to utilize for purposes of our analyses, we have been advised by the management of Aetna, and we have assumed, at your direction, that such
financial forecasts, estimates and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 3, 2017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">financial and operating data have
been reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of such management as to, and are a reasonable basis upon which to evaluate, the future financial and operating performance of Aetna,
such Synergies and the other matters covered thereby. With respect to the CVS Forecasts (including, without limitation, extrapolations therefrom) that we have been directed to utilize for purposes of our analyses, we have been advised by the
managements of CVS and Aetna, as the case may be, and we have assumed, at your direction, that such financial forecasts, estimates and other financial and operating data have been reasonably prepared in good faith on bases reflecting the best
currently available estimates and judgments of the respective managements of CVS and Aetna as to, and are a reasonable basis upon which to evaluate, the future financial and operating performance of CVS and the other matters covered thereby. We also
have assumed, with your consent, that the financial results, including, without limitation, the Synergies expected by the management of Aetna to result from the Merger, reflected in the financial forecasts, estimates and other financial and
operating data utilized in our analyses will be realized in the amounts and at the times projected. We express no opinion or view as to any financial forecasts, estimates or other financial or operating data or the assumptions on which they are
based. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied, at your direction, upon the assessments of the managements of Aetna and CVS, as the case may be, as to, among
other things, (i)&nbsp;the potential impact on Aetna and CVS of certain market, cyclical, competitive and other trends and developments in and prospects for, and governmental, regulatory and legislative policies and matters relating to or otherwise
affecting, the healthcare industry and healthcare benefits sector thereof and the retail, pharmacy and pharmacy services industries, including, without limitation, laws and regulations relating to government subsidized healthcare programs, capital
requirements and reimbursement, (ii)&nbsp;existing and future contracts, agreements and arrangements relating to, and the ability to attract, retain and/or replace, key commercial relationships of, Aetna and CVS, and (iii)&nbsp;the ability of CVS to
integrate the operations of Aetna and CVS. We have assumed, with your consent, that there will be no developments with respect to any such matters that would have an adverse effect on Aetna, CVS or the Merger (including the contemplated benefits
thereof) or that otherwise would be meaningful in any respect to our analyses or opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our opinion is necessarily based on
economic, monetary, market and other conditions as in effect on, and the information made available to us as of, the date hereof. It should be understood that subsequent developments may affect the conclusion expressed in this opinion and that we
assume no responsibility for advising any person of any change in any matter affecting this opinion or for updating or revising our opinion based on circumstances or events occurring after the date hereof. As you are aware, the credit, financial and
stock markets, and the industries in which Aetna and CVS operate, have experienced and continue to experience volatility and we express no opinion or view as to any potential effects of such volatility on Aetna or CVS (or their respective
businesses) or the Merger (including the contemplated benefits thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is understood that this opinion is intended for the benefit
and use of the Board (in its capacity as such) in connection with its evaluation of the Merger Consideration from a financial point of view. This opinion does not constitute a recommendation as to the course of action that Aetna (or the Board)
should pursue in connection with the Merger or otherwise address the merits of the underlying decision by Aetna to engage in the Merger, including in comparison to other strategies or transactions that might be available to Aetna or which Aetna
might engage in or consider. In connection with our engagement, we were not requested to, and we did not, solicit third-party indications of interest with respect to the acquisition of all or a portion of Aetna. This opinion does not constitute
advice or a recommendation to any shareholder as to how such shareholder should vote or act on any matter relating to the Merger or otherwise. We do not express any opinion as to the fairness, financial or otherwise, of the amount, nature or any
other aspect of any compensation or other consideration payable to any officers, directors or employees of any party to the Merger or any related entities, or any class of such persons or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 3, 2017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">any other party, relative to the
Merger Consideration or otherwise. We are not expressing any opinion as to the actual value of CVS Common Stock when issued in connection with the Merger or the prices at which Aetna Common Shares or CVS Common Stock (or any other securities) may
trade or otherwise be transferable at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we do not express any opinion or view as to any tax or other consequences
that might result from the Merger or otherwise, including, without limitation, the potential impact of changes in U.S. healthcare and tax laws, regulations and governmental and legislative policies on Aetna, CVS or the Merger (or the contemplated
benefits thereof), nor do we express any opinion or view as to, and we have relied, at your direction, upon the assessments of representatives of Aetna regarding, legal, regulatory, accounting, tax and actuarial matters relating to Aetna, CVS and
the Merger, as to which we understand Aetna obtained such advice as it deemed necessary from qualified professionals. We have assumed, with your consent, that the Merger will be consummated in accordance with its terms and in compliance with all
applicable laws, documents and other requirements, without waiver, modification or amendment of any material term, condition or agreement, and that, in the course of obtaining the necessary governmental, regulatory or third party approvals,
consents, releases, waivers, decrees and agreements for the Merger, no delay, limitation, restriction or condition, including any divestiture or other requirements or remedies, amendments or modifications, will be imposed or occur that would have an
adverse effect on Aetna, CVS or the Merger (including the contemplated benefits thereof) or that otherwise would be meaningful in any respect to our analyses or opinion. We further have assumed, with your consent, that the final executed Agreement
will not differ from the draft reviewed by us in any respect meaningful to our analyses or opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion is limited to the
fairness, from a financial point of view and as of the date hereof, of the Merger Consideration to be received by holders of Aetna Common Shares<B> </B>pursuant to the Agreement, without regard to individual circumstances of holders of Aetna Common
Shares that may distinguish such holders or the securities of Aetna held by such holders, and no opinion or view is expressed with respect to any consideration received in connection with the Merger by the holders of any other securities, creditors
or other constituencies of any party. Our opinion does not address any other terms, aspects or implications of the Merger, including, without limitation, the form or structure of the Merger or any terms, aspects or implications of any governance or
other arrangements, agreements or understandings entered into in connection with, related to or contemplated by the Merger or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, it is our opinion that, as of the date hereof, the Merger Consideration to be received by holders of
Aetna Common Shares<B> </B>pursuant to the Agreement is fair, from a financial point of view, to such holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very
truly yours, </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Allen &amp; Company LLC </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">ALLEN&nbsp;&amp; COMPANY LLC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B><A NAME="rom482402_156"></A>Annex D </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g482402g90y79.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>745&nbsp;Seventh&nbsp;Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>New&nbsp;York,&nbsp;NY&nbsp;10019<FONT STYLE="font-size:5pt">&nbsp;</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>United States&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">December&nbsp;3, 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Board of
Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">One CVS Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Woonsocket, Rhode Island 02895 </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Members of the Board of Directors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:ARIAL">We understand that CVS Health Corporation (the &#147;Company&#148;) intends to enter into a transaction (the &#147;Proposed Transaction&#148;) with
Aetna Inc. (&#147;Aetna&#148;) and Hudson Merger Sub Corp., a wholly owned subsidiary of the Company (&#147;Merger Sub&#148;), pursuant to which: (a)&nbsp;Merger Sub will be merged with and into Aetna with Aetna as the surviving corporation; and
(b)&nbsp;each common share, par value $0.01 per share, of Aetna (the &#147;Aetna Common Stock&#148;) issued and outstanding (other than shares of Aetna Common Stock held by Aetna as treasury stock and shares of Aetna Common Stock owned by the
Company or any of its Subsidiaries (as defined in the Agreement) (other than any such shares owned by the Company or any of its Subsidiaries in a fiduciary, representative or other capacity on behalf of other persons, whether or not held in a
separate account)) shall be converted into the right to receive, (i) 0.8378 shares of the common stock, par value $0.01 per share, of the Company (the &#147;Company Common Stock&#148;) and (ii)&nbsp;$145.00 in cash (the cash and stock consideration
described in the foregoing clauses (i)&nbsp;and (ii), collectively, the &#147;Consideration&#148;). The terms and conditions of the Proposed Transaction are set forth in more detail in the Agreement and Plan of Merger, dated as of December&nbsp;3,
2017, among Aetna, Merger Sub and the Company (the &#147;Agreement&#148;). The summary of the Proposed Transaction set forth above is qualified in its entirety by the terms of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:ARIAL">We have been requested by the Board of Directors of the Company to render our opinion with respect to the fairness, from a financial point of view, to
the Company of the Consideration to be paid by the Company in the Proposed Transaction. We have not been requested to opine as to, and our opinion does not in any manner address, the Company&#146;s underlying business decision to proceed with or
effect the Proposed Transaction or the likelihood of consummation of the Proposed Transaction or the Financing (as defined below). In addition, we express no opinion on, and our opinion does not in any manner address, the fairness of the Proposed
Transaction to, or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g46f93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:23pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"> Page
 2
 of 5 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
consideration received in connection therewith by, the holders of any class of securities of the Company or the amount or the nature of any compensation to any officers, directors or employees of
any parties to the Proposed Transaction, or any other class of persons, relative to the Consideration paid in the Proposed Transaction or otherwise. Our opinion does not address the relative merits of the Proposed Transaction as compared to any
other transaction or business strategy in which the Company might engage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:ARIAL">In arriving at our opinion, we reviewed and analyzed: (1)&nbsp;the
Agreement and the specific terms of the Proposed Transaction; (2)&nbsp;publicly available information concerning the Company and Aetna that we believe to be relevant to our analysis, including their respective Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016 and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended September&nbsp;30, June&nbsp;30 and March&nbsp;31, 2017;
(3) financial and operating information with respect to the business, operations and prospects of the Company furnished to us by the Company, including financial projections of the Company prepared by management of the Company (the &#147;Company
Projections&#148;); (4) financial and operating information with respect to the business, operations and prospects of Aetna furnished to us by the Company, including (i)&nbsp;financial projections of Aetna prepared by management of Aetna (the
&#147;Aetna Projections&#148;) and (ii)&nbsp;financial projections of Aetna prepared by management of the Company (the &#147;Company Aetna Projections&#148;); (5) the trading histories of the Company Common Stock and Aetna Common Stock for the last
three years as of December&nbsp;1, 2017 and a comparison of those trading histories with those of other companies that we deemed relevant; (6)&nbsp;a comparison of the historical financial results and present financial condition of the Company and
Aetna with each other and with those of other companies that we deemed relevant; (7)&nbsp;a comparison of the financial terms of the Proposed Transaction with the financial terms of certain other transactions that we deemed relevant; (8)&nbsp;the
pro forma impact of the Proposed Transaction on the future financial performance of the combined company, including (i)&nbsp;certain financial and operating information with respect to the business, operations and prospects of the Company on a pro
forma basis giving effect to the Proposed Transaction furnished to us by the Company, including financial projections of the Company on a pro forma basis giving effect to the Proposed Transaction prepared by management of the Company (the &#147;Pro
Forma Projections&#148;) and (ii)&nbsp;cost savings and operating synergies expected by the management of the Company to result from a combination of the businesses (the &#147;Expected Synergies&#148;); and (9)&nbsp;published estimates of
independent research analysts with respect to the future financial performance and price targets of the Company and Aetna. In addition, we (1)&nbsp;have had discussions with the management of the Company and Aetna concerning Aetna&#146;s businesses,
operations, assets, financial conditions and prospects, (2)&nbsp;have had discussions with the management of the Company concerning the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g46f93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:23pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"> Page
 3
 of 5 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
businesses, operations, assets, financial conditions and prospects and (3)&nbsp;have undertaken such other studies, analyses and investigations as we deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:ARIAL">In arriving at our opinion, we have assumed and relied upon the accuracy and completeness of the financial and other information used by us without any
independent verification of such information (and have not assumed responsibility or liability for any independent verification of such information) and have further relied upon the assurances of the management of the Company that they are not aware
of any facts or circumstances that would make such information inaccurate or misleading in any material respect. With respect to the Company Projections, upon the advice and at the instruction of the Company, we have assumed that such projections
have been reasonably prepared on a basis reflecting the best currently available estimates and judgments of the management of the Company as to the future financial performance of the Company and that the Company will perform substantially in
accordance with such projections. With respect to the Aetna Projections, upon the advice and at the instruction of the Company, we have assumed that such projections have been reasonably prepared on a basis reflecting the best currently available
estimates and judgments of the management of Aetna as to the future financial performance of Aetna. With respect to the Company Aetna Projections, upon the advice and at the instruction of the Company, we have assumed that such projections have been
reasonably prepared on a basis reflecting the best currently available estimates and judgments of the management of the Company as to the future financial performance of Aetna and that Aetna will perform substantially in accordance with such
projections. With respect to the Pro Forma Projections, upon the advice and at the instruction of the Company, we have assumed that such projections have been reasonably prepared on a basis reflecting the best currently available estimates and
judgments of the management of the Company as to the future financial performance of the Company on a pro forma basis giving effect to the Proposed Transaction, and that the pro forma Company will perform substantially in accordance with such Pro
Forma Projections. Furthermore, upon the advice and at the instruction of the Company, we have assumed that the amounts and timing of the Expected Synergies are reasonable and that the Expected Synergies will be realized substantially in accordance
with such estimates. We assume no responsibility for and we express no view as to any such projections or estimates or the assumptions on which they are based.<B> </B>In arriving at our opinion, we have not conducted a physical inspection of the
properties and facilities of the Company or Aetna and have not made or obtained any evaluations or appraisals of the assets or liabilities of the Company or Aetna. We are not actuaries, our services did not include any actuarial determination or
evaluation by us or any attempt to evaluate actuarial assumptions and we have relied on the Company&#146;s actuaries with respect to the adequacy of reserves for Aetna&#146;s insurance liabilities. Our opinion necessarily is based upon market,
economic and other conditions as they exist on, and can be evaluated as of, the date of this letter. We assume no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g46f93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:23pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"> Page
 4
 of 5 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
responsibility for updating or revising our opinion based on events or circumstances that may occur after the date of this letter. We express no opinion as to the prices at which the Aetna Common
Stock would trade following the announcement of the Proposed Transaction or the Company Common Stock would trade following the announcement or consummation of the Proposed Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:ARIAL">We have assumed the accuracy of the representations and warranties contained in the Agreement and all agreements related thereto. We have also assumed,
upon the advice and at the instruction of the Company, that all material governmental, regulatory and third party approvals, consents and releases for the Proposed Transaction will be obtained within the constraints contemplated by the Agreement and
that the Proposed Transaction will be consummated in accordance with the terms of the Agreement without waiver, modification or amendment of any material term, condition or agreement thereof. We do not express any opinion as to any tax or other
consequences that might result from the Proposed Transaction, nor does our opinion address any legal, tax, regulatory or accounting matters, as to which we understand that the Company has obtained such advice as it deemed necessary from qualified
professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:ARIAL">Based upon and subject to the foregoing, we are of the opinion as of the date hereof that, from a financial point of view, the
Consideration to be paid by the Company in the Proposed Transaction is fair to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:ARIAL">We have acted as financial advisor to the Company in
connection with the Proposed Transaction and will receive fees for our services a portion of which is payable upon rendering this opinion and a substantial portion of which is contingent upon the consummation of the Proposed Transaction. In
addition, the Company has agreed to reimburse our expenses and indemnify us for certain liabilities that may arise out of our engagement. We and our affiliates have performed various investment banking and financial services for the Company, Aetna
and their respective affiliates in the past, and expect to perform such services in the future, and have received, and expect to receive, customary fees for such services. Specifically, in the past two years, we and our affiliates have performed the
following investment banking and financial services: (A)&nbsp;for the Company or its affiliates, (i)&nbsp;acting as exclusive financial advisor to the Company in connection with the pending sale of its RxCrossroads reporting unit for
$735&nbsp;million, (ii)&nbsp;having acted as Joint Placement Agent on a $243&nbsp;million debt sale leaseback private placement in August 2017, (iii) having acted as Joint Bookrunner and <FONT STYLE="white-space:nowrap">Co-Syndication</FONT> Agent
on the refinancing of the Company&#146;s $1&nbsp;billion existing <FONT STYLE="white-space:nowrap">5-year</FONT> revolving credit facility, (iv)&nbsp;having acted as Joint Bookrunner, Joint Lead Arranger and Co-Documentation Agent on the issuance of
a new $1&nbsp;billion revolving credit facility to the Company in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g46f93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:23pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"> Page
 5
 of 5 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
May 2017, (v) having acted as Sole Bookrunner, Sole Lead Arranger and Administrative Agent in the creation of a $2.5&nbsp;billion bilateral revolving credit facility for the Company in January
2017, (vi) having acted as Sole Structuring Advisor and Joint Placement Agent on a $205&nbsp;million debt sale leaseback private placement by the Company in July 2016, (vii) having acted as Joint Dealer Manager on a $3.1&nbsp;billion tender offer by
the Company for senior notes in May 2016, (viii) having acted as Joint Active Bookrunner on a $3.5&nbsp;billion senior notes offering by the Company in May 2016, (ix) having acted as exclusive financial advisor to the Company in the
$1.9&nbsp;billion acquisition of Target Corporation&#146;s pharmacy and clinic businesses in December 2015 and (x)&nbsp;acting as a tier 1 lender under certain of the Company&#146;s revolving credit facilities and (B)&nbsp;for Aetna or its
affiliates, (i)&nbsp;having acted as exclusive financial advisor to Aetna in connection with the sale of its domestic group life insurance, group disability insurance and absence management businesses to Hartford Life and Accident Insurance Company
for $1.45&nbsp;billion in November 2017, (ii)&nbsp;having acted as Senior <FONT STYLE="white-space:nowrap">Co-Manager</FONT> on a $1&nbsp;billion bond offering by Aetna in August 2017, (iii)&nbsp;having acted as Bridge Lender on a $13&nbsp;billion
bridge loan and $3.2&nbsp;billion delayed-draw term loan to Aetna in June 2016, (iv) having acted as Joint Bookrunner on a $13&nbsp;billion bond offering by Aetna in June 2016 and (v)&nbsp;acting as a lender under Aetna&#146;s revolving credit
facility. In addition, the Company and its Board of Directors have requested of Barclays and/or its affiliates to participate, and Barclays and/or such affiliates have committed to participate, in financing transactions to facilitate the Proposed
Transaction (the &#147;Financing&#148;), including acting as Joint Lead Arranger, Joint Bookrunner, Administrative Agent and Active Joint Bookrunner, and we will receive customary fees and indemnification in connection with the Financing. Also, we
and our affiliates have executed various share repurchase, hedging, derivative and other securities transactions and provided other risk management and equity origination services for the Company and its affiliates, as well as executed various
hedging, derivative and other securities transactions and provided other risk management and equity origination services for Aetna and its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:ARIAL">Barclays Capital Inc., its subsidiaries and its affiliates engage in a wide range of businesses from investment and commercial banking, lending, asset
management and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> services. In the ordinary course of our business, we and our affiliates may actively trade and effect transactions in the equity, debt and/or other securities
(and any derivatives thereof) and financial instruments (including loans and other obligations) of the Company and Aetna for our own account and for the accounts of our customers and, accordingly, may at any time hold long or short positions and
investments in such securities and financial instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:ARIAL">This opinion, the issuance of which has been approved by our Fairness Opinion Committee,
is for the use and benefit of the Board of Directors of the Company and is rendered to the Board of Directors in connection with its consideration of the Proposed Transaction. This opinion is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g46f93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:23pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"> Page
 6
 of 6 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
intended to be and does not constitute a recommendation to any stockholder of the Company as to how such stockholder should vote with respect to the Proposed Transaction. </P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Very truly yours, </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:ARIAL">/s/ Barclays Capital Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:ARIAL">BARCLAYS CAPITAL INC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">D-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="right"><B><A NAME="rom482402_157"></A>Annex E </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g482402g88f83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B><U>PERSONAL AND CONFIDENTIAL </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">December&nbsp;3, 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">One CVS Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Woonsocket, Rhode Island 02895 </P> <P STYLE="margin-top:28pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Ladies and
Gentlemen: </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">You have requested our opinion as to the fairness from a financial point of view to CVS Health Corporation (the &#147;Company&#148;) of
the Aggregate Consideration (as defined below) to be paid by the Company for each outstanding common share, par value $0.01 per share (the &#147;Aetna Common Shares&#148;), of Aetna Inc. (&#147;Aetna&#148;) pursuant to the Agreement and Plan of
Merger, dated as of December&nbsp;3, 2017 (the &#147;Agreement&#148;), by and among the Company, Hudson Merger Sub Corp. (&#147;Acquisition Sub&#148;), and Aetna. Pursuant to the Agreement, Acquisition Sub will be merged with and into Aetna and each
outstanding Aetna Common Share (other than the Excluded Shares (as defined in the Agreement)) will be converted into $145.00 in cash (the &#147;Cash Consideration&#148;) and 0.8378 shares of common stock, par value $0.01 per share (the &#147;Company
Common Stock&#148;), of the Company (the &#147;Stock Consideration&#148;; taken in the aggregate with the Cash Consideration, the &#147;Aggregate Consideration&#148;). </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Goldman Sachs&nbsp;&amp; Co. LLC and its affiliates are engaged in advisory, underwriting and financing, principal investing, sales and trading,
research, investment management and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services for various persons and entities. Goldman Sachs&nbsp;&amp; Co. LLC and its affiliates and employees, and funds or
other entities they manage or in which they invest or have other economic interests or with which they <FONT STYLE="white-space:nowrap">co-invest,</FONT> may at any time purchase, sell, hold or vote long or short positions and investments in
securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments of the Company, Aetna and any of their respective affiliates and third parties, or any currency or commodity that may be involved in the
transaction contemplated by the Agreement (the &#147;Transaction&#148;). We have acted as financial advisor to the Company in connection with, and have participated in certain of the negotiations leading to, the Transaction. We expect to receive
fees for our services in connection with the Transaction, the principal portion of which is contingent upon consummation of the Transaction, and the Company has agreed to reimburse certain of our expenses arising, and indemnify us against certain
liabilities that may arise, out of our engagement. At your request and in connection with the consummation of the Transaction, (X)&nbsp;an affiliate of Goldman Sachs&nbsp;&amp; Co. LLC has entered into financing commitments and agreements to provide
the Company with a bridge facility and a term loan facility, in each case </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center">Securities and Investment Services Provided by Goldman Sachs &amp; Co. LLC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">E-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">December 3, 2017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Page Two </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">subject to the terms of such commitments and agreements and pursuant to which such affiliate expects to receive compensation and (Y)&nbsp;Goldman
Sachs&nbsp;&amp; Co. LLC expects to act as active lead joint bookrunner with respect to a bond issuance by the Company for which it expects to receive compensation. We have provided certain financial advisory and/or underwriting services to Aetna
and/or its affiliates from time to time for which our Investment Banking Division has received, and may receive, compensation, including having acted as lead bookrunner in the structuring of catastrophe bonds (aggregate principal amount
$200,000,000) by Vitality Re VII Limited, a vehicle linked to a portfolio of Aetna insurance products, in January 2016; as lead bookrunner in the structuring of catastrophe bonds (aggregate principal amount $200,000,000) by Vitality Re VIII Limited,
a vehicle linked to a portfolio of Aetna insurance products, in January 2017; and as <FONT STYLE="white-space:nowrap">co-manager</FONT> with respect to a public offering by Aetna of its <FONT STYLE="white-space:nowrap">3-7/8%</FONT> Senior Notes due
2047 (aggregate principal amount $1,000,000,000) in August 2017. We may also in the future provide financial advisory and/or underwriting services to the Company, Aetna and their respective affiliates for which our Investment Banking Division may
receive compensation. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In connection with this opinion, we have reviewed, among other things, the Agreement; annual reports to shareholders and
Annual Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> of the Company and Aetna for the five years ended December&nbsp;31, 2016; certain interim reports to shareholders and Quarterly Reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> of the Company and Aetna; certain other communications from the Company and Aetna to their respective shareholders; certain publicly available research analyst reports for the Company and Aetna;
certain internal financial analyses and forecasts for Aetna prepared by its management; certain internal financial analyses and forecasts for the Company, certain financial analyses and forecasts for Aetna and certain internal financial analyses and
forecasts for the Company pro forma for consummation of the Transaction, in each case, as prepared by the management of the Company and approved for our use by the Company (the &#147;Forecasts&#148;); and certain operating synergies projected by the
managements of the Company and Aetna to result from the Transaction, as approved for our use by the Company (the &#147;Synergies&#148;). We have also held discussions with members of the senior managements of the Company and Aetna regarding their
assessment of the past and current business operations, financial condition and future prospects of Aetna and with the members of senior management of the Company regarding their assessment of the past and current business operations, financial
condition and future prospects of the Company and the strategic rationale for, and the potential benefits of, the Transaction; reviewed the reported price and trading activity for the shares of Company Common Stock and the Aetna Common Shares;
compared certain financial and stock market information for the Company and Aetna with similar information for certain other companies the securities of which are publicly traded; reviewed the financial terms of certain recent business combinations
in the health insurance industry and in other industries; and performed such other studies and analyses, and considered such other factors, as we deemed appropriate. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">For purposes of rendering this opinion, we have, with your consent, relied upon and assumed the accuracy and completeness of all of the financial,
legal, regulatory, tax, accounting and other information provided to, discussed with or reviewed by, us, without assuming any responsibility for independent verification thereof. In that regard, we have assumed with your consent that the Forecasts
and the Synergies have been reasonably prepared on a basis reflecting the best currently available estimates and judgments of the management of the Company. We have not made an independent evaluation or appraisal of the assets and liabilities
(including any contingent, derivative or other <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> assets and liabilities) of the Company or Aetna or any of their respective subsidiaries and we have not been furnished
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">E-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">December 3, 2017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Page Three </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">with any such evaluation or appraisal.&nbsp;We are not actuaries and our services
did not include any actuarial determination or evaluation by us or any attempt to evaluate actuarial assumptions and we have relied on your actuaries with respect to reserve adequacy. In that regard, we have made no analysis of, and express no
opinion as to, the adequacy of the loss and loss adjustments expenses reserves, the future policy benefit reserves, the long-term business provision and claims outstanding or the embedded value of the Company and Aetna. We have assumed that all
governmental, regulatory or other consents and approvals necessary for the consummation of the Transaction will be obtained without any adverse effect on the Company or Aetna or on the expected benefits of the Transaction in any way meaningful to
our analysis. We also have assumed that the Transaction will be consummated on the terms set forth in the Agreement, without the waiver or modification of any term or condition the effect of which would be in any way meaningful to our analysis. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Our opinion does not address the underlying business decision of the Company to engage in the Transaction, or the relative merits of the Transaction as
compared to any strategic alternatives that may be available to the Company; nor does it address any legal, regulatory, tax or accounting matters. This opinion addresses only the fairness from a financial point of view to the Company, as of the date
hereof, of the Aggregate Consideration to be paid by the Company for each Aetna Common Share pursuant to the Agreement. We do not express any view on, and our opinion does not address, any other term or aspect of the Agreement or Transaction or any
term or aspect of any other agreement or instrument contemplated by the Agreement or entered into or amended in connection with the Transaction, including, the fairness of the Transaction to, or any consideration received in connection therewith by,
the holders of any class of securities, creditors, or other constituencies of the Company; nor as to the fairness of the amount or nature of any compensation to be paid or payable to any of the officers, directors or employees of the Company or
Aetna, or any class of such persons, in connection with the Transaction, whether relative to the Aggregate Consideration to be paid by the Company for each Aetna Common Share pursuant to the Agreement or otherwise. We are not expressing any opinion
as to the prices at which shares of Company Common Stock will trade at any time or as to the impact of the Transaction on the solvency or viability of the Company or Aetna or the ability of the Company or Aetna to pay their respective obligations
when they come due. Our opinion is necessarily based on economic, monetary, market and other conditions as in effect on, and the information made available to us as of, the date hereof and we assume no responsibility for updating, revising or
reaffirming this opinion based on circumstances, developments or events occurring after the date hereof. Our advisory services and the opinion expressed herein are provided for the information and assistance of the Board of Directors of the Company
in connection with its consideration of the Transaction and such opinion does not constitute a recommendation as to how any holder of shares of Company Common Stock should vote with respect to such Transaction or any other matter. This opinion has
been approved by a fairness committee of Goldman Sachs&nbsp;&amp; Co. LLC. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Based upon and subject to the foregoing, it is our opinion that, as of
the date hereof, the Aggregate Consideration to be paid by the Company for each Aetna Common Share pursuant to the Agreement is fair from a financial point of view to the Company. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Very truly yours, </P> <P STYLE="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="justify">/s/ Goldman Sachs&nbsp;&amp; Co. LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">(GOLDMAN SACHS&nbsp;&amp; CO. LLC)</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">E-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom482402_158"></A>Annex F </B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g482402g84j41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; margin-left:67%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Centerview Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:67%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">31 West 52nd Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:67%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">New York, NY 10019 </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; margin-left:67%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">December&nbsp;3, 2017 </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">CVS
Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">One CVS Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Woonsocket, RI 02895 </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Dear
Members of the Board of Directors: </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">You have requested our opinion as to the fairness, from a financial point of view, to
CVS Health Corporation, a Delaware corporation (&#147;CVS&#148;) of the Merger Consideration (as defined below) proposed to be paid by CVS pursuant to the Agreement and Plan of Merger proposed to be entered into (the &#147;Agreement&#148;) among
CVS, Hudson Merger Sub Corp, a Pennsylvania corporation and wholly owned subsidiary of CVS (&#147;Merger Sub&#148;), and Aetna Inc., a Pennsylvania corporation (&#147;Aetna&#148;). The Agreement provides that Merger Sub will be merged with and into
Aetna (the &#147;Merger&#148; and, collectively with the transactions contemplated by the Agreement, the &#147;Transaction&#148;), as a result of which Aetna will become a wholly owned subsidiary of CVS and each issued and outstanding common share,
$0.01 par value, of Aetna (the &#147;Aetna Shares&#148;) immediately prior to the effective time of the Merger (other than Aetna Shares held by Aetna as treasury stock or owned by CVS or any of its subsidiaries immediately prior to the effective
time of the Merger (other than any such shares owned CVS or any of its subsidiaries in a fiduciary, representative or other capacity on behalf of other persons, whether or not held in a separate account)) will be converted into the right to receive
(i) 0.8378 shares (the &#147;Share Consideration&#148;) of common stock, par value $0.01, of CVS (the &#147;CVS Shares&#148;) and (ii) $145.00 in cash without interest thereon (the &#147;Cash Consideration&#148; and taken together (and not
separately) with the Share Consideration, the &#147;Merger Consideration&#148;). The terms and conditions of the Transaction are more fully set forth in the Agreement. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We have acted as financial advisor to the Board of Directors of CVS for purposes of undertaking a fairness evaluation with
respect to the Transaction. We will receive a fee payable upon the rendering of this opinion. In addition, CVS has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may arise, out of our
engagement. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We are a securities firm engaged directly and through affiliates and related persons in a number of
investment banking, financial advisory and merchant banking activities. In the past </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">31 WEST 52ND STREET, 22ND FLOOR, NEW YORK, NY 10019 </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">PHONE: (212) 380-2650&nbsp;&nbsp;&nbsp;&nbsp;FAX: (212) 380-2651&nbsp;&nbsp;&nbsp;&nbsp;WWW.CENTERVIEWPARTNERS.COM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#969696">NEW&nbsp;&nbsp;YORK&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
LONDON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAN&nbsp;&nbsp;FRANCISCO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PALO&nbsp;
&nbsp;ALTO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LOS&nbsp;&nbsp;ANGELES </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">December
3, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
two years, we have not been engaged on a fee paying basis to provide financial advisory or other services to CVS or Aetna, and we have not received any compensation from CVS or Aetna during such
period. We may provide investment banking and other services to or with respect to CVS or Aetna or their respective affiliates in the future, for which we may receive compensation. In addition, David W. Dorman, Chairman of the Board of Directors of
CVS, is a partner in the ultimate general partner and the manager of Centerview Capital Technology Fund (Delaware), L.P. and Centerview Capital Technology <FONT STYLE="white-space:nowrap">Fund-A</FONT> (Delaware), L.P., together with a related
employee fund (collectively, &#147;Centerview Capital Technology&#148;), which are growth equity investment funds focused on the technology sector. Certain partners of Centerview Partners LLC are partners (either directly or indirectly) in the
ultimate general partner and the manager of Centerview Capital Technology, and serve on Centerview Capital Technology&#146;s investment committee. Centerview Partners LLC provides certain back office support to Centerview Capital Technology.
Mr.&nbsp;Dorman has no ownership interest in, and is not an employee of, Centerview Partners LLC. Certain (i)&nbsp;of our and our affiliates&#146; directors, officers, members and employees, or family members of such persons, (ii)&nbsp;of our
affiliates or related investment funds and (iii)&nbsp;investment funds or other persons in which any of the foregoing may have financial interests or with which they may <FONT STYLE="white-space:nowrap">co-invest,</FONT> may at any time acquire,
hold, sell or trade, in debt, equity and other securities or financial instruments (including derivatives, bank loans or other obligations) of, or investments in, CVS, Aetna or any of their respective affiliates, or any other party that may be
involved in the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In connection with this opinion, we have reviewed, among other things: (i)&nbsp;a draft of
the Agreement dated December&nbsp;3, 2017 (the &#147;Draft Agreement&#148;); (ii)&nbsp;Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Aetna for the years ended December&nbsp;31, 2016, December&nbsp;31, 2015 and
December&nbsp;31, 2014 and Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of CVS for the years ended December&nbsp;31, 2016, December&nbsp;31, 2015 and December&nbsp;31, 2014; (iii)&nbsp;certain interim reports to stockholders
and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Aetna and CVS; (iv)&nbsp;certain publicly available research analyst reports for Aetna and CVS; (v)&nbsp;certain other communications from Aetna and CVS to their
respective stockholders; (vi)&nbsp;certain internal information relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of Aetna, furnished to us by CVS for purposes of our analysis (collectively, the &#147;Aetna
Internal Data&#148;); (vii) certain financial forecasts, analyses and projections relating to Aetna prepared by the management of CVS and furnished to us by CVS for the purposes of our analysis (the &#147;CVS Aetna Forecasts&#148;); (viii) certain
internal information relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of CVS, including certain financial forecasts, analyses and projections relating to CVS, on both a standalone and <FONT
STYLE="white-space:nowrap">pro-forma</FONT> basis, prepared by the management of CVS and furnished to us by CVS for purposes of our analysis (the &#147;CVS Forecasts&#148;) (collectively, the &#147;CVS Internal Data&#148;); and (ix)&nbsp;and certain
cost savings and operating synergies projected by the management of CVS to result from the Transaction furnished to us by CVS for purposes of our analysis (the &#147;Synergies&#148;). We have participated in discussions with members of the senior
management and representatives of CVS regarding their assessment of the Aetna Internal Data, the CVS Aetna Forecasts, the CVS Internal Data (including, without limitation, the CVS Forecasts) and the Synergies, as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">December
3, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
appropriate, and the strategic rationale for the Transaction. In addition, we reviewed publicly available financial and stock market data, including valuation multiples, for Aetna and CVS and
compared that data with similar data for certain other companies, the securities of which are publicly traded, in lines of business that we deemed relevant. We also compared certain of the proposed financial terms of the Transaction with the
financial terms, to the extent publicly available, of certain other transactions that we deemed relevant and conducted such other financial studies and analyses and took into account such other information as we deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We have assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the
financial, legal, regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by us for purposes of this opinion and have, with your consent, relied upon such information as being complete and accurate. In that regard,
we have assumed, at your direction, that the Aetna Internal Data has been reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of Aetna as to the matters covered thereby and that the CVS
Internal Data (including, without limitation, the CVS Forecasts), the CVS Aetna Forecasts and the Synergies have been reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of CVS as to the
matters covered thereby, and we have relied, at your direction, on the Aetna Internal Data, the CVS Aetna Forecasts, the CVS Internal Data (including, without limitation, the CVS Forecasts) and the Synergies for purposes of our analysis and this
opinion. We express no view or opinion as to the Aetna Internal Data, the CVS Aetna Forecasts, the CVS Internal Data (including, without limitation, the CVS Forecasts), the Synergies or the assumptions on which they are based. In addition, at your
direction, we have not made any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> or otherwise) of Aetna or CVS, nor have we been furnished with
any such evaluation or appraisal, and we have not been asked to conduct, and did not conduct, a physical inspection of the properties or assets of Aetna or CVS. We are not actuaries and our services did not include any actuarial determination or
evaluation by us or any attempt to evaluate actuarial assumptions and we have relied on your actuaries with respect to reserve adequacy. In that regard, we have made no analysis of, and express no opinion as to, the adequacy of the loss and loss
adjustments expenses reserves, the future policy benefit reserves, the long-term business provision and claims outstanding or the embedded value of CVS and Aetna. We have assumed, at your direction, that the final executed Agreement will not differ
in any respect material to our analysis or this opinion from the Draft Agreement reviewed by us. We have also assumed, at your direction, that the Transaction will be consummated on the terms set forth in the Agreement and in accordance with all
applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be material to our analysis or this opinion, that the representations
and warranties made by CVS and Aetna in the Agreement are and will be true and correct in all respects material to our analysis and that, in the course of obtaining the necessary governmental, regulatory and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">December
3, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
other approvals, consents, releases and waivers for the Transaction, no delay, limitation, restriction, condition or other change, including any divestiture requirements or amendments or
modifications, will be imposed, the effect of which would be material to our analysis or this opinion. We have not evaluated and do not express any opinion as to the solvency or fair value of Aetna or CVS, or the ability of Aetna or CVS to pay their
respective obligations when they come due, or as to the impact of the Transaction on such matters, under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. We are not legal, regulatory, tax, actuarial or
accounting advisors, and we express no opinion as to any legal, regulatory, tax, actuarial or accounting matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We
express no view as to, and our opinion does not address, CVS&#146;s underlying business decision to proceed with or effect the Transaction, or the relative merits of the Transaction as compared to any alternative business strategies or transactions
that might be available to CVS or in which CVS might engage. This opinion is limited to and addresses only the fairness, from a financial point of view, as of the date hereof, to CVS of the Merger Consideration to be paid by CVS in the Merger
pursuant to the Agreement. We have not been asked to, nor do we express any view on, and our opinion does not address, any other term or aspect of the Agreement or the Transaction, including, without limitation, the structure or form of the
Transaction, or any other agreements or arrangements contemplated by the Agreement or entered into in connection with or otherwise contemplated by the Transaction, including, without limitation, the fairness of the Transaction or any other term or
aspect of the Transaction to, or any consideration to be received in connection therewith by, or the impact of the Transaction on, the holders of any class of securities, creditors or other constituencies of CVS or any other party. In addition, we
express no view or opinion as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors or employees of CVS or any party, or class of such persons
in connection with the Transaction, whether relative to the Merger Consideration to be paid by CVS in the Merger pursuant to the Agreement or otherwise. Our opinion, as expressed herein, relates in part to the relative values of Aetna and CVS. Our
opinion is necessarily based on financial, economic, monetary, currency, market and other conditions and circumstances as in effect on, and the information made available to us as of, the date hereof, and we do not have any obligation or
responsibility to update, revise or reaffirm this opinion based on circumstances, developments or events occurring after the date hereof. We express no view or opinion as to what the value of the CVS Shares actually will be when issued pursuant to
the Transaction or the prices at which the Aetna Shares or the CVS Shares will trade or otherwise be transferable at any time, including following the announcement or consummation of the Transaction. Our opinion does not constitute a recommendation
to any stockholder of CVS or any other person as to how such stockholder or other person should vote with respect to the Merger or otherwise act with respect to the Transaction or any other matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">December
3, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Our financial advisory services and the opinion expressed herein are provided
for the information and assistance of the Board of Directors of CVS (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transaction. The issuance of this opinion was approved
by the Centerview Partners LLC Fairness Opinion Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Based upon and subject to the foregoing, including the various
assumptions made, procedures followed, matters considered, and qualifications and limitations set forth herein, we are of the opinion, as of the date hereof, that the Merger Consideration to be paid by CVS in the Merger pursuant to the Agreement is
fair, from a financial point of view, to CVS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">/s/ Centerview Partners LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">CENTERVIEW PARTNERS LLC</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom482402_159"></A>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exculpation. </I>Section&nbsp;102(b)(7) of the Delaware General Corporation Law (&#147;DGCL&#148;) permits a corporation to provide in its
certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of
the director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;for unlawful payments of dividends or
unlawful stock repurchases, redemptions or other distributions, (iv)&nbsp;for any transaction from which the director derived an improper personal benefit; or (v)&nbsp;any act or omission before the adoption of such a provision in the certificate of
incorporation. CVS Health&#146;s amended and restated certificate of incorporation, as amended (&#147;CVS Health&#146;s certificate of incorporation&#148;), limits the personal liability of a director to CVS Health and its stockholders for monetary
damages for a breach of fiduciary duty as a director to the fullest extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification. </I>Section&nbsp;145 of
the DGCL provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent of the corporation. The
DGCL provides that Section&nbsp;145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Expenses, including attorneys&#146;
fees, incurred by any such person in defending any such action, suit or proceeding will be paid or reimbursed by CVS Health in advance of the final disposition of such action, suit or proceeding upon receipt by it of an undertaking of such person to
repay such expenses if it shall ultimately be determined that such person is not entitled to be indemnified by CVS Health. CVS Health&#146;s certificate of incorporation provides for indemnification of directors and officers of CVS Health against
liability they may incur in their capacities as such to the fullest extent permitted under the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Insurance. </I>CVS Health has in
effect directors and officers insurance, inclusive of fiduciary liability, with a combined limit of $475,000,000. CVS Health&#146;s employment practices liability insurance is subject to a limit of $125,000,000. The fiduciary liability and
employment practices liability insurance covers actions of directors and officers as well as other employees of CVS Health. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibits and Financial
Statement Schedules </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are included as exhibits to this Registration Statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement and Plan of Merger, dated as of December&nbsp;3, 2017, among CVS Health Corporation, Hudson Merger Sub Corp. and Aetna Inc. (included as Annex A to the joint proxy statement/prospectus which is part of this registration
statement and incorporated by reference herein) (schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> CVS Health agrees to furnish supplementally a copy of such schedules and
exhibits, or any section thereof, to the SEC upon request)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 1996; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective May&nbsp;13, 1998 (incorporated by reference to Exhibit 4.1A to the Registrant&#146;s Registration Statement
<FONT STYLE="white-space:nowrap">No.&nbsp;333-52055</FONT> on Form <FONT STYLE="white-space:nowrap">S-3/A</FONT> dated May&nbsp;18, 1998)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated
March&nbsp;22, 2007; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Merger dated May&nbsp;9, 2007 (incorporated by reference to Exhibit 3.1C to the Registrant&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> dated November&nbsp;1, 2007; Commission File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated
May&nbsp;13, 2010; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report On Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated
May&nbsp;10, 2012; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report On Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated
May&nbsp;13, 2013; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1G</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated
September&nbsp;3, 2014; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">By-laws</FONT> of the Registrant, as amended and restated (incorporated by reference to Exhibit 3.2 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated
January&nbsp;26, 2016)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Shearman&nbsp;&amp; Sterling LLP regarding the legality of the securities being issued*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bridge Facility Commitment Letter, dated December 3, 2017, among Barclays Bank PLC, Goldman Sachs Bank USA, Goldman Sachs Lending Partners LLC, Bank of America, N.A., Merrill Lynch, Pierce Fenner &amp; Smith Incorporated and CVS
Health Corporation (incorporated by reference to Exhibit 2.2 to the Registrant&#146;s Current Report on Form 8-K dated December 5, 2017)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joinder to Bridge Facility Commitment Letter, dated as of December 15, 2017, by and among Barclays Bank PLC, Goldman Sachs Bank USA, Goldman Sachs Lending Partners LLC, Bank of America, N.A., Merrill Lynch, Pierce, Fenner &amp;
Smith Incorporated, CVS Health Corporation and each of the Additional Commitment Parties party thereto (incorporated by reference to Exhibit 2.1 to the Registrant&#146;s Current Report on Form 8-K dated December 19, 2017)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Term Loan Agreement, dated as of December 15, 2017, by and among CVS Health Corporation, the lenders party thereto and Barclays Bank PLC, as administrative agent (incorporated by reference to Exhibit 10.1 to the Registrant&#146;s
Current Report on Form 8-K dated December 19, 2017)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to 364-Day Credit Agreement, dated as of December 15, 2017, among CVS Health Corporation, the lenders party thereto and The Bank of New York Mellon, as administrative agent (incorporated by reference to Exhibit 10.2
to the Registrant&#146;s Current Report on Form 8-K dated December 19, 2017)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Five Year Credit Agreement, dated as of December 15, 2017, among CVS Health Corporation, the lenders party thereto and The Bank of New York Mellon, as administrative agent (incorporated by reference to Exhibit
10.3 to the Registrant&#146;s Current Report on Form 8-K dated December 19, 2017)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Second Amended and Restated Credit Agreement, dated as of December 15, 2017, among CVS Health Corporation, the lenders party thereto and The Bank of New York Mellon, as administrative agent (incorporated by
reference to Exhibit 10.4 to the Registrant&#146;s Current Report on Form 8-K dated December 19, 2017)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Credit Agreement, dated as of December 15, 2017, among CVS Health Corporation, the lenders party thereto and The Bank of New York Mellon, as administrative agent (incorporated by reference to Exhibit 10.5 to the
Registrant&#146;s Current Report on Form 8-K dated December 19, 2017)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>15.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter from Ernst &amp; Young LLP regarding unaudited interim financial information</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>15.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter from KPMG LLP regarding unaudited interim financial information</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21 to the Registrant&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Shearman&nbsp;&amp; Sterling LLP (included as part of its opinion filed as Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Ernst&nbsp;&amp; Young LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of KPMG LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Powers of Attorney*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Proxy Card of CVS Health Corporation*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Proxy Card of Aetna Inc.*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Lazard Fr&egrave;res&nbsp;&amp; Co. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Allen&nbsp;&amp; Company LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Barclays Capital Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Goldman Sachs&nbsp;&amp; Co. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Centerview Partners LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Mark T. Bertolini*</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions of Lazard Fr&egrave;res&nbsp;&amp; Co. LLC, Allen&nbsp;&amp;
Company LLC, Barclays Capital Inc., Goldman Sachs&nbsp;&amp; Co. LLC and Centerview Partners LLC are included as Annexes B, C, D, E and F, respectively, to the joint proxy statement/prospectus which is part of this registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Undertakings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant
hereby undertakes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in
the effective registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such information in the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the termination of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining
liability under the Securities Act to any purchaser: each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed
in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part
of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale
prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(5) That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to
Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(6) That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this
registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form
with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other Items of the applicable form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(7) That every prospectus: (i)&nbsp;that is filed pursuant to paragraph (6)&nbsp;immediately preceding, or (ii)&nbsp;that purports to meet the
requirements of Section&nbsp;10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment
is effective, and that, for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) To respond to requests for information that is
incorporated by reference into the proxy statement/prospectus pursuant to Item&nbsp;4, 10(b), 11 or 13 of this Form <FONT STYLE="white-space:nowrap">S-4,</FONT> within one business day of receipt of such request, and to send the incorporated
documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved
therein, that was not the subject of and included in the registration statement when it became effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#ii482402_anxacov">Agreement and Plan of Merger, dated as of December&nbsp;
3, 2017, among CVS Health Corporation, Hudson Merger Sub Corp. and Aetna Inc. (included as Annex A to the joint proxy statement/prospectus which is part of this registration statement and incorporated by reference herein) (schedules and exhibits have been
omitted pursuant to Item 601(b)(2) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> CVS Health agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon request)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/0000950135-97-001475.txt">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Annual Report on Form
 <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 1996; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/0000950103-98-000528.txt">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective May&nbsp;
13, 1998 (incorporated by reference to Exhibit 4.1A to the Registrant&#146;s Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-52055</FONT> on Form <FONT STYLE="white-space:nowrap">S-3/A</FONT> dated May&nbsp;18,
1998)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000095010307000726/dp05079e_ex0301.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s
 Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated March&nbsp;22, 2007; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312507232584/dex31c.htm">Certificate of Merger dated May&nbsp;9, 2007 (incorporated by reference to Exhibit 3.1C to the Registrant&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> dated November&nbsp;1, 2007; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312510119116/dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current
Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated May&nbsp;13, 2010; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312512231727/d354761dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s
 Current Report On Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated May&nbsp;10, 2012; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000006480313000007/exhibit31certificateofamen.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the
 Registrant&#146;s Current Report On Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated May&nbsp;13, 2013; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1G</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000006480314000031/exhibit31certificateofamen.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the
 Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated September&nbsp;3, 2014; Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-01011)</FONT></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000006480316000070/exhibit32amendmenttoby-laws.htm"><FONT STYLE="white-space:nowrap">By-laws</FONT> of the Registrant, as amended and restated (incorporated by reference to Exhibit
 3.2 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated January&nbsp;26, 2016)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312518002957/d482402dex51.htm">Opinion of Shearman&nbsp;&amp; Sterling LLP regarding the legality of the securities being issued*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312517361800/d444237dex22.htm">Bridge Facility Commitment Letter, dated December 3, 2017, among Barclays Bank PLC, Goldman Sachs Bank USA, Goldman Sachs Lending Partners LLC,
 Bank of America, N.A., Merrill Lynch, Pierce Fenner &amp; Smith Incorporated and CVS Health Corporation (incorporated by reference to Exhibit 2.2 to the Registrant&#146;s Current Report on Form 8-K dated December 5, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312517373753/d508259dex21.htm">Joinder to Bridge Facility Commitment Letter, dated as of December 15, 2017, by and among Barclays Bank PLC, Goldman Sachs Bank USA, Goldman Sachs
 Lending Partners LLC, Bank of America, N.A., Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, CVS Health Corporation and each of the Additional Commitment Parties party thereto (incorporated by reference to Exhibit 2.1 to the
Registrant&#146;s Current Report on Form 8-K dated December 19, 2017) </A></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312517373753/d508259dex101.htm">Term Loan Agreement, dated as of December 15, 2017, by and among CVS Health Corporation, the lenders party thereto and Barclays Bank PLC, as administrative
agent (incorporated by reference to Exhibit 10.1 to the Registrant&#146;s Current Report on Form 8-K dated December 19, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312517373753/d508259dex102.htm">Amendment No. 1 to 364-Day Credit Agreement, dated as of December 15, 2017, among CVS Health Corporation, the lenders party thereto and The Bank
 of New York Mellon, as administrative agent (incorporated by reference to Exhibit 10.2 to the Registrant&#146;s Current Report on Form 8-K dated December 19, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312517373753/d508259dex103.htm">Amendment No. 1 to Five Year Credit Agreement, dated as of December 15, 2017, among CVS Health Corporation, the lenders party thereto and The Bank
 of New York Mellon, as administrative agent (incorporated by reference to Exhibit 10.3 to the Registrant&#146;s Current Report on Form 8-K dated December 19, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312517373753/d508259dex104.htm">Amendment No. 1 to Second Amended and Restated Credit Agreement, dated as of December 15, 2017, among CVS Health Corporation, the lenders party
 thereto and The Bank of New York Mellon, as administrative agent (incorporated by reference to Exhibit 10.4 to the Registrant&#146;s Current Report on Form 8-K dated December 19, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312517373753/d508259dex105.htm">Amendment No. 1 to Credit Agreement, dated as of December 15, 2017, among CVS Health Corporation, the lenders party thereto and The Bank of New
 York Mellon, as administrative agent (incorporated by reference to Exhibit 10.5 to the Registrant&#146;s Current Report on Form 8-K dated December 19, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>15.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d482402dex151.htm">Letter from Ernst &amp; Young LLP regarding unaudited interim financial information </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>15.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d482402dex152.htm">Letter from KPMG LLP regarding unaudited interim financial information </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000006480317000006/ex21subsidiariesoftheregis.htm">List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21 to the Registrant&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312518002957/d482402dex51.htm">Consent of Shearman&nbsp;&amp; Sterling LLP (included as part of its opinion filed as Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d482402dex232.htm">Consent of Ernst&nbsp;&amp; Young LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d482402dex233.htm">Consent of KPMG LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312518002957/d482402ds4.htm">Powers of Attorney* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312518021755/d482402dex991.htm">Form of Proxy Card of CVS Health Corporation* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312518021755/d482402dex992.htm">Form of Proxy Card of Aetna Inc.* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d482402dex993.htm">Consent of Lazard Fr&egrave;res&nbsp;&amp; Co. LLC </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d482402dex994.htm">Consent of Allen&nbsp;&amp; Company LLC </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d482402dex995.htm">Consent of Barclays Capital Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d482402dex996.htm">Consent of Goldman Sachs&nbsp;&amp; Co. LLC </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d482402dex997.htm">Consent of Centerview Partners LLC </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312518002957/d482402dex998.htm">Consent of Mark T. Bertolini* </A></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the Registrant, CVS Health Corporation, has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woonsocket, State of Rhode Island, on February&nbsp;9, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CVS Health Corporation</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David M. Denton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David M. Denton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Executive Vice President and Chief Financial Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Eva C. Boratto</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Executive Vice President&#151;Controller and Chief Accounting Officer (Principal Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">February&nbsp;9, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Richard M. Bracken</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C. David Brown II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alecia A. DeCoudreaux</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ David M. Denton</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">David M. Denton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Executive Vice President and Chief Financial Officer (Principal Financial Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Nancy-Ann</FONT> M. DeParle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">David W. Dorman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director and Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Anne M. Finucane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Larry J. Merlo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">President and Chief Executive Officer<BR>(Principal Executive Officer) and<BR>Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jean-Pierre Millon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mary L. Schapiro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;9, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Richard J. Swift</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">William C. Weldon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tony L. White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 9, 2018</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">*By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David M. Denton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David M. Denton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attorney-in-Fact </P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>2
<FILENAME>d482402dex151.htm
<DESCRIPTION>EX-15.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-15.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 15.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Letter re: Unaudited Interim Financial Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 8, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Shareholders </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health Corporation </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware of the incorporation by
reference in the Amendment No. 3 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> and the related Joint Proxy Statement/Prospectus of CVS Health Corporation for the registration of equity securities of our reports
dated May&nbsp;2, 2017, August&nbsp;8, 2017 and November&nbsp;6, 2017 relating to the unaudited condensed consolidated interim financial statements of CVS Health Corporation that are included in its Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
for the quarters ended, March&nbsp;31, 2017, June&nbsp;30, 2017 and September&nbsp;30, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:56%; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Ernst&nbsp;&amp; Young
LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>3
<FILENAME>d482402dex152.htm
<DESCRIPTION>EX-15.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-15.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 15.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 9, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford, Connecticut </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: Registration Statement No. 333-222412
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the subject registration statement, we acknowledge our awareness of the use therein of our reports dated May&nbsp;2, 2017, August&nbsp;3,
2017, and October&nbsp;31, 2017 related to our review of interim financial information of Aetna Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 436 under the Securities Act of
1933 (the&nbsp;Act), such reports are not considered part of a registration statement prepared or certified by an independent registered public accounting firm, or reports prepared or certified by an independent registered public accounting firm
within the meaning of Sections&nbsp;7 and 11 of the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford, Connecticut </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>d482402dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Independent Registered Public Accounting Firms&#148; in the Amendment&nbsp;3
to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> and the related Joint Proxy Statement/Prospectus of CVS Health Corporation for the registration of equity securities, and to the incorporation by reference therein of
our reports dated February&nbsp;9, 2017, with respect to the consolidated financial statements of CVS Health Corporation&nbsp;and the effectiveness of internal control over financial reporting of CVS Health Corporation&nbsp;incorporated by reference
in its Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2016, filed with the Securities and Exchange Commission, and included as Exhibit 13 to such Annual Report (Form <FONT
STYLE="white-space:nowrap">10-K).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:56%; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 8, 2018 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>5
<FILENAME>d482402dex233.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our reports dated February&nbsp;17, 2017, with respect to the consolidated balance sheets of Aetna Inc. and subsidiaries as of
December&nbsp;31, 2016 and 2015, and the related consolidated statements of income, comprehensive income, shareholders&#146; equity and cash flows for each of the years in the three-year period ended December&nbsp;31, 2016, the related financial
statement schedule, and the effectiveness of internal control over financial reporting as of December&nbsp;31, 2016, incorporated in the registration statement and in the related joint proxy statement/prospectus by reference and to the reference to
our firm under the heading &#147;Independent Registered Public Accounting Firms&#148; in the registration statement and in the related joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford, Connecticut </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 9, 2018 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>6
<FILENAME>d482402dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[LETTERHEAD OF LAZARD FRERES &amp; CO. LLC] </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">151 Farmington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford, Connecticut 06156 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of our opinion letter, dated December 3, 2017, to the Board of Directors of Aetna Inc. (&#147;Aetna&#148;) as Annex B to,
and reference to such opinion letter under the headings &#147;SUMMARY&#151;Opinions of Aetna&#146;s Financial Advisors&#151;Opinion of Lazard Fr&#232;res &amp; Co. LLC&#148; and &#147;AETNA PROPOSAL I: APPROVAL AND ADOPTION OF THE MERGER AGREEMENT
AND CVS HEALTH PROPOSAL I: APPROVAL OF THE STOCK ISSUANCE&#151;Opinions of Aetna&#146;s Financial Advisors&#151;Opinion of Lazard Fr&#232;res &amp; Co. LLC&#148; in, the joint proxy statement/prospectus relating to the proposed transaction involving
Aetna and CVS Health Corporation (&#147;CVS Health&#148;), which joint proxy statement/prospectus forms a part of the Registration Statement on Form S-4 of CVS Health (the &#147;Registration Statement&#148;). By giving such consent, we do not
thereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term &#147;expert&#148; as used in, or that we come within the category of persons whose consent is required under, the Securities
Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Lazard Fr&#232;res &amp; Co. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">LAZARD FRERES &amp; CO. LLC </P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 9, 2018 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>7
<FILENAME>d482402dex994.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[LETTERHEAD OF ALLEN&nbsp;&amp; COMPANY LLC] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aetna Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">151 Farmington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford, Connecticut 06156 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of our opinion letter, dated December&nbsp;3, 2017, to the Board of Directors of Aetna Inc. (&#147;Aetna&#148;) as Annex C
to, and reference to such opinion letter under the headings &#147;SUMMARY&#151;Opinions of Aetna&#146;s Financial Advisors&#151;Opinion of Allen&nbsp;&amp; Company LLC&#148; and &#147;AETNA PROPOSAL I: APPROVAL AND ADOPTION OF THE MERGER AGREEMENT
AND CVS HEALTH PROPOSAL I: APPROVAL OF THE STOCK ISSUANCE&#151;Opinions of Aetna&#146;s Financial Advisors&#151;Opinion of Allen&nbsp;&amp; Company LLC&#148; in, the joint proxy statement/prospectus relating to the proposed transaction involving
Aetna and CVS Health Corporation (&#147;CVS Health&#148;), which joint proxy statement/prospectus forms a part of the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of CVS Health (the &#147;Registration Statement&#148;).
By giving such consent, we do not thereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term &#147;expert&#148; as used in, or that we come within the category of persons whose consent is
required under, the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Allen&nbsp;&amp; Company LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">ALLEN&nbsp;&amp; COMPANY LLC </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 9, 2018 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>8
<FILENAME>d482402dex995.htm
<DESCRIPTION>EX-99.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.5 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g482402im.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>745 Seventh Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New&nbsp;York,&nbsp;NY&nbsp;10019</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>United
States</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 9, 2018 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF BARCLAYS CAPITAL INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
hereby consent to (i)&nbsp;the inclusion of our opinion letter, dated December&nbsp;3, 2017, to the Board of Directors of CVS Health Corporation (the &#147;Company&#148;), as an Annex to the joint prospectus/proxy statement that forms a part of
Amendment No. 3 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of the Company, as filed by the Company on February 9, 2018 (the &#147;Registration Statement&#148;), relating to the proposed business combination
transaction between the Company and Aetna Inc. and (ii)&nbsp;the references in the Registration Statement to such opinion and our firm in the Registration Statement under the headings &#147;Summary&#151;Opinions of CVS Health&#146;s Financial
Advisors&#148;, &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Background of the Merger&#148;, &#147;Aetna Proposal I: Approval and Adoption of the Merger
Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of Directors that CVS Health Stockholders Approve the Stock Issuance&#148;, &#147;Aetna
Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Opinions of CVS Health&#146;s Financial Advisors&#148; and &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement
and CVS Health Proposal I: Approval of the Stock Issuance&#151;Unaudited Prospective Financial Information&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In giving such consent, we do not admit
that we come within the category of persons whose consent is required under Section&nbsp;7 of the U.S. Securities Act of 1933, as amended, or the rules and regulations adopted by the U.S. Securities and Exchange Commission thereunder, nor do we
admit that we are experts with respect to any part of the Registration Statement within the meaning of the term &#147;experts&#148; as used in the U.S. Securities Act of 1933, as amended, or the rules and regulations of the U.S. Securities and
Exchange Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BARCLAYS CAPITAL INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Evan Matlin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Evan Matlin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>9
<FILENAME>d482402dex996.htm
<DESCRIPTION>EX-99.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.6 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g482402g88f83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 9, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board of
Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One CVS Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Woonsocket, Rhode Island 02895 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top">Amendment No. 3 to the Registration Statement on Form S-4 of </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CVS Health Corporation (File No. 333-222412), filed February 9, 2018 (the &#147;Registration Statement&#148;) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to our opinion letter,
dated December 3, 2017 (&#147;Opinion Letter&#148;), with respect to the fairness from a financial point of view of the Aggregate Consideration (as defined in the Opinion Letter) to be paid by CVS Health Corporation (the &#147;Company&#148;) for
each outstanding common share, par value $0.01 per share, of Aetna Inc. (&#147;Aetna&#148;) pursuant to the Agreement and Plan of Merger, dated as of December 3, 2017, by and among the Company, Hudson Merger Sub Corp. and Aetna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Opinion Letter is provided for the information and assistance of the Board of Directors of the Company in connection with its consideration of the
transaction contemplated therein. We understand that the Company has determined to include our opinion in the Registration Statement. In that regard, we hereby consent to the reference to our Opinion Letter under the captions
&#147;Summary&#151;Opinions of CVS Health&#146;s Financial Advisors&#148;, &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Background of the Merger&#148;,
&#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of Directors that CVS Health
Stockholders Approve the Stock Issuance&#148;, &#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Opinions of CVS Health&#146;s Financial Advisors&#148; and
&#147;Aetna Proposal I: Approval and Adoption of the Merger Agreement and CVS Health Proposal I: Approval of the Stock Issuance&#151;Unaudited Prospective Financial Information&#148; and to the inclusion of the foregoing opinion in the Joint Proxy
Statement/Prospectus included in the Registration Statement. Notwithstanding the foregoing, it is understood that our consent is being delivered solely in connection with the filing of the Registration Statement and that our Opinion Letter is not to
be used, circulated, quoted or otherwise referred to for any other purpose, nor is it to be filed with, included in or referred to, in whole or in part in any registration statement (including any subsequent amendments to the Registration
Statement), proxy statement or any other document, except in accordance with our prior written consent. In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section&nbsp;7 of the
Securities Act of 1933 or the rules and regulations of the Securities and Exchange Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Goldman Sachs &amp; Co. LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(GOLDMAN SACHS &amp; CO. LLC)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>10
<FILENAME>d482402dex997.htm
<DESCRIPTION>EX-99.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Centerview Partners LLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One CVS Drive
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Woonsocket, RI 02895 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of our opinion letter, dated December 3, 2017, to the Board of Directors of CVS Health Corporation (&#147;CVS
Health&#148;), as Annex F to, and reference to such opinion letter under the headings &#147;SUMMARY&#151;Opinions of CVS Health&#146;s Financial Advisors &#151;Opinion of Centerview Partners LLC&#148;, &#147;AETNA PROPOSAL I: APPROVAL AND ADOPTION
OF THE MERGER AGREEMENT AND CVS HEALTH PROPOSAL I: APPROVAL OF THE STOCK ISSUANCE &#151;Background of the Merger&#148;, &#147;AETNA PROPOSAL I: APPROVAL AND ADOPTION OF THE MERGER AGREEMENT AND CVS HEALTH PROPOSAL I: APPROVAL OF THE STOCK ISSUANCE
&#151;CVS Health&#146;s Reasons for the Merger; Recommendation of the CVS Health Board of Directors that CVS Health Stockholders Approve the Stock Issuance&#148;, &#147;AETNA PROPOSAL I: APPROVAL AND ADOPTION OF THE MERGER AGREEMENT AND CVS HEALTH
PROPOSAL I: APPROVAL OF THE STOCK ISSUANCE &#151;Opinions of CVS Health&#146;s Financial Advisors&#151;Opinion of Centerview Partners LLC&#148; and &#147;AETNA PROPOSAL I: APPROVAL AND ADOPTION OF THE MERGER AGREEMENT AND CVS HEALTH PROPOSAL I:
APPROVAL OF THE STOCK ISSUANCE &#151;Unaudited Prospective Financial Information&#148; in the proxy statement/prospectus relating to the proposed transaction involving CVS Health and Aetna Inc. (&#147;Aetna&#148;), which proxy statement/prospectus
forms a part of Amendment No. 3 to the Registration Statement on Form S-4 of CVS Health (the &#147;Registration Statement&#148;). In giving such consent, we do not admit that we come within the category of persons whose consent is required under
Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder nor do we hereby admit that we are experts with respect to any part of the Registration Statement
within the meaning of the term &#147;experts&#148; as used in the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Centerview Partners LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CENTERVIEW PARTNERS LLC</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 9, 2018 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g482402g04o86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g04o86.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1<>4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             'D   'C          $                          0
M           !XP   'D                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   'D     4F=H=&QO;F<   'C    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   !Y
M     %)G:'1L;VYG   !XP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     3A"24T$#      ,IP    $   "@    *    >
M $L    ,BP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ * "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M  %^24DJ  @    ,   ! P !    \P0   $! P !    /@$   (! P #
MG@    8! P !     @   !(! P !     0   !4! P !     P   !H!!0 !
M    I    !L!!0 !    K    "@! P !     @   #$! @ >    M    #(!
M @ 4    T@   &F'!  !    Z    " !   (  @ "   "3T $"<    )/0 0
M)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ,CHR.2 P
M-SHT-SHS.0    0  ) '  0    P,C(Q : #  $   #__P   J $  $   #C
M 0   Z $  $   !Y            !@ # 0,  0    8    : 04  0   &X!
M   ; 04  0   '8!   H 0,  0    (    ! @0  0   'X!   " @0  0
M            2     $   !(     0   #A"24T#_0      "
M_^$!@$E)*@ (    #    0,  0   /,$   ! 0,  0   #X!   " 0,  P
M )X    & 0,  0    (    2 0,  0         5 0,  0    ,    : 04
M 0   *0    ; 04  0   *P    H 0,  0    (    Q 0( '@   +0    R
M 0( %    -(   !IAP0  0   .@    @ 0  "  (  @ P ,   $   #  P
M 0   $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,3(Z,CD@
M,#<Z-#<Z,SD    $  "0!P $    ,#(R,0&@ P !    __\   *@!  !
MXP$   .@!  !    >0            8  P$#  $    &    &@$%  $   !N
M 0  &P$%  $   !V 0  * $#  $    "     0($  $   !^ 0   @($  $
M             , #   !    P ,   $   #_X4%-:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O
M8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q
M(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @
M/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R
M+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T
M179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @
M(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#I"-S,P.3-&.3-$14-%-S$Q
M.3$X.$)"138Q,$1"0S8P-3PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#I".3,P.3-&.3-$14-%-S$Q.3$X
M.$)"138Q,$1"0S8P-3PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#XX.#,S1$0R034Y0T0W-44Y-C%&-S4S
M1C-$-C8W-3 U-3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z0C8S,#DS1CDS1$5#13<Q,3DQ.#A"0D4V,3!$0D,V,#4\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,3<M,3(M,CE4,#<Z-#<Z,S0K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@:6UA9V4O:G!E
M9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV
M97)T960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D(W,S Y,T8Y,T1%0T4W,3$Y,3@X0D)%
M-C$P1$)#-C U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#$W+3$R+3(Y5# W.C0W.C,T*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z0C@S,#DS1CDS1$5#13<Q,3DQ.#A"0D4V,3!$0D,V,#4\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,3<M,3(M,CE4,#<Z-#<Z,SDK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV
M97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D(Y,S Y,T8Y,T1%0T4W,3$Y,3@X0D)%
M-C$P1$)#-C U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#$W+3$R+3(Y5# W.C0W.C,Y*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED
M.D(X,S Y,T8Y,T1%0T4W,3$Y,3@X0D)%-C$P1$)#-C U/"]S=%)E9CII;G-T
M86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED
M.D(W,S Y,T8Y,T1%0T4W,3$Y,3@X0D)%-C$P1$)#-C U/"]S=%)E9CID;V-U
M;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/C@X,S-$1#)!-3E#1#<U13DV,48W-3-&,T0V-C<U,#4U/"]S=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R
M;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q-RTQ,BTR.50P
M-SHP.3HT-RLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z
M36]D:69Y1&%T93XR,#$W+3$R+3(Y5# W.C0W.C,Y*S U.C,P/"]X;7 Z36]D
M:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C Q-RTQ,BTR
M.50P-SHT-SHS.2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1"  = '0# 1$  A$! Q$!_\0 '0    <! 0$
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MC%1NX3%76O(>GW+VD:EX?(N07I+Y&3\ZYKS^1,\K#M,G1=,2W"O.G_5V72#
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M61"G0=@OR=&MTFFVWDP&H4!AJUP_R^L->(*'!KH/!%'K5^;JR*OR9J,*ZEI
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5[P>EXO!Z7B\'I>+P>EXO!Z7B\__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g482402g09x94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g09x94.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1*:4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      $!    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    / %@ 90!R &\ >  @ #( ,P @ $, ;P!L &\ <@
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@              ^   !P<          0
M                   !              <'    ^
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG    ^     !29VAT;&]N9P
M!P<    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   /@     4F=H=&QO;F<   <'     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3004       $     CA"24T$#      (]0    $   "@    %@
M >   "E    (V0 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ %@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M,;[3L^R?Y)]7_D[^9_3_ &_[!_WH_9EX@DDI_]D .$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     8I)22H "     X   $$  $    F!P   0$$  $   #W     @$#  ,
M  "V     P$#  $    !    !@$#  $    "    $@$#  $    !    %0$#
M  $    #    &@$%  $   "\    &P$%  $   #$    ' $#  $    !
M* $#  $    "    ,0$" !X   #,    ,@$" !0   #J    :8<$  $
M 0  + $   @ "  ( ( EE@ 0)P  @"66 ! G  !!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C R.C X(#$U.C(Y.C,U     P !H ,  0
M /__   "H 0  0    <'   #H 0  0   /@            &  ,! P !
M!@   !H!!0 !    >@$  !L!!0 !    @@$  "@! P !     @    $"!  !
M    B@$   ("!  !              !(     0   $@    !    .$))30/]
M       (          #_X0&,24DJ  @    .   !!  !    )@<   $!!  !
M    ]P    (! P #    M@    ,! P !     0    8! P !     @   !(!
M P !         !4! P !     P   !H!!0 !    O    !L!!0 !    Q
M !P! P !     0   "@! P !     @   #$! @ >    S    #(! @ 4
MZ@   &F'!  !      $  "P!   (  @ " #  P   0   , #   !    061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP,CHP." Q-3HR.3HS
M-0    ,  : #  $   #__P   J $  $    '!P   Z $  $   #X
M    !@ # 0,  0    8    : 04  0   'H!   ; 04  0   ((!   H 0,
M 0    (    ! @0  0   (H!   " @0  0              P ,   $   #
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M"O_$ "<0  (" P$  @$%  ,!      4&! <" P@!  D4$A,5%B$1%R(8_]H
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M%=N_4^M03LR ;=AO'ZV&;0J#3+^["/-FO7_(KCP\,BZ?PQRUL0HMKV[\=O\
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g482402g11n44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g11n44.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5_&:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^3VMA<&E?4&%R=&YE<G,@;&]G;SPO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z
M=&ET;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM
M;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM
M9R\B/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A
M=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @
M/'AM<#I#<F5A=&5$871E/C(P,38M,#<M,314,3@Z,#DZ,SDK,#4Z,S \+WAM
M<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C Q-BTP
M-RTQ-%0Q.#HP.3HS.2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,38M,#<M,314,3@Z,#DZ,SDK,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*
M(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ,3(\+WAM<$=);6<Z:&5I9VAT/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM
M9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y
M:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-
M=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!
M0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'
M0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/
M1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E'
M:%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!8T%%04%W
M15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!
M449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%1
M04-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!
M1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2
M>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=:
M:$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR
M:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K
M0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!
M04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:
M17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S
M4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K
M4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D
M;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM
M<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!
M.54T<7!85C%A,FQT2F,S57E7.70F(WA!.T-P96%E5F=I26\S3$UZ14%!94IW
M13!O1$-V3B\U:#99=6IK*U=V3F9L=3)V;G%F<E=P6&MB=W!'05%Z2VM49W5W
M4&EA9E!+-5I",$DF(WA!.V)9-#DY=UAZ-S5O.'HK5G)X;F9Z6BMC;7$V,%=C
M*W)P6&PV,&4R9V].<4DQ4F)T.'E0=C8U5V0O4#AE9$)Y26=J:TM92F,K6F9Y
M0W,F(WA!.W R87DX<6%Z-6<R,FLQ9E5H86QI0E-R0WI1;B]!26(W<UEI=5A,
M.&542W!(<71S4'IJ,&I38FHQ9$$X:#9,675$5D=M92]U5T<Y9G0F(WA!.T<T
M:C,R>5!H-S)F,"]R5'=N=E R375G+S5Y."].13-A>E-7*VQT1'EQ,7-)2E%P
M6"M53C9P8V9F:VIK:W@O3'AF44@U5F9N;F]0;GHF(WA!.VI:3EIZ-E9R6$AK
M8E-51C1P04%72FAN0V=(644P64MF0W53>#5X23$Q8V9*9TUD*VE.+U!"+TYA
M9FPY9$XU5T8V9%DY840P=C!A2E<F(WA!.W5/2'%$;GA%44PP<#%X,48X3WDT
M2S1T,WIR13,O3U-42T<O-3)I:#A294$O8V0X,34X6"ML.7)N9G5V-E R274S
M:"\U>5)K<E$K6D(F(WA!.U1R>F4U5'(O04MX1T-S,SE,-U4O=78V4#)0<6)Y
M94Y22&Q,4D)Q6F1T4T9H82]85VQ02U%Z*VEV<48R,W$S3W14;3%X6'=I*V1/
M='DF(WA!.U9X1W4Y3CAM=V5$+T%*.69M<G%&:G%54&QR>3EE>5=K.7)36%4W
M=3-C;S1D:#A%05IA2%I4>6%H-V=D:FUP,2MQ25!$12LY,D]K,#0F(WA!.TDT
M<$(U4W8U:V5F+T%0<5ET4B\V4UIF*V%S,6@Q5U@K8V9M-3-G43=G;EAL9GI,
M*UHS;4Q7-U133$18.5%A-'5N-#AJ8U,X555B=3<F(WA!.V(O6E9D>FMS5V).
M:VM):5(S67IX-#12<V=0<7943$IR3%0W93!A95<V84-.56$U;EEV3$E13C-D
M:C-9-S4P<TDP04]B<$I3<S(X-B\F(WA!.U!0>G!E-D9O.6YP*VU83#(R;S,X
M:&1P;VU+>4I"1G5A16)J:S5!*U%/87IT5%5N2$5#2G%28S-164)/4DI'=V5,
M<"M94&YK+SE,-BLF(WA!.R]W0U(X;CEC,%@U>DXO3VPX,V(O04IB2"].2'E:
M4#A!;"\X06U6-6AT+TYD:"ML.55U3')4<#,Y0S13959N4E),.$MV.%).3TQ5
M3F8F(WA!.T1-;E(V-EEY:FEK5$9P,4]K9UE(:$%"9E(K9%,X*S=&5D<Y6FMS
M<FAL3D=73GEP2%5%2V-J32MK<V]C=RM8+SAE9610*W(S92]W1$DF(WA!.SDO
M-C5X=C4S3B]0;#@S<"]Y,E K85!K-R](;FY4+W$Y,W8X07E09BMU4#4S3B]0
M;#@Q+TQ9+S5O*U1V.&5E9% K<C-E+W=$23DO-C0F(WA!.R]N8S,X*UAZ6#AT
M:B]M:C5,:R]-1'IS:'%.8G9#96YX4W-W*S5Q-&I7-78U>"MA4'EU3"MA13!S
M4'IF."LR:D1L9G)D2418,#4T;S(F(WA!.T(K8DM&9CA!-&),;V1Q6C0Y8CDW
M5DQ166HP<#9,-4\O3W943E9N:G-D86A85')U46A5=49.8F1M4%DX=FEJ<C<Q
M2'9M,C!V83!:;F@F(WA!.VU/12]9-B]59&Y3:4QJ=5!T4G8U,&%V<65L*U9R
M5S0P,C=L=$IN=F\T,FQH8V]X47=Y:W)59'%Q37,W5WEY:&E":6$Y6#9#,3EN
M630F(WA!.WEY15-&-V9Q94PO-#@X-F8Y6'4Y+W=#4C<O,7IN+WIU8BMF3#5U
M-B],62\U;RM4=CAE9610*W(S92\X04DY+S8T+VYC,S@K6'I8.'0F(WA!.VHO
M;6HU4'%'-W4W87IT2G)U-VQ70S%T;S)L;FUK259%:E%&;5II96=50W!Z<WEA
M95=!=#AN*V10*V-W=%%U3E5V8DA29$(P*SDX=3@F(WA!.W94:$]P<$Q+.#9O
M9C=X-'<V2T%X1E95:6\K955Y2E!D5&QX=T%D9#!Q,#,O04IY.#AX5T,O=T-J
M*U9.1F=C1&='=&\U65)W,E!'9UDF(WA!.S=B94]!5T\W-69T6DA#1#%+3&(O
M04IZ0W8W9RMP9CA!:S-43&TT3WAL3'179S9$-#!C+VIH,U!/=FMJ=U(P2E)-
M2"]/6#)K<D5O;B\F(WA!.T%#.7,U2F0K5'@S4TEP,S)O<'1(23(Y.$ER=4-$
M:%!E<%AF+T%$;#-B4V)76&M,5#1$43=Z5$-B-'9(-%E)9'9B0DMU9T-2:#=Y
M54XF(WA!.R]W0D1E*V4P:4U/;F%*;SEL1'9X55)4='AR,T%%>4Q7=2]4265*
M261Y9GDX5#-P8F-F.$%/5#,U=C-*2FHQ2S-T2SEO8E-!,"]W0U(F(WA!.W%Y
M-59,3%!V6FI"1'544G8K8VAF3D=P+VPQ<4]H-FQQ13A0;4I:65I,1%=,5FI"
M2DQ&-F]-<U5J43A/2D$V16)&9&HO04I51&YL=S F(WA!.VM904I8,&5A>F$Q
M<DXP,TLV=C=I9&EA:WEY=35Q0E%F84HW6FEY8VM"=W5B:#$T=DLW2V5O3$5J
M2VEY1#=R+TQR+WE8,VQJ+T%,6DXF(WA!.VHO,41*;3EW+U)(,T(P*U@V>C<P
M2BM:=FYQ,CAM*U9B:E5M-'1F4R]U3D]G4#=C-T$P2D@X<69A8C=U*U8V;DXT
M8TPV.4=71$9X>7(F(WA!.V\K3TQI-W5B>39L=3=Q4G!R;31D<%IP5TY76C-0
M2FU0=5-C-7E2<S)89&=5=51+:7IF55@U1R]L-2]H,U$O,'AQ15A(5TY544YX
M668F(WA!.T9$8FXT:VHY;6(W5&913S)B+W,O4SA%94DO569U9%)R32]%945C
M9SE0>EEU12M59GI4.'IF-&@X-U@Y>D<O2S!T;2MQ5V4Y4C9C2DDF(WA!.TQ$
M,F0K5&94;DIA+TXT;55N;TYN;W1*:31-64A6:3AE64QL26A-1$HY5F9L,35I
M+U0O;$=X=FYB;&-O=F]89F,K<D8X2DHO,6A2=G F(WA!.WIS9$1N.%A%1#$U
M1C5R5C1U1$E2,%I*;5<T>6AQ2"LX1GHO>&EF.$$T:6-H:RMK*S5L1#9G*U%S
M-%(V,3)+=7A6,DMU>%8R2W-R,40F(WA!.WIP8V%N-41G,$,K9'!B;7=V27!,
M5U9T>6)C4E-Q5DHO>4-W03EJ-UIM>C%:;F='3UA/371V9%)C5T]N16-V1T]O
M*S-::6U95&Q/>%8F(WA!.SE.95I0>E0O04,Y.',V;VUL-C=R=')986<V3$E,
M959J>4-U84M7-&=H83 O87IV1$U"-4]/3U)&:&E'<6%,+WIJ4C4R2$]E5'DO
M8S,F(WA!.T5L9C-T<F-W,G1Y4V4W1T(T<%-D='5745!"-W9S8D%C9S<R3S-V
M.$%Z:#4K5C$W2#8K;F%L<61Q<VQ':DUC,$4P5E!B;$574"]"-%(F(WA!.T1Z
M5#0U-FA$84HO>FAN-4IT3E13-#%45C=Z53=&2VLR4$9B8T]A:6=E4D-8-#!R
M54Q1*S1W0T(V;%1Q1#!$,6I44'EL+TQ$5$Q95S$F(WA!.W U5S!S4G(S:W19
M<&Y0.$%R4U-Q-W0Y2GE8:'@W;6\U2F0V5RM:=GE(+TMJ>D1!,&0Q-65T8E-9
M:6E85VYO=&Y+<#=.5T5+<D5F-6$F(WA!.VM91&I(=51(3$ED6&@R<V8X-&0V
M<&%88SAT;#5M<S P<TU046MV:V5/44$Y;C0Q4W1D<6<W*T$V6E1,1V9*>4DV
M9TAO:S<O.#0R5%(F(WA!.T%Q=FYB>3A:1DY#<C-*4VQ/=&1M+U9L2F@U>"MB
M64TS:U53=B]/375V2VY-*V%.0C15-6-V<DUL2V1A,3E026Y#92M0>E0T-#=I
M="\F(WA!.S551DAB>#AR>GIZ-6-G-C!R9&EL0E1U=U1+>F<O<%(K8DQX+S9-
M=FML;R],-WE00V5&>BM91VY#445I:T9T9'IR468U87)42VIJ:B\F(WA!.T%$
M:#ER6C1K=C5P*W@Y8V53-&)7,3AL-D9$0F-R9%=S1VTR:5)89T)26EDP9U%,
M249B-&Q$06-Q2'!M,WAB44AU9%AK,VMF92MC9GHF(WA!.U4X,GAE8W1E839J
M,')63')48D941%E&1SE+0VA9,6PT;4-6:C9T069T2V%52&).4'%C=FE3=6I1
M9'!G>#A!<7AB>GDV4492=W1O8EDF(WA!.TQU47-P6GHQ,EE.23(K,UI2;41*
M>6<Y2"])=CAU>C5K,3,Y3%@X6$Q29$MD5UE-2W).8T0T:VDS,DE8-U0O45 R
M<WET1'!V16QX2#8F(WA!.U$T,G)Z.$5A2$UV<51/9V1/>%@X>B]-+RM(4$ID
M+V92=G=U-58K<E=21W@Y86%Q9W(W;W9*+V]Z1C%U8G<X4E!8:TA),'5,:FU"
M,&8F(WA!.TII6GE"96E#=DAK5U-)5$%Y970O:T@U:"MR-G1D-DA+,S=U*U0Q
M<F-(+V9S42M)1"]7:C-0*W)M-3='>C%-=U X5')/,#A6>$5U-3<F(WA!.VYN
M4G5K54Y1+W="-$QN+VI%+SA!>$4U1$HY2CEZ2T@Q0CAH6G=J,7)S5F4S+VQX
M*UA(:WI74$IM;F%J<4]N979E>BMT-G-V<E1P6&@F(WA!.U!):2]#:VER.6Q1
M3FAN4C9$45EC;4=-<%)S;2MP-WHU=6PQ97)Y47E'351T.$\U4')R.&UF244P
M9D=/>6MT;3,K3TME56XO:V\P9R\F(WA!.T1-;5A:3T$X:%AX3%)(=$A+3W0O
M0C5**UEV-654*U5R=4HT<%1C-EID16DS;5E!3W),=55E;3%A9$-/=6%06&%%
M-$-+,VE88F%45FHF(WA!.TM/-E%98FUV8W0R2W5X5C)+=G)B5TY!,%!7-U4R
M;7-A9F)A:F%M=C=M-FE36DXO04]'<&YE;4E03C5%4TDU4$0O3R\O041H.35+
M,5HF(WA!.S-U9DQ&-4QO1GDR-71M0G5R56XR5C)75DLO-C5(=&M/1'5B-#9G
M.55&*U90+T],5W-E52]..6QR97,V-49D5V1G+W)X,DYP-GE#4UHF(WA!.U(K
M-TUH2E%C55E"<6(Q<'9T:U)J<S)A5%!/0TM$-DQY-7AN67$W1E5V.'<V0G!F
M;4123'I29%9H12MN,S!::6YJ4%=H,T)5.6U59TTF(WA!.W W2&9)>6E#2TM9
M>4E.:#@W-G0K5F8X07IJ2G!M<GIA5F9E6DQU=W8W6B]3=4Q:<'=/1#EF:5IO
M1TAF>'!M2DM%3&]K+VHT3UE-;5$F(WA!.VDV0VQ**U<O+T],.%%$;GIJ8T91
M86-5=6]8<EAX0S(W3FM$:GAF>FHK4&=K6DUV9"M0;718>34O>FEP66MT3#5G
M=F)Z:C!J<D\Y5%0F(WA!.V]$1&)P*W9).$](=E T*T1,:7ID=R](>%).=#5Z
M+S5X:#!Q44Y:*U=B;3A+2%EY4D=D5V]F-6)Q-&]A*S1W94IG2#A*+TAX6&=Z
M2'$F(WA!.WIF>G(K96UH95=.13!3,S!R4R]89E9.3VAU;W)&2F9Q;W,W86%*
M5$-P.4I7;V5*;T91:6Q/=E1,8S)R14%!0GI(>6%S96U-:6)0278F(WA!.T%F
M369N0F1E=5=U2DY,9VAN66QJ3S%X9C--<'(T=&,S17DO.$QM<'DU3TQP.2\V
M4S=(2$1H-B]C:"],2&PO579-974R;6HV96=A-G8F(WA!.TA#2V%55D9'-T\Q
M3VEO;TI/5E%X;6-H16178S5I27-V=$1Y=#5A,#=Y,6].<&\R;G)30S%3:&,O
M86MC-W9),RM5>F(O04YM9$QI>$,F(WA!.T5214]J>5I$3U9L3F-S65!N;B]N
M269Z4CED.'=7=6=13E=$5$4Y5S1!-WIZ045!+S9S9$MF-GAZ;BLQ<S%Y14(P
M9'@R9FEQ4$8S=DLF(WA!.T5Z5$8R45HO*UAF:V\V+V]F;6$X6D]45V1N>',O
M2#9X>3E98V9F:D1X+S)76C)J,'9I46UE-&)E+VXK:'AT4FXT2E)(95=(<&UU
M8S$F(WA!.TY.1#%3-#!R5F)457)F.$%V<E-62E9(63A457%F6FAS8VQI>4=%
M:$ED1TTT0U5413E8,6Y96'1V9C).=F4R>F-R935J4V%*=D9854TF(WA!.U!W
M3V1X0UEL15-(279+>FE9:V<Y2&%H+W9"8R\X66XO04]);D)K*VLK-5EF54AY
M1FY#4%=U>%8Y2B]L1"]W0U,W,&XO04M/4"MO;5@F(WA!.T]V-TPO=T%8:CAF
M=DQZ;78O=G!F1#=G>DA-.7<S;4@U*UAT<VYL>7=S;4E.,4YD:6%.93133TXQ
M6G9V:U5:<'4R<&IW>$AR8G,K>30F(WA!.VYJ2C95.$MZ;6YE3WA6,DMU>%8W
M9G$Q:"]W035(6&MK;7%A6G%M:6%9=3=7+VPR4THU=T5'-G).9#AA;5-M>F-+
M3%AP-#4S1E1/+S0F(WA!.RLU-6-(2'EE82M9=BMC<&9Z3CAO6%5U:BMA+TIL
M=&$V>6]R2$E*6EDT2$A4;6<O9D-22SDQ;'A%-4UX:&ED=UAQ9C5!+VU:<G8U
M:2LF(WA!.U5R+UAD66=T<F%A1%5:3$M'0S!6,5%2>'=1>6=N,4AK67-4364O
M,%I:16YQ,5I90TIO4%1-:S%/>%8R2W5X5CA8+SA!3U56;D9B+VTF(WA!.S=D
M>7 Y<3=T3%=A5"]7169P9CA!15EH;4)N*V]U=S O,$(U8DAM35A)0TIJ>7-S
M9VE9.'%,24DV839U8G%26DQI4G!:1E-/2E=9,4DF(WA!.U-&0DA'=GE614-J
M,GE%:7E!6$IL6EI".5%F.$%/3UAK>E0W1'EY9DUP9$QJ5615-5)Q>6M(,$E9
M,W V6'-Z379*=CA!635T*WHX244F(WA!.V5,<5A783-+5$QH-D(W0FUX8TI#
M879Q9')P5VPS97!85&-B97IH9655+S5+2U=O2SEZ4V=Y1U-9:D5Y4%)L0TIK
M44(Q9D=E<39P9&$F(WA!.W1Q=#-Q9#!A,T8U33@X=FA6,DIO4%ED0FY(-4IM
M56I).5AP25)%44%/:6EM56QS1#9K+TIF4E P6#5"<VYD94TR;VQR,E-V:$IT
M2"\F(WA!.T%-:S%5-3%86FU,9W=J>C-D1')S;D9K4&QS.$<X-39**VA03FUP
M-EE&-'AW5'-90B]W05939DA(+W=!27=Z;718:3A02DM0;3=Z5#4F(WA!.T]/
M06ML4UII=#<S-SAJ9DU0,3=Y,TQP37(Q;C!Y5#DR1#$Y0U5L;"MD2#5$-W,V
M9G-F4'A9*T$X-"]C-DQT3$9W>C1V-7HP3%50.$$F(WA!.V5#-2\T>% O04U2
M3V)42CE*.7IR-&952'E&;D-05W5X5FYF;&XX,W1D.'8V2F)A4F$R9'),0F)C
M*T5K;VLU;C%*1VM.94QG9%@X33(F(WA!.V5N-U5N:6=)04-G-$]B45%Y4TUI
M5'5M12]W0V98;70T>7-6;EI23V8Y,F-*5TDK44UL4'9Y,EAB5U5J65)91'-V
M2#-L9VUT-CEQ,G4F(WA!.UAZ6#)Q6$Q83G=W;T=A9T-R+TMQ:6EQ4%E:<DTR
M86536$9),EA/>#1O=T921D),.'%:<GA&25EM;$-K>&]Y;WHY9WI!;%(Y4$4T
M83(F(WA!.W1B5UE&9&ER,W)Z0BMA+VUH3E4Q0S X;F53<G)Z5F%A4$DP1W!A
M:70Q1EIX0S14*SAH='A)<VI81%)N-%@T1%IT<S=R:C4P3U1Y;W@F(WA!.VET
M>E9P0F%E9F9Y9B]/97=B>7(U:71M,#=81EEO=6QA9T)"95%Z+UIB-G)-97)G
M:C=)*TDP*TI+64Q%=6),9VQ$8V-M4R]K-2M5.'8F(WA!.S5A,FUS859$<6@Q
M3%-B,C57-W-226YP>7A-53E/4EA!2E)I5E)0:5=L861":V]X235S8VU4:7 V
M2FLR<#)+=7A6,DMV;E@X=U!Z2R\F(WA!.S5X,W5F3C)O3C5G.'8S=7-A>EIU
M8D=E-FI53D<S,61I:$5D8FU.2T%G-SA2;4A/8T-D=V9X.%A,:$1)0G-72EAF
M;FXO04IX;V0O.$$F(WA!.U(O270K-DU0:4Q43D%19EE2,U0O04LX<6Q,2#-(
M-71O:&LW,&]V.$%Z0BM1:W@U5V9L5%9R8VLQ2TQF04M"5'-:1$]C<&Q+2&-F
M;3(F(WA!.WAJ:S=X.&M.2#5G+TM/24U%.&]8.7AV.$)M,55O9CA!:VY"+UA+
M>DM(8V9N*WAL=WHW>#AV,G-I.'HS6&M047!.3C4O;#5'='9Q9&@F(WA!.V)A
M:&%Z4'%T*S1D3&U)4V)%1TU646MO=W Q1F5H=S540TYE:FU/.'-C66Q++U8Y
M9UEH<4]Q*U9B=5)M=$Y#9E1L3F5#45AK:V=".2\F(WA!.UA356MF4U!N-#1K
M-5)04VY):4-/<D]F>4\O36ME5G1D3VPS,' O44=P=49K6G1H1$]F:%-A;%-!
M1#EL+V%H+UIY+U(V;G<U569P3%0F(WA!.W%C2$A'>'I$-G)"0D92=40P3V(U
M,41Y4"]N27)Z4CE3.'4R,F=1=E,T,5-4,4QG03=I,VA)3D0O04LP;D@W:FUQ
M-U9Z5D%22%8R1V<F(WA!.W@S3&DW;GIW;6,X6&-*;F]E;51A<'$Q;'!S4#DW
M951X=TEF07E-1G%F;%A(2$%Z:TEJ<59L3&AI5#-0<W4Q=&]B5S%H=%E&-'=W
M27,F(WA!.U53*T-O07%J-VAN87AI04M$>D5J6G-V15 K8V=D13E(5V10,6E.
M84IE4D=#66HO9FM*<4-F;6HP+W=":FY09',T<6U*.3=U97I-;'@F(WA!.TUE
M-359;6%2,G)-9GET.'AF;U1Z:&%34TYX=&)W+U9,;F5G-'EK0E=0*W$O12],
M33-S-U T955(;V1N1C%U3&IX:V12=2MJ.5$O,V<F(WA!.W5F.$%J12\O04)%
M-3%U5#94-VYN26952'E&;D-05W5X5C)+=7A6,DMO>E-D2#%,5C<V3W@P-C-A
M-75:1#A+24]G-VQJ,%5$=51L;4PF(WA!.T9,2DQH:4Q,1V5334):3D(V5#4X
M.&PR+VQ8.'1,2S%$0U<K;C%'2U,K;DA2;CE#64)6<G9X46)$-E0S>F(V,U-$
M1'!W3W!K3"M29&(F(WA!.W!T46-U66YP=S=F35!+<S!J=$A9<2MW:VIJ:E5Q
M:6A&2DQ%2T%"5FE763=D>515-3-Z>41!=GI(+TI$>48U.414-G!A1S$Q96Q)
M.5@F(WA!.W-Y27)G54AW.#EI<V=(*U=$-T5:0U5!5WE'57AE9#(O:T@O;DI,
M>4YQ1G,S;#=Z1W9M+WDO8GE*>3!U.&M33V530E-+>&-R=FU)+V@F(WA!.S)"
M4V)B=S=:1&AK3U1B>'=L>C)E*U=&>3DQ6E<Y>3A%;'$X,&%Y3F)404-337-!
M4VIH4W<U3#!.0U)L;TYH>'E+5CA+2%EQ=W8X,E F(WA!.TUV;6924$MS<2M6
M=$MU=%4X=U@Q8F5Y1G1#.'%W16HT<#57031R=T(K14XQ8C)">7),26=B3FU+
M24HS-5!K3S O27HX,S=P=S,K1W(F(WA!.W9N2S%#,'AJ:DI9;G%X:V1A9DTU
M:65(23E(3SA74&5N15@O3T]8-7E&9T<P04E0-6IE5U9".3!X3U)/0V9C;S%%
M3SE8+W=#:&1V>F<F(WA!.U)Q1%%G-"]M5S=S-F9J34UR3VUY9#,S379Z14\Y
M2W(S.'$O>D@P-5,Q,35C=G=I-W,X8TQ42T(Q<5=I-6I+6EE::F]7=UI9;G%(
M,%8F(WA!.S5H+TQK96(O04UL=DQT=D9&>#$S5&1*<S5T4$Q$:3--5S!F<5%.
M6' V9T90.6%N:&UD:W=C94ED-$1H47DX1U$Y>$PU8S102$EY3W F(WA!.U8P
M2E9L26]14G-14FUL3'11<DIL6EI".4YF:T0K6E V63!W95=D5&QR<65N>"\V
M1DLU*TMA,UAB:G8Q84QP-W(X:6,S4%HK<#1H=T@F(WA!.VU(5C9Z0G=N:4A)
M=DI0>E<X,"\T:C@X86AD>'9Z<S=D=G%L:U%A:C!O4U)Y2',W.&XK;DY4<F,S
M:5I#96Y*,D]M>#A%04=,2FU%6$HF(WA!.U)U;C-T-5DS560S6GI08C--2C52
M5%)K<39M;$MG:G!G16I%,DYI:WA"1D9K0V9M1#4U+S9V,3DO>5!K+W)L=C5Z
M3B]/4'I99FQS9C@F(WA!.S!F2E,Q2'I.-6@Q84))3E0Q2S1V255B;6MC.&I/
M;V%H1E%'2C-O8W)Y86EC>%5I4S)1>%%I8D%!46%:43)Q9TI"<4]U0E@P,S51
M.'<F(WA!.R]P+WE,1&9U,TLU*W)V1&1E4')22U99;B]7*S$Y3V1J<',O:31/
M3')7-WIE9D8T95=U;'9M4$]/96MD:7(P<GEH*U1F*TEV3'1P<E F(WA!.S98
M*W$O5W95+V-F5G95-"MN2S!F,G964W1E1F5M8F93.6QE3&I%*TMR.'90,W5U
M,4AA2&AZ365'-C@O,DIY4"MC96A89E@Y=BM95"\F(WA!.T%++UIK9GE(+U0K
M>CER5"]!0W(O045F="]9;4]N9FM(-69H:T18,F]83C)"*W=G4T94."]T=#EX
M>39(675-9E539G-A-3EQ5%!)04TF(WA!.R]W0D4X=39*;V1T.5<P<7IJ=%EZ
M5&U51EAA;E%U-U9:=G!/8E!$9VAJ1E)&3W9Y-7!43GE.<T@O040W+T%/55!S
M+SA!=&]2+SAM2G,F(WA!.S$S8E@Y,% V,S9#-3-:9CDT9C9V-E$X17IM2&5U
M>%8Y52MD9$(Q6%@O3&0S<%=L87I0;T8W8SA!;7%7<6AP63%$9W5&,U%J:V]+
M,58F(WA!.V=2,7)N95-"23)E4V=11'5,9D]0;7)Y="]W035595%R:C9Z;V9M
M2R\X,#991%-/84EF6' V1V]!;'1,9UA$,7 O2GI!.&$U5E)"-G4F(WA!.U-*
M46PU2E19+W=$3U1(-3@V4BLW,6YY+TAD,#-:<G%W=6)E5VDY9#1Z1V<Y+V=W
M94I86#AF66YW26Q0=% O-7I:44M%,5!Y:W=K1E$F(WA!.SAL=F5B2'(P4C1D
M=3,W5U0T>7A/;C@P>&LO-7I7.'-"14U8;'$Y6GE0,V=A84I11"]K:T)U6#-$
M2&I09"M0:VHX=C5O3V8X035Z8G,F(WA!.V=33&)Y:$I)2S='4R]74&(V3&54
M15I$,4,O;"].2F)N+VY-=GIJ3%@V;F]';E%E2').4$XR+WE7:'ES-5IE5$UA
M94M5,U@O3U9F-7(F(WA!.S-417A35T9K1#!70S)Q0G148C%M;$]64WI3-S)9
M,#A62T@O;DE(.#=R<4<T=6]D65 Q93!65W584WES>6E",D-,>4IH4#)M3D)L
M9FHF(WA!.WHW,F9G43=K4&(O;C<K8G-C>GEJ>D1)5VMR>4115WIR=6$W23!2
M5F9O1U8O;4IJ<7HX0TAC;6QN+W=!-4=F;7A%=TUU<5)824A54U<F(WA!.W1U
M060O=T1I=$DX:BMB>60V+VQO9'HV=CAO86YC-G(U5#!85DQR:CEA=C=#,75P
M*T%O=G%447$W8U)V459B3G)J;&-15#-/='E#<$4F(WA!.V5B=S<X."]Y8S%A
M5%=:=DTO;'5Z839T-W-'5%4W4T5C<%5M<CA5<5)J-&U%;E9G;TI"<65H>E=A
M,U-M*TM)8R]3-F=6=WEE2&A75FDF(WA!.W)!<7EM:DMD:4-/>'I5;#)!4FUN
M6#$U65AC9#-:>E!B,TU*<DA.1V5,2V%5,DDY:FM226<R16M!:6DR;59&;49D
M3S)13$E+>5I!<V<F(WA!.W)P:U=3251!>58P=TI8-$9E;B]K=#5I.4-45F1"
M;65K9#5!.7AB02\W.6I1:'=09&LS+S)/8FIS;E!81D$Y4F)R93!-5CA-*S1V
M34TF(WA!.S W<VY9<2MK+W=!;V8O2F0V5"\P8V8X05543&Y8.6PO-'9(-"]E
M6&Y.9CA!,S!V:#EW6FIM931B<U9D:7)Z8C@K+SA!;$0W4"]T;U(F(WA!.R]W
M1$II8DY2,C$O9$0K="MG=7DW3"]V1"]6+U-(9VUC=S<Q,DMV<U1/*V519&EQ
M;DIC,CAC<V-5:W%*3$Y54E)S=T10>#8X461Z5#(F(WA!.W=7;6MK.'=F;"\U
M2#AW:"\P,V].:F9V24M.3DYB>&UB+UEY,#E25#AM=T=!4TIK8VEW;2LO=T-C
M6"]Y575J>5A1;7182G%79W4W<&$F(WA!.S=5<'AA4FQ!*U%W8T%::E!*6F$O
M.#1T+VMN04=%;6AY6$I*,F%7.'5W4CAV5&QJ+T%">$5!<'IY5S9N+T%--#!F
M:V5T=%9T3&)45G(F(WA!.U0V=W0Y8VIC.4(K+VQK5#A-:DQ(2#-*:FUN-S!R
M="\K8U9V>6MU-'AC,E8W<45T=3EE1'<S54UK6C1N:65,96LQ845(=FQF-65*
M-FXF(WA!.S=0,4TO=T%X261%,SAX9FQ**U<K9R]L9F1E5S5B-#9*<$US,%5T
M,7)%-TDP,&LV<U!437)%2W S,C1G065&35HT;VE.6%-)6EI'5C@F(WA!.S-H
M=7$O;% U2FIE=6IF;4QP1GEH1WDS9DM!9RM(2TUZ,2MD0FU&3$9(<$E/6DA,
M3')%<%!D9FQL<3A$34Q05DY&,55*53%S=%5S,DHF(WA!.TAI16MK:6M.9D1J
M6$M:66E/;RM98DDU4C-(-5!S5'E$8GI7,VM8>35B>G%5;6@P=7EJ;%$Y5EIB
M9$%W,CA#33-'2#9"-V<V<DPY4CDF(WA!.S90,3-28D183DAU.4IV,#4R;#5'
M635!3FE/-G-P-TUR04UP-T596G=%;VM&14I'2G-0:E1Z<F]E=#9"-6IU=$<Q
M958U-3=2<5)4>44F(WA!.W0V:U(S:F1#>%!W<W4Y2S=D3V]Z;3@X2E%K66PS
M;4M9;$=W:WE::FQU0TE42WEY0V(K5SE(;C%R6$Q$4V].<$PR6DE1,SAO62]%
M,RLF(WA!.WA&5&AX67I/46E/<4IZ-%EK.7HV+W0O2R]L>4-#3T-05$Q8:$5Q
M;VQ967EA2TM#<$LW-3%O=U%!<6<X.&,P>C%+<B]H-U%0*W)B82\F(WA!.SAI
M22\K86-09W<W:#AL.%=F95AF;T11=BMR8F$O=T1);5 X035P>#A'2#@P9DIF
M1FXS;C5V1G9Z>#AT46%D<DYL<61P0VM.<F5X1TLF(WA!.U)),4-Q2EE4,6]!
M04]335!U3V,W,GAP>$=9:T)S6&,Y;35J2TII95EE6C5P,UI)<E,Y4G5.3C%#
M0RMT>E-70G=W2&E/:DMF6FAS8VXF(WA!.VIM65-"2%)J3TEK2TM&>41*,DMV
M<% X04M(+WE896LO.4A(+T%&17DU,2]:9BM,>"M0,VPU>E@O04XY3#1F8T=9
M-6YU1S=&6%EQ.#(F(WA!.R]0=B]!2E$K>B\W845F.$%Y66UZ561T9C-1+W)F
M;TQS=7DO-W<O,68P:#1*;DU/.61I<C=%>G9N:TA9<6Q8;51Y;C5B.'IA9610
M,2\F(WA!.U193E-T1'5)-3!$1E0O36IF85)V9%-$:UI20C5S;WE)-5!(3F8O
M-7A*.'-Z4TY,-5HX=V%L-69,06=18WID47%/=U5&-'!A1#-K3U8F(WA!.VY#
M3"]!1TYW,4(V<TEU+RMC3R]02G5(35!M-C-N46MN,5IL=45C-SE3;TUN+T5S
M:6-0:U!X.$=W86=)<E-V.$%N1&9Z13!L9%4X-'(F(WA!.T5G-G)A=U-Y:RLQ
M6DI)<69C8V9!2&-%2%5H-E U4B\U>&4O3$Q16E5U<BM'8E@W-5-'36UO4%=,
M:T17;V=12VA(=$IY>5%W:G$Q>3$F(WA!.T5J>3)E=%<Q=&)7='9(8C(P4U%7
M.%-H26]9,4-)<6IO1E9A041,44MA0V)31#AW9DI&;#4Q.'1484)E,T5T<D).
M2DA)6F]1<&-'2F<F(WA!.W=(>$%J9DE:369'2V)-951H3G9,1B\U>$HX<&HO
M<&0S+W=$=TU0.$%Z5&U.*U1(935(-7<Y>6]V+T]*+VQ59CE,<2LO-$=(+T%*
M<'<F(WA!.V9K4C-P+T](=65Y849P35=J-DAP,FM1=3!K5VY7,$YP2$DY3U1,
M0D=)=WI5,G%1=5IK23A)03=N16Q+>5-J<VMX658K668U539$-3,F(WA!.V4P
M;79:6F)3-W-W>4IC=V-E5%)T=G=F:T150G1X-&(K3UEU;S!S8W18<UA)=S9G
M-"M41'@O=T$T>"M74B]W0DQE.2LV3"]M;DU8*U,F(WA!.V\Y-6-J*U5*9'DX
M9C@T>BM74B\P='(S-V]V.$%M;DDO>51$=DLO>6A,=41)4$I8-4PV0C56,7A.
M670W>31U-VE+3C!I5UE)1E5Y1&DF(WA!.U<K14$Q-#%(,#5D<"MZ-#1P8U%*
M3%AM,6MP>#1A96A:<TA$9&ER<U934'IH-5(P+WI4<%,V9&5U.%-P2W,P8W-D
M3U-S;TDO84)'-%DF(WA!.VI-8E9A5T]A4$-7+U0V9S1P5T=&9CAQ0CAV9CE8
M2S<O04]36"].3V$W*U))9GII-78X<50W9S<O04I51#5E+S9U5C,O04UK=BMA
M8V8F(WA!.S5%:"]/2R]Y<%!U1'8K5D$K6'8K<FQD+SAK=BMA8V8U16@O3TLO
M>7!0=41V*U9!*UAV.$%Q-5AF+TI,+T%*<'@O:U-(.#1R+T%#<% F(WA!.W5$
M4&9,2&PK,SAV-DAB85)B4U!.1&)C*TUK;$]2.5-2<$179T$V=FTP,"M!66]#
M039/0FUY;DI)>5!63DUU86Y9<3=&56@X-2M53% F(WA!.WI6<&-7;C-C.&M%
M8U4V,T%E3&IY3$MJ<%0T9V1V:GI&,65L1V500U17.752<#E18U5R039-32\U
M540U92]W0W)L9"\X:W8X06UN3F8F(WA!.R]):U U>&-Z*U9*.7=D+WEO2'DY
M+W="6$LW+S5*9CA!3D]0.&E1+VY&9C55;C-"-FIM-F17-T9867$W1EA9<3=&
M6%EQ-T9867$W1E@F(WA!.UEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EAM2#5T9FU*-78X;%@K:F9567)#
M-W,F(WA!.TYA=6A:;TIO-6QL:&,X9'E6;#1Y03%*-DPO2$958C4V.#DK869)
M9'1B-GAR1G!A-G8U96%626(K-7-L:W1B:3(Y46A69C!:2DQH6E8F(WA!.W)T
M.71C5EHW85AD=F57:TXS8D]*3&4T:E=71U%D1U)W1U4O4T1I<7)I<FE105-4
M441C:S1Q.#<O04,Q+TXR,C@V*UDO34]K3&%M>2\F(WA!.U)44G99<34O9517
M>FII6E=&9C5Q2&(Y;&PV-'$Y17A6,DMS3B].8GI2-6DX<6558G9Z2&\X9')C
M:E1W:EA.<&1*2E8P95)9*U-32DDF(WA!.VY(:'EQ459.9C%Q<%%N;E X=S(O
M3'EZ.#8R=')P=6]X>5=3-FID85%Q5#)S<7AE;C9J<D9/6F)H6%I26')'2S1Q
M>6YY2#4P,'IZ;C4F(WA!.UAS+TU';DDX54XP1T1W4U4U>'E2<U5D1%19,%EB
M2'5..%9:0FER2'901W5A,W!':U%V;U9N2&8V>F58549P6E=S>DUS6DUJ,6M:
M>74F(WA!.S1626QD>64Q2S1Q>%0X>E!Z03@U*U%V2W%A.60R,FY8<DY02&)T
M8E)E=6=$4T)J55--9'=/2#AU2W!N-6XQ,SAX.4PX<U,V,W Y<' F(WA!.W5P
M3D)%3&UA>E54<$PV44%:+U1(26@R5F%N:E56*V4R1E=B>%-X>7A*3$=E56-I
M:&M99'=254A!<3=&6&M8-6DO;7@U,#AH95DT4# F(WA!.VAP5G1Q4&Q*;6AA
M-3%',5=73V5&3&@U1E9'5FYD95DY16UV4G5N=VLT<3E.=$Y5:#%N4DET4S!+
M-VAL:79):$Q:6%1+6EEI1T=X6E8F(WA!.V%.:C1%8V=2:7%1*U$Y63@V87),
M<7)E65DY4&=I<TQU87AH:G-L;$Q33D-6+V9&-4A)5E-$.6IJ6#-(47%S=7A6
M5'5&=4=G:U<S9$DF(WA!.S5Y<$55:VEM4D9B<U=13D=72'1Y2'IX5C5D*UA8
M-6@K969.*W9E871(;2]2;6Y4958W<&)/5U)B964T5UIJ2E!'>$@K:W<X441B
M*R\F(WA!.UA&5U17,G1E94Q(>F1A-EIR;'):,T=H-FA(271P<3%I:WE&3'%-
M8S%I=4DU2&Q#0C0Q8FEW66EU,U4T<7DO1EA9<3AS+W=#5FAE940F(WA!.RMB
M8F512V%9<V8Q53-Q86PV1G=X.5!H>4-M2#9W=GA6,BLS-RLR2V]Y5#AZ9%HP
M3#AW3D\X;V5A-T,S5U!7='1(,6UY9&A(23E14%0F(WA!.VQG:S5-:#5';7IN
M96YJ<W$Y2'A6,DMS4S@V*V5(,%!69$,P1%0T63=J6&9-57IX5U-Z<U9G:6IH
M54Y,3DM60EDX45)X454U2'5-5E$F(WA!.VYM<GI"-3DX='):6%@Q97@Q;E1R
M;3=T-U,W:VAJ;71*8E9B:5I9:$U585<U17%$;%$P2VM%:G181E=%+S@U3T5H
M9DI*04Q%87EH0VDF(WA!.VQ4.6Y95F]-5EI&*UHR:65D4%!U:&8T5G-D34]I
M-F)E>E).<6UP-FA,8G5W:&AD6E%S14YR3&-&;4QQ=C)M6'!4=EA&6&]/:F%8
M8F$F(WA!.U1P1FIP5G)8-G1P.79&87=6-BMN0V=J5W8P3&EQ3'A6:EAN>E5$
M1G!C5VQX<DQ*4')-;W1'4S-2<$I28D5C<G Q5E!I,FA$2T<W37DF(WA!.S1Q
M.&0X,S,X2&Q$.#AF3#-N1S%T3&EW,&97,%A3.5=%.$0R-F-Q0TE%5C1I:7 V
M8F8W1$-R-DAW2S=&5T%F;C,O=T-3:#AY9CA922\F(WA!.RM4.&5+=DQ.8R]-
M9GI4-6(O2C=Y='!596QI>3!R5V1.=#=*+TTU8WIP0VMS440P=#!65T5N<#AI
M2W0R,C55>%8W5"M74&Q,4U!+;FLF(WA!.W)4=$HP;38K=E=G5#%X9F)5;F%F
M-'I)=$-11F%V=VEV5$97531Q-&=':$EQ4G508G1I<GAV+VY+,R]Y5G%F.$%B
M4G0O*TE367%(<F4F(WA!.VUG2%1,54AC1T=0+T%)9TU64DE!04%!;T)S04U6
M9&ER2#<W5'1-,6Y6=&$P8E5R9&)M>G5D3G,P=5E82'=S:VMT,DME24DT,7(R
M-FHF(WA!.T98:3)G-FQQ,S5(961$-60Q<5-3-"],>E=P4RML-FDQ5T9Q-TAF
M;#)(1W8W>%(Q1DA(8UEP93)E54=I93$Q0U=)<7E3-FID=7-I54DF(WA!.UE'
M53!9161D<U5*-VER<U9F4#A!*U1R*UEL+TU$.#)Z;V-6<$QC+W!C-UAS:VMA
M8W9R3C=W+W4P:U!Z>%-8<'8U5%A0;4LU.'%Y>2LF(WA!.UDQ0V$R9%)V>&5X
M<CEH2%<V9%%Q9&9G5E%!=G141D1-.%9D:7)W:E4U-RM$+VY+1U-7=W16=F)P
M3D5Q;',P;V@U+T(P1&Q705!Z=W$F(WA!.V<O2W5O;C@P4'IG4S8X>G%.179F
M2F)&.5 X<G0X8W)Y2S1,5%!-94EB,#5&46M+=CAT3G%N07(V1'A6,DMV3G9Z
M:"]+,U4O3B]W0VDF(WA!.SE9.'9A9TY,.'HV13=35T9W>%I564U1,T9M54U6
M25I146%(=4-..6Q71U=F-7IF;50U3C%3>3!N.#%.0VI85')U45%P<G1V>$,O
M-C<F(WA!.V-#.$PP-FM$9U%.-F1S5EI$*V0O:WIZ>#5T=3E#:3!(5#1(=#E'
M=7AE=F-83G=S6'%U07!6155":4)S45-C5F5P,D4Y,5!A4GDS5G,F(WA!.V)/
M-&(K.'0R9%I/2CEM46M%67%I359D:7)%3DQG.#%4*V9R>E4Y5C!T661+:G12
M6F%.36LX8VIO1V-Y6$QZ2C%";5I)9T]*3D])<FDF(WA!.W%69FYR-4DQ5'IP
M-4LO43)L5VE81V]I-&IU3&%A4U)9:VAA33!9<U<S4$M.,E5!1$974F51,C@Q
M<C5B<S=8>E1A<$)Q.7!%:TTX.%4F(WA!.W%Z2D]52$@Q45)1:&UP5F=2,4\R
M2W-I>%9G;C5Z-D(U;3AY*U)R,WDU;T9Q<W1Z<5AP0U,U:VU71DEK:6U353EA
M<S--2GAP5$963'DF(WA!.S$U275.42]+>41Y4C5V,#5)4D):<%I33DA+:WES
M67A33V%*:%%Q>4968F-B2'AX5DLO>64X=F9M9#5.=%@X=&$W0D)Q96=W4W-.
M33$F(WA!.T=+-%534E)&:G-9;D%9;V9T059Q=E1F86ER,51&6%EQ.'0O4')Y
M:C5Y.#9E6%E03#)G5T544FDU:G5P-S(T;E=-9G4Q8T)%5&1I874F(WA!.TMS
M869,=FER,$AY."MP3F\Y<75P5V8Q2SEJ:E=/84%33$UV2E9!2E(Q-G%E,5%$
M-UEQ;4]+=7A6:'1M9D]O+TU'.'8U=$E64$PY>&$F(WA!.U<Y;$9)='I'6F<P
M13!R*W,X9E1I4D]D9WA)<#<T<6TS;E1Y9&]V;2]Y.6,V2'$X6$\R;D95:T90
M56EK2#)*67EE:DPO04=(631Q;% F(WA!.S53951T4SAN95-B8GDO<4UY6$9X
M85182$=E36MQ.%1433!454\V+T%2.%!B<&ER37-657)Q5V%+,VMK9VA.>$MO
M<6M+<W%L:C1C;4DF(WA!.T$K;D98:B\U5V559GI%.'%E6B].=7-A<F\X339E
M6C=O6&=3,G4T:3!4:5=A5&EE65%%9C92,3ES5EIB<6<O35!6+TU':U=S5VUX
M850F(WA!.S5B:'5K=717=5=U56MU6FA"*SAJ:59)>%)585)6-2]%86IB<%=Q
M<D]-5F1I<G@Q=DMF-6AF.')R2&YT9$=H+U)8,5@V:6)9,V-F,6HF(WA!.S K
M1E!5<%1H>35F<SAU;F9#<4HO3F(X<F9-3W!E63E*.#AE4C-I=%!.;6YU<3-#
M>DU%4V5)0V<U:U9"25=Q340Y<$13=7=W2SE*,$<F(WA!.S<Q;38P,D]45V)"
M9$\Q06)45SAC<7IX,4%&5U)W0CA*4%-O<FEQ65EQ>$AZ0EHK95EF3T9L<D]H
M3&(S5VMP84<R,5!46C5J0SAR1U0F(WA!.VMK:TQC2%501G8X06%O0T-2-VA6
M3%!0,VQ(5B]Z071T3S!E.'-X<&5I45AK5C=Q36QX2DA*8U-I2&M"1$-K2FQ1
M0BM7-W,S5#EN1E@F(WA!.R\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @
M('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)
M1#YX;7 N9&ED.C<Q0C-#0C P0S T.44V,3$X.$4V.#4S.$4Y1$8R.31"/"]X
M;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C<Q0C-#0C P0S T.44V,3$X.$4V.#4S.$4Y1$8R.31"/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/G5U:60Z-D9$.#$Q0D$Y0CE#1$8Q,3A$13-$0S<Q.#$V,T$Q040\+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I
M=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C<P
M0C-#0C P0S T.44V,3$X.$4V.#4S.$4Y1$8R.31"/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C<P
M0C-#0C P0S T.44V,3$X.$4V.#4S.$4Y1$8R.31"/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z-D9$.#$Q0D$Y0CE#1$8Q,3A$13-$0S<Q.#$V,T$Q040\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO
M;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1C<W1C$Q-S0P
M-S(P-C@Q,3@R,D$X,C@S,T$R,$0X.3@\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3,M,3(M,#54,30Z,#@Z
M,C<M,#4Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H36%C:6YT
M;W-H*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-S%",T-",#!#,#0Y138Q,3@X138X
M-3,X13E$1C(Y-$(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,38M,#<M,314,3@Z,#DZ,SDK,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A
M=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL
M;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @
M(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+R(^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G
M97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y4
M<G5E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @
M/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S
M5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ
M92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I
M;3IW/C<Y,BXP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH
M/C8Q,BXP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET
M/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G
M95-I>F4^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE
M<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.
M86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4
M>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y7:&ET93PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D)L86-K/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y004Y43TY%(#$U,S4@4$,\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1I;G0^,3 P
M+C P,# P,#PO>&UP1SIT:6YT/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4R+CDY
M.3DY-SPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C,X+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @
M(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F
M.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ -P"! P$1  (1 0,1 ?_$ !X   ,
M @,  P            @)"@ '!08+ 0,$_\0 /Q   00#  $# @(( @4-
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M((/<$'L0>X/8ZF:U'N+9.A[S';)U+:2J;=X@:2#CI\,.+/?&&EP7HV1:2-,
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%Y^S7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g482402g18f24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g18f24.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1_ 4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      %;    $     $
M  MP<FEN=$]U='!U=     <     0VQR4V5N=6T     0VQR4P    !21T)#
M     $YM("!415A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @ "@ ,0 Y #D
M.  I        26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L
M 0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   5 &$ >@ P #$ -0 Q "T > !E '( ;P!X "T ,0 X "  1P!/ $\ 1
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             !,0  !C$          0
M                   !              8Q   !,0
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   !,0    !29VAT;&]N9P
M!C$    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   3$     4F=H=&QO;F<   8Q     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3004       $     SA"24T$#      6'@    $   "@    'P
M >   #H@   6 @ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M                  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 !_^X
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M:'68_P!JL?;2RS=E>M]CKII_G4E/_]DX0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !+DU-
M "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0   &H!
M*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0
M *0   #0 (+M8@  )Q  @NUB   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,3@Z,#(Z,#$@,#@Z-34Z,S(   .@ 0 #     ?__  "@ @ $
M     0  !C&@ P $     0   3$         !@$#  ,    !  8   $:  4
M   !   !'@$;  4    !   !)@$H  ,    !  (   (!  0    !   !+@("
M  0    !              !(     0   $@    !.$))30/]       (
M  $   #_X0$P34T *@    @ !P$2  ,    !      $:  4    !    8@$;
M  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
MD(=I  0    !    I    -    /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP,CHP,2 P.#HU-3HS,@   Z !  ,
M   !__\  * "  0    !   &,: #  0    !   !,0         & 0,  P
M  $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$
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MA&R+5PR>M55&[E%1)3;3.H%\.^:.<2_K"_/\LY_I(H_TB)Y=6J/\BJD$F_\
M3%5K,.M6JE>?R4"Y_P +4;:ZZX;[C?\ &[(XUQA/.N,8]N5XQC&,8QC&,8Q^
M,8Q_VQC&/_6,8_XQCWWSSSSSSSU1OTEY?YI-%Q:V#'GBC"RTW&5X9>RR6I0&
M=L!>'C]X?]A%+&4H/NB)2-8_KW_9L=Y+9JV_5M_92T_5G\RIP3R=RQ68-%6;
M6_-//]?61)XV;R5@A%-UT*&\@WU9,/TH/2N!'&$\[1U_.?TI+OU-,?G/XU]8
*]YYYYYYYYY[_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g482402g18u21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g18u21.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2>>4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      %;    $     $
M  MP<FEN=$]U='!U=     <     0VQR4V5N=6T     0VQR4P    !21T)#
M     $YM("!415A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @ "@ ,0 Y #D
M.  I        26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L
M 0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   5 &$ >@ P #$ -0 Q "T > !E '( ;P!X "T ,0 X "  1P!/ $\ 1
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             "S@  !8T          0
M                   !              6-   "S@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "S@    !29VAT;&]N9P
M!8T    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   LX     4F=H=&QO;F<   6-     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3004       $     SA"24T$#      =^P    $   "@    40
M >   )?@   =WP 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M                  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 !_^X
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M?]"ZW'NLK]/^9J2FK_BSQF873>K=-J,T]/ZOE8M+BUH>65^EM=>^IE?K6_\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(
M P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $  @
M 3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D    T "WB5
M "<0 +>)4   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X
M.C R.C Q(# X.C4W.C4T   #H $  P    '__P  H ( !     $   6-H ,
M!     $   +.          8! P #     0 &   !&@ %     0   1X!&P %
M     0   28!*  #     0 "   " 0 $     0   2X" @ $     0
M        2     $   !(     3A"24T#_0      "      !    _^$!,$U-
M "H    (  <!$@ #     0     !&@ %     0   &(!&P %     0   &H!
M*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0
M *0   #0   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,3@Z,#(Z,#$@,#@Z-3<Z-30   .@ 0 #     ?__  "@ @ $
M     0  !8V@ P $     0   LX         !@$#  ,    !  8   $:  4
M   !   !'@$;  4    !   !)@$H  ,    !  (   (!  0    !   !+@("
M  0    !              /      0   \     !_^$_E&AT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7
M-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)835 @0V]R92 U+C$N,B(^"B \
M<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O
M,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B"B @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&AO=&]S:&]P+S$N,"\B"B @("!X;6QN<SIX;7!-33TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B"B @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @>&UP.D-R96%T;W)4;V]L/2)!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*2(*(" @>&UP.D-R96%T941A
M=&4](C(P,3@M,#(M,#%4,#@Z-3 Z-3DM,#<Z,# B"B @('AM<#I-;V1I9GE$
M871E/2(R,#$X+3 R+3 Q5# X.C4W.C4T+3 W.C P(@H@("!X;7 Z365T861A
M=&%$871E/2(R,#$X+3 R+3 Q5# X.C4W.C4T+3 W.C P(@H@("!D8SIF;W)M
M870](FEM86=E+V5P<V8B"B @('!H;W1O<VAO<#I#;VQO<DUO9&4](C B"B @
M('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z1D8U.$1!,C@V.# W13@Q,3@V
M,C!#0C(U.3@P0CDT-S<B"B @('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z
M1D,U.$1!,C@V.# W13@Q,3@V,C!#0C(U.3@P0CDT-S<B"B @('AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#I&0S4X1$$R.#8X,#=%.#$Q.#8R
M,$-",C4Y.#!".30W-R(^"B @(#QX;7!-33I(:7-T;W)Y/@H@(" @/')D9CI3
M97$^"B @(" @/')D9CIL:0H@(" @("!S=$5V=#IA8W1I;VX](F-R96%T960B
M"B @(" @('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z1D,U.$1!,C@V.# W
M13@Q,3@V,C!#0C(U.3@P0CDT-S<B"B @(" @('-T179T.G=H96X](C(P,3@M
M,#(M,#%4,#@Z-3 Z-3DM,#<Z,# B"B @(" @('-T179T.G-O9G1W87)E06=E
M;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B\^"B @(" @/')D
M9CIL:0H@(" @("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@(" @("!S=$5V=#II
M;G-T86YC94E$/2)X;7 N:6ED.D9$-3A$03(X-C@P-T4X,3$X-C(P0T(R-3DX
M,$(Y-#<W(@H@(" @("!S=$5V=#IW:&5N/2(R,#$X+3 R+3 Q5# X.C4W.C0Y
M+3 W.C P(@H@(" @("!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*2(*(" @(" @<W1%=G0Z8VAA;F=E9#TB+R(O
M/@H@(" @(#QR9&8Z;&D*(" @(" @<W1%=G0Z86-T:6]N/2)S879E9"(*(" @
M(" @<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#I&134X1$$R.#8X,#=%.#$Q
M.#8R,$-",C4Y.#!".30W-R(*(" @(" @<W1%=G0Z=VAE;CTB,C Q."TP,BTP
M,50P.#HU-SHU-"TP-SHP,"(*(" @(" @<W1%=G0Z<V]F='=A<F5!9V5N=#TB
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RDB"B @(" @('-T179T.F-H
M86YG960](B\B+SX*(" @(" \<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB
M8V]N=F5R=&5D(@H@(" @("!S=$5V=#IP87)A;65T97)S/2)F<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9B(O/@H@
M(" @(#QR9&8Z;&D*(" @(" @<W1%=G0Z86-T:6]N/2)D97)I=F5D(@H@(" @
M("!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8B+SX*(" @(" \
M<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB<V%V960B"B @(" @('-T179T
M.FEN<W1A;F-E240](GAM<"YI:60Z1D8U.$1!,C@V.# W13@Q,3@V,C!#0C(U
M.3@P0CDT-S<B"B @(" @('-T179T.G=H96X](C(P,3@M,#(M,#%4,#@Z-3<Z
M-30M,#<Z,# B"B @(" @('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I(@H@(" @("!S=$5V=#IC:&%N9V5D/2(O
M(B\^"B @(" \+W)D9CI397$^"B @(#PO>&UP34TZ2&ES=&]R>3X*(" @/'AM
M<$U-.D1E<FEV961&<F]M"B @("!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.D9%-3A$03(X-C@P-T4X,3$X-C(P0T(R-3DX,$(Y-#<W(@H@(" @<W12968Z
M9&]C=6UE;G1)1#TB>&UP+F1I9#I&0S4X1$$R.#8X,#=%.#$Q.#8R,$-",C4Y
M.#!".30W-R(*(" @('-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I
M9#I&0S4X1$$R.#8X,#=%.#$Q.#8R,$-",C4Y.#!".30W-R(O/@H@(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\
M/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ .0!Q P$1  (1 0,1 ?_$ !T
M 0 " P # 0             ("08'"@$$!0O_Q  O$  !! ,  @$$ 0,"!P
M   % P0&!P$""  )$Q$2%!4A"A88(D$D.%=WF+74_\0 % $!
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MK)78.+L7SE!T?,-8X".'W P2D[>HA Q4JHAJQ'.UT0R'P'@/ > \!X#P'@/
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M5QS3'VB3-N\.7$I87QYQMC&LB>5AVS H,6?)_P"G.Q )!XHR<9_C4"SQKGY
MR/G[AHE";W)=>=*W>>Z?ZK?09U6<:E*\685G3=&UZ6(LB\FAG/%+C2TFWA#.
M9$Q85S-)5-9U9ED2;4$*8NIJB&0W$J!C'5GN"];O%4V-5;T3U/!XE;@%J(<D
M:@ CI98EJ);R)D+)1UCF!UW'Y3(D21\<:$DA#)TQ;K/!;] KIC SY'F@:1A7
MN[H.T(\C):JY)]G=FL'*+MRTVA_K[OUTS=MVSM1JDLUDA($+ARVK[&NCEGIK
M)/ER@KKJY3;.DG+9 /L2'M'V&W>+>QWE/U=656ZLA'*"Q]R>P&T*;IBOX61(
M-D]/W9VF*JF]W7=-Q@C1WH[6C[4'$OWF6[H5L?$.-=M_ F+P-RWGB;C+F_E%
M27[3YU1=6QZ"DIE^"J+0D9ABFHY,DQXI=X16%"%BKMY@,+5?.]QHG5DRV74R
MA]V0]#H;CP7T#T9Q!T(_GI:,NN++*M2QQD19!6!$?8;FS:<DU2[#B91PY;O8
M_P#H,2'4ZV=LDB&C_1!V*<L4]WC4J+"9?@/ > \!X#P'@/ > \"*,3_YQ;C_
< .SM4_\ NY?X$KO > \!X#P'@/ > \!X#P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g482402g22g61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g22g61.jpg
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M+<"6464@:64(V0H21XT\T#U:Y\4LD?9S@GTM:AL_$R6S7D$E>YN._P L,@#
M20RPWYXW 8!@&0*PY 'T(![:%^PV(I^N'GA</#9N[M)$X! >.2*W(C , 1R7
M##D ?0C.E):2H-T%S4T-:QDEC=V8%0!'(](HWFV1408K'R._3&QT\T:.>OV8
MU5<OV3TPLLBPQ22N<)%&\CD#)"HI9B!Z]@>VC'(ZQ1O(V>,:,[8&3Q12QP/4
MX'EHJW)WLO\ 6/Q?QMH>2C).*M6)EZ4W0767QNLO3]=!55@TAMG.,';9"DJ+
M*8$.&<EX5;=EFE-A=#7#FE/B@DP-'XF=-W[L-)1N%=IY5ABGLUXDKF1V"QAF
MCLRR('8A0SQ*JYRY5<D9&KUSLEJU'5 N0F5UC2:>&-82[GBH+)/(ZAF(')HP
MHSEBHR0/'A/G/E#IYW]-R3Q-J[++:6G*@E>HA$R5MV%%,V6>DT=8V1@MW1G-
M:L1E:<R2&1KOB1_"(CAGCV.Z;50WBI+2W"NEB"12!R4>)$Q&!+!(06BE3S5T
MP0>QRI(.DO[?4W.N]6Y"LT3@@9 YQL1@21/^DDB^892#Z'(R-/Z\*\EU_-'#
MW&/+%:-\F%R1@\OLF5ZO^*ZM?H:82Q)JY).R?$EK22)@)7HGB^0=SF]T5%]*
M-N=%]MW&]M[GDU*W8K%_+F(960.!Z!U4.!['2[7JK4;MJFYY-5L30%L8Y>$[
M(' ]F ##[#I0#CWVA>N3E\NPNB<76X"L,L37CWG,.F=16-HGS,J*:12!":+9
MPN(3M-\>UH17$I(DL;I457>F,M_$7I7;E2);,EMU1,Q;; )4C^D?2)6:&L<>
M7&.5N.,$#1HL=9[!25(UF>PRHN8Z47B*G8?2'9HH3CRPLAQCOC59]5WMG]3'
M1_DA-_R*-B]-AI[,6G,U/'=]970%)9'^?TZ"Z$O*',W(<1\D3QQSV5D]8A?P
M0IC82S 829W3_7&Q]1V&ITC:@M!&D6"Y"D3RHF.;1-%+/$Q0$$H9!)QRP4JK
M%96S]4[5O4S5JQGBL!2ZPV8T1I%7](QF.25&*CN5YAL98*0K$?;VWNKC?=,W
M47QX %HK+^JOD'8461Y(QTYDTF?*KM)8#4K=/'72/<.-?9F4N&V$LA60&SCA
MSU$Q#J\\J%_SK7IVGOFS7':%/RA3K2V:5D*!,'@0RF N!R:&<*8V1B5!99 .
M:*1\ZGV:MNNV66:-?G*T,DU6< "0-$I<Q%AW,<H4H5.5!(<#DH.F1NJ#@7;Z
MCD35V,6:N+JFT-^NVHK6BS=;JUN5FX]XKX_,XGLII*6]ON.")F\>Z&UJ.3:F
M*C?D2]Z/H,]HX;JGNJZP"FQ;M5@IP(9XXI88A6ECEG>OX7&YN%M=P0"2**ZH
M^<ACEHR&7YA:IAFA:*2-T%^U[A!%6B4RHCQQ^#(DDKQ<,6+EA;:@.D=D#YF)
M7JOX@F6N8Y8RCHRYXV/MG]0?(6NU.^%Y/H./A=QH[S7C8)]IH"'XB#2V95U#
MD'D4,DE%.[-1FMIG34KWU,JA*^N>X-T*K<5NM]IIUZ]1J,UQJL,59K?APCYH
MP1K$;&)6$H\<KXF) )!RP_U9U80]3[=6ABKFG)9,$4<)L!(AXYB0(9L2?G!X
MI7GA_K'+ZOJSK3O6#[J_3QTE: WCZ6"ZY4Y5KXXW6>,QTH0X&;EGB9..-K=2
M<YP=29/ ]LOTVM"O;85CXI+"N"B('DEI.G.@=YZAA6X#%0V]R>%JR&+S@'!:
MM70<I%![<W:&-B"$D8J0*[9>D=RWF-; *5*C$\9Y@Q:7'8F&)?J=0>W)FC0G
M(5F(( KKS_*".3)R9'9KIQPM4&KE^%#>;B_OR6M[_I^(2!39J)[O'\JT5B=_
MNB=D[+O8OA!1"CQ]ZM2-ZF*K#"O[ \LY\_\ BUK8_AS6 'B[G.S>ICKQQC]@
M:20_OT!SD?93\C<A;SD(JN#IRMWL]1LB:FN61:^KGT]X==S5P"S*Z90PI#G#
M"K*YTBP1,\U5W=?18I5A2IU*:NTBU*L%99'QSD$$21!WQVY,$Y-CMDG&B%5@
M%6M7K!F<5X(8 [8Y.(HUC#-CMR;CDX[9.B<='_NS[_I#X7KN%Z+B3([.JK;S
M07D%U;Z"YK3UFORT,E@4<08@9(1Y._P_%$<_R5S_ +KZPW4?P]J=1;G)N<NX
MV*TDD4,1BCAB=,0KP!RS!LL/PUE=ZZ.K[S>>])=F@=XXXRB1QLN(UX@Y8@Y/
MKH4%@>9:GG6E@1(6?9&$GG%3.\I23#)GD$D2N_BDFFD?(]W[N<J^B"B+&BH@
M"HBJB*/)54 *!]@  &M>JJBJBC"HH50/(*HP /N QHRW2M[Q%UTK]/&*X'S_
M $_4.EEQC-(Z/76'(!U:VU+T>IN]/(4=0"Y*=Z*/)<_(HQE[Y2CB1*DL/=&1
MC7?OAO%OV\VMVFWB: 6C#FNE-7\-8:\4 5)FL =Q%R_DNQ8]CYG$;OT4F[[E
M/N$FY21"<Q9A6LK\%BBCB"K(9QYA.7\G@%CV.AU\X\R<P=:/.UOR)H*:;1\A
M;>:OK*C)86CLC(PP*T6,"GSN:I!W6EK/"*/&B]GRFG&%RDFDS2D$2.79;5MN
MV],[3'2AE$-.J'>2Q;E12SNQ>2:>5O#C4L3[*BJ%50 HUI:%*EL6WI6CD$5:
M ,[S6)%4LSDL\DKG@@))] J@ *!@::R]HSH]V_2IP3I+/E(%:3D?F"^K=':Y
MA\D<A66SE)7S!YBGMUA?+"R]>^QN;6Q'BE?\A'9AUI+8K (V-H!^(?4=7?\
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M(>KCII)IX@K$@%PH()PZ+^(:F"ILNZ5K$L\*+7K7*_AOXD48"QK9262,J\:
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M AL+I'L9(]K$D5JN<V.1S6]U:QRHC566 @30EL\1+&6QYX#C.,X[X^T:!\1
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*:T!=>]>U[7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g482402g27l76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g27l76.jpg
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MQ  ;   " @,!                "00( P8'!?_$ #,0   & @$!!08%!0$
M      $" P0%!@<( !$2&"&8UQ,5&4%55PD4,5%A(B,H4F."_\0 '0$!  ("
M P$!              4( P0! @8)!__$ #\1  $# @(&!0D&!04       $"
M P0%$0 &!P@2$R$Q%5:3EM07&#1!4E-QT=(B(R11<[(6)3)A@3-"E,'"_]H
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M*,:+/Y!RBS9MB@9=RX.":*13'*0HG.;H!0$YBE#K^IC 'SYOJ4$@J40 .9/
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7#LF2XX\YNVFVVF]M9V&T(;39*4@?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g482402g45i23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g45i23.jpg
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M 08$!00" P        $"$2$Q Q)!47&188&Q\!,B4J'!,D)B<H+1HL+Q_]H
M# ,!  (1 Q$ /P#?QX > '@!X!G7]GQ\UV#[)O7;ZR:07)QJK3;A"[PZME@I
MTF(L=0M1D'E:PKI&<-=;E0OW'88)<<ZPM:7H1:T:[L#*67&8,UL=(_+&4_\
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M<>LX:6) 0&;LN:@U(,XKH,97V(D@7"AM2GXDLE-&'5X32Y-W^%[[#<>""O\
M+/'^D^-P.U:QHP0:!@=P[POG0-K&ECTTY&CWW8C09@\W7FYF?B$KK48 ,CC
ML;"FHB&5K6\^^\XZH5MNKX))=%H-!X(9X?>-%_QLW]ZA>'RRL.4'HGM!_8^R
MQWW^Z3].YW%UTF5K4QI/WRZ/-C-A%$J2ZAR,W.B09CB%+A-_8=(84Y<HTNLL
M6O?$T/>#F'@!X > '@!X > '@!X > '@!X > '@!X!GYWR',[N^HFXEJV!)*
M14./.*]P]!D9[T&2@.BQ;B*VC3D=EN4XUB*](:7^TY[&67,Y5*AN)3\EC)26
DAT3K9R\9)=E9H&\',/ #P \ / #P \ / #P \ / #P \ __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g482402g46f93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g46f93.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1+04&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]       $@ U     0 M    !@       3A"24T#]P      '
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         %X   ()          $                          0
M       ""0   %X                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   %X     4F=H=&QO;F<   ()    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   !>
M %)G:'1L;VYG   ""0    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      (Y     $   "@    '0   >   #9@
M   (R  8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M7JMC?V/F6M,M./86D=P6':N7P.LV=/Z8<.JDB[(>\LR+"&5"=M)>'.^EZ/\
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MN=MQ:FV;G6 #<ZUVYE?I4_R__2E6^%_7NN8]!RK^D[<>)GU=0#_I&M8ZRO\
MMU>Q&^LG2+<[$J.(T&S&G;2(;N8X!KF5\-:]NUGIJOTCZS>I8W"ZFWT[Y%8M
M(V@O/M]/(J=_,7/_ .VK/^"24__0[;ZQ])MR+:\['8;G5-+;,9NCKC_VFJ%G
MT:*_6?\ K.0[^;QO4_KLY',?738W'98+CCL%=MXXLMES\BRO]VGU7^E1_P %
M6O2UY]U]OU8=DN'3;+:G_GNQZV6XTSKM99;C>[_PK9Z*2FGTVBC.O&,YI=>V
MT6FMKMKKL=S/0R&4?]V.GV>GG^G_ -J*?5J_2+N_J[T<]'Z77AO>+;R769%K
M1 =8\Z[6G\UC=E3/Y#%B_4W_ )L"QWV0V'JL'<<P-%Y9^=]F;674>C^_]E_]
M"EUB2GDNIYU-/UJ;D6ASJL0,:_8-QG98?;_5=D-4NJY=_P!874XO3L6STV.+
MC?:TL:'$&OW._-J:UVYW^%L_,J76:I)*>6KKHZQU>K +C9T_IE)9,EOJO&VE
MS]S=KMN[]W_1?Z.]6.J?5KIE'3LBW QMF16W>TASG$AA#[&-#W/^G6'-70ID
ME/+,ZG7?]4+J]X-M+1BN'<ASFLI='\JAW_GQ%P.EU=4^K%50AM['VNJ>?S7^
MI9[7_P#!V-]EBZ75))3RO2,X9>)?]7<]WI9&QU5!>9<('\R[]ZW'^G7_ *:C
M^H@],ZQ=T%UF%U*A[6%Q>W;$AQT>:]Y8RZBR-_L=_P"HNGL_9_KCU?1]>6QN
MV[Y_P?TO?_45@QW_ !24YF#UE^<Y]]>.^CI]3"Y^1?H7N'YM%;2?T;&^ZR_=
M_P '_P 7SWU<ZQC=-;>[)9:3D!A&QA/&\N#OH_Z1=JEJDIY89%?UDZQ52YCZ
M\#&K=:ZM\M<\F*]=A]GT_9[_ *'J_P"E5KJ7U8Z95T_(LP,;9DL9NK(<]Q.T
M[W5M#W/_ )QK=BWTR2G%^K'4J;ND!KGC=A LL)[5CW4O_J^C[?\ K:I?4IV[
M[:XR'.])Q!!&A]5W?^4Y=1JDDIQ^H]?;TSJ0HRJW?9'U-<VYK2=MA=8U[7?F
MO;L;7]#])7_UQ8_5;:OK%F45]*J<\M!9=E%A:T-<6QO<[\VGWO\ ?_UE=AV3
M=O))3__9.$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<  @ $, 4P V     0 X0DE-!"(      7Y-30 J    "  , 0   P    $%
M     0$  P    $"T    0(  P    ,   "> 08  P    $  @   1(  P
M  $  0   14  P    $  P   1H !0    $   "D 1L !0    $   "L 2@
M P    $  @   3$  @   !X   "T 3(  @   !0   #2AVD !     $   #H
M   !(  (  @ "  ]"0   "<0 #T)    )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$W.C$R.C(Q(# Y.C$T.C$W      20   '    !# R
M,C&@ 0 #     ?__  "@ @ $     0   @F@ P $     0   %X
M!@$#  ,    !  8   $:  4    !   !;@$;  4    !   !=@$H  ,    !
M  (   (!  0    !   !?@("  0    !              !(     0   $@
M   !.$))30/]       (          #_X0& 34T *@    @ # $   ,    !
M!0    $!  ,    ! M    $"  ,    #    G@$&  ,    !  (   $2  ,
M   !      $5  ,    !  ,   $:  4    !    I $;  4    !    K $H
M  ,    !  (   $Q  (    >    M $R  (    4    TH=I  0    !
MZ    2  "  (  @   /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q-SHQ,CHR,2 P.3HQ-#HQ-P     $D   !P    0P
M,C(QH $  P    '__P  H ( !     $   ()H , !     $   !>
M  8! P #     0 &   !&@ %     0   6X!&P %     0   78!*  #
M 0 "   " 0 $     0   7X" @ $     0             #P     $   /
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M 0 !! (!! ,     ! 4#!@$"!P@3$1(4%0D6(@ 7(2,8)#+_Q  4 0$
M                _\0 %!$!                     /_:  P# 0 "$0,1
M #\ ZU;?[51A]6><Z?RK:]S6(VP5-W;QCG@MH6;!@,!"':L]'M/,/)NVAT%5
MZ+ETAD.DPS++(3.)MP@4'@OMRC\EZ'Z+'N'3[.XI)N&3?D,]_9V9_J:6J*::
MJEA)NX[1FKD="SKXR2=Q8X\XAS,9KB>/7Z@T'\?G\@>WL@KHE4LM25U"\4&,
M!OKHB.*+3/*VS*(!T+'B8?<<(6M,AA@-UDEFBGP<-+#\.<218"2=E]*>@$WJ
ME'YMXW6>4M2']%AN(S7H']K%B"S$/826$!QJ!CO]L.8T6NH>8E.^^2#8(IMM
M8\;$:A(O,'J#I?4.K=;XAU^AUNL7GE<4!);6DL#SZT;'N7$'(-G#"4N:&:74
MH,Y=+^;G<H60R(H%<2!O',$*]I^X7?FB[T6HU"O(K5(6KWLW1(V8K4F=!6RG
M BE+(#.L9AP!GLY8'D>N&<1$6)-%><1_0K36<'#[/T4N@<2Z'U.KX5-2JK0G
M-R2:,,3D*&?ZY5(T$CF_"*#(D&.CTUTTD'*CVQB7237.V,?9L%;!_N3U94>,
M4/T?;>7<69\GN3B-;^#76]N77(73<YL)'L3&U+-7!X-RE,_$(&U=:Z8D%D)'
MBQ)MKH#>^@O6P'):]S46F5,N_P#5.U?K(N9T#\G5;--EMH%B%C8)OMEW  'G
M8B#?%CX]S2\RPZE!BBGL00UE9>^\EMWH&.BUOS^SY_9G485O_P!O8KM)9*,!
M( 47K.1*\=0 EQX(AB6R&A#M88S)X]]Q]1-OR,!AYR](=![)W;TCS=ZFJ(-4
MXA9S*VL9)A7$3IG)+:;(H4RLI#7)P7U_75DW<S44(?$AF^LD7P0Z_!L!$]:=
MY*\\<>87=(  ZN1[I#6*/7F,!A8[ZPN&$7W@Y$7%A,)\Q)1VQVF@D^)<RBQZ
M:ZRYWQ%( RYUZ-ZGVCQ]/W#FB*FS=97"6"0RGG NSZ\:RJS0K!Z1? *]";1L
M&R"(8Y+B5E/KLP-$#(Q\$^Q,(:FD>W5%D\=N?132%,MN*$5Q63*O!H9.O)ZG
M#IB*N5\$+)F6I EAD.1M-18S9#!%+ C.YFWX!!6H0>R^J_2*A_PWAL%'Y<)Z
M-[+7I+JP@>[V-=0>?UXC+O9<J8P1N#'CBQQ"UQP0ZR*:/"&8/&J7+W&\VAF0
M8'F;WV!&YMR3L5=Y%) L'KI55L_/!K1E.^U9;/=70A$#MYLP&-3; *\R1R!"
M1YT9:;Q2%ZY^^,*%?35=NE<]!].H^JEB5-GH<(X,^()?Q,!WLIJUJA99.-<P
MB#%IES9E,1+)K$.OK]@8R;ZA)CYAPKGL;5E9C]$R,6=JT.@:DP!B[:;3RPJ$
MS%Z?MIKM+KC?>):L,DBATSN05-'",+%,1)#'N%L_\%O.+D#U#T/?WR-BH4A4
MNBU0:8X:4>(\VVR17L3\3>37&I&NM9A1M\R0[9T_ L*DG&<Q'P;; WW0:"W[
M'_)9<*NDZ'<.:FUKAZ\O^U48P<-^)!^"ATW!A((BF^$<N2VQY(^'XB/IG'Q3
MQ;_Y8#W^5KK_ .-?HOT-YZMS.M6FMU>M-.K6'L^%VPMS,U5KTCXO>^-,EGS-
M_P (*T%#SY,*E( >ZD9'WDPZEB@ !M8.Q=OYQZ2O##S+>+*3Z)*6VVH]%_>U
MM:!4>=T385C0%X"ICOD\N,8-=-^RE!E'DL<)$.P@LLWPS$@S(W6X;M_%(]>D
M$_>P1<S_ -KG'W2XDFT.3.%M+!P3)GZ9WG8)YT["3[_\Y/V&/KG;.WW[ FJ)
M0XIFOC]5ZL?NKCY+M]9166D+U^HE=J=0M+8;4X<&]C ![$V 1-^VEW*(8,8B
MC$+<MB$5D<!ZAG!N^SN%=>_E#\ZM[?.*+42.;"JJ>?-O%HGC8-1>CJE6NDOU
MU%UFFL3(8:'.F<YTW-52?XQYAVP%N)1P8.L.QI8PF"28 ALDSQ08(,*WQ&,)
M!F7;7$I)$F<1P0:?=++OG&L>NVV?I_H*M_XY,8;=)]MW33.-HK/V_?XML9^N
M,ZCV#H;;7Z?7.=L8^RQ:?3_GZ?;]N,?_ #_H-3U_I=TZ/ZZ6'T3C-E[GS[R]
MHP33+J^V3*U6W9;$'_[YYIK?Y!#/ZHNUB71!:C2DK+"O()VEAAFCQ,'Q_P :
M#9I1+KZ+\ZV9"=3&E?LPG0TE-9FAL#TZMS".N.%(, DF#*D"6?TC[RQ9=AR=
MC?FCQK]^<9 9^?\ AR)I[][=2]C"YN7<EN!/7U5)VWSM7Y+\=LOCKD\R[Z_C
M8UJN+(WPLD^WY]/U0$&_WP?/ID'>]4^4:IZ@F&?U2Z;TGMG*YXEB:V*"9-]U
MI>1@K4MK]DC GA9 ?9HW!>*&($T+--AQ^S'@80%9#G 8>-O3W36VO5N1][&E
M?7[A]D!JQMI101&R.M)B;"NDC:["ZP#$F %UHGX7$4(VS<(H;<L75@,86:!]
M];^<#^^<TLJJB.$M+ZD4B:)J_<FJ\HZ 8)W! !8 -]12-,K3'Z&(FJYML 3!
MZDK;FPJ5>OZVPN@CPYRN.?Q1^X6_= 1FA-<XZMYM:$;J?JVMGK]KR&8 4,X6
ME5&LIF)+9RQWTT@-'"LXM=42Q;;#-2M-OE!E#J[HU'K7.ZVOJM45B*%"Z+2.
M$0./:*#3[(XX8HH(]Y)LC A"PCKE"V*3\%&E"6HE,(BA8 &."JW?POSZ[=7M
M'9\].[G4+Q;=(!F9M"O2^J:1K1@%BV).)*!6\L=%?XJA?B02<\C6>6#6>?,D
MN,;8#''@7A@O/;5SU,3>T>M^,")O]T#L8QU^ND )6S#14ZL#Y0WTB4$L\0,F
M"], JB8&BPR&?-KL3H0#A($2ZM($M950XB4H$ZU$M@SK'C$2Y4%"O#ASK%''
M%C&@T$>F=8XHX_\ CZ:1Z:_37 )LK\$<F3<QZ?QQ9:^F!\YZI9E5I;5Z%S7?
MB2&J&8K0<>N3RU66<0.:18E%,P=LQ((#2+HLD:[:D2$ 5+?YAYS=?/R[SH\V
M:'5-%7$R"N.C-P)[,DGK8>H5?>C%Q C!_ME\.F(99- H83A)"PBHMQ328Y %
M;#PKSZY<8JW'.JVBRW_6@[$0T&_;:A)+Q55,^D.FB0<^/1@$Q5CZ01#0AM B
MQL!#+H-H,RJEY, 2?C/C>A\@=@6DBZ=/Z?:$8A8-5:].MFUBAI@YHFZ\K>J*
M-!!%:LLA?)(#(;L,23J%+.&/) *23#, N2?QP\QK.7']8[+Z5K&E@+W.>PUK
MIP%?&;E[YESDAB.HJH<)DF/GFQIL1I)G327?33Z:[;8R#/<#X'2?.E)*HM%)
M>G+3K QLYS"RE@GNCFS. (8B8LP!:KBG^V!>+%%MN-F7&D>-=Y=_ICZ!HB/-
M%)SZ&']*KG5M27K*#%<=+59RK2KV==J%E?KAZ 6F+/FDU&B6XQD-H'IK*E4S
MZ1ZS03;D!YYMYHI/+^L],[(D>7%E:NK2ERV85ZQ4%)8<DM=6L6BD4-$O,%C
MVUP$%H0P,^P'_KFS/-C6? 03HOC=!=^D6?JE?['W;E%INNB>*VXYG>M*^K=Q
M(DP*!=\X>59$FLL"Q?!%IO\ D[QQRYEGBACEEDVV K<0\^<V\_H6:6A@,)2K
K P_<6FSV-C([M5K;?]GT8/6TVD?SR:?-/M% *.(%%*261&+J2:9-.'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g482402g54x49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g54x49.jpg
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M 0$! 0$! 0$! 0$! 0$!_\  $0@ ,P E P$1  (1 0,1 ?_$ !@  0 # 0
M              H " D%_\0 .A    8" 0(!!P@+ 0       0(#! 4&!P@
M"1,1$A05%B$QMPHB.#E#=X/#%QHD05%8=(>3E\+6_\0 &P$  04! 0
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M"7F ;MF SV#[T>P1QX:S-XZ-4;#U#D-.6%E7(PN0]N(76K+.(LQW#%OUT>W
M8I)O@*#9PL8(EV94C=17H"]%T@E,J4M;_P#&FJ$49VT_*+*]&Y1?Q=9UQ=6'
M$;"<6CD;0XR $7<YN&1=F0]8V5?&KN8E@HNW#SQG /)A8RQ>TBZFV!UE#-7L
ML.(IY,MA00S@"9( X][G=D>?C 'U1QSTGB_8\I!S:Z#J2U%2C[M<,2.#Q:<
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MYG"O.OXGUOPIF&8^@MJAE+(UHR#"73*F,DK;*/)Q_3ZHZJKJKQTK(N%'4@:
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K2IUL+Q@JG/PW:@"8V=Z5F&-R ,F->]K&$>0!C)AS@,!X Y4ZSD6K#:O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g482402g84j41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g84j41.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1+24&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]       $@ U     0 M    !@       3A"24T#]P      '
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         )X   .Y          $                          0
M       #N0   )X                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   )X     4F=H=&QO;F<   .Y    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   ">
M %)G:'1L;VYG   #N0    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     CA"24T$#      (Y@    $   "@    &P   >   #*@
M   (R@ 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MDIIU]*P:\S+S6U@W=0977E3JU[:@]E<L/M^A9L>B8&%C]/P<? QAMHQ:VU5
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  0P!3 #8    ! #A"24T$(@     !?DU- "H    (  P!   #
M 02P   ! 0 #     0#A   ! @ #     P   )X!!@ #     0 "   !$@ #
M     0 !   !%0 #     0 #   !&@ %     0   *0!&P %     0   *P!
M*  #     0 "   !,0 "    '@   +0!,@ "    %    -*':0 $     0
M .@   $@  @ "  ( #T)    )Q  /0D    G$$%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,3<Z,3(Z,C$@,#DZ,C<Z-3(     !)    <    $
M,#(R,: !  ,    !__\  * "  0    !   #N: #  0    !    G@
M   & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@  P
M  $  @   @$ !     $   %^ @( !     $              $@    !
M2     $X0DE- _T       @          /_A 8!-30 J    "  , 0   P
M  $$L    0$  P    $ X0   0(  P    ,   "> 08  P    $  @   1(
M P    $      14  P    $  P   1H !0    $   "D 1L !0    $   "L
M 2@  P    $  @   3$  @   !X   "T 3(  @   !0   #2AVD !     $
M  #H   !(  (  @ "    \     !   #P     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$W.C$R.C(Q(# Y.C(W.C4R      20   '
M!# R,C&@ 0 #     ?__  "@ @ $     0   [F@ P $     0   )X
M    !@$#  ,    !  8   $:  4    !   !;@$;  4    !   !=@$H  ,
M   !  (   (!  0    !   !?@("  0    !              /      0
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M  (1 0,1 ?_$ !X   (" P # 0             '!0@$!@D" PH!_\0 -A
M 00#  $"!0(#!0D     !0,$!@<! @@ "1$2$Q05(18Q%T%1&"(D,G@9)BE"
M1V%QD:'_Q  4 0$                     _\0 %!$!
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M;!52)3"\?*:*L$\MM_ 8>O4%#+T*'Z=&V0%.T;(PL=.QJ=QM,A(VTG;R\J.
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MTS67Q_-U7#22II\+WQGZMQC *;T[<X_M1>L#_KWBW[?Z,>6L9_;W_GC.,_\
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MVL?791>/@P+<>'3:!=V(IELZ&.7:>76P*JF^ ::H0<(CE8R^]0<)$609MG]
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M_>2>J+Y((JJ.3*FHAY:F],:2BMP=P2&03.50@!)'R\!&SJ59V4D<S@L0.?>
MU>%S;W=0L78PMN$C18VLX-DP+LJX7>*!.\U<W5KR92L1Y]IK20C*O@#1Z.A(
M<^?>2E_'1C]^[*JC6YXW]4:(M4R1!\[;9-O2CEO]3EHDXU'H-&C8)6D*+A]
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;@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g482402g85b19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g85b19.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[13F4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!KF9F         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  (#P     $  CA"24T$)@      #@             _@   .$))300-
M   $    >#A"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          CA"24T#]       $@ U     0 M
M!@       3A"24T#]P      '   _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              (4   %0          $
M                     0             !4    (4
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   (4     4F=H=&QO;F<
M  %0    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   "%     %)G:'1L;VYG   !4     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ /P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M &E5PNB]/PL3[%57ZE!B6W$VDAL-IK+KM[G,HK:RNK^HKR22D3L7&>"UU3'
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M^K>O;L24_P#_V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #
M     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !
M,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0
M +P   #H "&Q    )Q  (;$    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,3@Z,#(Z,#@@,3 Z,3DZ-#  <G(R.3,W-#<       .@ 0 #
M     ?__  "@ @ $     0   5"@ P $     0   (4         !@$#  ,
M   !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!
M  0    !   !1@("  0    !              !(     0   $@    !.$))
M30/]       (          #_X0%(34T *@    @ " $2  ,    !      $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    )    L(=I  0    !    O    .@   /
M     0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.#HP,CHP." Q,#HQ.3HT, !R<C(Y,S<T-P       Z !  ,    !__\  * "
M  0    !   !4* #  0    !    A0         & 0,  P    $ !@   1H
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #H
MD@,!$0 "$0$#$0'_Q  >  $  @(" P$             !P@!!@0% @,)"O_$
M #40  $% 0 ! P,"! 0%!0    4! @,$!@< "!$4$A,Q%2$6(D&A47&!P1<C
M)"4T89'1X?#_Q  4 0$                     _\0 %!$!
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M ZP6#NZ#L>+D([@#F7?!+2%JD7N4KSZ,@+-]9IV$CCN[G-,E)I^J9>'J@LV
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MW"9+#L])K),Q\L3U7 #=#5HWX+X:,=JC86$'<+VW.MENB?&NO%![]=5!:/\
M@SJ4]OIV>NZ072DS1"Z6N$K=/H\-:^ 'Y,53)4-P]@R0.V6X+-0I"/\  WD
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M3_<:VGHP2S3JV">6O9_23PNP2R^DJP.)Y@X9$R07I0E?P'@/ > \!X#P'@/
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5E6O''!6K01QPP0QLBB8UC6M0/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g482402g86h55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g86h55.jpg
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M=ARB%%AO.-<^BOJ"A''O^T^38_OUI(V-P$]T=X-N,!1LG8^39=3P;) YZ@I
ME!+OGT1.ZK&I8\^3QRG/E<*0I[R(!X[+[!SG&,=6=*9SG.,8QC>>T,YSG/\
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M^F,J)00;:KFN?HX=C"E'ZK[D>2TZ79.Z^Z"^G?6[+=C&9>:;6;EX= X6=EF
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MV$E0W<9:+C9:+,* .&<QEM\4AUI>,I7G'I]-:3FNP.*GJB+^"Z9#_J>_%O\
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MV/XDZZ#C)6QO2$?N<C6,\@NQAMY#<9B(TZ+;RU=;7.R6(\MR0PV%7ZAS0?\
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HP:$54]%5/N7C5 _ZOG@C_4AY"_\ 37IG_@OT:]ZS_:+_ )E_KK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g482402g88f83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g88f83.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MM45<7GZ[JNQ[A?7%@2&BQ*^05FI!2I\91JJB0;"KTN?+&V^QT((,DE'J!''
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MYRQ$P<W2(C7YQ4_+I2TE 4#$HV)8I&>\-%I6/<3]]LJU++<8BV-,-#+P4E5
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M?WT_Q5B:-\VR:J?+$MUXMQVO&WK,5JZK\X\N(1!5M(-?51/?C"0J!5FMU12
M1.<4[:#ZP&"TF)-+&"S%UT^RH@0:""BA,W$141$7.+UFNLSTA:#"& P& P&
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M_AS&\A];Z<'9E)U'Z MFUJ2G>>/[42]$^@5S_)*RLGU=LP@MAUF^<$?:57C
M1IOFN_'?LS<TXDLTFR;$:^X5.:*_!3,6U-3$5G6](VCOM]^K1J]LU^8/"?GM
MMOWU18P65,] >@52T#54KIK2_O29!=MGT,IH=24N)18K"X+Y&:6 +S'T!5W
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M3!SBT\&WM*(G>G\.IJHN/[;J9UQ/O9Y SM<)[U/+\!3+ZN+E52QZ3LN#SMF
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M##"K-MRSO/'JVZJ+5_3UY'^8?G7T:KOBPD57'8B-E?XK2?UG(OG4A$9C+(H
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M&/:FJ-@-6=NZC.9SQ)',-08N;1BI/N54"(4C\Y2N98F8T\_ZG;OUW9T7Y/\
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M'5=V8*]V@K<'03,-L.A.+LFD!)A2+P&R,6X-XYI6#@(*PK[C /1FL.QBA[%
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0>GW?KTV^_=_IS;M@,#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g482402g89e77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g89e77.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1X64&AO=&]S:&]P(#,N,  X0DE-! 0
M     "D< 5H  QLE1QP!6@ #&R5'' (   )H !P"4  -5VEL;&EA;2!/<G1I
M>@ X0DE-!"4      !"O(E^J'O!2<#RCGR)?657P.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MP     $  0/      0 !.$))300F       .             #^    X0DE-
M _(       H  /_______P  .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))300*       !   X0DE-
M)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@              N    80          0
M                   !              &$    N
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG    N     !29VAT;&]N9P
M 80    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   +@     4F=H=&QO;F<   &$     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !, * # 2(  A$! Q$!_]T !  *_\0!/P
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M;MHH;M8._P#*>[]Y[W>^S^6N2_Q<LP:VYE;FN9U4$>JVP0[T/\#Z(/N]/?\
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M;?L8VBU_KWO_ .)N7:)]4E/_V3A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %*34T *@
M  @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    .    L(=I
M  0    !    P    .P +,)2   G$  LPE(  "<0061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q-SHQ,CHS," R,SHS,SHR,P!7:6QL:6%M($]R
M=&EZ      .@ 0 #     ?__  "@ @ $     0   82@ P $     0   +@
M        !@$#  ,    !  8   $:  4    !   !.@$;  4    !   !0@$H
M  ,    !  (   (!  0    !   !2@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%,34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    .    L(=I  0    !
M    P    .P   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q-SHQ,CHS," R,SHS,SHR,P!7:6QL:6%M($]R=&EZ
M  .@ 0 #     ?__  "@ @ $     0   82@ P $     0   +@
M!@$#  ,    !  8   $:  4    !   !.@$;  4    !   !0@$H  ,    !
M  (   (!  0    !   !2@("  0    !              /      0   \
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M 0$! 0$! 0$! ?_  !$( #P ?P,!$0 "$0$#$0'_Q  ?   !! (# 0$
M       )!0<("@0& 0,+  +_Q !!$  !! (! P0  P,'"0D    $ @,%!@$'
M" D1$@ 3%"$*%2(6%S(C,3@Y47:V&!D:)"9WD9:U0D556&%D@=/6_\0 ' $
M 00# 0                $$!08" P<(_\0 3Q$  @$# @0" PH'# D%
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M'"VF&,@KG?TW;Q/#(9B,#2K>B ,YZS?"HA#&-@6D(9V!S_14:=0P/60>IQY
MJW0JX#?NPHF.7NTH3VM@;)B5!ZCBY$?'R*IK@U.,DVO#;O?(\O?<82F/=PTA
M\6H,M.#D+'M1H[;_ )5X,(%/%+A??IP1:JPWCA/63?HTWYO0B/YP@->-\0,A
M%E$WO:;S$'X<@QA#C\U,9(\V.^ZU%?K_ /)+]J]LZ]XR0$CAR'U;$HO-Z'8<
M7X+O5O%[0,>:COX*?@*;EJ1&6G'TBZ$-KSE;?BBC>ZCQ3QKFUX5&V8[11<7
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M':/DWCR)'+SSPZ1&6EZ.<><QS+';6EO:/:VEO*;@F9U>:6;0T:DA/0C2-'<
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8\&.RX6Y[CCCGF0IQ7FXM7?R4K.2BO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g482402g90y79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402g90y79.jpg
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M 0$! 0$! 0$! ?_  !$( "< Y@,!$0 "$0$#$0'_Q  =   " P$! 0$!
M       ("08'"@4$ P "_\0 .1   04  @$$ 0,!! @' 0  ! $" P4&!P@1
M"1(3%  5(4$B%A<C,0H8,E%889?6&2528G&!@I+_Q  > 0 " @,! 0$!
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M#)R"ZO\ QMN+?'G^Y#D'PG[*OZ_G?"?_ '[?'X>O^2!LGZ?XPP?7_P"QO_\
M]]*7_P"T=TGIU_T;[7TC]9_%,3TC_P /10=;?4UX![&[&OXZ&"U7'NXN%DCH
M:S8#UCJK0%1Q/G6NJ+RJL#8?U)T,4KX1+46J4QS6CU[S"Y(QW#CD#V\[OH6*
M?GF-QN=PU7M*[9Q3+'R:*R* A]JG:0D_CP9#!-K,LPJ)DWPI0R<&CB#WD<6\
MN9^KJ::^;U39<A)AC*6?53FEE7@!-FI0R5&U87\R5@9+1=32E\C"JLO>0JEB
MRJB(JJJ(B)Y55_9$1/\ -57^$3\ WIM9GI]S]1'W,S^WI6_/7JQ=?^)+XS'X
M>LN^:M17D/",=DR@Z['CGQR+$\!NK)8:ZS);+X9\M!37-<KE=&EA\\;H48_2
MO;+O&T4DY7,6*>HXUZQ<K\36U^4-!1W0^<8N5?'7(]2[;UJH_IT+P]A0?I*N
M4/?+Q9H>4L:_KE/)<BYNHXJUB<$ZO5P*K0EV%5C..&Q-QT'T'NQ>/R%7N[@^
M5Y0)<#M-ZT-A1&#P[;J?ILP,6U91I)N1)FF30(K?,@X=MQK2QDM1'-57QEM9
MY<U/*>47\G8>TE-U1EA^3<;DF*GM8(8()4!_?Y3;5V"X2YZQ/T2IGZGZ^O0F
M9_$/LXRPM>Q\&YK"I?$F@V;6R+#5QTZFNO?U#' V(B1ZD#^W[B.OZ3+'.1^U
M]7QQU7H.TYV%N['/W6;X]U)&5'L@(+JLK>1%IXJU)"YHU#(F$(O:Z(EK$C1R
M2221K_A^QP$P'&=G/\DW>-DYFFB]4R&=QH9-E=YU+#\#%LK$BH"\P T*3R7,
M]TQT&"C\W6&XV[G*EJ/"6+YMLZUDK>*R&'U3-MP:KE561IU-LG'A3@WL'X[&
M5VY.H#A'MZP1D,_D[9A'3WO/0]P[?;@9;C?29(#!UU,7;6UY;59L4I>@).AJ
MJX<<"/W_ "3PU-J2^9\C6QM#1GL>LR*SL<J\-W>*JV'=DL_C\H_-/MJK5J=:
MRHA516@[+S-Y=.T#M5EB,#,E+9GK$!TF-\ ^Y;%\_P![9*V$U',8&KK%3'/O
M7LG>I6 8_*NM+I5%*JCW=[%T+SB810(0B![2ED2)V_@8],UZICL)S13]>N']
MES!>UL]S68Z"KFFJ!#1@#+%]K>5E' ,(06CH$)6:S9)%$]%6=8_A:K7/1S99
MHVI6]ZVK$ZK2L!4L95E@ M-4QRJ\5J=BX;&K5T/QP%<H(HG\D3W3UB.DCSE;
MD.AQ3H.P;]DZ;,C3U]5)C:"+*:MBW-W)4\:M-=UB)5YI9<$@ H_FR/CB8DHF
M!CZA^H1@.W6RT^&H,7H<9=9W--U,;+VQK#F6M;'9AU1RBH!X=&\$FRK5D21%
M1["T5OCXW>2+REP9F^+L3CLQ>R]'+5+^0G&E-)%A,UK$UVV4^3S=8(7+18[>
MWITE4]?ZH]!K@7W5ZMSSL&9UO%:]EM>R.(PXYL1R=NE9B]3&XBC9E/Q>DB55
MUNGW]T3!#8B8Z=L^IQW$[96?4C-9_:$\1V_(F1N;!U,?=U&E%IV9RY>Q\U>)
M;CD4]C(P6VABG0"PB5\"E#3!%-&FEK_O<;BKC*ORAD+V(5M%3!92JB+:*=O'
MMM3?J#,"]E5B[2!EE8R#SH*(/Q,%R_( O\,EY_YSN<$8?%;$[0[^V8'(6IQU
MK(X_,(H1B,@8DRJB^EM"V8HO+!D5K822O.HZ[H2QE7Y/6Z@]O,3V^PUSJLQ4
M'9:ZR]PRGU&2M#1K RK<7 I538P'"QP,,J[:",I@A+Q0Y?N5UF*X9&BLGGU>
M4N+<QQ9F:F,R-I.2J9&K-O'92LIB$V84<*LH-+".56:IDN6KAC1\3Z[(/^;(
MAN\"<]:WSWK60S>&HV<+D<+D!Q^:P-VPFU8I$]<OHVUV4@H;%*^H7"AQ(0?R
M*EQ!*Z(%C97VC[%4G5SBDKE;04!VFKQ+RFHUJ*P\,"PGFN998HI!I#FNAF=!
M\3II8$\/4=DTS5\0N1>;QQH=SD?9E:S1NIQ[VT[=SY5A+7H *@"90P4S!C!]
MT )_<>20&8_-$QW>:N6<;PMH]C>,KB[69J5\ECL;-"E9KU;369%AK DE9B5L
ME79+#7]%XA8R)Z+F)J?A+O!E>4^'=AV!U^+N.&N'LFZ2&+7[2U"+31$CSH(9
M'GZRJ&E,L(QSWPU$,D"22V=[.E+4CG'0&QBR;<.'LEK>UXO1\5EZNV;5DX$B
MQ6(K-7\ &!Y53>L66"I!&B"M$)]HUZ0_+LL2DU$R#<<>Y'";MQ_G^5,_KN0X
M]T#!R0!GMBO5W?B[4L\%@<73I).Q:!5HET%FN".[DV1CJ*K-E5@$AA?^LQ0G
MWAE7P]UPWG) 0GO=]ZPT4>=.E'C=[%,2DH\ON9H19/'NC>29!(C%;\T,,GNB
M:6Z7M-NHIJL[5OV%U]S>V/"B@5](L*.OB^7<R.&$V#UZ%"U&/=U[#,>A2O&4
M_B$XNUD;%/0.(MHV^NCNGY-K*AB;!I&9'Y'X?C<-LK%I.8ZA+GJ/MF/("SZA
M'SR7K,U.A+*JS^MVK!MPXI92 :W>5UHL38)XAYDF4_+4$T+XYIF,>QPZN:Y?
M:[PJ?GLK[3K6/2JTG?\ &/J.,06Y^&?6[Y,"8$AX<C= X(0*8F&=)B.L=?7Y
M@/X@]',6'T;'$.=K9"NMC'5:>S5+TKA35I9#)LX7%L @8P1(23U$IZ3'7TIO
MD_G*UT>MU]E_B?>M]+<VQ9#GN\OL;$^<T^?_ #_99#IR'M1J(C&N;&Q&,8Q$
M9W6]*K4,7BJ\]OAK8ZI66$1'U70@%(#]/OHD0CK,S,S$D4S)3UK=Y"YFRV4V
M+965P(+-O.Y2V^T9_P!=VU<;8NV.W^J".ZQYB,0(@/8(=!B('P$]O^<PN,/[
MG*C7_H6 ^$P=N>H01:L=L-B9-86,:.%8Q60F'$$%S#,]@K2)Y988(GN\I]UN
M(]%#/#LQ89;LN+ ;%EYDS^8L(6LX">@>01@1ADQ+2[?YAG]]<L^Y3F:WJ$Z+
M_BEE/622Q#*=) US)3V2YZ_+!3(J<PB9X @4)(IFNI/2.@P9KDS7<5::LV^%
MO#,_IJ:7YZZT!GD@(A>J>UZ))$]C_CE:KF2M1[4EB<Z-_F-SD6>YS#XO.XJQ
MB<S33>H7![7UGA!K.(^XF8*)'\L_83(SVET*.A#'2#:7F\YJV<H9_7,E:P^8
MQK?+3OTFDFP@NG0H PF)[3#^6P/L6+DP*)$IB:Z[)=BN3^Q6D'U_+%]#H]"!
M60TH]G^G @SMK!I)I81%^I#"Q(892)Y6QQM:QTDLDKVND<YWY <3JNO:?1.A
MKN.7C:A-8^5+-K9EC.V"*6.8UA24 ,=".8&!Z1$1^IESV\;CR)F%9S=<Y9SN
M4"JJJ-FPJM7A==,F2E BFBM7&(EA3)0F#*3F3(B^_3D?]'HWEY)H>R/',I,Y
M&==48S8"#22.4>MMA#[6I,>+#Y]C)+8>U'^[(B*^5*D)KG>(6HBF^Y2F@BUW
M(P,#9@[E0RZ?F8DQ6T!(OUD4FIDA'[><YC^KU8-['<A<66[8>9(J#48O) ,E
M/C3;0Q]5A+#ZB"M(L*AI?<D--,3/08CUI[_%5]6"^LI!,(.E]6:=#)!V A]L
MY"R9"9(XQF)C=:IDGSOE<D38TDHU1Z/5&K^[7?YJGY9<LW8_VQ!*A.7-XR%2
MQ6)$R?Q7&^$>R!CN[I&Y]=OW'ZQZH\<NMF/?4R+!J&M7YS-[3<8 D8U_.38+
MR$<P$#!8WH4%/2?L?W],K]6#E;KA8< VV,*M\/K>:#K;.KA!J4FINM3E'"WH
M!=[;'%U[R"J&K)S\%K5+";+ VV)/AB@&G6"4@)??;+K._)W>KEU5<QC-236O
M_C3+:[-3&Y*&TGJIUDJ? +NV5WCK68-(G-9:3,V!WB#7#]\N\<16N+;VO6+^
MMY[D.S>Q4ZPG'/HY'-8,D9*J_)7K+ZI-?BZ+<4N]2E=@UC>=96M2F2LVU^WZ
M0O!G('%/#FXV.\J[#.IRK?4=EF<_:PRB6+*"@KSH(+\D&=K)@FW\]M,@<1$<
M<Y%?6B6"-40T2233]TFY8/9MLP^*PME%_P#PU2N5LA>K&+:Y7KKU&=);@F0=
M-(*P>4@(@![VHZ^131CH^PKC3:M'X^V38-GI6L3_ (XRF-N8;%7EFBV.*Q=2
MPI64=69 LK1E&WF?'!H UM2G7M0,HL5S(Z^U7.5?UTX&Y!Y4*? ME35#PLH%
M/[7):;*X7].S07Q*ONG@;93Q&V+(T<^.I#L"?'L@>J!GC;37[YNF#UI0G\>W
M:%N3<'6)KXFK_/R#N_\ 0#^.!*1,](*RU"^O4X],SS=R54XEXQVK=WDJ;F.H
M'7P=9O28N[!?_P":8>MV?U,7\Q@6+<!$D%%%IW3M44QDIY*X"W^8X0XM[(ZP
M@HH;G'5[MC?MLD4R-E;(!/575B1*OR2E;$M=8>.US$1]?4C6#))66*>RSW7M
MWP>1W'8^/\6"ULT[&8:9\1#XBE\.79J(6/T*\4O\,0R8F>C[+$2(RC\U$VX\
M7;3AN-]*Y?SK7O5R5G-FB/.!><!J'5;1R-IISW&_8'SG;2HD8@JM%-H2,;7Y
M-5_1_D_^][JIPKL)B/LV;,<'E[V1SO=.^]Q4DN3LR"47]VSV$].MHJ+X1T9T
M<C$^.1GY6GS#KG^%N2MNQ0K\=><JW(TAB.@12RXCDZRU_M((7;BMUC]"20S]
MC/J[_P!MVY_X]X0XZV V^:Y&OU\-DS(NK2R>ND>"NM=$S,BRTW'S=Z3T[@L@
M8QV&/H1?67-:+U1S@ZK_ %6/-.2$8G\K\65W9[E_^$0/PJ_[U1/Y_"C[3DRS
MDV\<?I7U'*-G_P#+)89$?^+O_P!_V] ;^(18%/!N*5,_=OD3 H&/[R&%V:U/
M3_Z17GU[O22S]37],B#K<>O6MTG(>]NK1UE&,X&0,46GH")#E*:HZBQCT+FS
M+/YA;%&[WJC$7\P^Y^]9?RT":K'Q8Q^"PE2M%<F0X6L9:O *?'/?#".[$A ?
MGDBCM^^GK9]B.+HU?;TRS>55FIF-KVC(W9MBJ:QUT*H8MI6?-'BE JQ<PSR=
M5P EW?77TFW'YFCY%]2.H Z^@PMQL?9 +29N3/1?'45V2RVM@O[N\JF#HD(N
M>& K+*RJ8XTA&;7J$(.R-KX84:_*Y"Y@?;_:=O+BG+%H#<??&^7=:?E,EC#H
MTJ=F63)LO,=8KHLD4FR7PYID4B9^J^M?P^-V[W?T*W%59<:\'+M?,8@\2';0
MJ8'"9U64R>3I0J(4G%*JTKENB 0"(JE6KJ$1)8>G&>K7V,N>'^$J7C;(V,U7
MJ>:C+:I.L!)71& X2D'$=J(QY8U20>>[GMJFE^1?'R51-W'$J3(V2)4_;#H5
M3:MPMY_*5PLXW44UK24-&"4[-7&-C&RP2CM8%0*UJWV_]&RJI)1(3(E8#[[.
M6\AH''&.U# VV4LWR+8O4+-M!D%BKK.-4B<T*6!,$EN19>H8Z3G^ND_(B$PR
M!,(1Z2W5+)9?B>N[%ZNC"M>0=\39/QI=D+$1)D,A6G$U$,U3'.QZ!6^A,#..
M(M8E0AU(^K$&>/%-8M-Z_N=Y+R>2V>QH6-N-K8+!KKCE55V$$93*O2NT0VB"
M8\M6BIJ4KK%_+BW%EK(80H\,<]BG!^#PFC5.6LYC:]W:]I=<+7WVT@T\#@*E
MEM!;*(,$HKW\M8KV;+KJ_P"<6-*DA)*!EL;#4>5.)\!S3BKCC_DG.5^ES5R-
M+#*.9#&XD$A\;F0VE.8K'$55P"YWS V0;XB1I6HYCU:KF.6W6]FS>HY>IG-?
MONQ^0IL$P8HIA;@@HDZUI76 LU71'8ZNV"6P)F)CKTF':W?1M6Y%US(:KM^(
MJYC#Y%)K--A8DVLV0(57J%B1EM+(5I+R5;E<@<ED1(ETDAD#O4=HZ_CWT[]3
M@Z^:26OH:WAO%5DLZ,;-.)G-EC(A7RMC1(TE>+2I)(V-$8CO=[41J(GX:> K
MC\YSMC,T\1%]RQM>7L"'60!M_$Y<F0,E,E(PVWVC)3,_IU^_OTL?NZQM75?:
M=G-9JF;*N,I\?:[3-D##&(Q&PZZ"2. B!@R1CNXH&(&)Z]/KIZ'_ -$FD9!Q
M1S9HT8B26O(5%2.D\?N]F?S:'L9Y_E(UTLCD3^/E5?Y7\F_N_N2>SZA0Z_5;
M W+D#_:;V0E,ST_VHQ\1_GVQ_;T+/X<6.A6C<C9?M_->VS&XZ2_O&+PXV1'K
M_LSF"G_+OG^\^G;?B@^K'/2.?5.Y!O\ E[DGA7I%QK-]F_UFCI=%L60N>Z(8
MNTEEKLD#9K"ONC"JJ^6YV%Y#,BLA ;1V:^$A:]'%]MN#I:M@-NYAV /'1Q>/
MN4,5)Q$$Q=<0?DW5N_Z)UEXU,53(/LWE<K]?SS$UL^]G:LIONW\=>V_3V>7*
M9[+8[+;! 3)+2ZZPZF"K7)7^8*]&J60S^26?TNJ.-N=(@(+TOOJI+8=2?47I
M,%=FO4.MY)T'#%N9*SZK+>IU,Q.=S=M,SW*T<0RP(S.D:CG*R.%D:O<C45R'
M+DL4<H<"V\W44/E?@*.VU5!/DFK:QH!>R%8)^I-BD!D:$](ZR4ETCKTCTJW!
MY6^"/=MC=6R-@OCU-ORO'E^PP? -^AFS;BL/>8/=,*18M-PV7B"F1 !'NGI$
ME&H+E_B[-<T\9;7BS70)-0[6A,IR9/C9+-7DR-2:LN VO_H2PI+2$.WKGN_I
M8:% YWEJ*BUSZML>0U'8L1LF+/LNXBZJVL>Z1%RQF1L56S'WX+E<FU7Q'W*7
M'$?<^KH=]TO#\B:;L6E9Y4,QFQ8RQCW%V";*K3B#IY"O!?EBUCK@5[]0I^AL
MUU%/6(F/69[H/O\ 0]1>[9?$>\E_3:_4Z"PX5VT#GO:#'?LM7#X^^@^1&,D@
M=H8Q!P["160MH-$<8URQR(JV$\VX2CRCP^G:<*/G?C:*-NQ!1$2XJ)5H/*TC
MZ=9$XHDUC4#U.;M!*ICN&>E.?M=VC+<#>X^QH6SG\2KF\I:X[V)4E,5AR@W9
M7K^37W=HDN<J*$U[1S"QQ>7LOB9$XGT5O9#17OJ,=O\ .]8..K0B+@[AVR+L
MN0=17.20$HZME:!J]'#+X>,3('\W]B,0KHYXI;4^SMHWS4UA+(.-- H4N!>+
M+_(N>K 6Y;7776P6-?':Y2; R_&T3#Z8L6]GXQE^D@0UDUJLP%I(B9QY=RV3
M]VW/>)X8U.XX.-./[CKNUYJI,'6L6J9Q5S>56R()331Y)UO7.X6 =VS=OB3*
M%DC5;/JY8]^&ZC<38[CZH_1>-\ER+G:<RJJF/:'75P.2T8>;89[5<]XGVOD2
M4DM[_LV\H4Q,LI\T+W1CVO96,SRCLV5SEKY>?R>!OVE6;)1+7V'9/'MODKKT
MB&^+IV@N(\=46@L12!#$Y]^. +6N!M&U_5:'X=J&"VW$T+%&B)Q7J5*V"R]?
M$!8Z3)%7A\E!M>1>6^=9CC.R:RGX^D#SEPFSB5W"495/EN8X])>7-D'8?7!.
MY%%-F6>MLJ@V3V);E4U6D=//2LEDL AJU;"(50B)IF??NFTW;YVC_&!*M9'5
M"H4JE=R.]R<"Q(0NQ7M*'K\5=NSW6@MR(I<RQ""9#5@$X_8/R5QR.B3QP#L?
MA>0%Y?)Y"Y7M>*M9VU%ELMIW:%@^WY[\=2[,>W'"9VJR:<VP3-=S&"R/DKJ[
MPWREK!-YH,P.+M!JHJCGTM/&*#9VM05. 5]*ZD46:.U:)/6C.KIS(Y2J]CB8
M!)XARR8I !K_ "-M>N8QN%HY%C<0RRNX&.M$UU:M:6#E^:H,,$JTL"PR'@HA
M6^86;0(U+(6]W#A;C[=<ZC9\KA4IV)-%V-;F*"T5[MZ@YM5WQLB?A,;T(;42
M51E@3=4&7*0P%/:!Y#.=<Q8<<\O\A8<]CX"Z'76U4Z-6N_Q9XSY!W(,OCQ-'
M(4DD4#XO+)OZ?C_S1/RTG3<K6SFIX+-+8$INXRI9[Y*(@0-0R/DZ_P!!]DA)
M 4Q,3/W]^OY\.3--M:OR-M^MOKL^7CM@R50UB$EWM&VV&RKM&9:OS=XK,(F"
M@>H_7U%)$&*HQI4?F6&OD A.E:J.062U;9.K&3^%58OOI3VOU?=X^?Z!:1KY
MA?XDOR:H6/AD]<6O!\F*\3$,E'?XO+ _ZL%^62^^DS'7ZGIZC=?"WCIQD8JM
M_#_E?"^7 3X(M^+Y'@D_V;*>K8B8^Q@IB"[9Z53HKQC8Y9'R-C9&Q[W.<Y&M
M9&UJJ^615\(C6M15557]D3_=[OS1NVX@3(B@1&)F9+I$",1U+K,S$1'3]9ZQ
M]?<_MZE>*QI=P (R1F0B(B/4C*9B! 8^_N9F(B(_O_>8ZTE?VC'1)(BN1LL$
M9$:N:K'/AGC9-%)[7M:]&S1RQJQ7-3W-E1?'^7F&7K8F D)1(L&#"?TF1,8(
M9[9Z3]Q,%TF.L?77]>GHBXND0E(S$28M-9])@H$U&2S#N'K$R!K,2B)^I"8Z
M_7K1)_HY^2M22^S_ "/-"^.DA_L)B0"E;_@GVLZW%]<00O1/'R5(L%*XABK[
MD;<#*B>%5?Q-O<=D%&[7<>)1+ABY:8/7K*UQXEI*?WZ-)C8&?_DE^GJRKV58
MJRM>ZY0ED%,1Q-!+9B>U]EDV7V%C^W=52BJ9_?W%U<Q^\^M0OXL/I\/607&<
M2T_:?U!]CQO?VMM4T?(?,G.5I8V]&HBV8HU=)N]='((X\<P1%FFK(!G+,/*W
MXIW(U$>K'-M,RVSV^-N"\3L%&M5M7<%J>FUJ]6Y#?C-98'"XLA9"6*;T +!L
MB 8,]P1UZCUB:$->T3'\V^ZS8=0REZ]1QFU\@\EWK=_&^#YJ4U#V;/ :)M)L
M(B6MIJ3,L2<0#2Z1!=)@UNPWI=776S%7'/G7WE[2&VO%P,^LL*F^  $O8*>J
M8I-I<T=_4H.&XFG"9*?/6F4\320H"GPGH3%"$6(=%]QU3D'+U-)WK5L>JML;
M@QB+5)SV4RMV9\=:K<I6I8V M.D4!83;*5N8N"3XR-JF-Y7]EF0X?UW(<H\4
M[[F'WM*JMSMNCE:U1.27CZ(2^]D,=E*,)KR['UP9:93L8\1=74Z5VH<M:'E3
MZ87>/>]C9-9Q-R\2-=[K'T$.JI-<.$+7%:',QV(=/9P7H8$0U?\ JE0?9U"0
M'A##_J0A[ON0(8%*;8#;W%<.8708QFS:L#*F&RUT\;;Q;',>NAD20VW7*DUQ
M&_XUI%>U)(<QGQVH_E,\+@2@V^S'W*;/RX6=T;?6IR.S:_BUYO'9Y-=-1V6P
MXVD8^XO)UZP*JQ>H6KE"%VJR4Q<1:GSI%]8[%L/_ %:^PU%M^:L'U[EMK&'C
MSC&QK+SD\F@B@.L'Z2^; A$0 9)(H)UID\:5*M=%,:)$MOH;.M.E'49TD93]
ML.BW</J.;WH*J#SNPU[-/7%WB-*(H4I/L)[5K8Y-;)Y98P\@4POBT*[TB<,B
M" /OLY7QNR<B:QQ0=^VO4].N4LENC<6"K-HLMDX7#0K5VN16LW<'K[V346RP
MA<WLK;J6&*E,F'B[A]Z>IO._5Z+@SCK'\H9^SR$^+*XT9=9C,!T%,N4^*D:(
M02#M;,V"#^QY=S6P20A$O4B8?Y6_&LCVYN*N&N3M+Y&+<L]E-=O5\H&67L,U
M,CD&W;<9/NMRP%NQ%=1G^**J6#$W+CL ^V>O2)P<_P#N8X+Y-X7'C34\#NF*
MN8%FO.T\<CA<.C%X^<%V8\4-=7V*Y84N<"_(4U&NNXO*Q7?';)E!"^BCR@EE
M@.7.'S"?)&6TM9NJ6&1_F1]9J@4J+>(9OGR@U?8YT$B9OA&M(O4>GETKO$%]
MWFN37SFK[4I?1>2Q]C#6S&/J+.,=-JJ3)_=CZ]]H#/ZR%+I]0,=2M_#GW2+F
MJ[WH-AW5V$S-/9L<LYZD5+.5HH7@3'[)J7,37:R/J(;D^L=9.>G>];*T2'A+
MB"E]WA;#E,FT1GG_ &DJ,E<B*[Q_/L_7$3S_ ![_ /G^:7M"K=VX;3;Z?2-:
M76Z_V^5E*C8C_?\ #G_N]=/^(U=A?&^A8[N^[6[MNP/]XH8'(HDNG^S.2B/\
MN[_/TGG9\0]@L+U4XHY59N=59<#\H3: :;)5FAT4>?Q]V-I;NO@%OLY]S]$6
M'4)4SVP%I -\4Q:D!',A+0*6R:K$[3HV:Y+V;6IPN-K[IKHTF!E+%&@5[*TS
MQ]1YLI7_  _,@\;-D*SJQL[A5 .3)J\HUT"V+0>5=8X/T;=QV;-W.,=T9DU,
MP-/*Y<,5@,BO+Y&JM.3Q'R/PV5YJ*+;M:ZM/8Q\MK616_P".=MYWI1#=:+/A
MJ31\39,6BY:!A$S_ ##-;'ONM;^H>/G&)$/*1CP\;H?J_J-6%5C UZ%"$ FM
M.M*:8UZ:^Y=G(5?;(H;/DV7=8<;;VJC61%3%^#^ABV(5U%N6H^3P6766.?XV
M@Y4IK6P3%EOL=3P[<X]/+Z)@DXS>:X(Q6_LO6BR6=^7T\B6IMO@2KZ_E?#\N
ME6I)K5/.AM>P-F[CVV2!#ULICG<V\0#R?)^F1<5DS">?/Q?>GUMRRQ]G\?)]
M<>K^3Q^_M^+S_'X:?:$"8U#:C'M^06R*!O\ K>$,95E'7_9[V6>W_/N]+%_$
M:99GD;05%W?##27L1UZ]GR6YV^-KM_;N\2J?=T^^G9U_2/3K.E)-:7U(ZZ2U
M3HGBLXCQ8TJPJBL2R"IQP[EJ^/V^5EO <R=/\TF;(COZD7\43EU=A7*&^C9@
MH9.TY=@P?7K\=UMC:LQU_P"C-4TR'[=DCT^NGJQ?VZ.J/X(XD.D0$D="UQ)R
M'3M^77QZ:^0&>G_3&^JR+/W\D%U^^OHH/P=>C/Z5CZP=HE?U#^I[O;^N<I8J
MK1/_ %K")H+OV_\ /PE.K_\ \>?X_&1]J];S\IPWIU^'KF7LS/\ J]S*53K_
M -]J(_W^DG]_=WXO DHZ]/Q+=-<I=.O]7C3E,CT_S_\ @.[I_L]?V]<CT:ZC
M]/ZHWQZL\.ON9-;8->J?N^(;-XJG:B+_ "ULM9/X_P#<KOS:]V%KS\F4T1/6
M*6J8NO,?V)E_+6Y_WR-D/]T1ZT/X?-#XG!N3M3'2<IR!G;<3T_4$XG7<?$=?
MWB#I,_WS/^?IF?(>[SO&&%UO(>L+0+.8R@L]%;S_ -/R*)6"R$N'&8YS4F-+
M>Q@@ S7?(49/ -$BR2M15YP6&O;%F<7@L8KS7\M>KT*H??;Y;#!7!LF(GL4J
M)EKF3'1:@,RZ",SZ<?:]FQ.F:UG=KSCXK8C7L7<RU]OUW^"FDW$I(E(PRP^1
M%%9,3W.L,6H.IG$3E]ZN=R>*\EVCY3[4]BZW;WVRT_ZF[$ 9"HI[P?/RZ&60
M0Y[R+K19^05N?R@P60H&P-+^6H-L&D_ ^&!9;&.1^)]ERG'&M<;:&_#T\3CO
MCQF'92U:IG>&B(M3$+J4;PLF]DF.REV3E7;:2B5]\&?;2]PK[@]'P7-6[\W<
MM5-DR>PYKYDZW5P./H9)6*+*F2+)$W(9;%FF,7A$5L#BQ7%COH6+<.\9+5+*
M7[N<\\:<X]BY.;^%1M=0-M*?*E6_]J:RKJ+6#:9EBUD-B#'4W5Z-(-^C5>==
M&1(3#.IT!:/']C8YII;P_I6PZ=H4:?MYXN[\>WDEU?PVQ8M5CQ&1F+!UW%9J
M4V"SY=B_! ($'A-70^O<(COW'\GZ=R3RW/)''*L]BXN8_!OOSFJ5*A=7L6&B
M::[E8:.1R:C5^'TL20--JV_)4Z"5VP)GK6X@Y "Y7XKXZY*KUC0;<XS.Z?XH
ME\M%(MZL8LT!W[K[9:\V0@&=BJJQS#R,555J_E8>TX-VL[+GM??W>3#9:_CN
MXOU8%6RQ2G1_<7J$'!/[@8S^_J]?0=JK;QI&I[A4[/#LNO8G,]@3UA#;])+[
M%6?['4L&VLP9^Q8HAG[CUG,]8SCVNQW93+;^E>T0SDG#5]I<,'5T1":')FR4
M#;5LD?M5BD4T%"/&YJ_*A%;/,K_,C?#[>U+.ORO'^3P=N):K7\RZO5D_S!-'
M*)B[-:1+KU@+973*)_+(6 'I^6>M27\0+5*FO\P8/:L<45[&WZU5N9 5=5MC
M+8*P6+&]!AV]LMQR\6H)B>^&TV,DNIQT;#Z8O7NGX6ZTY?5O@AFVO-5;4<B:
M.T^/Q,VEM _MXNBBD5K9/IUE$:P^2-WE?UBXMWM>Z%T",67W$;S:V[D')8R#
M(,1J-BU@<?6[OR?+K.\66ND,3(^6Q=3*1*.G_-*M49B#@^KS>S/BFAQWP[A,
MX2P9L7(M.AMN7N]O\R,?>K_(UW& 4Q!?'IXRR-DA+[_$,A?*)E<J@3KW>$R7
M)N0O\%NZ,+29+3@25MU3'L<Z L9[FR,<U\;HYQBA2(X2P3A983 #8!S0YX"H
M(I6!G"YK*:]E*6:PMQV/R>.>-BI;1,0:F1$C,2)00,6P")3DL$U.29J:!K,A
MEF-FUG!;C@<IK&S8RMF,%F:IT\CC[0S*GI*8*)@@(&I<E@@^M90:[%6PM5BN
MU;E 8YK^W?I<\D<#K;<H\'6%GON-Z5\EY.%$]8N1L&($Y2G&RL#; S0UM4D;
M2%NZ5HUH'&QQ)E-"*$1:NL!XN]QV W2*VM[E7KX7/W(&D#BB#P&::Z/%"8\L
MG-"Q9DO'%.W+*S2* 5:)C0K13]SS[*MOXRF]NG&MJYM&HXXBR;*P%(;;K**Y
M>>;!#7A<9:I1@8;.1QT*NUP&76,>":[;LDEZ?'J7%E@6W%_9K4*5_9VD;:9#
MDNT5\]M8"#&!5\^:TTS$=-;64;#83:R[E8II(PMBRX)**:,1*/\ G/V^*2^M
ML?'N.A47[DULIKU:("LAK%.>&0QPST"M7*4DFQ3&82MC$%5!:Y8 F#VJ>\2Q
M8JWM+YDS4OG$XT;N!W"YW,O6T)L5ZC</F3")9>N -E=BGD3&;#DHMCD&O?"F
MLNWN]T:S^JY9&[6!4%YO2<M0_9CX0RU)+9VG*/-,9=/2\1RFSHZ.LK,71V\[
M-1K7VCP:UQ],)8:.W'S,F@11-HG*^3J:O6X]LW@QF*G)Q:M9EKNPZN"3)7KU
M)$3/D9<L, J]6%]QR+5)2 DH9)A.5/;W@KV_W^9*6+;FL_&#^#C]836EJ;^W
MV #%8K*VB$?"G'5%&NW?EW:J#1:LV6,&R4+0;VYS]'UNR&2ZVMMJ?1\N27!G
M*W8K34DGSU$'(5V#'657'V?(5C)9<QQ]101U 39V0.,N?UW3J"#+I9A8FKXS
MR&1V2YF=_P D#JM?+ G&:W1?U\B<%2DB58;$ST%UUADV2'^I7B@B.0[I0+F_
M#X71\;K/#^%:C(7=?;:SVZY2M PNYMN4 5V*:B&)DJN,2$5P I_EO\Y "Q;V
MBM&^MXB1RAY7>Z,B*6*5%<OET<K%C<B_[D5JJGG_ /GS^RH1K]P6*8HBZB8$
M$Q_>"&1Z3/\ GUG_ ']>O^86QE TN2T(_F*,#7TCZ$EE!C/Z_?28Z_YS^O\
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MPQ;6!2J\K6ISY\K2,/'$O<I[LJW.F(Q?%_&N'SE#$YC-8[\5NYGXE2YG7C8
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MO7L[Z@1/5/N$#C-74V&FXAN^(L<3=5U.H_Z[F=,_3[F1^EI(2YAA+#[U5+7
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MN5+*R38JVJSQ--BN]1FIR&@:VK(@,2$IB:0_U3^K?_#=P-_TBP'_ &_^2_\
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ME*A>5-R9:*Y,Y"&24!)E(].Z>NYLFE:=N055;?J>M[2N@33HKV/!XS-KIF^
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M@T#IIG1QM=(]7:N-W3<,,IR,1M>R8I%BRVX]&-S>2HI=;= PZTU56RH#L-@
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MYX)ZT\2];JRWI>(ZF]H:B\*C/L*L_9:W0UBGLC;"IPM9?7-C7UYT\,<,)9@
MHQ)D(XT14LT8T#8_;GR#L^_V:MS:+5.[:IJE"+*,3C*%CPR4G"6V*51#WJ I
M(E*>QBU$;"6($PY+W&?#VB<0TK^-T.ADL70R3QM6J5G8,[EJ<VA 5S913RF0
MMU:EABP6M]BJE+K"U)!YL%*H#Y<A]5.N/*]M+?\ (/#& TE\0Y'E7I%",'=G
M.1$1JV%O6H%8V'M1$:S[I,_L;_2WPGE/S[P7)6_:S6&E@MMSF/I!'1=)=UC:
M:8GKUA%6QY4(ZS/6?"L.L_<]9^_6/;.$.(]XO'E-JX\U;,91LQ+LFW%H1DK,
MQTZ?*OTXKV[7;$=!^0YO;'6!Z1,Q,QXVX4XCX>%($XNXWQN$88UK#ILU05]:
M=8M8ONC;964,*6%BD:HBQ_>*G^/Q_1[?SD[!MVT;4P&['G\MFB5,DD<A=?82
MB2CH4UZYGX$24?1>%8=W[]?4@U#CK0] 2U&E:AKVL!8B!M'A\74IV;<#/48N
M6UKBU;[)_H^2YO9TCMZ=/7IW'#W$O)I !?)'%_'O(!=5#,-5D[7&9S4D5PY#
MV2D0 37E<=()#/)&R2:,=T;)7L8YZ.<UJICP^T[-KRW*P&Q9S"*LF#+"\1EK
M^-!YA$B!N&G82+2 9D0(X*1B9B)B)GUFV30=%W)M5^W:9JFTOHK8FD[8M>Q.
M:;44XA-JJS,E4LFA;3 28"I$3(1(HF8B8@W^J?U;_P"&[@;_ *18#_M_\['^
MDOD;_K]NG_%&;_\ />HU_H.X5_[(>,?^ ]6_]*]>D/JWUFKBQ; #KQP<"<"3
M 8$:)Q1A!BQ"QI6S#%"D0T+)8"!YF,EAFB>V2*1C7L<US45,;>1N07J8A^];
M@Y+EFIR6[-FF*:I@R#%L KLB:S"9$P*)$AF8F)B?6:OPKPY4>FU5XHXVK6:S
MEV*]A&CZREZ'I,6)<EJ\8+%-4P1-; (3 Q@AF)B)]7M^0WT3/7.MZBJT%58T
M=[6 7-+<!$UMM46H@Y];9UQL+QS 3P2HY1BPRH)'PD#3QR0S1/='(QS7*BYZ
MMJS1LHN4K#JENJY=BM:K--%BN])P:G(<LA8IJS&#!@$) 400S$QZU;U&EE*5
MO&Y*G5R&/OUW4[U&ZA5JG<J6%DJQ6M5G":7UWJ,EM2T"6P"(3&1F8]57@.NW
M!/%=R_1<;\1<?8F_D$GKWW6;R]55VJ@$OBD("^^,,PI!)Y(87RCME2&1T,2N
M8JQL]LES>][GLM0:&?VC.9BD+0>-3(9*U9K0Y8D*W>!C)7+0$S@62/<,&72?
MS3U@^K<3<9:3D"RVH:'JNN90T-JED</A:-&]-5Q ;J_RDI%T(:2ED:8.%D2P
MF1F0'I]=1U[X$V]X;I]IPEQ)KM)9?7_4=!IN.<A?79_U1H0A?NVMI3E'%?6#
M''$@^:=_PC00P1^V*-C6X\=O&Z8>FG'8G;]GQ="OW^"CC\]E:51/D836>*M6
MM+2OR-,V'V!'<PR,NI%,SES7%7&&R9*QF=BXYT7/9>YXOEY7,ZE@<GD;7@2N
MNCY%V[0?9=X:ZE(5Y&EXTK6L>@ ,19U-34^=J:VAS]574='3!#5M134X0U;5
M5=<'$V 0"NKPXH1 @A8&,A'%&BC@@B8V.)C6-1$C]NW:OVK%V]9L7;EMS+%J
MW;<RQ9LO:4FU[WN(VN<PYDV,81&93)%,S/7U,<?CJ&)HT\7BJ-3&XW'UTTZ&
M/H5DTZ-*I7"%(JU*M<%HK5T+$5I2E8+6 B "(Q$>H=ON).+>5!8PN2N.L5NQ
MX&JP9-7FJB]E#1RJJJ"18"3D O\ +E5)!)89$555'(JK^=7";/L>MM)VOY[+
MX5ASU9.,R%JD+>D=/YP(: .CI]=K1,?\O7 VC1-*W9 5]PU/7=G4L9%,9W#4
M,F=>)GK/QFVT-;6+K,SW(-91,S,3]^J8I>CW46@LF6U=U[XS4V*1)HEL<_%=
M"QRM7W,?'7W+SZ]CF.\.8K14]CD:YGAS45)9;YBY1O5RK6-YV'PD,@4(O'48
M0S]3!.J0AQ1,?4]63UCK$]8GT/,=[;>!\7;&]4XITWY '# FWBEY%('$]PD%
M7(3:J@0S$2,BF.V8B1Z3$>BC%%&!&'#"&@##$AC'%$%AC'&&'A8D<, \$361
M0PQ1M:R.*-K6,8U&M:B(B?@Y8QCF&US#:UIDQC6$1L89S)$9F4R1F13,D13,
LE,S,S,^C4E*:R55ZZEH0A8*2A*Q4E*EC K6I80(+6 Q @ # B,1$1$1Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g482402im.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g482402im.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ -@#S P$1  (1 0,1 ?_$ *T   (" P$! 0
M       )" H!!0<& @0!  (" P$! 0$            (!PD!!08$ @,*$
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M+E7(=V=O]_?<<K'UE02%*V-IF0E*$SDD2EX?4F+;>..*,,XXL#..V*E9#+"
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M^V?RCX?<7<77&3RG=)-'+.2)U1:S C3K'-%85R+%=")BCR35DHW<??*++/'
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M"W9?LT5QYSM(!,W!=BNO0+^?TT'MF+%-A6=U^R$3*1%W,ILDCK(.B 47"9#
MH7U"]QUW[G^VJT8-2(SG#'%*LN^;S2?L;4HR*D>2-QEMZ"8E("4--VE=U=XS
M>Y)X]SCXUW<C:R^?O6/T-J\2L 2)ZSA]FDDBQ2$6^X5P8K-OS)6N3EAG"5K#
ME/B7MKSH@P57-9K.YK"C)>ITRJ1S(AW3E_?)TZ;5=4@=Y$.]),IE5R;-#Q;S
MYD&.8:KCBF0/WCJY-O&4FTJ.JC/KL$R!XZ#2$ZY=[?;)D6<M<GOE)M[+!#S$
MO]1W])\Q,^4AZ0E/D=0D.->!UR9"AFE?Y <J+:VOC_'YCI&=X:PO"/7DO3*:
M]12,8C.PR+Y^9W)D /\ 6NJFVW'[81%IN(,FO/).9_WFL4L6"V4Z64ZR2Z\V
M E;DQ*8)2-NLC,Z2A.^8L0L_&N ?[9ITH.07&L74DC52&GEEQ*""3+:E4CI.
M%02D[WF4W-MN!Q 1$0W^&_3;Q#3,W*Y)NOR,*5_J(/Y](6&W6_\ 9U"*EA/M
M0L>O\X9QQNP[B_/V&\!9K;5Q&>6XJVM#$_+7'T4W,M*OL161Y,$J>96D4Q#[
MF2_$QEA.NY,!#=SJ+6[A$0#20Y)F=\Q&[5^,O/*;J#.HH5J *7@-7&"2-!N!
M D9R)E*4/IB6#V3,[/19#2TZ7*>88K0"H*94HR;>D#_ED3IMGUBPS[6_MK,.
M"RV=+5(SL?;Y[)UO!A3)ID85P9X;A^UY5FZJP 42R,T\>JNG)0#RD(B [F V
ME4Y;Y+_W_4,;0M#"&AO:.FQZ9"D@]2 )2)UF3#E\/<4-\<MOF:%OJ=4$NCJX
MT0DI41T!)F- .D-Z,.P[_H ;%_J.P#OJ)EI_H@SDH#0^1B9D[''U,J'N4)D_
M_:/#\XIQ^Y99X^?Y_P"1Y!9T!HZM6#'T _6(45@;-Z_%09I,>Q,#&4]#O4W(
M "?N 0\=6^]M]@J4]M2:"C2XY5U+=0O:C0J4L$)G/Z>$4;=TE]HZWN;=>K%M
MHH:1UA)6J<MK9F0)>7G#_;1[HW"NG4TLXQRRA<'[>-3,PJU4AIEY.OW"30@)
MLA2<,&;5B911,""==0A$]]Q'8-(%;.U_G*[W=ZB%E=:8<J)EUU02D()U,YB9
M^D](L:JN[K@C'\<IJPWE#]8S1! ::25**@D>T@@@:CK%?;!F.LA\[>:;N_QD
M$O%0$QE0,EY!ETDS'@J976<RWED(EQ)E*1HO-.&3)-N@D4?455$3;=@&'3^Y
M]D^-\$<&MX;4U*7\G5;OVB*<+*MSCJ-NXIF9!!$S**W^.\1R3N-YW7F%-3"A
MQM5P_<&I6C8E*6U;AJ)#<H?Q\8ESR,MZON*^X/CWC_5I)1[A_'$H_BW#]LL(
M,Y!G!*!)9+GVZJ8]BI701I8QFJ'_ !V$HB!MQB# ;(_V]<!U_(5\;339C=VQ
M\&IWE*RGXD%)F$RG\ATF9:R&D3;RE<W>YSN-H.,[8M@XI8G2PY)4P^6DK4X[
MIUGLV^0'GUAQS?VW>$#80.''.D'.D7H*RDXL ]"["9-6742$1'Q#;8=*0YW!
M\T*FXO(*Q2G'-)!H22H])AL&0$/+3=K_  32U+1:QVA#Z&@%.'Y%'<!U]RR)
M^H A&OO <9J;@_(>*KCBVF15)I=OJSNN+1E<8$CXQE::XZ,\2< 1N7L([?QD
M@!NXP]YS-Q'<1#3L]F7(%RS>U5^(Y,^X]<6W%K0MQ9)^-T%#B0)Z@@*\--VD
MNL5Y=\O%MGP#(+=DF&4R*.@VIW?&#M^1!!!F9^AUZ^,/$XL\AH[+7":N99/(
MI_EJYC2987(#*%%5G9Z+#N&DN+H=^])1W]B#DO<(")%P,'B&D@Y.X^J\0YFJ
M<092?V[ER"*>0F"V^K<T$SF2&_M)UF09DQ8#Q/R;1Y;P+2Y@%?\ S:2U*<>!
MZARF2=\QT_J2F-):Z17X]H@22G..O/G12"*U/R;*E,.W<*KB/3.([%'Q KD1
MU89WBM5%!P [:ZI"$-&II4&1W$I1MEJ=1J)Q6IV5&ENW<PFYM*4M?P53@)]L
ME+W3T$@>LM8G%[OG"$'S=[RLQ?"]SYFF@AF."CD# ,@P2*"3&^HHH]HJ/(TA
M"I2 @ F,AVJ^*9A&"NS[G*GH:P<39<^56MZ:J9Q9"0A2QJT2)32?TA1('26H
MAB.][M_#]+_W@P] ;N+.U-2VT@;E;3_J"0F% ]5#4G4F.G>U'SH/EJJMN..5
MI@B^1*?%B2A3,@N'?>*<Q0(4T4NZ5W%S8Z\V, #N(G<M  X>8A]<=W9<&56$
M7K_?^-- X[6U <4EL:-34#.7@E1!5I*2M.BHZSLQ[A&,XLRN,<H>4<FH:,_M
MR\=:EL!0(*CJ5IF1J9[?H(3]R?Q)D3@IRX">@&B\8PC[J&2\0V;TE3Q4G%'D
M%)((E58.U)9>,.N=@^;@/<"0@;H4Y=.3Q1E5B[A.(UXO=U@OO,?'5[#_ %6W
M&QL2XI)Z!8 4F0E(ZZSA'>8\.R/MSYD1DMM"EL-U"*BE*DD-*2Y_4+25#4ED
MDH5,DS$/@Q![P/%*Y4^/?Y%G97%=Q3:)#.5Z5@9>68??%(4%U(*7AVCU)\P5
M.'<0#@DL4H@!B@(:17,>T+F"P7I]BPT*+C:%N%33Z%@;FR9)*P5>U<AJ!H(L
M4P?OBX<OE@8JLGJW:&__ !@/-+09)< &X((&J">A.OUCWF*_<+@.3&:HC%?&
MNG3MHK$6)Y;)V5K+'N82M5JOH"H*;2%9*%!]*3LVN4J#8%O0(0IC*B4X$$-<
MGF'!5ZXVQ4Y+GS[-+<'-*>D2H*<</ZE$C1(1X@$_@8[/".Y"T\J9@C'>/J5Z
MHM:)_N*I22E*/%*1/_,)Z]80O[L5D;V/G+D "J&<LZQ$T*MK>D/>9-1A$-GS
MU$.W_DD,@.X?Y>(>.G][3[14TG;\*A#;B:RK=J'&]@!)7(I!(5, #H//QBMW
MO#O]!<.XLMO/I^"D2RVM2M $ @E(V_\ CUA_,%[E7"*%I\ *N=H%+[. B&JD
M<2)LBK]N+2.00%L9H2(,<RR1D^T2@/\ E\=(#6=MW-U7>:M?]DK%_-5+4A?L
MD"J<U SE(]=9CZ18O8^Z?@6@QNA;J[XS\E/0MH6V@*))0E( .GA(CUA/G(S.
M!/<[Y=84PCB\TTWP_$2ITRN9-F>.>R28=TE>;@>.%056B+6!9"W8^J!5"B<P
MB!>_;3:<=<>U7;+Q#>,XRQEQ.7NH"6SH=JG#M:25#0G>9F0E,RD0(2OD_D6C
M[LN:+-A6)N/+Q1EW<I*AM2I#7O63*1U2#+7H(=>R]MKA"S*B9/CM2E#-RID*
M9TI-+F.HGL4RRH*2QDSJ'[=Q$0\1TFSO<+S)<$NH=O\ 5H5\AF4AI)VSG(%+
M8($O*6D/S0]K7!ENK%.KQ^C4%,)!*U.K&[03DIPB<_(2A+OO"<5J+A>8PS=\
M3TR&H].G8F9I,S'5Z/381Z,]%JGF8U\X(CL4[U_&.W)/4,(G."'4>FG3[+.4
M+EF@NN+957U#]P4I+E.IU97[.CB4S.H)\#.4](0GOKXGL. MVK(\3HF&+<9M
M/!M 2/DG-!)&H/3H1K#JO;OSDUSQQ0QA8%GQ'=EK$.G0K<4#;N$INHD)%^LN
M @!MY!@D@Y P_P"0*[AI)^=L*JL&Y,N5G"-M$NH6XT=9%*R5:$^LQZ0_O;5G
ME+G?%5LN)6%7&GI4,N G4;  )CZ?C%>7W:["VLW.2V1XK JWKE9QS6%/2[3)
MD7+&IR3Q,XB(["F:8$! !VU8CV@6JJL_!;UQ6E"5U:JI24$ZD('LE]"#+SBL
M+O6O*+QW#IM[)IE,TK5,V5;CT5+>DZREKKX@>,6UJ>U;M*E5FK<H DVKD&@B
M)1'M!)&*9E3 O7;MV !#54MZ<6J]U+BOO74NS_%Q47,XM3M(QRAI4@? W2L;
M0"9"32.GB1]9PM'-'N+UKCAS%EL)99,X:8PD:+39F.M48S.]=5*Q22DF+HDV
MU;(JNG,%(M2)B*B9#J-CI;]IBF$2SWA/;EE')O&'^[L1VNWIBO=0IK<$EQI.
MTI"02!,3(!,I^<X6;.^Z*T\7<UO83F"F48RNA:6A9.J'5#W*493D9ZB<A+01
MVR]<_P#A;"T:5L+[.5 LS-6,<*?QZ"DBSDY. NW,7\2G7VY%':AW@#Z1DU2$
M(7?8XE#<=<18N#^7+G?VJ!NR5]/6M/ ?)L4$C:K[@X0!(>BCKTG':93W#<*L
M8K4UM3>K=54SM.K:RE>JMR?M4E,I_P#FG%>WVRL2S^7N;E:R%4H!Y"X\QO;9
MV_2[Q(B@1L(T<C+?QBIE> 7T3/'(2!$P1*/=Z"2@B';JP[N4S:AQ#A=.$5CR
M7,EJZ%MAQI83O&B9N2 F#(%0/G*9G%9/:SA%9G7/S6:6MM3&/4%S-2DH"@V4
MI63L!/6<P#]91<(U4S%W<:-=@T=)E2=(D<I%.DIZ:Y2K$%1$Y54CB50I@]1-
M0@&*;Q*8-PZZ^FEN,HV-J4#_ )I^[\X_!^F8J4*:?2%-K6%D>$Q_T](K$^Z+
M[4'(;(E_L_('#%GELR!+[N)*BS2Z)+= MD!.8C&N@0B#66BVX&,)$TBE<"(C
MW 8?/IR>$^X2TXQ;6\5OK2*9K8$!U*0-P E-1\S*9]81[N [;;YE=X<S7'G3
M459!FT3-*1J=J4=!*<AY2$5QHCCER2O.1SXDJF%,D3614EB(.JRWK$FBZCBJ
M*J(D<2CA=$C..9]R1A%98Y" 4HCOT'3-7#E/#+?;!=EUJ"@MS00H2(,*78^'
M,WJ[D;(FWNM.!>U:E D3GU&G\HM=^TA[2U^X=6!YGS-UY<IY-M%5=U@^*JA)
M^O4(V#E#(N%F]V=%*9K:Y5JX2 Z"9 ^W:* )B&.(]$4Y>Y=IL[";1;TH_9,O
M;T/[=KP,YE*5?<$DSF"!%AW"'"E;@B#<+C43<>:*5M=6U>1*.FX"0!A_B2::
M1 (F4"%+T H=.W8  "].GE*  '[!J!R-BU*TW+.XGS)TG_"&';0@(#3:RIMO
MVC7H!X?A./L0 ?'?^H>(?N'[AK\W$AU.U4Y3!_$1^TAK+J4R]90O^X>U_P ,
MKU:['=K5CJ<F+/;9E]/S\FXOUS*H_E)%<[ATX,1&<(DF!E%![2% "$* %*
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/AV_#;?\ ;;68Q&=$$?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
